Nephrology 7E 2016 PDF - PDFCOFFEE.COM (2024)

ellis d. avner william e. harmon patrick niaudet norishige yoshikawa francesco emma stuart l. goldstein Editors

Pediatric Nephrology Seventh Edition

OFFICIALLY ENDORSED BY

1 3Reference

Pediatric Nephrology

Ellis D. Avner • William E. Harmon Patrick Niaudet • Norishige Yoshikawa Francesco Emma • Stuart L. Goldstein Editors

Pediatric Nephrology Seventh Edition

With 506 Figures and 310 Tables

Editors Ellis D. Avner Department of Pediatrics Medical College of Wisconsin Children’s Research Institute Children’s Hospital Health System of Wisconsin Milwaukee, WI, USA

William E. Harmon Boston Children’s Hospital Harvard Medical School Boston, MA, USA

Patrick Niaudet Service de Néphrologie Pédiatrique Hôpital Necker-Enfants Malades Université Paris-Descartes Paris, France

Norishige Yoshikawa Department of Pediatrics Wakayama Medical University Wakayama City, Japan

Francesco Emma Division of Nephrology Bambino Gesù Children’s Hospital – IRCCS Rome, Italy

Stuart L. Goldstein Division of Nephrology and Hypertension The Heart Institute Cincinnati Children’s Hospital Medical Center, College of Medicine Cincinnati, OH, USA

ISBN 978-3-662-43595-3 ISBN 978-3-662-43596-0 (eBook) ISBN 978-3-662-43597-7 (print and electronic bundle) DOI 10.1007/978-3-662-43596-0 Library of Congress Control Number: 2015954467 Springer Heidelberg New York Dordrecht London # Springer-Verlag Berlin Heidelberg 2009, 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer-Verlag GmbH Berlin Heidelberg is part of Springer Science+Business Media (www. springer.com)

Preface

Through its past six editions, Pediatric Nephrology has become the standard medical reference for health care professionals treating children with kidney disease. This new edition, published 6 years since the previous version, reflects the tremendous increase in critical information required to translate molecular and cellular pathophysiology into the prevention, diagnosis, and therapy of childhood renal disorders. This text is particularly targeted to pediatricians, pediatric nephrologists, pediatric urologists, and physicians in training. It is also targeted to the increased number of health care professionals comprising the multidisciplinary teams required to provide comprehensive care for children with kidney disease and their families: geneticists, genetic counselors, nurse specialists, dialysis personnel, nutritionists, social workers, and mental health professionals. Finally, this reference is designed to serve the needs of primary care physicians (internists and family practitioners) as well as internist nephrologists who are increasingly involved in the initial evaluation and/or the longitudinal care of children with renal disease under different health care delivery systems evolving throughout the world. To keep pace with the dramatic changes in pediatric renal medicine since the publication of the previous edition, the content of the seventh edition of Pediatric Nephrology has been completely revised, updated, and enlarged. The seventh edition contains 83 chapters in 3 volumes, which are organized into 12 main sections. The text begins with an overview of the basic developmental anatomy, biology, and physiology of the kidney, which provides the basic information necessary to understand the developmental nature of pediatric renal diseases. This is followed by a comprehensive coverage of the evaluation, diagnosis, and therapy of specific childhood kidney diseases, including the extensive use of clinical algorithms. Of special note is a section focused on rapidly evolving research methodologies, which are being translated into new clinical approaches and therapies for many childhood renal diseases. The final sections focus on comprehensive, state-of-the-art reviews of acute and chronic renal failure in childhood. Many chapters of the seventh edition have been completely rewritten by new authors, all recognized as global authorities in their respective areas. The remainder of the text has been totally revised, with junior authors often joining senior authors from the previous edition. The number of contributors has increased by 20 %. In addition to the new section on Global Pediatric Nephrology, which focuses on unique aspects of pediatric nephrology practice v

vi

and the epidemiology of pediatric renal disease in different regions of the world, all of the chapters reflect a global perspective. This has been achieved through a dynamic, evolving relationship between the Editors and the International Pediatric Nephrology Association (IPNA). This has led to the continued endorsement of Pediatric Nephrology as the standard global reference text in the field of childhood kidney disease. We are proud that the IPNA logo adorns the cover of Pediatric Nephrology in recognition of this endorsement. The Editors look forward to this dynamic interaction with IPNA to take advantage of future opportunities that such collaboration may provide in the areas of education and outreach. Other major changes are also evidenced by the new publication of the seventh edition of Pediatric Nephrology as a basic reference handbook in the SpringerReference series. Representing advances in state-of-the-art electronic publishing, there are regularly updated online versions of each chapter of this text at SpringerLink.com. The new publishing format has led to a welcome expansion of the published text to three volumes and the increased utilization of high-resolution, color figures. Further, two new Editors, Professor Francesco Emma of Ospedale Pediatrico Bambino Gesu in Rome, Italy, and Professor Stuart L. Goldstein of the University of Cincinnati, USA, have joined the Editorial Team. The addition of new Editors continues to provide a dynamic mixture of continuity, new ideas, new perspectives, and globalism, which has distinguished each new edition of the text. Professors Emma and Goldstein join the four Editors from the sixth edition: Senior Editor and Emeritus Professor Ellis D. Avner, from the Medical College of Wisconsin, USA, and Professors William E. Harmon M.D. of Harvard University, USA, Patrick Niaudet, from the Hôpital Necker-Enfants Malades in Paris, France; and Norishige Yoshikawa from Wakayama, Japan. The current Editors are internationally recognized leaders in complementary areas of pediatric nephrology and along with the more than 150 contributors reflect the global nature of the text and the subspecialty it serves. The Editors wish to thank a number of individuals whose efforts were critical in the success of this project. The book would never have reached this seventh edition without the dedication of our professional colleagues at Springer, Gabriele Schroder, Sandra Lesny, Gregory Sutorius, and particularly Mr. Andrew Spencer, Senior Editor of Major Reference Works, who served as our “guide for the perplexed” in all aspects of project management. We thank our families, and particularly our wives (Jane, Diane, Claire, Hiro, and Elizabeth) for their support and understanding. In particular, the Senior Editor wishes to recognize his lifetime partner in all endeavors, Jane A. Avner, Ph.D., for her extraordinary editorial assistance. And finally, we thank our mentors, our students, and most importantly, our patients and their families. Without them, our work would lack purpose.

Preface

Preface

vii

Finally, the Editors wish to dedicate this seventh edition of Pediatric Nephrology to three former Editors who passed away in 2014. Professors Martin Barratt, Malcolm A. “Mac” Holiday, and Robert Vernier were extraordinary physicianscientists who served as mentors to a generation of pediatric nephrologists. This text would not exist without their efforts, commitment, and selfless contributions. Ellis D. Avner William E. Harmon Patrick Niaudet Norishige Yoshikawa Francesco Emma Stuart L. Goldstein

Contents

Volume 1 Part I

Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1

1

Embryonic Development of the Kidney . . . . . . . . . . . . . . . . . Carlton Bates, Jacqueline Ho, and Sunder Sims-Lucas

3

2

Development of Glomerular Circulation and Function Alda Tufro and Ashima Gulati

....

37

3

Renal Tubular Development . . . . . . . . . . . . . . . . . . . . . . . . . . Michel Baum

61

4

Clinical Perinatal Urology . . . . . . . . . . . . . . . . . . . . . . . . . . . . David A. Diamond and Richard S. Lee

97

5

Renal Dysplasia/Hypoplasia . . . . . . . . . . . . . . . . . . . . . . . . . . 115 Paul Goodyer and Indra R. Gupta

6

Developmental Syndromes and Malformations of the Urinary Tract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135 Chanin Limwongse

Part II

Homeostasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

179

7

Physiology of the Developing Kidney: Sodium and Water Homeostasis and Its Disorders . . . . . . . . . . . . . . . . . . . . . . . . 181 Nigel Madden and Howard Trachtman

8

Physiology of the Developing Kidney: Potassium Homeostasis and Its Disorder . . . . . . . . . . . . . . . . . . . . . . . . . 219 Lisa M. Satlin and Detlef Bockenhauer

9

Physiology of the Developing Kidney: Acid-Base Homeostasis and Its Disorders . . . . . . . . . . . . . . . . . . . . . . . . 247 Peter D. Yorgin, Elizabeth G. Ingulli, and Robert H. Mak

10

Bone Developmental Physiology . . . . . . . . . . . . . . . . . . . . . . . 279 MH Lafage-Proust ix

x

Contents

11

Physiology of the Developing Kidney: Disorders and Therapy of Calcium and Phosphorous Homeostasis . . . . . . . 291 Amita Sharma, Rajesh V. Thakker, and Harald J€uppner

12

Nutrition Management in Childhood Kidney Disease: An Integrative and Lifecourse Approach . . . . . . . . . . . . . . . . 341 Lauren Graf, Kimberly Reidy, and Frederick J. Kaskel

13

Physiology of the Developing Kidney: Fluid and Electrolyte Homeostasis and Therapy of Basic Disorders (Na/H2O/K/Acid Base) . . . . . . . . . . . . . . . . . . . . . . 361 Isa F. Ashoor and Michael J. G. Somers

Part III Translational Research Methods

....................

423

14

Translational Research Methods: Basics of Renal Molecular Biology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425 Gian Marco Ghiggeri, Maurizio Bruschi, and Simone Sanna-Cherchi

15

Translational Research Methods: The Value of Animal Models in Renal Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447 Jordan Kreidberg

16

Basics of Clinical Investigation . . . . . . . . . . . . . . . . . . . . . . . . 473 Susan L. Furth and Jeffrey J. Fadrowski

17

Genomic Methods in the Diagnosis and Treatment of Pediatric Kidney Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 499 Karen Maresso and Ulrich Broeckel

18

Translational Research Methods: Renal Stem Cells . . . . . . . 525 Kenji Osafune

19

Translational Research Methods: Tissue Engineering of the Kidney and Urinary Tract . . . . . . . . . . . . . . . . . . . . . . . . . . . 571 Austin G. Hester and Anthony Atala

Part IV Clinical Approach to the Child with Suspected Renal Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

593

20

Clinical Evaluation of the Child with Suspected Renal Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595 Mohan A. Shenoy and Nicholas J. A. Webb

21

Laboratory Investigation of the Child with Suspected Renal Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 613 George van der Watt, Fierdoz Omar, Anita Brink, and Mignon McCulloch

Contents

xi

22

Growth and Development of the Child with Renal Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 637 Bethany Foster

23

Diagnostic Imaging of the Child with Suspected Renal Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 667 Jonathan Loewen and Larry A. Greenbaum

24

Pediatric Renal Pathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . 705 Agnes B. Fogo

Part V

Glomerular Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

751

25

Congenital Nephrotic Syndrome . . . . . . . . . . . . . . . . . . . . . . . 753 Hannu Jalanko and Christer Holmberg

26

Inherited Glomerular Diseases . . . . . . . . . . . . . . . . . . . . . . . . 777 Michelle N. Rheault and Clifford E. Kashtan

27

Idiopathic Nephrotic Syndrome in Children: Genetic Aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 805 Olivia Boyer, Kálmán Tory, Eduardo Machuca, and Corinne Antignac

28

Idiopathic Nephrotic Syndrome in Children: Clinical Aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 839 Patrick Niaudet and Olivia Boyer

29

Immune-Mediated Glomerular Injury in Children . . . . . . . . 883 Michio Nagata

30

Complement-Mediated Glomerular Injury in Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 927 Zoltán Prohászka, Marina Vivarelli, and George S. Reusz

31

Acute Postinfectious Glomerulonephritis in Children . . . . . . 959 Bernardo Rodríguez-Iturbe, Behzad Najafian, Alfonso Silva, and Charles E. Alpers

32

Immunoglobulin A Nephropathies in Children (Includes HSP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 983 Koichi Nakanishi and Norishige Yoshikawa

33

Membranoproliferative and C3-Mediated GN in Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1035 Christoph Licht, Magdalena Riedl, Matthew C. Pickering, and Michael Braun

34

Membranous Nephropathy in Children . . . . . . . . . . . . . . . . . 1055 Rudolph P. Valentini

xii

Contents

Volume 2 Part VI

Tubular Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1077

35

Nephronophthisis and Medullary Cystic Kidney Disease in Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1079 Friedhelm Hildebrandt

36

Childhood Polycystic Kidney Disease . . . . . . . . . . . . . . . . . . . 1103 William E. Sweeney Jr., Meral Gunay-Aygun, Ameya Patil, and Ellis D. Avner

37

Aminoaciduria and Glycosuria in Children . . . . . . . . . . . . . . 1155 Israel Zelikovic

38

Renal Tubular Disorders of Electrolyte Regulation in Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1201 Olivier Devuyst, Hendrica Belge, Martin Konrad, Xavier Jeunemaitre, and Maria-Christina Zennaro

39

Renal Tubular Acidosis in Children . . . . . . . . . . . . . . . . . . . . 1273 Raymond Quigley and Matthias T. F. Wolf

40

Nephrogenic Diabetes Insipidus in Children . . . . . . . . . . . . . 1307 Nine V. A. M. Knoers and Elena N. Levtchenko

41

Cystinosis and Its Renal Complications in Children . . . . . . . 1329 William A. Gahl and Galina Nesterova

42

Pediatric Fanconi Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . 1355 Takashi Igarashi

43

Primary Hyperoaxaluria in Children . . . . . . . . . . . . . . . . . . . 1389 Pierre Cochat, Neville Jamieson, and Cecile Acquaviva-Bourdain

44

Pediatric Tubulointerstitial Nephritis . . . . . . . . . . . . . . . . . . . 1407 Uri S. Alon

Part VII

Kidney Involvement in Systemic Diseases . . . . . . . . . . . 1429

45

Renal Involvement in Children with Vasculitis . . . . . . . . . . . 1431 Seza Ozen and Diclehan Orhan

46

Renal Involvement in Children with Systemic Lupus Erythematosus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1449 Patrick Niaudet, Brigitte Bader-Meunier, and Rémi Salomon

47

Renal Involvement in Children with HUS . . . . . . . . . . . . . . . 1489 Carla M. Nester and Sharon P. Andreoli

Contents

xiii

48

Sickle Cell Nephropathy in Children . . . . . . . . . . . . . . . . . . . 1523 Connie Piccone and Katherine MacRae Dell

49

Diabetic Nephropathy in Children . . . . . . . . . . . . . . . . . . . . . 1545 M. Loredana Marcovecchio and Francesco Chiarelli

50

Renal Manifestations of Metabolic Disorders in Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1569 Francesco Emma, William G. van’t Hoff, and Carlo Dionisi Vici

51

Infectious Diseases and the Kidney in Children . . . . . . . . . . 1609 Jennifer Stevens, Jethro A. Herberg, and Michael Levin

52

Nephrotoxins and Pediatric Kidney Injury . . . . . . . . . . . . . . 1655 Takashi Sekine

Part VIII

Urinary Tract Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1693

53

Urinary Tract Infections in Children . . . . . . . . . . . . . . . . . . . 1695 Elisabeth M. Hodson and Jonathan C. Craig

54

Vesicoureteral Reflux and Renal Scarring in Children . . . . . 1715 Tej K. Mattoo, Ranjiv Mathews, and Indra R. Gupta

55

Pediatric Obstructive Uropathy . . . . . . . . . . . . . . . . . . . . . . . 1749 Bärbel Lange-Sperandio

56

Pediatric Bladder Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . 1779 Etienne Berard

57

Urolithiasis in Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1821 Vidar Edvardsson

58

Pediatric Renal Tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1869 Elizabeth Mullen, Jordan Kreidberg, and Christopher B. Weldon

Volume 3 Part IX

Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1905

59

Epidemiology of Hypertension in Children . . . . . . . . . . . . . . 1907 Midori Awazu

60

Pathophysiology of Pediatric Hypertension . . . . . . . . . . . . . . 1951 Ikuyo Yamaguchi and Joseph T. Flynn

61

Evaluation of Hypertension in Childhood Diseases . . . . . . . . 1997 Eileen D. Brewer and Sarah J. Swartz

xiv

62

Contents

Management of the Hypertensive Child . . . . . . . . . . . . . . . . . 2023 Demetrius Ellis and Yosuke Miyashita

Part X

Acute Renal Injury . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2099

63

Pathogenesis of Acute Kidney Injury . . . . . . . . . . . . . . . . . . . 2101 David P. Basile, Rajasree Sreedharan, and Scott K. Van Why

64

Evaluation and Management of Acute Kidney Injury in Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2139 Stuart L. Goldstein and Michael Zappitelli

Part XI

Chronic Renal Failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2169

65

Pathophysiology of Progressive Renal Disease in Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2171 H. William Schnaper

66

Management of Chronic Kidney Disease in Children . . . . . . 2207 Rene G. VanDeVoorde, Craig S. Wong, and Bradley A. Warady

67

Handling of Drugs in Children with Abnormal Renal Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2267 Guido Filler, Amrit Kirpalani, and Bradley L. Urquhart

68

Endocrine and Growth Abnormalities in Chronic Kidney Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2295 Franz Schaefer

69

Mineral and Bone Disorders in Children with Chronic Kidney Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2349 Katherine Wesseling-Perry and Isidro B. Salusky

70

Peritoneal Dialysis in Children . . . . . . . . . . . . . . . . . . . . . . . . 2381 Enrico Verrina and Claus Peter Schmitt

71

Hemodialysis in Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2433 Lesley Rees

72

Immunology of Pediatric Renal Transplantation . . . . . . . . . 2457 Elizabeth G. Ingulli, Stephen I. Alexander, and David M. Briscoe

73

Pediatric Renal Transplantation . . . . . . . . . . . . . . . . . . . . . . . 2501 Nancy M. Rodig, Khashayar Vakili, and William E. Harmon

74

Immunosuppression for Pediatric Renal Transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2553 Jodi M. Smith, Thomas L. Nemeth, and Ruth A. McDonald

75

Complications of Pediatric Renal Transplantation . . . . . . . . 2573 Vikas R. Dharnidharka and Carlos E. Araya

Contents

xv

Part XII

IPNA: Global Pediatric Nephrology . . . . . . . . . . . . . . . . . 2605

76

IPNA: Global Pediatric Nephrology, Introduction and Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2607 Pierre Cochat and Isidro B. Salusky

77

AFPNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2613 Mignon McCulloch, Hesham Safouh, Amal Bourquia, and Priya Gajjar

78

ALANEPE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2631 Vera Koch, Nelson Orta, and Ramon Exeni

79

AsPNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2639 Hui-Kim Yap, Man-Chun Chiu, Arvind Bagga, and Hesham Safouh

80

Pediatric Nephrology in North America Victoria F. Norwood and Maury Pinsk

81

ANZPNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2673 Deborah Lewis

82

ESPN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2681 Rosanna Coppo

83

JSPN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2687 Kazumoto Iijima

. . . . . . . . . . . . . . . . 2665

Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2697

Contributors

Cecile Acquaviva-Bourdain Centre de référence des maladies rénales rares Néphrogones, Hôpital Femme Mère Enfant, Hospices Civils de Lyon & Université de Lyon, Lyon, France Service Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France Stephen I. Alexander Discipline of Paediatrics and Child Health, The University of Sydney, Sydney, New South Wales, Australia Division of Nephrology, Children’s Hospital at Westmead, Sydney, New South Wales, Australia Uri S. Alon Section of Pediatric Nephrology, The Children’s Mercy Hospital and Clinics, University of Missouri at Kansas City, School of Medicine, Kansas City, MO, USA Charles E. Alpers Department of Pathology, University of Washington, Seattle, WA, USA Sharon P. Andreoli Division of Nephrology, Indianapolis, IN, USA Corinne Antignac Laboratory of Hereditary Kidney Diseases, Inserm UMR 1163, Paris, France Paris Descartes, Sorbonne Paris Cité University, Imagine Institute, Paris, France Department of Genetics, MARHEA reference center, Necker – Enfants Malades Hospital, Paris, France Carlos E. Araya University of Central Florida and Nemours Children’s Hospital, Orlando, FL, USA Isa F. Ashoor Division of Nephrology, Children’s Hospital, New Orleans, LA, USA Anthony Atala School of Medicine, Department of Urology, Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, NC, USA

xvii

xviii

Contributors

Ellis D. Avner Department of Pediatrics, Medical College of Wisconsin, Children’s Research Institute, Children’s Hospital Health System of Wisconsin, Milwaukee, WI, USA Midori Awazu Department of Pediatrics, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan Brigitte Bader-Meunier Service d’Immunologie et Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France

Rhumatologie

Arvind Bagga Division of Nephrology, All India Institute of Medical Sciences, New Delhi, India David P. Basile Indiana University School of Medicine, Indianapolis, IN, USA Carlton Bates Department of Pediatrics, Division of Pediatric Nephrology, Children’s Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Michel Baum Departments of Pediatrics and Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA Hendrica Belge Zurich Institute for Human Physiology, University of Zurich, Institute of Physiology, Zurich Center for Integrative Human Physiology (ZIHP), Z€ urich, Switzerland Etienne Berard Pediatric Nephrology Unit, Universitary Hospital of Nice (France), Nice, France Detlef Bockenhauer Great Ormond Street Hospital, Institute of Child Health, University College London, London, UK Amal Bourquia Paediatric Nephology, Red Cross War Memorial Children’s Hospital, Dept. of Paediatric Medicine, University of Cape Town, Western Cape, South Africa Olivia Boyer Service de Néphrologie Pédiatrique, Hôpital Necker-Enfants Malades, Université Paris-Descartes, Paris, France Michael Braun Renal Section, Department of Pediatrics, Texas Children’s Hospital, Balyor College of Medicine, Houston, TX, USA Eileen D. Brewer Department of Pediatrics Renal Section, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA Anita Brink Department of Pediatrics and Child Health (Nuclear Medicine), University of Cape Town, Red Cross War Memorial Children’s Hospital, Cape Town, South Africa David M. Briscoe Department of Pediatrics, Harvard Medical School, Boston, MA, USA Division of Nephrology, Transplant Research Program, Boston Children’s Hospital, Boston, MA, USA

Contributors

xix

Ulrich Broeckel Department of Pediatrics, Medical College of Wisconsin and Children’s Hospital of Wisconsin, Milwaukee, WI, USA Maurizio Bruschi Laboratory of Physiopathology of Uremia, Division of Nephrology, Dialysis and Transplantation, Istituto Giannina Gaslini, Genoa, Italy Francesco Chiarelli University of Chieti, Chieti, Italy Man-Chun Chiu Department of Pediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong Kong University, Kowloon, Hong Kong Pierre Cochat Centre de référence des maladies rénales rares Néphrogones, Hôpital Femme Mère Enfant, Hospices Civils de Lyon & Université de Lyon, Lyon, France IBCP-UMR 5305 CNRS, Université Claude-Bernard Lyon 1, Lyon, France Rosanna Coppo Nephrology Dialysis and Transplantation Unit, Azienda Ospedaliera-Universitaria Città della Salute e della Scienza di Torino, Regina Margherita Children’s University Hospital, Turin, Italy Jonathan C. Craig Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead, Sydney, NSW, Australia Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia Katherine MacRae Dell Center for Pediatric Nephrology, Department of Pediatrics, Cleveland Clinic Children’s and Case Western Reserve University, Cleveland, OH, USA Olivier Devuyst Zurich Institute for Human Physiology, University of Zurich, Institute of Physiology, Zurich Center for Integrative Human Physiology (ZIHP), Z€urich, Switzerland Vikas R. Dharnidharka Pediatric Nephrology, Washington University School of Medicine and St. Louis Children’s Hospital, St. Louis, MO, USA David A. Diamond Department of Urology, Harvard Medical School, Boston Children’s Hospital, Boston, MA, USA Carlo Dionisi Vici Division of Metabolic Diseases, Bambino Gesù Children’s Hospital – IRCCS, Rome, Italy Vidar Edvardsson Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland and Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland Demetrius Ellis Department of Pediatrics, Division of Pediatric Nephrology, Children’s Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Francesco Emma Division of Nephrology, Bambino Gesù Children’s Hospital – IRCCS, Rome, Italy

xx

Ramon Exeni Department of Nephrology, Children’s Hospital “San Justo”, Buenos Aires, Argentina Jeffrey J. Fadrowski Department of Pediatrics, John Hopkins University School of Medicine, Baltimore, MD, USA Guido Filler Departments of Pediatrics, Medicine, and Pathology Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada Children’s Hospital of Western Ontario, Children’s Health Research Institute (CHRI), London, ON, Canada Joseph T. Flynn Division of Nephrology, Seattle Children’s Hospital; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA Agnes B. Fogo Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA Bethany Foster The Research Institute of the McGill University Health Centre, Montreal, QC, Canada Susan L. Furth Departments of Pediatrics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA William A. Gahl Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA Priya Gajjar Paediatric Nephology, Red Cross War Memorial Children’s Hospital, Dept. of Paediatric Medicine, University of Cape Town, Western Cape, South Africa Gian Marco Ghiggeri Laboratory of Physiopathology of Uremia, Division of Nephrology, Dialysis and Transplantation, Istituto Giannina Gaslini, Genoa, Italy Stuart L. Goldstein Division of Nephrology and Hypertension, The Heart Institute, Cincinnati Children’s Hospital Medical Center, College of Medicine, Cincinnati, OH, USA Paul Goodyer Division of Pediatric Nephrology, Montreal Children’s Hospital, McGill University, Montreal, QC, Canada Lauren Graf Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA Larry A. Greenbaum Department of Pediatric Radiology, Emory University School of Medicine, Atlanta, GA, USA Ashima Gulati Department of Pediatrics, Nephrology Section, Yale School of Medicine, New Haven, CT, USA

Contributors

Contributors

xxi

Meral Gunay-Aygun Medical Genetics Branch, The Intramural Program of the Office of Rare Diseases, National Human Genome Research Institute, Bethesda, MD, USA Department of Pediatrics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA Indra R. Gupta Department of Pediatrics and Department of Human Genetics, Division of Pediatric Nephrology, Montreal Children’s Hospital, McGill University, Montréal, QC, Canada William E. Harmon Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA Jethro A. Herberg Imperial College London, London, UK Austin G. Hester School of Medicine, Department of Urology, Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, NC, USA Friedhelm Hildebrandt Harvard Medical School, Boston, MA, USA Jacqueline Ho Department of Pediatrics, Division of Pediatric Nephrology, Children’s Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Elisabeth M. Hodson Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead, Sydney, NSW, Australia Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia Christer Holmberg Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland Takashi Igarashi National Center for Child Health and Development (NCCHD), Tokyo, Japan Kazumoto Iijima Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan Elizabeth G. Ingulli Department of Pediatrics, University of California, San Diego, CA, USA Division of Nephrology, Rady Children’s Hospital San Diego, San Diego, CA, USA Kidney Transplant Program, Rady Children’s Hospital, San Diego, CA, USA Hannu Jalanko Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland Neville Jamieson Department of Surgery, Addenbrookes Hospital, Cambridge University Teaching Hospitals, Cambridge, UK Xavier Jeunemaitre Department of Molecular Genetics, Hôpital Européen George Pompidou, Paris, France

xxii

Harald J€ uppner Departments of Medicine and Pediatrics, Endocrine Unit and Pediatric Nephrology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA Clifford E. Kashtan Department of Pediatrics, Division of Pediatric Nephrology, University of Minnesota Masonic Children’s Hospital, Minneapolis, MN, USA Frederick J. Kaskel Division of Pediatric Nephrology, Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA Amrit Kirpalani Departments of Pediatrics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada Nine V. A. M. Knoers Departments of Medical Genetics, University Medical Centre Utrecht, Utrecht, The Netherlands Vera Koch Instituto da Criança- Pediatric Nephrology Unit, Department of Pediatrics, University of Sao Paulo Medical School, Sao Paulo, Brazil Martin Konrad Department of General Pediatrics, Pediatric Nephrology, University Hospital, M€unster, Germany Jordan Kreidberg Children’s Hospital Boston, Boston, MA, USA MH Lafage-Proust INSERM U 1059, Université de Lyon, Saint-Etienne, France Bärbel Lange-Sperandio Dr. v. Hauner Children’s Hospital, Department of Pediatric Nephrology, LMU, Munich, Germany Richard S. Lee Department of Urology, Harvard Medical School, Boston Children’s Hospital, Boston, MA, USA Michael Levin Department of Medicine, Imperial College London, London, UK Elena N. Levtchenko Department of Pediatric Nephrology, Department of Growth and Regeneration, University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium Deborah Lewis Sydney, NSW, Australia Christoph Licht Division of Nephrology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada Research Institute, Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada Department of Paediatrics, University of Toronto, Toronto, ON, Canada Chanin Limwongse Department of Medicine, Division of Medical Genetics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkoknoi, Bangkok, Thailand Jonathan Loewen Department of Pediatric Radiology, Emory University School of Medicine, Atlanta, GA, USA

Contributors

Contributors

xxiii

Eduardo Machuca Department of Nephrology, Medical School, Pontificia Universidad Católica de Chile, Santiago, Chile Nigel Madden NYU Langone Medical Center and NYU School of Medicine, New York, NY, USA Robert H. Mak Pediatric Nephrology, University of California, San Diego, CA, USA Pediatric Nephrology Division, Rady Children’s Hospital, San Diego, CA, USA M. Loredana Marcovecchio University of Chieti, Chieti, Italy Karen Maresso Section of Genomic Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA Ranjiv Mathews The Nevada School of Medicine, The Johns Hopkins School of Medicine, Las Vegas, NV, USA Tej K. Mattoo Pediatric Nephrology and Hypertension, Wayne State University School of Medicine, Children’s Hospital of Michigan, Detroit, MI, USA Mignon McCulloch Department of Paediatric Intensive Care/Nephrology, University of Cape Town, Red Cross War Memorial Children’s Hospital, Cape Town, Western Cape, South Africa Ruth A. McDonald Division of Nephrology, Seattle Children’s, University of Washington, Seattle, WA, USA Yosuke Miyashita Department of Pediatrics, Division of Pediatric Nephrology, Children’s Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Elizabeth Mullen Hematology Oncology, Dana-Farber/Boston Children’s Blood Disorders and Cancer Center, Boston, MA, USA Michio Nagata Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan Behzad Najafian Department of Pathology, University of Washington, Seattle, WA, USA Koichi Nakanishi Department of Pediatrics, Wakayama Medical University, Wakayama City, Japan Thomas L. Nemeth Department of Pharmacy, Seattle Children’s, University of Washington, Seattle, WA, USA Carla M. Nester Stead Family Department of Pediatrics, Department of Internal Medicine, Divisions of Nephrology, University of Iowa Children’s Hospital, Carver College of Medicine, Iowa City, IA, USA Galina Nesterova Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

xxiv

Patrick Niaudet Service de Néphrologie Pédiatrique, Hôpital NeckerEnfants Malades, Université Paris-Descartes, Paris, France Victoria F. Norwood University of Virginia, Charlottesville, VA, USA Fierdoz Omar Chemical Pathology, University of Cape Town and National Health Laboratory Service, Red Cross Children’s Hospital and Groote Schuur Hospital, Cape Town, South Africa Diclehan Orhan Department of Pediatric Pathology, Hacettepe University, Sihhiye, Ankara, Turkey Nelson Orta Service of Pediatric Nephrology, Children’s Hospital “Jorge Lizarraga”, University of Carabobo, Valencia, Venezuela Kenji Osafune Center for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo-ku, Kyoto, Japan Seza Ozen Department of Pediatrics, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey Ameya Patil Department of Pediatrics, Medical College of Wisconsin, Children’s Research Institute, Children’s Hospital Health System of Wisconsin, Milwaukee, WI, USA Connie Piccone Rainbow Babies and Children’s Hospital, Cleveland, OH, USA Matthew C. Pickering Centre for Complement and Inflammation Research, Imperial College, London, UK Maury Pinsk University of Alberta, Edmonton, AB, Canada Zoltán Prohászka 3rd Department of Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary Raymond Quigley Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA Lesley Rees Department of Nephrology, Great Ormond Street Hospital for Children NHS Trust, London, UK Kimberly Reidy Division of Pediatric Nephrology, Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA George S. Reusz 1st Department of Pediatrics, Faculty of Medicine, Semmelweis University, Budapest, Hungary Michelle N. Rheault Department of Pediatrics, Division of Pediatric Nephrology, University of Minnesota Masonic Children’s Hospital, Minneapolis, MN, USA Magdalena Riedl Research Institute, Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada Department of Paediatrics, Innsbruck Medical University, Innsbruck, Tyrol, Austria

Contributors

Contributors

xxv

Nancy M. Rodig Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA Bernardo Rodríguez-Iturbe Nephrology Service, Hospital Universitario, Maracaibo, Estado Zulia, Venezuela Hesham Safouh Faculty of Medicine, Center for Pediatric Nephrology and Transplantation (CPNT), Cairo University, Orman, Giza, Egypt Rémi Salomon Service de Néphrologie Pédiatrique, Hôpital Necker-Enfants Malades, Université Paris-Descartes, Paris, France Isidro B. Salusky Division of Pediatric Nephrology, Clinical Translational Research Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA Simone Sanna-Cherchi Division of Nephrology, Columbia University, College of Physicians and Surgeons, New York, NY, USA Lisa M. Satlin Department of Pediatrics, Division of Pediatric Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Franz Schaefer Division of Pediatric Nephrology, University Children’s Hospital, Heidelberg, Germany Claus Peter Schmitt Centre for Pediatric and Adolescent Medicine, Heidelberg, Germany H. William Schnaper Division of Kidney Diseases, Ann and Robert H. Lurie Children’s Hospital of Chicago, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Takashi Sekine Department of Pediatrics, Toho University Faculty of Medicine, Meguro-ku, Tokyo, Japan Amita Sharma Department of Pediatrics, Pediatric Nephrology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA Mohan A. Shenoy Department of Pediatric Nephrology, Royal Manchester Children’s Hospital, Manchester, UK Alfonso Silva Nephrology Service, Hospital Universitario, Maracaibo, Estado Zulia, Venezuela Sunder Sims-Lucas Department of Pediatrics, Division of Pediatric Nephrology, Children’s Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Jodi M. Smith Division of Nephrology, Seattle Children’s, University of Washington, Seattle, WA, USA Michael J. G. Somers Division of Nephrology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA Rajasree Sreedharan Medical College of Wisconsin, Milwaukee, WI, USA Jennifer Stevens University Hospital Wales, Cardiff, S. Wales, UK

xxvi

Sarah J. Swartz Department of Pediatrics Renal Section, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA William E. Sweeney Jr. Department of Pediatrics, Medical College of Wisconsin, Children’s Research Institute, Children’s Hospital Health System of Wisconsin, Milwaukee, WI, USA Rajesh V. Thakker Radcliffe Department of Medicine, Academic Endocrine Unit, University of Oxford, OCDEM (Oxford Centre for Diabetes, Endocrinology and Metabolism), The Churchill Hospital Headington, Oxford, UK Kálmán Tory Laboratory of Hereditary Kidney Diseases, Inserm UMR 1163, Paris, France Department of Pediatrics, Semmelweis University, Budapest, Hungary Howard Trachtman NYU Langone Medical Center and NYU School of Medicine, New York, NY, USA Alda Tufro Department of Pediatrics, Nephrology Section, Yale School of Medicine, New Haven, CT, USA Bradley L. Urquhart Departments of Pediatrics, Department of Medicine, Physiology and Pharmacology, Western University, London, ON, Canada Children’s Health Research Institute (CHRI), London, ON, Canada Khashayar Vakili Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA Rudolph P. Valentini Pediatric Nephrology, Children’s Hospital of Michigan, Detroit, MI, USA Wayne State University School of Medicine, Detroit, MI, USA George van der Watt Chemical Pathology, University of Cape Town and National Health Laboratory Service, Red Cross Children’s Hospital and Groote Schuur Hospital, Cape Town, South Africa Scott K. Van Why Medical College of Wisconsin, Milwaukee, WI, USA William G. van’t Hoff Great Ormond Street Hospital, London, UK Rene G. VanDeVoorde Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA Enrico Verrina Nephrology, Dialysis and Transplantation Unit, Giannina Gaslini Childrens Hospital, Genoa, Italy Marina Vivarelli Division of Nephrology and Dialysis, Children’s Hospital Bambino Gesù-IRCCS, Rome, Italy Bradley A. Warady Pediatric Nephrology, Children’s Mercy Hospital, Kansas City, MO, USA Nicholas J. A. Webb Department of Pediatric Nephrology, Royal Manchester Children’s Hospital, Manchester, UK

Contributors

Contributors

xxvii

Christopher B. Weldon Department of Surgery, Boston Children’s Hospital and Harvard Medical School, Boston, MA, USA Katherine Wesseling-Perry Division of Pediatric Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA Matthias T. F. Wolf Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA Craig S. Wong Pediatric Nephrology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA Ikuyo Yamaguchi Division of Pediatric Nephrology, University of Texas School of Medicine at San Antonio, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA Hui-Kim Yap Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore Peter D. Yorgin Pediatric Nephrology, University of California, San Diego, CA, USA Pediatric Nephrology Division, Rady Children’s Hospital, San Diego, CA, USA Norishige Yoshikawa Department of Pediatrics, Wakayama Medical University, Wakayama City, Japan Michael Zappitelli Pediatrics, Division of Nephrology, Montreal Children’s Hospital, McGill University Health Center, Montreal, QC, Canada Israel Zelikovic Department of Physiology and Biophysics, Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel Division of Pediatric Nephrology, Rambam Medical Center, Haifa, Israel Maria-Christina Zennaro Inserm U970, Paris Cardiovascular Research Center, Paris, France

Part I Development

1

Embryonic Development of the Kidney Carlton Bates, Jacqueline Ho, and Sunder Sims-Lucas

Contents Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4

Studying the Kidney and Urinary Tract Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

5

Development of the Metanephros . . . . . . . . . . . . . . . . . .

7

Nephron Formation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Specification of Nephron Progenitors/Cap Mesenchyme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Nephron Induction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Nephron Segmentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Glomerulogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Molecular Control of Podocyte Terminal Differentiation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Molecular Control of Glomerular Capillary Tuft Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

8 10 11 12 12 13 13

Renal Stroma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

Vascular Development of the Kidney . . . . . . . . . . . . . . Angiogenesis Versus Vasculogenesis . . . . . . . . . . . . . . . . . Origins of the Peritubular Capillary Endothelia . . . . . . Molecular Control of Renal Vascular Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Collecting System Development . . . . . . . . . . . . . . . . . . . . Ureteric Bud Induction and Outgrowth . . . . . . . . . . . . . . . Renal Branching Morphogenesis . . . . . . . . . . . . . . . . . . . . . Patterning of the Medullary and Cortical Collecting Ducts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Lower Urinary Tract Development . . . . . . . . . . . . . . . . Anatomic and Functional Development . . . . . . . . . . . . . . Molecular Control of Ureter and Bladder Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Bladder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ureter–Bladder Anastomosis . . . . . . . . . . . . . . . . . . . . . . . . .

14 15 16 17 17 17 19 20 21 21 23 25 25

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

C. Bates (*) • J. Ho • S. Sims-Lucas Department of Pediatrics, Division of Pediatric Nephrology, Children’s Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA e-mail: [emailprotected]; [emailprotected]; [emailprotected] # Springer-Verlag Berlin Heidelberg 2016 E.D. Avner et al. (eds.), Pediatric Nephrology, DOI 10.1007/978-3-662-43596-0_1

3

4

Introduction The mammalian kidney functions as a key regulator of water balance, acid–base homeostasis, maintenance of electrolytes, and waste excretion. The performance of these activities depends on the development of specific cell types in a precise temporal and spatial pattern, to produce a sufficient number of nephrons. Over the past several decades, considerable advances have been made in understanding the molecular basis for this developmental program. Defects in this program result in congenital anomalies of the kidney and urinary tract, which are the leading causes of chronic kidney disease and renal failure in children. These developmental disorders range from renal malformations, such as renal aplasia (absence of the kidney), dysplasia (failure of normal renal differentiation), and hypoplasia (smaller kidneys), to urinary tract abnormalities such as vesicoureteral reflux and duplicated collecting systems. This chapter describes the embryology of the kidney and urinary tract, as a means to understand the developmental origins of these disorders. Human kidney development starts in the fifth week of gestation, and new nephrons are formed until approximately 32–34 weeks gestation [1–3]. Remarkably, nephron endowment is quite variable ranging from 200,000 to 1.8 million nephrons per person [4]. While the human kidney continues to grow after 34 weeks gestation, this occurs due to the growth and maturation of existing nephrons, rather than the formation of new nephrons. The mature mammalian kidney cannot compensate for nephron loss due to renal injury by the de novo generation of nephrons [2, 5]. Therefore, the number of nephrons present at birth in an individual is an important determinant of long-term kidney health. Therefore, reduced nephron number is associated with hypertension and chronic kidney disease [6, 7]. Critical determinants of nephron endowment are structural development and three-dimensional nephron patterning. The formation of kidneys in utero involves the coordinated regulation of critical developmental processes: differentiation,

C. Bates et al.

morphogenesis, and regulation of cell number. Differentiation is the process by which precursor cells or tissues mature into more specialized cells. During kidney development, renal mesenchymal cells have the potential to differentiate into nephron epithelia or stromal cells and interstitial fibroblasts. Morphogenesis describes the process whereby cells and tissues acquire threedimensional patterns. This is particularly important in the kidney, as the three-dimensional relationship between the nephrons, the vasculature, and the collecting system is critical for normal kidney structural function. Finally, the regulation of cell number at different stages of development is crucial. Such regulation maintains a balance between cellular proliferation and programmed cell death or apoptosis. All of these processes are integrated tightly and regulated both spatially and temporally in normal renal development. The molecular control of these developmental processes has been the subject of several recent comprehensive reviews [8–14]. Genetic, epigenetic, and environmental factors all regulate differentiation, morphogenesis, and cell number within the developing kidney. Mutational analyses in animal models have provided significant insights into the genetic control of renal development. Genes critical for kidney development in animal models include transcription factors that act as master regulators of other genes, growth factors that signal to other cells, and adhesion molecules that regulate how cells interact with each other and with the extracellular matrix. Increasingly, analyses of humans with congenital renal malformations (such as renal aplasia or duplex kidneys) have identified gene mutations originally described in animal models [15]. Recent studies have also implicated epigenetic mechanisms (defined as heritable changes in gene activity that are not caused by changes in DNA sequence) in regulating nephron formation. Two major classes of epigenetic molecules that appear to regulate renal development include chromatin remodeling proteins and regulatory RNAs such as miRNAs [16–22]. Finally, environmental influences that may interact with genetic and

1

Embryonic Development of the Kidney

epigenetic factors are also important in determining nephron number and patterning. For example, vitamin A deficiency leads to decreased nephron number in rodents and has been implicated in decreased renal size in humans [23, 24].

Studying the Kidney and Urinary Tract Development The methods for studying the molecular and genetic control of kidney development have continued to evolve over the past several decades. Visualization of tissue morphology and expression of individual genes and proteins in the developing kidney have traditionally been performed on tissue sections by general staining (e.g., hematoxylin and eosin), detecting messenger RNA (mRNA) via in situ hybridization or protein via immunohistochemistry (Fig. 1a–c). The advent of high-throughput technologies to detect gene expression with microarrays and more recently by high-throughput RNA sequencing has resulted in the ability to assay the transcriptome of the developing kidney and/or different kidney tissue compartments in an unbiased fashion. These techniques have led to large public databases that describe the gene expression of the developing kidney, including the GenitoUrinary Development Molecular Anatomy Project (URL: www. gudmap.org) and Eurexpress (URL: www. eurexpress.org) [25–27]. A classical technique to analyze kidney development is to culture rodent embryonic kidneys in vitro as explants. Studies using these methods were the first to show that reciprocal interactions between the metanephric mesenchyme and the ureteric bud are critical to induce the formation of new nephrons and ureteric branching (Fig. 1d) [28]. Moreover, kidney explants still allow one to modulate the expression and function of specific genes and proteins using reagents such as antisense oligonucleotides or blocking antibodies [29, 30]. While these experiments have been illuminating, the growth of embryonic kidney explants differs from kidney development in vivo in several key ways: lack of blood flow,

5

growth limitations from diffusion of the culture media across the air–media interface, and distortions in the three-dimensional kidney architecture as explants flatten in culture. Recently, several methods to generate more physiological and quantifiable three-dimensional reconstructions of developing kidneys and urinary tracts have been developed. One method utilizes exhaustive serial sectioning through developing kidneys, histological staining, projection of each serial image onto a monitor to identify each tissue lineage, and rendering of the serial images into a three-dimensional image (Fig. 1e) [31, 32]. This technique allows for the quantification of both developing nephron structures and the branching ureteric tree. Another method uses optical projection tomography to image through the full thickness of a developing kidney that has been whole mount stained for a specific tissue and also permits the quantification of these elements [33]. Physical, chemical, and genetic strategies can be used to manipulate developing kidneys in vivo. For example, ureteric obstruction in utero in sheep and monkeys results in hydronephrotic kidneys with renal dysplasia [34, 35]. In addition, dietary manipulations including high doses of vitamin A or dietary protein restriction result in kidney and urinary tract defects [36, 37]. Transgenic approaches have also been used to drive gene expression in specific spatiotemporal patterns, usually in the mouse. In these experiments, a transgenic construct consisting of a tissue-specific promoter and the gene of interest is randomly inserted into the genome, leading to expression of that gene in a tissue-specific pattern. The limitations of this approach include: (1) that the random insertion can result in unintended changes in gene expression (due to other nearby promoters/enhancers near the site of integration), (2) that the insertion of the transgene into the genome may lead to loss of function of an endogenous gene, and that (3) epigenetic factors may silence the construct. The increased utilization of bacterial artificial chromosome (BAC) constructs, which contain more of endogenous promoter elements than are found in traditional plasmid constructs, has led to more faithful and reliable transgene expression.

6

Fig. 1 Experimental methods utilized to study kidney development. (a) Hematoxylin and eosin (H&E)-stained tissue section of a control postnatal day 0 mouse kidney. The ureteric bud is outlined in yellow, and the arrow points to the cap metanephric mesenchyme. (b) In situ hybridization in a control mouse embryonic day 16.5 tissue section for the transcription factor, Wt1, which stains the metanephric mesenchyme and developing glomeruli. (c) Immunofluorescent staining in a control embryonic day 14.5 mouse tissue section for the transcription factor, Wt1 (red), and lotus tetragonolobus lectin (LTL, green), which stains the proximal tubule. (d) Embryonic culture of a transgenic embryonic day 11.5 HoxB7GFP mouse kidney,

C. Bates et al.

demonstrating branching ureteric structures (green) after 5 days of growth. (e) 3D reconstruction of an embryonic day 13.5 mouse kidney with the ureteric epithelium depicted in pink and developing nephron types including renal vesicles (blue), comma-shaped bodies (red), S-shaped bodies (purple), and glomeruli (green) (Reproduced with kind permission from Springer Science +Business Media: Sims-Lucas S. Kidney Development: Methods and Protocols, Methods in Molecular Biology, vol. 886, 2012, pp 81, Figure 3F) (f) H&E-stained tissue section of a postnatal day 0 mouse kidney lacking microRNAs in the ureteric lineage using a conditional knockout approach (HoxB7Cre; Dicerflx/flx)

1

Embryonic Development of the Kidney

As opposed to transgenic approaches, homologous recombination is the method whereby a gene is “knocked-out of” or “knocked-into” the mouse genome. Using these methods, a gene of interest is deleted so that it becomes nonfunctional, or a gene (such as a green fluorescent reporter) is added to the genome at a specific locus. A limitation to traditional knockout techniques is that global loss of function of the gene may result in extrarenal effects (such as early embryonic lethality), which can impact or severely limit the study of the gene’s function in the kidney. Given these limitations, it has become more common to perform conditional gene targeting (e.g., with the Cre–loxP system) (Fig. 1f) and/or inducible gene targeting (e.g., with tamoxifen), allowing for kidney- and/or urinary tract-specific gene deletion (using a kidney zebrafish specific Cre-) and/or at a particular time (driving induction of gene targeting with a drug). While most investigators using genetically modified animals utilize mice, a growing number of scientists study kidney development in other model systems, such as avians, zebrafish, and Xenopus. These simple systems are obviously limited by their inability to recapitulate the complex regulation of development previously described in three-dimensional mammalian kidney formation. However, their simplicity has advantages in isolating possible molecular pathways involved in specific renal developmental processes. These systems produce larger number of embryos in a shorter period of time than in mammals. Many of these models, such as zebrafish and Xenopus, have only a one-dimensional pronephric tubule as a kidney. However, many of the genes which pattern such simple structures have important roles in mammalian metanephric kidney development. Increasingly, investigators using have utilized more sophisticated techniques such as transgenic fish to examine the roles of genes or drugs in modifying nephron progenitor populations [38]. Finally, the advent of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPRassociated protein (Cas) techniques should eventually allow relatively quick and easy genetic modifications of any animal model desired [39].

7

Development of the Metanephros The mesoderm forms as one of the three embryonic germ layers during gastrulation. The mammalian kidney develops from the intermediate mesoderm, lying between the somites and lateral plate mesoderm, on the posterior abdominal wall of the developing embryo. In mammals, three pairs of embryonic kidneys develop from the intermediate mesoderm: the pronephros, the mesonephros, and the metanephros (Fig. 2). At their maximal development, the pronephros and mesonephros extend from the cervical to the lumbar levels of the developing embryo. The pronephric and mesonephric nephrons are induced to differentiate by signals from the adjacent pronephric/mesonephric ducts, paired epithelial tubules running in a longitudinal course along the embryo on either side of the midline. The mesonephric duct (also known as the Wolffian duct) continues to grow caudally in the embryos to eventually fuse with the cloaca, which eventually gives rise to the bladder. The pronephros is not functional in mammals, but is the functional kidney in larval fish [40] and frogs [41]. The mesonephros becomes the mature kidney in these lower species and is functional in mammals during embryogenesis. Ultimately, the pronephros and mesonephros largely degenerate in mammals. Portions of the mesonephros and mesonephric duct persist in mammals as the rete testis, efferent ducts, epididymis, vas deferens, seminal vesicle, and prostate in males [42]. In mammalian females, remnants of the mesonephric tubules persist as the epoophroron and paroophoron. The mature mammalian kidney, the metanephros, is derived from two tissues, the ureteric bud and metanephric mesenchyme (see a recent review in Ref. [13]). Starting at approximately embryonic day 10.5 in the mouse and the 5th week of gestation in humans, reciprocal inductive signals cause the ureteric bud to grow out from the caudal portion of the mesonephric duct and the metanephric mesenchyme to condense around the ureteric bud to form nephron progenitors. The ureteric bud ultimately gives rise to the collecting system, including the collecting ducts, renal calyces, renal pelvis, and ureters [2, 43]. In turn, the nephrogenic metanephric mesenchyme

8

Fig. 2 Schematic overview of kidney development. Mammalian kidney development begins with the formation of the nephric duct, which is divided into three segments: pronephros, mesonephros, and metanephros. The pronephros degenerates in mammals, whereas the mesonephros forms the male reproductive organs (rete testis, efferent ducts, epididymis, vas deferens, seminal vesicles, and prostate). The metanephros becomes the mature mammalian kidney and is derived from inductive interactions between the metanephric mesenchyme and the ureteric bud (Reproduced with kind permission from Springer Science +Business Media: Moritz K, et al. Factors Influencing Mammalian Kidney Development: Implications for Health in Adult Life, Morphological Development of the Kidney, Advances in Anatomy and Cell Biology, volume 196, 2008, pp 9–16, figure number 1)

C. Bates et al.

limbs of the loops of Henle, and the distal convoluted tubule [2, 43]. Just after the condensation of nephrogenic mesenchyme around the ureteric bud, stromal metanephric mesenchyme (or renal stroma) develops adjacent to the nephrogenic mesenchyme. The renal stroma develops into perivascular cells, vascular smooth muscle, fibroblasts, mesangial cells, renin-producing cells, and even some peritubular endothelial cells (see below). The transcription factor, Odd-skipped related 1 (Osr1), is one of the several key molecules necessary to specify portions of the posterior intermediate mesoderm to become the mesonephric duct, ureteric bud, and metanephric mesenchyme (nephrogenic and stromal) [44]. Osr1-expressing cells in the intermediate mesoderm have been shown to give rise to most of the cellular components of the metanephric kidney, including the nephron, vascular cells, interstitial cells, and the mesonephric duct (including its derivatives, viz., the ureteric bud/collecting system) [45]. Other molecules critical for specification and development of the mesonephric duct include the transcription factors Paired box 2 (Pax2) [46], Pax8 [47], Lim homeobox 1 (Lhx1) [48], Gata binding protein 3 (Gata3) [49], and the receptor tyrosine kinase, Ret [50]. Many key signaling pathways have been shown to drive reciprocal interactions between the ureteric epithelium, the renal mesenchymal lineages, and the renal vasculature. Ureteric bud outgrowth depends on inductive signals from nephron progenitors [51–53], stromal cells [54–58], and angioblasts [59, 60], as well as from itself [61]. The nephrogenic mesenchyme relies in part on signaling from the ureteric bud and renal stroma for self-renewal and for initiation of nephron formation [8, 11, 62–64]. Subsequent nephrogenesis (i.e., patterning and differentiation of nephron epithelia) is highly dependent on factors from both ureteric epithelial and stromal cells [57, 65, 66].

Nephron Formation differentiates into the epithelial cells that comprise the mature nephron, including the parietal cells and podocytes of the glomerulus, the proximal convoluted tubule, the ascending and descending

The metanephric mesenchyme gives rise to nephrogenic mesenchyme or nephron progenitors, which self-renew and have the capacity to

1

Embryonic Development of the Kidney

9

form the multiple epithelial cell types of the nephron. Much research is geared toward understanding this progenitor cell population, which is critical for determining nephron endowment and thus long-term kidney health. Anatomically, there are several steps that take place in nephron formation. After the ureteric bud has penetrated the metanephric mesenchyme, nephron progenitors condense around the first ureteric ampulla, forming “cap mesenchyme.” As the ureteric bud continues to branch and elongate, the nephrogenic mesenchyme continues to form new caps surrounding each ureteric tip. After the initial few ureteric branches, the earliest cap mesenchymal cells receive spatiotemporal cues to begin the differentiation process to form epithelialized renal vesicles [67]. Subsequent growth and differentiation of the renal vesicle results in formation of the comma-shaped body, which then lengthens to form the S-shaped body. The lower limb of the S-shaped body begins to differentiate into glomerular podocytes. During this time, endothelial cells migrate into the cleft of the lower limb of the S-shaped body and will ultimately form the glomerular capillary loops [68, 69]. Simultaneously, nascent mesangial cells, derived from renal stroma (see below), also migrate into this cleft. Thus, the lower limb of the S-shaped body forms the immature glomerulus.

Concurrently, the middle and upper limbs of the S-shaped body elongate and differentiate into nephron tubules including proximal tubules, loops of Henle (including descending and ascending limbs), and distal convoluted tubules. The terminal ends of the distal convoluted tubules eventually connect to ureteric epithelia, which ultimately form the collecting system (collecting ducts, renal pelvis, and ureters) (Fig. 3). Nephrogenesis repeats in a radial fashion with the first nephrons forming in the juxtamedullary regions and last in the peripheral cortex, until the full complement of nephrons is reached. During prenatal and/or postnatal life, each nephron increases in size and complexity as it matures. Starting in the first month of life, maturing proximal tubules transition from a columnar to cuboidal epithelium, develop microvilli, and increase their tubular dimensions [70, 71]. While the earliest limbs of the Henle loop are located in the renal cortex, subsequent maturation and elongation of these limbs in utero results in the loops pushing through the corticomedullary boundary in term infants [72–74]. Postnatal maturation results in the Henle loops eventually reaching the inner renal medulla in the mature kidney. Thus, the urinary concentrating capacity of newborn infants is limited by a reduced medullary tonicity gradient, due to the relatively shorter

Fig. 3 H&E-stained sections showing the four stages of nephron formation in mice. (a) Image of a renal vesicle, the first stage of nephron formation. (b) Image of a commashaped body that has differentiated from a vesicle. (c) Image of an S-shaped body, the third stage of nephron formation. (d) Image of an immature glomerulus that

differentiated from the lower limb of the S-shaped body (Reproduced with kind permission from Springer Science +Business Media: Sims-Lucas S. Analysis of 3D Branching Pattern: Hematoxylin and Eosin Method, Methods in Molecular Biology, volume 886, pp 73–86, 2012, Figure 3, panels A–D)

10

loops of Henle. Finally, as the distal convoluted tubule matures, a portion of the cells are found in close proximity to the future vascular pole of the developing glomerulus, where they develop into the macula densa [72].

Specification of Nephron Progenitors/ Cap Mesenchyme Differentiation of the intermediate mesoderm and metanephric mesenchyme into nephron progenitors and their derivatives is genetically defined by the sequential upregulation of several transcription factors, cell adhesion molecules, and growth factors. The intermediate mesoderm and early metanephric mesenchyme express the transcription factors Sal-like 1 (Sall1) [75], Sine oculis homeobox homolog 1 (Six1) [76], Eyes absent homolog 1 (Eya1) [77, 78], and the secreted peptide growth factor, Glial-derived neurotrophic factor (Gdnf) [79]. Induction of cap mesenchyme/nephron progenitors by the ureteric bud tips is marked by expression of transcription factors such as Wilms tumor 1 (Wt1) [80]; Cbp/p300interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1 (Cited1) [81]; and Sine oculis homeobox homolog 2 (Six2) [82], as well as the transmembrane molecules cadherin-11 [83] and α8 integrin [84]. The earliest epithelial derivative of the cap mesenchyme, the renal vesicle, is marked by the transcription factors Pax2 [85] and Lhx1 [86]. The use of tissue-specific gene knockouts generally via conditional transgenic techniques has revealed the importance of several transcription factors (including many mentioned above) in the specification of the cap mesenchyme. Conditional homozygous deletion of Eya1 [78], Six1 [76], Pax2 [87, 88], Wt1 [80], Sall1 [75], Six2 [82], or Lhx1 [86, 89] leads to bilateral renal aplasia or severe renal dysgenesis from defects in cap mesenchyme specification and/or differentiation; these mesenchymal defects are often accompanied by ureteric induction and/or branching abnormalities due in large part to loss of GDNF signaling from the metanephric mesenchyme. Pax2 mutant mice generate a metanephric

C. Bates et al.

mesenchyme that is unable to differentiate into nephrons and fail to form the mesonephric duct, which is required for ureteric bud induction [88]. In Lhx1 [86, 89] and Sall1 [75] mutants, the metanephric mesenchyme does induce ureteric bud formation, but it fails to elongate and branch, and the mesenchyme is once again unable to differentiate into nephrons. In Wt1 mutants, a defective metanephric mesenchyme is formed, but rapidly undergoes apoptosis [80]. Six2, a specific marker of nephron progenitors, is required for the maintenance of progenitor cells, but not for nephron differentiation; deletion of Six2 in mice results in the formation of ectopic nephron tubules and the rapid depletion of nephron progenitor cells [82]. Similarly, the p53–E3 ubiquitin ligase, murine double minute 2 (Mdm2), appears critical for the maintenance of nephron progenitor cells [91]. Recent studies have identified factors that govern the delicate balance of self-renewal and differentiation of nephron progenitors, including WNT genes. Studies from the mid-1990s showed that lithium chloride, a potent inducer of Wnt signaling, was able to drive tubulogenesis in isolated rodent metanephric mesenchyme cultures [92–94]. More recently Wnt9b, secreted from ureteric bud cells, was shown to be required for the differentiation of nephron progenitor cells. Genetic deletion of Wnt9b resulted in a failure of nephron progenitors to undergo the mesenchymal to epithelial transition that is required to form the renal vesicle [95]. A subsequent study revealed that Wnt9b, along with signals from the renal stroma (see below), plays an essential role in mediating the decision of nephron progenitors to self-renew or differentiate [64, 96]. Another major signaling pathway that has been shown to mediate nephron progenitor survival is the fibroblast growth factor (FGF) signaling pathway. FGF ligands are secreted peptides that bind and signal through their receptor tyrosine kinases, FGF receptors (FGFRs). Isolated nephrogenic zone cell culture studies revealed that addition of FGF1, 2, 9, and 20 ligands drives the expression of nephron progenitor markers and progenitor proliferation [97]. More recently, in vivo mouse studies showed that Fgf9 and Fgf20 are critical for

1

Embryonic Development of the Kidney

maintaining nephron progenitor survival, proliferation, and competence to respond to inductive signals; furthermore, FGF20 mutations in humans were shown to be associated with severe renal dysplasia [98]. Other work in mice has identified that the Fgfrs critical for metanephric mesenchyme development are Fgfr1 and Fgfr2. Conditional deletion of Fgfr1 and Fgfr2 in the metanephric mesenchyme leads to severe renal dysgenesis [99–101]. Several studies have shown that a balance between cell survival and apoptosis is necessary for normal nephron progenitor function. Classic in vitro studies using isolated metanephric mesenchyme have shown that nephron progenitors undergo massive apoptosis when cultured without an inducer [102]. Coculture with isolated ureteric buds or heterologous inducers, such as embryonic spinal cords, dampens apoptosis and drives progenitor survival [43, 52]. Other studies have identified several factors that when added to metanephric mesenchyme or nephrogenic zone cell cultures drive progenitor survival, including transforming growth factor-β2 (TGF-β2), TGFα, leukemia inhibitory factor (LIF), epidermal growth factor (EGF), FGF2, and bone morphogenetic protein 7 (BMP7) [62, 103–105]. Whether some or all of these factors act as endogenous nephron progenitor inducers remains to be determined. Counterbalancing cell survival, apoptosis is required for normal nephron progenitor function. Moreover, suppression of apoptosis via pharmaceutical or genetic means leads to kidney malformations including abnormal ureteric branching and defective nephrogenesis [106, 107]. Relative “overabundance” of nephron progenitors also leads to epithelial and/or stromal cell defects [108, 109]. Recent studies have revealed the importance of epigenetic mechanisms that regulate nephron progenitor specification, survival, and potential for differentiation. Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histones, which then modulate (usually stimulate) gene transcription. Recent work has revealed that Class I HDACs are highly expressed in nephron progenitors and are required for the proper expression of several key developmental genes

11

including Osr1, Eya1, Pax2, Wt1, and Wnt9b (among others) [16]. MicroRNAs (miRNAs) are small noncoding RNAs that bind to specific mRNA targets to block translation and promote mRNA degradation. Conditional targeting of dicer, an enzyme required for the processing of all miRNAs, in mouse nephron progenitors, led to a loss of the progenitors due to excessive apoptosis, likely from upregulation of the proapoptotic protein, Bim [22]. A more recent study revealed that conditional deletion of a specific miRNA cluster, the miR-17~92 complex, in nephron progenitors led to decreases in progenitor proliferation, fewer numbers of nephrons, proteinuria, and podocyte damage. Moreover, this report was the first to identify a specific miRNA cluster essential for kidney development [110].

Nephron Induction The initial differentiation step of nephron progenitors is to undergo a mesenchymal to epithelial transition to form the renal vesicle. In vitro experiments utilizing isolated rodent metanephric mesenchymal rudiments (similar to and including some of the survival studies noted above) have identified exogenous factors that stimulate nephron progenitors to undergo tubulo-epithelial differentiation [52]. Some of these growth factors can act alone or in concert with others and include FGF2 [111], LIF [63, 105, 112], TGFβ2 [105, 113], growth/differentiation factor-11 (GDF-11) [105, 114], and WNT1/4 [115, 116]. Sequestration of Wnt ligands in intact rodent kidney explants by addition of secreted frizzled-related proteins (sFrps) leads to decreases in mesenchyme-derived tubulogenesis [117]. More recent mouse genetic experiments have identified at least some of the critical endogenous pathways and growth factors necessary for the induction of the mesenchymal to epithelial transition. For example, global deletion of Wnt4, normally expressed in renal vesicles, did not perturb cap mesenchyme formation; however, the mutant nephron progenitors were completely unable to form renal vesicles [95]. Conditional deletion of Fgf8 in the metanephric mesenchyme leads to a block of nephrogenesis beyond the renal

12

vesicle stage. Fgf8 likely normally acts with Wnt4 to drive Lhx1 expression [118, 119]. Interestingly, global deletion of Fgfr-like 1, a membrane-bound Fgf receptor that lacks an intracellular tyrosine kinase domain, also leads to a block in nephrogenesis similar to Fgf8 conditional mutants [120].

C. Bates et al.

glomeruli and proximal tubules [127]. In vivo, conditional deletion of Notch2 or Rbpsuh in mouse metanephric mesenchyme leads to an absence of proximal tubules and glomerular epithelium [128]. Finally, ectopic Notch expression in nephron progenitor cells results in the premature differentiation of the progenitors into proximal nephron epithelia [130].

Nephron Segmentation Glomerulogenesis Establishment of a proper proximal–distal axis is critical for normal nephron segmentation. Negative reciprocal interactions between Wt1 and Pax2 at early stages of nephron development appear vital to proximal–distal axis patterning [121–123]. In the S-shaped body, Wt1 is localized to the lower limb and inhibits Pax2 expression, which together drives cells toward podocyte fates [124]. Transgenic mice with overexpression of Pax2 throughout the embryo including developing nephrons develop glomerular defects and renal cystic dysplasia [125]. In contrast Pax2 is expressed in the upper limb of the S-shaped body and represses Wt1 expression, stimulating these cells to become proximal and distal tubular nephron segments [118, 126]. Two other transcription factors critical for proximal–distal axis patterning of the nephron include Lhx1 and Brain specific homeobox 1 (Brn1), both of which are expressed at the renal vesicle stage. Conditional deletion of Lhx1 throughout the metanephric mesenchyme blocks nephrogenesis at the renal vesicle stage and also leads to a loss of Brn1 expression [86]. Conditional targeting of Brn1 in the metanephric mesenchyme does not block proximal nephrogenesis; however, the loop of Henle fails to form, and distal convoluted tubules fail to terminally differentiate [73]. These results suggest that Lhx1 acts earlier in nephron patterning than Brn1, which is a critical distal nephron patterning. Notch receptor signaling, mediated largely by Recombining binding protein suppressor of hairless (Rbpsuh), appears critical for proximal nephron patterning [127–129]. Use of a Notch inhibitor in mouse metanephric kidney explants led to a loss of proximal cell fates, including

Glomerulogenesis is initiated when the commashaped body differentiates into the S-shaped body [2, 131]. During this time, immature podocytes along the lower limb are highly proliferative and have a columnar shape with apical cell attachments and a single-layer basement membrane [131]. Concurrently, endothelial and mesangial cell progenitors are recruited into the lower cleft of the S-shaped body, which will become the vascular pole [132]. While mesangial cells originate from the renal stroma (see below), the developmental origin of the glomerular endothelium is still unclear. Transplantation of avascular rodent embryonic kidney rudiments under neonatal kidney capsule led to the formation of endothelial precursors or angioblasts originating from the graft metanephric mesenchyme [132–134]. However, engraftment of embryonic rat kidney rudiments onto avian chorioallantoic membrane led to vascular ingrowth of avian vessels into the rat glomeruli [135]. As will be expanded on in the Vascular Development section below, it is likely that both processes/sources contribute to the formation of glomerular capillaries. As the S-shaped body matures, the lower cleft transforms into a cup shape configuration. At this time the podocytes lose their proliferative ability [136] and differentiate, forming foot processes and slit diaphragms, specialized intracellular junctions critical for proper glomerular filtration [137, 138]. Concurrently, the composition of the glomerular basement membrane changes from laminin-1 to laminin-11 and from α -1 and α -2 type IV collagen chains to α -3, α -4, and α -5 type IV collagen chains [139]. Several mouse knockout mice models have shown how

1

Embryonic Development of the Kidney

failure in these transitions leads to structural and functional glomerular basement membrane defects [140–142]. At this stage of development, the nascent mesangial cells act as a scaffold for the formation of the glomerular capillary loops and ultimately form the supportive core for the entire glomerulus via the deposition of extracellular matrix [143, 144]. Developing glomerular endothelial cells branch extensively during this time and begin differentiating into fenestrated endothelia [2] (see Vascular section below). By 32–34 weeks gestation, glomerulogenesis/ nephrogenesis ceases in humans, whereas it persists in mice and rats for 7–10 days following full gestation [2]. In newborn humans, the superficial glomeruli are the most immature and are smaller than the deeper juxtamedullary glomeruli [71]. While no new glomeruli are formed after birth, they continue to grow and mature postnatally, reaching their adult size at approximately three and a half years of age [71].

Molecular Control of Podocyte Terminal Differentiation Transcription factors and epigenetic factors, including microRNAs, have been shown to be critical for podocyte differentiation. Examples of essential transcription factors include Wt1, podocyte expressed 1 (Pod1), Lim homeobox 1b (Lmx1b), and Mafb. Several studies utilizing murine genetic knockout models of Wt1 have demonstrated its critical roles in mediating podocyte differentiation [145–148]. In humans, WT1 mutations can lead to diffuse mesangial sclerosis, characterized by podocyte differentiation defects resulting in varied glomerular lesions and proteinuria, and can occur as an isolated disease or in association with Denys–Drash or Frasier syndromes [149–152]. Deletion of Pod1, expressed in stromal cells, leads to nonautonomous podocyte defects at the capillary loop stage in mice [153]. Genetic deletion of Lmx1b or Mafb leads to podocyte differentiation defects past the capillary loop stage [154, 155]. Furthermore, mutations in the LMX1b gene in humans lead to nail–patella syndrome, which is often associated

13

with glomerular basement membrane thickening and proteinuria that can progress to chronic kidney disease [156, 157]. Three studies recently showed the importance of microRNAs in maintaining differentiated podocytes in the mouse. Targeted ablation of dicer in murine podocytes, resulting in a loss of all miRNAs, led to podocyte injury, severe proteinuria, and tubular damage starting 2 weeks after birth [20, 158, 159].

Molecular Control of Glomerular Capillary Tuft Development There are several signaling cascades that have been implicated in the homing and maturation of the endothelial and mesangial precursors to form the glomerular capillary tuft. Vascular endothelial growth factor (VEGF), which is secreted from the podocytes at the S-shaped body stage, promotes recruitment of endothelial precursors to the vascular cleft [160, 161]. Angiopoietin-1 and -2, growth factors expressed by podocytes and mesangial cells, respectively, are also critical for normal glomerular capillary development [162]. Mesangial cell recruitment into the cleft is largely mediated by the secretion of plateletderived growth factor (PDGF)-B by endothelial cells, which binds PDGF receptor-β (PDGFRβ) on the mesangial cell progenitors [163]. Mice that lack either Pdgfβ or Pdgfrβ fail to form glomerular capillary tufts demonstrating the importance of mesangial cell recruitment [164, 165]. Finally, Notch2 and its ligand Jagged1 are critical for glomerular endothelial and mesangial cell development. Notch2 hypomorphic mice and Notch2/ Jagged1 compound heterozygous mice develop glomerular aneurysms and possess no mesangial cells [166].

Renal Stroma The renal stroma, like the nephrogenic mesenchyme, is derived from Osr1-positive intermediate mesoderm and the metanephric mesenchyme [167, 168]. A hallmark of the initial renal stroma is the expression of the transcription factor,

14

Foxd1, which is seen as early as E11.5 in the mouse. The renal stroma is initially located at the periphery of the kidney and interdigitates between the developing nephron units and ureteric tips. One function of the early renal stroma is to support framework for the developing vessels, nephron progenitors, and ureteric epithelia. As embryonic kidney development progresses, stromal cells are present in both the peripheral renal cortex and the medulla surrounding developing collecting ducts. At this time, the cortical stroma expresses Foxd1, Aldehyde dehydrogenase 1 family, member A2 (Raldh2), Retinoic acid receptor α (Rarα), and Rarβ2, while the medullary stroma expresses Fgf7, Pod1, and Bmp4. Many of these stromally expressed genes have been shown to be critical for nephrogenesis and ureteric branching morphogenesis by virtue of mouse knockout studies [54, 55, 57, 58, 153, 169]. At birth, many of the developmental stromal cells have undergone apoptosis and are replaced by nephron segments such as loops of Henle [170]. Many stromal derivatives do survive giving rise to fibroblasts, lymphocyte-like cells, glomerular mesangial cells, renin-expressing cells, vascular smooth muscle cells, pericytes, and a subpopulation of peritubular endothelial cells [168, 170, 171]. As noted, signaling from the renal stroma is critical for ureteric morphogenesis. Three genes/ pathways expressed within the stroma, retinoic acid, Foxd1, and Pod1, modulate ureteric branching by regulating expression of Ret, a receptor tyrosine kinase expressed in ureteric tips and required for ureteric development (see below). Vitamin A is converted to its active form, retinoic acid, by the enzyme Raldh2 in the renal stroma. Moreover, blockade of retinoic acid signaling in mice, by deletion of Raldh2 or by combined deletion of the retinoic acid receptors, Rarα and Rarβ2, leads to hypoplastic kidneys with a reduction in the number of ureteric branches; the ureteric branching defects are linked to the downregulation of Ret expression in mutant embryos, which in the case of the retinoic acid receptor mutants can be rescued by forced re-expression of Ret in the ureteric tissues [55, 56, 172]. Foxd1 (expressed in cortical stroma

C. Bates et al.

and the renal capsule) or Pod1 (found in medullary stroma) appears to appropriately restrict Ret expression to ureteric tips; genetic deletion of either gene leads to mis-expression of Ret throughout the entire ureteric tree and subsequent ureteric branching defects [54, 57, 153, 173]. Cross talk from the stroma is also critical for nephron development. Mouse genetic studies show that Foxd1 and Pod1 are necessary for normal nephron patterning (in addition to ureteric morphogenesis) [54, 153]. Loss of Foxd1 in mice leads to premature differentiation of stromal cells, which inhibits Bmp7-mediated nephron progenitor differentiation [174]. Two recent studies have shown how complete ablation of renal cortical stroma with diphtheria toxin leads to abnormally thickened nephron progenitor caps and a decreased ability of progenitors to differentiate [64, 175]. Mechanistically, it appears that loss of the protocadherin Fat4 in the stroma perturbs the activity of the transcription factors, Yap and Taz, which in turn disrupts Wnt9b signaling and nephron differentiation [64]. Thus, in addition to providing a “framework” for the rest of the developing kidney, the renal stroma actively signals to other renal lineages and differentiates into cells that populate the mature kidney.

Vascular Development of the Kidney The adult kidney receives approximately 25 % of the cardiac output. Furthermore, the adult kidney has a high complex vascular network with different functions and therefore different specialized endothelia depending on location [176]. Specifically, three major types of endothelial cells are present within the kidney, including fenestrated (in glomerular capillaries), fenestrated with diaphragms (in peritubular capillaries and ascending vasa recta), and continuous capillaries (in descending vasa recta) (Fig. 4). Not surprisingly, these various endothelial cell types have heterogeneous expression profiles and often appear to have different developmental origins [21, 177, 178].

1

Embryonic Development of the Kidney

15

Fig. 4 Electron microscopy demonstrating the varied renal endothelium. (a, e) Glomerular capillaries contain fenestrated endothelium without diaphragms (e, arrows) and share a basement membrane (*) with podocyte foot processes (large arrowhead) that are separated by slit diaphragms (small arrowhead). (b, f, g) Peritubular capillaries have fenestrated endothelial cells that are covered with diaphragms (f, g, arrows) and have a thick basement membrane (*) separating them from the tubular cells. (c, h, i) Ascending vasa recta (AVR) also have fenestrated

endothelium with diaphragms (c, h, i, arrow). (d, h, i) Descending vasa recta (DVR) possess endothelium that is non-fenestrated, thick, and continuous (d, h, i). RBC red blood cell, EC endothelial cell. Panels (a–d) scanning electron micrographs. Panels (e–i) transmission electron micrographs (Reproduced with kind permission from Springer Science+Business Media: Stolz DB and SimsLucas S. Unwrapping the origins and roles of the renal endothelium, Pediatr Nephrol. 2015;30(6):865–72, Figure 2)

Angiogenesis Versus Vasculogenesis

progenitors (marked by Flk1/Vegfr2) form primitive vascular networks, particularly within the renal stroma, that subsequently join with and are pruned by the angiogenic vessels [182]. The vasculogenic endothelial cell progenitors within the kidney appear to arise from the Osr1-expressing intermediate mesoderm, as is the case with the rest of the metanephric kidney [45]. Finally, specification of the endothelium (whether angiogenic or vasculogenic in origin), including arterial, venous, capillary, or lymphatic fates, is driven by growth factor signaling pathways and

Blood vessels can form by angiogenesis, in which new vessels sprout from existing vessels, or by vasculogenesis, in which de novo vessels form from endothelial progenitors (Fig. 5). Extensive linage tracing experiments and transplantation studies have shown that both of likely occur in renal vascular formation [176, 179–181]. The early renal artery and efferent arterioles appear to be primary sites from which new angiogenic vessels sprout within the developing kidney. Simultaneously, renal endothelial

16

C. Bates et al.

Fig. 5 Schematic diagram of vascular formation in the developing mouse kidney. Top panels. Angiogenic vessels (red) grow out from the major branches of the renal artery and track with the branching ureteric epithelium (orange). Middle panels. Vasculogenic vessels form from progenitor cells (yellow, middle panel) within the metanephric mesenchyme (blue) and form a primitive vascular plexus (yellow, right panel). Bottom panels. Schematic

diagrams depicting how a combination of angiogenesis and vasculogenesis likely leads to vessel formation in the kidney. E10.5–12.5 = embryonic days 10.5–12.5 (Reproduced with kind permission from Springer Science +Business Media: Stolz DB and Sims-Lucas S. Unwrapping the origins and roles of the renal endothelium, Pediatr Nephrol. 2015;30(6):865–72, Figure 1)

transcription factors, including Vegf, Ephrin, Notch, and Sox [183].

peritubular capillaries has been less well defined. Recent studies, however, have found that peritubular capillaries arise from a combination of resident endothelial progenitors as well as invading angiogenic vessels [182, 184, 185]. One intriguing study found that Foxd1-positive renal cortical stroma cells give rise to a subset of the peritubular endothelia but not the glomerular endothelia [184].

Origins of the Peritubular Capillary Endothelia While the formation of glomerular capillaries has been extensively studied (see above), the origin of

1

Embryonic Development of the Kidney

Molecular Control of Renal Vascular Development A key signaling pathway mediating renal vascular development is the VEGF pathway. VEGF ligands are expressed early in the metanephric mesenchyme and later in the developing glomerular podocytes, distal tubules, and collecting ducts and at low levels in the proximal tubules [68, 69]. Developing endothelial cells, including those that arise from existing vessels and those forming de novo, express VEGF receptors; thus, VEGF signaling appears to drive both angiogenesis and vasculogenesis within the kidney. Interestingly, Vegfr2 is present on the apical surface of ureteric epithelium, which likely accounts for the stimulatory role of Vegf on ureteric growth [132, 186]. Hypoxia-inducible factors (HIFs), a family of transcriptions factors, are likely master regulators of angiogenesis and vasculogenesis within the developing kidney [187]. These molecules are activated during periods of low oxygenation, as occurs during embryogenesis, and are downregulated postnatally. The HIF genes are largely located in the nephrogenic zone, including podocytes, developing collecting ducts, and developing endothelial cells [187, 188]. HIF proteins induce expression of VEGF ligands, Vegfr1, and Vegfr2 during kidney development by directly binding to hypoxia-responsive elements on those genes [189–192]. Angiopoietin (Ang) growth factors that bind to Tie receptors also appear to have critical roles in renal vascular development and are at least in part regulated by HIF and VEGF signaling [193, 194]. Ang1, which is expressed in the metanephric mesenchyme, maturing nephron tubules, and podocytes, signals through Tie2, which is expressed on endothelial cells [195]. Conditional deletion of Ang1 or Tie2 in mice leads to glomerular capillary defects including endothelial cells that do not attach to the basement membrane [196, 197]. Ang2, expressed in vascular smooth muscle cells and pericytes, binds to Tie1 that is expressed by endothelial cells. Genetic deletion of Ang2 leads to upregulation of Tie2 signaling and significant defects in renal peritubular capillaries [198].

17

The Notch signaling pathway appears to regulate renal angiogenic vessel outgrowth [199]. Notch receptors induce sprouting by stimulating the expression of Vegfr2 in vascular tip cells. Simultaneously Notch inhibits Vegfr2 signaling in adjacent vascular stalk cells, causing them to remain dormant. Thus Notch regulates the pattern of branching in angiogenic vessels.

Collecting System Development Ureteric bud formation begins in the 5th week of gestation in humans and at embryonic day 10.5 in mice. As noted previously, signals from the metanephric mesenchyme cause the ureteric bud to form from the mesonephric duct and then invade the mesenchyme. Overall, collecting duct system development includes (i) ureteric bud outgrowth, (ii) branching of the ureteric bud, and (iii) patterning of the collecting duct system, all of which is discussed in more detail below.

Ureteric Bud Induction and Outgrowth Failure of ureteric bud outgrowth results in renal aplasia, which can occur unilaterally or bilaterally [200]. The GDNF–RET signaling pathway is crucial for bud outgrowth. The receptor tyrosine kinase RET and its coreceptor GFRα1 are expressed in the mesonephric duct, the initial ureteric bud, and later in the branching ureteric tips, while its ligand, GDNF, is present in the metanephric mesenchyme (Fig. 6) [201–203]. Targeted deletion of Gdnf, Ret, or Gfrα1 in mice generally results in bilateral renal aplasia due to a lack of ureteric bud outgrowth [202, 204–209]. Heterozygous mutations of RET have also been identified in humans with bilateral renal aplasia, and a rare RET polymorphism has been reported in individuals with nonsyndromic vesicoureteral reflux [210, 211]. Moreover, the renal aplastic phenotype is not fully penetrant in a subset of Gdnf / or Ret/ mutant mice [202, 204], suggesting that other molecular pathways play a role in ureteric bud outgrowth. Some examples of other pathways include signaling through integrins such as

18

C. Bates et al.

Fig. 6 Schematic diagram of the molecular control of ureteric bud induction. GDNF is secreted from the metanephric mesenchyme and binds to its receptor, Ret (and its coreceptor GFRα1) on the mesonephric duct, to induce ureteric bud formation. Slit2/Robo2 and FoxC1 inhibit the domain of GDNF expression and thus limit ureteric

bud induction to a single site from the mesonephric duct. Sprouty1 (in the mesonephric duct) and Bmp4 (in tailbudderived mesenchyme around the mesonephric duct) repress GDRF–Ret signaling and thus restrict ureteric bud induction to its proper site

α8 integrin [84] and enzymes involved in proteoglycan synthesis such as heparan sulfate 2-sulfotransferase (Hs2st) [212]. Many studies have focused on the molecular mechanisms that regulate GDNF–RET expression and/or signaling. Prior to kidney development, Ret is expressed throughout the mesonephric duct, and Gdnf is present throughout the intermediate mesoderm adjacent to the mesonephric duct [50, 201]. At the time of ureteric bud induction, Gdnf expression becomes restricted to the posterior intermediate mesoderm next to the site of ureteric bud outgrowth; once the ureteric bud has invaded the mesenchyme, Ret expression becomes restricted to ureteric bud tips [50]. In vitro studies with Gdnf-soaked agarose beads show that the entire length of the mesonephric duct is competent to respond to Gdnf by initiating ectopic ureteric bud formation [201, 213]. Moreover, mice that ectopically express Gdnf or Ret in vivo develop renal malformations such as duplex kidney and hydronephrosis [214, 215]. Together, these data show that GDNF–RET signaling is highly spatially regulated for a single ureteric bud to form in the correct location from the mesonephric duct.

At least three genes, Foxc1, Slit2, and Robo2, are thought to be crucial in restricting Gdnf to the posterior intermediate mesoderm (Fig. 6). Homozygous mutant mice for all three genes develop ectopic ureteric buds, multiple ureters, hydroureter, and anterior expansion of Gdnf expression [216, 217]. Foxc1 encodes a transcription factor co-expressed with Gdnf in the metanephric mesenchyme [216]. In the central nervous system, the secreted protein Slit2 functions as a chemorepellent during migration of axons that express its receptor Robo2 [218, 219]. In the developing kidney, Slit2 is expressed in the mesonephric duct, and Robo2 is detected in the metanephric mesenchyme [220]. ROBO2 missense mutations in humans have been identified in families with vesicoureteral reflux and/or duplex kidneys [221]. Two other genes, Sprouty1 (Spry1) and Bmp4, act in a negative feedback loop with GDNF–RET signaling (Fig. 6). Loss of Spry1, which is normally expressed in the mesonephric duct, results in ectopic ureteric bud induction, multiple ureters, multiplex kidneys, and hydroureter [222, 223]. Spry1 mutant embryonic kidneys have increased expression of Gdnf and GDNF–RET

1

Embryonic Development of the Kidney

target genes and have increased sensitivity to GDNF-induced ureteric induction in organ culture. Bmp4 is expressed in the tailbud-derived mesenchyme (different than renal mesenchyme) immediately next to the mesonephric duct and ureteric bud [169, 224]. Mice heterozygous for Bmp4 have ectopic or duplicated ureteric buds, resulting in hypodysplastic kidneys, hydroureteronephrosis, and ureteral duplications [225, 226]. In vitro, Bmp4 has been shown to block the ability of Gdnf to induce ureteric bud outgrowth from the mesonephric duct [85, 227]. BMP4 mutations have also been described in humans with renal tract malformations [228]. The downstream effects of GDNF–RET signaling, namely, ureteric bud proliferation, survival, and ureteric outgrowth and branching, are mediated by the transcription factors, Etv4 and Etv5. Combined deletion of Etv4 and Etv5 causes bilateral renal aplasia in mice [229]. Etv4 and Etv5 drive expression of several critical genes in the ureteric bud tip, including Wnt11, Cxcr4, Mmp14, Myb, and Met [229]. Furthermore, genetic deletion studies in mice have shown that Wnt11 is necessary for normal Gdnf expression in the metanephric mesenchyme [230].

Renal Branching Morphogenesis After growing into the metanephric mesenchyme, the ureteric bud bifurcates into a T-shaped structure. The ureteric bud then continues to branch, ultimately generating about 15 generations of branches, with the earliest branches remodeling to form the calyces and renal pelvis [231]. The process of ureteric branching includes (1) expansion of the ureteric bud at its leading tip (termed the ampulla), (2) division of the ampulla to form new branches, and (3) elongation of newly formed branches [232, 233]. In humans, during the first 9 generations of branching, ureteric bud tips induce formation of new nephrons from the surrounding cap mesenchyme at about a 1:1 ratio [2]. Ureteric bud branching is completed by the 20th–22nd week of human gestation, and subsequent collecting duct maturation occurs by elongation of peripheral (cortical) segments and

19

remodeling of central (medullary) segments [2]. At this stage, four to seven new nephrons are induced around each tip of a terminal collecting duct branch [2, 43]. Localized cell proliferation contributes to initial ureteric bud outgrowth from the mesonephric duct, formation and growth of ampullae, and elongation of ureteric branches [61, 108, 234, 235]. Cell survival is also critical for normal renal branching morphogenesis; defects in cell survival are associated with renal cystic dysplasia and urinary tract dilatation. Moreover, targeted deletion of bcl2 [236] and AP-2 [237], genes critical for cell survival, results in increased apoptosis and collecting duct cysts in mice. In addition, experimental models of fetal and neonatal urinary tract obstruction lead to apoptosis in dilated collecting ducts [238, 239]. Several signaling pathways are necessary for branching morphogenesis. In addition to its role in ureteric bud induction, GDNF–RET signaling has been shown to be critical for ureteric branching in vivo and in vitro [213, 215]. As noted, Wnt11, expressed in ureteric tips, is necessary for maintaining normal Gdnf expression; conversely, Wnt11 expression is reduced when Gdnf signaling is absent. Furthermore, Wnt11 mutant mice have defective ureteric branching morphogenesis and thus develop renal hypoplasia [230, 240]. Finally, conditional targeting of β-catenin, a key mediator of canonical Wnt signaling, in the ureteric lineage results in aberrant branching, loss of ureteric bud tip gene expression, and premature expression of differentiated collecting duct genes [241, 242]. Fibroblast growth factor signaling is also critical for ureteric branching. In vitro studies have shown that exogenous Fgf ligands differentially modulate ureteric bud growth and proliferation [243]. FGF10 preferentially stimulates proliferation at ureteric bud tips, whereas FGF7 increases cell proliferation throughout the developing collecting ducts [243]. In vivo, global deletion of Fgf7 or Fgf10 in mice results in ureteric branching defects and hypoplastic kidneys [58, 244]. Conditional targeting studies in mice have revealed that Fgfr2 is likely the key Fgf receptor mediating effects on ureteric branching [245–247]. Loss of

20

Fgfr2 in the ureteric bud results in hypoplastic ureteric ampullae with reduced proliferation and increased apoptosis, ultimately leading to a significant reduction in ureteric branching and hypoplastic kidneys. In addition, an interesting study revealed that while combined loss of Sprouty1 and Gdnf in mice largely rescues ureteric defects compared to when either locus is deleted alone, additional loss of Fgf10 in the combined mutants led to complete loss of ureteric branching and renal aplasia [248]; thus, FGF signals appear to be able to largely substitute for GDNF in promoting ureteric morphogenesis in the absence of Sprouty1. Finally, a combination of in vitro and in vivo experiments revealed that Fgf signaling acts in a coordinated fashion with Wnt11 and Gdnf to regulate ureteric morphogenesis, in concert with Sprouty genes [249].

Patterning of the Medullary and Cortical Collecting Ducts From the 22nd–34th week of human gestation [2] and embryonic day 15 birth in mice [43], the cortical (peripheral) and medullary (central) regions of the kidney become established. The relatively compact, circumferential renal cortex comprises approximately 70 % of the mature kidney volume [250]. The renal medulla develops modified a cone shape and occupies the remainder of the mature kidney volume [250]. The apex of the medullary cone consists of collecting ducts converging in the inner medulla and is termed the papilla. Ultimately, medullary collecting ducts become morphologically distinct from cortical collecting ducts. Medullary collecting ducts become elongated and linear and remain relatively unbranched in a region devoid of glomeruli. In contrast, collecting ducts in the renal cortex remain branched and induce nephrogenic cap mesenchyme to form nephrons throughout nephrogenesis. These morphological differences are likely due in part to distinct axes of growth in the developing renal cortex and medulla. The renal cortex grows circumferentially, which preserves the organization of the peripheral tissues, including

C. Bates et al.

differentiating glomeruli, nephron tubules, and collecting ducts [250]. In contrast, the developing renal medulla expands longitudinally, perpendicular to the axis of cortical growth, due to elongation of outer medullary collecting ducts [250]. Stromal cells may be a source of stimulatory cues for the medullary growth [250]; studies have shown that mice lacking the stromal transcription factors Foxd1 and Pod1 have abnormal medullary collecting duct patterning [54, 66, 251]. Finally, apoptosis appears to participate in remodeling the branched medullary ureteric tissues into elongated tubules, as programmed cell death normally occurs prominently in developing medullary ureteric epithelia that become the papilla, calyces, and renal pelvis [108]. Multiple genes have been implicated in the differentiation of cortical and medullary collecting ducts, including those that encode for soluble growth factors (Fgf7, Fgf10, Bmp4, Bmp5, and Wnt7b), proteoglycans (Gpc3), cell cycle regulatory proteins (p57KIP2), and components of the renin–angiotensin axis (angiotensin and angiotensin type 1 and 2 receptors). Fgf7 mutant mice have marked papillary underdevelopment, while Fgf10 null kidneys exhibit medullary dysplasia with fewer loops of Henle and medullary collecting ducts, increased medullary stroma, and enlargement of the renal calyx [58, 244]. The ability of FGF ligands to bind properly to their receptors requires interactions with cell surface proteoglycans, including glypicans [252]. Glypican-3 (GPC3) is required for normal medullary patterning in humans and mice [253, 254]. Moreover, the medullary dysplasia observed in Gpc3-deficient mice appears to result from unrestrained proliferation and overgrowth of the ureteric bud and collecting ducts, followed by aberrant apoptosis [253, 254]. The Gpc3/ medullary defects appear to be driven by altered responses of mutant collecting duct cells to growth factors including Fgfs [254–256]. Finally, mice lacking the cell cycle protein p57KIP2 demonstrate medullary dysplasia, with fewer inner medullary collecting ducts [257]. Together, these studies reveal the importance of balanced cell proliferation and apoptosis in medullary collecting duct patterning.

1

Embryonic Development of the Kidney

Proper elongation and growth of medullary collecting ducts also appears to rely on oriented cell divisions. Studies have shown that canonical Wnt signaling in collecting ducts via Wnt7b leads to proper oriented cell division and survival [258, 259]. Furthermore, α3β1 integrin and the receptor tyrosine kinase c-Met act in concert to regulate Wnt7b expression and signaling in medullary collecting ducts [259]. Finally, angiotensin (Agt) and angiotensin receptors (Agtrs) appear critical for the development of the renal calyces, pelvis, and ureter. Mice lacking Agt or Agtr1 genes demonstrate progressive widening of the calyx and atrophy of the papillae and underlying medulla [260, 261]. These defects appear to be caused by decreased proliferation of the smooth muscle cells that line the renal pelvis. Loss of Agtr2 causes a range of renal anomalies secondary to ureteric mispatterning, including vesicoureteral reflux, duplex kidney, renal ectopia, ureteropelvic Fig. 7 H&E-stained sections from E15.5 and P1 mouse ureters and bladders. E15.5 ureters and bladders have early urothelium (u), an inner layer of mesenchyme (future lamina propria, arrows), and an outer layer of condensing mesenchyme (future muscle, m). P1 ureters and bladders have a more stratified urothelium (u) and well-developed lamina propria (arrows) and outer muscle (m) layers. The adventitial layer of fibroblasts that surrounds the muscle in both tissues is not labeled. Ureters =100 magnification; bladders =40 magnification

21

or ureterovesical junction stenoses, renal dysplasia or hypoplasia, multicystic dysplastic kidney, and renal aplasia [107].

Lower Urinary Tract Development Anatomic and Functional Development Concurrent with metanephric kidney formation, the embryonic ureter and bladder develop the former functioning to propel urine into the latter which stores urine until an appropriate time to expel it via the urethra. Similar to the kidney, the ureter and bladder undergo maturation largely due to reciprocal interactions between an epithelium (i.e., urothelium) and surrounding mesenchyme that forms the lamina propria, muscle, and adventitia (Fig. 7). For a recent detailed review on anatomic and molecular control of lower urinary tract development, see [262].

22

Ureter development begins simultaneously with metanephric kidney development around the 5th week of gestation in humans and at E10.5 in the mouse, when the ureteric bud arises from the mesonephric duct [262]. Thus the embryonic origin of the ureteral urothelium is the intermediate mesoderm, the same as the metanephric kidney. By E11.5 in the mouse, the ureteric bud has been segmented into a distal portion that will develop into the ureter and a proximal end that has invaded the metanephric mesenchyme to eventually branch and form the collecting ducts and renal pelvis (see above). The mesenchyme surrounding the early developing ureter consists largely of tailbud-derived mesenchyme that appears to be crucial for directing the distal ureteric bud toward a ureter fate [263]. Between E10.5 and E13.5, the nascent ureter transitions from attaching to the nephric duct to emptying directly into the early bladder (see below). By E13.5, a thin outer ring of ureteral mesenchyme condenses and expresses alpha smooth muscle actin (αSMA) mRNA, the first marker of differentiation toward a smooth muscle fate [264]. αSMA protein expression is not noted until E14.5 in the proximal portion of the ureter (nearest the kidney) and then throughout the entire length of ureter by E16.5; thus, ureter muscle development progresses in a rostral to caudal direction [265]. Concurrent with development of the mesenchymal layers, the ureteral urothelium gradually matures from a simple epithelium to a stratified epithelium consisting of at least three cell types: basal, intermediate, and superficial/ umbrella cells. Each of these cell types has distinct structural features and molecular markers [266]; moreover, recent data strongly suggests that urothelial basal cells, arising from the original ureteric epithelium, serve as the progenitors for other ureteral urothelial cell types [266]. A unique feature of urothelium (compared with other epithelia) is the apical expression of urothelial plaques, consisting of uroplakins, which likely have several functions, including providing a permeability barrier and acting as a binding site for uropathogenic E. coli [266]. An important function of the ureter is to continuously propel urine from the renal pelvis to the

C. Bates et al.

bladder. The ability of the ureter to undergo peristaltic waves of contraction followed by relaxation appears to be intrinsic and not dependent on urine flow; cultured explants of E13.5 mouse ureters attached to kidneys begin to undergo spontaneous peristaltic contractions within a few days, as do isolated and cultured E15.5 ureters [268]. Elegant studies recently identified a population of pacemaker cells at the junction of the renal pelvis and the kidney that express hyperpolarization-activated cation-3 (Hcn3) channels (a family of channels that are also present in cardiac pacemakers) [269]. Loss of Hcn3 activity in mice leads to abnormal coordination and frequency of ureter contractions [269]. Following this study, another described a population of secondary pacemakers that are located in the muscle of the mouse proximal ureter (starting at the ureteropelvic junction) and that have morphological and molecular features similar to intestinal pacemakers including expression of c-kit [268]. Thus, like the cardiac conduction system, the ureter has primary and secondary pacemakers that act to drive urinary propulsion in a coordinated fashion. The embryonic bladder initially forms around the 5th gestational week in humans and at E11.5–12.5 in the mouse [262, 270]. Unlike the ureter, bladder urothelium is derived from the endodermal urogenital sinus, formed from the ventral region of the cloaca. At E11.5–12.5, the urogenital sinus further subdivides into an anterior portion, which will become the bladder, and a posterior portion that forms the urethra and portions of the female vagina. The mesenchyme that surrounds the bladder urothelium is largely thought to be from splanchnic mesoderm, although fate-mapping studies reveal that tailbud mesenchyme also contributes to bladder mesenchyme (similar to the ureter) [263]. By E13.5, the bladder is recognized as a distinct structure that is attached directly to the ureters. As is the case with ureters, αSMA mRNA expression in the developing bladder muscle precedes protein expression; mRNA expression appears as early as E11.5 in mice [264], while protein expression begins at E13.5 [270]. Unlike the ureter (and many other organs with smooth muscle such as the intestine)

1

Embryonic Development of the Kidney

23

that has a thin ring of mesenchyme that begins to differentiate into muscle, the entire outer half of the bladder mesenchyme condenses simultaneously and strongly expresses αSMA by E15.5 [264, 271]. Similar to the ureter, the bladder urothelium matures from a simple epithelium to a stratified epithelium, consisting of cell types similar to the ureter, most of which also express uroplakins and urothelial plaques [266]. While bladder urothelial basal cells were originally thought to be the progenitor cell for the other urothelial cell types, recent careful lineage tracing studies revealed the presence of a previously unidentified transient population of cells, known as “P” cells that serve as the progenitors in embryos [272]; moreover, there are dynamic changes in relative composition of bladder urothelial cell types throughout development (Fig. 8). P-cell

Foxa2+ Upk+ P63+ Shh+ Krt5–

l-cell

Foxa2– Upk+ P63+ Shh+ Krt5–

S-cell

Foxa2– Upk+ P63– Shh– Krt5–

B-cell

Foxa2– Upk– P63+ Shh+ Krt5+

While the connection of the ureters with the bladder is critical, how this occurs has been the subject of some debate. What is clear is that between E12.5 and E13.5, the common nephric duct (caudal portion of the mesonephric duct between the ureter base and future bladder) moves adjacent to the bladder, allowing for the ureters and rostral nephric ducts (future male gonadal excretory ducts) to separate and empty directly into the bladder. The triangular portion of the bladder demarcated by the entry points of the ureters and the bladder neck (where the remaining embryonic nephric ducts empty) is known as the trigone. Historically the common nephric duct was thought to become incorporated into the bladder to form the trigone. However, elegant fatemapping studies reveal that the common nephric duct undergoes complete apoptosis starting at E12.5 in the mouse and that the urothelium of the trigone originates entirely from the bladder urothelium [273]. Moreover, a separate study showed that the muscle present in the trigone arises mostly from the bladder with only a few fibers emanating from ureteral muscle [274]. Thus, the trigone originates mostly from bladder tissues and not the mesonephric duct.

100%

Molecular Control of Ureter and Bladder Development

75% 50% 25% 0% E11

E13

E14

E16

E18

Adult

Fig. 8 Graph demonstrating the proportion of different murine bladder urothelial cell types during development. “P” cells, an early transient progenitor population appear first, followed dynamic changes in the proportion of their derivatives [intermediate (I ), superficial (S), and basal (B) cells] through adulthood. Immunohistochemical markers of each cell type are listed (Foxa2 forkhead box A2, Upk uroplakins, P63 tumor protein P63, Shh sonic hedgehog, Krt5 keratin 5) (Reproduced with kind permission from Elsevier. Gandhi, D, et al. Retinoid signaling in progenitors controls specification and regeneration of the urothelium. Developmental Cell, volume 26, pp 469–482, 2013, adapted from Figure 2)

Ureter The pathways critical for early ureteric bud formation were already covered in the section on kidney development above. Thus, an overview of the molecular control of ureter development will be presented in this section (Fig. 9). Once the ureteric bud has formed, Bmp4 is secreted by tailbud-derived mesenchyme surrounding the distal ureteric bud, driving the epithelium toward a urothelial fate; moreover, ectopic Bmp4 expression around proximal portions of the ureteric bud directs it to become urothelium instead of collecting duct epithelium [263]. The transcription factor Tbx18 is also critical for normal urothelial development and is expressed throughout the mesenchyme investing the distal ureter. The genetic ablation of Tbx18 in mice leads to

24

C. Bates et al.

Ptch Hcn3 Smo Shh Gli3R

Muscle Fzd

UPKs

Kit β-catenin

Wnt

Tbx18

lc

ell s

Ptch

s

ell

m

ce Tshz3 le SMC genes

c us

Dlg1

th

m

oo

ve

Sm

Agtr1 Cnb1

Bmp4 receptor

Ad

Urothelium

lls

Smo Smad

tia

St

c al

nti

Ur ot

he

lia

Bmp4 Shh ro

Lamina propria (stromal cells)

Adventitia

Adventitia

AngII

Fig. 9 Genetic pathways regulating ureter development. The cell layers of the developing ureter include the urothelium (green) and mesenchymal lamina propria/stromal cells (pink), smooth muscle (yellow), and adventitia (blue). Tbx18, expressed in mesenchyme, is critical for smooth muscle and urothelial development. Uroplakins (UPKs) are not only markers of urothelium but critical for urothelial morphogenesis. Sonic hedgehog (Shh) is secreted by urothelium, binding to patched (Ptch) receptors to regulate morphogenesis of smooth muscle and Hcn3 and c-Kit expressing pacemakers [via interactions with Smoothened (Smo) and Gli3 repressor (Gli3R)]. Other Shh targets including Bmp4 (acting through Smad

proteins) and Tshz3 regulate smooth muscle morphogenesis. Wnt ligands in urothelium bind to Fzd receptors and stabilize β-catenin to stimulate smooth muscle development and repress adventitial expansion. Angiotensin 2 (AngII) binds to type 1 receptors (Agtr1) that along with calcineurin b1 subunits also pattern smooth muscle. Dlg1 is critical for lamina propria/stromal cell morphogenesis (Reproduced with kind permission from Wiley Periodicals, Inc. Rasouly, HM and Lu W. Lower urinary tract development and disease. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, volume 5, pp 307–342, adapted from Figure 3)

severe mispatterning of the mesenchyme and then secondary defects in urothelial development [277]. Finally, not only are uroplakins markers of urothelial maturation, but they are also critical for normal urothelial morphogenesis. Loss of either uroplakin II or uroplakin IIIa leads to severe urothelial plaque defects, hypoplastic superficial cells, urothelial leakiness, hydronephrosis, and vesicoureteral reflux [276, 277]. Moreover, mutations in UPKIIIa in humans have been associated with severe renal dysplasia and reflux [279], whereas the role of UPKII in humans is still unclear [279].

Signaling from the ureteral urothelium has also been shown to be critical for mesenchymal patterning. The growth factor, Sonic hedgehog (Shh), is secreted by the urothelium and binds to its receptor, Patched 1, in surrounding mesenchyme. Conditional ablation of Shh in developing ureteric epithelium leads to loss of mesenchymal proliferation and smooth muscle differentiation [265]. Furthermore, Shh signaling from urothelium has also been shown to be critical for the formation of Hcn3 and c-kit expressing pacemakers within the ureteral muscle, via the hedgehog signaling mediators Smoothened and Gli13

1

Embryonic Development of the Kidney

repressor [268]. In addition, downstream targets of Shh signaling have been identified as necessary for ureteral muscle development. One target, Bmp4, is essential for normal ureteral muscle investment around the ureter, particularly at the ureterovesical junction (in addition to having its aforementioned role in urothelial differentiation) [280]. The transcription factor, Teashirt 3 (Tshz3), downstream of both Shh and Bmp4, is critical for proximal ureteral smooth muscle differentiation and for normal ureteral peristaltic function; deletion of Tshz3 in mice leads to severe muscle patterning defects and congenital hydronephrosis [281]. A role for SHH in human urinary tract development was confirmed in patients with Pallister–Hall syndrome, who have mutations in GLI3 and urinary tract anomalies such as hydroureter and hydronephrosis [268, 282]. Finally, Wnt ligands are also secreted by the urothelium, bind to frizzled receptors in the mesenchyme, and signal primarily by stabilization of β-catenin (Ctnnb1). Genetic ablation of Ctnnb1 leads to failure of mesenchymal proliferation and differentiation into smooth muscle cells, with concurrent expansion of the outer adventitial fibroblast layer [283]. Other genes within the ureteral mesenchyme have been shown to be critical for normal mesenchymal development. As alluded to, loss of the transcription factor Tbx18 leads to decreased proliferation and failure of smooth muscle differentiation and ultimately severe hydroureteronephrosis [275]. Similarly, conditional ablation of the calcineurin b1 subunit in developing ureteral mesenchyme leads to reduced smooth muscle proliferation and hydronephrosis [284]. Furthermore, genetic ablation of the angiotensin type 1 receptor (which is expressed in ureteral mesenchyme) leads to smooth muscle hypoplasia, lack of peristalsis, and ultimately hydronephrosis [285]. Finally, discs large homolog 1 (Dlg1) is the only gene identified to date that is necessary for lamina propria/stromal cell development; genetic deletion of Dlg1 in mice led to an absence of the entire ureteral lamina propria layer and disorganized muscle development [286].

25

Bladder Compared with the ureter, much less is known about the molecular control of bladder development. Some of the pathways critical for formation of the urogenital sinus (future bladder) have been identified. Bidirectional signaling between ephrin-B2 and EphB2, a ligand and its receptor tyrosine kinase, is critical for septation of the cloaca into the ventral urogenital sinus and the dorsal anorectal canal [287]. Sonic hedgehog signaling is also critical for the formation of the urogenital sinus. In mice, the loss of Shh or compound mutations in the downstream hedgehog mediators, Gli2 and Gli3, leads to failure of cloacal septation [288]. During later stages of bladder formation, urothelial cell stratification is dependent on retinoid signaling emanating from the lamina propria surrounding the urothelium; forced expression of a dominant negative retinoic acid receptor in developing mouse urothelium leads to a loss of S cells, I cells, and uroplakins [272]. There are also some limited data on genetic pathways critical for bladder mesenchyme development. As is true in the ureter, several studies have shown that Shh signaling from the bladder urothelium is necessary for bladder mesenchyme morphogenesis; loss of Shh in mice leads to a complete loss of smooth muscle formation [289–292]. Another mouse line, termed the megabladder mouse (mgb/), is a random transgene insertional mutant that lacks outer mesenchymal condensation, has very limited αSMA expression, and ultimately develops a massive bladder with no functional detrusor [271]. While the gene disrupted in mgb/ mice is still unknown, Shh signaling appears perturbed, and the bladders lack expression of myocardin, a transcription factor critical for smooth muscle development [293].

Ureter–Bladder Anastomosis There are some data on genetic pathways necessary for the proper connection between the ureter and bladder, i.e., apoptosis of the common nephric duct starting at E12.5 in mice. Retinoid signaling

26

from the bladder has been shown to be critical for this process. Genetic ablation of retinaldehyde dehydrogenase-2, an enzyme expressed in the urogenital sinus and necessary for retinoic acid synthesis, led to persistence of the common nephric duct with ureters ending blindly in the mesonephric duct [273]. In addition, Ret has also been shown to be essential for ureter–bladder anastomosis. Mice with a point mutation in tyrosine 1015, the phospholipase Cγ binding site on Ret (RetY1015), have a persistent common nephric duct due to enhanced proliferation and decreased apoptosis [294]. Lower urinary tract defects contribute substantially to chronic kidney disease in children, necessitating a better understanding about the genes regulating lower urinary tract morphogenesis. While our understanding of the molecular control of ureter and bladder development trails that of the kidney, more studies are emerging on how the ureter and bladder form.

References 1. Osathanondh V, Potter EL. Development of human kidney as shown by microdissection. Arch Path. 1966;82:391–402. 2. Potter EL. Normal and abnormal development of the kidney. Chicago: Year Book Medical Publishers; 1972. 3. Hinchliffe SA, Sargent PH, Howard CV, Chan YF, van Velzen D. Human intrauterine renal growth expressed in absolute number of glomeruli assessed by the disector method and Cavalieri principle. Lab Invest. 1991;64(6):777–84. 4. Hughson M, Farris 3rd AB, Douglas-Denton R, Hoy WE, Bertram JF. Glomerular number and size in autopsy kidneys: the relationship to birth weight. Kidney Int. 2003;63(6):2113–22. 5. Rodriguez MM, Gomez AH, Abitbol CL, Chandar JJ, Duara S, Zilleruelo GE. Histomorphometric analysis of postnatal glomerulogenesis in extremely preterm infants. Pediatr Dev Pathol. 2004;7(1):17–25. 6. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med. 2003;348(2):101–8. 7. Hoy WE, Hughson MD, Singh GR, Douglas-DentonR, Bertram JF. Reduced nephron number and glomerulomegaly in Australian Aborigines: a group at high risk for renal disease and hypertension. Kidney Int. 2006;70(1):104–10.

C. Bates et al. 8. Piscione TD, Rosenblum ND. The molecular control of renal branching morphogenesis: current knowledge and emerging insights. Differentiation. 2002;70(6):227–46. 9. Dressler GR. The cellular basis of kidney development. Annu Rev Cell Dev Biol. 2006;22:509–29. 10. Costantini F. Renal branching morphogenesis: concepts, questions, and recent advances. Differentiation. 2006;74(7):402–21. 11. Shah MM, Sampogna RV, Sakurai H, Bush KT, Nigam SK. Branching morphogenesis and kidney disease. Development. 2004;131(7):1449–62. 12. Yu J, McMahon AP, Valerius MT. Recent genetic studies of mouse kidney development. Curr Opin Genet Dev. 2004;14(5):550–7. 13. Little MH, McMahon AP. Mammalian kidney development: principles, progress, and projections. Cold Spring Harb Perspect Biol [Research Support, N.I. H., Extramural Review]. 2012;4(5):1–18. 14. Costantini F, Kopan R. Patterning a complex organ: branching morphogenesis and nephron segmentation in kidney development. Dev Cell [Research Support, N.I.H., Extramural Review]. 2010;18(5):698–712. 15. Hwang DY, Dworschak GC, Kohl S, Saisawat P, Vivante A, Hilger AC, et al. Mutations in 12 known dominant disease-causing genes clarify many congenital anomalies of the kidney and urinary tract. Kidney Int. 2014;85(6):1429–33. 16. Chen S, Bellew C, Yao X, Stefkova J, Dipp S, Saifudeen Z, et al. Histone deacetylase (HDAC) activity is critical for embryonic kidney gene expression, growth, and differentiation. J Biol Chem [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2011;286(37): 32775–89. 17. Chen S, El-Dahr SS. Histone deacetylases in kidney development: implications for disease and therapy. Pediatr Nephrol [Review]. 2013;28(5):689–98. 18. McLaughlin N, Wang F, Saifudeen Z, El-Dahr SS. In situ histone landscape of nephrogenesis. Epigenetics [Research Support, N.I.H., Extramural]. 2014;9 (2):222–35. 19. Ho J, Kreidberg JA. The long and short of microRNAs in the kidney. J Am Soc Nephrol. 2012;23(3):400–4. 20. Ho J, Ng KH, Rosen S, Dostal A, Gregory RI, Kreidberg JA. Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol. 2008;19(11):2069–75. 21. Marrone AK, Stolz DB, Bastacky SI, Kostka D, Bodnar AJ, Ho J. MicroRNA-17~92 is required for nephrogenesis and renal function. J Am Soc Nephrol. 2014;25(7):1440–52. 22. Ho J, Pandey P, Schatton T, Sims-Lucas S, Khalid M, Frank MH, et al. The pro-apoptotic protein Bim is a microRNA target in kidney progenitors. J Am Soc Nephrol [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2011;22(6): 1053–63.

1

Embryonic Development of the Kidney

23. Lelievre-Pegorier M, Vilar J, Ferrier ML, Moreau E, Freund N, Gilbert T, et al. Mild vitamin A deficiency leads to inborn nephron deficit in the rat. Kidney Int. 1998;54(5):1455–62. 24. Goodyer P, Kurpad A, Rekha S, Muthayya S, Dwarkanath P, Iyengar A, et al. Effects of maternal vitamin A status on kidney development: a pilot study. Pediatr Nephrol [Multicenter Study Research Support, Non-U.S. Gov’t]. 2007;22(2):209–14. 25. Harding SD, Armit C, Armstrong J, Brennan J, Cheng Y, Haggarty B, et al. The GUDMAP database–an online resource for genitourinary research. Development. 2011;138(13):2845–53. 26. McMahon AP, Aronow BJ, Davidson DR, Davies JA, Gaido KW, Grimmond S, et al. GUDMAP: the genitourinary developmental molecular anatomy project. J Am Soc Nephrol. 2008;19(4):667–71. 27. Diez-Roux G, Banfi S, Sultan M, Geffers L, Anand S, Rozado D, et al. A high-resolution anatomical atlas of the transcriptome in the mouse embryo. PLoS Biol [Research Support, Non-U.S. Gov’t]. 2011;9(1): e1000582. 28. Avner ED, Ellis D, Temple T, Jaffe R. Metanephric development in serum-free organ culture. In Vitro Cell Dev Biol. 1982;18:675–82. PMID: 7129481. 29. Sariola H, Saarma M, Sainio K, Arumae U, Palgi J, Vaahtokari A, et al. Dependence of kidney morphogenesis on the expression of nerve growth factor receptor. Science [Research Support, Non-U.S. Gov’t]. 1991;254(5031):571–3. 30. Woolf AS, Kolatsi-Joannou M, Hardman P, Andermarcher E, Moorby C, Fine LG, et al. Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros. J Cell Biol [Research Support, Non-U.S. Gov’t]. 1995;128(1–2):171–84. 31. Sims-Lucas S. Analysis of 3D branching pattern: hematoxylin and eosin method. Methods Mol Biol. 2012;886:73–86. 32. Sims-Lucas S, Argyropoulos C, Kish K, McHugh K, Bertram JF, Quigley R, et al. Three-dimensional imaging reveals ureteric and mesenchymal defects in Fgfr2-mutant kidneys. J Am Soc Nephrol. 2009;20(12):2525–33. 33. Short KM, Combes AN, Lefevre J, Ju AL, Georgas KM, Lamberton T, et al. Global quantification of tissue dynamics in the developing mouse kidney. Dev Cell [Research Support, Non-U.S. Gov’t]. 2014;29(2):188–202. 34. Tarantal AF, Han VK, Cochrum KC, Mok A, daSilva M, Matsell DG. Fetal rhesus monkey model of obstructive renal dysplasia. Kidney Int [Research Support, U.S. Gov’t, P.H.S.]. 2001;59(2):446–56. 35. Yang SP, Woolf AS, Quinn F, Winyard PJ. Deregulation of renal transforming growth factor-beta1 after experimental short-term ureteric obstruction in fetal sheep. Am J Pathol [Research Support, Non-U.S. Gov’t]. 2001;159(1):109–17.

27 36. Welham SJ, Riley PR, Wade A, Hubank M, Woolf AS. Maternal diet programs embryonic kidney gene expression. Physiol Genomics [Research Support, Non-U.S. Gov’t]. 2005;22(1):48–56. 37. Tse HK, Leung MB, Woolf AS, Menke AL, Hastie ND, Gosling JA, et al. Implication of Wt1 in the pathogenesis of nephrogenic failure in a mouse model of retinoic acid-induced caudal regression syndrome. Am J Pathol [Research Support, Non-U.S. Gov’t]. 2005;166(5):1295–307. 38. Sanker S, Cirio MC, Vollmer LL, Goldberg ND, McDermott LA, Hukriede NA, et al. Development of high-content assays for kidney progenitor cell expansion in transgenic zebrafish. J Biomol Screen [Research Support, N.I.H., Extramural]. 2013;18 (10):1193–202. 39. Liu L, Fan XD. CRISPR-Cas system: a powerful tool for genome engineering. Plant Mol Biol. 2014;85 (3):209–18. 40. Drummond IA, Majumdar A, Hentschel H, Elger M, Solnica-Krezel L, Schier AF, et al. Early development of the zebrafish pronephros and analysis of mutations affecting pronephric function. Development. 1998;125:4655–67. 41. Vize PD, Seufert DW, Carroll TJ, Wallingford JB. Model systems for the study of kidney development: use of the pronephros in the analysis of organ induction and patterning. Dev Biol. 1997;188:189–204. 42. Staack A, Donjacour AA, Brody J, Cunha GR, Carroll P. Mouse urogenital development: a practical approach. Differentiation. 2003;71(7):402–13. 43. Saxen L. Organogenesis of the kidney. Cambridge: Cambridge University Press; 1987. 44. James RG, Kamei CN, Wang Q, Jiang R, Schultheiss TM. Odd-skipped related 1 is required for development of the metanephric kidney and regulates formation and differentiation of kidney precursor cells. Development. 2006;133(15):2995–3004. 45. Mugford JW, Sipila P, McMahon JA, McMahon AP. Osr1 expression demarcates a multi-potent population of intermediate mesoderm that undergoes progressive restriction to an Osr1-dependent nephron progenitor compartment within the mammalian kidney. Dev Biol [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2008;324(1): 88–98. 46. Dressler GR, Deutsch U, Chowdhury K, Nornes HO, Gruss P. Pax-2, a new murine paired-box-containing gene and its expression in the developing excretory system. Development. 1990;109:787–95. 47. Bouchard M, Souabni A, Mandler M, Neubuser A, Busslinger M. Nephric lineage specification by Pax2 and Pax8. Genes Dev [Research Support, Non-U.S. Gov’t]. 2002;16(22):2958–70. 48. Fujii T, Pichel JG, Taira M, Toyama R, Dawid IB, Westphal H. Expression patterns of the murine LIM class homeobox gene lim1 in the developing brain and excretory system. Dev Dyn. 1994;1:73–83.

28 49. Grote D, Souabni A, Busslinger M, Bouchard M. Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development. 2006;133(1): 53–61. 50. Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development. 1993;119:1005–17. 51. Erickson RA. Inductive interactions in the development of the mouse metanephros. J Exp Zool. 1968;169(1):33–42. 52. Grobstein C. Morphogenetic interaction between embryonic mouse tissues separated by a membrane filter. Nature. 1953;172:869–71. 53. Grobstein C. Inductive interaction in the development of the mouse metanephros. J Exp Zool. 1955;130:319–40. 54. Hatini V, Huh SO, Herzlinger D, Soares VC, Lai E. Essential role of stromal mesenchyme in kidney morphogenesis revealed by targeted disruption of Winged Helix transcription factor BF-2. Genes Dev. 1996;10:1467–78. 55. Mendelsohn C, Batourina E, Fung S, Gilbert T, Dodd J. Stromal cells mediate retinoid-dependent functions essential for renal development. Development. 1999;126:1139–48. 56. Batourina E, Gim S, Bello N, Shy M, ClagettDame M, Srinivas S, et al. Vitamin A controls epithelial/mesenchymal interactions through Ret expression. Nat Genet. 2001;27:74–8. 57. Levinson RS, Batourina E, Choi C, Vorontchikhina M, Kitajewski J, Mendelsohn CL. Foxd1-dependent signals control cellularity in the renal capsule, a structure required for normal renal development. Development [Research Support, U.S. Gov’t, P.H.S.]. 2005;132(3):529–39. 58. Qiao J, Uzzo R, Obara-Ishihara T, Degenstein L, Fuchs E, Herzlinger D. FGF-7 modulates ureteric bud growth and nephron number in the developing kidney. Development. 1999;126:547–54. 59. Gao X, Chen X, Taglienti M, Rumballe B, Little MH, Kreidberg JA. Angioblast-mesenchyme induction of early kidney development is mediated by Wt1 and Vegfa. Development. 2005;132(24):5437–49. 60. Tufro-McReddie A, Norwood VF, Aylor KW, Botkin SJ, Carey RM, Gomez RA. Oxygen regulates vascular endothelial growth factor-mediated vasculogenesis and tubulogenesis. Dev Biol. 1997;183(2):139–49. 61. Meyer TN, Schwesinger C, Bush KT, Stuart RO, Rose DW, Shah MM, et al. Spatiotemporal regulation of morphogenetic molecules during in vitro branching of the isolated ureteric bud: toward a model of branching through budding in the developing kidney. Dev Biol. 2004;275(1):44–67. 62. Barasch J, Qiao J, McWilliams G, Chen D, Oliver JA, Herzlinger D. Ureteric bud cells secrete multiple factors, including bFGF, which rescue renal progenitors from apoptosis. Am J Physiol. 1997;273:F757–67.

C. Bates et al. 63. Barasch J, Yang J, Ware CB, Taga T, Yoshida K, Erdjument-Bromage H, et al. Mesenchymal to epithelial conversion in rat metanephros is induced by LIF. Cell. 1999;99(4):377–86. 64. Das A, Tanigawa S, Karner CM, Xin M, Lum L, Chen C, et al. Stromal-epithelial crosstalk regulates kidney progenitor cell differentiation. Nat Cell Biol. 2013;15(9):1035–44. 65. Yang J, Blum A, Novak T, Levinson R, Lai E, Barasch J. An epithelial precursor is regulated by the ureteric bud and by the renal stroma. Dev Biol. 2002;246(2):296–310. 66. Cui S, Schwartz L, Quaggin SE. Pod1 is required in stromal cells for glomerulogenesis. Dev Dyn. 2003;226(3):512–22. 67. Clark AT, Bertram JF. Molecular regulation of nephron endowment. Am J Physiol. 1999;276(4 Pt 2): F485–97. 68. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65 (6):2003–17. 69. Simon M, Rockl W, Hornig C, Grone EF, Theis H, Weich HA, et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/ VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. J Am Soc Nephrol. 1998;9(6):1032–44. 70. Evan AP, Gattone 2nd VH, Schwartz GJ. Development of solute transport in rabbit proximal tubule. II. Morphologic segmentation. Am J Physiol. 1983;245(3):F391–407. 71. Fetterman GH, Shuplock NA, Philipp FJ, Gregg HS. The growth and maturation of human glomeruli and proximal convolutions from term to adulthood: studies by microdissection. Pediatrics. 1965;35:601–19. 72. Neiss WF. Histogenesis of the loop of Henle in the rat kidney. Anat Embryol. 1982;164(3):315–30. 73. Nakai S, Sugitani Y, Sato H, Ito S, Miura Y, Ogawa M, et al. Crucial roles of Brn1 in distal tubule formation and function in mouse kidney. Development. 2003;130(19):4751–9. 74. Neiss WF, Klehn KL. The postnatal development of the rat kidney, with special reference to the chemodifferentiation of the proximal tubule. Histochemistry. 1981;73(2):251–68. 75. Nishinakamura R, Matsumoto Y, Nakao K, Nakamura K, Sato A, Copeland NG, et al. Murine homolog of SALL1 is essential for ureteric bud invasion in kidney development. Development. 2001;128:3105–15. 76. Xu PX, Zheng W, Huang L, Maire P, Laclef C, Silvius D. Six1 is required for the early organogenesis of mammalian kidney. Development. 2003;130(14): 3085–94. 77. Kalatzis V, Sahly I, El-Amraoui A, Petit C. Eya1 expression in the developing ear and kidney: towards the understanding of the pathogenesis of Branchio-

1

Embryonic Development of the Kidney

Oto-Renal (BOR) syndrome. Dev Dyn. 1998;213:486–99. 78. Xu P-X, Adams J, Peters H, Brown MC, Heaney S, Maas R. Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia. Nat Genet. 1999;23:113–7. 79. Hellmich HL, Kos L, Cho ES, Mahon KA, Zimmer A. Embryonic expression of glial cell-line derived neurotrophic factor (GDNF) suggests multiple developmental roles in neural differentiation and epithelialmesenchymal interactions. Mech Dev. 1996;54:95–105. 80. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, et al. WT-1 is required for early kidney development. Cell. 1993;74:679–91. 81. Boyle S, Shioda T, Perantoni AO, de Caestecker M. Cited1 and Cited2 are differentially expressed in the developing kidney but are not required for nephrogenesis. Dev Dyn [Research Support, N.I.H., Extramural]. 2007;236(8):2321–30. 82. Self M, Lagutin OV, Bowling B, Hendrix J, Cai Y, Dressler GR, et al. Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney. EMBO J. 2006;25(21):5214–28. 83. Cho EA, Patterson LT, Brookhiser WT, Mah S, Kintner C, Dressler GR. Differential expression and function of cadherin-6 during renal epithelium development. Development. 1998;125(5):803–12. 84. M€uller U, Wang D, Denda S, Meneses JJ, Pedersen RA, Reichardt LF. Integrin α8β1 is critically important for epithelial-mesenchymal interactions during kidney morphogenesis. Cell. 1997;88:603–13. 85. Brophy PD, Ostrom L, Lang KM, Dressler GR. Regulation of ureteric bud outgrowth by Pax2dependent activation of the glial derived neurotrophic factor gene. Development. 2001;128:4747–56. 86. Kobayashi A, Kwan KM, Carroll TJ, McMahon AP, Mendelsohn CL, Behringer RR. Distinct and sequential tissue-specific activities of the LIM-class homeobox gene Lim1 for tubular morphogenesis during kidney development. Development [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, P.H.S.]. 2005;132(12):2809–23. 87. Rothenpieler UW, Dressler GR. Pax-2 is required for mesenchyme-to-epithelium conversion during kidney development. Development. 1993;119:711–20. 88. Torres M, Gomez-Pardo E, Dressler GR, Gruss P. Pax-2 controls multiple steps of urogenital development. Development. 1995;121:4057–65. 89. Tsang TE, Shawlot W, Kinder SJ, Kobayashi A, Kwan KM, Schughart K, et al. Lim1 activity is required for intermediate mesoderm differentiation in the mouse embryo. Dev Biol. 2000;223(1):77–90. 90. Shawlot W, Behringer RR. Requirement for Lim1 in head-organizer function. Nature. 1995;374:425–30. 91. Hilliard SA, Yao X, El-Dahr SS. Mdm2 is required for maintenance of the nephrogenic niche. Dev Biol. 2014;387(1):1–14.

29 92. Davies JA, Garrod DR. Induction of early stages of kidney tubule differentiation by lithium ions. Dev Biol. 1995;167(1):50–60. 93. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol. 1997;185(1):82–91. 94. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93(16):8455–9. 95. Carroll TJ, Park JS, Hayashi S, Majumdar A, McMahon AP. Wnt9b plays a central role in the regulation of mesenchymal to epithelial transitions underlying organogenesis of the mammalian urogenital system. Dev Cell. 2005;9(2):283–92. 96. Karner CM, Das A, Ma Z, Self M, Chen C, Lum L, et al. Canonical Wnt9b signaling balances progenitor cell expansion and differentiation during kidney development. Development [Research Support, N.I. H., Extramural Research Support, Non-U.S. Gov’t]. 2011;138(7):1247–57. 97. Brown AC, Adams D, de Caestecker M, Yang X, Friesel R, Oxburgh L. FGF/EGF signaling regulates the renewal of early nephron progenitors during embryonic development. Development [Research Support, American Recovery and Reinvestment Act Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2011;138(23):5099–112. 98. Barak H, Huh SH, Chen S, Jeanpierre C, Martinovic J, Parisot M, et al. FGF9 and FGF20 maintain the stemness of nephron progenitors in mice and man. Dev Cell. 2012;22(6):1191–207. 99. Hains D, Sims-Lucas S, Kish K, Saha M, McHugh K, Bates CM. Role of fibroblast growth factor receptor 2 in kidney mesenchyme. Pediatr Res [Research Support, N.I.H., Extramural]. 2008;64(6):592–8. 100. Poladia DP, Kish K, Kutay B, Hains D, Kegg H, Zhao H, et al. Role of fibroblast growth factor receptors 1 and 2 in the metanephric mesenchyme. Dev Biol [Research Support, N.I.H., Extramural]. 2006;291(2):325–39. 101. Sims-Lucas S, Cusack B, Baust J, Eswarakumar VP, Masatoshi H, Takeuchi A, et al. Fgfr1 and the IIIc isoform of Fgfr2 play critical roles in the metanephric mesenchyme mediating early inductive events in kidney development. Dev Dyn [Research Support, N.I. H., Extramural]. 2011;240(1):240–9. 102. Bard JB. Growth and death in the developing mammalian kidney: signals, receptors and conversations. Bioessays. 2002;24(1):72–82. 103. Dudley AT, Godin RE, Robertson EJ. Interaction between FGF and BMP signaling pathways regulates development of metanephric mesenchyme. Genes Dev. 1999;13:1601–13. 104. Koseki C, Herzlinger D, Al-Awqati Q. Apoptosis in metanephric development. J Cell Biol. 1992;119(5): 1327–33. 105. Plisov SY, Yoshino K, Dove LF, Higinbotham KG, Rubin JS, Perantoni AO. TGF beta 2, LIF and FGF2

30 cooperate to induce nephrogenesis. Development. 2001;128(7):1045–57. 106. Araki T, Saruta T, Okano H, Miura M. Caspase activity is required for nephrogenesis in the developing mouse metanephros. Exp Cell Res. 1999;248(2): 423–9. 107. Nishimura H, Yerkes E, Hohenfellner K, Miyazaki Y, Ma J, Hunley TE, et al. Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. Mol Cell. 1999;3:1–10. 108. Coles HSR, Burne JF, Raff MC. Large-scale normal cell death in the developing rat kidney and its reduction by epidermal growth factor. Development. 1993;117:777–84. 109. Winyard PJD, Nauta J, Lirenman DS, Hardman P, Sams VR, Risdon RA, et al. Deregulation of cell survival in cystic and dysplastic renal development. Kidney Int. 1996;49:135–46. 110. Marrone AK, Stolz DB, Bastacky SI, Kostka D, Bodnar AJ, Ho J. MicroRNA-17~92 is required for nephrogenesis and renal function. J Am Soc Nephrol. 2014;25(7):1440–52. 111. Karavanov AA, Karavanova I, Perantoni A, Dawid IB. Expression pattern of the rat Lim-1 homeobox gene suggests a dual role during kidney development. Int J Dev Biol. 1998;42:61–6. 112. Stewart CL, Kaspar P, Brunet LJ, Bhatt H, Gadi I, Kontgen F, et al. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature. 1992;359(6390):76–9. 113. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, et al. TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes. Development. 1997;124:2659–70. 114. McPherron AC, Lawler AM, Lee SJ. Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat Genet. 1999;22(3):260–4. 115. Herzlinger D, Qiao J, Cohen D, Ramakrishna N, Brown AMC. Induction of kidney epithelial morphogenesis by cells expressing wnt-1. Dev Biol. 1994;166:815–8. 116. Kispert A, Vainio S, McMahon AP. Wnt-4 is a mesenchymal signal for epithelial transformation of metanephric mesenchyme in the developing kidney. Development. 1998;125:4225–34. 117. Yoshino K, Rubin JS, Higinbotham KG, Uren A, Anest V, Plisov SY, et al. Secreted Frizzled-related proteins can regulate metanephric development. Mech Dev. 2001;102(1–2):45–55. 118. Grieshammer U, Cebrian C, Ilagan R, Meyers E, Herzlinger D, Martin GR. FGF8 is required for cell survival at distinct stages of nephrogenesis and for regulation of gene expression in nascent nephrons. Development [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. 2005;132(17):3847–57.

C. Bates et al. 119. Perantoni AO, Timofeeva O, Naillat F, Richman C, Pajni-Underwood S, Wilson C, et al. Inactivation of FGF8 in early mesoderm reveals an essential role in kidney development. Development. 2005;132(17): 3859–71. 120. Gerber SD, Steinberg F, Beyeler M, Villiger PM, Trueb B. The murine Fgfrl1 receptor is essential for the development of the metanephric kidney. Dev Biol. 2009;335(1):106–19. 121. Majumdar A, Lun K, Brand M, Drummond IA. Zebrafish no isthmus reveals a role for pax2.1 in tubule differentiation and patterning events in the pronephric primordia. Development. 2000;127(10): 2089–98. 122. Wallingford JB, Carroll TJ, Vize PD. Precocious expression of the Wilms’ tumor gene xWT1 inhibits embryonic kidney development in Xenopus laevis. Dev Biol. 1998;202(1):103–12. 123. Ryan G, Steele-Perkins V, Morris JF, Rauscher 3rd FJ, Dressler GR. Repression of Pax-2 by WT1 during normal kidney development. Development. 1995;121(3):867–75. 124. Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DA, Housman D. Expression of the Wilms’ tumor gene WT1 in the murine urogenital system. Genes Dev. 1991;5:1345–56. 125. Dressler GR, Wilkinson JE, Rothenpieler UW, Patterson LT, Silliams-Simons L, Westphal H. Deregulation of Pax-2 expression in transgenic mice generates severe kidney abnormalities. Nature. 1993;362:65–7. 126. Dressler GR, Douglass EC. Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci U S A. 1992;89: 1179–83. 127. Cheng HT, Miner JH, Lin M, Tansey MG, Roth K, Kopan R. Gamma-secretase activity is dispensable for mesenchyme-to-epithelium transition but required for podocyte and proximal tubule formation in developing mouse kidney. Development. 2003;130(20): 5031–42. 128. Cheng HT, Kim M, Valerius MT, Surendran K, Schuster-Gossler K, Gossler A, et al. Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron. Development. 2007;134 (4):801–11. 129. Wang P, Pereira FA, Beasley D, Zheng H. Presenilins are required for the formation of comma- and S-shaped bodies during nephrogenesis. Development. 2003;130(20):5019–29. 130. Boyle SC, Kim M, Valerius MT, McMahon AP, Kopan R. Notch pathway activation can replace the requirement for Wnt4 and Wnt9b in mesenchymal-toepithelial transition of nephron stem cells. Development [Research Support, N.I.H., Extramural]. 2011;138(19):4245–54. 131. Kreidberg JA. Podocyte differentiation and glomerulogenesis. J Am Soc Nephrol. 2003;14(3): 806–14.

1

Embryonic Development of the Kidney

132. Robert B, St John PL, Hyink DP, Abrahamson DR. Evidence that embryonic kidney cells expressing flk-1 are intrinsic, vasculogenic angioblasts. Am J Physiol. 1996;271(3 Pt 2):F744–53. 133. Hyink DP, Tucker DC, St John PL, Leardkamolkarn V, Accavitti MA, Abrass CK, et al. Endogenous origin of glomerular endothelial and mesangial cells in grafts of embryonic kidneys. Am J Physiol. 1996;270(5 Pt 2):F886–99. 134. Ricono JM, Xu YC, Arar M, Jin DC, Barnes JL, Abboud HE. Morphological insights into the origin of glomerular endothelial and mesangial cells and their precursors. J Histochem Cytochem. 2003;51(2):141–50. 135. Sariola H, Ekblom P, Lehtonen E, Saxen L. Differentiation and vascularization of the metanephric kidney grafted on the chorioallantoic membrane. Dev Biol. 1983;96(2):427–35. 136. Nagata M, Nakayama K, Terada Y, Hoshi S, Watanabe T. Cell cycle regulation and differentiation in the human podocyte lineage. Am J Pathol. 1998;153(5):1511–20. 137. Garrod DR, Fleming S. Early expression of desmosomal components during kidney tubule morphogenesis in human and murine embryos. Development. 1990;108(2):313–21. 138. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003;83(1): 253–307. 139. Miner JH, Sanes JR. Collagen IValpha 3, alpha 4, and alpha 5 chains in rodent basal laminae: sequence, distribution, association with laminins, and developmental switches. J Cell Biol. 1994;127(3):879–91. 140. Miner JH, Li C. Defective glomerulogenesis in the absence of laminin alpha5 demonstrates a developmental role for the kidney glomerular basement membrane. Dev Biol. 2000;217(2):278–89. 141. Miner JH, Sanes JR. Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): implications for Alport syndrome. J Cell Biol. 199;135(5):1403–13. 142. Noakes PG, Miner JH, Gautam M, Cunningham JM, Sanes JR, Merlie JP. The renal glomerulus of mice lacking s-laminin/laminin ß2: nephrosis despite molecular compensation by laminin ß1. Nature Genet. 1995;10:400–6. 143. Ekblom P. Formation of basement membranes in embryonic kidney: an immunohistological study. J Cell Biol. 1981;91:1–10. 144. Sariola H, Timpl R, von der Mark K, Mayne R, Fitch JM, Linsenmayer TF, et al. Dual origin of glomerular basement membrane. Dev Biol. 1984;101:86–96. 145. Gao F, Maiti S, Sun G, Ordonez NG, Udtha M, Deng JM, et al. The Wt1+/R394W mouse displays glomerulosclerosis and early-onset renal failure characteristic of human Denys-Drash syndrome. Mol Cell Biol. 2004;24(22):9899–910. 146. Patek CE, Little MH, Fleming S, Miles C, Charlieu JP, Clarke AR, et al. A zinc finger truncation of murine

31 WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome. Proc Natl Acad Sci U S A. 1999;96(6):2931–6. 147. Hammes A, Guo JK, Lutsch G, Leheste JR, Landrock D, Ziegler U, et al. Two splice variants of the Wilms’ tumor 1 gene have distinct functions during sex determination and nephron formation. Cell. 2001;106(3):319–29. 148. Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D, Hammes A, et al. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet. 2002;11(6):651–9. 149. Yang Y, Jeanpierre C, Dressler GR, Lacoste M, Niaudet P, Gubler MC. WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis. Am J Pathol. 1999;154 (1):181–92. unfeld J-P, 150. Barbaux S, Niaudet P, Gubler M-C, Gr€ Jaubert F, Kuttenn F, et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet. 1997;17:467–70. 151. Klamt B, Koziell A, Poulat F, Wieacker P, Scambler P, Berta P, et al. Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1+/KTS splice isoforms. Hum Mol Genet. 1998;7:709–14. 152. Coppes MJ, Liefers GJ, Higuchi M, Zinn AB, Balfe JW, Williams BR. Inherited WT1 mutation in DenysDrash syndrome. Cancer Res. 1992;52(21):6125–8. 153. Quaggin SE, Schwartz L, Cui S, Igarashi P, Deimling J, Post M, et al. The basic-helix-loop-helix protein pod1 is critically important for kidney and lung organogenesis. Development. 1999;126:5771–83. 154. Sadl V, Jin F, Yu J, Cui S, Holmyard D, Quaggin S, et al. The mouse Kreisler (Krml1/MafB) segmentation gene is required for differentiation of glomerular visceral epithelial cells. Dev Biol. 2002;249 (1):16–29. 155. Miner JH, Morello R, Andrews KL, Li C, Antignac C, Shaw AS, et al. Transcriptional induction of slit diaphragm genes by Lmx1b is required in podocyte differentiation. J Clin Invest. 2002;109(8): 1065–72. 156. Dreyer SD, Zhou G, Baldini A, Winterpacht A, Zabel B, Cole W, et al. Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat Genet. 1998;19:47–50. 157. Lemley KV. Kidney disease in nail-patella syndrome. Pediatr Nephrol [Research Support, Non-U.S. Gov’t Review]. 2009;24(12):2345–54. 158. Harvey SJ, Jarad G, Cunningham J, Goldberg S, Schermer B, Harfe BD, et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol. 2008;19(11): 2150–8. 159. Shi S, Yu L, Chiu C, Sun Y, Chen J, Khitrov G, et al. Podocyte-selective deletion of dicer induces

32 proteinuria and glomerulosclerosis. J Am Soc Nephrol. 2008;19(11):2159–69. 160. Kitamoto Y, Tokunaga H, Tomita K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J Clin Invest. 1997;99(10):2351–7. 161. Tufro A, Norwood VF, Carey RM, Gomez RA. Vascular endothelial growth factor induces nephrogenesis and vasculogenesis. J Am Soc Nephrol. 1999;10(10):2125–34. 162. Woolf AS, Yuan HT. Angiopoietin growth factors and Tie receptor tyrosine kinases in renal vascular development. Pediatr Nephrol. 2001;16(2):177–84. 163. Lindahl P, Hellström M, Kalén M, Karlsson L, Pekny M, Pekna M, et al. Paracrine PDGF-B/PDGFRß signaling controls mesangial cell development in kidney glomeruli. Development. 1998;125:3313–22. 164. Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 1994;8:1875–87. 165. Soriano P. Abnormal kidney development and hematological disorders in PDGF ß-receptor mutant mice. Genes Dev. 1994;8:1888–96. 166. McCright B, Gao X, Shen L, Lozier J, Lan Y, Maguire M, et al. Defects in development of the kidney, heart and eye vasculature in mice homozygous for a hypomorphic Notch2 mutation. Development. 2001;128:491–502. 167. Li W, Hartwig S, Rosenblum ND. Developmental origins and functions of stromal cells in the normal and diseased mammalian kidney. Dev Dyn. 2014;243 (7):853–863. 168. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, Non-P.H.S.]. 2010;176(1): 85–97. 169. Miyazaki Y, Oshima Y, Fogo A, Hogan BLM, Ichikawa I. Bone morphogenetic protein 4 regulates the budding site and elongation of the mouse ureter. J Clin Invest. 2000;105:863–73. 170. Cullen-McEwen LA, Caruana G, Bertram JF. The where, what and why of the developing renal stroma. Nephron Exp Nephrol [Review]. 2005;99(1):e1–8. 171. Lemley KV, Kriz W. Anatomy of the renal interstitium. Kidney Int. 1991;39(3):370–81. 172. Rosselot C, Spraggon L, Chia I, Batourina E, Riccio P, Lu B, et al. Non-cell-autonomous retinoid signaling is crucial for renal development. Development [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2010;137(2):283–92. 173. Quaggin SE, Vanden Heuvel GB, Igarashi P. Pod-1, a mesoderm-specific basic-helix-loop-helix protein expressed in mesenchymal and glomerular epithelial cells in the developing kidney. Mech Dev. 1998;71:37–48.

C. Bates et al. 174. Fetting JL, Guay JA, Karolak MJ, Iozzo RV, Adams DC, Maridas DE, et al. FOXD1 promotes nephron progenitor differentiation by repressing decorin in the embryonic kidney. Development. 2014;141(1): 17–27. 175. Hum S, Rymer C, Schaefer C, Bushnell D, SimsLucas S. Ablation of the renal stroma defines its critical role in nephron progenitor and vasculature patterning. PLoS One. 2014;9(2):e88400. 176. Stolz DB, Sims-Lucas S. Unwrapping the origins and roles of the renal endothelium. Pediatr Nephrol. 2014. 177. Yu J, Valerius MT, Duah M, Staser K, Hansard JK, Guo JJ. Identification of molecular compartments and genetic circuitry in the developing mammalian kidney. Development. 2012;139(10):1863–73. 178. Brunskill EW, Potter SS. Gene expression programs of mouse endothelial cells in kidney development and disease. PLoS One. 2010;5(8):e12034. 179. Abrahamson DR, Robert B, Hyink DP, St John PL, Daniel TO. Origins and formation of microvasculature in the developing kidney. Kidney Int Suppl [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S. Review]. 1998;67:S7–11. 180. Robert B, St John PL, Abrahamson DR. Direct visualization of renal vascular morphogenesis in Flk1 heterozygous mutant mice. Am J Physiol [Research Support, U.S. Gov’t, P.H.S.]. 1998;275(1 Pt 2): F164–72. 181. Sequeira Lopez ML, Gomez RA. Development of the renal arterioles. J Am Soc Nephrol. 2011;22(12): 2156–65. 182. Lancrin C, Sroczynska P, Serrano AG, Gandillet A, Ferreras C, Kouskoff V, et al. Blood cell generation from the hemangioblast. J Mol Med [Research Support, Non-U.S. Gov’t Review]. 2010;88(2):167–72. 183. Kume T. Specification of arterial, venous, and lymphatic endothelial cells during embryonic development. Histol Histopathol. 2010;25(5):637–46. 184. Sims-Lucas S, Schaefer C, Bushnell D, Ho J, Logar A, Prochownik E, et al. Endothelial progenitors exist within the kidney and lung mesenchyme. PLoS One. 2013;8(6):e65993. 185. Schmidt-Ott KM, Chen X, Paragas N, Levinson RS, Mendelsohn CL, Barasch J. c-kit delineates a distinct domain of progenitors in the developing kidney. Dev Biol [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2006;299(1):238–49. 186. Marlier A, Schmidt-Ott KM, Gallagher AR, Barasch J, Karihaloo A. Vegf as an epithelial cell morphogen modulates branching morphogenesis of embryonic kidney by directly acting on the ureteric bud. Mech Dev [Research Support, Non-U.S. Gov’t]. 2009;126(3–4):91–8. 187. Freeburg PB, Robert B, St John PL, Abrahamson DR. Podocyte expression of hypoxia-inducible factor (HIF)-1 and HIF-2 during glomerular development. J Am Soc Nephrol. 2003;14(4):927–38. 188. Steenhard BM, Freeburg PB, Isom K, Stroganova L, Borza DB, Hudson BG, et al. Kidney development

1

Embryonic Development of the Kidney

and gene expression in the HIF2alpha knockout mouse. Dev Dyn. 2007;236(4):1115–25. 189. Kappel A, Ronicke V, Damert A, Flamme I, Risau W, Breier G. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/ enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood. 1999;93(12):4284–92. 190. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem. 1997;272(38):23659–67. 191. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem. 1995;270(22):13333–40. 192. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5’ enhancer. Circ Res. 1995;77(3):638–43. 193. Woolf AS, Gnudi L, Long DA. Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol. 2009;20(2):239–44. 194. Simon MP, Tournaire R, Pouyssegur J. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J Cell Physiol. 2008;217(3): 809–18. 195. Kolatsi-Joannou M, Li XZ, Suda T, Yuan HT, Woolf AS. Expression and potential role of angiopoietins and Tie-2 in early development of the mouse metanephros. Dev Dyn. 2001;222(1):120–6. 196. Jeansson M, Gawlik A, Anderson G, Li C, Kerjaschki D, Henkelman M, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest. 2011;121(6):2278–89. 197. Tachibana K, Jones N, Dumont DJ, Puri MC, Bernstein A. Selective role of a distinct tyrosine residue on Tie2 in heart development and early hematopoiesis. Mol Cell Biol. 2005;25(11):4693–702. 198. Pitera JE, Woolf AS, Gale NW, Yancopoulos GD, Yuan HT. Dysmorphogenesis of kidney cortical peritubular capillaries in angiopoietin-2-deficient mice. Am J Pathol. 2004;165(6):1895–906. 199. Tung JJ, Tattersall IW, Kitajewski J. Tips, stalks, tubes: notch-mediated cell fate determination and mechanisms of tubulogenesis during angiogenesis. Cold Spring Harb Perspect Med. 2012;2(2):a006601. 200. Piscione TD, Rosenblum ND. The malformed kidney: disruption of glomerular and tubular development. Clin Genet. 1999;56(5):343–58. 201. Sainio K, Suvanto P, Davies J, Wartiovaara J, Wartiovaara K, Saarma M, et al. Glial-cell-linederived neurotrophic factor is required for bud initiation from ureteric epithelium. Development. 1997;124:4077–87.

33 202. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature. 1994;367:380–3. 203. Enomoto H, Araki T, Jackman A, Heuckeroth RO, Snider WD, Johnson EMJ, et al. GFRα 1-deficient mice have deficits in the enteric nervous system and kidneys. Neuron. 1998;21:317–24. 204. Pichel JG, Shen L, Sheng HZ, Granholm A-C, Drago J, Grinberg A, et al. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature. 1996;382:73–6. 205. Sanchez MP, Silos-Santiago I, Frisen J, He B, Lira SA, Barbacid M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature. 1996;382:70–3. 206. Schuchardt A, D'Agati V, Pachnis V, Costantini F. Renal agenesis and hypodysplasia in ret-k mutant mice result from defects in ureteric bud development. Development. 1996;122:1919–29. 207. Cacalano G, Farinas I, Wang LC, Hagler K, Forgie A, Moore M, et al. GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney. Neuron. 1998;21:53–62. 208. Jain S, Encinas M, Johnson EM, Jr., Milbrandt J. Critical and distinct roles for key RET tyrosine docking sites in renal development. Genes Dev [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2006;20(3):321–33. 209. Jain S, Knoten A, Hoshi M, Wang H, Vohra B, Heuckeroth RO, et al. Organotypic specificity of key RET adaptor-docking sites in the pathogenesis of neurocristopathies and renal malformations in mice. J Clin Invest [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2010;120(3): 778–90. 210. Skinner MA, Safford SD, Reeves JG, Jackson ME, Freemerman AJ. Renal aplasia in humans is associated with RET mutations. Am J Hum Genet. 2008;82(2):344–51. 211. Yang Y, Houle AM, Letendre J, Richter A. RET Gly691Ser mutation is associated with primary vesicoureteral reflux in the French-Canadian population from Quebec. Hum Mutat [Research Support, Non-U.S. Gov’t]. 2008;29(5):695–702. 212. Bullock SL, Fletcher JM, Beddington RSP, Wilson VA. Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes Dev. 1998;12:1894–906. 213. Pepicelli CV, Kispert A, Rowitch D, McMahon AP. GDNF induces branching and increased cell proliferation in the ureter of the mouse. Dev Biol. 1997;192:193–8. 214. Srinivas S, Wu Z, Chen C-M, D’Agati V, Costantini F. Dominant effects of RET receptor misexpression and ligand-independent RET signaling on ureteric bud development. Development. 1999;126:1375–86.

34 215. Shakya R, Jho EH, Kotka P, Wu Z, Kholodilov N, Burke R, et al. The role of GDNF in patterning the excretory system. Dev Biol. 2005;283(1):70–84. 216. Kume T, Deng K, Hogan BL. Murine forkhead/ winged helix genes Foxc1 (Mf1) and Foxc2 (Mfh1) are required for the early organogenesis of the kidney and urinary tract. Development. 2000;127:1387–95. 217. Grieshammer U, Le M, Plump AS, Wang F, TessierLavigne M, Martin GR. SLIT2-mediated ROBO2 signaling restricts kidney induction to a single site. Dev Cell. 2004;6(5):709–17. 218. Tessier-Lavigne M, Goodman CS. The molecular biology of axon guidance. Science. 1996;274:1123–33. 219. Brose K, Bland KS, Wang KH, Arnott D, Henzel W, Goodman CS, et al. Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell. 1999;96:795–806. 220. Piper M, Georgas K, Yamada T, Little M. Expression of the vertebrate Slit gene family and their putative receptors, the Robo genes, in the developing murine kidney. Mech Dev. 2000;94:213–7. 221. Lu W, van Eerde AM, Fan X, Quintero-Rivera F, Kulkarni S, Ferguson H, et al. Disruption of ROBO2 is associated with urinary tract anomalies and confers risk of vesicoureteral reflux. Am J Hum Genet [Comparative Study]. 2007;80(4):616–32. 222. Basson MA, Watson-Johnson J, Shakya R, Akbulut S, Hyink D, Costantini FD, et al. Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1. Dev Biol. 2006;299(2):466–77. 223. Basson MA, Akbulut S, Watson-Johnson J, Simon R, Carroll TJ, Shakya R, et al. Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Dev Cell. 2005;8(2):229–39. 224. Dudley AT, Robertson EJ. Overlapping expression domains of bone morphogenetic protein family members potentially account for limited tissue defects in BMP7 deficient embryos. Dev Dyn. 1997;208:349–62. 225. Pope IV JC, Brock III JW, Adams MC, Stephens FD, Ichikawa I. How they begin and how they end: classis and new theories for the development and deterioration of congenital anomalies of the kidney and urinary tract, CAKUT. J Am Soc Nephrol. 1999;10:2018–28. 226. Ichikawa I, Kuwayama F, Pope JCT, Stephens FD, Miyazaki Y. Paradigm shift from classic anatomic theories to contemporary cell biological views of CAKUT. Kidney Int. 2002;61(3):889–98. 227. Bush KT, Sakurai H, Steer DL, Leonard MO, Sampogna RV, Meyer TN, et al. TGF-beta superfamily members modulate growth, branching, shaping, and patterning of the ureteric bud. Dev Biol. 2004;266(2):285–98. 228. Weber S, Taylor JC, Winyard P, Baker KF, SullivanBrown J, Schild R, et al. SIX2 and BMP4 mutations associate with anomalous kidney development. J Am

C. Bates et al. Soc Nephrol [Research Support, Non-U.S. Gov’t]. 2008;19(5):891–903. 229. Lu BC, Cebrian C, Chi X, Kuure S, Kuo R, Bates CM, et al. Etv4 and Etv5 are required downstream of GDNF and Ret for kidney branching morphogenesis. Nat Genet [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2009;41 (12):1295–302. 230. Majumdar A, Vainio S, Kispert A, McMahon J, McMahon AP. Wnt11 and Ret/Gdnf pathways cooperate in regulating ureteric branching during metanephric kidney development. Development. 2003;130(14):3175–85. 231. Al-Awqati Q, Goldberg MR. Architectural patterns in branching morphogenesis in the kidney. Kidney Int. 1998;54:1832–42. 232. Watanabe T, Costantini F. Real-time analysis of ureteric bud branching morphogenesis in vitro. Dev Biol. 2004;271(1):98–108. 233. Lin Y, Zhang S, Tuukkanen J, Peltoketo H, Pihlajaniemi T, Vainio S. Patterning parameters associated with the branching of the ureteric bud regulated by epithelial-mesenchymal interactions. Int J Dev Biol. 2003;47(1):3–13. 234. Fisher CE, Michael L, Barnett MW, Davies JA. Erk MAP kinase regulates branching morphogenesis in the developing mouse kidney. Development. 2001;128(21):4329–38. 235. Michael L, Davies JA. Pattern and regulation of cell proliferation during murine ureteric bud development. J Anat. 2004;204(4):241–55. 236. Sorenson CM, Rogers SA, Korsmeyer SJ, Hammerman MR. Fulminant metanephric apoptosis and abnormal kidney development in bcl-2-deficient mice. Am J Physiol. 1995;268:F73–81. 237. Moser M, Pscherer A, Roth C, Becker J, M€ ucher G, Zerres K, et al. Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2ß. Genes Dev. 1997;11:1938–48. 238. Chevalier RL. Growth factors and apoptosis in neonatal ureteral obstruction. J Am Soc Nephrol. 1996;7:1098–105. 239. Tarantal AF, Han VK, Cochrum KC, Mok A, daSilva M, Matsell DG. Fetal rhesus monkey model of obstructive renal dysplasia. Kidney Int. 2001;59:446–56. 240. Kispert A, Vainio S, Shen L, Rowitch DH, McMahon AP. Proteoglycans are required for maintenance of Wnt-11 expression in the ureter tips. Development. 1996;122:3627–37. 241. Bridgewater D, Cox B, Cain J, Lau A, Athaide V, Gill PS, et al. Canonical WNT/beta-catenin signaling is required for ureteric branching. Dev Biol. 2008;317(1):83–94. 242. Marose TD, Merkel CE, McMahon AP, Carroll TJ. Beta-catenin is necessary to keep cells of ureteric bud/Wolffian duct epithelium in a precursor state. Dev Biol. 2008;314(1):112–26.

1

Embryonic Development of the Kidney

243. Qiao J, Bush KT, Steer DL, Stuart RO, Sakurai H, Wachsman W, et al. Multiple fibroblast growth factors support growth of the ureteric bud but have different effects on branching morphogenesis. Mech Dev. 2001;109(2):123–35. 244. Ohuchi H, Hori Y, Yamasaki M, Harada H, Sekine K, Kato S, et al. FGF10 acts as a major ligand for FGF receptor 2 IIIb in mouse multi-organ development. Biochem Biophys Res Commun. 2000;277:643–9. 245. Poladia DP, Kish K, Kutay B, Hains D, Kegg H, Zhao H, et al. Role of fibroblast growth factor receptors 1 and 2 in the metanephric mesenchyme. Dev Biol. 2006;291(2):325–39. 246. Sims-Lucas S, Cusack B, Eswarakumar VP, Zhang J, Wang F, Bates CM. Independent roles of Fgfr2 and Frs2alpha in ureteric epithelium. Development. 2011;138(7):1275–80. 247. Zhao H, Kegg H, Grady S, Truong HT, Robinson ML, Baum M, et al. Role of fibroblast growth factor receptors 1 and 2 in the ureteric bud. Dev Biol. 2004;276(2):403–15. 248. Michos O, Cebrian C, Hyink D, Grieshammer U, Williams L, D'Agati V, et al. Kidney development in the absence of Gdnf and Spry1 requires Fgf10. PLoS Genet. 2010;6(1):e1000809. 249. Chi L, Zhang S, Lin Y, Prunskaite-Hyyrylainen R, Vuolteenaho R, Itaranta P, et al. Sprouty proteins regulate ureteric branching by coordinating reciprocal epithelial Wnt11, mesenchymal Gdnf and stromal Fgf7 signalling during kidney development. Development. 2004;131(14):3345–56. 250. Cebrian C, Borodo K, Charles N, Herzlinger DA. Morphometric index of the developing murine kidney. Dev Dyn. 2004;231(3):601–8. 251. Bard J. A new role for the stromal cells in kidney development. Bioessays. 1996;18(9):705–7. 252. Bonneh-Barkay D, Shlissel M, Berman B, Shaoul E, Admon A, Vlodavsky I, et al. Identification of glypican as a dual modulator of the biological activity of fibroblast growth factors. J Biol Chem. 1997;272:12415–21. 253. Cano-Gauci DF, Song H, Yang H, McKerlie C, Choo B, Shi W, et al. Glypican-3-deficient mice exhibit developmental overgrowth and some of the renal abnormalities typical of SimpsonGolabi-Behmel syndrome. J Cell Biol. 1999;146:255–64. 254. Grisaru S, Cano-Gauci D, Tee J, Filmus J, Rosenblum ND. Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis. Dev Biol. 2001;231:31–46. 255. Jackson SM, Nakato H, Sugiura M, Jannuzi A, Oakes R, Kaluza V, et al. Dally, a drosophila glypican, controls cellular responses to the TGF-ß-related morphogen Dpp. Development. 1997;124:4113–20. 256. Tsuda M, Kamimura K, Nakato H, Archer M, Staatz W, Fox B, et al. The cell-surface proteoglycan dally regulates wingless signalling in Drosophila. Nature. 1999;400:276–80.

35 257. Zhang P, Liégeois NJ, Wong C, Finegold M, Thompson JC, Silverman A, et al. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature. 1997;387:151–8. 258. Yu J, Carroll TJ, Rajagopal J, Kobayashi A, Ren Q, McMahon AP. A Wnt7b-dependent pathway regulates the orientation of epithelial cell division and establishes the cortico-medullary axis of the mammalian kidney. Development [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2009;136(1):161–71. 259. Liu Y, Chattopadhyay N, Qin S, Szekeres C, Vasylyeva T, Mahoney ZX, et al. Coordinate integrin and c-Met signaling regulate Wnt gene expression during epithelial morphogenesis. Development [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2009;136(5):843–53. 260. Niimura F, Labostky PA, Kakuchi J, Okubo S, Yoshida H, Oikawa T, et al. Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest. 1995;96:2947–54. 261. Miyazaki Y, Tsuchida S, Nishimura H, Pope IV JC, Harris RC, McKanna JM, et al. Angiotensin induces the urinary peristaltic machinery during the perinatal period. J Clin Invest. 1998;102:1489–97. 262. Rasouly HM, Lu W. Lower urinary tract development and disease. Wiley Interdiscip Rev Syst Biol Med. 2013;5(3):307–42. 263. Brenner-Anantharam A, Cebrian C, Guillaume R, Hurtado R, Sun TT, Herzlinger D. Tailbud-derived mesenchyme promotes urinary tract segmentation via BMP4 signaling. Development. 2007;134(10): 1967–75. 264. McHugh KM. Molecular analysis of smooth muscle development in the mouse. Dev Dyn. 1995;204(3): 278–90. 265. Yu J, Carroll TJ, McMahon AP. Sonic hedgehog regulates proliferation and differentiation of mesenchymal cells in the mouse metanephric kidney. Development [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. 2002;129(22):5301–12. 266. Wu XR, Kong XP, Pellicer A, Kreibich G, Sun TT. Uroplakins in urothelial biology, function, and disease. Kidney Int. 2009;75(11):1153–65. 267. Weiss RM, Guo S, Shan A, Shi H, Romano RA, Sinha S, et al. Brg1 determines urothelial cell fate during ureter development. J Am Soc Nephrol. 2013;24(4):618–26. 268. Cain JE, Islam E, Haxho F, Blake J, Rosenblum ND. GLI3 repressor controls functional development of the mouse ureter. J Clin Invest [Research Support, Non-U.S. Gov’t]. 2011;121(3):1199–206. 269. Hurtado R, Bub G, Herzlinger D. The pelvis-kidney junction contains HCN3, a hyperpolarizationactivated cation channel that triggers ureter peristalsis. Kidney Int. 2010;77(6):500–8.

36 270. Price KL, Woolf AS, Long DA. Unraveling the genetic landscape of bladder development in mice. J Urol [Research Support, Non-U.S. Gov’t]. 2009;181(5):2366–74. 271. Singh S, Robinson M, Nahi F, Coley B, Robinson ML, Bates CM, et al. Identification of a unique transgenic mouse line that develops megabladder, obstructive uropathy, and renal dysfunction. J Am Soc Nephrol. 2007;18(2):461–71. 272. Gandhi D, Molotkov A, Batourina E, Schneider K, Dan H, Reiley M, et al. Retinoid signaling in progenitors controls specification and regeneration of the urothelium. Dev Cell [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2013;26(5):469–82. 273. Batourina E, Tsai S, Lambert S, Sprenkle P, Viana R, Dutta S, et al. Apoptosis induced by vitamin A signaling is crucial for connecting the ureters to the bladder. Nat Genet. 2005;37(10):1082–9. 274. Viana R, Batourina E, Huang H, Dressler GR, Kobayashi A, Behringer RR, et al. The development of the bladder trigone, the center of the anti-reflux mechanism. Development. 2007;134(20):3763–9. 275. Airik R, Bussen M, Singh MK, Petry M, Kispert A. Tbx18 regulates the development of the ureteral mesenchyme. J Clin Invest. 2006;116(3):663–74. 276. Kong XT, Deng FM, Hu P, Liang FX, Zhou G, Auerbach AB, et al. Roles of uroplakins in plaque formation, umbrella cell enlargement, and urinary tract diseases. J Cell Biol. 2004;167(6):1195–204. 277. Hu P, Deng FM, Liang FX, Hu CM, Auerbach AB, Shapiro E, et al. Ablation of uroplakin III gene results in small urothelial plaques, urothelial leakage, and vesicoureteral reflux. J Cell Biol. 2000;151(5): 961–72. 278. Jenkins D, Bitner-Glindzicz M, Malcolm S, Hu CC, Allison J, Winyard PJ, et al. De novo Uroplakin IIIa heterozygous mutations cause human renal adysplasia leading to severe kidney failure. J Am Soc Nephrol. 2005;16(7):2141–9. 279. Jenkins D, Bitner-Glindzicz M, Malcolm S, Allison J, de Bruyn R, Flanagan S, et al. Mutation analyses of Uroplakin II in children with renal tract malformations. Nephrol Dial Transplant. 2006; 21(12):3415–21. 280. Wang GJ, Brenner-Anantharam A, Vaughan ED, Herzlinger D. Antagonism of BMP4 signaling disrupts smooth muscle investment of the ureter and ureteropelvic junction. J Urol. 2009;181(1): 401–7. 281. Caubit X, Lye CM, Martin E, Core N, Long DA, Vola C, et al. Teashirt 3 is necessary for ureteral smooth muscle differentiation downstream of SHH and BMP4. Development [Research Support, Non-U.S. Gov’t]. 2008;135(19):3301–10. 282. Kang S, Graham Jr JM, Olney AH, Biesecker LG. GLI3 frameshift mutations cause autosomal

C. Bates et al. dominant Pallister-Hall syndrome. Nat Genet. 1997;15(3):266–8. 283. Trowe MO, Airik R, Weiss AC, Farin HF, Foik AB, Bettenhausen E, et al. Canonical Wnt signaling regulates smooth muscle precursor development in the mouse ureter. Development. 2012;139:2009–3108. 284. Chang CP, McDill BW, Neilson JR, Joist HE, Epstein JA, Crabtree GR, et al. Calcineurin is required in urinary tract mesenchyme for the development of the pyeloureteral peristaltic machinery. J Clin Invest. 2004;113(7):1051–8. 285. Miyazaki Y, Tsuchida S, Nishimura H, Pope JCt, Harris RC, McKanna JM, et al. Angiotensin induces the urinary peristaltic machinery during the perinatal period. J Clin Invest [Research Support, Non-U.S. Research Support, U.S. Gov’t, Gov’t P.H.S.]. 1998;102(8):1489–97. 286. Mahoney ZX, Sammut B, Xavier RJ, Cunningham J, Go G, Brim KL, et al. Discs-large homolog 1 regulates smooth muscle orientation in the mouse ureter. Proc Natl Acad Sci U S A. 2006;103(52):19872–7. 287. Dravis C, Yokoyama N, Chumley MJ, Cowan CA, Silvany RE, Shay J, et al. Bidirectional signaling mediated by ephrin-B2 and EphB2 controls urorectal development. Dev Biol. 2004;271(2):272–90. 288. Mo R, Kim JH, Zhang J, Chiang C, Hui CC, Kim PC. Anorectal malformations caused by defects in sonic hedgehog signaling. Am J Pathol. 2001; 159(2):765–74. 289. Baskin L, DiSandro M, Li Y, Li W, Hayward S, Cunha G. Mesenchymal-epithelial interactions in bladder smooth muscle development: effects of the local tissue environment. J Urol. 2001;165(4): 1283–8. 290. DiSandro MJ, Li Y, Baskin LS, Hayward S, Cunha G. Mesenchymal-epithelial interactions in bladder smooth muscle development: epithelial specificity. J Urol. 1998;160(3 Pt 2):1040–6; discussion 79. 291. Cao M, Tasian G, Wang MH, Liu B, Cunha G, Baskin L. Urothelium-derived Sonic hedgehog promotes mesenchymal proliferation and induces bladder smooth muscle differentiation. Differentiation [Research Support, N.I.H., Extramural]. 2010; 79(4–5):244–50. 292. Cheng W, Yeung CK, Ng YK, Zhang JR, Hui CC, Kim PC. Sonic Hedgehog mediator Gli2 regulates bladder mesenchymal patterning. J Urol [Research Support, Non-U.S. Gov’t]. 2008;180(4):1543–50. 293. DeSouza KR, Saha M, Carpenter AR, Scott M, McHugh KM. Analysis of the Sonic Hedgehog signaling pathway in normal and abnormal bladder development. PLoS One [Research Support, N.I.H., Extramural]. 2013;8(1):e53675. 294. Hoshi M, Batourina E, Mendelsohn C, Jain S. Novel mechanisms of early upper and lower urinary tract patterning regulated by RetY1015 docking tyrosine in mice. Development. 2012;139(13):2405–15.

2

Development of Glomerular Circulation and Function Alda Tufro and Ashima Gulati

Contents

Introduction

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 Development of the Kidney Vasculature . . . . . . . . . . . 38 Vasculogenesis and Angiogenesis . . . . . . . . . . . . . . . . . . . . 38 The Glomerular Filtration Barrier . . . . . . . . . . . . . . . . . 41 Components of the GFB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 Glomerular Filtration Barrier (GFB) Selective Permeability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 Glomerular Hemodynamics and Assessment of Renal Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Renal Blood Flow: Basic Concepts . . . . . . . . . . . . . . . . . . . Perinatal Considerations for Renal Blood Flow and GFR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . The Concept of Clearance . . . . . . . . . . . . . . . . . . . . . . . . . . . .

46 47 47 50

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53

A. Tufro (*) • A. Gulati Department of Pediatrics, Nephrology Section, Yale School of Medicine, New Haven, CT, USA e-mail: [emailprotected] # Springer-Verlag Berlin Heidelberg 2016 E.D. Avner et al. (eds.), Pediatric Nephrology, DOI 10.1007/978-3-662-43596-0_2

From the Malpighian corpuscle description and Bowman’s sketch to defining its ultrastructure and molecular function, the ways we look at the kidney glomerulus have evolved tremendously. The first systematic exploration of the body with a microscope led to the identification of “Malpighian corpuscles” as “glands” within the kidney [1]. Two centuries later, a more sophisticated microscope enabled Sir William Bowman to identify glomerular capillary tufts in animal and human kidneys and demonstrate a relationship between the capillary tuft and the renal tubule [2]. Since then, the understanding of the human glomerulus as a specialized structure uniquely adapted for renal filtration at the proximal part of the nephron has considerably advanced. The human definitive kidney is a highly complex organ system with an average number of ~1 million functional units called nephrons. Nephrogenesis involves the development of the glomerulus (glomerulogenesis) and the renal tubule (tubulogenesis) from mesenchymal progenitors residing in the metanephric mesenchyme and ureteric bud. The specification, maintenance, and commitment of nephron progenitors and the regulatory processes that transform nephron progenitors into a functional nephron are detailed elsewhere ([3]; see ▶ Chaps. 1, “Embryonic Development of the Kidney,” and ▶ 18, “Translational Research Methods: Renal Stem Cells” in this text). The current chapter aims to 37

38

combine established knowledge and new findings pertaining to the structural and functional aspects of glomerular development, describe intricacies of the glomerular filtration barrier at the molecular level, and provide insight into future research areas. Three attributes make the human glomerulus a fascinating focus of research and clinical significance: first is the synchrony among vasculogenesis, angiogenesis, and epithelial and stromal differentiation; second, the glomerular unique ultrastructure provides controlled regulation of filtration while acting as a barrier; and third, the glomerulus is the major controller of renal hemodynamics and provides functional advantages for effective filtration. Each of these attributes and their relevance for clinical use will be discussed in the following sections.

Development of the Kidney Vasculature The kidney vasculature develops in a patterned fashion, allowing structural and functional development of the glomerular circulation that eventually handles 20 % of the cardiac output for the purpose of clearing metabolic waste products and toxins and maintaining fluid and electrolyte balance [4]. The complex architecture of the renal vasculature is essential for the organ function and comprises an arterial tree and three capillary beds. Single renal arteries branch and direct over 90 % of the renal blood flow to glomeruli in the renal cortex. The glomerular capillary bed length amplifies the area for filtration, allowing the highest fluid outflow rate in the body. Glomerular capillaries are flanked by high-resistance afferent and efferent arterioles, which regulate the rate of blood flow through the capillary bed and thereby glomerular filtration. Two postglomerular capillary networks emerge in series from efferent arterioles. Efferent arterioles from superficial glomeruli give rise to cortical peritubular capillaries, while those from the juxtamedullary glomeruli give rise to vasa recta. Close alignment of the postglomerular microvasculature with cortical and medullary renal tubules is critical for oxygen

A. Tufro and A. Gulati

delivery to all nephron segments and for fluid and solute reabsorption from them. As a result of fluid removal by glomerular ultrafiltration, oncotic pressure in postglomerular capillaries increases above hydrostatic pressure. Thus, peritubular capillaries are poised for fluid and solute reabsorption.

Vasculogenesis and Angiogenesis The formation of the kidney vasculature comprises in situ differentiation of endothelial cells from hemangioblasts present in the metanephric mesenchyme and capillary assembly, a process called vasculogenesis, and angiogenesis wherein capillary growth occurs by the sprouting and/or splitting of existing capillaries within or surrounding the developing kidney [5–9]. In vivo, vasculogenesis and angiogenesis might occur sequentially or simultaneously [10].

Vasculogenesis and Angiogenesis Contribute to the Kidney Vasculature The origin of kidney endothelial cells and the mechanisms involved in kidney vascularization have been extensively examined in experimental models and debated for quite some time. Genetic fate mapping and the identification of molecular guidance cues from angiogenic factors have largely resolved these controversies. The hypothesis of extrarenal angiogenic origin of kidney endothelial cells is supported by elegant interspecies transplantation experiments and by the absence of vascular development in embryonic kidneys cultured ex vivo [11–13]. As shown in other embryonic vascular beds [14], Sariola and colleagues showed evidence of angiogenesis in undifferentiated embryonic mouse kidney rudiments after the transplantation onto avian chorioallantoic membrane [15, 16]. Indeed, grafts were well vascularized, and both the glomerular and the vessel endothelium expressed an avian nuclear marker, suggesting that the glomerular endothelium is derived from extrinsic (avian) vasculature rather than by the differentiation of endothelial cells native to the metanephric mesenchyme [15–17]. Abrahamson et al. demonstrated that

2

Development of Glomerular Circulation and Function

embryonic kidneys grafted under the renal capsule of newborn mice were vascularized by host endothelium, whereas adult hosts failed to vascularize the grafts [18], suggesting that the angiogenic activity of the host is crucial to this process. The hypothesis of the endogenous, vasculogenic origin of glomerular endothelial cells is supported by the identification of native endothelial precursors in the metanephric mesenchyme, by the exposure of avascular metanephric kidneys to hypoxia or angiogenic factors, and by grafting experiments [18–21]. These findings were facilitated by the landmark discovery of vascular endothelial growth factor (VEGF) receptors Flk1 and Flt1, as indispensable for endothelial differentiation and vascular assembly and thus genetic markers of endothelial precursors [22–24]. Flk1+ and Flt1+ angioblasts were detected within the avascular metanephric mesenchyme [19–21], demonstrating that endothelial progenitors in situ enable vasculogenesis in the developing kidney [25–28]. Flt-1 and Flk-1 are expressed in isolated cells before any morphologic evidence of vascular development in the metanephric blastema [25]. Within 24 h in culture, Flk-1-expressing cells align to form cord-like structures, followed by the acquisition of lumen and typical endothelial cell phenotype in the following 2 days. As renal vascularization proceeds, Flt-1 and Flk-1 are expressed in contiguous endothelial cells [25]. Exposure of avascular kidney rudiments to hypoxia similar to that occurring in embryonic tissues leads Flk1+ angioblasts present within the metanephric blastema to form primitive vascular networks via the upregulation of VEGF [29]. Similarly, exposure to exogenous VEGF enables avascular embryonic kidneys to develop capillaries [25, 30]. Genetically tagged LacZFlk1+ embryonic mouse kidneys grafted into the anterior chamber of the rat eye develop glomeruli vascularized by graft rather than host endothelial cells [31]. Remarkably, the glomerular basement membrane and mesangial matrix were noted to be exclusively of graft origin, implying the selfsufficient capability of the metanephric mesenchyme to form the glomerulus [19]. Furthermore, Tie-1/LacZ metanephros transplanted into the

39

nephrogenic cortex of wild-type mice develop transgene-expressing glomerular capillary loops [31]. In contrast, glomerular Tie-1/LacZ + vessels do not develop in rudiments placed in organ culture on 20 % O2 [31]. This capability of Flk1+ angioblasts to give rise to a primitive vasculature has subsequently been confirmed in vitro and in vivo explant assays [18, 19, 32, 33]. These observations imply that endothelial progenitors present at the onset of mouse nephrogenesis differentiate and undergo morphogenesis to become glomerular capillaries when experimental conditions resemble those found in the metanephros in vivo, such as moderate hypoxia. Together, a large body of experimental data demonstrates that both vasculogenesis and angiogenesis contribute to the formation of kidney vasculature under the influence of a variety of growth factors and guidance proteins. Blood vessels are comprised of endothelial cells and associated vascular mural cells including pericytes and vascular smooth muscle cells. While the data outlined above provide evidence for the presence of endothelial progenitors in the metanephric blastema as well as ingrowing endothelial cells, genetic fate mapping experiments demonstrate that Foxd1+ cells present at the periphery of the metanephric blastema give rise to most vascular mural cells, thus contributing to the overall vascular structural development [34].

Angiogenic Factor Signaling Is Critical for Patterning the Kidney Vasculature The kidney endothelium undergoes specification into distinct histological types in arteries, veins, capillaries, and lymphatics, including continuous endothelium or endothelium fenestrated with diaphragms. This specification is adapted to the tissue permeability characteristics and is determined by local microenvironmental cues, irrespectively of the endothelial cell lineage [35]. For example, the grafting of embryonic vessels with fenestrated endothelium into the brain resulted in tight continuous endothelium typical of the blood-brain barrier [36]. Though the progenitor lineage might contribute to endothelial cell heterogeneity within the kidney, endothelium specification by local environmental cues involves dynamic cross

40

talk between various signaling pathways that communicate by way of growth factors [37]. Soluble angiogenic factors and guidance proteins including VEGF-A, basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), and semaphorin 3A play a key role in kidney vascularization. VEGF-A is a pleiotropic glycoprotein originally described as a vascular permeability and endothelial growth factor [38–40]. VEGF is a direct-acting specific endothelial cell mitogen that stimulates angiogenesis and regulates embryonic vessel development in a gene dosagedependent manner [41]. VEGF-A is required for endothelial cell differentiation, survival, proliferation, and migration, as well as for vascular assembly, maintenance, and remodeling; thus it is critical for physiological angiogenesis [42, 43]. During kidney development, VEGF-A expressed in the metanephric mesenchyme acts as a chemoattractant for endothelial cells and directs their migration toward developing nephrons [30]. Glomerular development starts when nephrons are at the S-shaped body stage, at which time podocytes differentiate and express VEGF-A, leading endothelial progenitors to migrate into and differentiate in the adjacent “vascular cleft.” Podocytes synthesize three VEGF-A isoforms (VEGF121-165-189) by alternative splicing [44]. VEGF-A isoforms with differences in size, membrane, and extracellular matrix-binding properties (VEGF121 and the most abundant VEGF165 are secreted) enable gradient formation and endothelial cell chemoattraction [30]. The glomerular endothelium forms a single capillary loop initially that later forms the mature glomerular tuft. VEGF-A is indispensable for normal development of glomerular capillaries [45] and to acquire their fenestrated phenotype [46–48]. The principal source of VEGF-A in the renal glomerulus is the podocyte [49]. Continuous expression of VEGF-A in podocytes and tubular cells and of Flk1 on the adjacent endothelia induces and maintains the fenestrated endothelia and also regulates vascular permeability [26, 48, 50, 51]. Podocytes and tubular cells express VEGF-A throughout life, unlike other tissues that cease expressing VEGF-A at the completion of

A. Tufro and A. Gulati

development [25, 26]. Moreover, tightly regulated VEGF-A is required to establish and maintain a normal podocyte phenotype, i.e., foot processes linked by slit diaphragms, as revealed by both loss- and gain-of-function mouse models [45, 52–54]. VEGF-A signals in autocrine and paracrine fashion in podocytes, renal tubules, and endothelial cells promoting the survival, proliferation, and migration in vitro and in vivo [44, 45, 55–62]. VEGF-A receptors are most abundant in endothelial cells, but they are expressed by multiple cells, including podocytes and tubular cells [44, 57, 59, 60, 62–64]. Two VEGF-A tyrosine kinase receptors, VEGFR-1 [previously known as fms-like tyrosine kinase-1 (Flt-1)] and VEGFR-2 [formerly murine fetal liver kinase 1 (flk-1)/human kinase insert domain receptor (KDR)], and two co-receptors, neuropilin-1 and neuropilin-2 (NRP1 and NRP2), have been described. VEGF-A signals are transduced through VEGFR2 and NRP1 and NRP2 amplify VEGFR2 signals, while VEGFR1 functions mostly as a decoy [65]. The importance of VEGF-A signaling for embryonic vascular development is illustrated by gene deletion experiments. Both heterozygous and homozygous VEGF-A knockout mice die during embryogenesis due to major vascular defects [66, 67]. Flk-1deficient mice die in utero because of an early defect in the development of hematopoietic cells and endothelial cells [22]. Flt-1-deficient mice die later in utero, due to the disorganization of the early embryonic vasculature [23, 68]. Hypoxia leads to the stabilization of HIF-1α, a transcriptional activator of hypoxia-inducible genes, including VEGF-A, erythropoietin, and other angiogenic factors expressed in the kidney, such as angiopoietin-1, angiopoietin-2, PDGFBB, and FGFβ [10, 69]. Although it is likely that several signaling pathways contribute to the angiogenic response to hypoxia in kidney development resulting in glomerular vascularization, undoubtedly VEGF-A plays a critical role [10]. Accordingly, the deletion of podocyte VEGF-A reduces the glomerular endothelial cells [45]. In contrast, the ablation of semaphorin 3A, a guidance protein that functions as a negative regulator of endothelial cell survival and

2

Development of Glomerular Circulation and Function

migration, which is also secreted by podocytes [70, 71], results in glomerular capillary hyperplasia [72]. Conversely, excess podocyte semaphorin 3A leads to glomerular endothelial apoptosis and a low number of glomerular endothelial cells [72]. Together, these studies indicate that glomerular capillary development depends on pro- and antiangiogenic signaling pathways shared with other vascular beds, while it is clear that podocytes play a key role controlling glomerulogenesis. Other hypoxia-regulated angiogenic factors control the relationship between endothelial and mesangial cells during glomerular development, as revealed by targeted deletion experiments. The ablation of PDGF B, or its receptor PDGFR beta, expressed by endothelial and mesangial cells, respectively, and involved in vessel maturation, results in glomeruli with aneurysm-like glomerular capillaries and lacking mesangial cells [73, 74]. Similarly, the targeted ablation of CXCL12, its receptor CXCR4 or RBP-J, a transducer of notch signaling, and angiopoietin1 results in single-loop or ballooned glomerular capillaries associated with mesangial cell deficit in some mutants [75–79]. The studies summarized here illustrate the critical role of hypoxiaregulated angiogenic factors and their signaling in the differentiation, proliferation, migration, and mutual regulation among glomerular endothelium, mesangial cells, and podocytes. The development of postglomerular capillary beds is thought to be driven and regulated by a similar array of angiogenic factors secreted by renal tubules and endothelial or mural cell precursors, including VEGF-A, angiopoietins, stromal cell-derived factor-1, erythropoietin, and angiotensin II. These factors are involved in the remarkable alignment of postglomerular capillaries with the renal tubules. The deletion of VEGF-A from developing renal tubules results in a hypoplastic medulla with fewer peritubular capillaries [79, 80]. Angiopoietin-2 regulates peritubular capillary architecture by promoting vascular mural cell differentiation in the presence of VEGF [81]. SDF-1 signaling from vascular mural cell progenitors to its receptor in endothelial cells regulates the size and distribution of

41

peritubular capillaries [77]. Moreover, vasa recta postnatal development is controlled by angiotensin II and mediated by increased tubular VEGF secretion [82]. Notably, the deletion of Foxd1 progenitors, a transcription factor expressed in the renal stroma, disrupts peritubular capillary development, recruitment of vascular mural cells, and nephron patterning [4]. This suggests that regulators of the local environment, as discussed above in regard to hypoxia, directly or indirectly influence epithelial-endothelial-mural cell cross talk and ultimately the patterning of the renal vasculature.

The Glomerular Filtration Barrier The renal glomerulus controls the filtration of water and solutes while at the same time acting as a barrier retaining vital molecules such as plasma proteins. The glomerular filter functions as a semipermeable, macromolecular sieve capable of excluding molecules larger than serum albumin (MM 66,400) [83, 84]. The glomerular filtration barrier (GFB) separating the vasculature from the urinary space consists of a three-layered in-series structural arrangement of highly specialized cells that interact with one another (Fig. 1). The components of the GFB include three layers: the fenestrated endothelial cells lined by a glycocalyx, the glomerular basement membrane (GBM), and the slit diaphragm, which links the neighboring podocyte foot processes.

Components of the GFB Table 1 and see also ▶ Chaps. 1, “Embryonic Development of the Kidney,” and ▶ 18, “Translational Research Methods: Renal Stem Cells” of this text.

The Podocyte Podocytes, the glomerular visceral epithelial cells that reside within the Bowman’s space and bathe in the glomerular filtrate, are a specialized and anatomically unique feature of the glomerulus. The podocyte has microtubule-based cellular

42

A. Tufro and A. Gulati

Fig. 1 Ultrastructure of a typical glomerular capillary loop: podocyte foot processes ( fp), slitdiaphragm (thin arrow), glomerular basement membrane (GBM), capillary (cap) endothelial cell (EC) with fenestrations (thick arrows)

extensions known as primary processes and actin-based interdigitating secondary processes known as foot processes, which rest on the GBM [85, 86]. Mature podocyte foot processes are connected by modified adherens junctions called slit diaphragms (SD). During glomerulogenesis, columnar podocytes are joined by tight junctions, which migrate toward the basal side and acquire SD features as differentiation proceeds. The major molecular components of the glomerular filtration barrier are described in Table 1. The ultrastructure of the SD has been conventionally studied using transmission electron microscopy (TEM) (Fig. 1), EM tomography, and scanning EM [87–90]. Rodewald and Karnovsky described the SD as “zipper structure arrangement” with regular pores with a mean width of ~40A, which would restrict the passage of most serum proteins [87]. Tryggvason et al. [89] provided new insight into the threedimensional molecular structure of the podocyte slit diaphragm by identifying the extracellular domain of nephrin as the backbone of the SD and irregular pores with similar average width. Recent examination of the slit diaphragm using scanning EM challenges the view of an ordered “zipper-like” SD structure and suggests a heteroporous structure with ellipsoidal pores of ~120 A radius measured by digital morphometry [90]. Tracer studies followed by TEM show that

the filtration of large molecules such as ferritin (MM ~500,000) is hindered at the GBM, whereas smaller proteins such as horseradish peroxidase (MM 40,000) are filtered by the GBM but retained by the SD [91–93]. In addition to its structural function as a filtration barrier and cell-cell junction, the SD is a signaling protein complex that dynamically determines podocyte cell behavior. Extracellular domains of nephrin, neph1, P-cadherin, and FAT1 contribute to the SD protein complex, which includes multiple scaffolding, receptors, and actin-binding proteins, through direct and indirect protein interactions. The list of SD complex members is ever growing, and their roles are documented in gene ablation experiments, as well as human mutations leading to proteinuria and glomerular disease ([94–111], Table 1).

The Glomerular Basement Membrane The GBM is the extracellular gel-like matrix component that lies between podocytes and endothelial cells, composed of four major macromolecules: laminin, type IV collagen, nidogen, and heparan sulfate proteoglycan [112] (see Table 1). In the mature GBM, laminin is a trimer consisting of α5, β2, and γ1 laminin chains (α5β2γ1 or 521), and collagen IV is a trimer consisting of α3, α4, and α5 chains [113]. In contrast, laminin α1β2γ1 and α1 and α2 collagen IV

2

Development of Glomerular Circulation and Function

43

Table 1 Known molecular components of the glomerular filtration barrier (Refs. [94–113]) Protein/ localization Slit diaphragm Nephrin

Neph-family proteins (Neph1–3)

Podocin

Gene

Function

Characteristic

References

NPHS1

Finnish form of congenital nephrotic syndrome Infantile nephrotic syndrome Autosomal recessive inheritance Phenotype of the mice lacking Neph1 resembles that of nephrin-deficient mice

Transmembrane protein localized to SD

[94–100, 103, 104]

Neph1–3 are components of the SD

[101, 102]

Transmembrane protein interacts with nephrin and neph1 Multidomain scaffolding protein at the SD

[105, 106]

Component of SD

[110]

Component of SD

[111]

Adhesion molecule, large protocadherin at SD contains a larger extracellular domain than traditional cadherins Present in cytoplasmic component of SD

[195]

Zinc finger transcription factor and RNA-binding protein

[193]

Neph1 (Kirrel) Neph2 (Kirrel3) Neph3 (Kirrel2) NPHS2

CD2-associated protein

CD2AP

Phospholipase C epsilon 1

PLCE1

Transient receptor potential cation channel subfamily C member 6 FAT

TRPC6

Zonula occludens-1

Podocyte WT-1

Autosomal recessive steroidresistant nephrotic syndrome (infantile and childhood) Autosomal recessive infantile steroid-resistant nephrotic syndrome Autosomal recessive infantile and early childhood steroidresistant nephrotic syndrome; major gene of DMS Autosomal dominant Juvenile and adult onset FSGS

FAT

Component of SD, co-localizes with ZO-1

ZO-1

Most commonly associated with tight junctions, sometimes associated with adherens junctions

WT-1

First identified as a tumor suppressor gene for Wilms tumor Expression restricted to the podocyte Denys-Drash syndrome – diffuse mesangial sclerosis within the glomeruli Frasier syndrome – glomerulosclerosis

[107–109]

[195]

(continued)

44

A. Tufro and A. Gulati

Table 1 (continued) Protein/ localization LMX1B

Pod1/epicardin/ capsulin

Gene LMX1B

Pod1

Integrins

Function Regulates podocyte-specific gene expression; KO mice show reduced expression of foot processes Unique role in renal development and in the patterning of the skeletal system; mutation causes nail-patella syndrome KO mice glomerular development arrests at single capillary loop stage Alpha3beta1 integrin Major integrin expressed by podocytes Important for podocyte differentiation Receptor for some isoforms of laminin Major laminin-binding integrin Alpha1beta1 Alpha2beta 2 are collagen IV receptors Maintains podocyte cell separation Deficient mice are susceptible to hypertension

Podocalyxin

Podxl

GLEPP1

GLEPP1

Synaptopodin

Synaptopodin

Foot process assembly

Alpha-actinin 4

ACTN4

VEGF-A

VEGF

Angiopoietin-1

Angiopoietin-1

Familial FSGS has been described Endothelial cell mitogen for endothelial cell differentiation, survival, proliferation, and migration Remodeling and maturation of capillaries

GBM Laminin

LAMB2 (humans)

Juvenile isoforms LM-111 and LM-511 replaced by mature isoform LM-521 in mature glomeruli No known human mutations in LAMA1/B1/C1/A5 Mutations in human LAMB2 gene known (Pierson syndrome)

Characteristic LIM-homeodomain transcription factor

References [193]

Basic helix-loop-helix transcription factor

[193]

Adhesion protein in the GBM

[194]

Sulfated cell surface sialomucin-charged protein Cell surface protein Receptor tyrosine phosphatase Actin-associated cytoskeletal protein Actin-binding protein

[195]

[113]

Glycoprotein

[25, 26]

70 kDa glycoprotein

[31]

Large (~800 kd) heterotrimer of alpha, beta, and gamma glycoprotein chains

[194]

[195]

[195]

(continued)

2

Development of Glomerular Circulation and Function

45

Table 1 (continued) Protein/ localization Type-IV collagen

Nidogen

Agrin (most abundant) and perlecan

Gene COL4A3, A4, A5

Function Alpha-1,2 in early nephron, shift to 3,4,5 subunits in mature GBM Mutations in human COL4A3, A4 (autosomal recessive), A5 (most common, X-linked) genes – Alport syndrome One of the integral basement membrane protein Function not yet determined Negatively charged GBM components originally thought to contribute to the charge selective barrier (however, current evidence challenges this REF)

are expressed in the developing GBM [114]. Specific basement membrane protein isoforms are crucial for glomerular development, morphology, and function, as mutations in laminin β2 (LAMB2) or collagen IV (Alport) alter the GBM structure and lead to progressive glomerular disease. The mechanisms for transitions from immature to adult-type isoforms of the GBM proteins are not completely understood, but these substitutions are important for the structural and functional integrity of the GFB [113, 115–117]. It has long been accepted that the net negative charge of the GBM is a crucial component of the glomerular capillary wall’s filtration barrier to plasma albumin, which is also negatively charged and should therefore be repelled by the GBM [91]. However, the concept of charge selectivity has recently been called into question. Removal of these negatively charged proteoglycans has no effect on the glomerular filtration barrier permeability to either albumin or to a negatively charged tracer [118]. It has been suggested that GBM charge plays a minor role in imparting the glomerular filter with charge selectivity and argued that the GBM functions as a gel where macromolecules traffic by diffusion depending on their molecular size [119] or their size and anionic charge [120].

Characteristic Triple helical heterotrimer of collagen IV alpha chains

References [194]

Two isoforms A and B, each consisting of a single polypeptide chain

[112, 113]

Heparan sulfate proteoglycans with negatively charged sulfated glycosaminoglycan side chains

[112, 113]

The Glomerular Endothelial Cell Layer and Its Contributions to the Filtration Barrier The endothelium functions as a barrier, regulates vasomotor tone, and controls tissue inflammation and thrombosis. Glomerular endothelial cells form a fenestrated capillary bed and play a role in the filtration function [121]. Endothelial fenestrations are transcellular holes that allow the plasma flowing through the capillaries to reach the GBM, even though fenestrations are plugged by a glycocalyx-like material consisting of sulfated proteoglycans and glycoproteins that impart barrier properties [51, 55–57]. The glomerular endothelial surface layer has a thickness similar to that of the GBM consisting of two elements, the glycocalyx and the cell coat [122]. It has been proposed that the endothelial glycocalyx might contribute significantly to the GFB permselectivity [122–127]. The glycocalyx components are covalently bound to the endothelial cell membrane and are attached to the glycocalyx by charge-charge interactions [128, 129]. Damage to the glycocalyx and endothelial cell coat causes proteinuria in the absence of detectable damage to the GBM or the podocytes, but the evidence remains indirect [130, 131].

46

As discussed above, the assembly and integrity of endothelial cells are regulated by angiogenic factor signaling. VEGF-A is necessary for the survival of endothelial cells, to establish and maintain the integrity of endothelial fenestrae, as demonstrated by knockdown and loss of function in vivo experiments, and endothelial cell damage leading to TMA in humans treated with VEGF-A receptor blockers [35, 46, 47, 61]. Angiopoietin-1 produced by mural cells supports endothelial cell survival and decreases vascular permeability by inhibiting VEGF-induced eNOS activation [132]. Angiopoietin-2 is stored in Weibel-Palade bodies and secreted by activated endothelial cells. Angiopoietin-2 and angiopoietin-1 compete for signaling via the Tie2 receptor; in the presence of VEGF-A, angiopoietin-2 leads to angiogenesis, whereas in the absence of VEGF-A, it causes endothelial cell apoptosis [133]. Davis et al. showed that podocyte-specific overexpression of angiopoietin-2 leads to apoptosis of glomerular endothelial cells, without affecting the podocytes [134]. In addition, mesangial cells affect the glomerular endothelial cell properties and promote glomerular endothelial cell survival by inactivating TGFβ [78, 135–138].

Glomerular Filtration Barrier (GFB) Selective Permeability The glomerular filtration barrier has size-selective properties and differentially handles molecules of varying size. Small molecules up to the size of inulin filter freely, whereas large molecules such as plasma proteins are held back. The sieving coefficient for a particular molecule is the ratio of its concentration in the glomerular filtrate relative to the plasma concentration. The GFB pore theory assumes that the capillary wall consists of cylindrical pores of two or various sizes allowing size-selective passage of molecules through them [139–143]. The fiber matrix theory, an extension of the pore theory, posits that the GFB consists of pores filled with a fiber matrix [144]. Various mathematical models have been proposed and applied to the porous substructure of the barrier to predict macromolecular sizes that will be

A. Tufro and A. Gulati

compatible for crossing the barrier. In general, there has been a discrepancy between these calculations and the in vivo descriptions of molecular sieving, suggesting that other mechanisms might be involved [145, 146]. Kedem and Katchalsky have proposed flux equations for defining the physical properties of the GFB and require no specification of its substructure [147]. Charge selectivity has been an age-old phenomenon assumed to operate at the level of the GBM due to the presence of negatively charged proteoglycans, which were thought to repel the anionic proteins. However, present-day emphasis is on the endothelial layer glycocalyx property conferring charge selectivity to the GFB. Smithies proposed that the size selectivity of the glomerulus resides solely in the GBM, which functions as a concentrated gel and macromolecules permeate mostly by diffusion and also by fluid flow (convection). Hence, this gel permeation/ diffusion model suggests that lower filtration rate causing lower water flow and thus a higher concentration of proteins in the proximal tubular fluid and the tubular mechanisms of reabsorption saturate earlier to increase proteinuria [119]. Data from children with nephrotic syndrome fit this hypothesis [148], provided the degree of podocyte effacement is also taken into account, suggesting that the latter influences the size selectivity of the GFB beyond limitations of GFR. Recently, Moeller and colleagues proposed an electrokinetic model, whereby a local electric field “streaming potential” is established across the glomerular filter that prevents plasma proteins from entering or crossing the filter [120]. This hypothesis fits data from several previous models but awaits further experimental confirmation.

Glomerular Hemodynamics and Assessment of Renal Function The molecular basis of glomerular architecture discussed previously argues that the glomerular structure provides functional advantages leading to controlled glomerular filtration. Mammalian glomerular capillary pressure averages 50 mmHg, which is approximately 50 % of the

2

Development of Glomerular Circulation and Function

mean systemic arterial pressure, with waveform characteristics similar to the central aorta [149]. The glomerular capillaries form a highpressure system with about 4 times the pressure of systemic capillaries and confer a functional advantage due to higher blood flow rates enabling higher clearance as they filter large volumes of plasma (~180 l/day).

Renal Blood Flow: Basic Concepts Renal blood flow is approximately 1 L/min (20 % of cardiac output) Fig. 2. Renal plasma flow is the portion of the renal blood flow available for ultrafiltration: RPF = (1-Hct)*RBF, thus given a normal Hct of 40 %, RPF is approximately 600 ml/min. Renal blood flow (RBF) is determined systemically by the renal perfusion pressure that depends on the systemic arterial blood pressure (SBP) and locally by the renal vascular resistance (RVR), so RBF/SBP/RVR. The unique architecture of the renal vasculature enables to control the RVR at two sites, the afferent and efferent arterioles, where significant pressure drops occur, leading to relatively high glomerular capillary pressure and low peritubular

20

Fraction of cardiac output perfusing the kidneys %

15

10

5

Age, days

0 15

20

30

40

50

60

Fig. 2 Renal blood flow as a percentage of cardiac output, plotted versus age, in growing rats between 17 and 60 days of age (From Ref. [196])

47

capillary pressure. Thus changes in arteriolar resistance lead to changes in glomerular plasma flow and glomerular capillary pressure, which can influence GFR. For example, during sympathetic stimulation or increased angiotensin II, both afferent and efferent resistance increase; thus RPF decreases, but GFR remains constant due to the opposite effect of afferent and efferent resistance on GFR. This intrinsic autoregulation occurring via neurohumoral mechanisms is mainly a consequence of local adjustment of RVR secondary to changes in efferent arteriolar tone. The efferent arteriole is normally in a state of only partial constriction, and any increase or decrease in blood flow is accompanied by a reciprocal change in glomerular filtration pressure, with the result that the filtration rate remains relatively unchanged [150–152]. Though the efferent arteriole seems to take precedence over the afferent as a controller of renal hemodynamics, the contributions of pre-and postglomerular vasculature vary owing to specific circumstances. The efferent arteriole seems to be the major regulator of renal blood flow during conditions of stress or after the administration of angiotensin-converting enzyme inhibitors or receptor blockers [150–152]. However, the large increase in RPF to the remnant kidney after a nephrectomy leads to a dramatic decrease in afferent arteriole resistance, driving a rapid increase in GFR. Generally, increased glomerular plasma flow leads to increased GFR. The reduction in hematocrit in euvolemic patients increases RPFs and is a mechanism contributing to hyperfiltration injury in anemic states [153]. Under normal conditions, the glomerular filtrate is a steady fraction of the RPF, the so-called filtration fraction (FF) [149]. FF = GFR/RPF. Because normal GFR is 125 ml/min and RPF 600 ml/min, normal FF is 0.2. FF is higher at low RPF and when efferent arteriole resistance is increased.

Perinatal Considerations for Renal Blood Flow and GFR The fetal human kidney main function from gestation week 16 onwards is to produce urine to

48

A. Tufro and A. Gulati

maintain normal amniotic fluid volume, as the fetal fluid-electrolyte homeostasis and solute clearance are achieved through the placenta and maternal kidney function. Though nephrogenesis is complete by 34–36 weeks of gestation, the efficiency of the renal excretory system akin to most other organ systems is age dependent even in postnatal life related to structural maturation [154]. It is of utmost importance to the clinician to be aware of the functional capacity of the newborn kidney and the extreme states of vulnerability posed by prematurity and at the same time understand the expected sequence of physiologic adaptations of kidney function that shall occur with time during a successful transition to extrauterine life. The proportion of cardiac output flowing through the kidney increases with gestational and postnatal age; the fetal kidney is receiving only 2–3 % of the cardiac output in animals and humans alike [155–157]. The low fetal renal blood flow, which does not attain adult levels until 2 years of age, forms the basis for reduced capacity for glomerular filtration in the newborn period and early childhood [158] Fig. 3. The normally low GFR in neonates is further decreased in premature infants due to 2 160 GFR, ml/ min/ 1.73m

150

100

50

Age, months

0 0

5

10

15

Fig. 3 Glomerular filtration rate (GFR) during the first year of life (From Ref. [197])

lower renal perfusion, incomplete nephrogenesis, or reduced nephron number associated with prematurity Figs. 4 and 5. The most elaborate quantitative data on postnatal RPF in neonates and small children has been provided from the measurement of renal extraction ratios of PAH. PAH clearance in neonates increases from about 65 % to attain 90 % of adult value by 5 months of age. RPF increased from about 140 ml/min/1.73 m2 at 8 days of age in a full-term infant to 580 ml/min/1.73 m2 at 5 months of age. Comparatively, the RPF in normal adults is 625 ml/min [159]. In preterm neonates, the RPF (PAH clearance) is presumably lower, though not measured. The renal hemodynamic alterations between fetal and adult life are mainly accompanied by a gradual decrease in RVR and consequent increments in RBF [160]. See comment in PubMed Commons below. Inulin clearance of premature and term neonates remains low despite the correction for body size [161]. This has been attributed to factors related to the low permeability of the glomerular filtration barrier, small available surface area for filtration, low systemic arterial pressure, and relatively high resistance of the afferent glomerular arteriole [154]. Measurements of filtration pressure in guinea pigs suggest a 2.5-fold increase within the first 2 postnatal months. This in conjunction with maturational changes in permeability of the filtration barrier and increase in available surface area for filtration could account for a 20-fold increase in GFR [162]. GFR increases during postnatal development and maturation in various animal species [163, 164]. Barnett et al. showed that GFR in preterm infants does not increase postnatally as rapidly as in full-term infants [165]. The overall developmental pattern of postnatal GFR changes in the humans suggests nonlinear increments in GFR that are much more pronounced with postnatal age beyond 34 weeks of gestation, coinciding with the time when nephrogenesis is completed, as compared to much slower GFR increases at lower gestational age (Fig. 6) [166]. However, this has been questioned by recent estimates of GFR [167]. Overall, neonates constitute a high-risk group requiring thoughtful fluid management and choice

2

Development of Glomerular Circulation and Function

Fig. 4 Creatinine clearance measured within 24–40 h of birth in 30-week premature to 40-week full-term infants (From Ref. [198])

49

CREATININE CLEARANCE (ml/min/1.73 M2) r = 0.643 p = < .001

50 40

30 20

10

26

26

30

32

34

36

38

40

GESTATION (Weeks)

PLASMA CREATININE (mg/dl)

1.8 1− 30 days n = 52 r = −0.575 p < 0.001

1.6 1.4

31− 94 days n = 29 r = 0.006 PNS

1.2 1.0 0.8 0.6 0.4 0.2

10

20

30

40

50

60

70

80

90

100

AGE (Days)

Fig. 5 Plasma creatinine values during the first 3 months of life in low-birth-weight infants (less than 2,000 g). (From Ref. [199])

and dosage of exogenous agents, aiming at primum non nocere.

GFR: Basic Concepts Our understanding of the GFR has followed a distinct timeline with advances in evaluation of

renal hemodynamics and knowledge of glomerular physiology. The classical concept of glomerular filtration stems from Ludwig’s filtration theory that states that water and solutes move across the glomerular filtration barrier due to a hydrostatic pressure difference that favors filtration [168].

50

A. Tufro and A. Gulati

creatinine clearance (ml / min)

6 5 4 3 2 1

28

30

32 34 36 gestational age (wks)

38

40

Fig. 6 Increase in creatinine clearance with GA (gestational + postnatal ages). Infants studied at birth were grouped for GA and are represented by mean values 1 SD connected by the solid line (y = 0.170 4.95, r = 0.51, P T/p.Cys603Ser c.1811delT/p.Leu604fs c.1817G>C/p.Cys606Ser c.1834G>T/p.Gly612X c.1897G>A/p.Gly633Arg c.1934G>C/p.Cys645Ser c.1935C>A/p.Cys645X c.1951C>T/p.Arg651X c.1954C>T/p.Arg652X (2 f) c.1977A>C/p.Arg659Ser

c.2020A>T/p.Lys674X c.2145delA/p.Glu716fs c.2270C>G/p.Ser757X c.2275C>T/p.Pro759Ser c.2306_07inv/p.Leu769Pro c.2310C>A/p.Asn770Lys c.2327A>G/p.Gln776Arg c.2413T>C/p.Ser805Pro c.2445C>A/p.Ser815Arg c.2527T>C/p.Ser843Pro c.2630T>C/p.Leu877Pro c.2753G>A/p.Trp918X c.2799+1G>A/Splicing (3 f) c.2936T>C/p.Leu979P

mutations (litterature)

c.402T>C/p.Phe134X c.488C>G/p.Ser163X c.1004delG/p.Ser335,fs c.1131dupT/p.Glu378,fs (2 f) c.1308T>A/p.Cys436X c.1375delT/p.Ser459,fs c.1509insA/p.Tyr503X c.1609C>T/p.Arg537X(2 f)

c.1768C>T/p.Arg590X

c.2017C>T/p.Arg673X c.2024C>G/p.Ser675X c.2125delA/p.Thr709,fs c.2365G>T/.p.Gly789X/Splicing c.2365+3delA/splicing c.2453C>T/p.Ser818L (2 f) c.2460insA/p.His821,fs c.2771T>C/p.Leu924P c.2839C>T/p.Arg947X c.2871dupC/p.Ala958,fs c.2899C>T/p.Gln967X c.2915A>G/p.Glu972G

Fig. 9 NR3C2 mutations in renal pseudohypoaldosteronism type I. The NR3C2 gene is represented with its intron/exon structure (exons are represented by boxes or black lines, introns by spaces in between). Eight exons [2–9] code for the functional domains of the MR protein. NR3C2 mutations identified in PHA1 are depicted on the

gene. The functional domains of the MR are indicated. DBD, DNA binding domain; LBD, ligand binding domain; (PHA.NET), unpublished mutations identified in the context of the clinical and research network PHA.NET (PI: M-C. Zennaro, Paris)

α-ENaC mutations on the renin–aldosterone system, growth, and pubertal development of PHA1 patients [482]. Three patients homozygous for nonsense and frameshift mutations in α-ENaC presented short stature, poor growth, and growth hormone tests compatible with the diagnosis of GH deficiency. In all patients, there was an

age-dependent normalization in the urinary Na/K ratios accompanied by an exaggerated renin–aldosterone system response probably contributing to age-dependent amelioration. In contrast, one patient compound heterozygous for a missense mutation and for a frameshift mutation of α-ENaC presented normal growth, normal

38

Renal Tubular Disorders of Electrolyte Regulation in Children

puberty, and decrease of renin–aldosterone axis activity with age. These results demonstrate distinct genotype–phenotype relationships in generalized PHA1 patients that depend on the degree of functional ENaC impairment. If undetected during the first week of life, multisystem PHA1 can lead to neonatal death; however, if detected, the patients may lead near normal lives on a lifelong high-salt diet [483]. Extensive genetic investigation of PHA1 patients in recent years has also shown that the disease comprises a continuum of phenotypically and/or biologically distinct entities that may challenge the current genetic classification of the disease. Indeed, investigation of heterozygote carriers of a α-ENaC p.Ser562Pro mutation, responsible for generalized PHA1 in homozygous patients, revealed a subclinical salt-losing phenotype with increased sweat sodium and chloride concentrations without additional hormonal or clinical manifestation [484]. Furthermore, recessively inherited ENaC mutations, associated with partial loss of channel function, may result in a mild phenotypic expression of PHA, with a saltlosing disorder in a premature infant, but only a biological phenotype in a sibling born at term [485]. We recently observed a case of recessive PHA1 with an extremely severe phenotype of dehydration and hyperkalemia, but without cutaneous or pulmonary phenotype, caused by MR mutations [486]. These cases broaden the spectrum of clinical phenotypes in renal PHA1 and support corresponding genetic screening for the disease in patients with isolated renal salt-losing syndromes and/or failure to thrive.

Treatment and Prognosis Treatment of PHA1 consists in the replacement of salt loss and rehydration, as well as correction of hyperkalemia and acidosis in the acute phase of the disease. Since the main differential diagnosis is congenital adrenal hyperplasia or isolated deficiency in aldosterone synthase (CMOI and CMOII) [487], replacement therapy with fludrocortisone and hydrocortisone may be undertaken while confirming the diagnosis by hormonal measurements. Early postnatal hyperkalemia may sometimes complicate antenatal Bartter syndrome

1251

(aBS, due to mutation in the potassium channel ROMK) [488]. Its association with hyponatremia and hyperreninemic hyperaldosteronism may erroneously suggest the diagnosis of PHA1. However, hyperkalemia appears usually very early and normalizes by the end of the first postnatal week, whereas PHA1 is characterized by permanent hyperkalemia. Other distinctive features of aBS patients are metabolic alkalosis as well as hypercalciuria and nephrocalcinosis. Also maternal hydramnios, present in aBS, is a rare event in generalized PHA1. After the acute period, treatment consists in salt supplementation. The doses vary depending on the severity of the disease. Neonatal genetic diagnosis on cord blood may allow rapid diagnosis and management of the condition in affected offspring from PHA1 families with identified mutations. In renal and secondary PHA1, 3–20 mEq/kg/day of Na given as NaCl and NaHCO3 are sufficient to compensate for the salt loss and are followed by rapid clinical and biochemical improvement. The expansion of extracellular volume results in increased tubular flow and delivery of sodium to the distal nephron, creating a favorable gradient for potassium secretion. Nevertheless, ion exchange resins are often associated to the treatment to normalize potassium levels. The amount of sodium required depends on the severity of the symptoms and is deduced from the normalization of plasma potassium concentration and plasma renin. Since renal PHA1 improves with age, treatment can be discontinued after a variable period of time in most patients, generally around age 18–24 months. Older children are generally asymptomatic on a normal salt intake and show a normal growth and psychomotor development, although they may evolve on the lower percentiles of the growth curve, despite adequate medical therapy [489]. In contrast to renal PHA1, generalized PHA1 represents a therapeutic challenge. No evidencebased treatment has been described, and therapeutic intervention is patient specific. Generally, high doses of sodium (between 20 and 50 mEq/kg/day) are used, together with ion exchange resins and dietary manipulations to reduce potassium levels. Corticoid treatment is sometimes associated and seems to provide some additional benefit.

1252

Administration of indomethacin may be useful in occasional patients [490]. Symptomatic treatment is necessary for the respiratory tract illnesses and to correct the skin phenotype. Only few cases of generalized PHA1 followed up for several years or into adulthood have been described: treatment is necessary throughout life, consisting of salt supplementation (8–20 g NaCl/day) and ion exchange resins [460, 491]

References 1. Bartter F, Pronove P, Gill Jr J, MacCardle R. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med. 1962;33:811–28. 2. Jeck N, Schlingmann KP, Reinalter SC, Kömhoff M, Peters M, Waldegger S, Seyberth HW. Salt handling in the distal nephron: lessons learned from inherited human disorders. Am J Physiol Regul Integr Comp Physiol. 2005;288(4):R782–95. 3. Greger R. Ion transport mechanisms in thick ascending limb of Henle’s loop of mammalian nephron. Physiol Rev. 1985;65:760–97. 4. Reilly RF, Ellison DH. Mammalian distal tubule: physiology, pathophysiology and molecular anatomy. Physiol Rev. 2000;80:277–313. 5. Hoenderop JG, Bindels RJ. Epithelial Ca2+ and Mg2+ channels in health and disease. J Am Soc Nephrol. 2005;16:15–26. 6. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet. 1996;13:183–8. 7. Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, Lifton RP. Genetic heterogeneity of Bartter’s syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet. 1996;14:152–6. 8. Birkenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz I, Beekmann F, Fekete A, Omran H, Feldmann D, Milford DV, Jeck N, Konrad M, Landau D, KnoersNV AC, Sudbrak R, Kispert A, Hildebrandt F. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet. 2001;29:310–4. 9. Simon DB, Bindra RS, Mansfield TA, NelsonWilliams C, Mendonca E, Stone R, Schurman S, Nayir A, Alpay H, Bakkaloglu A, RodriguezSoriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, Lifton RP. Mutations in the chloride channel gene, CLCNKB, cause Bartter’s syndrome type III. Nat Genet. 1997;17:171–8.

O. Devuyst et al. 10. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, Gainza FJ, Gitelman HJ, Lifton RP. Gitelman’s variant of Bartter’s syndrome, inherited hypokalemic alkalosis, is caused by mutations in the thiazide sensitive Na-Cl cotransporter. Nat Genet. 1996;12:24–30. 11. Konrad M, Vollmer M, Lemmink HH, Van Den Heuvel LP, Jeck N, Vargas-Poussou R, Lakings A, Ruf R, Deschenes G, Antignac C, Guay-Woodford L, KnoersNV SHW, Feldmann D, Hildebrandt F. Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J Am Soc Nephrol. 2000;11:1449–59. 12. McCredie DA, Rotenberg E, Williams AL. Hypercalciuria in potassium-losing nephropathy: a variant of Bartter’s syndrome. Aust Paediatr J. 1974;10(5):286–95. 13. Proesmans W. Bartter syndrome and its neonatal variant. Eur J Pediatr. 1997;156(9):669–79. 14. Vargas-Poussou R, Feldmann D, Vollmer M, Konrad M, Kelly L. Novel molecular variants of the Na-K-2Cl cotransporter gene are responsible for antenatal Bartter syndrome. Am J Hum Genet. 1998;62:1332–40. 15. Seyberth HW, Koniger SJ, Rascher W, Kuhl PG, Schweer H. Role of prostaglandins in hyperprostaglandin E syndrome and in selected renal tubular disorders. Pediatr Nephrol. 1987;1:491–7. 16. Kockerling A, Reinalter SC, Seyberth HW. Impaired response to furosemide in hyperprostaglandin E syndrome: evidence for a tubular defect in the loop of Henle. J Pediatr. 1996;129:519–28. 17. International Collaborative Study Group for Bartterlike Syndromes. Mutations in the gene encoding the inwardly-rectifying renal potassium channel, ROMK, cause the antenatal variant of Bartter syndrome: evidence for genetic heterogeneity. Hum Mol Genet. 1997;6(1):17–26. 18. Bettinelli A, Ciarmatori S, Cesareo L, Tedeschi S, Ruffa G, Appiani AC, Rosinini A, Crumieri G, Mercuri B, Sacco M, Leozappa G, Binda S, Cecconi M, Navone C, Curcio C, Syren ML, Casari G. Phenotypic variability in Bartter syndrome type I. Pediatr Nephrol. 2000;14:940–5. 19. Nielsen S, Maunsbach AB, Ecelbarger CA, Knepper MA. Ultrastructural localization of Na-K-2Cl cotransporter in thick ascending limb and macula densa of rat kidney. Am J Physiol Renal Physiol. 1998;275:F885–93. 20. Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol. 2003;284:F11–21. 21. Adachi M, Asakura Y, Sato Y, Tajima T, Nakajima T, Yamamoto T, Fujieda K. Novel SLC12A1 (NKCC2) mutations in two families with Bartter syndrome type 1. Endocr J. 2007;54:1003–7. 22. Kurtz CL, Karolyi L, Seyberth HW, Koch MC, Vargas R, Feldmann D, Vollmer M, Knoers NV, Madrigal G, Guay-Woodford LM. A common

38

Renal Tubular Disorders of Electrolyte Regulation in Children

NKCC2 mutation in Costa Rican Bartter’s syndrome patients: evidence for a founder effect. J Am Soc Nephrol. 1997;8(11):1706–11. 23. Castrop H, Schnermann JB. Isoforms of the renal Na-K-2Cl cotransporter NKCC2: expression and functional significance. Am J Physiol Renal Physiol. 2008;295(4):F859–66. 24. Wang W, Sackin H, Giebisch G. Renal potassium channels and their regulation. Annu Rev Physiol. 1992;54:81–96. 25. Nichols CG, Lopatin AN. Inward rectifier potassium channels. Annu Rev Physiol. 1997;59:171–91. 26. Feldmann D, Alessandri JL, Deschênes G. Large deletion of the 50 end of the ROMK1 gene causes antenatal Bartter syndrome. J Am Soc Nephrol. 1998;9(12):2357–9. 27. Flagg TP, Tate M, Merot J, Welling PA. A mutation linked with Bartter’s syndrome locks Kir 1.1a (ROMK1) channels in a closed state. J Gen Physiol. 1999;114(5):685–700. 28. Schulte U, Hahn H, Konrad M, Jeck N, Derst C, Wild K, Weidemann S, Ruppersberg JP, Fakler B, Ludwig J. pH gating of ROMK (K(ir)1.1) channels: control by an Arg-Lys-Arg triad disrupted in antenatal Bartter syndrome. Proc Natl Acad Sci U S A. 1999;96 (26):15298–303. 29. Jeck N, Derst C, Wischmeyer E, Ott H, Weber S, Rudin C, Seyberth HW, Daut J, Karschin A, Konrad M. Functional heterogeneity of ROMK mutations linked to hyperprostaglandin E syndrome. Kidney Int. 2001;59:1803–11. 30. Starremans PG, van der Kemp AW, Knoers NV, van den Heuvel LP, Bindels RJ. Implications of mutations in the human renal outer medullary potassium channel (ROMK2) identified in Bartter syndrome. Pflugers Arch. 2002;443(3):466–72. 31. Peters M, Jeck N, Reinalter S, Leonhardt A, Tonshoff B, Klaus G, Konrad M, Seyberth HW. Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med. 2002;112:183–90. 32. Madrigal G, Saborio P, Mora F, Rincon G, GuayWoodford LM. Bartter syndrome in Costa Rica: a description of 20 cases. Pediatr Nephrol. 1997; 11(3):296–301. 33. Vaisbich MH, Fujimura MD, Koch VH. Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol. 2004;19(8):858–63. 34. Seyberth HW, Rascher W, Schweer H, K€ uhl PG, Mehls O, Schärer K. Congenital hypokalemia with hypercalciuria in preterm infants: a hyperprostaglandinuric tubular syndrome different from Bartter syndrome. J Pediatr. 1985;107(5):694–701. 35. Shoemaker L, Welch TR, Bergstrom W, Abrams SA, Yergey AL, Vieira N. Calcium kinetics in the hyperprostaglandin E syndrome. Pediatr Res. 1993;33(1):92–6. 36. Rodríguez-Soriano J, Vallo A, Aguirre M. Bone mineral density and bone turnover in patients with Bartter syndrome. Pediatr Nephrol. 2005;20(8):1120–5.

1253

37. Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S. Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl co-transporter. J Am Soc Nephrol. 2006;17(8): 2136–42. 38. Schachter AD, Arbus GS, Alexander RJ, Balfe JW. Non-steroidal antiinflammatory drug-associated nephrotoxicity in Bartter syndrome. Pediatr Nephrol. 1998;12:775–7. 39. Chaudhuri A, Salvatierra Jr O, Alexander SR, Sarwal MM. Option of pre-emptive nephrectomy and renal transplantation for Bartter’s syndrome. Pediatr Transplant. 2006;10(2):266–70. 40. Rudin A. Bartter’s syndrome: a review of 28 patients followed for 10 years. Acta Med Scand. 1988;224: 165–71. 41. Reinalter SC, Grone HJ, Konrad M, Seyberth HW, Klaus G. Evaluation of long-term treatment with indomethacin in hereditary hypokalemic salt-losing tubulopathies. J Pediatr. 2001;139:398–406. 42. Taugner R, Waldherr R, Seyberth HW, Erdös EG, Menard J, Schneider D. The juxtaglomerular apparatus in Bartter’s syndrome and related tubulopathies. An immunocytochemical and electron microscopic study. Virchows Arch A Pathol Anat Histopathol. 1988;412(5):459–70. 43. Okada M, Lertprasertsuke N, Tsutsumi Y. Quantitative estimation of rennin-containing cells in the juxtaglomerular apparatus in Bartter’s and pseudo-Bartter’s syndromes. Pathol Int. 2000;50: 166–8. 44. Finer G, Shalev H, Birk OS, Galron D, Jeck N, SinaiTreiman L, Landau D. Transient neonatal hyperkalemia in the antenatal (ROMK defective) Bartter syndrome. J Pediatr. 2003;142(3):318–23. 45. Ji W, Foo JN, O’Roak BJ, Zhao H, Larson MG, Simon DB, Newton-Cheh C, State MW, Levy D, Lifton RP. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet. 2008;40(5):592–9. 46. Tobin MD, Tomaszewski M, Braund PS, Hajat C, Raleigh SM, Palmer TM, Caulfield M, Burton PR, Samani NJ. Common variants in genes underlying monogenic hypertension and hypotension and blood pressure in the general population. Hypertension. 2008;51(6):1658–64. 47. Devuyst O. Salt wasting and blood pressure. Nat Genet. 2008;40(5):495–6. 48. Welling PA. Rare mutations in renal sodium and potassium transporter genes exhibit impaired transport function. Curr Opin Nephrol Hypertens. 2014; 23(1):1–8. 49. Mourani CC, Sanjad SA, Akatcherian CY. Bartter syndrome in a neonate: early treatment with indomethacin. Pediatr Nephrol. 2000;14(2):143–5. 50. Starremans PG, Kersten FF, Knoers NV, van den Heuvel LP, Bindels RJ. Mutations in the human

1254 Na-K-2Cl cotransporter (NKCC2) identified in Bartter syndrome type I consistently result in nonfunctional transporters. J Am Soc Nephrol. 2003;14(6):1419–26. 51. Acuña R, Martínez-de-la-Maza L, Ponce-Coria J, Vázquez N, Ortal-Vite P, Pacheco-Alvarez D, Bobadilla NA, Gamba G. Rare mutations in SLC12A1 and SLC12A3 protect against hypertension by reducing the activity of renal salt cotransporters. J Hypertens. 2011;29(3):475–83. 52. Monette MY, Rinehart J, Lifton RP, Forbush B. Rare mutations in the human Na-K-Cl cotransporter (NKCC2) associated with lower blood pressure exhibit impaired processing and transport function. Am J Physiol Renal Physiol. 2011;300(4):F840–7. 53. Schwalbe RA, Bianchi L, Accili EA, Brown AM. Functional consequences of ROMK mutants linked to antenatal Bartter’s syndrome and implications for treatment. Hum Mol Genet. 1998;7(6):975–80. 54. Peters M, Ermert S, Jeck N, Derst C, Pechmann U, Weber S, Schlingmann KP, Seyberth HW, Waldegger S, Konrad M. Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int. 2003;64(3):923–32. 55. Fang L, Li D, Welling PA. Hypertension resistance polymorphisms in ROMK (Kir1.1) alter channel function by different mechanisms. Am J Physiol Renal Physiol. 2010;299(6):F1359–64. 56. Massa G, Proesmans W, Devlieger H, Vandenberghe K, Van Assche A, Eggermont E. Electrolyte composition of the amniotic fluid in Bartter syndrome. Eur J Obstet Gynecol Reprod Biol. 1987;24(4):335–40. 57. Shalev H, Ohaly M, Meizner I, Carmi R. Prenatal diagnosis of Bartter syndrome. Prenat Diagn. 1994;14:996–8. 58. Yang T, Park JM, Arend L, Huang Y, Topaloglu R, Pasumarthy A, Praetorius H, Spring K, Briggs JP, Schnermann J. Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line. J Biol Chem. 2000;275(48):37922–9. 59. Kömhoff M, Jeck ND, Seyberth HW, Gröne HJ, N€using RM, Breyer MD. Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int. 2000;58(6):2420–44. 60. Reinalter SC, Jeck N, Brochhausen C, Watzer B, N€using RM, Seyberth HW, Kömhoff M. Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int. 2002;62(1):253–60. 61. Konrad M, Weber S. Recent advances in molecular genetics of hereditary magnesium-losing disorders. J Am Soc Nephrol. 2003;14(1):249–60. 62. Dai LJ, Bapty B, Ritchie G, Quamme GA. PGE2 stimulates Mg2+ uptake in mouse distal convoluted tubule cells. Am J Physiol. 1998;275:F833–9.

O. Devuyst et al. 63. Leonhardt A, Timmermanns G, Roth B, Seyberth HW. Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome. J Pediatr. 1992; 120(4 Pt 1):546–54. 64. Schurman SJ, Bergstrom WH, Shoemaker LR, Welch TR. Angiotensin II reduces calcium uptake into bone. Pediatr Nephrol. 2004;19(1):33–5. 65. Takahashi N, Chernavvsky DR, Gomez RA, Igarashi P, Gitelman HJ, Smithies O. Uncompensated polyuria in a mouse model of Bartter’s syndrome. Proc Natl Acad Sci U S A. 2000;97:5434–9. 66. Lorenz JN, Baird NR, Judd LM, Noonan WT, Andringa A, Doetschman T, Manning PA, Liu LH, Miller ML, Shull GE. Impaired renal NaCl absorption in mice lacking the ROMK potassium channel, a model for type II Bartter’s syndrome. J Biol Chem. 2002;277:37871–80. 67. Wagner CA, Loffing-Cueni D, Yan Q, Schulz N, Fakitsas P, Carrel M, Wang T, Verrey F, Geibel JP, Giebisch G, Hebert SC, Loffing J. Mouse model of type II Bartter’s syndrome. II. Altered expression of renal sodium- and water-transporting proteins. Am J Physiol Renal Physiol. 2008;294(6):F1373–80. 68. Lu M, Leng Q, Egan ME, Caplan MJ, Boulpaep EL, Giebisch GH, Hebert SC. CFTR is required for PKA-regulated ATP sensitivity of Kir1.1 potassium channels in mouse kidney. J Clin Invest. 2006;116 (3):797–807. 69. Rodriguez-Soriano J. Bartter’s syndrome comes of age. Pediatrics. 1999;103:663–4. 70. Kleta R, Basoglu C, Kuwertz-Bröking E. New treatment options for Bartter’s syndrome. N Engl J Med. 2000;343:661–2. 71. Haas NA, Nossal R, Schneider CH, Lewin MA, Ocker V, Holder M, Uhlemann F. Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter’s syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib. Pediatr Crit Care Med. 2003;4(2):249–51. 72. Fletcher JT, Graf N, Scarman A, Saleh H, Alexander SI. Nephrotoxicity with cyclooxygenase 2 inhibitor use in children. Pediatr Nephrol. 2006;21(12): 1893–7. 73. Wong W, Hulton SA, Taylor CM, Raafat F, Lote CJ, Lindop G. A case of neonatal Bartter’s syndrome. Pediatr Nephrol. 1996;10(4):414–8. 74. Puricelli E, Bettinelli A, Borsa N, Sironi F, Mattiello C, Tammaro F, Tedeschi S, Bianchetti MG, Italian Collaborative Group for Bartter Syndrome. Long-term follow-up of patients with Bartter syndrome type I and II. Nephrol Dial Transplant. 2010;25(9):2976–81. 75. Landau D, Shalev H, Ohaly M, Carmi R. Infantile variant of Bartter syndrome and sensorineural deafness: a new autosomal recessive disorder. Am J Med Genet. 1995;59:454–9. 76. Jeck N, Reinalter SC, Henne T, Marg W, Mallmann R, Pasel K, Vollmer M, Klaus G, Leonhardt A, Seyberth HW, Konrad M. Hypokalemic salt-losing tubulopathy

38

Renal Tubular Disorders of Electrolyte Regulation in Children

with chronic renal failure and sensorineural deafness. Pediatrics. 2001;108, E5. 77. Brennan TM, Landau D, Shalev H, Lamb F, Schutte BC, Walder RY, Mark AL, Carmi R, Sheffield VC. Linkage of infantile Bartter syndrome with sensorineural deafness to chromosome 1p. Am J Hum Genet. 1998;62:355–61. 78. Estevez R, Boettger T, Stein V, Birkenhager R, Otto E, Hildebrandt F, Jentsch TJ. Barttin is a Clchannel beta-subunit crucial for renal Cl reabsorption and inner ear K+ secretion. Nature. 2001;414:558–61. 79. Shalev H, Ohali M, Kachko L, Landau D. The neonatal variant of Bartter syndrome and deafness: preservation of renal function. Pediatrics. 2003; 112(3 Pt 1):628–33. 80. Zaffanello M, Taranta A, Palma A, Bettinelli A, Marseglia GL, Emma F. Type IV Bartter syndrome: report of two new cases. Pediatr Nephrol. 2006; 21(6):766–70. 81. Miyamura N, Matsumoto K, Taguchi T, Tokunaga H, Nishikawa T, Nishida K, Toyonaga T, Sakakida M, Araki E. Atypical Bartter syndrome with sensorineural deafness with G47R mutation of the beta-subunit for ClC-Ka and ClC-Kb chloride channels, barttin. J Clin Endocrinol Metab. 2003;88(2):781–6. 82. García-Nieto V, Flores C, Luis-Yanes MI, Gallego E, Villar J, Claverie-Martín F. Mutation G47R in the BSND gene causes Bartter syndrome with deafness in two Spanish families. Pediatr Nephrol. 2006; 21(5):643–8. 83. Kitanaka S, Sato U, Maruyama K, Igarashi T. A compound heterozygous mutation in the BSND gene detected in Bartter syndrome type IV. Pediatr Nephrol. 2006;21(2):190–3. 84. Waldegger S, Jeck N, Barth P, Peters M, Vitzthum H, Wolf K, Kurtz A, Konrad M, Seyberth HW. Barttin increases expression and changes current properties of ClC-K channels. Pflugers Arch. 2002;444:411–8. 85. Riazuddin S, Anwar S, Fischer M, Ahmed ZM, Khan SY, Janssen AG, Zafar AU, Scholl U, Husnain T, Belyantseva IA, Friedman PL, Riazuddin S, Friedman TB, Fahlke C. Molecular basis of DFNB73: mutations of BSND can cause nonsyndromic deafness or Bartter syndrome. Am J Hum Genet. 2009; 85(2):273–80. 86. Janssen AG, Scholl U, Domeyer C, Nothmann D, Leinenweber A, Fahlke C. Disease-causing dysfunctions of barttin in Bartter syndrome type IV. J Am Soc Nephrol. 2009;20(1):45–53. 87. Fischer M, Janssen AG, Fahlke C. Barttin activates ClC-K channel function by modulating gating. J Am Soc Nephrol. 2010;21(8):1281–9. 88. Jentsch TJ, Poet M, Fuhrmann JC, Zdebik AA. Physiological functions of CLC Cl-channels gleaned from human genetic disease and mouse models. Annu Rev Physiol. 2005;67:779–807. 89. Schlingmann KP, Konrad M, Jeck N, Waldegger P, Reinalter SC, Holder M, Seyberth HW, Waldegger S.

1255

Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med. 2004;350: 1314–9. 90. Nozu K, Inagaki T, Fu XJ, Nozu Y, Kaito H, Kanda K, Sekine T, Igarashi T, Nakanishi K, Yoshikawa N, Iijima K, Matsuo M. Molecular analysis of digenic inheritance in Bartter syndrome with sensorineural deafness. J Med Genet. 2008;45(3):182–6. 91. Rickheit G, Maier H, Strenzke N, Andreescu CE, De Zeeuw CI, Muenscher A, Zdebik AA, Jentsch TJ. Endocochlear potential depends on Cl channels: mechanism underlying deafness in Bartter syndrome IV. EMBO J. 2008;27:2907–17. 92. Nomura N, Tajima M, Sugawara N, Morimoto T, Kondo Y, Ohno M, Uchida K, Mti K, Bachmann S, Soleimani M, Ohta E, Ohta A, Sohara E, Okado T, Rai T, Jentsch TJ, Sasaki S, Uchida S. Generation and analysis of R8L barttin knockin mouse. Am J Physiol Renal Physiol. 2011;301:F297–307. 93. Nomura N, Kamiya K, Ikeda K, Yui N, Chiga M, Sohara E, Rai T, Sakaki S, Uchida S. Treatment with 17-allylamino-17-demethoxygeldanamycin ameliorated symptoms of Bartter syndrome type IV caused by mutated Bsnd in mice. Biochem Biophys Res Commun. 2013;441(3):544–9. 94. Nozu K, Fu XJ, Nakanishi K, Yoshikawa N, Kaito H, Kanda K, Krol RP, Miyashita R, Kamitsuji H, Kanda S, Hayashi Y, Satomura K, Shimizu N, Iijima K, Matsuo M. Molecular analysis of patients with type III Bartter syndrome: picking up large heterozygous deletions with semiquantitative PCR. Pediatr Res. 2007;62(3):364–9. 95. Brochard K, Boyer O, Blanchard A, Loirat C, Niaudet P, Macher MA, Deschenes G, Bensman A, Decramer S, Cochat P, Morin D, Broux F, Caillez M, Guyot C, Novo R, Jeunemaître X, Vargas-Poussou R. Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. Nephrol Dial Transplant. 2009;24(5):1455–64. 96. Vargas-Poussou R, Dahan K, Kahila D, Venisse A, Riveira-Munoz E, Debaix H, Grisart B, Bridoux F, Unwin R, Moulin B, Haymann JP, Vantygehem MC, Rigothier C, Dussol B, Godin M, Nivet H, Dubourg L, Tack Y, Gimenez-Roqueplo AP, Houiller P, Blanchard A, Devuyst O, Jeunemaître X. Spectrum of mutations in Gitelman Syndrome. J Am Soc Nephrol. 2011;22:693–703. 97. Rodríguez-Soriano J, Vallo A, Pérez de Nanclares G, Bilbao JR, Castaño L. A founder mutation in the CLCNKB gene causes Bartter syndrome type III in Spain. Pediatr Nephrol. 2005;20(7):891–6. 98. Keck M, Andrini O, Lahuna O, Burgos J, Cid LP, Sepulveda FV, L’Hoste S, Blanchard A, Vargas-Poussou R, Lourdel S, Teulon J. Novel CLCNKB mutations causing Bartter syndrome affect channel surface expression. Hum Mut. 2013;34: 1269–78. 99. Zelikovic I, Szargel R, Hawash A, Labay V, Hatib I, Cohen N, Nakhoul F. A novel mutation in the chloride

1256 channel gene CLCNKB as a cause of Gitelman and Bartter syndromes. Kidney Int. 2003;63:24–32. 100. Andrini O, Keck M, L’Hoste S, Briones R, MansourHendili L, Grand T, Sepúlveda FV, Blanchard A, Lourdel S, Vargas-Poussou R, Teulon J. CLCNKB mutations causing mild Bartter syndrome profoundly alter the pH and Ca2+ dependence of ClC-Kb channels. Pflugers Arch. 2014;466(9):1713–23. 101. Matsumura Y, Uchida S, Kondo Y, Miyazaki H, Ko SB, Hayama A, Morimoto T, Liu W, Arisawa M, Sasaki S, Marumo F. Overt nephrogenic diabetes insipidus in mice lacking the CLC-K1 chloride channel. Nat Genet. 1991;21(1):95–8. 102. Barlassina C, Dal Fiume C, Lanzani C, Manunta P, Guffanti G, Ruello A, Bianchi G, Del Vecchio L, Macciardi F, Cusi D. Common genetic variants and haplotypes in renal CLCNKA gene are associated to salt-sensitive hypertension. Hum Mol Genet. 2007;16(13):1630–8. 103. Cappola TP, Matkovich SJ, Wang W, van Booven D, Li M, Wang X, Qu L, Sweitzer NK, Fang JC, Reilly MP, Hakonarson H, Nerbonne JM, Dorn 2nd GW. Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardiorenal axis in interindividual heart failure risk variation. Proc Natl Acad Sci U S A. 2011;108(6): 2456–61. 104. Westland R, Hack WW, van der Horst HJ, Uittenbogaard LB, van Hagen JM, van der Valk P, Kamsteeg EJ, van den Heuvel LP, van Wijk JA. Bartter syndrome type III and congenital anomalies of the kidney and urinary tract: an antenatal presentation. Clin Nephrol. 2012;78(6):492–6. 105. Bettinelli A, Borsa N, Bellantuono R, Syrèn ML, Calabrese R, Edefonti A, Komninos J, Santostefano M, Beccaria L, Pela I, Bianchetti MG, Tedeschi S. Patients with biallelic mutations in the chloride channel gene CLCNKB: long-term management and outcome. Am J Kidney Dis. 2007;49(1): 91–8. 106. Schurman SJ, Perlman SA, Sutphen R, Campos A, Garin EH, Cruz DN, Shoemaker LR. Genotype/phenotype observations in African Americans with Bartter syndrome. J Pediatr. 2001;139(1):105–10. 107. Adachi M, Tajima T, Muroya K, Asakura Y. Classic Bartter syndrome complicated with profound growth hormone deficiency: a case report. J Med Case Rep. 2013;7:283. 108. Jeck N, Konrad M, Peters M, Weber S, Bonzel KE, Seyberth HW. Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. Pediatr Res. 2000;48:754–8. 109. Fukuyama S, Hiramatsu M, Akagi M, Higa M, Ohta T. Novel mutations of the chloride channel Kb gene in two Japanese patients clinically diagnosed as Bartter syndrome with hypocalciuria. J Clin Endocrinol Metab. 2004;89(11):5847–50. 110. Sun H, Demirci H, Shields CL, Shields JA. Sclerochoroidal calcification in a patient with classic

O. Devuyst et al. Bartter’s syndrome. Am J Ophthalmol. 2005; 139:365–6. 111. Robitaille P, Merouani A, He N, Pei Y. Bartter syndrome in two sisters with a novel mutation of the CLCNKB gene, one with deafness. Eur J Pediatr. 2011;170(9):1209–11. 112. Walker SH. Severe Bartter syndrome in blacks. N Engl J Med. 1971;285(20):1150. 113. Calò LA. Vascular tone control in humans: insights from studies in Bartter’s/Gitelman’s syndromes. Kidney Int. 2006;69(6):963–6. 114. Stoff JS, Stemerman M, Steer M, Salzman E, Brown RS. A defect in platelet aggregation in Bartter’s syndrome. Am J Med. 1980;68(2):171–80. 115. Clive DM, Stoff JS, Cardi M, MacIntyre DE, Brown RS, Salzman EW. Evidence that circulating 6keto prostaglandin E1 causes the platelet defect of Bartter’s syndrome. Prostaglandins Leukot Essent Fatty Acids. 1990;41(4):251–8. 116. Sardani Y, Qin K, Haas M, Aronson AJ, Rosenfield RL. Bartter syndrome complicated by immune complex nephropathy. Case report and literature review. Pediatr Nephrol. 2003;18:913–8. 117. Blethen SL, Van Wyck JJ, Lorentz WB, Jennette JC. Reversal of Bartter’s syndrome by renal transplantation in a child with focal, segmental glomerular sclerosis. Am J Med Sci. 1985;289:31–6. 118. Su IH, Frank R, Gauthier BG, Valderrama E, Simon DB, Lifton RP, Trachtman H. Bartter syndrome and focal segmental glomerulosclerosis: a possible link between two diseases. Pediatr Nephrol. 2000; 14:970–2. 119. Bartter FC. So-called Bartter’s syndrome. N Engl J Med. 1969;281(26):1483–4. 120. Takahashi M, Yanagida N, Okano M, Ishizaki A, Meguro J, Kukita K, Tamaki T, Yonekawa M, Kawamura A, Yokoyama T. A first report: living related kidney transplantation on a patient with Bartter’s syndrome. Transplant Proc. 1996;28(3): 1588. 121. Watanabe T, Tajima T. Renal cysts and nephrocalcinosis in a patient with Bartter syndrome type III. Pediatr Nephrol. 2005;20(5):676–8. 122. Torres VE, Young Jr WF, Offord KP, Hattery RR. Association of hypokalemia, aldosteronism, and renal cysts. N Engl J Med. 1990;322(6):345–51. 123. Jeck N, Waldegger P, Doroszewicz J, Seyberth H, Waldegger S. A common sequence variation of the CLCNKB gene strongly activates ClC-Kb chloride channel activity. Kidney Int. 2004;65:190–7. 124. Jeck N, Waldegger S, Lampert A, Boehmer C, Waldegger P, Lang PA, Wissinger B, Friedrich B, Risler T, Moehle R, Lang UE, Zill P, Bondy B, Schaeffeler E, Asante-Poku S, Seyberth H, Schwab M, Lang F. Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to hypertension. Hypertension. 2004;43(6):1175–81. 125. Geller DS. A genetic predisposition to hypertension? Hypertension. 2004;44:27–8.

38

Renal Tubular Disorders of Electrolyte Regulation in Children

126. Kokubo Y, Iwai N, Tago N, Inamoto N, Okayama A, Yamawaki H, Naraba H, Tomoike H. Association analysis between hypertension and CYBA, CLCNKB, and KCNMB1 functional polymorphisms in the Japanese population-the Suita study. Circ J. 2005;69(2):138–42. 127. Meyers AM, Feldman C, Sonnekus MI, Ninin DT, Margolius LP, Whalley NA. Chronic laxative abusers with pseudo-idiopathic oedema and autonomous pseudo-Bartter’s syndrome. A spectrum of metabolic madness, or new lights on an old disease? S Afr Med J. 1990;78(11):631–6. 128. D’Avanzo M, Santinelli R, Tolone C, Bettinelli A, Bianchetti MG. Concealed administration of frusemide simulating Bartter syndrome in a 4.5year-old boy. Pediatr Nephrol. 1995;9(6):749–50. 129. Ramos E, Hall-Craggs M, Demers LM. Surreptitious habitual vomiting simulating Bartter’s syndrome. JAMA. 1980;243(10):1070–2. 130. Colussi G, Rombolà G, Airaghi C, De Ferrari ME, Minetti L. Pseudo-Bartter’s syndrome from surreptitious diuretic intake: differential diagnosis with true Bartter’s syndrome. Nephrol Dial Transplant. 1992; 7(9):896–901. 131. Gladziwa U, Schwarz R, Gitter AH, Bijman J, Seyberth H, Beck F, Ritz E, Gross P. Chronic hypokalaemia of adults: Gitelman’s syndrome is frequent but classical Bartter’s syndrome is rare. Nephrol Dial Transplant. 1995;10(9):1607–13. 132. Whyte MP, Shaheb S, Schnaper HW. Cystinosis presenting with features suggesting Bartter syndrome. Case report and literature review. Clin Pediatr (Phila). 1985;24(8):447–51. 133. Emma F, Pizzini C, Tessa A, Di Giandomenico S, Onetti-Muda A, Santorelli FM, Bertini E, Rizzoni G. “Bartter-like” phenotype in Kearns-Sayre syndrome. Pediatr Nephrol. 2006;21(3):355–60. 134. Walker SH, Firminger HI. Familial renal dysplasia with sodium wasting and hypokalemic alkalosis. Am J Dis Child. 1974;127(6):882–7. 135. Kennedy JD, Dinwiddie R, Daman-Willems C, Dillon MJ, Matthew DJ. Pseudo-Bartter’s syndrome in cystic fibrosis. Arch Dis Child. 1990;65(7):786–7. 136. Bates CM, Baum M, Quigley R. Cystic fibrosis presenting with hypokalemia and metabolic alkalosis in a previously healthy adolescent. J Am Soc Nephrol. 1997;8(2):352–5. 137. Koshida R, Sakazume S, Maruyama H, Okuda N, Ohama K, Asano S. A case of pseudo-Bartter’s syndrome due to intestinal malrotation. Acta Paediatr Jpn. 1994;36(1):107–11. 138. Vanhaesebrouck S, Van Laere D, Fryns JP, Theyskens C. Pseudo-Bartter syndrome due to Hirschsprung disease in a neonate with an extra ring chromosome 8. Am J Med Genet A. 2007;143A(20):2469–72. 139. Langhendries JP, Thiry V, Bodart E, Delfosse G, Whitofs L, Battisti O, Bertrand JM. Exogenous prostaglandin administration and pseudo-Bartter syndrome. Eur J Pediatr. 1989;149(3):208–9.

1257

140. Landau D, Kher KK. Gentamicin-induced Bartterlike syndrome. Pediatr Nephrol. 1997;11(6):737–40. 141. Chou CL, Chen YH, Chau T, Lin SH. Acquired Bartter-like syndrome associated with gentamicin administration. Am J Med Sci. 2005;329:144–9. 142. Lieber IH, Stoneburner SD, Floyd M, McGuffin WL. Potassium-wasting nephropathy secondary to chemotherapy simulating Bartter’s syndrome. Cancer. 1984;54(5):808–10. 143. Pedro-Botet J, Tomas S, Soriano JC, Coll J. Primary Sjögren’s syndrome associated with Bartter’s syndrome. Clin Exp Rheumatol. 1991;9(2):210–2. 144. Casatta L, Ferraccioli GF, Bartoli E. Hypokalaemic alkalosis, acquired Gitelman’s and Bartter’s syndrome in chronic sialoadenitis. Br J Rheumatol. 1997;36(10):1125–8. 145. G€ ullner HG, Bartter FC, Gill Jr JR, Dickman PS, Wilson CB, Tiwari JL. A sibship with hypokalemic alkalosis and renal proximal tubulopathy. Arch Intern Med. 1983;143(8):1534–40. 146. Ertekin V, Selimoglu AM, Orbak Z. Association of Bartter’s syndrome and empty sella. J Pediatr Endocrinol Metab. 2003;16(7):1065–8. 147. Addolorato G, Ancarani F, Leggio L, Abenavoli L, de Lorenzi G, Montalto M, Staffolani E, Zannoni GF, Costanzi S, Gasbarrini G. Hypokalemic nephropathy in an adult patient with partial empty sella: a classic Bartter’s syndrome, a Gitelman’s syndrome or both? Panminerva Med. 2006;48(2):137–42. 148. Jest P, Pedersen KE, Klitgaard NA, Thomsen N, Kjaer K, Simonsen E. Angiotensin-converting enzyme inhibition as a therapeutic principle in Bartter’s syndrome. Eur J Clin Pharmacol. 1991; 41(4):303–5. 149. Kim JY, Kim GA, Song JH, Lee SW, Han JY, Lee JS, Kim MJ. A case of living-related kidney transplantation in Bartter’s syndrome. Yonsei Med J. 2000; 41(5):662–5. 150. Brimacombe JR, Breen DP. Anesthesia and Bartter’s syndrome: a case report and review. AANA J. 1993;61(2):193–7. 151. Vetrugno L, Cheli G, Bassi F, Giordano F. Cardiac anesthesia management of a patient with Bartter’s syndrome. J Cardiothorac Vasc Anesth. 2005;19(3): 373–6. 152. Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians. 1966;79: 221–35. 153. Bettinelli A, Bianchetti MG, Girardin E, Caringella A, Cecconi M, Appiani AC, Pavanello L, Gastaldi R, Isimbaldi C, Lama G, et al. Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: Bartter and Gitelman syndromes. J Pediatr. 1992;120:38–43. 154. Sutton RA, Mavichak V, Halabe A, Wilkins GE. Bartter’s syndrome: evidence suggesting a distal tubular defect in a hypocalciuric variant of the syndrome. Miner Electrolyte Metab. 1992;18(1):43–51.

1258 155. Tsukamoto T, Kobayashi T, Kawamoto K, Fukase M, Chihara K. Possible discrimination of Gitelman’s syndrome from Bartter’s syndrome by renal clearance study: report of two cases. Am J Kidney Dis. 1995; 25(4):637–41. 156. Hebert SC, MountDB GG. Molecular physiology of cation-coupled Cl cotransport: the SLC12 family. Pflugeers Arch. 2004;447:580–93. 157. Gamba G, Saltzberg SN, Lombardi M, Miyanoshita A, Lytton J, Ma H, Brenner BM, Hebert SC. Primary structure and functional expression of a cDNA encoding the thiazide-sensitive, electroneutral sodium-chloride cotransporter. Proc Natl Acad Sci U S A. 1993;90:2749–53. 158. Moreno E, Cristóbal PS, Rivera M, Vázquez N, Bobadilla NA, Gamba G. Affinity-defining domains in the Na-Cl cotransporter: a different location for Cl and thiazide binding. J Biol Chem. 2006;281(25): 17266–75. 159. Takeuchi Y, Mishima E, Shima H, Akiyama Y, Suzuki C, Suzuki T, Kobayashi T, Suzuki Y, Nakayama T, Takeshima Y, VazquezN IS, Gamba G, Abe T. Exonic mutations in the SLC12A3 gene cause exon skipping and premature termination in Gitelman Syndrome. J Am Soc Nephrol. 2014;26:1–9. 160. Lemmink HH, Knoers NV, Karolyi L, van Dijk H, Niaudet P, Antignac C, Guay-Woodford LM, Goodyer PR, Carel JC, Hermes A, Seyberth HW, Monnens LA, van den Heuvel LP. Novel mutations in the thiazide-sensitive NaCl cotransporter gene in patients with Gitelman syndrome with predominant localization to the C-terminal domain. Kidney Int. 1998;54:720–30. 161. Reissinger A, Ludwig M, Utsch B, Prömse A, Baulmann J, Weisser B, Vetter H, Kramer HJ, Bokemeyer D. Novel NCCT gene mutations as a cause of Gitelman’s syndrome and a systematic review of mutant and polymorphic NCCT alleles. Kidney Blood Press Res. 2002;25:354–62. 162. Riveira-Munoz E, Chang Q, Godefroid N, Hoenderop JG, Bindels RJ, Dahan K, Devuyst O, Belgian Network for Study of Gitelman Syndrome. Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome. J Am Soc Nephrol. 2007; 18(4):1271–83. 163. Nozu K, Iijima K, Nozu Y, Ikegami E, Imai T, Jun Fu X, Kaito H, Nakanishi K, Yoshikawa N, Matsuo M. A deep intronic mutation in the SLC12A3 gene leads to Gitelman syndrome. Pediatr Res. 2009; 66:590–3. 164. Lo YF, Nozu K, Iijima K, Morishita T, Huang CC, Yang SS, Sytwu HK, Fang YW, Tseng MH, Lin SH. Recurrent deep intronic mutations in the SLC12A3 gene responsible for Gitelman Syndrome. Clin J Am Soc Nephrol. 2011;6:630–9. 165. Riveira-Munoz E, Devuyst O, Belge H, Jeck N, Strompf L, Vargas-Poussou R, Jeunemaître X, Blanchard A, Knoers NV, Konrad M, Dahan K.

O. Devuyst et al. Evaluating PVALB as a candidate gene for SLC12A3-negative cases of Gitelman’s syndrome. Nephrol Dial Transplant. 2008;23:3120–5. 166. Kunchaparty S, Palcso M, Berkman J, Velazquez H, Desir GV, Bernstein P, Reilly RF, Ellison DH. Defective processing and expression of thiazide-sensitive Na-Cl cotransporter as a cause of Gitelman’s syndrome. Am J Physiol. 1999;277:F643–9. 167. de Jong JC, van der Vliet WA, van den Heuvel L, Willems PHGM, Knoers NVAM, Bindels RJM. Functional expression of mutations in the human NaCl cotransporter: evidence for impaired routing mechanisms in Gitelman’s syndrome. J Am Soc Nephrol. 2002;13:1442–8. 168. Sabath E, Meade P, Berkman J, De los Heros P, Moreno E, Bobadilla NA, Vazquez N, Ellison DH, Gamba G. Pathophysiology of functional mutations of the thiazide-sensitive Na-Cl cotransporter in Gitelman disease. Am J Physiol Renal Physiol. 2004;287:F195–203. 169. Schultheis PJ, Lorenz JN, Meneton P, Nieman ML, Riddle TM, Flagella M, Duffy JJ, Doetschman T, Miller ML, Shull GE. Phenotype resembling Gitelman’s syndrome in mice lacking the apical Na+-Cl cotransporter of the distal convoluted tubule. J Biol Chem. 1998;273:29150–5. 170. Loffing J, Vallon V, Loffing-Cueni D, Aregger F, Richter K, Pietri L, Bloch-Faure M, Hoenderop JG, Shull GE, Meneton P, Kaissling B. Altered renal distal tubule structure and renal Na+ and Ca2+ handling in a mouse model for Gitelman’s syndrome. J Am Soc Nephrol. 2004;15:2276–88. 171. Morris RG, Hoorn EJ, Knepper MA. Hypokalemia in a mouse model of Gitelman’s syndrome. Am J Physiol Renal Physiol. 2006;290:F1416–20. 172. Belge H, Gailly P, Schwaller B, Loffing J, Debaix H, Riveira-Munoz E, Beauwens R, Devogelaer JP, Hoenderop JG, Bindels RJ, Devuyst O. Renal expression of parvalbumin is critical for NaCl handling and response to diuretics. Proc Natl Acad Sci U S A. 2007;104(37):14849–54. 173. Nijenhuis T, Hoenderop JG, Loffing J, van der Kemp AW, van Os CH, Bindels RJ. Thiazide-induced hypocalciuria is accompanied by a decreased expression of Ca2+ transport proteins in kidney. Kidney Int. 2003;64(2):555–64. 174. Hoenderop JG, van der Kemp AW, Hartog A, van Os CH, Willems PH, Bindels RJ. The epithelial calcium channel, ECaC, is activated by hyperpolarization and regulated by cytosolic calcium. Biochem Biophys Res Commun. 1999;261(2):488–92. 175. Ellison DH. Divalent cation transport by the distal nephron: insights from Bartter’s and Gitelman’s syndromes. Am J Physiol Renal Physiol. 2000;279(4):F616–25. 176. Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest. 2005;115:1651–8.

38

Renal Tubular Disorders of Electrolyte Regulation in Children

177. Reilly RF, Huang CL. The mechanism of hypocalciuria with NaCl cotransporter inhibition. Nat Rev Nephrol. 2011;7:669–74. 178. Dai LJ, Ritchie G, Kerstan D, Kang HS, Cole DE, Quamme GA. Magnesium transport in the renal distal convoluted tubule. Physiol Rev. 2001;81:51–84. 179. Schlingmann KP, Weber S, Peters M, Nejsum LN, Vitzthum H, Klingel K, Kratz M, Haddad E, Ristoff E, Dinour D, Syrrou M, Nielsen S, Sassen M, Waldegger S, Seyberth HW, Konrad M. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet. 2002;31:166–70. 180. Loffing J, Loffing-Cueni D, Hegyi I, Kaplan MR, Hebert SC, Le Hir M, Kaissling B. Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int. 1996;50:1180–90. 181. Yang SS, Lo YF, Wu CC, Lin SW, Yeh CJ, Chu P, Sytwu HK, Uchida S, Sasaki S, Lin SH. SPAKknockout mice manifest Gitelman syndrome and impaired vasoconstriction. J Am Soc Nephrol. 2010; 21(11):1868–77. 182. Godefroid N, Riveira-Munoz E, Saint-Martin C, Nassogne MC, Dahan K, Devuyst O. A novel splicing mutation in SLC12A3 associated with Gitelman syndrome and idiopathic intracranial hypertension. Am J Kidney Dis. 2006;48(5):e73–9. 183. Knoers NV. Gitelman syndrome. Adv Chronic Kidney Dis. 2006;13(2):148–54. 184. Cruz DN, Simon DB, Nelson-Williams C, Farhi A, Finberg K, Burleson L, Gill JR, Lifton RP. Mutations in the Na-Cl cotransporter reduce blood pressure in humans. Hypertension. 2001;37(6):1458–64. 185. Balavoine AS, Bataille P, Vanhille P, Azar R, Noël C, Asseman P, Soudan B, Wémeau JL, Vantyghem MC. Phenotype-genotype correlation and follow-up in adult patients with hypokalemia of renal origin suggesting Gitelman syndrome. Eur J Endocrinol. 2011;165:665–73. 186. Berry MR, Robinson C, Karte Frankl FE. Unexpected clinical sequelae of Gitelman syndrome: hypertension in adulthood is common and females have higher potassium requirements. Nephrol Dial Transplant. 2013;28:1533–42. 187. Punzi L, Calò L, Schiavon F, Pianon M, Rosada M, Todesco S. Chondrocalcinosis is a feature of Gitelman’s variant of Bartter’s syndrome. A new look at the hypomagnesemia associated with calcium pyrophosphate dihydrate crystal deposition disease. Rev Rhum Engl Ed. 1998;65(10):571–4. 188. Bourcier T, Blain P, Massin P, Gr€ unfeld JP, Gaudric A. Sclerochoroidal calcification associated with Gitelman syndrome. Am J Ophthalmol. 1999; 128(6):767–78. 189. Nicolet-Barousse L, Blanchard A, Roux C, Pietri L, Bloch-Faure M, Kolta S, Chappard C, Geoffroy V, Morieux C, Jeunemaitre X, Shull GE, Meneton P, Paillard M, Houillier P, De Vernejoul MC. Inactivation of the Na-Cl co-transporter (NCC) gene is

1259

associated with high BMD through both renal and bone mechanisms: analysis of patients with Gitelman syndrome and Ncc null mice. J Bone Miner Res. 2005;20(5):799–808. 190. Bettinelli A, Tosetto C, Colussi G, Tommasini G, Edefonti A, Bianchetti MG. Electrocardiogram with prolonged QT interval in Gitelman disease. Kidney Int. 2002;62(2):580–4. 191. Foglia PE, Bettinelli A, Tosetto C, Cortesi C, Crosazzo L, Edefonti A, Bianchetti MG. Cardiac work up in primary renal hypokalaemiahypomagnesaemia (Gitelman syndrome). Nephrol Dial Transplant. 2004;19(6):1398–402. 192. Pachulski RT, Lopez F, Sharaf R. Gitelman’s not so benign syndrome. N Engl J Med. 2005;353:850–1. 193. Srinivas SK, Sukhan S, Elovitz MA. Nausea, emesis, and muscle weakness in a pregnant adolescent. Obstet Gynecol. 2006;107(2 Pt 2):481–4. 194. von Vigier RO, Ortisi MT, la Manna A, Bianchetti MG, Bettinelli A. Hypokalemic rhabdomyolysis in congenital tubular disorders: a case series and a systematic review. Pediatr Nephrol. 2010;25:861–6. 195. Kumagai H, Matsumoto S, Nozu K. Hypokalemic rhabdomyolysis in a child with Gitelman’s syndrome. Pediatr Nephrol. 2010;25:953–5. 196. Cortesi C, Lava SA, Bettinelli A, Tammaro F, Giannini O, Caiata-Zufferey M, Bianchetti MG. Cardiac arrhythmias and rhabdomyolysis in BartterGitelman patients. Pediatr Nephrol. 2010;25(10): 2005–8. 197. Ducarme G, Davitian C, Uzan M, Belenfant X, Poncelet C. Pregnancy in a patient with Gitelman syndrome: a case report and review of literature. J Gynecol Obstet Biol Reprod (Paris). 2007; 36(3):310–3. 198. Bianchetti MG, Edefonti A, Bettinelli A. The biochemical diagnosis of Gitelman disease and the definition of “hypocalciuria”. Pediatr Nephrol. 2003; 18(5):409–11. 199. Colussi G, Bettinelli A, Tedeschi S, De Ferrari ME, Syrén ML, Borsa N, Mattiello C, Casari G, Bianchetti MG. A thiazide test for the diagnosis of renal tubular hypokalemic disorders. Clin J Am Soc Nephrol. 2007;2(3):454–60. 200. Vigano C, Amoruso C, Barretta F, Minnici G, Albisetti W, Syrèn ML, Bianchetti MG, Bettinelli A. Renal phosphate handling in Gitelman syndrome – the results of a case–control study. Pediatr Nephrol. 2013;28:65–70. 201. Azak A, Huddam B, Koçak G, Ortabozkoyum L, Uzel M, Duranay M. Gitelman syndrome complicated with dysglycemia. Acta Diabetol. 2011;48:249–50. 202. Tseng MH, Yang SS, Hsu YJ, Fang YW, Wu CJ, Tsai JD, Hwang DY, Lin SH. Genotype, phenotype, and follow-up in Taiwanese patients with salt-losing tubulopathy associated with SLC12A3 mutation. J Clin Endocrinol Metab. 2012;97(8):E1478–82. 203. Ren H, Qin L, WangW MJ, Zhang W, Shen PY, Shi H, Li X, Chen N. Abnormal glucose metabolism and

1260 insulin sensitivity in Chinese patients with Gitelman syndrome. Am J Nephrol. 2013;37(2):152–7. 204. Joo KW, Lee JW, Jang HR, Heo NJ, Jeon US, Oh YK, Lim CS, Na KY, Kim J, Cheong HI, Han JS. Reduced urinary excretion of thiazide-sensitive Na-Cl cotransporter in Gitelman syndrome: preliminary data. Am J Kidney Dis. 2007;50(5):765–73. 205. Bulucu F, Vural A, Yenicesu M, Caglar K. Association of Gitelman’s syndrome and focal segmental glomerulosclerosis. Nephron. 1998;79:244. 206. Hanevold C, Mian A, Dalton R. C1q nephropathy in association with Gitelman syndrome: a case report. Pediatr Nephrol. 2006;21(12):1904–8. 207. Ceri M, Unverdi S, Altay M, Unverdi H, Kurultak I, Yilmaz R, Ensari A, Duranay M. Focal segmental glomerulosclerosis in association with Gitelman syndrome. Int Urol Nephrol. 2011;43:905–7. 208. Demoulin N, Aydin S, Cosyns JP, Dahan K, Cornet G, Auberger I, Loffing J, Devuyst O. Gitelman syndrome and glomerular proteinuria: a link between loss of sodium-chloride cotransporter and podocyte dysfunction? Nephrol Dial Transplant. 2014;29:iv117–20. 209. Cruz DN, Shaer AJ, Bia MJ, Lifton RP, Simon DB; Yale Gitelman’s and Bartter’s Syndrome Collaborative Study Group. Gitelman’s syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int. 2001;59:710–7. 210. Coto E, Rodriguez J, Jeck N, Alvarez V, Stone R, Loris C, Rodriguez LM, Fischbach M, Seybert HW, Santos F. A new mutation (intron 9 +1 G>T) in the SLC12A3 gene is linked to Gitelman syndrome in Gypsies. Kidney Int. 2004;65:25–9. 211. Lin SH, Cheng NL, Hsu YJ, Halperin ML. Intrafamilial phenotype variability in patients with Gitelman syndrome having the same mutations in their thiazide-sensitive sodium/chloride cotransporter. Am J Kidney Dis. 2004;43:304–12. 212. Riveira-Munoz E, Chang Q, Bindels RJ, Devuyst O. Gitelman syndrome: towards genotype-phenotype correlations? Pediatr Nephrol. 2007;22:326–32. 213. Hu DC, Burtner C, Hong A, Lobo PI, Okusa MD. Correction of renal hypertension after kidney transplantation from a donor with Gitelman syndrome. Am J Med Sci. 2006;331(2):105–9. 214. Sassen MC, Jeck N, Klaus G. Can renal tubular hypokalemic disorders be accurately diagnosed on the basis of the diuretic response to thiazide? Nat Clin Pract Nephrol. 2007;3(10):528–9. 215. Panichpisal K, Angulo-Pernett F, Selhi S, Nugent KM. Gitelman-like syndrome after cisplatin therapy: a case report and literature review. BMC Nephrol. 2006;7:10. 216. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23(5):460–4. 217. Ren H, Wang WM, Chen XN, Zhang W, Pan XX, Wang XL, Lin Y, Zhang S, Chen N. Renal involvement and followup of 130 patients with primary Sjögren’s syndrome. J Rheumatol. 2008;35(2): 278–84.

O. Devuyst et al. 218. Persu A, Lafontaine JJ, Devuyst O. Chronic hypokalaemia in young women – it is not always abuse of diuretics. Nephrol Dial Transplant. 1999; 14(4):1021–5. 219. Schwarz C, Barisani T, Bauer E, Druml W. A woman with red eyes and hypokalemia: a case of acquired Gitelman syndrome. Wien Klin Wochenschr. 2006; 118(7–8):239–42. 220. Rodríguez-Soriano J. Bartter and related syndromes: the puzzle is almost solved. Pediatr Nephrol. 1998; 12(4):315–27. 221. Shaer AJ. Inherited primary renal tubular hypokalemic alkalosis: a review of Gitelman and Bartter syndromes. Am J Med Sci. 2001;322(6): 316–32. 222. Colussi G, Rombolà G, De Ferrari ME, Macaluso M, Minetti L. Correction of hypokalemia with antialdosterone therapy in Gitelman’s syndrome. Am J Nephrol. 1994;14(2):127–35. 223. Morton A. Eplerenone in the treatment of Gitelman syndrome. Intern Med J. 2008;38:377. 224. Morton A, Panitz B, Bush A. Eplerenone for Gitelman syndrome in pregnancy. Nephrology. 2011;16:349–50. 225. Ito Y, Yoshida M, Nakayama M, Tsutaya S, Ogawa K, Maeda H, Miyata M, Oiso Y. Eplerenone improved hypokalemia in a patient with Gitelman’s syndrome. Intern Med. 2012;51(1):83–6. 226. Blanchard A, Vargas-Poussou R, Valle M, CaumontPrim A, Allard J, Desport E, Dubourg L, Monge M, Bergerot D, Baron S, Essig M, Bridoux F, Tack I, Azizi M. Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. J Am Soc Nephrol. 2014;26:1–8. 227. Zannad F, McMurray JJ, Krum H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21. 228. Liaw LC, Banerjee K, Coulthard MG. Dose related growth response to indometacin in Gitelman syndrome. Arch Dis Child. 1999;81(6):508–10. 229. Mayan H, Gurevitz O, Farfel Z. Successful treatment by cyclooxyenase-2 inhibitor of refractory hypokalemia in a patient with Gitelman’s syndrome. Clin Nephrol. 2002;58(1):73–6. 230. Bettinelli A, Metta MG, Perini A, Basilico E, Santeramo C. Long-term follow-up of a patient with Gitelman’s syndrome. Pediatr Nephrol. 1993;7(1): 67–8. 231. Bonfante L, Davis PA, Spinello M, Antonello A, D’Angelo A, Semplicini A, Calò L. Chronic renal failure, end-stage renal disease, and peritoneal dialysis in Gitelman’s syndrome. Am J Kidney Dis. 2001;38(1):165–8. 232. Calò LA, Marchini F, Davis PA, Rigotti P, Pagnin E, Semplicini A. Kidney transplant in Gitelman’s syndrome. Report of the first case. J Nephrol. 2003; 16(1):144–7.

38

Renal Tubular Disorders of Electrolyte Regulation in Children

233. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature. 1993;366(6455):575–80. 234. Garrett JE, Capuano IV, Hammerland LG, Hung BC, Brown EM, Hebert SC, Nemeth EF, Fuller F. Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem. 1995;270(21):12919–25. 235. Bai M, Trivedi S, Kifor O, Quinn SJ, Brown EM. Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function. Proc Natl Acad Sci USA. 1999;96:2834–9. 236. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001;81:239–97. 237. Bapty BW, Dai LJ, Ritchie G, Canaff L, Hendy GN, Quamme GA. Mg2+/Ca2+ sensing inhibits hormonestimulated Mg2+ uptake in mouse distal convoluted tubule cells. Am J Physiol. 1998;275:F353–60. 238. Quamme GA. Control of magnesium transport in the thick ascending limb. Am J Physiol. 1989; 256(2 Pt 2):197–210. 239. Hebert SC, Brown EM, Harris HW. Role of the Ca2+sensing receptor in divalent mineral ion homeostasis. J Exp Biol. 1997;200(Pt 2):295–302. 240. Thakker RV. Diseases associated with the extracellular calcium-sensing receptor. Cell Calcium. 2004; 35(3):275–82. 241. Chou YH, Brown EM, Levi T, Crowe G, Atkinson AB, Arnqvist HJ, Toss G, Fuleihan GE, Seidman JG, Seidman CE. The gene responsible for familial hypocalciuric hypercalcemia maps to chromosome 3q in four unrelated families. Nat Genet. 1992;1(4): 295–300. 242. Pollak MR, Brown EM, Chou YH, HebertSC MSJ, Steinmann B, Levi T, Seidman CE, Seidman JG. Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell. 1993;75: 1297–303. 243. Pollak MR, Brown EM, Estep HL, McLaine PN, Kifor O, Park J, Hebert SC, Seidman CE, Seidman JG. Autosomal dominant hypocalcaemia caused by a Ca2+-sensing receptor gene mutation. Nat Genet. 1994;8:303–7. 244. Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P, Brown EM, Thakker RV. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calciumsensing receptor. N Engl J Med. 1996;335:1115–22. 245. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, Chikatsu N, Fujita T. Association between activating mutations of calcium-sensing receptor and Bartter’s syndrome. Lancet. 2002;360:692–4.

1261

246. Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaitre X, Paillard M, Planelles G, Dechaux M, Miller RT, Antignac C. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartterlike syndrome. J Am Soc Nephrol. 2002;13:2259–66. 247. Gunn IR, Gaffney D. Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann Clin Biochem. 2004;41(Pt 6):441–58. 248. Foley Jr TP, Harrison HC, Arnaud CD, Harrison HE. Familial benign hypercalcemia. J Pediatr. 1972; 6:1060–7. 249. Marx SJ, Attie MF, Levine MA, Spiegel AM, Downs Jr RW, Lasker RD. The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. Medicine (Baltimore). 1981;60:397–412. 250. Heath 3rd H. Familial benign (hypocalciuric) hypercalcemia. A troublesome mimic of mild primary hyperparathyroidism. Endocrinol Metab Clin North Am. 1989;3:723–40. 251. Bilezikian JP, Potts Jr JT, Fuleihan G-H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab. 2002;12:5353–61. 252. Auwerx J, Demedts M, Bouillon R. Altered parathyroid set point to calcium in familial hypocalciuric hypercalcaemia. Acta Endocrinol (Copenh). 1984; 106(2):215–8. 253. Pearce SH, Trump D, Wooding C, Besser GM, Chew SL, Grant DB, Heath DA, Hughes IA, Paterson CR, Whyte MP, et al. Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest. 1995;96(6):2683–92. 254. Hendy GN, D’Souza-Li L, Yang B, Canaff L, Cole DE. Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat. 2000;16(4): 281–96. 255. Sarli M, Fradinger E, Zanchetta J. Hypocalciuric hypercalcemia due to de novo mutation of the calcium sensing receptor. Medicina (B Aires). 2004;64(4): 337–9. 256. Timmers HJ, Karperien M, Hamdy NA, de Boer H, Hermus AR. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J Intern Med. 2006;260(2):177–82. 257. Attie MF, Gill Jr JR, Stock JL, Spiegal AM, Downs Jr RW, Levine MA, Marx SJ. Urinary calcium excretion in familial hypocalciuric hypercalcemia: persistence of relative hypocalciuria after induction of hypoparathyroidism. J Clin Invest. 1983;72:667–76. 258. Kifor O, Moore Jr FD, Delaney M, Garber J, Hendy GN, Butters R, Gao P, Cantor TL, Kifor I, Brown EM, Wysolmerski J. A syndrome of hypocalciuric

1262 hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J Clin Endocrinol Metab. 2003;88(1):60–72. 259. Hillman DA, Scriver CR, Pedvis S, Shragovitch I. Neonatal familial primary hyperparathyroidism. N Engl J Med. 1964;270:483–90. 260. Waller S, Kurzawinski T, Spitz L, Thakker R, Cranston T, Pearce S, Cheetham T, van’t Hoff WG. Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. Eur J Pediatr. 2004;163(10):589–94. 261. Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, Brown EM, Seidman JG, Seidman CE. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet. 1995;11(4):389–94. 262. Tu Q, Pi M, Karsenty G, Simpson L, Liu S, Quarles LD. Rescue of the skeletal phenotype in CasRdeficient mice by transfer onto the Gcm2 null background. J Clin Invest. 2003;111(7):1029–37. 263. G€unther T, Chen ZF, Kim J, Priemel M, Rueger JM, Amling M, Moseley JM, Martin TJ, Anderson DJ, Karsenty G. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature. 2000;406(6792):199–203. 264. Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med. 2005;257:27–37. 265. Brown EM. Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. Endocrinol Metab Clin North Am. 2000;29:503–22. 266. Brown EM. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell Biochem. 2007;45:139–67. 267. Sato K, Hasegawa Y, Nakae J, Nanao K, Takahashi I, Tajima T, Shinohara N, Fujieda K. Hydrochlorothiazide effectively reduces urinary calcium excretion in two Japanese patients with gain-of-function mutations of the calcium-sensing receptor gene. J Clin Endocrinol Metab. 2002;87(7):3068–73. 268. Vezzoli G, Arcidiacono T, Paloschi V, Terranegra A, Biasion R, Weber G, Mora S, Syren ML, Coviello D, Cusi D, Bianchi G, Soldati L. Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome. J Nephrol. 2006;19(4):525–8. 269. Fine KD, Santa Ana CA, Porter JL, Fordtran JS. Intestinal absorption of magnesium from food and supplements. J Clin Invest. 1991;2:396–402. 270. Quamme GA. Recent developments in intestinal magnesium absorption. Curr Opin Gastroenterol. 2008;2:230–5. 271. de Rouffignac C, Quamme G. Renal magnesium handling and its hormonal control. Physiol Rev. 1994; 2:305–22. 272. Quamme GA. Renal magnesium handling: new insights in understanding old problems. Kidney Int. 1997;5:1180–95.

O. Devuyst et al. 273. Simon DB, Lu Y, Choate KA, Velazquez H, Al-Sabban E, Praga M, Casari G, Bettinelli A, Colussi G, Rodriguez-Soriano J, McCredie D, Milford D, Sanjad S, Lifton RP. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science. 1999;285(5424):103–6. 274. Konrad M, Schaller A, Seelow D, Pandey AV, Waldegger S, Lesslauer A, Vitzthum H, Suzuki Y, Luk JM, Becker C, et al. Mutations in the tightjunction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet. 2006;5:949–57. 275. Michelis MF, Drash AL, Linarelli LG, De Rubertis FR, Davis BB. Decreased bicarbonate threshold and renal magnesium wasting in a sibship with distal renal tubular acidosis (Evaluation of the pathophysiological role of parathyroid hormone). Metab Clin Exp. 1972;10:905–20. 276. Manz F, Scharer K, Janka P, Lombeck J. Renal magnesium wasting, incomplete tubular acidosis, hypercalciuria and nephrocalcinosis in siblings. Eur J Pediatr. 1978;2:67–79. 277. Rodriguez-Soriano J, Vallo A, Garcia-Fuentes M. Hypomagnesaemia of hereditary renal origin. Pediatr Nephrol. 1987;3:465–72. 278. Rodriguez-Soriano J, Vallo A. Pathophysiology of the renal acidification defect present in the syndrome of familial hypomagnesaemia-hypercalciuria. Pediatr Nephrol. 1994;4:431–5. 279. Praga M, Vara J, Gonzalez-Parra E, Andres A, Alamo C, Araque A, Ortiz A, Rodicio JL. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Kidney Int. 1995;5:1419–25. 280. Benigno V, Canonica CS, Bettinelli A, von Vigier RO, Truttmann AC, Bianchetti MG. Hypomagnesaemia-hypercalciuria-nephrocalcinosis: a report of nine cases and a review. Nephrol Dial Transplant. 2000;5:605–10. 281. Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, Bonzel KE, Seeman T, Sulakova T, Kuwertz-Broking E, et al. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol. 2001;9: 1872–81. 282. Zimmermann B, Plank C, Konrad M, Stohr W, Gravou-Apostolatou C, Rascher W, Dotsch J. Hydrochlorothiazide in CLDN16 mutation. Nephrol Dial Transplant. 2006;8:2127–32. 283. Konrad M, Hou J, Weber S, Dotsch J, Kari JA, Seeman T, Kuwertz-Broking E, Peco-Antic A, Tasic V, Dittrich K, et al. CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol. 2008;1:171–81. 284. Godron A, Harambat J, Boccio V, et al. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: phenotype-genotype correlation

38

Renal Tubular Disorders of Electrolyte Regulation in Children

and outcome in 32 patients with CLDN16 or CLDN19 mutations. Clin J Am Soc Nephrol. 2012; 7(5):801–9. 285. Claverie-Martin F, Garcia-Nieto V, Loris C, et al. Claudin-19 mutations and clinical phenotype in Spanish patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. PLoS One. 2013;8(1), e53151. 286. Hirano T, Kobayashi N, Itoh T, Takasuga A, Nakamaru T, Hirotsune S, Sugimoto Y. Null mutation of PCLN-1/Claudin-16 results in bovine chronic interstitial nephritis. Genome Res. 2000;5:659–63. 287. Ohba Y, Kitagawa H, Kitoh K, Sasaki Y, Takami M, Shinkai Y, Kunieda T. A deletion of the paracellin-1 gene is responsible for renal tubular dysplasia in cattle. Genomics. 2000;3:229–36. 288. Will C, Breiderhoff T, Thumfart J, et al. Targeted deletion of murine Cldn16 identifies extra- and intrarenal compensatory mechanisms of Ca2+ and Mg2+ wasting. Am J Physiol Renal Physiol. 2010;298(5):F1152–61. 289. Blanchard A, Jeunemaitre X, Coudol P, Dechaux M, Froissart M, May A, Demontis R, Fournier A, Paillard M, Houillier P. Paracellin-1 is critical for magnesium and calcium reabsorption in the human thick ascending limb of Henle. Kidney Int. 2001;6:2206–15. 290. Muller D, Kausalya PJ, Claverie-Martin F, Meij IC, Eggert P, Garcia-Nieto V, Hunziker W. A novel claudin 16 mutation associated with childhood hypercalciuria abolishes binding to ZO-1 and results in lysosomal mistargeting. Am J Hum Genet. 2003;6:1293–301. 291. Hou J, Renigunta A, Konrad M, Gomes AS, Schneeberger EE, Paul DL, Waldegger S, Goodenough DA. Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J Clin Invest. 2008;2:619–28. 292. Bockenhauer D, Feather S, Stanescu HC, et al. Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N Engl J Med. 2009; 360(19):1960–70. 293. Scholl UI, Choi M, Liu T, et al. Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. Proc Natl Acad Sci U S A. 2009;106(14):5842–7. 294. Scholl UI, Dave HB, Lu M, Farhi A, NelsonWilliams C, Listman JA, Lifton RP. SeSAME/EAST syndrome – phenotypic variability and delayed activity of the distal convoluted tubule. Pediatr Nephrol. 2012;27(11):2081–90. 295. Zhang C, Wang L, Zhang J, Su XT, Lin DH, Scholl UI, Giebisch G, Lifton RP, Wang WH. KCNJ10 determines the expression of the apical Na-Cl cotransporter (NCC) in the early distal convoluted tubule (DCT1). Proc Natl Acad Sci U S A. 2014;111 (32):11864–9. 296. Neusch C, Rozengurt N, Jacobs RE, et al. Kir4.1 potassium channel subunit is crucial for

1263

oligodendrocyte development and in vivo myelination. J Neurosci. 2001;21(15):5429–38. 297. Meij IC, Koenderink JB, van Bokhoven H, Assink KF, Groenestege WT, de Pont JJ, Bindels RJ, Monnens LA, van den Heuvel LP, Knoers NV. Dominant isolated renal magnesium loss is caused by misrouting of the Na(+), K(+)-ATPase gammasubunit. Nat Genet. 2000;3:265–6. 298. Geven WB, Monnens LA, Willems HL, Buijs WC, ter Haar BG. Renal magnesium wasting in two families with autosomal dominant inheritance. Kidney Int. 1987;5:1140–4. 299. Meij IC, Van Den Heuvel LP, Hemmes S, Van Der Vliet WA, Willems JL, Monnens LA, Knoers NV. Exclusion of mutations in FXYD2, CLDN16 and SLC12A3 in two families with primary renal Mg(2+) loss. Nephrol Dial Transplant. 2003;3:512–56. 300. Sweadner KJ, Arystarkhova E, Donnet C, Wetzel RK. FXYD proteins as regulators of the Na, K-ATPase in the kidney. Ann N Y Acad Sci. 2003;382–387. 301. Arystarkhova E, Wetzel RK, Sweadner KJ. Distribution and oligomeric association of splice forms of Na (+)-K(+)-ATPase regulatory gamma-subunit in rat kidney. Am J Physiol Renal Physiol. 2002;3: F393–407. 302. Arystarkhova E, Donnet C, Asinovski NK, Sweadner KJ. Differential regulation of renal Na, K-ATPase by splice variants of the gamma subunit. J Biol Chem. 2002;12:10162–72. 303. Jones DH, Li TY, Arystarkhova E, Barr KJ, Wetzel RK, Peng J, Markham K, Sweadner KJ, Fong GH, Kidder GM. Na, K-ATPase from mice lacking the gamma subunit (FXYD2) exhibits altered Na+ affinity and decreased thermal stability. J Biol Chem. 2005;19:19003–11. 304. Glaudemans B, van der Wijst J, Scola RH, et al. A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia. J Clin Invest. 2009;119(4):936–42. 305. van der Wijst J, Glaudemans B, Venselaar H, et al. Functional analysis of the Kv1.1 N255D mutation associated with autosomal dominant hypomagnesemia. J Biol Chem. 2010;285(1):171–8. 306. Geven WB, Monnens LA, Willems JL, Buijs W, Hamel CJ. Isolated autosomal recessive renal magnesium loss in two sisters. Clin Genet. 1987;6:398–402. 307. Groenestege WM, Thebault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S, van den Heuvel LP, van Cutsem E, Hoenderop JG, Knoers NV, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007;8:2260–7. 308. Paunier L, Radde IC, Kooh SW, Conen PE, Fraser D. Primary hypomagnesemia with secondary hypocalcemia in an infant. Pediatrics. 1968;2:385–402. 309. Anast CS, Mohs JM, Kaplan SL, Burns TW. Evidence for parathyroid failure in magnesium deficiency. Science. 1972;49:606–68.

1264 310. Shalev H, Phillip M, Galil A, Carmi R, Landau D. Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998;2:127–30. 311. Milla PJ, Aggett PJ, Wolff OH, Harries JT. Studies in primary hypomagnesaemia: evidence for defective carrier-mediated small intestinal transport of magnesium. Gut. 1979;11:1028–133. 312. Matzkin H, Lotan D, Boichis H. Primary hypomagnesemia with a probable double magnesium transport defect. Nephron. 1989;1:83–6. 313. Walder RY, Shalev H, Brennan TM, Carmi R, Elbedour K, Scott DA, Hanauer A, Mark AL, Patil S, Stone EM, et al. Familial hypomagnesemia maps to chromosome 9q, not to the X chromosome: genetic linkage mapping and analysis of a balanced translocation breakpoint. Hum Mol Genet. 1997; 9:1491–7. 314. Walder RY, Landau D, Meyer P, Shalev H, Tsolia M, Borochowitz Z, Boettger MB, Beck GE, Englehardt RK, Carmi R, et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet. 2002;2:171–4. 315. Schlingmann KP, Sassen MC, Weber S, Pechmann U, Kusch K, Pelken L, Lotan D, Syrrou M, Prebble JJ, Cole DE, et al. Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia. J Am Soc Nephrol. 2005;10:3061–9. 316. Jalkanen R, Pronicka E, Tyynismaa H, Hanauer A, Walder R, Alitalo T. Genetic background of HSH in three Polish families and a patient with an X;9 translocation. Eur J Hum Genet. 2006;1:55–62. 317. Guran T, Akcay T, Bereket A, et al. Clinical and molecular characterization of Turkish patients with familial hypomagnesaemia: novel mutations in TRPM6 and CLDN16 genes. Nephrol Dial Transplant. 2012;27(2):667–73. 318. Lainez S, Schlingmann KP, van der Wijst J, et al. New TRPM6 missense mutations linked to hypomagnesemia with secondary hypocalcemia. Eur J Hum Genet. 2013;2013. 319. Chubanov V, Schlingmann KP, Wäring J, et al. Hypomagnesemia with secondary hypocalcemia due to a missense mutation in the putative pore-forming region of TRPM6. J Biol Chem. 2007; 282(10):7656–67. 320. Nadler MJ, Hermosura MC, Inabe K, Perraud AL, Zhu Q, Stokes AJ, Kurosaki T, Kinet JP, Penner R, Scharenberg AM, et al. LTRPC7 is a Mg.ATPregulated divalent cation channel required for cell viability. Nature. 2001;6837:590–5. 321. Voets T, Nilius B, Hoefs S, van der Kemp AW, Droogmans G, Bindels RJ, Hoenderop JG. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem. 2004; 279(1):19–25. 322. Cole DE, Quamme GA. Inherited disorders of renal magnesium handling. J Am Soc Nephrol. 2000; 10:1937–47.

O. Devuyst et al. 323. Chubanov V, Waldegger S, Mederos y Schnitzler M, Vitzthum H, Sassen MC, Seyberth HW, Konrad M, Gudermann T. Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proc Natl Acad Sci U S A. 2004;9:2894–9. 324. Schmitz C, Dorovkov MV, Zhao X, Davenport BJ, Ryazanov AG, Perraud AL. The channel kinases TRPM6 and TRPM7 are functionally nonredundant. J Biol Chem. 2005;45:37763–71. 325. Groenestege WM, Hoenderup JG, van den Heuvel L, Knoers N, Bindels RJ. The epithelial Mg2+ channel transient receptor potential melastatin 6 is regulated by dietary Mg2+ contents and estrogens. J Am Soc Nephrol. 2006;17:1035–43. 326. Nijenhuis T, Hoenderup JG, Bindels RJ. Downregulation of Ca2+ and Mg2+ transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc Nephrol. 2004;15:549–57. 327. Ikari A, Okude C, Sawada H, Takahashi T, Sugatani J, Miwa M. Downregulation of TRPM6-mediated magnesium influx by cyclosporine A. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:333–43. 328. Stuiver M, Lainez S, Will C, et al. CNNM2, encoding a basolateral protein required for renal Mg2+ handling, is mutated in dominant hypomagnesemia. Am J Hum Genet. 2011;88(3):333–43. 329. Goytain A, Quamme GA. Functional characterization of ACDP2 (ancient conserved domain protein), a divalent metal transporter. Physiol Genomics. 2005; 22(3):382–9. 330. Meyer TE, Verwoert GC, Hwang SJ, et al. Genomewide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels. PLoS Genet. 2010;6(8). 331. Arjona FJ, de Baaij JH, Schlingmann KP, et al. CNNM2 mutations cause impaired brain development and seizures in patients with hypomagnesemia. PLoS Genet. 2014;10(4), e1004267. 332. Wang CY, Shi JD, Yang P, et al. Molecular cloning and characterization of a novel gene family of four ancient conserved domain proteins (ACDP). Gene. 2003;306:37–44. 333. de Baaij JH, Stuiver M, Meij IC, et al. Membrane topology and intracellular processing of cyclin M2 (CNNM2). J Biol Chem. 2012;287(17):13644–55. 334. Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet. 1997;17(4):384–5. 335. Lindner TH, Njolstad PR, Horikawa Y, et al. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta. Hum Mol Genet. 1999;8(11):2001–8. 336. Faguer S, Decramer S, Chassaing N, et al. Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood. Kidney Int. 2011;80(7):768–76.

38

Renal Tubular Disorders of Electrolyte Regulation in Children

337. Heidet L, Decramer S, Pawtowski A, et al. Spectrum of HNF1B mutations in a large cohort of patients who harbor renal diseases. Clin J Am Soc Nephrol. 2010; 5(6):1079–90. 338. Adalat S, Woolf AS, Johnstone KA, et al. HNF1B mutations associate with hypomagnesemia and renal magnesium wasting. J Am Soc Nephrol. 2009; 20(5):1123–31. 339. Ferre S, de Baaij JH, Ferreira P, et al. Mutations in PCBD1 cause hypomagnesemia and renal magnesium wasting. J Am Soc Nephrol. 2014;25(3): 574–86. 340. Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, et al. A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science. 2004;5699:1190–4. 341. Agus ZS. Hypomagnesemia. J Am Soc Nephrol. 1999;10:1616–22. 342. Schlingmann KP, Konrad M, Seyberth HW. Genetics of hereditary disorders of magnesium homeostasis. Pediatr Nephrol. 2004;19:13–25. 343. Gal P, Reed MD. Medications. In: Behrman RE, Kliegman R, Jenson HB, editors. Textbook of pediatrics. Philadelphia: Saunders; 2000. p. 2270. 344. Ranade VV, Somberg JC. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to human. Am J Ther. 2001;8: 345–57. 345. Ryan MP. Magnesium and potassium-sparing diuretics. Magnesium. 1986;5:282–92. 346. Netzer T, Knauf H, Mutschler E. Modulation of electrolyte excretion by potassium retaining diuretics. Eur Heart J. 1992;13(Suppl G):22–7. 347. Bundy JT, Connito D, Mahoney MD, Pontier PJ. Treatment of idiopathic renal magnesium wasting with amiloride. Am J Nephrol. 1995;15:75–7. 348. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, O’Donnell CJ, Musone SL, Camargo AL, Drake JA, Levy D, Hirschhorn JN, Vasan RS. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension. 2007;49:846–56. 349. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33–41. 350. Meneton P, Galan P, Bertrais S, Heudes D, Hercberg S, Menard J. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations. J Hum Hypertens. 2008;22:550–8. 351. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies–a review of the current literature. Horm Metab Res. 2012;44:157–62. 352. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black

1265

and white subjects with resistant hypertension. Hypertension. 2002;40:892–6. 353. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J. 1966;95:1109–19. 354. Stowasser M, Gunasekera TG, Gordon RD. Familial varieties of primary aldosteronism. Clin Exp Pharmacol Physiol. 2001;28:1087–90. 355. Mulatero P, di Cella SM, Williams TA, Milan A, Mengozzi G, Chiandussi L, Gomez-Sanchez CE, Veglio F. Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation italian pedigree. J Clin Endocrinol Metab. 2002;87: 3187–91. 356. Aglony M, Martinez-Aguayo A, Carvajal CA, Campino C, Garcia H, Bancalari R, Bolte L, Avalos C, Loureiro C, Trejo P, Brinkmann K, Giadrosich V, Mericq V, Rocha A, Avila A, Perez V, Inostroza A, Fardella CE. Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and biochemical presentation. Hypertension. 2011;57:1117–21. 357. Pizzolo F, Trabetti E, Guarini P, Mulatero P, Ciacciarelli A, Blengio GS, Corrocher R, Olivieri O. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting. J Hum Hypertens. 2005;19:325–7. 358. Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, Schiavone D, Williams TA, Einaudi S, La Grotta A, Rabbia F, Veglio F. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension. 2011;58:797–803. 359. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension. 1998;31:445–50. 360. Mantero F, Armanini D, Biason A, Boscaro M, Carpene G, Fallo F, Opocher G, Rocco S, Scaroni C, Sonino N. New aspects of mineralocorticoid hypertension. Horm Res. 1990;34:175–80. 361. Mulatero P, Veglio F, Pilon C, Rabbia F, Zocchi C, Limone P, Boscaro M, Sonino N, Fallo F. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab. 1998;83: 2573–5. 362. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoidremediable aldosteronism. J Clin Endocrinol Metab. 1997;82:3570–3. 363. Stowasser M, Bachmann AW, Tunny TJ, Gordon RD. Production of 18-oxo-cortisol in subtypes of primary aldosteronism. Clin Exp Pharmacol Physiol. 1996;23:591–3.

1266 364. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoidremediable aldosteronism and human hypertension. Nature. 1992;355:262–5. 365. Curnow KM, Mulatero P, Emeric-Blanchouin N, Aupetit-Faisant B, Corvol P, Pascoe L. The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme. Nat Struct Biol. 1997;4:32–5. 366. Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI, White PC. Glucocorticoidsuppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci U S A. 1992;89:8327–31. 367. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun. 1995;207:565–71. 368. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266–81. 369. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab. 2000;85:3313–8. 370. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol. 1991;18: 283–6. 371. Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL, Krek AL. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol. 1992;19: 319–22. 372. Stowasser M, Gordon RD. Primary aldosteronism: learning from the study of familial varieties. J Hypertens. 2000;18:1165–76. 373. Stowasser M, Gunasekera TG, Gordon RD. Familial varieties of primary aldosteronism. Clin Exp Pharmacol Physiol. 2001;28:1087–90. 374. Medeau V, Assie G, Zennaro MC, Clauser E, Plouin PF, Jeunemaitre X. Familial aspect of primary hyperaldosteronism: analysis of families compatible with primary hyperaldosteronism type 2. Ann Endocrinol (Paris). 2005;66:240–6. 375. Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, Gordon RD, Stratakis CA. A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet. 2000;37:831–5.

O. Devuyst et al. 376. Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, Kelemen L, Jeske Y, Veglio F, Stowasser M. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J Hypertens. 2008;26:1577–82. 377. So A, Jeske YW, Gordon RD, Duffy D, Kelemen L, Stowasser M. No evidence for coding region mutations in the retinoblastoma-associated Kruppel-associated box protein gene (RBaK) causing familial hyperaldosteronism type II. Clin Endocrinol (Oxf). 2006;65:829–31. 378. Jeske YW, So A, Kelemen L, Sukor N, Willys C, Bulmer B, Gordon RD, Duffy D, Stowasser M. Examination of chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II. Clin Exp Pharmacol Physiol. 2008;35:380–5. 379. Pallauf A, Schirpenbach C, Zwermann O, Fischer E, Morak M, Holinski-Feder E, Hofbauer L, Beuschlein F, Reincke M. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience. Horm Metab Res. 2012;44:215–20. 380. Geller DS, Zhang JJ, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human Mendelian hypertension featuring non-glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab. 2008;93:3117–23. 381. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Akerstrom G, Wang W, Carling T, Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768–72. 382. Oki K, Plonczynski MW, Luis Lam M, GomezSanchez EP, Gomez-Sanchez CE. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology. 2012;153:1774–82. 383. Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley FL, Farhi A, Wang WH, Lifton RP. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A. 2012;109:2533–8. 384. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, Hurt DE, Lin L, Xekouki P, Stratakis CA, Chrousos GP. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab. 2012;97: E1532–9. 385. Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, Fischer E, Tizzani D, Pallauf A, Viola A, Amar L, Williams TA, Strom TM, Graf E, Bandulik S, Penton D, Plouin PF, Warth R, Allolio B, Jeunemaitre X, Veglio F,

38

Renal Tubular Disorders of Electrolyte Regulation in Children

Reincke M. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension. 2012;59:235–40. 386. Monticone S, Hattangady NG, Penton D, Isales CM, Edwards MA, Williams TA, Sterner C, Warth R, Mulatero P, Rainey WE. A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. J Clin Endocrinol Metab. 2013;98:E1861–5. 387. Adachi M, Muroya K, Asakura Y, Sugiyama K, Homma K, Hasegawa T. Discordant genotypephenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: a patient report and review of the literature. Horm Res Pediatry. 2014;82:138–42. 388. Liddle G, Bledsoe T, Coppage WS. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians. 1963;76:199–213. 389. Botero-Velez M, Curtis JJ, Warnock DG. Brief report: Liddle’s syndrome revisited – a disorder of sodium reabsorption in the distal tubule. N Engl J Med. 1994;330:178–81. 390. Shimkets RA, Warnock DG, Bositis CM, NelsonWilliams C, Hansson JH, Schambelan M, Gill JR, Ulick S, Milora RV, Findling JW, et al. Liddle’s syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994;79:407–14. 391. Jeunemaitre X, Bassilana F, Persu A, Dumont C, Champigny G, Lazdunski M, Corvol P, Barbry P. Genotype-phenotype analysis of a newly discovered family with Liddle’s syndrome. J Hypertens. 1997;15:1091–100. 392. Baker E, Jeunemaitre X, Portal AJ, Grimbert P, Markandu N, Persu A, Corvol P, MacGregor G. Abnormalities of nasal potential difference measurement in Liddle’s syndrome. J Clin Invest. 1998;102:10–4. 393. Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, Canessa C, Iwasaki T, Rossier B, Lifton RP. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet. 1995;11:76–82. 394. Yang KQ, Lu CX, Xiao Y, Liu YX, Jiang XJ, Zhang X, Zhou XL. Molecular genetics of Liddle’s syndrome. Clin Endocrinol (Oxf). 2014;82(4):611–4. 395. Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger JD, Rossier BC. Amiloridesensitive epithelial Na+ channel is made of three homologous subunits. Nature. 1994;367:463–7. 396. Jasti J, Furukawa H, Gonzales EB, Gouaux E. Structure of acid-sensing ion channel 1 at 1.9 A resolution and low pH. Nature. 2007;449:316–23. 397. Rossier BC. Epithelial sodium channel (ENaC) and the control of blood pressure. Curr Opin Pharmacol. 2014;15:33–46. 398. Snyder PM, Price MP, McDonald FJ, Adams CM, Volk KA, Zeiher BG, Stokes JB, Welsh MJ.

1267

Mechanism by which Liddle’s syndrome mutations increase activity of a human epithelial Na+ channel. Cell. 1995;83:969–78. 399. Schild L, Lu Y, Gautschi I, Schneeberger E, Lifton RP, Rossier BC. Identification of a PY motif in the epithelial Na channel subunits as a target sequence for mutations causing channel activation found in Liddle syndrome. EMBO J. 1996;15:2381–7. 400. Rotin D, Staub O, Haguenauer-Tsapis R. Ubiquitination and endocytosis of plasma membrane proteins: role of Nedd4/Rsp5p family of ubiquitinprotein ligases. J Membr Biol. 2000;176:1–17. 401. Staub O, Verrey F. Impact of Nedd4 proteins and serum and glucocorticoid-induced kinases on epithelial Na+ transport in the distal nephron. J Am Soc Nephrol. 2005;16:3167–74. 402. Firsov D, Schild L, Gautschi I, Merillat AM, Schneeberger E, Rossier BC. Cell surface expression of the epithelial Na channel and a mutant causing Liddle syndrome: a quantitative approach. Proc Natl Acad Sci U S A. 1996;93:15370–5. 403. Warnock DG. Liddle syndrome: an autosomal dominant form of human hypertension. Kidney Int. 1998;53(1):18–24. 404. Teiwes J, Toto RD. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am J Hypertens. 2007;20:109–17. 405. Swift PA, MacGregor GA. The epithelial sodium channel in hypertension: genetic heterogeneity and implications for treatment with amiloride. Am J Pharmacogenomics. 2004;4:161–8. 406. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton RP. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119–23. 407. Rafestin-Oblin ME, Souque A, Bocchi B, Pinon G, Fagart J, Vandewalle A. The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. Endocrinology. 2003;144:528–33. 408. New MI, Levine LS, Biglieri EG, Pareira J, Ulick S. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab. 1977;44:924–33. 409. Ulick S, Ramirez LC, New MI. An abnormality in steroid reductive metabolism in a hypertensive syndrome. J Clin Endocrinol Metab. 1977;44:799–802. 410. Stewart PM. Mineralocorticoid hypertension. Lancet. 1999;353:1341–7. 411. Ulick S, Tedde R, Mantero F. Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1990;70: 200–6. 412. Li A, Tedde R, Krozowski ZS, Pala A, Li KX, Shackleton CH, Mantero F, Palermo M, Stewart PM. Molecular basis for hypertension in the “type II variant” of apparent mineralocorticoid excess. Am J Hum Genet. 1998;63:370–9.

1268 413. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase – tissue specific protector of the mineralocorticoid receptor. Lancet. 1988;2:986–9. 414. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet. 1995;10:394–9. 415. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, Whorwood CB. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet. 1996;347:88–91. 416. Morineau G, Marc JM, Boudi A, Galons H, Gourmelen M, Corvol P, Pascoe L, Fiet J. Genetic, biochemical, and clinical studies of patients with A328V or R213C mutations in 11betaHSD2 causing apparent mineralocorticoid excess. Hypertension. 1999;34:435–41. 417. New MI, Geller DS, Fallo F, Wilson RC. Monogenic low renin hypertension. Trends Endocrinol Metab. 2005;16:92–7. 418. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR, Mullins JJ. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J Clin Invest. 1999;103:683–9. 419. Gourmelen M, Saint-Jacques I, Morineau G, Soliman H, Julien R, Fiet J. 11 beta-Hydroxysteroid dehydrogenase deficit: a rare cause of arterial hypertension. Diagnosis and therapeutic approach in two young brothers. Eur J Endocrinol. 1996;135:238–44. 420. Palermo M, Delitala G, Sorba G, Cossu M, Satta R, Tedde R, Pala A, Shackleton CH. Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome? J Endocrinol Invest. 2000;23:457–62. 421. Wilson RC, Nimkarn S, New MI. Apparent mineralocorticoid excess. Trends Endocrinol Metab. 2001; 12:104–11. 422. Gordon RD, Klemm SA, Tunny TJ, Stowasser M. Chapter 125: Gordon syndrome: a sodiumvolume-dependent form of hypertension with a genetic basis. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven; 1995. 423. Achard JM, Disse-Nicodeme S, Fiquet-Kempf B, Jeunemaitre X. Phenotypic and genetic heterogeneity of familial hyperkalaemic hypertension (Gordon syndrome). Clin Exp Pharmacol Physiol. 2001;28: 1048–52. 424. Disse-Nicodeme S, Achard JM, Desitter I, Houot AM, Fournier A, Corvol P, Jeunemaitre X. A new locus on chromosome 12p13.3 for pseudohypoaldosteronism type II, an autosomal dominant form of hypertension. Am J Hum Genet. 2000;67:302–10. 425. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford DV, Lipkin GW, Achard JM,

O. Devuyst et al. Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X, Lifton RP. Human hypertension caused by mutations in WNK kinases. Science. 2001;293:1107–12. 426. Xu BE, Lee BH, Min X, Lenertz L, Heise CJ, Stippec S, Goldsmith EJ, Cobb MH. WNK1: analysis of protein kinase structure, downstream targets, and potential roles in hypertension. Cell Res. 2005; 15:6–10. 427. Vidal-Petiot E, Elvira-Matelot E, Mutig K, Soukaseum C, Baudrie V, Wu S, Cheval L, Huc E, Cambillau M, Bachmann S, Doucet A, Jeunemaitre X, Hadchouel J. WNK1-related familial hyperkalemic hypertension results from an increased expression of L-WNK1 specifically in the distal nephron. Proc Natl Acad Sci U S A. 2013;110(35): 14366–71. 428. Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Valimaki MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML, Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW, Hunley TE, Nelson RD, Trachtman H, Cole TR, Pinsk M, Bockenhauer D, Shenoy M, Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, Gharavi AG, Goilav B, Lifton RP. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature. 2012;482:98–102. 429. Louis-Dit-Picard H, Barc J, Trujillano D, MisereyLenkei S, Bouatia-Naji N, Pylypenko O, Beaurain G, Bonnefond A, Sand O, Simian C, Vidal-Petiot E, Soukaseum C, Mandet C, Broux F, Chabre O, Delahousse M, Esnault V, Fiquet B, Houillier P, Bagnis CI, Koenig J, Konrad M, Landais P, Mourani C, Niaudet P, Probst V, Thauvin C, Unwin RJ, Soroka SD, Ehret G, Ossowski S, Caulfield M, International Consortium for Blood P, Bruneval P, Estivill X, Froguel P, Hadchouel J, Schott JJ, Jeunemaitre X. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet. 2012;44(456–460):S451–3. 430. Schumacher FR, Sorrell FJ, Alessi DR, Bullock AN, Kurz T. Structural and biochemical characterization of the KLHL3-WNK kinase interaction important in blood pressure regulation. Biochem J. 2014;460: 237–46. 431. Kahle KT, Wilson FH, Leng Q, Lalioti MD, O’Connell AD, Dong K, Rapson AK, MacGregor GG, Giebisch G, Hebert SC, Lifton RP. WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion. Nat Genet. 2003;35:372–6. 432. Hadchouel J, Delaloy C, Faure S, Achard JM, Jeunemaitre X. Familial hyperkalemic hypertension. J Am Soc Nephrol. 2006;17:208–17.

38

Renal Tubular Disorders of Electrolyte Regulation in Children

433. Hoorn EJ, Nelson JH, McCormick JA, Ellison DH. The WNK kinase network regulating sodium, potassium, and blood pressure. J Am Soc Nephrol. 2011;22:605–14. 434. Uchida S. Regulation of blood pressure and renal electrolyte balance by Cullin-RING ligases. Curr Opin Nephrol Hypertens. 2014;23:487–93. 435. Chaves-Canales M, Zhang C, Soukaseum C, Moreno E, Pacheco-Alvarez D, Vidal-Petiot E, Castañeda-Bueno M, Vazquez N, Rojas-Vega L, Meermeier NP, Rogers S, Jeunemaitre X, Yang CL, Ellison DH, Gamba G, Hadchouel J. The WNKSPAK-NCC cascade revisited: WNK1 stimulates the activity of the NaCl cotransporter via SPAK, an effect antagonized by WNK4. Hypertension. 2014;64: 1047–53. 436. Lalioti MD, Zhang J, Volkman HM, Kahle KT, Hoffmann KE, Toka HR, Nelson-Williams C, Ellison DH, Flavell R, Booth CJ, Lu Y, Geller DS, Lifton RP. Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. Nat Genet. 2006;38: 1124–32. 437. San-Cristobal P, Pacheco-Alvarez D, Richardson C, Ring AM, Vazquez N, Rafiqi FH, Chari D, Kahle KT, Leng Q, Bobadilla NA, Hebert SC, Alessi DR, Lifton RP, Gamba G. Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. Proc Natl Acad Sci U S A. 2009;106:4384–9. 438. Ohta A, Schumacher FR, Mehellou Y, Johnson C, Knebel A, Macartney TJ, Wood NT, Alessi DR, Kurz T. The CUL3-KLHL3 E3 ligase complex mutated in Gordon’s hypertension syndrome interacts with and ubiquitylates WNK isoforms: diseasecausing mutations in KLHL3 and WNK4 disrupt interaction. Biochem J. 2013;451:111–22. 439. Wakabayashi M, Mori T, Isobe K, Sohara E, Susa K, Araki Y, Chiga M, Kikuchi E, Nomura N, Mori Y, Matsuo H, Murata T, Nomura S, Asano T, Kawaguchi H, Nonoyama S, Rai T, Sasaki S, Uchida S. Impaired KLHL3-mediated ubiquitination of WNK4 causes human hypertension. Cell Rep. 2013;3:858–68. 440. Delaloy C, Lu J, Houot AM, Disse-Nicodeme S, Gasc JM, Corvol P, Jeunemaitre X. Multiple promoters in the WNK1 gene: one controls expression of a kidneyspecific kinase-defective isoform. Mol Cell Biol. 2003;23:9208–21. 441. Xu BE, Min X, Stippec S, Lee BH, Goldsmith EJ, Cobb MH. Regulation of WNK1 by an autoinhibitory domain and autophosphorylation. J Biol Chem. 2002;277:48456–62. 442. Piala AT, Moon TM, Akella R, He H, Cobb MH, Goldsmith EJ. Chloride sensing by WNK1 involves inhibition of autophosphorylation. Sci Signal. 2014;7: ra41. 443. Bazúa-Valenti S, Chávez-Canales M, Rojas-Vega L, González-Rodríguez X, Vázquez N, Rodríguez-

1269

Gama A, Argaiz ER, Melo Z, Plata C, Ellison DH, García-Valdés J, Hadchouel J, Gamba G. The effect of WNK4 on the Na+-Cl cotransporter is modulated by intracellular chloride. J Am Soc Nephrol. 2015;26 (8):1781–6. 444. Achard JM, Warnock DG, Disse-Nicodeme S, FiquetKempf B, Corvol P, Fournier A, Jeunemaitre X. Familial hyperkalemic hypertension: phenotypic analysis in a large family with the WNK1 deletion mutation. Am J Med. 2003;114:495–8. 445. Mayan H, Gurevitz O, Farfel Z. Successful treatment by cyclooxyenase-2 inhibitor of refractory hypokalemia in a patient with Gitelman’s syndrome. Clin Nephrol. 2002;58:73–6. 446. Sanjad S, Mansour F, Hernandez R, Hill L. Severe hypertension, hyperkalemia, and renal tubular acidosis responding to dietary sodium restriction. Pediatrics. 1982;69:317–24. 447. Glover M, O’Shaughnessy KM. SPAK and WNK kinases: a new target for blood pressure treatment? Curr Opin Nephrol Hypertens. 2011;20:16–22. 448. Zennaro MC, Hubert EL, Fernandes-Rosa FL. Aldosterone resistance: structural and functional considerations and new perspectives. Mol Cell Endocrinol. 2012;350:206–15. 449. Cheek DB, Perry JW. A salt wasting syndrome in infancy. Arch Dis Child. 1958;33:252–6. 450. Hanukoglu A. Type I pseudohypoaldosteronism includes two clinically and genetically distinct entities with either renal or multiple target organ defects. J Clin Endocrinol Metab. 1991;73:936–44. 451. Geller DS. Mineralocorticoid resistance. Clin Endocrinol (Oxf). 2005;62:513–20. 452. Zettle RM, West ML, Josse RG, Richardson RM, Marsden PA, Halperin ML. Renal potassium handling during states of low aldosterone bio-activity: a method to differentiate renal and non-renal causes. Am J Nephrol. 1987;7:360–6. 453. Rodriguez-Soriano J, Ubetagoyena M, Vallo A. Transtubular potassium concentration gradient: a useful test to estimate renal aldosterone bio-activity in infants and children. Pediatr Nephrol. 1990;4: 105–10. 454. Escoubet B, Couffignal C, Laisy JP, Mangin L, Chillon S, Laouenan C, Serfaty JM, Jeunemaitre X, Mentre F, Zennaro MC. Cardiovascular effects of aldosterone: insight from adult carriers of mineralocorticoid receptor mutations. Circ Cardiovasc Genet. 2013;6:381–90. 455. Oberfield SE, Levine LS, Carey RM, Bejar R, New MI. Pseudohypoaldosteronism: multiple target organ unresponsiveness to mineralocorticoid hormones. J Clin Endocrinol Metab. 1979;48:228–34. 456. Wong GP, Levine D. Congenital pseudohypoaldosteronism presenting in utero with acute polyhydramnios. J Matern Fetal Med. 1998;7:76–8. 457. Speiser PW, Stoner E, New MI. Pseudohypoaldosteronism: a review and report of two new cases. Adv Exp Med Biol. 1986;196:173–95.

1270 458. Kerem E, Bistritzer T, Hanukoglu A, Hofmann T, Zhou Z, Bennett W, MacLaughlin E, Barker P, Nash M, Quittell L, Boucher R, Knowles MR. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med. 1999;341:156–62. 459. Martin JM, Calduch L, Monteagudo C, Alonso V, Garcia L, Jorda E. Clinico-pathological analysis of the cutaneous lesions of a patient with type I pseudohypoaldosteronism. J Eur Acad Dermatol Venereol. 2005;19:377–9. 460. Belot A, Ranchin B, Fichtner C, Pujo L, Rossier BC, Liutkus A, Morlat C, Nicolino M, Zennaro MC, Cochat P. Pseudohypoaldosteronisms, report on a 10-patient series. Nephrol Dial Transplant. 2008;23: 1636–41. 461. Rodriguez-Soriano J, Vallo A, Oliveros R, Castillo G. Transient pseudohypoaldosteronism secondary to obstructive uropathy in infancy. J Pediatr. 1983;103: 375–80. 462. Bulchmann G, Schuster T, Heger A, Kuhnle U, Joppich I, Schmidt H. Transient pseudohypoaldosteronism secondary to posterior urethral valves – a case report and review of the literature. Eur J Pediatr Surg. 2001;11:277–9. 463. Watanabe T, Nitta K. Transient hyporeninemic hypoaldosteronism in acute glomerulonephritis. Pediatr Nephrol. 2002;17:959–63. 464. Vantyghem MC, Hober C, Evrard A, Ghulam A, Lescut D, Racadot A, Triboulet JP, Armanini D, Lefebvre J. Transient pseudo-hypoaldosteronism following resection of the ileum: normal level of lymphocytic aldosterone receptors outside the acute phase. J Endocrinol Invest. 1999;22:122–7. 465. Deppe CE, Heering PJ, Viengchareun S, Grabensee B, Farman N, Lombes M. Cyclosporine a and FK506 inhibit transcriptional activity of the human mineralocorticoid receptor: a cell-based model to investigate partial aldosterone resistance in kidney transplantation. Endocrinology. 2002;143: 1932–41. 466. Verrey F, Pearce D, Pfeiffer R, Spindler B, Mastroberardino L, Summa V, Zecevic M. Pleiotropic action of aldosterone in epithelia mediated by transcription and post-transcription mechanisms. Kidney Int. 2000;57:1277–82. 467. Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol. 2005;19: 2211–21; Stockand JD (2002) New ideas about aldosterone signaling in epithelia. Am J Physiol Renal Physiol 282:F559–576. 468. Armanini D, Kuhnle U, Strasser T, Dorr H, Butenandt I, Weber P, Stockigt JR, Pearce P, Funder JW. Aldosterone receptor deficiency in pseudohypoaldosteronism. N Engl J Med. 1985;313:1178–81. 469. Kuhnle U, Nielsen MD, Tietze HU, Schroeter CH, Schlamp D, Bosson D, Knorr D, Armanini D. Pseudohypoaldosteronism in eight families: different

O. Devuyst et al. forms of inheritance are evidence for various genetic defects. J Clin Endocrinol Metab. 1990;70:638–41. 470. Geller DS, Rodriguez-Soriano J, Vallo Boado A, Schifter S, Bayer M, Chang SS, Lifton RP. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet. 1998;19:279–81. 471. Riepe FG, Finkeldei J, de Sanctis L, Einaudi S, Testa A, Karges B, Peter M, Viemann M, Grotzinger J, Sippell WG, Fejes-Toth G, Krone N. Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1. J Clin Endocrinol Metab. 2006;91:4552–61. 472. Pujo L, Fagart J, Gary F, Papadimitriou DT, Claes A, Jeunemaitre X, Zennaro MC. Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. Hum Mutat. 2007; 28:33–40. 473. Zennaro MC, Keightley MC, Kotelevtsev Y, Conway GS, Soubrier F, Fuller PJ. Human mineralocorticoid receptor genomic structure and identification of expressed isoforms. J Biol Chem. 1995;270:21016–20. 474. Sartorato P, Lapeyraque AL, Armanini D, Kuhnle U, Khaldi Y, Salomon R, Abadie V, Di Battista E, Naselli A, Racine A, Bosio M, Caprio M, PouletYoung V, Chabrolle JP, Niaudet P, De Gennes C, Lecornec MH, Poisson E, Fusco AM, Loli P, Lombes M, Zennaro MC. Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J Clin Endocrinol Metab. 2003;88:2508–17. 475. Geller DS, Zhang J, Zennaro MC, Vallo-Boado A, Rodriguez-Soriano J, Furu L, Haws R, Metzger D, Botelho B, Karaviti L, Haqq AM, Corey H, Janssens S, Corvol P, Lifton RP. Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults. J Am Soc Nephrol. 2006;17:1429–36. 476. Sartorato P, Khaldi Y, Lapeyraque AL, Armanini D, Kuhnle U, Salomon R, Caprio M, Viengchareun S, Lombes M, Zennaro MC. Inactivating mutations of the mineralocorticoid receptor in type I pseudohypoaldosteronism. Mol Cell Endocrinol. 2004;217: 119–25. 477. Fernandes-Rosa FL, Hubert EL, Fagart J, Tchitchek N, Gomes D, Jouanno E, Benecke A, Rafestin-Oblin ME, Jeunemaitre X, Antonini SR, Zennaro MC. Mineralocorticoid receptor mutations differentially affect individual gene expression profiles in pseudohypoaldosteronism type 1. J Clin Endocrinol Metab. 2011;96:E519–27. 478. Rossier BC, Baker ME, Studer RA. Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited. Physiol Rev. 2015;95:297–340. 479. Chang SS, Grunder S, Hanukoglu A, Rosler A, Mathew PM, Hanukoglu I, Schild L, Lu Y, Shimkets RA, Nelson-Williams C, Rossier BC, Lifton RP.

38

Renal Tubular Disorders of Electrolyte Regulation in Children

Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet. 1996;12:248–53. 480. Strautnieks SS, Thompson RJ, Gardiner RM, Chung E. A novel splice-site mutation in the gamma subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families. Nat Genet. 1996;13:248–50. 481. Rossier BC, Pradervand S, Schild L, Hummler E. Epithelial sodium channel and the control of sodium balance: interaction between genetic and environmental factors. Annu Rev Physiol. 2002; 64:877–97. 482. Hanukoglu A, Edelheit O, Shriki Y, Gizewska M, Dascal N, Hanukoglu I. Renin-aldosterone response, urinary Na/K ratio and growth in pseudohypoaldosteronism patients with mutations in epithelial sodium channel (ENaC) subunit genes. J Steroid Biochem Mol Biol. 2008;111:268–74. 483. Edelheit O, Hanukoglu I, Shriki Y, Tfilin M, Dascal N, Gillis D, Hanukoglu A. Truncated beta epithelial sodium channel (ENaC) subunits responsible for multi-system pseudohypoaldosteronism support partial activity of ENaC. J Steroid Biochem Mol Biol. 2010;119:84–8. 484. Riepe FG, van Bemmelen MX, Cachat F, Plendl H, Gautschi I, Krone N, Holterhus PM, Theintz G, Schild L. Revealing a subclinical salt-losing phenotype in heterozygous carriers of the novel S562P

1271

mutation in the alpha subunit of the epithelial sodium channel. Clin Endocrinol. 2009;70:252–8. 485. Dirlewanger M, Huser D, Zennaro MC, Girardin E, Schild L, Schwitzgebel VM. A homozygous missense mutation in SCNN1A is responsible for a transient neonatal form of pseudohypoaldosteronism type 1. Am J Physiol Endocrinol Metab. 2011;301:E467–73. 486. Hubert EL, Teissier R, Fernandes-Rosa FL, Fay M, Rafestin-Oblin ME, Jeunemaitre X, Metz C, Escoubet B, Zennaro MC. Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1. J Am Soc Nephrol. 2011;22:1997–2003. 487. New MI. Inborn errors of adrenal steroidogenesis. Mol Cell Endocrinol. 2003;211:75–83. 488. Finer G, Shalev H, Birk OS, Galron D, Jeck N, SinaiTreiman L, Landau D. Transient neonatal hyperkalemia in the antenatal (ROMK defective) Bartter syndrome. J Pediatr. 2003;142:318–23. 489. Loomba-Albrecht LA, Nagel M, Bremer AA. Pseudohypoaldosteronism type 1 due to a novel mutation in the mineralocorticoid receptor gene. Horm Res Paediatr. 2010;73:482–6. 490. Mathew PM, Manasra KB, Hamdan JA. Indomethacin and cation-exchange resin in the management of pseudohypoaldosteronism. Clin Pediatr. 1993;32:58–60. 491. Hanukoglu A, Hanukoglu I. Clinical improvement in patients with autosomal recessive pseudohypoaldosteronism and the necessity for salt supplementation. Clin Exp Nephrol. 2010;14:518–9.

Renal Tubular Acidosis in Children

39

Raymond Quigley and Matthias T. F. Wolf

Contents

Introduction

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1273 Historical Development of Classification of RTA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1273 Physiology of Acid Secretion . . . . . . . . . . . . . . . . . . . . . 1275 Proximal Renal Tubular Acidosis (Type II RTA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pathophysiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fanconi Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Etiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Congenital Isolated Proximal RTA . . . . . . . . . . . . . . . . . Congenital Fanconi Syndrome . . . . . . . . . . . . . . . . . . . . . Acquired Isolated Proximal RTA . . . . . . . . . . . . . . . . . . . Acquired Fanconi Syndrome . . . . . . . . . . . . . . . . . . . . . . .

1279 1279 1282 1282 1282 1284 1286 1286

Distal Renal Tubular Acidosis (Type 1 RTA) . . . 1286 Pathophysiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1286 Etiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1288 Type III Renal Tubular Acidosis . . . . . . . . . . . . . . . . . 1290 Type IV Renal Tubular Acidosis . . . . . . . . . . . . . . . . . Pathophysiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Etiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Aldosterone Deficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Aldosterone Resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1291 1291 1291 1291 1292 1292

Diagnosis and Treatment of Renal Tubular Acidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1293 Differentiating Proximal and Distal RTA . . . . . . . . . . 1296 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1296 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1296

R. Quigley (*) • M.T.F. Wolf Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA e-mail: [emailprotected] # Springer-Verlag Berlin Heidelberg 2016 E.D. Avner et al. (eds.), Pediatric Nephrology, DOI 10.1007/978-3-662-43596-0_35

Renal tubular acidosis (RTA) is a condition in which there is a defect in renal excretion of hydrogen ion, or reabsorption of bicarbonate, or both, which occurs in the absence of or out of proportion to an impairment in the glomerular filtration rate [1]. Thus, RTA is distinguished from the renal acidosis that develops as a result of advanced chronic kidney disease [2–4]. Albright originally described the disease as “renal acidosis resulting from tubular insufficiency without glomerular insufficiency” to emphasize this distinction [5]. The term was reduced to “renal tubular acidosis” by Pines and Mudge in their studies published in 1951 [6]. These renal tubular abnormalities can occur as an inherited disease or can result from other disorders or toxins that affect the renal tubules.

Historical Development of Classification of RTA The historical development of renal tubular acidosis parallels the historical development of our understanding of renal physiology. As with many complex diseases, investigations into disease processes improve our understanding of normal physiology, and, in turn, the advances in basic physiologic research shed light on pathophysiology and mechanisms of diseases. This is apparent in the historical development of renal tubular 1273

1274

acidosis, which began in the early twentieth century and is now extending into the molecular biologic era as medicine has entered the twentyfirst century. In addition, some of the confusion with the classification scheme of RTA stems from its historical development. At the British Paediatric Association meeting in 1935, Lightwood described six infants out of an autopsy series of 850 that had “calcium infarction” of the kidneys [7]. This would later be recognized as the first report of infants with nephrocalcinosis from renal tubular acidosis. Butler et al. described a series of four infants with similar findings in 1936 [8]. In addition to nephrocalcinosis, these infants were also found to have hyperchloremia and acidosis, suggesting that there was a relationship between the biochemical findings and nephrocalcinosis. It was not clear from these first reports if the biochemical findings were the cause of the calcium deposits in the kidneys or were the result of damage to the renal tubules from the calcinosis. The first description of the potential pathophysiologic explanation for these findings was put forward by Albright et al. in 1946 [5]. In this classic description of various forms of osteomalacia, the authors also outlined the treatment of these patients with a solution of citric acid and sodium citrate that was advocated by Dr Shohl. Albright described this form of acidosis as “renal acidosis resulting from tubular insufficiency without glomerular insufficiency” to distinguish this form of acidosis from the acidosis that occurs in renal failure. The entity of “infantile renal acidosis” was then described by Lightwood in 1953 in a series of 35 infants [9]. This was a larger series of infants than his first description, and they had similar clinical histories and biochemical findings as the series by Butler [8]. The first description of an adult with similar findings was made in 1945 by Baines et al. [10]. During the 1940s and 1950s, a number of cases of renal tubular acidosis were described and led to investigations of the renal acidification defect [4, 11]. The primary feature in these patients was the inability to lower their urine pH despite having mild to moderate acidosis. This became the defining characteristic of this disease as reported in a series

R. Quigley and M.T.F. Wolf

of studies by Elkinton [12–14]. In the classic report by Pines and Mudge, the term “renal tubular acidosis” was used to replace the previously more cumbersome term of “renal acidosis resulting from tubular insufficiency without glomerular insufficiency” [6]. This new term was emphasized in an editorial review by Elkinton and has remained the term for this disease ever since [12]. Thus, at the end of the 1950s, renal tubular acidosis was thought to be a disease process that limited the ability of the kidneys to lower the urine pH, despite the fact that the patient had mild to moderate acidosis. Although the concept of glomerular filtration had been well established in the early twentieth century, the measurement of the rate of glomerular filtration in humans had not yet been performed. This was accomplished by the pioneering work of Homer Smith. He was one of the first to conceive of the idea of a renal excretion system in which there was a high glomerular filtration rate which required tubular reabsorption of solutes [15]. The fact that the glomerular filtration rate was very high and was followed by tubular modifications of the urine had profound effects on the ideas of bicarbonate handling and acid secretion. The disorder of renal tubular acidosis was initially thought to be due to the inability of the kidney to maintain the steep pH gradient in the distal nephron segment. The idea that this disorder could arise from the inability of the proximal tubule to recover the filtered bicarbonate was first suggested in 1949 by Stapleton [16]. He reported a patient that had significant amounts of bicarbonate in the urine at low concentrations of serum bicarbonate. This idea was further advanced by Soriano in a report of two patients that demonstrated an abnormally low threshold for bicarbonate excretion [17, 18]. Based on their findings in these patients, Soriano and Edelmann proposed classifying patients with RTA as having either distal or proximal tubule defects. This was the initial description of the need for a classification scheme for this disease, suggesting that there could be multiple causes for this disease process. The dichotomy of proximal and distal RTA was firmly established in the classic review by Rodriguez-Soriano and Edelmann which summarized the understanding of the pathophysiology at

39

Renal Tubular Acidosis in Children

that time [1]. The nomenclature of type I and type II RTA was established by the end of the 1960s in a review by Morris [19]. In this review, distal RTA was referred to as type I (or classic) and proximal RTA as type II. The author also described a type III RTA as those patients that displayed features consistent with both forms of RTA. In 1972, McSherry et al. described several patients that displayed characteristics of classic type I RTA but in addition had a reduced threshold for bicarbonate reabsorption [20]. These patients seemed to fit the description of type III RTA. Subsequently, the reabsorption of bicarbonate in these patients normalized so that they were thought to have classic type I RTA with a developmental immaturity of the proximal tubule. Since that time, type III RTA has been essentially dropped from the classification scheme of RTA. It is interesting to note that the review by Gennari and Cohen did not mention type III RTA [21]. In the middle of the twentieth century, the discovery of aldosterone revolutionized our understanding of the physiology of sodium and potassium metabolism [22]. Subsequently, it was found that patients with aldosterone deficiency had a form of RTA that resembled that of distal RTA, but the patients had hyperkalemia and not hypokalemia [23, 24]. This form of RTA was then referred to as type IV RTA. More recently, other defects in distal nephron transporters have also been characterized and resemble the findings of type IV RTA. Although they are not true aldosterone-deficient syndromes, they also are described as type IV RTA since these patients also have hyperkalemia. To add to the confusion, a review published in 1986 classified RTAs as type I (distal), type II (proximal), and type III (aldosterone-deficient RTA) [25]. In recent years, there have been suggestions to clarify the classification of RTAs in a scheme that is based more on the pathophysiologic mechanism of the disease [26, 27]. While this might eventually be the preferred nomenclature, most practicing nephrologists continue to use the historical classification. The other schemes will be discussed as part of the pathophysiology of RTA. Over the past century, advances in renal physiology, acid–base chemistry, and molecular

1275

genetics have greatly improved our understanding of the various forms of renal tubular acidosis. Currently, the diagnosis and classification of the various types of renal tubular acidosis continue to rely on biochemical measurements of blood and urine. During the twenty-first century, however, the diagnosis of renal tubular acidosis may eventually be made by a molecular genetic approach and not by extensive biochemical testing.

Physiology of Acid Secretion The kidney is the primary organ for long-term acid–base regulation. Thus, an understanding of the normal renal excretion of acid is necessary to understand the defects present in patients with RTA (see also ▶ Chap. 9, “Physiology of the Developing Kidney: Acid-Base Homeostasis and Its Disorders”). The typical Western diet generates approximately 1 mmol of H+/kg of body weight in adults [28]. In addition, children generate acid from the production of hydroxyapatite in growing bone and thus generate a total of approximately 2–3 mmol of H+/kg of body weight [29–31]. The acid generated from the diet and bone growth necessitates the excretion of acid by the kidneys. The amount of acid excreted by the kidneys is referred to as net acid excretion (NAE) and is expressed quantitatively as NAE ¼ UNH4 þ þ UTA UHCO3 V; where V is the urine flow rate, UNH

4

þ

is the urine

ammonium concentration, UTA is the urine titratable acid concentration, and UHCO3 is the urine bicarbonate concentration. Thus, the components of acid secretion can be thought of as bicarbonate reclamation to prevent bicarbonate loss, ammonium excretion, and titratable acid excretion. The processes for maintaining acid–base balance are quite complex, but the basic concepts will be reviewed so that the pathophysiologic changes in RTA can be described. The kidneys are responsible for the excretion of nitrogenous waste products, principally urea, that are generated from our diet. In mammalian

1276

R. Quigley and M.T.F. Wolf Blood

Tubular lumen HCO3– NHE3 Na+ H+

Na+

H+

HCO3–

NBC1 Na+

3HCO3–

+

H + HCO3– CA IV CA II H2O + CO2

H2O + CO2 Glutamine Glutaminase

NHE3 Na+ NH4+

NH4+

NH3

NH3

Glutamate Glutamate dehydrogenase α-Ketoglutarate HCO3– Glucose

H+ NH4+

Fig. 1 Model of bicarbonate reabsorption by a proximal tubule cell. The Na–K–ATPase located in the basolateral membrane generates and maintains the low intracellular sodium concentration. Protons are excreted into the tubule lumen by the sodium–proton exchanger (NHE3) where they combine with bicarbonate to form carbonic acid. In the presence of carbonic anhydrase IV (CAIV), the carbonic acid is hydrolyzed to water and carbon dioxide

which enter the cell and recombine to form carbonic acid by the action of intracellular carbonic acid II (CAII). The carbonic acid ionizes into a proton which is then excreted into the lumen and bicarbonate which is transported by the sodium bicarbonate symporter (NBC1) into the bloodstream (Reprinted with permission from Fry and Karet [216])

kidneys, urea is excreted primarily by filtration, which requires having a high filtration rate so this can be accomplished. The average adult will filter about 150–180 l of blood per day. Because bicarbonate is freely filtered in the glomerulus, a large amount of bicarbonate (about 4,000 mEq/day in an adult) must be reabsorbed by the tubules each day to prevent loss of base. The bulk of the filtered bicarbonate is reabsorbed in the proximal tubule by mechanisms that are illustrated in Fig. 1. A number of proteins, both transporters and enzymes, work in concert to reclaim approximately 80 % of the filtered bicarbonate in this tubule segment [32–36]. The initial step in the reabsorption of bicarbonate is the secretion of protons into the tubular

lumen. About two thirds of the proton secretory rate is provided by the sodium–proton antiporter [37–39]. The isoform that is present on the luminal membrane of the proximal tubule has been termed NHE3 (sodium–hydrogen exchanger 3). In addition to the secretion of protons, NHE3 also secretes ammonium ions by acting as a sodium–ammonium exchanger [40–42]. Metabolic acidosis increases both NHE3 expression and ammonia secretion via AT1 receptor activation [43, 44]. The energy for proton and ammonium secretion by the antiporter is derived from the low intracellular sodium concentration that is maintained by the basolaterally located sodium–potassium ATPase. There is evidence that approximately one third of the proton

Renal Tubular Acidosis in Children

BICARBONATE (mMols/100 ml. glomerular filtrate)

39

1277

J.L.A. R.F.P W.A.S

3.2 2.8

red

filte

reabsorbed

2.4 2.0 1.6 1.2 0.8

d

ete

r exc

0.4

10

12

14

16

18

20

22

24

26

28

30

32

34

36

38

40

PLASMA BICARBONATE (mMols/L)

Fig. 2 Bicarbonate titration curves for normal humans. At low concentrations of serum bicarbonate, all of the filtered load can be reabsorbed. The process of bicarbonate reabsorption is saturable, so once the delivered bicarbonate

rate exceeds the transport maximum, bicarbonate will be excreted in the urine (Reprinted with permission from Pitts et al. [51])

secretory rate is provided by a proton ATPase located in the luminal membrane [39, 45]. This transporter derives its energy directly from ATP. Once the hydrogen ion is in the lumen of the proximal tubule, it combines with bicarbonate to form carbonic acid, which will then form carbon dioxide and water as shown in the following equation:

for secretion into the tubule lumen, while the bicarbonate ion is then transported through the basolateral membrane by the sodium bicarbonate cotransporter, NBC [34, 49, 50]. The overall process for reabsorbing bicarbonate in the proximal tubule is saturable [51]. This is illustrated in Fig. 2. When the serum bicarbonate concentration is within the normal range, the filtered load of bicarbonate can be almost completely reabsorbed. If the serum bicarbonate concentration begins to rise, the filtered load of bicarbonate will then exceed the reabsorption rate of the kidney, and bicarbonate will then be excreted into the urine. This has been studied in humans who were administered bicarbonate to determine the point at which bicarbonate would appear in the urine [51]. The data from these experiments form a titration curve (see Fig. 2). The threshold at which bicarbonate is excreted thus determines the normal serum concentration of bicarbonate. An additional task in maintaining acid–base balance for the proximal tubule is the generation of ammonia to serve as a buffer to efficiently

Hþ þ HCO3 !H2 CO3 þ CO2 :

carbonic anhydrase

! H2 O

The enzyme, carbonic anhydrase, is critical for catalyzing this process [46–48]. One isoform of this enzyme (carbonic anhydrase IV) is located in the brush border membrane of the proximal tubule and serves to catalyze the forward reaction, while another isoform of the enzyme (carbonic anhydrase II) is located inside the tubule cell for catalyzing the reverse reaction [46]. Thus, carbon dioxide and water can move rapidly into the proximal tubule cell and recombine to form carbonic acid which will ionize to form bicarbonate and a hydrogen ion. The hydrogen ion is then available

1278

excrete the bulk of the acid that is generated from our diet. It has long been recognized that the excretion of ammonium is critical to the overall excretion of acid by the kidneys [52]. This is primarily due to ammonium’s ability to buffer hydrogen ions. To excrete 100 mmol of unbuffered H+ at a pH of 4.0 ([H+] = 104 mol/l) would require a volume of 1,000 l of urine. The reaction of ammonia and H+ to form ammonium has a pKa of approximately 9.0 [53]. Thus, at a pH of 7.0, 99 % of all the ammonia in the urine is in the form of ammonium ion and is excreted as ammonium chloride, limiting the amount of free hydrogen ions in the urine. Thus, the ammonium excretion rate is a quantitatively more important factor for the excretion of acid than the urine pH. This can also create confusion in the assessment of a patient’s ability to excrete acid. The equation that defines net acid excretion (see above) does not include information about the urine pH. Since the pKa of the ammonia–ammonium equilibrium is 9, if the patient is excreting a large amount of protons as ammonium, the pH will tend to rise even though the amount of acid being excreted has increased. The tubular handling of ammonia and ammonium is complex [42, 54–56]. Briefly, ammonia is generated in the proximal tubule by the metabolism of glutamine and is secreted into the tubule lumen by the sodium–proton exchanger, NHE3, as the ammonium ion (see Fig. 1). The diffusion of ammonia gas across the proximal tubule apical membrane accounts for a small fraction of the total excretion of ammonia. The ammonium ions are then reabsorbed into the interstitium by the thick ascending limb of Henle to be secreted again by the collecting ducts [55–57]. The generation of ammonia by the proximal tubule can be upregulated in the presence of acidosis by fiveto tenfold over baseline in adults [52, 58, 59]. The ability of the neonatal kidney to upregulate ammonium excretion is somewhat limited and can prolong the recovery phase of acidosis in infants. The upregulation of ammonium production and secretion serves as the principal means of correcting acidosis that is due to non-renal causes. As will be seen below, the inability of

R. Quigley and M.T.F. Wolf

the kidney to secrete acid as ammonium is a key feature of RTA. The thick ascending limb of Henle is responsible for the continued reabsorption of bicarbonate as well as ammonium [60–62]. The transporters involved include the sodium–hydrogen exchanger (NHE3); the sodium–potassium-2 chloride cotransporter, NKCC2; and the sodium–potassium ATPase [60]. The thick ascending limb of Henle reabsorbs approximately 10 % of the filtered bicarbonate. The distal nephron is responsible for the secretion of protons that are then buffered by ammonia and titratable acid. The cell type in the collecting duct that is responsible for this is the alphaintercalated cell that is depicted in Fig. 3. The luminal membrane has a proton ATPase that utilizes ATP directly to secrete protons into the lumen of the tubule [63–66]. This generates a bicarbonate ion that is then excreted through the basolateral membrane by the anion exchanger AE1 in exchange for a chloride ion [67, 68]. The chloride can then exit the cell by the potassium chloride cotransporter (KCC) or the chloride channel, CLC-Kb [69, 70]. Carbonic anhydrase II is critical for the formation of the carbonic acid in the cell that ionizes into the proton and bicarbonate ion [47]. In beta-intercalated cells the polarity of transporters is reversed with pendrin as the apical Cl/ HCO3 exchanger, thus secreting HCO3 into the tubule lumen and H+ ATPase and H+/K+ ATPase at the basolateral membrane. Beta-intercalating cells convert to alpha-intercalating cells when exposed to acidosis. This conversion is promoted by the protein hensin which if absent induces RTA in mice [71, 72]. The principal cells of the collecting duct are responsible for the reabsorption of sodium and the secretion of potassium and thus do not directly secrete protons into the tubular fluid. However, these processes influence the rate of acid secretion indirectly by affecting the electrical potential difference across the epithelium. Thus, disease processes or drugs that have a primary effect on sodium or potassium transport in the collecting duct can eventually lead to acid–base disturbances.

39

Renal Tubular Acidosis in Children

1279

Tubular lumen

Blood H+

H+

Cl–

HCO3–

H+–ATPase NH3

H+ 2–

HPO4

H+ + HCO3–

K+ H+/K+–ATPase NH4+ HPO42–

CA II

H2O + CO2

HCO3– AE1 Cl–

K+ KCC4 Cl–

CIC-Kb

Fig. 3 Model of acid excretion in an alpha-intercalated cell in the distal nephrons. Protons are excreted into the tubule lumen by the proton ATPase and are buffered by ammonia or titratable acid (mostly phosphate). Inside the cell, carbonic anhydrase II (CAII) provides the protons and bicarbonate through the hydration of carbon dioxide to

form carbonic acid. Bicarbonate is excreted into the bloodstream by action of the chloride bicarbonate exchanger (AE1) on the basolateral membrane. Chloride homeostasis is maintained by the potassium chloride cotransporter (KCC4) and the chloride channel (ClC-Kb) (Reprinted with permission from Fry and Karet [216])

As discussed above, the proximal tubule generates ammonia that is eventually excreted as ammonium as a mechanism for acid excretion. The other major buffers in the urine are referred to as titratable acids and include phosphate, sulfate, and many other anions. Of the many buffers available, the quantitatively most significant is phosphate. Phosphate exists in the blood as several different ionic species (H3PO4, H2PO41, HPO42, and PO43) with H2PO41 and HPO42 being the most abundant at physiologic pH. The pK for the equilibrium between H2PO41 and HPO42 is 6.8; thus, at a normal blood pH of 7.4, the ratio of H2PO41: HPO42 is approximately 4:1. As the urine passes through the collecting duct where the pH is lower, HPO42 can accept protons and be converted to H2PO41 and will aid in the buffering of excreted acid. In addition to bicarbonate reabsorption and ammonia generation, the proximal tubule reabsorbs almost the entire filtered load of glucose and amino acids as well as approximately 85 % of the filtered load of phosphate. These processes are coupled to the apical membrane sodium

electrochemical gradient and are thus driven by the low intracellular sodium concentration and the negative electrical potential inside the cell. Diseases that affect the ability of the proximal tubule cell to maintain this gradient result in a condition known as the Fanconi syndrome [73]. This is a form of proximal tubule dysfunction that includes proximal RTA, glucosuria, aminoaciduria, and phosphaturia. As will be discussed below, most forms of proximal RTA are associated with the Fanconi syndrome.

Proximal Renal Tubular Acidosis (Type II RTA) Pathophysiology As discussed above, the transport of bicarbonate in the proximal tubule is a saturable process. Thus, the transport of bicarbonate exhibits the typical titration curve which has a threshold for bicarbonate reabsorption as illustrated in Fig. 2 [51]. This threshold for the reabsorption of bicarbonate is the

1280

R. Quigley and M.T.F. Wolf

BICARBONATE mmoles/100ml GLOMERULAR FILTRATE

4.0 *S.K.

3.6

*W.F.

D

RE

TE FIL

3.2 2.8 2.4 REABSORBED

2.0 1.6 1.2 0.8

EXCRETED

0.4

12

14

16

18 20 22 24 26 28 30 SERUM BICARBONATE mmoles/liter

32

34

36

Fig. 4 Bicarbonate titration curves for patients with proximal renal tubular acidosis. Patients with proximal RTA have a reduced threshold for bicarbonate reabsorption and will thus excrete significant amounts of bicarbonate in their

urine at lower serum bicarbonate concentrations. Thus, their titration curves are shifted to the left (Reprinted with permission from Soriano et al. [18])

main factor determining the serum bicarbonate concentration. If the serum bicarbonate concentration rises above the threshold, the filtered load will exceed the transport maximum for reabsorption and bicarbonate will be excreted. This will bring the serum concentration down until it matches the threshold, and then all of the filtered bicarbonate is again reabsorbed. The hallmark of proximal RTA is a reduced threshold for the reabsorption of bicarbonate as illustrated in Fig. 4, and thus, these patients will have a low serum bicarbonate concentration [18, 74]. When the serum bicarbonate concentration increases and approaches the normal range, patients with proximal RTA will develop bicarbonaturia. Their bicarbonate titration curve is similar to that of normal patients, but it is shifted down (see Fig. 4). It is important to note that the threshold for bicarbonate excretion is

generally in the 14–18 mEq/l range and remains stable [1, 18]. This reduction in the capacity for reabsorption of bicarbonate makes the treatment of patients with proximal RTA difficult. Most patients require well over 6 mEq/kg/day of bicarbonate therapy to make an improvement in their serum bicarbonate concentration [75, 76]. As the patient is treated with bicarbonate and the serum bicarbonate rises, bicarbonate excretion will increase dramatically with little increase in the serum bicarbonate concentration. In addition, the distal delivery of the non-reabsorbable anion will obligate the excretion of sodium and potassium. This leads to volume depletion and an increase in the serum aldosterone concentration [77]. The combination of the increased distal delivery of sodium and the elevated aldosterone concentration leads to a marked excretion of potassium. Thus, many patients with

39

Renal Tubular Acidosis in Children

1281

8.5 8.0

URINE pH

7.5 7.0 6.5 6.0 5.5 5.0 4.5

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 SERUM BICARBONATE mmoles / liter

Fig. 5 Urine pH of patients with proximal RTA. When patients with proximal RTA become acidotic, their serum bicarbonate concentration falls below the threshold for

excretion. Because their distal nephron is intact, they can lower their urinary pH to values less than 6.0 (Reprinted with permission from Rodriguez-Soriano et al. [1])

proximal RTA become hypokalemic during the treatment of the disease. Although the treatment of these patients can be difficult, their overall acid–base balance is generally good. In patients with proximal RTA, when the serum bicarbonate remains at or below the threshold for bicarbonate excretion, the patient can reclaim the filtered load of bicarbonate and will remain in relative acid–base balance [17, 18, 75]. This is due to the fact that the patient’s distal nephron remains intact and is able to excrete the acid generated from their diet and will help prevent the patient from developing a large base deficit. This is reflected in the fact that their urine pH can decrease to less than 5 (Fig. 5) [1]. Thus, while most patients with proximal RTA have a low serum bicarbonate, it will remain constant because the patient remains in acid–base balance. The acid–base balance of patients with pure proximal RTA has been extensively studied [75, 76]. At baseline, the patients were found to be in acid–base balance with normal ammonium and titratable acid excretion and did not develop a base deficit. When challenged with an ammonium chloride load, they were able to increase the excretion of acid in the form of ammonia as well as titratable acid [75].

While the excretion of ammonium increased in this study, it is unclear if patients with proximal RTA have the same capacity to increase ammonia excretion as normal individuals. Because the proximal tubule is the site of ammoniagenesis, there could conceivably be a defect in the ammonia generation rate. When these patients were loaded with ammonium chloride, their excretion of acid was increased; however, the ratio of ammonia excretion to titratable acid excretion remained constant [17, 18, 75]. This brought into question their ability to increase ammonia excretion in the face of an acid load and thus would probably not be able to recover from acidosis as well as a normal patient would. It was also thought that the level of ammonium excretion could be considered low for the chronic acidotic state [75]. A more recent study has indicated that while patients with proximal RTA are in balance at baseline, when their acidosis worsens, they cannot fully compensate [78]. In this study, patients with proximal RTA were loaded with ammonium chloride for 3 days. Previous studies had been performed with an acute ammonium chloride load. The chronic loading demonstrated that the patients with proximal RTA indeed had an inability to increase their ammonium excretion as compared to the normal control subjects [78].

1282

Interestingly, the patients with proximal RTA were able to lower their urine pH to a value below the control subjects’ urine pH (4.66 vs. 5.00). This was thought to be due to the fact that the normal subjects had higher amounts of ammonium in their urine to buffer the protons. The mechanism for the ability to maintain acid–base balance is due in part to an increase in titratable acid excretion [75]. Because of their intact distal nephrons, these patients can also lower their urine pH to the 4.5–5 range. However, this usually occurs at very low serum pH values and is depicted in Fig. 5 [1]. Calcium excretion rates in patients with proximal RTA were found to be within the normal range, indicating that there was no loss of calcium from their bones [75, 76]. There was also no evidence of rickets or osteomalacia in these patients with isolated proximal RTA [75].

R. Quigley and M.T.F. Wolf

(i.e., rickets), generalized aminoaciduria, and glucosuria [73]. Later, it was found that the tubular reabsorption of bicarbonate was impaired, and the definition then included proximal RTA [1]. Recent reports indicate that severe osteomalacia can develop in adult patients with the Fanconi syndrome [79, 80]. Hypokalemia also develops in most patients with this disorder [81]. There are numerous diseases that present with the Fanconi syndrome, but they appear to have a final common pathway for the proximal tubule dysfunction. A number of studies have indicated that depletion of the intracellular ATP store is responsible for the loss of the transmembrane sodium gradient [82, 83]. This then leads to the inability to secrete protons and reabsorb glucose, phosphate, and amino acids.

Etiology Fanconi Syndrome As discussed above, the proximal tubule is also responsible for the reabsorption of glucose, amino acids, and phosphate by sodium-dependent transport systems (see also ▶ Chaps. 41, “Cystinosis and Its Renal Complications in Children,” ▶ 42, “Pediatric Fanconi Syndrome,” and ▶ 50, “Renal Manifestations of Metabolic Disorders in Children”). Many of the processes that interfere with the reclamation of bicarbonate are due to a defect in maintaining a low intracellular concentration of sodium and will thus affect the reabsorption of all of these solutes. This condition is known as the Fanconi syndrome which can be thought of as a global dysfunction of the proximal tubule [73]. Thus, proximal RTA can be divided into isolated proximal RTA, which is relatively rare, and Fanconi syndrome, which is actually a more common cause of proximal RTA. This will be an important point in the clinical presentation and workup of these patients. In addition to the problems with bicarbonate wasting, patients with the Fanconi syndrome have additional pathophysiologic changes. The original definition of the Fanconi syndrome consisted of skeletal findings secondary to hypophosphatemia

As with most clinical disease processes, isolated proximal RTA and the Fanconi syndrome can occur as an inherited defect or as an acquired disease. We will first discuss the congenital causes of this syndrome and then review the acquired causes.

Congenital Isolated Proximal RTA As mentioned above, isolated proximal RTA is rare [84]. The initial descriptions of isolated proximal RTA were of infants that had a transient form of the disease [1, 76, 85]. This form was found predominately in males and appeared to improve after several years of life. Patients presented with failure to grow and repeated bouts of vomiting and dehydration. This form follows a sporadic inheritance pattern and has no known cause. There is a well-described kindred of patients from Puerto Rico that have isolated proximal RTA that follows an autosomal dominant pattern of inheritance [75]. To date, there are no reports of a gene defect in this family. Interestingly, the patients are more severely affected as infants, but tend to have less of a problem when they are older. This suggests that either the defect is

39

Renal Tubular Acidosis in Children

attributable to a developmental transporter or to compensation with age by other transport processes in the more distal nephron segments. Children in these families have moderate acidosis and do not grow at normal rates unless they receive treatment [75]. As discussed above, treatment with alkali therapy does not fully correct their acidosis because of the increased excretion of the administered base, but treatment will allow them to grow at near-normal rates. In recent years, another family with isolated proximal RTA that has an autosomal dominant inheritance pattern has been reported [86]. The clinical features of this family were very similar to the previous report [75]. A candidate gene approach was taken in an attempt to determine the genetic defect in this family. Extensive sequencing was done on many of the genes known to be involved in the proximal tubule reabsorption of bicarbonate; carbonic anhydrase II and IV as well as carbonic anhydrase XIV; NBC1; NHE2, NHE3, and NHE8 as well as the sodium proton exchanger regulatory proteins NEHRF1 and NEHRF2; and the chloride bicarbonate exchanger, SLC26A6. However, no defects were found. The authors concluded that either additional proteins are involved in the regulation of bicarbonate reabsorption or that there might have been defects in transcription factors that could regulate the expression of these genes [86]. A rare cause of isolated proximal RTA is a mutation in the sodium bicarbonate cotransporter, NBC1, which is inherited in an autosomal recessive pattern [87–89]. The initial patients described were two brothers that had proximal RTA as well as eye and dental abnormalities [90]. Since then, only a few other patients have been described with these features [87, 90, 91]. Other patients were found to have developmental delay, short stature, pancreatitis, band keratopathy, cataract, glaucoma, and basal ganglia calcification [92, 93]. These patients were found to have a mutation in the SLC4A4 gene which encodes the sodium bicarbonate cotransporter, NBC1. NBC1 is a large transmembrane protein formed by 1,035 amino acids and is responsible for transporting bicarbonate out of the proximal tubule cell and

1283

into the bloodstream [88, 91, 94, 95]. Although SLC4A4 mutations are very rare causes of isolated proximal RTA, they have demonstrated the critical function of NBC1 in the proximal tubule reabsorption of bicarbonate. The sodium bicarbonate cotransporter NBC1 is critical in the membrane transport of bicarbonate [50, 67, 68, 96–98]. This class also includes the chloride bicarbonate exchanger that will be discussed in the section on distal RTA. The sodium-coupled bicarbonate transporter NBC1 is expressed primarily at the basolateral membrane in the proximal tubule and is also found in other tissues such as the eyes as well as the heart [88]. This kidney-specific isoform is determined by alternate splicing of the gene. Defects in this transporter result in proximal RTA due to the inhibition of bicarbonate transport in the proximal tubule. Because of the distribution of the protein in the eye, patients also develop ocular defects such as band keratopathy, cataracts, and glaucoma [88, 99]. Recently it was found that some SLC4A1 mutations cause a defect in protein trafficking, while other SLC4A4 mutations result in reduced protein activity [92, 100, 101]. Defects in carbonic anhydrase cause dysfunction of the proximal tubule, but because of its distribution in the distal nephron, these defects cause combined proximal and distal RTA [102, 103]. These will be discussed in detail below in the section on Type III RTA. The sodium–hydrogen exchangers have been considered candidate genes for the cause of isolated proximal RTA; however, to date there have been no defects found in these genes. To determine the role of these exchangers in overall acid–base balance, knockout mouse models have been generated. The primary sodium–hydrogen exchanger in the apical membrane of the proximal tubule is NHE3 [37]. Mice that have had NHE3 knocked out have a modest metabolic acidosis [104]. They have an elevated serum aldosterone level as well as upregulation of colonic sodium transporters indicating that these animals have evidence of volume contraction [104]. Perfusion of the proximal tubules in vitro shows a reduced ability to acidify the urine [105]. As discussed above, a recent study in patients with isolated

1284

proximal RTA failed to detect a defect in any known gene for bicarbonate transport including NHE3 [86]. Another mouse model of proximal RTA was developed recently [106]. The TASK2 K+ channel is located in the proximal tubule and appears to regulate bicarbonate transport. When this channel was knocked out, the animals developed acidosis which was due to renal bicarbonate wasting [106]. TASK2 is a member of the two-pore domain channel family and is sensitive to changes in extracellular pH. Amino acids in the extracellular loop seem to be responsible for pH sensing [107]. TASK2 may contribute to the basolateral membrane potential thus driving Na+-base transport via NBC1 [101].

Congenital Fanconi Syndrome There are a number of genetic defects that result in the Fanconi syndrome. These are listed in Table 1 and will be described briefly. The most common cause of congenital Fanconi syndrome is cystinosis which is an autosomal recessive disorder [108–110]. This disease results from a defect in the gene CTNS which encodes for the lysosomal membrane transporter, cystinosin [109, 111]. Lysosomes are organelles responsible for degradation of proteins within the cell. Cystinosin is responsible for the transport of cystine out of the lysosome so that the organelle can continue to function. In the disease cystinosis, cystine accumulates within the lysosome of the cells throughout the body [110]. It is not clear how this leads to the Fanconi syndrome, but it appears to be related to the depletion of intracellular ATP [82, 83]. The other diseases that result in the Fanconi syndrome are much more rare. One in particular is worth mentioning because it is thought to be the cause of the syndrome first described by Fanconi [112–117]. This is a defect in the facilitative glucose transporter GLUT2. This transporter is responsible for transporting glucose out of the proximal tubule cell and into the bloodstream. Thus, a mutation in this protein would lead to accumulation of glucose within the

R. Quigley and M.T.F. Wolf

proximal tubule. It is unclear how this would cause the Fanconi syndrome, but could be due to the consumption of intracellular phosphate by the accumulated glucose. Hereditary fructose intolerance is of interest because this served as a useful model for the study of the Fanconi syndrome [118, 119]. The cause of the Fanconi syndrome in this disorder is thought to be due to the depletion of intracellular phosphate that occurs when the cell is presented with a load of fructose. Patients with this disorder tend to have normal renal function and no acid–base disturbance when they remain on a fructose-restricted diet. The oculocerebrorenal syndrome of Lowe is due to a mutation in the OCRL1 gene which encodes for the enzyme, phosphatidylinositol 4,5-bisphosphate 5-phosphatase [120]. This causes an accumulation of phosphatidylinositol 4,5-bisphosphate in the cells which presumably leads to the Fanconi syndrome. OCRL1 was shown to have various cellular functions ranging from membrane trafficking, endocytic recycling, phagocytosis, ciliogenesis, cell adhesion, and polarity to actin polymerization [121, 122]. The syndrome is inherited in an X-linked pattern. Mutations in OCRL1 are also identified in approximately 15 % of patients with Dent disease, initially called Dent disease type 2 [123]. Presently, it is not well understood how loss of OCRL1 function leads to the symptoms associated with Lowe syndrome and Dent-2 disease. Dent disease is caused by mutations in the chloride channel encoded by the gene, CLCN5 [124–128]. The original term for this disorder was X-linked hypercalciuric nephrolithiasis. The chloride channel that the gene encodes for is found in intracellular organelles and appears to be critical for maintaining pH gradients. CLCN5 encodes a two chloride (Cl)/proton (H+) exchanger rather than a pure Cl channel. Using a mouse model that uncoupled the proton exchange activity of the molecule, CLCN5 was converted into a pure Cl channel. Compared to CLCN5 knockout mice (ATP)-dependent acidification of renal endosomes was intact in these animals, but endocytosis of the proximal tubule was also impaired thus suggesting that endosomal

39

Renal Tubular Acidosis in Children

1285

Table 1 Inherited causes of the Fanconi syndrome Disease Cystinosis Tyrosinemia Fanconi–Bickel syndrome Hereditary fructose intolerance Dent’s disease type 1 Dent’s disease type 2 Lowes syndrome Galactosemia Fanconi renotubular syndrome 3 Wilson’s disease

Gene defect Cystinosin (CTNS) Fumarylacetoacetase GLUT 2 Fructose-1-phosphate aldolase (ALDOB)

Inheritance AR AR AR AR

OMIM 219800 276700 138160 229600

CLCN5 OCRL1 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase deficiency (OCRL1) Galactose-1-phosphate uridylyltransferase (GALT) EHHADH

X X

300009 300555 309000

AR AD

230400 615605

ATPase, Cu(2+)-transporting, beta polypeptide (ATP7B)

AR

277900

AD autosomal dominant, AR autosomal recessive, X x-linked

chloride concentration, which is raised by CLCN5 in exchange for protons accumulated by the H+ATPase, may play a role in endocytosis [129]. Loss of CLCN5 function also alters receptor-mediated endocytosis and trafficking of megalin and cubilin thus explaining low molecular weight proteinuria. CLNC5 interacts with a kinesin family member 3B (KIF3B), a heterotrimeric motor protein that facilitates fast anterograde translocation of membranous organelles [130]. CLCN5 knockout mice are characterized by reduced surface expression of NHE3 in proximal tubules, and it was shown that CLCN5 may contribute to RTA by interfering with the exocytic trafficking of NHE3 [131]. Interestingly, carbonic anhydrase type III seems to be upregulated in the urine of patients with Dent disease due to CLCN5 mutations and in megalin knockout mice [132]. Overall, it is not well understood how this defect results in the Fanconi syndrome. Other diseases that lead to the Fanconi syndrome include galactosemia and tyrosinemia [133–135]. These disease processes can also be controlled by diet. Rarely, other forms of glycogen storage disease can result in the Fanconi syndrome [136–138]. Mitochondrial defects can also rarely be associated with the Fanconi syndrome [139–142]. Alterations of gene products involved in oxidative phosphorylation as BCS1L, UQCC2,

and FBXL4, which are all expressed in mitochondria, were shown to cause proximal RTA in humans [143–145]. Recently, mutations in the transcription factor HNF1 alpha have been associated with dysfunction of the proximal tubule [146]. In addition, these defects result in maturity-onset diabetes of the young type 3 (MODY3) [147]. This syndrome has been reproduced in a mouse model [148]. Thus, it appears that this transcription factor is a key regulator of glucose metabolism and could impact the function of the proximal tubule. Interestingly, HNF1 alpha was also shown to regulate the expression of CLCN5 in the proximal tubule [149]. Mutations in EHHADH were found to be inherited in an autosomal dominant fashion in a large kindred with renal Fanconi syndrome with prominent rickets, renal bicarbonate loss, and development of RTA [150]. The encoded EHHADH protein is mostly expressed in peroxisomes along the terminal segments of the proximal tubule and is involved in fatty acid oxidation. The mutant protein is mistargeted to mitochondria resulting in impaired mitochondrial oxidative phosphorylation. Interestingly, Ehhadh knockout mice did not have renal Fanconi syndrome indicating that the EHHADH mutation in humans causes the phenotype by a dominant negative effect [150].

1286

Acquired Isolated Proximal RTA Most diseases and toxins that affect the proximal tubule result in the Fanconi syndrome; thus, it is rare for isolated proximal RTA to be acquired. The primary cause of isolated proximal RTA is the inhibition of carbonic anhydrase (CA) [151–154]. Acetazolamide is given to treat pseudotumor cerebri and some forms of glaucoma. One side effect of this treatment is the development of proximal RTA. Indeed, this is often used as a marker of treatment adequacy. A number of other medicines can also cause CA inhibition, e.g., hydrochlorothiazide and topiramate [151–153, 155, 156].

Acquired Fanconi Syndrome There are many toxins and medications including heavy metals that are now known to affect the proximal tubule and result in the Fanconi syndrome [154, 157–159]. In particular, a number of well-documented cases of Fanconi have been reported with valproic acid [160, 161]. These appear to be reversible processes, but the time of resolution can be significant. Chinese herbs containing aristolochic acid have also been associated with the Fanconi syndrome [162, 163]. Other agents that have been associated with the Fanconi syndrome include aminoglycosides, ifosfamide, cisplatin, the antiviral agent tenofovir, and salicylate [164–172]. Disease processes that cause the Fanconi syndrome are either immune-mediated diseases or paraproteinemia syndromes. For example, Sjögren’s disease will typically cause distal RTA but has been reported to cause the Fanconi syndrome [173]. The classic paraproteinemia that results in the Fanconi syndrome is multiple myeloma [174–176]. Other conditions that are associated with the Fanconi syndrome include vitamin D deficiency [177, 178]. The mechanism of action for this process is not well understood. In addition, proximal RTA has been reported in pregnancy and with paroxysmal nocturnal hemoglobinuria [179, 180].

R. Quigley and M.T.F. Wolf

Distal Renal Tubular Acidosis (Type 1 RTA) Pathophysiology The hallmark of distal RTA is the inability to lower the urine pH maximally in the face of moderate to severe systemic acidosis [1]. This is clearly shown in Fig. 6 where the urine pH is graphed against the serum bicarbonate concentration. As can be seen in the normal individuals, the urine pH decreases to a value of approximately 4.5–5.0, but the patients with distal RTA fail to reduce their urine pH below 6.5. While this feature has been known for many years and was the initial defining characteristic of RTA, the causes of this dysfunction have only recently been elucidated. The primary function of the distal nephron in acid–base homeostasis is excretion of the acid generated by the metabolism of our diet. As described earlier, the typical Western diet generates approximately 1 mmol of acid per kilogram of body weight [28]. Children have an additional 1–2 mmol of acid per kilogram body weight that is generated from the formation of hydroxyapatite in the growing bone. Thus, the distal nephron in the growing child has the task of excreting between 1 and 3 mmol of acid per kilogram [29–31]. If the distal nephron is not capable of performing this function, the patient will use the existing buffers in the body to buffer this acid. Most of the pathophysiologic consequences of distal RTA are due to the accumulation of acid. Even though the proximal tubule is functioning normally to reabsorb the filtered load of bicarbonate, the patient will continue to accumulate acid and develop an ever increasing base deficit. After the bicarbonate buffers in the extracellular fluid space are depleted, the bones begin to serve as the buffer source for the accumulated acid. Hydroxyapatite can be dissolved to liberate hydroxyl ions to help in the neutralization of the acid. Studies in patients with distal RTA have shown that they are in negative calcium balance due to the reabsorption of bone [1]. This will lead to nephrocalcinosis and nephrolithiasis.

39

Renal Tubular Acidosis in Children

1287

8.5 8.0

URINE pH

7.5 7.0 6.5 6.0 5.5 5.0 4.5

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 SERUM BICARBONATE mmoles /liter

Fig. 6 Urine pH of patients with distal RTA. Because patients with distal RTA cannot excrete hydrogen ions against a gradient in the distal nephron, they are unable to

significantly lower their urine pH, even when they become very acidotic (Reprinted with permission from RodriguezSoriano et al. [1])

Fig. 7 Nephrocalcinosis in a patient with distal RTA (Reprinted with permission from Serrano and Batlle [183])

Another contributing factor to the development of nephrocalcinosis is the fact that citrate reabsorption in the proximal tubule will be increased to help provide for base equivalents [181, 182]. The resulting hypocitraturia will contribute to the development of nephrocalcinosis and nephrolithiasis. This can be used to help differentiate distal RTA from proximal RTA as seen in Fig. 7 [183]. In growing bones, the acid–base disturbance will lead to rickets, whereas in the older patient, they will develop osteomalacia. The description of this was provided by Albright in 1946 [5]. Nephrocalcinosis has also been associated with increased production of red cells [184, 185]. It is

not clear what the mechanism is in these patients. Erythrocytosis has been observed in some patients with distal RTA, presumably as a result of the nephrocalcinosis [184, 185]. The proximal tubule provides ammonia that is delivered to the distal nephrons to serve as a buffer. The previous paradigm of a passive, lipid-phase NH3 diffusion and NH4+ trapping has been replaced by a model in which transporter-mediated movement of NH3 and NH4+ occurs. In the proximal tubule NH4+is secreted by NHE3 and different potassium channels [41, 186]. In the thick ascending limb, NH4+ reabsorption involves NKCC2 and NHE4. In the

1288

collecting duct aquaporins and Rh glycoproteins such as Rhbg and Rhcg participate in NH4+ secretion [42, 187–190]. Recently, it has been appreciated that the rate of ammonium excretion in patients with distal RTA is less than that of normal subjects [26, 27, 191]. This is presumably due to the fact that ammonia that is not converted to ammonium ion by the secretion of protons can then diffuse back into the bloodstream and is subsequently not excreted. There have been a number of reports of patients with distal RTA that have hyperammonemia at the time of presentation when they are extremely acidotic [192–194]. This presentation may be more common than previously thought. In one small cohort of 11 patients with either ATP6V1B1 or ATP6V0A4 mutations, four patients presented with hyperammonemia at disease onset [195]. They do not have liver dysfunction, but they have an inability to excrete the ammonia generated in the proximal tubule. This phenomenon has led some investigators to postulate that the excretion of ammonium be used as a new classification scheme of RTA [191]. While this could result in a more physiologic scheme for the classification of RTA, this is probably not practical at the present time. The measurement of ammonium in the urine is not a routine laboratory test. Methods for estimating ammonium excretion will be discussed in the section on clinical aspects. Another pathophysiologic finding in patients with classical distal RTA is hypokalemia [196, 197]. The exact mechanism for this is not entirely clear but is at least partially due to elevated aldosterone concentrations in these patients [198]. Careful studies have indicated that the aldosterone concentration is routinely elevated in patients with distal RTA. A few patients had aldosterone concentrations in the normal range, but were inappropriately normal for the degree of hypokalemia. It was thought that the patients were mildly volume depleted because of mild proximal tubule dysfunction. The hypokalemia can be severe and cause muscle paralysis [199]. This has occasionally been the presenting sign of RTA [200, 201]. Patients with distal RTA also seem to be at a higher risk for rhabdomyolysis due to hypokalemia. In a report describing

R. Quigley and M.T.F. Wolf

14 patients with hypokalemic rhabdomyolysis, 7 patients carried the diagnosis of distal RTA [202].

Etiology Congenital Distal RTA Congenital forms of distal RTA are divided into autosomal dominant (type Ia) and autosomal recessive with (type Ib) and without (type Ic) hearing loss. The molecular basis for these forms of inherited distal RTA has become clear over the past few years and has greatly improved our understanding of the molecular basis of renal acid–base metabolism. Autosomal dominant distal RTA is caused by mutations in the anion exchanger (AE1) that is located in the basolateral membrane of the alphaintercalated cells of the collecting duct. This exchanger is responsible for the basolateral exit of bicarbonate into the bloodstream. Thus, if the protein is not functioning, acid secretion into the tubule lumen will be limited. The biology of AE1 has proven to be very interesting [67, 203, 204]. The exchanger is also located in the red cell membrane where it was first discovered and was termed “band 3 protein” [204]. While it serves to function in the red blood cell as an anion exchanger, it also binds to other membrane proteins and contributes to the stability of the red cell membrane. Tetrameric AE1 forms a macrocomplex with ankyrin and the Rh complex proteins that attaches the macrocomplex to the erythrocyte cytoskeleton through binding of ankyrin [205, 206]. This macrocomplex may be involved in gas exchange. Rh-associated glycoprotein (RhAG) and aquaporin 1(AQP1) are also members of this macrocomplex and also form gas channels for CO2 and in the case of RhAG also for NH3. Interestingly, this multiprotein complex combines with AE1 and Rh complex proteins which are important players for bicarbonate reabsorption and ammonia secretion, not only in the erythrocyte but also in the collecting duct [42]. Mutant AE1 is unable to exchange anions and causes the red blood cell to leak monovalent cations [207]. This cation leak seems to be more

39

Renal Tubular Acidosis in Children

prominent in the cold and may be less significant in warmer, tropical climate [208]. Thus, heterozygous defects in AE1 cause destabilization of the erythrocyte membrane, resulting in mild to moderate hemolytic anemia which is characteristic for hereditary spherocytosis and Southeast Asian ovalocytosis (SAO) [203]. The mutations in AE1 that result in autosomal dominant distal RTA are located in different areas of the molecule than the mutations causing the red cell membrane defects [209, 210]. Different isoforms of AE1 are expressed in red blood cells and the kidney with a truncated renal AE1 version. Most heterozygous mutations causing hereditary spherocytosis and SAO are located in the truncated part which is not expressed in the kidney, and so most patients with these disorders do not have RTA. In temperate countries, dRTA caused by SLC4A1 mutations is rare and is almost invariably autosomal dominant. Red cell morphology is usually unaffected as AE1 is only reduced by 20–30 % [206]. An exception is patients in the tropics and particularly in Southeast Asia where patients more frequently have homozygous or compound heterozygous mutations in the gene SLC4A1, which encodes AE1 [211–214]. These patients develop dRTA and frequent hemolysis, which can become lifethreatening. The mutations in tropical dRTA are different from those found in the nontropical countries and frequently include a deletion of the residues 400–408, which also causes SAO [215]. The clinical symptoms are typically more severe with an earlier age of onset in patients with homozygous or compound SLA4A1 mutations compared to patients with autosomal dominant distal RTA who tend to develop a less severe form of RTA [216, 217]. The higher prevalence of recessive familial dRTA in the tropics is possibly caused by a protective effect of these mutations against malaria, and as pointed out above the cation leak caused by AE1 mutations may not be that prominent in warmer climates [215]. The autosomal recessive distal RTA with hearing loss (type Ib) was found to be due to mutations in a subunit (ATP6V1B1) of the proton pump located on the apical membrane of the alphaintercalated cell of the collecting duct [218].

1289

This led to the discovery of the proton pump location in the inner ear [219, 220]. The proton pump is a key transporter in the secretion of hydrogen ions [63–66]. It is a complex molecule with multiple subunits that are specific to the location in the body. Subsequent to the initial discovery, a number of other mutations have been discovered that are responsible for autosomal recessive distal RTA with hearing loss [221, 222]. In 1996, a large family with this form of RTA and hearing loss was reported [223]. The defect has been recently determined to be a truncating mutation of the ATP6V1B1 gene. The altered subunit is impaired from organizing with the rest of the proton pump for complete function [224]. As families were characterized for mutations in the proton pump, it was clear that some of the families did not have hearing loss and did not have defects in the ATP6V1B1 subunit. This led to the designation of autosomal recessive distal RTA without hearing loss (type Ic). Defects in a separate subunit (ATP6V0A4 or also called ATP6N1B) were found to be the cause in the initial families studied [225]. Subsequently, a number of patients developed hearing loss later in life. These patients were found to have a [226] defect in subunits that were found in the inner ear [222]. The human phenotype of ATP6V0A4 mutations was recapitulated in an Atp6v0a4 knockout mouse model characterized by dRTA and hearing loss. In addition these animals had impaired sense of smell [227, 228]. Distal RTA has also been described in patients with medullary sponge kidney (MSK). Interestingly, two patients with mutations in ATP6V1B1 and ATP6V0A4 were reported who in addition to dRTA and late hearing loss also had MSK [229, 230]. Mouse models of distal RTA have also been developed. A mouse model that lacks AE1 (slc4a1) has been produced and found to have many of the same features as the human disease [231]. The importance of the potassium chloride transporter KCC4 for function of the alphaintercalated cells was shown in a knockout model [69]. These mice had features of distal RTA. A mouse that lacked the transcription factor

1290

Foxi1 was shown to have distal RTA [232]. This transcription factor is evidently important in the development of the alpha-intercalated cells. There are no known human mutations in this factor, but the mouse model raises the possibility of this being another gene to consider in human disease.

Acquired Distal RTA The most common cause of acquired distal RTA is immunologic destruction of the alpha-intercalated cells. This occurs most frequently with Sjögren’s syndrome [233, 234]. Distal RTA in Sjögren’s has been reported to occur in about one third of the patients and after a duration of 10 years [200, 234]. It can also occur in patients with systemic lupus erythematosus and has been reported in a patient with Graves’ disease [235–237]. Distal RTA has also been reported in renal transplant patients; however, it is not clear if this is immune mediated or secondary to the medications [238]. A number of medications have been found to cause distal RTA. The classic example is amphotericin [239]. This model has been used to study the pathogenesis of RTA in the laboratory [240, 241]. The primary defect in acid secretion due to amphotericin appears to be an increase in the permeability of the collecting duct cells to hydrogen ions. This would then prevent the formation of the gradient that is necessary to secrete protons into the urine. While these results helped explain the pathophysiology of the backleak and are important clinically, this probably does not apply to patients with inherited defects that result in distal RTA. Other medications that are known to cause distal RTA include lithium, foscarnet, and melphalan [242–244]. The mechanisms for these effects are not clear. Acquired distal RTA can also result from the treatment of hypophosphatemic rickets [245]. This is probably a result of the nephrocalcinosis that develops from the high dose of vitamin D these patients receive. Examination of patients with idiopathic hypercalciuria also demonstrated some defects in renal acidification [246]. An interesting association of distal RTA and ingestion of vanadate has been proposed as a

R. Quigley and M.T.F. Wolf

mechanism for the high endemic rate of RTA in northeastern Thailand [247]. These patients develop severe hypokalemia, and it is thought that this could be due to inhibition of the H–K–ATPase by vanadate. There is a high level of vanadate in the soil in this area, and experiments with rats have shown that administration of vanadate can lead to renal tubular acidosis [248]. Glue sniffing has been listed as a cause of distal RTA; however, careful examination of a patient with acidosis from glue sniffing suggests a different cause of the acidosis [249]. The toluene in the glue is rapidly metabolized to hippuric acid which is promptly excreted by the kidneys. When measurements were made of ammonium excretion rates, they were found to be normal. Thus, the conclusion is that while there might be some renal tubule damage from the glue sniffing, the bulk of the acidosis results from hippuric acid production. The prompt excretion of the hippurate prevents the development of an increase in the anion gap [249].

Type III Renal Tubular Acidosis Type III RTA refers to a form of renal tubular acidosis that has features of both proximal RTA and distal RTA. During the middle of the twentieth century, a number of patients were found to have features of both forms of RTA, and the third type of RTA was suggested. It was subsequently found that these patients had distal RTA with a transient form of proximal RTA. Thus, the term fell out of favor and had not been used. More recently, a form of RTA that occurs with some forms of osteopetrosis has been characterized that seems to meet the criteria for the designation of type III RTA. This association was originally described in 1972 [250]. Subsequently, the defect was found to be a mutation in the gene for carbonic anhydrase II [102]. After the initial finding of the genetic defect, a number of other patients have been described with similar clinical findings [103, 251, 252]. These patients have other extrarenal findings such as cerebral calcifications as well as the bone problems associated with osteopetrosis [103]. It should be pointed out that osteopetrosis can be caused by a defect in a

39

Renal Tubular Acidosis in Children

number of different genes that affect the osteoclast [253]. Thus, the finding of osteopetrosis does not imply that the patient will have a defect in carbonic anhydrase II and will develop RTA. The form of osteopetrosis associated with the carbonic anhydrase deficiency is the syndrome known as Guibaud–Vainsel syndrome or marble brain disease [253].

Type IV Renal Tubular Acidosis The effects of aldosterone on electrolyte balance have been extensively studied since the discovery of aldosterone in the 1950s [22]. The initial findings demonstrated dramatic effects of aldosterone on sodium reabsorption and potassium secretion. In the latter half of the twentieth century, it became clear that aldosterone also had effects on acid–base balance. With the recent advances in molecular biology, the mechanisms involved in the genetic causes of type IV RTA have been elucidated [254]. Type IV RTA was initially used to describe patients that developed acidosis from aldosterone deficiency. This could occur as an inherited defect, such as congenital adrenal hyperplasia, or could be acquired as in Addison’s disease. The principal feature that distinguished type IV RTA from classic type I RTA was the finding of hyperkalemia. Patients with type IV RTA are hyperkalemic, while many of the patients presenting with classic type I RTA were hypokalemic. This led investigators to believe that the cause of this form of RTA was aldosterone deficiency. Later it became apparent that many of the patients were not aldosterone deficient, but had a decreased responsiveness of the renal tubules to aldosterone and hence developed hyperkalemic RTA. Currently the term type IV RTA is applied to all forms of hyperkalemic RTA, regardless of the serum aldosterone concentration.

Pathophysiology The primary effect of aldosterone on the collecting duct is to stimulate sodium reabsorption and

1291

potassium secretion in the principal cells [255]. This results in an enhancement of the lumennegative electrical potential that can then help promote proton secretion. Aldosterone also has direct effects on the alpha-intercalated cells to promote proton secretion by upregulating the expression of the proton ATPase as well as carbonic anhydrase [255]. The effect of aldosterone on ammonia excretion is not clear. There is evidence that aldosterone deficiency could directly inhibit the production of ammonia, while other studies indicate that the effect could be secondary to hyperkalemia [256–258]. Ammonia secretion in patients with aldosterone deficiency was low and was shown to increase after administration of mineralocorticoid; however, it was still not clear if the effect could be secondary to changes in potassium concentration. Patients that are aldosterone deficient or resistant to the actions of aldosterone have increased excretion of sodium which leads to volume depletion and potentially a decrease in the glomerular filtration rate [259, 260]. Thus, many of the symptoms of this process are secondary to the volume depletion. The acidosis in most patients with type IV RTA is not as severe as in other forms of RTA [259]. Thus, the main clinical problem with most of these patients is hyperkalemia. Treatment often relies on restricting the intake of potassium but will ultimately depend on the cause of the RTA.

Etiology As discussed above, type IV RTA can result from a deficiency of aldosterone or from a resistance of the renal tubules to the actions of aldosterone.

Aldosterone Deficiency Aldosterone deficiency can be the result of a global dysfunction of the adrenal gland, referred to as Addison’s syndrome, or it can be the result of isolated aldosterone or mineralocorticoid deficiency. The most common inherited form of mineralocorticoid deficiency is congenital adrenal hyperplasia (CAH) which is due to

1292

21-hydroxylase deficiency [261, 262]. Other infants can present with isolated aldosterone synthase deficiency which is not a severe disease process since the glucocorticoid pathway remains intact [263].

Aldosterone Resistance There are a number of inherited and acquired conditions that result in resistance of the tubules to the action of aldosterone. The pathway for aldosterone action includes the mineralocorticoid receptor and the epithelial sodium channel (ENaC). Defects in both of these components result in type IV RTA. Because of the renal tubular resistance to aldosterone, aldosterone concentrations in the blood are quite elevated. Thus, this is referred to as pseudohypoaldosteronism (PHA). Defects in the mineralocorticoid receptor lead to an autosomal dominant form of PHA [264]. This form is the least severe of the PHAs, and patients tend to improve as they get older. This is presumably due to compensation by other pathways to reabsorb sodium and secrete potassium and hydrogen ions. An autosomal recessive form of PHA is due to defects in ENaC [265]. Patients with this form can be severely affected since the final pathway for sodium regulation in the collecting duct involves ENaC. In addition, they have severe pulmonary problems at birth because ENaC is present in the lungs and is a key factor in the reabsorption of fluid from the lung space after birth. Both of these forms of PHA lead to salt loss and volume depletion. Patients tend to be hypotensive and dehydrated. Additionally, plasma concentrations of renin and aldosterone are quite elevated because of the volume depletion. A form of PHA that occurs in patients that are hypertensive was originally thought to be due to a “chloride shunt” in the collecting duct and was referred to as PHA type 2 or Gordon’s syndrome [266]. These patients are characterized by having hyperkalemia and acidosis, but have a low concentration of renin and aldosterone in their plasma. This led investigators to hypothesize that the paracellular pathway in the collecting

R. Quigley and M.T.F. Wolf

duct was allowing chloride to be reabsorbed at a higher rate than was needed [267]. This would cause the electrical potential difference in the tubule to decrease and would thus decrease the excretion of potassium and protons. Recent discoveries have shown that PHA type 2 is due to defects in WNKs (with no lysine kinases) [268]. Specifically, there are families with the syndrome that have mutations in WNK1 and some with mutations in WNK4. The biology of the WNKs has turned out to be very complicated and is beyond the scope of this chapter. However, they seem to be key players in the regulation of potassium and blood pressure. Other patients with PHA type 2 were found to have mutations in genes for CUL3 and KLHL3, which encode Cullin-3 and Kelch-like-3 proteins [269, 270]. The mutations found in KLHL3 are all in a domain that is important for substrate and Cullin binding. Both proteins are involved in ubiquitination. KLHL3 is expressed in the distal convoluted tubule and collecting duct, whereas CUL3 is strongly expressed in the proximal tubule but also weaker in the distal convoluted tubule and collecting duct. KLHL3 downregulates NCC expression at the cell surface [270]. Both CUL3 and KLHL3 decrease WNK4 levels by ubiquitination and subsequent degradation [271]. In particular, patients with CUL3 mutations seem to present early in infancy with hyperkalemia, hypertension, and metabolic acidosis [269, 272].

Acquired Addison’s disease can be an autoimmune disease or can be the result of damage to the adrenal gland from infection or infarction. Treatment involves replacing the adrenal hormones as needed as well as treating the underlying infection. In adult patients, diabetes is a leading cause of type IV RTA as a result of hyporeninemic hypoaldosteronism [273]. There are other disease processes that also lead to a decrease in production of renin that would then lead to a decrease in aldosterone secretion. If the patient has type IV RTA from acquired hypoaldosteronism, treatment with mineralocorticoids will correct the defect [274].

39

Renal Tubular Acidosis in Children

Tubular resistance to aldosterone can occur as a result of a number of different processes. Autoimmune diseases can lead to interstitial nephritis that decreases the tubule responsiveness to aldosterone [275]. Patients with systemic lupus erythematosus classically develop type 1 RTA, but have been reported to present with type IV RTA [226]. Infections such as acute pyelonephritis can also cause a resistance to aldosterone action. Probably the most common cause of acquired type IV RTA in the pediatric age range is obstruction of the urinary tract. The mechanism by which obstruction causes resistance of the tubule to aldosterone is not clear, but this is commonly seen in patients with posterior urethral valve or with prune-belly syndrome. Type IV RTA can also been seen in patients with a renal transplant [276]. This could be due to either an immune-mediated mechanism, or it could be related to medications used for the treatment of rejection. In particular, calcineurin inhibitors are known to cause type IV RTA [238, 277]. Other medications that are known to interfere with the action of aldosterone include angiotensinconverting enzyme inhibitors (ACE inhibitors), heparin, prostaglandin inhibitors (NSAIDs), and a number of potassium-sparing diuretics. These would include amiloride and trimethoprim which block the epithelial sodium channel and spironolactone which blocks the mineralocorticoid receptor [254].

Diagnosis and Treatment of Renal Tubular Acidosis The diagnosis of renal tubular acidosis represents a challenge to the clinician for a number of reasons. Depending on the severity of the disease presentation, the patient could present with findings consistent with proximal and distal RTA. The patients are also many times quite volume depleted at presentation, and it is not clear how much this impacts the serum chemistries. In addition, patients with infections can be septic and in shock. Thus, the complete evaluation of a patient for renal tubular acidosis might have to occur after the acute illness has subsided.

1293

As with any complex disease, the diagnosis of RTA begins with clinical suspicion. If the disease is not being considered in the differential diagnosis, then a definitive diagnosis will not be made. There have been a number of recent reviews that outline practical guidelines for the diagnosis and management of RTA [278–281]. This section of the chapter will focus on the reasoning behind the laboratory testing that is recommended for the workup of patients with suspected RTA. The inherited forms of renal tubular acidosis present almost uniformly with failure to grow and repeated episodes of vomiting and dehydration [1, 76]. It should be emphasized that most of these patients are very ill appearing at the time of presentation. The patient with failure to grow that otherwise appears healthy has a much lower probability of having RTA. A recent study examined patients referred for failure to thrive that had serum chemistries indicating the possibility of RTA [282]. Simply performing a venous blood gas analysis in the patients demonstrated the absence of acidosis. The first step in the evaluation of patients with an acidosis is to determine the serum anion gap [283–286]. Patients with RTA are characterized by having a normal anion gap. This is also referred to as a hyperchloremic metabolic acidosis. Interpretation of the anion gap can occasionally be misleading. Other factors can affect the anion gap such as serum protein concentrations, calcium, and other anions such as phosphate [284, 287]. Thus, the determination of a normal anion gap acidosis can only be correctly made when these factors are taken into account. Although renal tubular acidosis should be suspected in these patients with metabolic acidosis with a normal anion gap, there are other disorders to consider in the differential diagnosis such as gastrointestinal loss of bicarbonate. The workup of these patients is therefore designed to differentiate whether the acidosis is of renal or extrarenal origin. Thus, it is necessary to examine the response of the kidney to the metabolic acidosis. As discussed above, the normal renal response to metabolic acidosis is to increase ammonium chloride excretion as a way to enhance hydrogen ion excretion to correct the acidosis. Unfortunately,

1294

R. Quigley and M.T.F. Wolf 200

A Phosphate < 20mM/L. Phosphate 20 -49mM/L. Phosphate > 50mM/L.

Urine Bicarbonate Concentration in mEq/L.

150

100

50

5.5

6.0

6.5 Urine pH

7.0

7.5

8.0

Fig. 8 Urinary bicarbonate concentration as a function of urinary pH. As can be seen, once the urine pH becomes less than 6.5, the concentration of bicarbonate is less than

10 mEq/l. This might have an impact in determining the urinary anion gap (Reprinted with permission from Kennedy et al. [307])

measuring ammonium in the urine is not a routine function in most hospital laboratories. Over time, several approaches have been taken to estimate the urinary excretion of ammonium to determine if the kidney is responding normally [288–292]. The measurement of the urine pH can be helpful but also can be misleading in the diagnosis of RTA [293]. Where it tends to be helpful is in

determining whether or not there is bicarbonate in the urine (see Fig. 8). The simplest test that was devised is to measure the urine sodium, potassium, and chloride concentrations and calculate the urinary anion gap using the following equation: Urinary anion gap ¼ UNa þ UK UCl ;

39

Renal Tubular Acidosis in Children

where UNa is the urinary sodium concentration, UK the urinary potassium concentration, and UCl the urinary chloride concentration. This approach is based on the fact that the unmeasured cations and anions are constant and that ammonium would be the primary cation other than sodium and potassium that would be excreted with chloride. The amount of ammonium in the urine when the anion gap is zero turned out to be 80 mmol/l. The other assumptions in this approach are that there is no appreciable bicarbonate in the urine and the patient is not receiving medications that are excreted in the urine in ionic form such as penicillins. If the urine pH is less than 7, the urinary bicarbonate will be less than 10 mmol/l (see Fig. 8). This simple approach has been verified in normal controls as well as patients with RTA and gastrointestinal causes of acidosis [288, 290]. Modifications to the urinary anion gap calculation have been made to expand its application to conditions that could yield misleading results. If patients are excreting other anions, ammonium would be excreted with the unmeasured anion instead of chloride. Thus, the urinary anion gap would underestimate the amount of ammonium in the urine. The osmolal gap was developed to take this into account [291]. The osmolal gap is calculated by the following equation: Urine osmolal gap ¼ measured urine osmolality calculated urine osmolality: The calculated osmolality is determined by the following equation: Calculated osmolality ¼ Na þ K þ Cl þ HCO3 urea nitrogen 2:4 glucose : þ 18 þ

This was shown to correctly account for the unmeasured anions in patients with ketoacidosis [291]. An additional modification was then developed because of the difficulty in measuring the

1295

urine bicarbonate concentration. This method replaces the urine bicarbonate and chloride measurement by multiplying the sum of the sodium and potassium concentrations by 2 [289]. Urine NH4 þ

urea glucose þ Urineosm 2 ðNa þ K Þ þ 2:8 18 ¼ 2 þ

þ

where the quantity in the brackets is the calculated urine osmolality. The above approaches are designed to estimate the amount of ammonium in the urine. Normal controls have about 80 mmol/l of ammonium in the urine [290]. What makes the test work well in the evaluation of acidosis is the fact that normal individuals will have an increase in their ammonium excretion but the patients with RTA will not. A recent study examined the correlation of these techniques with actual measurement of urinary ammonium [294]. This study concluded that the correlation many times was not good and that direct measurement of the urinary ammonium would be a better method. Another problem with this approach is that neonates were found to have a poor correlation between urinary anion gap and urinary ammonium concentration [295]. Another approach to examine the urine for proton secretory rate is to measure the urine and blood pCO2 during bicarbonate loading [296–298]. The idea is to take advantage of the low level of carbonic anhydrase activity in the distal nephron. When the patient is loaded with bicarbonate, the delivery to the proximal tubule will exceed the transport maximum, and significant amounts of bicarbonate will be delivered to the distal nephron. If the patient has a normal proton secretory rate, hydrogen ions will be secreted into the tubule lumen. Although there is CA II in the distal nephron, the rate of reaction is slow enough that the carbon dioxide will be excreted in the urine and not reabsorbed. Under these conditions, normal individuals will have a urinary pCO2 of greater than 70 mmHg or a blood–urine pCO2 of greater than 30 mmHg. Patients with a defect in hydrogen ion secretion will have a urinary pCO2 of less than 70 mmHg or

1296

a blood–urine pCO2 of less than 30 mmHg. This method has been shown to be useful in neonates as well as adults [298]. Other tests might be indicated if the results of the above remain indeterminate. Traditionally, the patient’s ability to acidify the urine is tested using acute or chronic loading with ammonium chloride [279]. Because of the unpalatable nature of the ammonium loading, urinary acidification can be evaluated using a combination of a mineralocorticoid and furosemide [299].

Differentiating Proximal and Distal RTA Once it has been determined that the patient has RTA, it is necessary to determine if it is a proximal or distal defect. Usually this can be determined by the associated findings in the patient. As outlined above, most patients with proximal RTA have the Fanconi syndrome. Thus, it is very helpful to evaluate the urine for glucosuria and phosphaturia. If these are normal but the patient is suspected of having a proximal tubule defect, it might be necessary to perform a bicarbonate titration to find the threshold for bicarbonate excretion [279]. The serum potassium concentration will also help determine if the patient has a type IV RTA. Another useful determination is a renal sonogram or X-ray to determine if the patient has nephrocalcinosis (see Fig. 7). Patients with distal RTA have hypocitraturia and therefore are much more likely to have nephrocalcinosis and form renal stones. Patients with proximal RTA are in relative acid–base balance so that they have normal amounts of citrate in their urine, and they do not excrete large amounts of calcium.

Treatment The treatment of RTA will of course be determined by the type and cause of RTA. The Fanconi syndrome due to cystinosis should be treated with cysteamine [300–303]. This will prevent further damage to the renal tubular cells by preventing the accumulation of cystine. However, these patients continue to have the Fanconi syndrome and

R. Quigley and M.T.F. Wolf

require large amounts of alkali therapy as well as phosphate and vitamin D. The sporadic forms of proximal RTA are also difficult to correct completely, but mild improvements in their acid–base status allow them to grow normally [75]. These patients tend to improve with age and will need less alkali as they grow. The treatment of distal RTA is somewhat more straightforward. The amount of alkali needed to correct the acidosis and maintain normal acid–base balance is much less than that needed in patients with proximal RTA. The dosage of alkali necessary has been recently studied. Using potassium citrate, investigators have found that 3–4 mEq/kg/day was necessary to normalize the urinary citrate excretion [304, 305]. A previous study had also indicated that the dosage of alkali needed to be higher in younger children and decreased to about 3 mEq/kg/day after the age of 6 years [77]. The importance of continued therapy in these children has been a recent concern [306]. It appears that subclinical acidosis could have long-term effects on the bone, resulting in osteoporosis. The loss of calcium from the bones would also lead to nephrocalcinosis and renal stone formation.

References 1. Rodriguez-Soriano J, Edelmann Jr CM. Renal tubular acidosis. Annu Rev Med. 1969;20:363–82. 2. Davies HE, Wrong O. Acidity of urine and excretion of ammonium in renal disease. Lancet. 1957;273 (6996):625. 3. Schwartz WB, Hall 3rd PW, Hays RM, Relman AS. On the mechanism of acidosis in chronic renal disease. J Clin Invest. 1959;38(1, Part 1):39–52. 4. Wrong O, Davies HE. The excretion of acid in renal disease. Q J Med. 1959;28(110):259–313. 5. Albright F, Burnett CH, et al. Osteomalacia and late rickets; the various etiologies met in the United States with emphasis on that resulting from a specific form of renal acidosis, the therapeutic indications for each etiological sub-group, and the relationship between osteomalacia and Milkman’s syndrome. Medicine. 1946;25(4):399–479. 6. Pines KL, Mudge GH. Renal tubular acidosis with osteomalacia; report of 3 cases. Am J Med. 1951;11 (3):302–11. 7. Lightwood R. Calcium infarction of the kidneys in infants. Arch Dis Child. 1935;10:205.

39

Renal Tubular Acidosis in Children

8. Butler AM, Wilson JL, Farber S. Dehydration and acidosis with calcification at renal tubules. J Pediatr. 1936;8(4):489–99. 9. Lightwood R, Payne WW, Black JA. Infantile renal acidosis. Pediatrics. 1953;12(6):628–44. 10. Baines AM, Barelay JA, Cooke WT. Nephrocalcinosis associated with hyperchloremia and low plasma bicarbonate. QJM. 1945;14:113–23. 11. Reynolds TB. Observations on the pathogenesis of renal tubular acidosis. Am J Med. 1958;25(4): 503–15. 12. Elkinton JR. Renal acidosis. Am J Med. 1960;28: 165–8. 13. Elkinton JR. The kidney and hydrogen ion metabolism. Bibl Paediatr. 1960;74:99–123. 14. Elkinton JR, Huth EJ, Webster Jr GD, Mc CR. The renal excretion of hydrogen ion in renal tubular acidosis. I. quantitative assessment of the response to ammonium chloride as an acid load. Am J Med. 1960;29:554–75. 15. Berliner RW. Homer Smith: his contribution to physiology. J Am Soc Nephrol. 1995;12:1988–92. 16. Stapleton T. Idiopathic renal acidosis in an infant with excessive loss of bicarbonate in the urine. Lancet. 1949;1(6556):683–5. 17. Rodriguez Soriano J, Boichis H, Stark H, Edelmann Jr CM. Proximal renal tubular acidosis. A defect in bicarbonate reabsorption with normal urinary acidification. Pediatr Res. 1967;1(2):81–98. 18. Soriano JR, Boichis H, Edelmann Jr CM. Bicarbonate reabsorption and hydrogen ion excretion in children with renal tubular acidosis. J Pediatr. 1967;71 (6):802–13. 19. Morris Jr RC. Renal tubular acidosis. Mechanisms, classification and implications. N Engl J Med. 1969;281(25):1405–13. 20. McSherry E, Sebastian A, Morris Jr RC. Renal tubular acidosis in infants: the several kinds, including bicarbonate-wasting, classic renal tubular acidosis. J Clin Invest. 1972;51(3):499–514. 21. Gennari FJ, Cohen JJ. Renal tubular acidosis. Annu Rev Med. 1978;29:521–41. 22. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88(6): 2364–72. 23. Perez GO, Oster JR, Vaamonde CA. Renal acidosis and renal potassium handling in selective hypoaldosteronism. Am J Med. 1974;57(5):809–16. 24. Perez GO, Oster JR, Vaamonde CA. Renal acidification in patients with mineralocorticoid deficiency. Nephron. 1976;17(6):461–73. 25. Rocher LL, Tannen RL. The clinical spectrum of renal tubular acidosis. Annu Rev Med. 1986;37:319–31. 26. Carlisle EJ, Donnelly SM, Halperin ML. Renal tubular acidosis (RTA): recognize the ammonium defect and pH or get the urine pH. Pediatr Nephrol. 1991;5 (2):242–8. 27. Halperin ML, Goldstein MB, Richardson RM, Stinebaugh BJ. Distal renal tubular acidosis

1297 syndromes: a pathophysiological approach. Am J Nephrol. 1985;5(1):1–8. 28. Halperin ML, Jungas RL. Metabolic production and renal disposal of hydrogen ions. Kidney Int. 1983;24(6):709–13. 29. Chan JC. The influence of dietary intake on endogenous acid production. Theoretical and experimental background. Nutr Metab. 1974;16(1):1–9. 30. Chan JCM. Calcium and hydrogen ion metabolism in children with classic (type I/distal) renal tubular acidosis. Ann Nutr Metab. 1981;25(2):65–78. 31. Kildeberg P, Engel K, Winters RW. Balance of net acid in growing infants. Endogenous and transintestinal aspects. Acta Paediatr Scand. 1969;58(4):321–9. 32. Alpern RJ. Cell mechanisms of proximal tubule acidification. Physiol Rev. 1990;70(1):79–114. 33. Boron WF. Acid–base transport by the renal proximal tubule. J Am Soc Nephrol. 2006;17(9):2368–82. 34. Boron WF, Boulpaep EL. The electrogenic Na/HCO3 cotransporter. Kidney Int. 1989;36(3):392–402. 35. Boron WF, Fong P, Hediger MA, Boulpaep EL, Romero MF. The electrogenic Na/HCO3 cotransporter. Wien Klin Wochenschr. 1997;109(12–13):445–56. 36. DuBose Jr TD. Reclamation of filtered bicarbonate. Kidney Int. 1990;38(4):584–9. 37. Bobulescu IA, Moe OW. Na+/H+ exchangers in renal regulation of acid–base balance. Semin Nephrol. 2006;26(5):334–44. 38. Murer H, Hopfer U, Kinne R. Sodium/proton antiport in brush-border-membrane vesicles isolated from rat small intestine and kidney. Biochem J. 1976;154 (3):597–604. 39. Preisig PA, Ives HE, Cragoe Jr EJ, Alpern RJ, Rector Jr FC. Role of the Na+/H+ antiporter in rat proximal tubule bicarbonate absorption. J Clin Invest. 1987;80 (4):970–8. 40. Aronson PS, Suhm MA, Nee J. Interaction of external H+ with the Na+H+ exchanger in renal microvillus membrane vesicles. J Biol Chem. 1983;258(11):6767–71. 41. Kinsella JL, Aronson PS. Interaction of NH4+ and Li+ with the renal microvillus membrane Na+H+ exchanger. Am J Physiol. 1981;241(5):C220–6. 42. Weiner ID, Verlander JW. Role of NH3 and NH4+ transporters in renal acid–base transport. Am J Physiol Renal Physiol. 2011;300(1):F11–23. 43. Nagami GT. Role of angiotensin II in the enhancement of ammonia production and secretion by the proximal tubule in metabolic acidosis. Am J Physiol Renal Physiol. 2008;294(4):F874–80. 44. Nagami GT, Chang JA, Plato ME, Santamaria R. Acid loading in vivo and low pH in culture increase angiotensin receptor expression: enhanced ammoniagenic response to angiotensin II. Am J Physiol Renal Physiol. 2008;295(6):F1864–70. 45. Zimolo Z, Montrose MH, Murer H. H+ extrusion by an apical vacuolar-type H(+)-ATPase in rat renal proximal tubules. J Membr Biol. 1992;126(1):19–26. 46. Breton S. The cellular physiology of carbonic anhydrases. JOP. 2001;2(4 Suppl):159–64.

1298 47. Purkerson JM, Schwartz GJ. The role of carbonic anhydrases in renal physiology. Kidney Int. 2007;71(2):103–15. 48. Schwartz GJ. Physiology and molecular biology of renal carbonic anhydrase. J Nephrol. 2002;15 Suppl 5:S61–74. 49. Grassl SM, Aronson PS. Na+/HCO3-co-transport in basolateral membrane vesicles isolated from rabbit renal cortex. J Biol Chem. 1986;261(19):8778–83. 50. Romero MF, Hediger MA, Boulpaep EL, Boron WF. Expression cloning and characterization of a renal electrogenic Na+/HCO3 cotransporter. Nature. 1997;387(6631):409–13. 51. Pitts RF, Ayer JL, Schiess WA, Miner P. The renal regulation of acid–base balance in man. III. The reabsorption and excretion of bicarbonate. J Clin Invest. 1949;28(1):35–44. 52. Pitts RF. Renal production and excretion of ammonia. Am J Med. 1964;36:720–42. 53. Bank N, Schwartz WB. Influence of certain urinary solutes on acidic dissociation constant of ammonium at 37 degrees C. J Appl Physiol. 1960;15:125–7. 54. DuBose Jr TD, Good DW, Hamm LL, Wall SM. Ammonium transport in the kidney: new physiological concepts and their clinical implications. J Am Soc Nephrol. 1991;1(11):1193–203. 55. Karim Z, Szutkowska M, Vernimmen C, Bichara M. Renal handling of NH3/NH4+: recent concepts. Nephron Physiol. 2005;101(4):p77–81. 56. Karim Z, Szutkowska M, Vernimmen C, Bichara M. Recent concepts concerning the renal handling of NH3/NH4+. J Nephrol. 2006;19 Suppl 9:S27–32. 57. Good DW, Knepper MA. Ammonia transport in the mammalian kidney. Am J Physiol. 1985;248(4 Pt 2): F459–71. 58. Curthoys NP, Gstraunthaler G. Mechanism of increased renal gene expression during metabolic acidosis. Am J Physiol Renal Physiol. 2001;281(3): F381–90. 59. Madison LL, Seldin DW. Ammonia excretion and renal enzymatic adaptation in human subjects, as disclosed by administration of precursor amino acids. J Clin Invest. 1958;37(11):1615–27. 60. Capasso G, Unwin R, Rizzo M, Pica A, Giebisch G. Bicarbonate transport along the loop of Henle: molecular mechanisms and regulation. J Nephrol. 2002;15 Suppl 5:S88–96. 61. Good DW, Knepper MA, Burg MB. Ammonia and bicarbonate transport by thick ascending limb of rat kidney. Am J Physiol. 1984;247(1 Pt 2):F35–44. 62. Good DW, Knepper MA, Burg MB. Ammonia absorption by the thick ascending limb of Henle’s loop. Contrib Nephrol. 1985;47:110–5. 63. Breton S, Brown D. New insights into the regulation of V-ATPase-dependent proton secretion. Am J Physiol Renal Physiol. 2007;292(1):F1–10. 64. Karet FE. Physiological and metabolic implications of V-ATPase isoforms in the kidney. J Bioenerg Biomembr. 2005;37(6):425–9.

R. Quigley and M.T.F. Wolf 65. Valles P, Lapointe MS, Wysocki J, Batlle D. Kidney vacuolar H+ATPase: physiology and regulation. Semin Nephrol. 2006;26(5):361–74. 66. Wagner CA, Finberg KE, Breton S, Marshansky V, Brown D, Geibel JP. Renal vacuolar H+ATPase. Physiol Rev. 2004;84(4):1263–314. 67. Alper SL. Molecular physiology of SLC4 anion exchangers. Exp Physiol. 2006;91(1):153–61. 68. Romero MF, Fulton CM, Boron WF. The SLC4 family of HCO3 – transporters. Pflugers Arch. 2004;447 (5):495–509. 69. Boettger T, Hubner CA, Maier H, Rust MB, Beck FX, Jentsch TJ. Deafness and renal tubular acidosis in mice lacking the K-Cl co-transporter Kcc4. Nature. 2002;416(6883):874–8. 70. Kobayashi K, Uchida S, Mizutani S, Sasaki S, Marumo F. Intrarenal and cellular localization of CLC-K2 protein in the mouse kidney. J Am Soc Nephrol. 2001;12(7):1327–34. 71. Gao X, Eladari D, Leviel F, Tew BY, Miro-Julia C, Cheema FH, et al. Deletion of hensin/DMBT1 blocks conversion of beta- to alpha-intercalated cells and induces distal renal tubular acidosis. Proc Natl Acad Sci USA. 2010;107(50):21872–7. 72. Al-Awqati Q, Gao XB. Differentiation of intercalated cells in the kidney. Physiology (Bethesda). 2011;26 (4):266–72. 73. Harrison HE. The Fanconi syndrome. J Chronic Dis. 1958;7(4):346–55. 74. Quigley R. Proximal renal tubular acidosis. J Nephrol. 2006;19 Suppl 9:S41–5. 75. Brenes LG, Brenes JN, Hernandez MM. Familial proximal renal tubular acidosis. A distinct clinical entity. Am J Med. 1977;63(2):244–52. 76. Nash MA, Torrado AD, Greifer I, Spitzer A, Edelmann Jr CM. Renal tubular acidosis in infants and children. Clinical course, response to treatment, and prognosis. J Pediatr. 1972;80(5):738–48. 77. Rodriguez-Soriano J, Vallo A, Castillo G, Oliveros R. Natural history of primary distal renal tubular acidosis treated since infancy. J Pediatr. 1982;101(5):669–76. 78. Brenes LG, Sanchez MI. Impaired urinary ammonium excretion in patients with isolated proximal renal tubular acidosis. J Am Soc Nephrol. 1993;4(4): 1073–8. 79. Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi’s syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf). 1995;43(4):479–90. 80. Taylor HC, Elbadawy EH. Renal tubular acidosis type 2 with Fanconi’s syndrome, osteomalacia, osteoporosis, and secondary hyperaldosteronism in an adult consequent to vitamin D and calcium deficiency: effect of vitamin D and calcium citrate therapy. Endocr Pract. 2006;12(5):559–67. 81. Sebastian A, McSherry E, Morris Jr RC. On the mechanism of renal potassium wasting in renal tubular acidosis associated with the Fanconi syndrome (type 2 RTA). J Clin Invest. 1971;50(1):231–43.

39

Renal Tubular Acidosis in Children

82. Baum M. The cellular basis of Fanconi syndrome. Hosp Pract (Off Ed). 1993;28(11):137–42, 47–8. 83. Baum M. The Fanconi syndrome of cystinosis: insights into the pathophysiology. Pediatr Nephrol. 1998;12(6):492–7. 84. Gross P, Meye C. Proximal RTA: are all the charts completed yet? Nephrol Dial Transplant. 2008;23 (4):1101–2. 85. Morris Jr RC, McSherry E. Symposium on acid–base homeostasis. Renal acidosis. Kidney Int. 1972;1 (5):322–40. 86. Katzir Z, Dinour D, Reznik-Wolf H, Nissenkorn A, Holtzman E. Familial pure proximal renal tubular acidosis – a clinical and genetic study. Nephrol Dial Transplant. 2008;23(4):1211–5. 87. Igarashi T, Inatomi J, Sekine T, Cha SH, Kanai Y, Kunimi M, et al. Mutations in SLC4A4 cause permanent isolated proximal renal tubular acidosis with ocular abnormalities. Nat Genet. 1999;23(3):264–6. 88. Igarashi T, Sekine T, Inatomi J, Seki G. Unraveling the molecular pathogenesis of isolated proximal renal tubular acidosis. J Am Soc Nephrol. 2002;13(8): 2171–7. 89. Pushkin A, Kurtz I. SLC4 base (HCO3, CO32) transporters: classification, function, structure, genetic diseases, and knockout models. Am J Physiol Renal Physiol. 2006;290(3):F580–99. 90. Winsnes A, Monn E, Stokke O, Feyling T. Congenital persistent proximal type renal tubular acidosis in two brothers. Acta Paediatr Scand. 1979;68(6):861–8. 91. Shiohara M, Igarashi T, Mori T, Komiyama A. Genetic and long-term data on a patient with permanent isolated proximal renal tubular acidosis. Eur J Pediatr. 2000;159(12):892–4. 92. Dinour D, Chang MH, Satoh J, Smith BL, Angle N, Knecht A, et al. A novel missense mutation in the sodium bicarbonate cotransporter (NBCe1/SLC4A4) causes proximal tubular acidosis and glaucoma through ion transport defects. J Biol Chem. 2004;279(50):52238–46. 93. Igarashi T, Inatomi J, Sekine T, Seki G, Shimadzu M, Tozawa F, et al. Novel nonsense mutation in the Na+/ HCO3 cotransporter gene (SLC4A4) in a patient with permanent isolated proximal renal tubular acidosis and bilateral glaucoma. J Am Soc Nephrol. 2001;12(4):713–8. 94. Igarashi T, Ishii T, Watanabe K, Hayakawa H, Horio K, Sone Y, et al. Persistent isolated proximal renal tubular acidosis – a systemic disease with a distinct clinical entity. Pediatr Nephrol. 1994;8(1): 70–1. 95. Usui T, Hara M, Satoh H, Moriyama N, Kagaya H, Amano S, et al. Molecular basis of ocular abnormalities associated with proximal renal tubular acidosis. J Clin Invest. 2001;108(1):107–15. 96. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA. The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006;26 (5):352–60.

1299 97. Romero MF. Molecular pathophysiology of SLC4 bicarbonate transporters. Curr Opin Nephrol Hypertens. 2005;14(5):495–501. 98. Soleimani M, Burnham CE. Na+:HCO(3) cotransporters (NBC): cloning and characterization. J Membr Biol. 2001;183(2):71–84. 99. Suzuki M, Seki G, Yamada H, Horita S, Fujita T. Functional roles of electrogenic sodium bicarbonate cotransporter NBCe1 in ocular tissues. Open Ophthalmol J. 2012;6:36–41. 100. Toye AM, Parker MD, Daly CM, Lu J, Virkki LV, Pelletier MF, et al. The human NBCe1-A mutant R881C, associated with proximal renal tubular acidosis, retains function but is mistargeted in polarized renal epithelia. Am J Physiol Cell Physiol. 2006;291 (4):C788–801. 101. Kurtz I, Zhu Q. Proximal renal tubular acidosis mediated by mutations in NBCe1-A: unraveling the transporter’s structure-functional properties. Front Physiol. 2013;4:350. 102. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA. 1983;80(9):2752–6. 103. Sly WS, Whyte MP, Sundaram V, Tashian RE, Hewett-Emmett D, Guibaud P, et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N Engl J Med. 1985;313(3):139–45. 104. Schultheis PJ, Clarke LL, Meneton P, Miller ML, Soleimani M, Gawenis LR, et al. Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger. Nat Genet. 1998;19(3):282–5. 105. Choi JY, Shah M, Lee MG, Schultheis PJ, Shull GE, Muallem S, et al. Novel amiloride-sensitive sodiumdependent proton secretion in the mouse proximal convoluted tubule. J Clin Invest. 2000;105(8):1141–6. 106. Warth R, Barriere H, Meneton P, Bloch M, Thomas J, Tauc M, et al. Proximal renal tubular acidosis in TASK2 K+ channel-deficient mice reveals a mechanism for stabilizing bicarbonate transport. Proc Natl Acad Sci USA. 2004;101(21):8215–20. 107. Morton MJ, Abohamed A, Sivaprasadarao A, Hunter M. pH sensing in the two-pore domain K+ channel, TASK2. Proc Natl Acad Sci USA. 2005;102 (44):16102–6. 108. Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med. 2002;347(2):111–21. 109. Kalatzis V, Antignac C. Cystinosis: from gene to disease. Nephrol Dial Transplant. 2002;17 (11):1883–6. 110. Kalatzis V, Antignac C. New aspects of the pathogenesis of cystinosis. Pediatr Nephrol. 2003;18(3): 207–15. 111. Kalatzis V, Cherqui S, Antignac C, Gasnier B. Cystinosin, the protein defective in cystinosis, is a

1300 H(+)-driven lysosomal cystine transporter. Embo J. 2001;20(21):5940–9. 112. Fanconi G, Bickel H. Die chronische Aminoacidurie (AminosaEurediabetes oder nephrotisch-glukosurischer Zwerg-wuchs) bei der Glykogenose und der Cystinkrankheit. Helv Paediatr Acta. 1949;4(5): 359–96. 113. Santer R, Groth S, Kinner M, Dombrowski A, Berry GT, Brodehl J, et al. The mutation spectrum of the facilitative glucose transporter gene SLC2A2 (GLUT2) in patients with Fanconi-Bickel syndrome. Hum Genet. 2002;110(1):21–9. 114. Santer R, Schneppenheim R, Dombrowski A, Gotze H, Steinmann B, Schaub J. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet. 1997;17(3):324–6. 115. Santer R, Schneppenheim R, Dombrowski A, Gotze H, Steinmann B, Schaub J. Fanconi-Bickel syndrome – a congenital defect of the liver-type facilitative glucose transporter. SSIEM Award. Society for the Study of Inborn Errors of Metabolism. J Inherit Metab Dis. 1998;21(3):191–4. 116. Santer R, Schneppenheim R, Suter D, Schaub J, Steinmann B. Fanconi-Bickel syndrome – the original patient and his natural history, historical steps leading to the primary defect, and a review of the literature. Eur J Pediatr. 1998;157(10):783–97. 117. Santer R, Steinmann B, Schaub J. Fanconi-Bickel syndrome – a congenital defect of facilitative glucose transport. Curr Mol Med. 2002;2(2):213–27. 118. Morris Jr RC. An experimental renal acidification defect in patients with hereditary fructose intolerance. I. Its resemblance to renal tubular acidosis. J Clin Invest. 1968;47(6):1389–98. 119. Morris Jr RC. An experimental renal acidification defect in patients with hereditary fructose intolerance. II. Its distinction from classic renal tubular acidosis; its resemblance to the renal acidification defect associated with the Fanconi syndrome of children with cystinosis. J Clin Invest. 1968;47(7):1648–63. 120. Zhang X, Jefferson AB, Auethavekiat V, Majerus PW. The protein deficient in Lowe syndrome is a phosphatidylinositol-4,5-bisphosphate 5-phosphatase. Proc Natl Acad Sci USA. 1995;92 (11):4853–6. 121. Suchy SF, Nussbaum RL. The deficiency of PIP2 5-phosphatase in Lowe syndrome affects actin polymerization. Am J Hum Genet. 2002;71(6):1420–7. 122. Mehta ZB, Pietka G, Lowe M. The cellular and physiological functions of the Lowe syndrome protein OCRL1. Traffic. 2014;15(5):471–87. 123. Hoopes Jr RR, Shrimpton AE, Knohl SJ, Hueber P, Hoppe B, Matyus J, et al. Dent disease with mutations in OCRL1. Am J Hum Genet. 2005;76(2):260–7. 124. Devuyst O, Jouret F, Auzanneau C, Courtoy PJ. Chloride channels and endocytosis: new insights from Dent’s disease and ClC-5 knockout mice. Nephron Physiol. 2005;99(3):69–73.

R. Quigley and M.T.F. Wolf 125. Hryciw DH, Ekberg J, Pollock CA, Poronnik P. ClC-5: a chloride channel with multiple roles in renal tubular albumin uptake. Int J Biochem Cell Biol. 2006;38(7):1036–42. 126. Lloyd SE, Pearce SH, Fisher SE, Steinmeyer K, Schwappach B, Scheinman SJ, et al. A common molecular basis for three inherited kidney stone diseases. Nature. 1996;379(6564):445–9. 127. Wang SS, Devuyst O, Courtoy PJ, Wang XT, Wang H, Wang Y, et al. Mice lacking renal chloride channel, CLC-5, are a model for Dent’s disease, a nephrolithiasis disorder associated with defective receptor-mediated endocytosis. Hum Mol Genet. 2000;9(20):2937–45. 128. Claverie-Martin F, Ramos-Trujillo E, Garcia-Nieto V. Dent’s disease: clinical features and molecular basis. Pediatr Nephrol. 2011;26(5):693–704. 129. Novarino G, Weinert S, Rickheit G, Jentsch TJ. Endosomal chloride-proton exchange rather than chloride conductance is crucial for renal endocytosis. Science. 2010;328(5984):1398–401. 130. Reed AA, Loh NY, Terryn S, Lippiat JD, Partridge C, Galvanovskis J, et al. CLC-5 and KIF3B interact to facilitate CLC-5 plasma membrane expression, endocytosis, and microtubular transport: relevance to pathophysiology of Dent’s disease. Am J Physiol Renal Physiol. 2010;298(2):F365–80. 131. Lin Z, Jin S, Duan X, Wang T, Martini S, Hulamm P, et al. Chloride channel (Clc)-5 is necessary for exocytic trafficking of Na+/H+ exchanger 3 (NHE3). J Biol Chem. 2011;286(26):22833–45. 132. Gailly P, Jouret F, Martin D, Debaix H, Parreira KS, Nishita T, et al. A novel renal carbonic anhydrase type III plays a role in proximal tubule dysfunction. Kidney Int. 2008;74(1):52–61. 133. Aperia A, Bergqvist G, Linne T, Zetterstrom R. Familial Fanconi syndrome with malabsorption and galactose intolerance, normal kinase and transferase activity. A report on two siblings. Acta Paediatr Scand. 1981;70(4):527–33. 134. Endo F, Sun MS. Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells. J Inherit Metab Dis. 2002;25(3):227–34. 135. Kubo S, Sun M, Miyahara M, Umeyama K, Urakami K, Yamamoto T, et al. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. Proc Natl Acad Sci USA. 1998;95(16):9552–7. 136. Chen YT. Type I, glycogen storage disease: kidney involvement, pathogenesis and its treatment. Pediatr Nephrol. 1991;5(1):71–6. 137. Chen YT, Coleman RA, Scheinman JI, Kolbeck PC, Sidbury JB. Renal disease in type I glycogen storage disease. N Engl J Med. 1988;318(1):7–11. 138. Ozen H. Glycogen storage diseases: new perspectives. World J Gastroenterol. 2007;13(18):2541–53. 139. Niaudet P, Heidet L, Munnich A, Schmitz J, Bouissou F, Gubler MC, et al. Deletion of the mitochondrial DNA in a case of de Toni-Debre-Fanconi

39

Renal Tubular Acidosis in Children

syndrome and Pearson syndrome. Pediatr Nephrol. 1994;8(2):164–8. 140. Niaudet P, Rotig A. Renal involvement in mitochondrial cytopathies. Pediatr Nephrol. 1996;10(3): 368–73. 141. Niaudet P, Rotig A. The kidney in mitochondrial cytopathies. Kidney Int. 1997;51(4):1000–7. 142. Rotig A. Renal disease and mitochondrial genetics. J Nephrol. 2003;16(2):286–92. 143. Ezgu F, Senaca S, Gunduz M, Tumer L, Hasanoglu A, Tiras U, et al. Severe renal tubulopathy in a newborn due to BCS1L gene mutation: effects of different treatment modalities on the clinical course. Gene. 2013;528(2):364–6. 144. Gai X, Ghezzi D, Johnson MA, Biagosch CA, Shamseldin HE, Haack TB, et al. Mutations in FBXL4, encoding a mitochondrial protein, cause early-onset mitochondrial encephalomyopathy. Am J Hum Genet. 2013;93(3):482–95. 145. Tucker EJ, Mimaki M, Compton AG, McKenzie M, Ryan MT, Thorburn DR. Next-generation sequencing in molecular diagnosis: NUBPL mutations highlight the challenges of variant detection and interpretation. Hum Mutat. 2012;33(2):411–8. 146. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell. 1996;84(4): 575–85. 147. Pontoglio M. Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. J Am Soc Nephrol. 2000;11 Suppl 16:S140–3. 148. Pontoglio M, Prie D, Cheret C, Doyen A, Leroy C, Froguel P, et al. HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 2000;1(4): 359–65. 149. Tanaka K, Terryn S, Geffers L, Garbay S, Pontoglio M, Devuyst O. The transcription factor HNF1alpha regulates expression of chloride-proton exchanger ClC-5 in the renal proximal tubule. Am J Physiol Renal Physiol. 2010;299(6):F1339–47. 150. Klootwijk ED, Reichold M, Helip-Wooley A, Tolaymat A, Broeker C, Robinette SL, et al. Mistargeting of peroxisomal EHHADH and inherited renal Fanconi’s syndrome. N Engl J Med. 2014;370(2): 129–38. 151. Supuran CT. Carbonic anhydrases – an overview. Curr Pharm Des. 2008;14(7):603–14. 152. Supuran CT. Carbonic anhydrases as drug targets. Curr Pharm Des. 2008;14(7):601–2. 153. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev. 2003;23(2): 146–89. 154. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi’s syndrome. Am J Kidney Dis. 2003;41(2):292–309. 155. Guerrini R, Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin Pharmacother. 2006;7(6):811–23.

1301 156. Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res. 1997;35(4):241–56. 157. Barbier O, Jacquillet G, Tauc M, Cougnon M, Poujeol P. Effect of heavy metals on, and handling by, the kidney. Nephron Physiol. 2005;99(4):105–10. 158. Choudhury D, Ahmed Z. Drug-induced nephrotoxicity. Med Clin North Am. 1997;81(3):705–17. 159. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol. 2006;2 (2):80–91. 160. Lande MB, Kim MS, Bartlett C, Guay-Woodford LM. Reversible Fanconi syndrome associated with valproate therapy. J Pediatr. 1993;123(2):320–2. 161. Zaki EL, Springate JE. Renal injury from valproic acid: case report and literature review. Pediatr Neurol. 2002;27(4):318–9. 162. Izumotani T, Ishimura E, Tsumura K, Goto K, Nishizawa Y, Morii H. An adult case of Fanconi syndrome due to a mixture of Chinese crude drugs. Nephron. 1993;65(1):137–40. 163. Lee S, Lee T, Lee B, Choi H, Yang M, Ihm CG, et al. Fanconi’s syndrome and subsequent progressive renal failure caused by a Chinese herb containing aristolochic acid. Nephrology (Carlton). 2004;9 (3):126–9. 164. Ghiculescu RA, Kubler PA. Aminoglycosideassociated Fanconi syndrome. Am J Kidney Dis. 2006;48(6):e89–93. 165. James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy. 2004;24(3):415–8. 166. Melnick JZ, Baum M, Thompson JR. Aminoglycosideinduced Fanconi’s syndrome. Am J Kidney Dis. 1994;23(1):118–22. 167. Quimby D, Brito MO. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Read. 2005;15(7):357–64. 168. Rossi R, Pleyer J, Schafers P, Kuhn N, Kleta R, Deufel T, et al. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med Pediatr Oncol. 1999;32(3):177–82. 169. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol. 2003;41(3):190–7. 170. Skinner R, Pearson AD, Craft AW. Ifosfamide nephrotoxicity in children. Med Pediatr Oncol. 1994;22 (2):153–4. 171. Tsimihodimos V, Psychogios N, Kakaidi V, Bairaktari E, Elisaf M. Salicylate-induced proximal tubular dysfunction. Am J Kidney Dis. 2007;50(3): 463–7. 172. Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM. 2014;107(4):261–9. 173. Pessler F, Emery H, Dai L, Wu YM, Monash B, Cron RQ, et al. The spectrum of renal tubular acidosis in paediatric Sjogren syndrome. Rheumatology (Oxford). 2006;45(1):85–91.

1302 174. Decourt C, Bridoux F, Touchard G, Cogne M. A monoclonal V kappa l light chain responsible for incomplete proximal tubulopathy. Am J Kidney Dis. 2003;41(2):497–504. 175. Lacy MQ, Gertz MA. Acquired Fanconi’s syndrome associated with monoclonal gammopathies. Hematol Oncol Clin North Am. 1999;13(6):1273–80. 176. Messiaen T, Deret S, Mougenot B, Bridoux F, Dequiedt P, Dion JJ, et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine. 2000;79(3):135–54. 177. Guignard JP, Torrado A. Proximal renal tubular acidosis in vitamin D deficiency rickets. Acta Paediatr Scand. 1973;62(5):543–6. 178. Vainsel M, Manderlier T, Vis HL. Proximal renal tubular acidosis in vitamin D deficiency rickets. Biomedicine. 1975;22(1):35–40. 179. Firmin CJ, Kruger TF, Davids R. Proximal renal tubular acidosis in pregnancy. A case report and literature review. Gynecol Obstet Invest. 2007;63 (1):39–44. 180. Riley AL, Ryan LM, Roth DA. Renal proximal tubular dysfunction and paroxysmal nocturnal hemoglobinuria. Am J Med. 1977;62(1):125–9. 181. Brodwall EK, Westlie L, Myhre E. The renal excretion and tubular reabsorption of citric acid in renal tubular acidosis. Acta Med Scand. 1972;192 (1–2):137–9. 182. Simpson DP. Citrate excretion: a window on renal metabolism. Am J Physiol. 1983;244(3):F223–34. 183. Serrano A, Batlle D. Images in clinical medicine. Bilateral kidney calcifications. N Engl J Med. 2008;359(1):e1. 184. Feest TG, Proctor S, Brown R, Wrong OM. Nephrocalcinosis: another cause of renal erythrocytosis. Br Med J. 1978;2(6137):605. 185. Feest TG, Wrong O. Erythrocytosis and nephrocalcinosis. Nephrol Dial Transplant. 1992;7 (10):1071. 186. Simon EE, Merli C, Herndon J, Cragoe Jr EJ, Hamm LL. Effects of barium and 5-(N-ethyl-N-isopropyl)amiloride on proximal tubule ammonia transport. Am J Physiol. 1992;262(1 Pt 2):F36–9. 187. Good DW. Ammonium transport by the thick ascending limb of Henle’s loop. Annu Rev Physiol. 1994;56:623–47. 188. Westhoff CM, Ferreri-Jacobia M, Mak DO, Foskett JK. Identification of the erythrocyte Rh blood group glycoprotein as a mammalian ammonium transporter. J Biol Chem. 2002;277(15):12499–502. 189. Weiner ID, Hamm LL. Molecular mechanisms of renal ammonia transport. Annu Rev Physiol. 2007;69:317–40. 190. Wagner CA, Devuyst O, Bourgeois S, Mohebbi N. Regulated acid–base transport in the collecting duct. Pflugers Arch. 2009;458(1):137–56. 191. Kamel KS, Briceno LF, Sanchez MI, Brenes L, Yorgin P, Kooh SW, et al. A new classification for

R. Quigley and M.T.F. Wolf renal defects in net acid excretion. Am J Kidney Dis. 1997;29(1):136–46. 192. Miller SG, Schwartz GJ. Hyperammonaemia with distal renal tubular acidosis. Arch Dis Child. 1997;77(5):441–4. 193. Pela I, Seracini D. Hyperammonemia in distal renal tubular acidosis: is it more common than we think? Clin Nephrol. 2007;68(2):109–14. 194. Seracini D, Poggi GM, Pela I. Hyperammonaemia in a child with distal renal tubular acidosis. Pediatr Nephrol. 2005;20(11):1645–7. 195. Miura K, Sekine T, Takahashi K, Takita J, Harita Y, Ohki K, et al. Mutational analyses of the ATP6V1B1 and ATP6V0A4 genes in patients with primary distal renal tubular acidosis. Nephrol Dial Transplant. 2013;28(8):2123–30. 196. Batlle D, Moorthi KM, Schlueter W, Kurtzman N. Distal renal tubular acidosis and the potassium enigma. Semin Nephrol. 2006;26(6):471–8. 197. Sebastian A, McSherry E, Morris Jr RC. Renal potassium wasting in renal tubular acidosis (RTA): its occurrence in types 1 and 2 RTA despite sustained correction of systemic acidosis. J Clin Invest. 1971;50(3):667–78. 198. Muto S, Asano Y, Okazaki H, Kano S. Renal potassium wasting in distal renal tubular acidosis: role of aldosterone. Intern Med. 1992;31(8):1047–51. 199. Bresolin NL, Grillo E, Fernandes VR, Carvalho FL, Goes JE, da Silva RJ. A case report and review of hypokalemic paralysis secondary to renal tubular acidosis. Pediatr Nephrol. 2005;20(6):818–20. 200. Siamopoulos KC, Elisaf M, Drosos AA, Mavridis AA, Moutsopoulos HM. Renal tubular acidosis in primary Sjogren’s syndrome. Clin Rheumatol. 1992;11(2): 226–30. 201. Siamopoulos KC, Elisaf M, Moutsopoulos HM. Hypokalaemic paralysis as the presenting manifestation of primary Sjogren’s syndrome. Nephrol Dial Transplant. 1994;9(8):1176–8. 202. von Vigier RO, Ortisi MT, La Manna A, Bianchetti MG, Bettinelli A. Hypokalemic rhabdomyolysis in congenital tubular disorders: a case series and a systematic review. Pediatr Nephrol. 2010;25 (5):861–6. 203. Gallagher PG. Red cell membrane disorders. Hematol Am Soc Hematol Educ Progr. 2005;2005:13–8. 204. Tanner MJ. The structure and function of band 3 (AE1): recent developments (review). Mol Membr Biol. 1997;14(4):155–65. 205. Bruce LJ, Beckmann R, Ribeiro ML, Peters LL, Chasis JA, Delaunay J, et al. A band 3-based macrocomplex of integral and peripheral proteins in the RBC membrane. Blood. 2003;101(10):4180–8. 206. Bruce LJ. Red cell membrane transport abnormalities. Curr Opin Hematol. 2008;15(3):184–90. 207. Guizouarn H, Martial S, Gabillat N, Borgese F. Point mutations involved in red cell stomatocytosis convert the electroneutral anion exchanger 1 to a nonselective cation conductance. Blood. 2007;110(6):2158–65.

39

Renal Tubular Acidosis in Children

208. Bruce LJ, Ring SM, Ridgwell K, Reardon DM, Seymour CA, Van Dort HM, et al. South-East Asian ovalocytic (SAO) erythrocytes have a cold sensitive cation leak: implications for in vitro studies on stored SAO red cells. Biochim Biophys Acta. 1999;1416 (1–2):258–70. 209. Bruce LJ, Cope DL, Jones GK, Schofield AE, Burley M, Povey S, et al. Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene. J Clin Invest. 1997;100(7):1693–707. 210. Karet FE, Gainza FJ, Gyory AZ, Unwin RJ, Wrong O, Tanner MJ, et al. Mutations in the chloridebicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis. Proc Natl Acad Sci USA. 1998;95(11):6337–42. 211. Khositseth S, Sirikanaerat A, Khoprasert S, Opastirakul S, Kingwatanakul P, Thongnoppakhun W, et al. Hematological abnormalities in patients with distal renal tubular acidosis and hemoglobinopathies. Am J Hematol. 2008;83(6):465–71. 212. Wrong O, Bruce LJ, Unwin RJ, Toye AM, Tanner MJ. Band 3 mutations, distal renal tubular acidosis, and Southeast Asian ovalocytosis. Kidney Int. 2002;62(1):10–9. 213. Yenchitsomanus PT. Human anion exchanger1 mutations and distal renal tubular acidosis. Southeast Asian J Trop Med Public Health. 2003;34(3):651–8. 214. Yenchitsomanus PT, Sawasdee N, Paemanee A, Keskanokwong T, Vasuvattakul S, Bejrachandra S, et al. Anion exchanger 1 mutations associated with distal renal tubular acidosis in the Thai population. J Hum Genet. 2003;48(9):451–6. 215. Khositseth S, Bruce LJ, Walsh SB, Bawazir WM, Ogle GD, Unwin RJ, et al. Tropical distal renal tubular acidosis: clinical and epidemiological studies in 78 patients. QJM. 2012;105(9):861–77. 216. Fry AC, Karet FE. Inherited renal acidoses. Physiology (Bethesda). 2007;22:202–11. 217. Karet FE. Inherited distal renal tubular acidosis. J Am Soc Nephrol. 2002;13(8):2178–84. 218. Karet FE, Finberg KE, Nelson RD, Nayir A, Mocan H, Sanjad SA, et al. Mutations in the gene encoding B1 subunit of H+ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet. 1999;21(1):84–90. 219. Lang F, Vallon V, Knipper M, Wangemann P. Functional significance of channels and transporters expressed in the inner ear and kidney. Am J Physiol Cell Physiol. 2007;293(4):C1187–208. 220. Peters TA, Monnens LA, Cremers CW, Curfs JH. Genetic disorders of transporters/channels in the inner ear and their relation to the kidney. Pediatr Nephrol. 2004;19(11):1194–201. 221. Gil H, Santos F, Garcia E, Alvarez MV, Ordonez FA, Malaga S, et al. Distal RTA with nerve deafness: clinical spectrum and mutational analysis in five children. Pediatr Nephrol. 2007;22(6):825–8.

1303 222. Stover EH, Borthwick KJ, Bavalia C, Eady N, Fritz DM, Rungroj N, et al. Novel ATP6V1B1 and ATP6V0A4 mutations in autosomal recessive distal renal tubular acidosis with new evidence for hearing loss. J Med Genet. 2002;39(11):796–803. 223. Bajaj G, Quan A. Renal tubular acidosis and deafness: report of a large family. Am J Kidney Dis. 1996;27 (6):880–2. 224. Fuster DG, Zhang J, Xie XS, Moe OW. The vacuolarATPase B1 subunit in distal tubular acidosis: novel mutations and mechanisms for dysfunction. Kidney Int. 2008;73(10):1151–8. 225. Smith AN, Skaug J, Choate KA, Nayir A, Bakkaloglu A, Ozen S, et al. Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing. Nat Genet. 2000;26(1):71–5. 226. Li SL, Liou LB, Fang JT, Tsai WP. Symptomatic renal tubular acidosis (RTA) in patients with systemic lupus erythematosus: an analysis of six cases with new association of type 4 RTA. Rheumatology (Oxford). 2005;44(9):1176–80. 227. Lorente-Canovas B, Ingham N, Norgett EE, Golder ZJ, Karet Frankl FE, Steel KP. Mice deficient in H+ATPase a4 subunit have severe hearing impairment associated with enlarged endolymphatic compartments within the inner ear. Dis Model Mech. 2013;6(2):434–42. 228. Norgett EE, Golder ZJ, Lorente-Canovas B, Ingham N, Steel KP, Karet Frankl FE. Atp6v0a4 knockout mouse is a model of distal renal tubular acidosis with hearing loss, with additional extrarenal phenotype. Proc Natl Acad Sci USA. 2012;109(34): 13775–80. 229. Fabris A, Anglani F, Lupo A, Gambaro G. Medullary sponge kidney: state of the art. Nephrol Dial Transplant. 2013;28(5):1111–9. 230. Carboni I, Andreucci E, Caruso MR, Ciccone R, Zuffardi O, Genuardi M, et al. Medullary sponge kidney associated with primary distal renal tubular acidosis and mutations of the H+ATPase genes. Nephrol Dial Transplant. 2009;24(9):2734–8. 231. Stehberger PA, Shmukler BE, Stuart-Tilley AK, Peters LL, Alper SL, Wagner CA. Distal renal tubular acidosis in mice lacking the AE1 (band3) Cl/HCO3 exchanger (slc4a1). J Am Soc Nephrol. 2007; 18(5):1408–18. 232. Blomqvist SR, Vidarsson H, Fitzgerald S, Johansson BR, Ollerstam A, Brown R, et al. Distal renal tubular acidosis in mice that lack the forkhead transcription factor Foxi1. J Clin Invest. 2004;113(11):1560–70. 233. Cohen EP, Bastani B, Cohen MR, Kolner S, Hemken P, Gluck SL. Absence of H(+)-ATPase in cortical collecting tubules of a patient with Sjogren’s syndrome and distal renal tubular acidosis. J Am Soc Nephrol. 1992;3(2):264–71. 234. Pertovaara M, Korpela M, Kouri T, Pasternack A. The occurrence of renal involvement in primary Sjogren’s

1304 syndrome: a study of 78 patients. Rheumatology (Oxford). 1999;38(11):1113–20. 235. Bagga A, Jain Y, Srivastava RN, Bhuyan UN. Renal tubular acidosis preceding systemic lupus erythematosus. Pediatr Nephrol. 1993;7(6):735–6. 236. Caruana RJ, Barish CF, Buckalew Jr VM. Complete distal renal tubular acidosis in systemic lupus: clinical and laboratory findings. Am J Kidney Dis. 1985;6(1): 59–63. 237. Konishi K, Hayashi M, Saruta T. Renal tubular acidosis with autoantibody directed to renal collectingduct cells. N Engl J Med. 1994;331(23):1593–4. 238. Schwarz C, Benesch T, Kodras K, Oberbauer R, Haas M. Complete renal tubular acidosis late after kidney transplantation. Nephrol Dial Transplant. 2006;21(9):2615–20. 239. McCurdy DK, Frederic M, Elkinton JR. Renal tubular acidosis due to amphotericin B. N Engl J Med. 1968;278(3):124–30. 240. Roscoe JM, Goldstein MB, Halperin ML, Schloeder FX, Stinebaugh BJ. Effect of amphotercin B on urine acidification in rats: implications for the pathogenesis of distal renal tubular acidosis. J Lab Clin Med. 1977;89(3):463–70. 241. Stinebaugh BJ, Schloeder FX, Tam SC, Goldstein MB, Halperin ML. Pathogenesis of distal renal tubular acidosis. Kidney Int. 1981;19(1):1–7. 242. Hoorn EJ, Zietse R. Combined renal tubular acidosis and diabetes insipidus in hematological disease. Nat Clin Pract Nephrol. 2007;3(3):171–5. 243. Navarro JF, Quereda C, Gallego N, Antela A, Mora C, Ortuno J. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis. 1996;27(3):431–4. 244. Roscoe JM, Goldstein MB, Halperin ML, Wilson DR, Stinebaugh BJ. Lithium-induced impairment of urine acidification. Kidney Int. 1976;9(4):344–50. 245. Seikaly M, Browne R, Baum M. Nephrocalcinosis is associated with renal tubular acidosis in children with X-linked hypophosphatemia. Pediatrics. 1996;97(1): 91–3. 246. Bonilla-Felix M, Villegas-Medina O, Vehaskari VM. Renal acidification in children with idiopathic hypercalciuria. J Pediatr. 1994;124(4):529–34. 247. Nilwarangkur S, Nimmannit S, Chaovakul V, Susaengrat W, Ong-aj-Yooth S, Vasuvattakul S, et al. Endemic primary distal renal tubular acidosis in Thailand. Q J Med. 1990;74(275):289–301. 248. Dafnis E, Spohn M, Lonis B, Kurtzman NA, Sabatini S. Vanadate causes hypokalemic distal renal tubular acidosis. Am J Physiol. 1992;262(3 Pt 2):F449–53. 249. Carlisle EJ, Donnelly SM, Vasuvattakul S, Kamel KS, Tobe S, Halperin ML. Glue-sniffing and distal renal tubular acidosis: sticking to the facts. J Am Soc Nephrol. 1991;1(8):1019–27. 250. Vainsel M, Fondu P, Cadranel S, Rocmans C, Gepts W. Osteopetrosis associated with proximal and distal tubular acidosis. Acta Paediatr Scand. 1972;61 (4):429–34.

R. Quigley and M.T.F. Wolf 251. Borthwick KJ, Kandemir N, Topaloglu R, Kornak U, Bakkaloglu A, Yordam N, et al. A phenocopy of CAII deficiency: a novel genetic explanation for inherited infantile osteopetrosis with distal renal tubular acidosis. J Med Genet. 2003;40(2):115–21. 252. Nagai R, Kooh SW, Balfe JW, Fenton T, Halperin ML. Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification. Pediatr Nephrol. 1997;11 (5):633–6. 253. Del Fattore A, Cappariello A, Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone. 2008;42(1):19–29. 254. Karet FE. Mechanisms in hyperkalemic renal tubular acidosis. J Am Soc Nephrol. 2009;20(2):251–4. 255. Wagner CA, Geibel JP. Acid–base transport in the collecting duct. J Nephrol. 2002;15 Suppl 5:S112–27. 256. Sartorius OW, Calhoon D, Pitts RF. The capacity of the adrenalectomized rat to secrete hydrogen and ammonium ions. Endocrinology. 1952;51(5):444–50. 257. Sartorius OW, Calhoon D, Pitts RF. Studies on the interrelationships of the adrenal cortex and renal ammonia excretion by the rat. Endocrinology. 1953;52(3):256–65. 258. Welbourne TC, Francoeur D. Influence of aldosterone on renal ammonia production. Am J Physiol. 1977;233(1):E56–60. 259. DuBose Jr TD. Hyperkalemic hyperchloremic metabolic acidosis: pathophysiologic insights. Kidney Int. 1997;51(2):591–602. 260. DuBose Jr TD. Molecular and pathophysiologic mechanisms of hyperkalemic metabolic acidosis. Trans Am Clin Climatol Assoc. 2000;111:122–33; discussion 33–4. 261. White PC, New MI, Dupont B. Congenital adrenal hyperplasia (2). N Engl J Med. 1987;316(25):1580–6. 262. White PC, New MI, Dupont B. Congenital adrenal hyperplasia. (1). N Engl J Med. 1987;316(24): 1519–24. 263. White PC. Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinol Metab Clin North Am. 2001;30(1):61–79, vi. 264. Geller DS, Rodriguez-Soriano J, Vallo Boado A, Schifter S, Bayer M, Chang SS, et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet. 1998;19(3):279–81. 265. Chang SS, Grunder S, Hanukoglu A, Rosler A, Mathew PM, Hanukoglu I, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet. 1996;12(3): 248–53. 266. Gordon RD. Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. Hypertension. 1986;8(2):93–102. 267. Schambelan M, Sebastian A, Rector Jr FC. Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): role of

39

Renal Tubular Acidosis in Children

increased renal chloride reabsorption. Kidney Int. 1981;19(5):716–27. 268. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, et al. Human hypertension caused by mutations in WNK kinases. Science. 2001;293(5532):1107–12. 269. Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, et al. Mutations in Kelch-like 3 and Cullin 3 cause hypertension and electrolyte abnormalities. Nature. 2012;482(7383):98–102. 270. Louis-Dit-Picard H, Barc J, Trujillano D, MisereyLenkei S, Bouatia-Naji N, Pylypenko O, et al. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet. 2012;44(4):456–60, S1-3. 271. Shibata S, Zhang J, Puthumana J, Stone KL, Lifton RP. Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4. Proc Natl Acad Sci USA. 2013;110(19): 7838–43. 272. Tsuji S, Yamashita M, Unishi G, Takewa R, Kimata T, Isobe K, et al. A young child with pseudohypoaldosteronism type II by a mutation of Cullin 3. BMC Nephrol. 2013;14:166. 273. Knochel JP. The syndrome of hyporeninemic hypoaldosteronism. Annu Rev Med. 1979;30: 145–53. 274. Sebastian A, Schambelan M, Lindenfeld S, Morris Jr RC. Amelioration of metabolic acidosis with fludrocortisone therapy in hyporeninemic hypoaldosteronism. N Engl J Med. 1977;297(11): 576–83. 275. Kristjansson K, Laxdal T, Ragnarsson J. Type 4 renal tubular acidosis (sub-type 2) associated with idiopathic interstitial nephritis. Acta Paediatr Scand. 1986;75(6):1051–4. 276. Keven K, Ozturk R, Sengul S, Kutlay S, Ergun I, Erturk S, et al. Renal tubular acidosis after kidney transplantation–incidence, risk factors and clinical implications. Nephrol Dial Transplant. 2007;22(3): 906–10. 277. Olyaei AJ, de Mattos AM, Bennett WM. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. Drug Saf. 1999;21(6): 471–88. 278. Bagga A, Bajpai A, Menon S. Approach to renal tubular disorders. Indian J Pediatr. 2005;72(9):771–6. 279. Bagga A, Sinha A. Evaluation of renal tubular acidosis. Indian J Pediatr. 2007;74(7):679–86. 280. Soriano RJ. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002;13(8):2160–70. 281. Rodriguez-Soriano J, Vallo A. Renal tubular acidosis. Pediatr Nephrol. 1990;4(3):268–75. 282. Adedoyin O, Gottlieb B, Frank R, Vento S, Vergara M, Gauthier B, et al. Evaluation of failure to thrive: diagnostic yield of testing for renal tubular acidosis. Pediatrics. 2003;112(6 Pt 1):e463. 283. Emmett M, Narins RG. Clinical use of the anion gap. Medicine. 1977;56(1):38–54.

1305 284. Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol. 2007;2(1):162–74. 285. Kraut JA, Madias NE. Differential diagnosis of nongap metabolic acidosis: value of a systematic approach. Clin J Am Soc Nephrol. 2012;7(4):671–9. 286. Oh MS, Carroll HJ. The anion gap. N Engl J Med. 1977;297(15):814–7. 287. Kraut JA, Madias NE. Approach to patients with acid–base disorders. Respir Care. 2001;46(4): 392–403. 288. Batlle DC, Hizon M, Cohen E, Gutterman C, Gupta R. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med. 1988;318(10):594–9. 289. Dyck RF, Asthana S, Kalra J, West ML, Massey KL. A modification of the urine osmolal gap: an improved method for estimating urine ammonium. Am J Nephrol. 1990;10(5):359–62. 290. Goldstein MB, Bear R, Richardson RM, Marsden PA, Halperin ML. The urine anion gap: a clinically useful index of ammonium excretion. Am J Med Sci. 1986;292(4):198–202. 291. Halperin ML, Margolis BL, Robinson LA, Halperin RM, West ML, Bear RA. The urine osmolal gap: a clue to estimate urine ammonium in “hybrid” types of metabolic acidosis. Clin Invest Med. 1988;11 (3):198–202. 292. Kim GH, Han JS, Kim YS, Joo KW, Kim S, Lee JS. Evaluation of urine acidification by urine anion gap and urine osmolal gap in chronic metabolic acidosis. Am J Kidney Dis. 1996;27(1):42–7. 293. Richardson RM, Halperin ML. The urine pH: a potentially misleading diagnostic test in patients with hyperchloremic metabolic acidosis. Am J Kidney Dis. 1987;10(2):140–3. 294. Kirschbaum B, Sica D, Anderson FP. Urine electrolytes and the urine anion and osmolar gaps. J Lab Clin Med. 1999;133(6):597–604. 295. Sulyok E, Guignard JP. Relationship of urinary anion gap to urinary ammonium excretion in the neonate. Biol Neonate. 1990;57(2):98–106. 296. DuBose Jr TD, Caflisch CR. Validation of the difference in urine and blood carbon dioxide tension during bicarbonate loading as an index of distal nephron acidification in experimental models of distal renal tubular acidosis. J Clin Invest. 1985;75(4): 1116–23. 297. Kim S, Lee JW, Park J, Na KY, Joo KW, Ahn C, et al. The urine-blood PCO gradient as a diagnostic index of H(+)-ATPase defect distal renal tubular acidosis. Kidney Int. 2004;66(2):761–7. 298. Lin JY, Lin JS, Tsai CH. Use of the urine-to-blood carbon dioxide tension gradient as a measurement of impaired distal tubular hydrogen ion secretion among neonates. J Pediatr. 1995;126(1):114–7. 299. Walsh SB, Shirley DG, Wrong OM, Unwin RJ. Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: an

1306 alternative to ammonium chloride. Kidney Int. 2007;71(12):1310–6. 300. Kleta R, Bernardini I, Ueda M, Varade WS, Phornphutkul C, Krasnewich D, et al. Long-term follow-up of well-treated nephropathic cystinosis patients. J Pediatr. 2004;145(4):555–60. 301. Kleta R, Gahl WA. Pharmacological treatment of nephropathic cystinosis with cysteamine. Expert Opin Pharmacother. 2004;5(11):2255–62. 302. Kleta R, Kaskel F, Dohil R, Goodyer P, Guay-Woodford LM, Harms E, et al. First NIH/office of rare diseases conference on cystinosis: past, present, and future. Pediatr Nephrol. 2005;20(4): 452–4. 303. Schneider JA. Treatment of cystinosis: simple in principle, difficult in practice. J Pediatr. 2004;145(4): 436–8.

R. Quigley and M.T.F. Wolf 304. Domrongkitchaiporn S, Khositseth S, Stitchantrakul W, Tapaneya-olarn W, Radinahamed P. Dosage of potassium citrate in the correction of urinary abnormalities in pediatric distal renal tubular acidosis patients. Am J Kidney Dis. 2002;39(2):383–91. 305. Tapaneya-Olarn W, Khositseth S, Tapaneya-Olarn C, Teerakarnjana N, Chaichanajarernkul U, Stitchantrakul W, et al. The optimal dose of potassium citrate in the treatment of children with distal renal tubular acidosis. J Med Assoc Thai. 2002;85 Suppl 4: S1143–9. 306. Morris Jr RC, Sebastian A. Alkali therapy in renal tubular acidosis: who needs it? J Am Soc Nephrol. 2002;13(8):2186–8. 307. Kennedy Jr TJ, Orloff J, Berliner RW. Significance of carbon dioxide tension in urine. Am J Physiol. 1952;169(3):596–608.

Nephrogenic Diabetes Insipidus in Children

40

Nine V. A. M. Knoers and Elena N. Levtchenko

Contents

History

History . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1307 Definition and Clinical Manifestations . . . . . . . . . . 1307 Diagnostic Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1309 Cellular Physiology of Arginine Vasopressin’s Antidiuretic Action in the Distal Nephron . . . . . . 1309 Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1312 X-Linked Nephrogenic Diabetes Insipidus: Mutations in the AVPR2 Gene . . . . . . . . . . . . . . . . . . . 1312 Genotype-Phenotype Correlations in X-Linked NDI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1314 The Autosomal Recessive and Autosomal Dominant Forms of Nephrogenic Diabetes Insipidus: Mutations in the Aquaporin-2 Water Channel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1314 Differential Diagnosis Between the X-Linked and the Autosomal Forms of NDI . . . . . . . . . . . . . . . . . . 1316 Nephrogenic Diabetes Insipidus in Females . . . . . 1317 Acquired Nephrogenic Diabetes Insipidus . . . . . . 1317 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1318 Conventional Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1318

First familial cases with diabetes insipidus were described by McIlraith in 1892; however, he did not distinguish between renal and neurohormonal forms of the disorder [1]. The renal type of diabetes insipidus was appreciated as a separate entity more than 50 years ago, when it was described independently by two investigators: Forssman [2] in Sweden and Waring et al. [3] in the United States. In 1947, Williams and Henry [4] noticed that injection of antidiuretic hormone (ADH) in doses sufficient to induce systemic side effects could not correct the renal concentrating defect. They coined the term nephrogenic diabetes insipidus. Subsequent studies revealed active hormone in the serum and urine of affected persons and lent further support to the theory of renal unresponsiveness to vasopressin. Nephrogenic diabetes insipidus is synonymous with the terms vasopressin- or ADH-resistant diabetes insipidus and diabetes insipidus renalis.

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1321

Definition and Clinical Manifestations N.V.A.M. Knoers (*) Departments of Medical Genetics, University Medical Centre Utrecht, Utrecht, The Netherlands e-mail: [emailprotected] E.N. Levtchenko Department of Pediatric Nephrology, Department of Growth and Regeneration, University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium e-mail: [emailprotected] # Springer-Verlag Berlin Heidelberg 2016 E.D. Avner et al. (eds.), Pediatric Nephrology, DOI 10.1007/978-3-662-43596-0_36

Congenital nephrogenic diabetes insipidus (NDI) is a rare inherited disorder, characterized by insensitivity of the distal nephron to the antidiuretic effects of the neurohypophyseal hormone arginine vasopressin (AVP). As a consequence, the kidney loses its ability to concentrate urine, which may lead to severe dehydration and electrolyte 1307

1308

imbalance (hypernatremia and hyperchloremia). Patients with NDI have normal birth weight and pregnancies are not complicated by polyhydramnios. The urine-concentrating defect in NDI is present from birth, and manifestations of the disorder generally emerge within the first weeks of life. With breast milk feedings, infants usually thrive and do not develop signs of dehydration. This is because human milk has a low salt and protein content and therefore a low renal osmolar load. With cows’ milk formula feedings, the osmolar load to the kidney increases, resulting in an increased demand for free water. This is usually not provided by oral feeding, and therefore hypernatremic dehydration appears. Irritability, poor feeding, and poor weight gain are usually the initial symptoms [5]. Patients are eager to suck but may vomit during or shortly after the feeding. Dehydration is evidenced by dryness of the skin, loss of normal skin turgor, recessed eyeballs, increased periorbital folding, depression of the anterior fontanel, and a scaphoid abdomen. Intermittent high fever is a common complication of the dehydrated state, predominantly in very young children. Body temperature can be normalized by rehydration. Seizures can occur but are rare and most often seen during therapy, particularly if rehydration proceeds too rapidly. Constipation is a common symptom in children with NDI. Nocturia and nocturnal enuresis are common complaints later in childhood. Untreated, most patients fail to grow normally. In a retrospective study of 30 male NDI patients, most children grew below the 50th percentile, most of them having standard deviation (SD) scores lower than 1 [6]. Some well-treated patients, however, may achieve normal adult height. Catch-up growth occurs at least in some patients after normalization of water and electrolyte balance, especially in those with adherence to treatment. Bone maturation is generally not delayed [7]. Weight-for-height SD scores are initially low, followed by global normalization at school age [6]. Initial feeding problems and the ingestion of large amounts of low-caloric fluid resulting in a decreased appetite may play roles in failure to thrive seen in NDI [8, 9].

N.V.A.M. Knoers and E.N. Levtchenko

Furthermore, it is possible that repeated episodes of dehydration have some as yet undetermined negative effects on growth. Mental retardation has long been considered an important complication of untreated NDI and assumed to be a sequel of recurrent episodes of severe brain dehydration and cerebral edema caused by overzealous attempts at rehydration [10–12]. Additional evidence underscoring the assumption that NDI has adverse effects on the cerebrum is provided by several reports describing intracranial calcifications in NDI patients [13, 14]. Such lesions are generally considered to be the result of hemorrhage or necrosis. Most of the reported patients with cerebral calcifications were mentally retarded. Nowadays mental retardation is rare due to earlier recognition and treatment of NDI. Exact estimates of the current frequency of mental retardation under modern treatment are unknown, but in the largest psychometric study ever reported, only 2 of the 17 male NDI patients (aged 3–30 years) had a total intelligence quotient more than 2 SD below the norm. Fourteen patients had an intelligence score within or above the normal range and one patient had a general index score between 1 and 2 SD [15]. The psychological development of NDI patients is influenced by a persistent desire for drinking and the need for frequent voiding, which compete with playing and learning. Therefore, many NDI patients are characterized by hyperactivity, distractibility, short attention span, and restlessness. In the psychometric study mentioned earlier, the criteria for attention-deficit/ hyperactivity disorder were met in 8 of 17 tested NDI patients [15]. Persistent polyuria can result in the development of megacystis, trabeculated bladder wall, hydroureter, and hydronephrosis [6, 16, 17]. Urinary tract distension may be seen on ultrasound examination even in infants [18] and young children [19]. Potential complications of urinary tract dilatation are rupture of the urinary tract, infection, intractable pain, improper bladder function, and/or kidney failure. These complications may occur as early as the second decade of life. Large-capacity hypotonic bladder

40

Nephrogenic Diabetes Insipidus in Children

Table 1 Causes of secondary nephrogenic diabetes insipidus Monogenetic diseases associated with secondary NDI Renal Fanconi syndromes Bartter syndrome (type 1 or type 2) Familial hypomagnesemia with hypercalciuria and nephrocalcinosis Distal renal tubular acidosis (dRTA) Apparent mineralocorticoid excess (AME) Ciliopathies (nephronophthisis, Bardet–Biedl syndrome, etc.) Other renal diseases Obstructive uropathy Renal dysplasia Postischemic damage Amyloidosis Sarcoidosis Chronic renal failure Renal impairment in sickle-cell disease or trait Drug induced Lithium Ifosfamide Amphotericin B Tetracyclines Biochemical abnormalities Hypercalcemia, hypercalciuria, and nephrocalcinosis Hypokalemia

dysfunction might require clean intermittent catheterization [17]. Patients should be trained to void regularly in order to assure that maximal urinary bladder capacity remains within normal range. Both patient groups with AVPR2 and AQP2 mutations can develop urinary tract dilatation and bladder dysfunction [16, 20].

Diagnostic Procedures The observation of polyuria in a dehydrated infant, together with the finding of a high serum sodium concentration and inappropriately diluted urine (Uosm < Posm), provides presumptive evidence for a renal concentrating defect. To confirm the concentrating defect and to distinguish the renal form of diabetes insipidus from the central form, a vasopressin test is performed with 1-desamino-8-D-arginine vasopressin (DDAVP),

1309

a synthetic analogue of the natural arginine vasopressin that produces a high and prolonged antidiuretic effect. In the test, DDAVP (10 μg for infants 1 year old) is administered intranasally. Urine is collected during the subsequent 5.5 h. The first collected portion of the urine should be discarded. The maximal urine osmolality in any collected aliquot is chosen as a measure of the concentrating capacity [21]. After DDAVP administration, NDI patients are (1) unable to increase urinary osmolality, which remains below 200 mOsm/kg H2O (normal values: 600, between 1 and 2 years old between 600 and 800, >2 years old >800 mOsm/kg H2O), and (2) cannot reduce urine volume or free-water clearance. Plasma vasopressin levels are normal or only slightly increased in affected children. Other laboratory findings have been described, which mainly result from chronic dehydration. Serum sodium concentration is generally elevated and may be above 170 mmol/L. There is also an increase in serum chloride concentration and retention of urea and creatinine. All values are normalized by adequate rehydration. In addition, reduced glomerular filtration rate (GFR) and renal blood flow can return to normal when a normal hydration state has been achieved. The primary congenital form of NDI has to be differentiated from central diabetes insipidus (due to lack of AVP) and from the secondary or acquired forms, which are much more common [22]. In our experience, the urinary osmolality obtained after DDAVP administration in secondary disorders is always higher than in NDI. Several secondary causes, some of which will be discussed later, are listed in Table 1.

Cellular Physiology of Arginine Vasopressin’s Antidiuretic Action in the Distal Nephron The physiologic action of vasopressin on the renal collecting duct has been one of the most intensively studied processes in the kidney. Arginine vasopressin (AVP, ADH) is synthesized on the

1310

ribosomes of the magnocellular neurons of the supraoptic and paraventricular nuclei of the hypothalamus as a large biologically inactive bound form. Within storage granules, the hormone is cleaved into the biologically active form and transported down the neuronal axons to the posterior pituitary and stored there. Following appropriate stimuli, AVP is secreted from the posterior pituitary into the circulation as biologically active hormone. AVP release is regulated by changes in plasma osmolality (by >2 %) but can also occur in response to nonosmotic stimuli. These nonosmotic stimuli are generally related to changes in either total blood volume or the distribution of extracellular fluid. Patients with depleted effective circulating volume may secrete ADH even in the presence of low plasma osmolality. In addition, physical pain, emotional stress, and certain drugs (e.g., nicotine) influence the release of AVP. In its effector organ, the kidney, AVP binds to vasopressin type-2 (V2) receptors on the basolateral membrane of the principal inner medullary collecting duct cells and of the arcade cells (Fig. 1, review in Ref. [23]). The arcades are long, highly branched renal tubule segments that connect distal convoluted tubules of several deep and midcortical nephrons to the origin of cortical collecting ducts. Upon binding of AVP, the V2 receptor is activated and then stimulates GTP loading of the small GTPase-αGS – subunit of its coupled trimeric G-protein – eventually leading to dissociation of the G-protein from the receptor. GTP-αGS can then bind to the membraneassociated adenylate cyclase (AC), activating it, which results in an increase in intracellular cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). The elevated cAMP levels stimulate protein kinase A (PKA), leading to phosphorylation of AQP2 which in turn initiates a redistribution of aquaporin-2 (AQP2) water channels from intracellular vesicles to the apical plasma membrane, rendering this membrane water permeable. The increase in apical membrane permeability allows water to flow from the tubule lumen to the hypertonic medullary interstitium, via AQP2 in the apical membrane and via AQP3 and AQP4, constitutive water channels in the basolateral membrane. This then leads

N.V.A.M. Knoers and E.N. Levtchenko

to the formation of concentrated urine. Upon fluid intake, AVP release into the blood decreases, AQP2 is redistributed into intracellular vesicles, and water reabsorption is reduced. Katsura et al. have shown that the AVP-regulated recycling of AQP2 can occur at least six times with the same molecules [24]. In recent years, our knowledge of the AQP2 dynamics in the cell has increased significantly (Fig. 1). For further details the reader is also referred to several excellent reviews on this subject (review in Refs. [23, 25–28]). AQP2 is 1 of the 13 members of the aquaporin family of water channels. After transcription AQP2 is folded into its native monomeric conformation in the endoplasmic reticulum, and homotetramerization takes place [29]. The tetramers are forwarded to the Golgi apparatus, where two out of four monomers are complex N-glycosylated. These functional water channels are then stored in endosomal vesicles to be transported to the apical membrane [30]. Phosphorylation of a PKA-consensus site in AQP2, the serine at position 256 in the cytoplasmic carboxy-terminus, is absolutely essential for AQP2 delivery to the apical membrane [31, 32]. In addition, it has been shown that anchoring of PKA to PKA-anchoring proteins (AKAPs), which ensures targeting of PKA to AQP2-bearing vesicles, is another prerequisite for AVP-mediated AQP2 translocation [33]. Studies using oocytes as a model system indicated that for plasma membrane localization three out of four monomers in an AQP2 tetramer need to be phosphorylated [34]. PKA is the main kinase for AQP2 phosphorylation, but other kinases may potentially participate in the regulation of AQP2 trafficking. Besides PKA sites, putative phosphorylation sites for PKG, PKC, and casein kinase II are also present in the AQP2 sequence. The molecular machinery for the docking and fusion of AQP2-containing vesicles with the apical membrane is similar to the process of synaptic vesicle fusion with the presynaptic membrane and involves vesicle (v) SNAREs (soluble NSF attachment protein receptors) and target membrane (t) SNAREs. The apical membrane-specific t-SNARE is syntaxin 4, which interacts

40

Nephrogenic Diabetes Insipidus in Children

1311

Fig. 1 Intracellular signal transduction pathway initiated by AVP binding to V2R. Via activation of adenylate cyclase and cAMP-production stimulation, PKA is activated and phosphorylates its target proteins AQP2, Rho-GDI, and CREB-1. The transcription factor CREB1-p stimulates AQP2 transcription, Rho-GDI-p initiates actin reorganization required for AQP2 transport, and AQP2-p homotetramers are transported to the apical membrane. There they render the membrane permeable for water, which is reabsorbed from the passing pro-urine

and transported back into the bloodstream by AQP3 and AQP4. Rab5-mediated AQP2 endocytosis by clathrincoated vesicles is triggered by short-chain ubiquitination and leads to termination of the response. Internalized AQP2 vesicles are transported to early and late endosomes as well as multivesicular bodies (MVBs) for storage. From MVBs they can then either be lysosomally degraded or recycled via the Rab11-dependent slow-recycling pathway (From Ref. [23], with kind permission from Springer Science and Business Media)

specifically with the v-SNARE protein VAMP2 located on the cytoplasmic side of AQP2containing endosomal vesicles [35–38]. V- and t-SNAREs are recycled by the AAA-type ATPase

NSF. Reorganization of the actin cytoskeleton is another important mechanism required for AQP2 transport and accumulation at the apical membrane [39, 40]. The actin cytoskeleton most likely

1312

provides a network that anchors the AQP2bearing vesicles in the unstimulated cell. Vasopressin has been shown to depolymerize apical F-actin in rat inner medullary collecting duct, resulting in the fusion of AQP2-carrying vesicles with the apical membrane [41], indicating that reorganization of the apical actin network may be critical in promoting the trafficking of AQP2bearing vesicles. Rho inhibition through PKA-mediated phosphorylation of Rho-GDP dissociation inhibitor (Rho-GDI) is shown to be a key event for actin reorganization inducing AQP2 translocation [39, 40]. Counterbalancing increased expression on the plasma membrane, AQP2 is internalized. During this endocytotic process, AQP2 accumulates in clathrin-coated pits and is internalized via a clathrin-mediated process [42]. Endocytosis is regulated by short-chain ubiquitylation at lysine 270 (K270) in the AQP2 terminal tail [43, 44]. To be available for recycling, AQP2containing endosomes need to be redistributed to the perinuclear region. This process is mediated by dynein-dependent transport along microtubules [45, 46]. Specificity of the endocytotic AQP2 internalization is mediated by Rab5 protein, an effector-binding factor involved in plasma membrane-to-early-endosome transport [47]. From the endosomal system – early/late endosomes and/or multivesicular bodies (MVBs) – AQP2 is either recycled by the Rab11-dependent slow-recycling pathway or marked for lysosomal degradation [48]. Prolonged K270 ubiquitylation induces MVB trafficking and localization to internal vesicles of MVBs followed by lysosomal degradation, while deubiquitylation increases localization to early endosomes and the limiting membrane of MVBs and enables AQP2 recycling [44]. Long-term adaptation to circulating AVP levels, for instance, in a dehydrated state, is accomplished by increasing the expression of AQP2 mRNA and protein. PKA-mediated phosphorylation of a cAMP-responsive element-binding protein 1(CREB-1) stimulates synthesis of AQP2 by binding to the AQP2 gene promotor and activating its transcription, which increases intracellular AQP2 levels [49].

N.V.A.M. Knoers and E.N. Levtchenko

Genetics Three different inheritance patterns of NDI have been recognized. In most cases (about 90 %), NDI is transmitted as an X-linked recessive trait (MIM304800). In these families, female carriers who are usually unaffected transmit the disease to sons, who display the complete clinical picture [2, 4, 50]. In 1988, the major NDI locus was mapped to the distal region of the long arm of the X chromosome (Xq28) [51], and in 1992 mutations in the AVPR2 gene were shown to underlie X-linked NDI [52–54]. In a minority of families (about 10 %), the transmission and phenotypic characteristics of NDI are not compatible with an X-linked trait. In these families, females display the complete clinical picture of NDI and are clinically undistinguishable from affected male family members [55–57]. Family pedigrees suggested the existence of both an autosomal recessive (MIM 222000) and an autosomal dominant form (MIM 125800) of NDI. It was subsequently demonstrated that both autosomal forms of NDI are caused by mutations in the AVP-sensitive aquaporin-2 water channel [58, 59]. The prevalence of NDI is not exactly known, but the disease is assumed to be rare. The estimate of the prevalence of NDI in Quebec, Canada, is 8.8:1,000,000 males [60]. In the Dutch population of about 16 million, at least 50 different families are known.

X-Linked Nephrogenic Diabetes Insipidus: Mutations in the AVPR2 Gene The X-linked form of NDI is caused by inactivating mutations in the AVPR2 gene (MIM 300538) ([52–54], reviews in Refs. [23, 28, 61]). AVPR2 is a relatively small gene, consisting of three exons separated by two short intervening sequences (introns); two isoforms are known that are generated by alternative splicing [62]. AVPR2 is localized on the X chromosome on locus Xq28. The cDNA encodes a receptor protein of 371 amino acids, has a predicted molecular mass of approximately 40 kDa, and shares the general

40

Nephrogenic Diabetes Insipidus in Children

structure of a G-protein-coupled receptor consisting of seven hydrophobic transmembrane helices, connected by extracellular and intracellular loops. The receptor contains one unique consensus sequence site for N-linked glycosylation in the extracellular amino-terminus [63] and phosphorylation sites for G-protein-coupled receptor kinases (GRK) represented by a serine cluster in the carboxy-terminus [64, 65]. The N-terminal part of the protein including the first transmembrane domain and the positively charged first intracellular loop are important for proper insertion and orientation in the membrane [66]. A conserved glutamate-dileucine motif in the intracellular carboxy-terminal part of the receptor is essential for receptor transport from the endoplasmic reticulum (ER) to the Golgi apparatus [67]. Two conserved adjacent cysteines in the C-terminus are palmitoylated, thereby anchoring the carboxy tail to the plasma membrane and controlling the tertiary structure of this region of the receptor [68]. At this writing, more than 240 distinct disease-causing mutations in AVPR2 have been identified, and the number is constantly increasing ([69, 70] and review in Refs. [23, 28, 61] and www.hgmd.org). The mutations are not clustered in one domain of the V2 receptor but are scattered throughout the protein, except for the part coding for the N- and C-terminal tails of the receptor. More than 50 % of the mutations are missense mutations. Nucleotide deletions and insertions causing frameshifts (26 %), nonsense mutations (13 %), large deletions (7 %), large in-frame insertions/duplications (1 %), splice-site mutations (1 %), and complex rearrangements (2 %) account for the remainder of mutations ([12, 69], and review in Refs. [23, 28, 61, 71]). In addition to these disease-causing mutations, at least 21 AVPR2 variations that do not lead to disease are known. These non-disease-causing variations are most likely polymorphisms that can be found in more than 1 % of the population. The G12E mutation, for example, has also been found in non-affected individuals, suggesting that it belongs to this class of polymorphisms that do not exert a significant effect on proper functioning of the V2 receptor [72]. Several mutations are

1313

recurrent as evidenced by the fact that these mutations were found on different haplotypes in ancestrally independent families. The most frequent of these recurrent mutations (D85N, R106C, R113W, R137H, S167L, and R337X) occur at potential mutational hot spots. AVPR2 mutations seem to be present in all ethnical groups tested with no preference of one mutation for any ethnic group over others. The molecular mechanism underlying the renal insensitivity for AVP differs between mutants. As upcoming pharmacological treatments for NDI likely depend on the underlying mechanism, GPCR mutations in general and V2 mutations in particular have been divided in different classes according to their cellular fate [73, 74]. Class I comprises all mutations that lead to improperly processed or unstable mRNA, like promoter alterations, exon skipping, or aberrant splicing. This class also holds frameshift and nonsense mutations, which result in truncated proteins like W71X, 458delG (frameshift, 161X), and R337X. Class II mutations are missense or insertions/ deletions of one or more nucleotide triplets, resulting in fully translated proteins. Due to the mutation, however, mutant receptors are misfolded and retained in the endoplasmic reticulum (ER), as the ER is the organelle that has the cellular quality control over proper folding and maturation of synthesized proteins. Misfolded proteins are subsequently mostly targeted for proteasomal degradation [75]. Intracellular entrapment of missense V2R mutants and their rapid degradation likely represents the most important cause of NDI, as more than 50 % of the mutations in V2R are missense mutations and cellular expression revealed that most of these result in ER-retained proteins. The amount of retention and degradation varies within this class, since different mutations affect protein folding to a different extent, sometimes allowing partial transport of at least partially active receptors to the plasma membrane [76]. Class III mutations result in full-length receptors expressed at the cell surface, but interfere with proper interaction with their natural ligands, thereby causing reduced/abolished signaling [77].

1314

Class III mutations can be subdivided into two minor groups. IIIa mutations interfere with binding of or signal transduction to the coupled trimeric G-protein, leading to a reduced activation of adenylate cyclase and thus formation of cAMP. Mutations in this group are missense mutations and in-frame deletions, mostly located in transmembrane and intracellular domains. Examples are the D85N and P322S mutations [78]. IIIb mutations interfere with, or reduce, AVP binding. These mutations, which are also mostly missense and small in-frame deletions or insertions, especially involve residues thought to be in or close to the AVP-binding pocket, of which delR202 is a clear example [79]. Finally, class IV is assigned to all mutations that neither interfere with protein synthesis of maturation, not with ligand binding, but affect other aspects of protein function. The NDI R137H mutation, located in the well-conserved DRY/H motif of GPCRs, is the best-characterized example of this class. The effect of this mutation is constitutive internalization of V2, leading to reduced expression of the receptor in the plasma membrane and thereby reduced adenylate cyclase-dependent cAMP signaling upon AVP binding [80, 81]. Sometimes, mutants do not exert a full phenotype of a particular class and then often also show features of another class. For example, some V2R missense mutants are partially ER retained (class II), but are also partially expressed in the plasma membrane, where they might show a reduced G-protein coupling (class IIIa) or AVP binding (class IIIb). As such, it provides an explanation for the observed small antidiuretic response to high doses of DDAVP in NDI patients harboring such mutations [82].

N.V.A.M. Knoers and E.N. Levtchenko

manifestation, not at birth but later in childhood, and without growth retardation. Examples of mutations causing partial NDI are D85N, V88M, G201D, M311V, N317S, P322S, and S329R [83–86]. Functional studies of some of these mutations by in vitro expression systems have confirmed the partial phenotype of the NDI. P322S is the most remarkable of these three mutations, since another mutation substituting proline 322, namely, P322H, is associated with a severe phenotype. By in vitro expression of both P322H and P322S in COS-7 cells, Ala et al. [79] have shown that the P322H mutant had totally lost the ability to stimulate the Gs/adenylate cyclase system, whereas the P322S mutant was able to stimulate adenylate cyclase, albeit less than the wild-type receptor. Thus, the in vitro experiments closely correspond to the clinical phenotype. On the basis of threedimensional modeling of the P322H and P322S mutant receptors, a plausible hypothesis to explain the molecular basis for the mild phenotype of the P322S has been proposed. Based on this modeling, it is suggested that complete loss of function of the P322H receptor could be due, in part, to hydrogen bond formation between the His322 side chain and the carboxyl group of Asp85, which does not occur in the P322S receptor [79]. Intrafamilial variability of the X-linked NDI phenotype has also been described. A nice example is the case described by Kalenga et al., who reported a Belgian family in which the R137H mutation was associated with severe NDI in the proband but with very mild NDI in his affected brother [87]. Genetic and/or environmental modifying factors are likely to account for this intrafamilial phenotype variability.

The Autosomal Recessive and Autosomal Dominant Forms of Nephrogenic Diabetes Insipidus: Mutations in the Almost all mutations in the V2 receptor gene result Aquaporin-2 Water Channel Genotype-Phenotype Correlations in X-Linked NDI

in a uniform clinical NDI phenotype with polyuric manifestations in the first weeks of life and poor growth. There are, however, a few exceptions to this rule. Several mutations appear to be associated with a milder form of NDI, characterized by a later

Both the autosomal recessive and the autosomal dominant types of NDI are caused by mutations in the AQP2 water channel gene (MIM 107777; GenBank accession number z29491).

40

Nephrogenic Diabetes Insipidus in Children

The human AQP2 gene is a small gene consisting of 4 exons, comprising 5 kb genomic DNA. The 1,5 kb mRNA encodes a protein of 271 amino acids which has a predicted molecular weight of 29 kDa [88]. AQP2 belongs to a family of membrane integral proteins, aquaporins, which function as selective water transporters throughout the plant and animal kingdom. In mammals, 13 different aquaporins have been identified to date, 8 of which (aquaporins 1–4, 6–8, and 11) are highly expressed in the kidney. Like other aquaporins, AQP2 is assembled in the membrane as a homotetramer in which each 29 kDa monomer, consisting of six membrane-spanning α-helical domains and intracellular N- and C-termini, is a functional water channel. The six transmembrane domains are connected by five loops (A through E). The mechanism of selectivity for water of aquaporins in general has been revealed in the homologous AQP1 protein [89, 90] and has further been strengthened by molecular dynamics modeling approaches [91, 92] and was recently also confirmed for AQP2 [93]. The water pore is formed between the first and sixth transmembrane domains and is lined by the intracellular B-loop and the extracellular E-loop. AQP2 is exclusively localized in the apical membrane and a subapical compartment of collecting duct cells. It is upregulated by dehydration or AVP, indicating that it is the AVP-regulated water channel. To date, 46 putative disease-causing mutations in AQP2 have been identified in families with autosomal recessive NDI ([69, 70, 94–96], reviews in Refs. [23, 61, 71]). These include 38 missense mutations, 2 nonsense mutations, 3 small deletions, and 3 splice-site mutations. Most mutations are found between the first and last transmembrane domain of AQP2. Expression studies in Xenopus laevis oocytes have revealed that most AQP2 missense mutations that cause recessive NDI are class II mutations. Thus, these mutations lead to misfolding of the mutant protein, retention in the endoplasmic reticulum (ER), and rapid degradation of AQP2 (review in Refs. [23, 78]). In agreement with extensive degradation, AQP2 could not be detected in the urine of patients with recessive NDI [97]. When overexpressed in oocytes and Chinese hamster

1315

(CHO) cells, six of these AQP2 mutants (A147T, T126M, G64R, L22V, A47V, and T125M) confer water permeability [98, 99]. This indicates that at high expression levels, these AQP2 mutant proteins escape from the ER and are routed to the plasma membrane, where they are functional. In terms of possible treatment strategies, these results are of high importance, since they suggest that functional channels may be stimulated to reach the plasma membrane by restoring mutant trafficking (discussed later in treatment). One AQP2 missense mutation, P262L, located in the AQP2 C-terminal tail, a region until then believed to result in dominant NDI, surprisingly was found to be involved in recessive NDI [100]. In cell biological experiments, it was shown that the P262L mutant is a functional water channel that forms heterooligomers with wt-AQP2. These wt-AQP2/AQP2-P262L heterotetramers are located in the apical membrane, indicating that the apical sorting of wildtype AQP2 is dominant over the missorting signal of AQP2-P262L. This is different from dominant NDI, because in this form mutants retain wt-AQP2 in intracellular locations (see below). The recessive inheritance in the two patients encountered (patients were heterozygous for a R187C or A190T mutation on one allele, combined with a P262L mutation on the other allele) can be explained as follows: AQP2-R187C and AQP2-A190T are retained in the ER and do not interact with AQP2-P262L. AQP2-P262L folds properly and assembles in homotetramers, but will be retained mainly in intracellular vesicles. The consequent lack of sufficient AQP2 proteins in the apical membrane of the patients’ collecting duct cells explains their NDI phenotype. In the parents coding for wt-AQP2 and AQP2-R187C or AQP2-A190T, wt-AQP2 will not interact with either mutant but will form homotetrameric complexes, of which the insertion into the apical membrane will be regulated properly by vasopressin and will give a healthy phenotype. In the parents coding for wt-AQP2 and AQP2-P262L, both proteins likely assemble into heterotetramers. The dominancy of wt-AQP2 sorting on the localization of AQP2-P262L will result in proper AVP-regulated trafficking of the heterotetrameric

1316

complexes to the apical membrane and will also give a healthy phenotype [100]. At present ten families have been described with autosomal dominant NDI, initially uncovered due to father-to-son transmission of the disease. In these families subsequent sequencing of the AQP2 gene revealed putative disease-causing mutations of one AQP2 allele. The identified mutations in AQP2 comprise small deletions, insertions, and missense mutations ([69], review in Refs. [23, 101]). All mutations causing dominant NDI are located in the coding region of the C-terminal tail of AQP2, which is not part of the pore-forming segment but contains important sorting signals that govern intracellular transport of the protein [78, 102]. Indeed, all mutants AQP2 proteins found in dominant NDI appeared to be folded functional water channels that were sorted to other subcellular locations in the cell than wt-AQP2, e.g., late endosomes/lysosomes and the basolateral membrane. Because none of these mutants was misfolded, they were, in contrast to AQP2 mutants in recessive NDI, able to interact and form heterotetramers with wt-AQP2. Due to this wt-mutant interaction and the dominancy of the missorting signals in the mutant protein, the wt-mutant complexes are also missorted. Formation of heterotetramers with wt-AQP2 has been shown for most of the dominant AQP2 mutants. For instance, expression studies in polarized cell lines have revealed that the dominant AQP2E258K mutant is routed to the Golgi complex or late endosomes/lysosomes [59]. In co-expression studies with wild-type AQP2, a dominantnegative effect was observed, caused by impaired routing of wild-type AQP2 to the plasma membrane after hetero-oligomerization with the E258K mutant [103]. Mistargeting to the basolateral membrane has been reported for the AQP2-721delG, AQP2-763-772del, AQP2-812818del, and AQP2-779-780insA mutants [102, 104]. The AQP2-727delG mutant was shown to interfere with the routing of wild-type AQP2 to the apical membrane by its mistargeting to the basolateral membrane and late endosomes/lysosomes [104]. The loss of appropriate AQP2 heterotetramer trafficking in dominant NDI is

N.V.A.M. Knoers and E.N. Levtchenko

caused by several mechanisms. The phosphorylation site at Ser256, serving as an introducible apical sorting signal, may be inactivated, overruled by basolateral sorting signals, or reprogrammed to induce basolateral sorting, all causing intracellular misrouting ([105–108] and review in Ref. [23]). Dominant NDI patients have a milder phenotype when compared to milder recessive forms of NDI, suggesting that some wt-homotetramers are formed that are able to reach the apical membrane [103].

Differential Diagnosis Between the X-Linked and the Autosomal Forms of NDI With a few exceptions, no differences in clinical symptoms between X-linked and autosomal recessive forms of NDI can be observed, nor in the time of onset of the disease. Only in a minority of patients with the X-linked form of NDI, namely, those individuals carrying V2R mutations with partial insensitivity to AVP, the disease onset is not directly after birth but later in childhood. In general the initial symptoms in most autosomal dominant cases also appear later in childhood. Male patients with X-linked NDI can be discriminated from patients with autosomal recessive NDI on the basis of their extrarenal reaction to the intravenous administration of the synthetic V2-vasopressin analogue 1-desamino-8-D-arginine vasopressin (DDAVP). Patients with autosomal recessive NDI show a decrease in blood pressure, an accelerated heart rate, and an increase in von Willebrand factor, factor VIII, and tissuetype plasminogen activator levels, whereas in patients with X-linked NDI, these extrarenal responses are absent as a result of an extrarenal mutant V2R [109]. In female patients, the interpretation of this intravenous DDAVP test is more complicated. Although absence of the extrarenal responses to intravenous administration of DDAVP in females clearly points to the presence of a V2R defect, a normal response cannot be interpreted as indicative of a defect beyond the V2R and thus an AQP2 defect. For instance, a

40

Nephrogenic Diabetes Insipidus in Children

1317

symptomatic female patient described by Moses et al., who was shown to be heterozygous for a V2R mutation, showed a twofold increase in factor VIII activity after administration of DDAVP [110]. The discrepancy between the renal and extrarenal response to DDAVP in these female V2R mutation carriers might be explained by variability in the pattern of X-inactivation between different tissues.

In conclusion, clinical NDI phenotypes may correlate with the X-inactivation patterns in females with heterozygote V2R mutations. In some female carriers, however, the clinical phenotype cannot be predicted by evaluation of X-inactivation patterns in peripheral blood cells, probably due to the fact that X-inactivation ratios within an individual may vary between different tissues.

Nephrogenic Diabetes Insipidus in Females

Acquired Nephrogenic Diabetes Insipidus

Several families have been described in which females show classical clinical and laboratory features of NDI. After the identification of AQP2 mutations as a cause for autosomal recessive NDI, and in some cases for autosomal dominant NDI, a satisfying explanation for the complete manifestation of the disease in some females had been found. However, several families have been reported in which symptomatic females do not have an AQP2 defect but are heterozygous for a V2 receptor defect [111–114]. In some of these women, maximal urinary osmolality after DDAVP administration does not exceed 200 mosmol/L. Of interest, in some of the reported families, asymptomatic female family members shared the same V2 receptor mutation with the manifesting females [111, 115]. The most likely explanation for the existence of different phenotypes in carriers of a V2 receptor mutation, varying from no symptoms to complete manifestation of the disorder, is skewed X-inactivation [116]. This hypothesis was underlined by studies investigating the X-inactivation patterns in peripheral blood leukocytes of female carriers via the detection of a methylated trinucleotide repeat in the human androgen receptor gene [117]. In asymptomatic females random X-inactivation was found, while in most female carriers who showed clinical NDI symptoms, skewed X-inactivation patterns occurring preferentially to normal X alleles were recognized. In a few females with over clinical NDI, however, random X-inactivation was identified.

Although the hereditary forms of NDI are relatively rare, a wide range of pathologic conditions and drug treatments can lead to acquired NDI (Table 1). In our experience, the urine osmolality obtained after DDAVP administration in these acquired disorders is always higher than in congenital NDI. All these disorders have been shown to coincide with decreased expression of AQP2 or deregulated AQP2 trafficking to the apical membrane [118–123]. For instance, prolonged treatment with lithium, the drug of choice for treating bipolar disorders and prescribed to 1 in 1,000 of the population, leads to the development of NDI in at least 20% if treated individuals [124]. The development of lithium-NDI is believed to occur in two phases. In the first short-time phase, lithium causes a decrease in AQP2 expression ([125], review in Ref. [126]). Lithium enters the cells via epithelial sodium channel (ENaC) and accumulates in principal cells [125, 127]. How lithium downregulates AQP2 is not clear but likely involves glycogen synthase kinase type 3β, which is important in AVP-regulated antidiuresis and is inhibited by lithium [128–130]. Lithium also influences AQP2mediated water reabsorption by increased tubular release of prostaglandin E2 [129]. In the second phase, lithium reduces the percentage of principal cells in the collecting duct to the advantage of intercalated cells, involved in acid-base homeostasis [131]. The exact contribution of this collecting duct remodeling in the lithium-induced resistance to vasopressin remains to be elucidated.

1318

Treatment Conventional Treatment Symptomatic treatment of NDI is focused on establishing and maintaining normovolemia by replacing urinary water losses and reducing urinary volume. Adequate supply of fluid to prevent dehydration is the most important component of the therapy. For reducing urine output, a low-solute diet is applied to diminish the renal osmolar load and decrease obligatory water excretion [132]. Initially, a diet low in sodium (1 mmol/ kg per day) as well as protein (2 g/kg per day) was recommended. However, severe limitations of dietary protein may introduce serious nutritional deficiencies. Therefore, it is preferable to prescribe dietary restriction of sodium only. Diuretics such as hydrochlorothiazide (2–4 mg/kg per 24 h) were the first class of drugs shown to be effective in lowering the urine volume in NDI [133]. When combined with a reduction of salt intake, hydrochlorothiazide reduces urine volume by 20–50 % of baseline values. However, thiazide-induced hypokalemia may cause further impairment or urineconcentrating ability in patients with NDI. Another possible risk associated with hypokalemia is cardiac arrhythmia. Simultaneous administration of potassium salt is therefore advised in most cases. Very low daily sodium intake in combination with thiazide diuretics should be avoided to prevent the development of hyponatremia. There is ample evidence that the combined administration of hydrochlorothiazide with either a prostaglandin-synthesis inhibitor, such as indomethacin (2 mg/kg per 24 h), or the potassiumsparing diuretic amiloride, is much more effective in reducing urine volume than the thiazide diuretic alone [134–138]. Prolonged use of prostaglandinsynthesis inhibitors, however, is often complicated by gastrointestinal and hematopoietic side effects. Gastrointestinal complaints and complications include anorexia, nausea, vomiting, abdominal pain, ulceration, perforation, and hemorrhage. Hematopoietic reactions include neutropenia, thrombocytopenia, and, rarely, aplastic anemia.

N.V.A.M. Knoers and E.N. Levtchenko

In addition, renal dysfunction has been described during indomethacin therapy, most often consisting of a slight reduction in GFR. In patients, who are not tolerating indomethacin, selective inhibitors of cyclooxygenase-2 (COX-2) might be helpful [139]. Caution in using indomethacin and selective COX-2 inhibitors in NDI is warranted as their administration can potentially lead to the acute deterioration of renal function in dehydrated patients. Amiloride counterbalances the potassium loss from prolonged use of thiazides and thus prevents hypokalemia. Since amiloride appears to have only minor long-term side effects, the combination of hydrochlorothiazide (2–4 mg/kg/24 h) with amiloride (0.3 mg/kg/24 h) is the first choice of treatment. Our personal experience of more than 20 years with the amiloridehydrochlorothiazide combination, however, indicates that amiloride is less well tolerated in young children below the age of 4–6 years because of persistent nausea. Therefore we advise the temporary use of the combination of indomethacinhydrochlorothiazide in these young children. For a long time the following mechanism for the antidiuretic effect of thiazides in NDI has been proposed: thiazides reduce sodium reabsorption in the distal tubule by inhibition of the NaCl cotransporter (NCC). This subsequently results in increased sodium excretion, extracellular volume contraction, decreased glomerular filtration rate, and increased proximal sodium and water reabsorption. Consequently, less water and sodium reach the collecting tubules and less water is excreted [140, 141]. This long-standing hypothesis has been challenged by Magaldi, who reported new insights into the possible mechanism of action, based on microperfusion studies in rat inner medullary collecting duct (IMCD) [142, 143]. In these studies it was shown that in the absence of vasopressin, hydrochlorothiazide, when added to the luminal side, increased osmotic and diffusional water permeabilities, thus, decreasing water excretion. When prostaglandins were added, the effect of thiazides decreased. This finding may offer one explanation why indomethacin potentiates the effect of thiazides

40

Nephrogenic Diabetes Insipidus in Children

in NDI [143]. Antidiuretic effect of thiazides is associated with an increase in AQP2 expression in collecting duct cells [144]. Long-term side effects of chronic thiazide administration such as hyperuricemia, alterations in serum lipid spectrum, and glucose intolerance should be monitored. Although the drugs mentioned above reduce urine excretion, they are unable to achieve urine volumes produced in healthy individuals. Therefore the general problem remains, although the symptoms are relieved. Consequently, current research focuses on methods to treat NDI on a more causative level than solely try to fight the symptoms (Fig. 2; for detailed reviews [23, 28]).

Therapeutic Strategies for Treatment of X-Linked NDI Because in vitro expression studies reveal that the majority of AVPR2 mutations in X-linked NDI result in normal protein that is retained within the endoplasmic reticulum (ER), agents that restore plasma routing are under investigation as potential treatments. Promising agents are cellpermeable V2R antagonists and agonists that in vitro rescue the intracellular retention of several V2R mutants [145–148]. An important problem with the antagonists is that once the mutant V2R is rescued to the basolateral membrane, the antagonist needs to be displaced by high concentrations of AVP/DDAVP to induce cAMP signaling. Therefore, low-affinity antagonists are believed to have the highest clinical value. However, their efficiency in rescuing is lower than that of highaffinity ligands, and the high concentrations required to be administered for sufficient activity by low-affinity antagonists might lead to severe complications in patients. The use of non-peptide agonists has somewhat circumvented this problem since they do not need displacement to activate V2R. All high-affinity agonists have been shown to induce receptor maturation as well as translocation to the plasma membrane and to elicit a cAMP response [148]. The feasibility of treatment with these so-called pharmacologic “chaperones” has been tested in vivo. In individuals with NDI who have missense AVPR2 mutations, Bernier et al. showed

1319

that treatment with a non-peptide V1a receptor antagonist had beneficial effects on urine volume and osmolality starting a few hours after administration. However, the long-term effect of this drug could not be tested because the clinical development of this V1a receptor antagonist was interrupted during the course of this study as a result of possible interference with the cytochrome P450 metabolic pathway [147]. Remarkably, certain non-peptide V2R agonists, such as OPC51, VA88, and VA89, were shown to be able to intracellularly stimulate the V2R and increase cAMP production and AQP2 translocation to the apical membrane [149]. In contrast to pharmacochaperone-assisted folding and rescue of the receptors, the localization and maturation state of the V2R did not change upon activation, indicating that these compounds do not act as molecular chaperones. The mode of action by which receptors trapped intracellularly can still activate their coupled G-protein and how this stimulates adenylate cyclase is not yet understood. Future in vivo and clinical testing has to confirm whether the pharmacological chaperones and the intracellularly acting non-peptide agonists have the desired positive effects in patients and meet the safety requirements. In patients with X-linked NDI, bypassing the V2R could be an alternative way to treat the disease. By stimulation of the E-prostanoid receptor EP4, NDI symptoms were greatly reduced in a conditional AVPR2-deletion mouse model [150]. This was due to raised AQP2 levels, most probably as a consequence of cAMP production caused by EP4 stimulation. Recently, a similar effect was seen after stimulation of the EP2 receptor by the agonist butaprost [151]. The EP2 receptor is a more interesting candidate for treatment of NDI than the EP4 receptor since EP2 agonists have already been tested in clinical studies for other diseases and have shown promising results concerning safety issues. However, clinical trials in NDI are necessary to evaluate the effects and safety of EP2 agonists for this disorder. Another potential therapeutic strategy bypassing the V2R could be an activation of the

1320

Fig. 2 Therapeutic approaches to treat NDI. Approaches 1–4 focus on X-linked NDI, 5–6 are suited for autosomal recessive NDI, and 7 applies to autosomal dominant NDI. (1) Cell-penetrating V2R antagonists induce native folding and rescue V2R to the basolateral membrane. Displacement of the antagonist by high AVP/DDAVP concentrations is required to induce cAMP signaling. (2) Agonists function similarly, but do not need displacement to activate V2R. (3) ER-penetrating agonists can stimulate misfolded V2R without inducing maturation and induce prolonged signaling. (4) Stimulation of EP2 by butaprost activates

N.V.A.M. Knoers and E.N. Levtchenko

cAMP production as well as AQP2 phosphorylation and targets AQP2 to the apical membrane without involvement of V2R. (5) Glycerol acts as pharmacological chaperone in high concentrations, rescuing AQP2 mutants from the ER. (6) Hsp90-inhibitor 17-AAG enables AQP2 mutant escape from the ER. (7) Rolipram inhibits PDE-4 and increases AQP2 concentration in the apical membrane by slowing down dephosphorylation and downregulating re-internalization (From Ref. [23], with kind permission from Springer Science and Business Media)

40

Nephrogenic Diabetes Insipidus in Children

cGMP-signaling pathway. Several groups have shown that nitric oxide donors and atrial natriuretic factor stimulate the insertion of AQP2 in renal epithelial cells in vitro and in vivo via a cGMP-dependent pathway without increasing the expression of AQP2 [152, 153], and the selective cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra) prevents degradation of cGMP resulting in increased membrane expression in AQP2 in vitro and in vivo [154]. In a small number of NDI patients subjected to clinical trials with sildenafil citrate, no decreases in urine volume or increases in urine osmolality were observed (personal communication in Ref. [28]). Alternative AVP-independent strategies are the use of calcitonin, which has a vasopressin-like effect on AQP2 trafficking and urine-concentrating ability via cAMP-mediated mechanism [155] and of various statins (simvastatin, fluvastatin) that were reported to increase AQP2 expression and water reabsorption in the kidney via an as yet unknown mechanism [156, 157]. Very recently, using a systemic high-throughput chemical screening procedure, Nomura et al. identified AG-490 (an EGF receptor and JAK-2 kinase inhibitor) as a compound that stimulates AQP2 exocytosis, induces AQP2 membrane accumulation, and stimulates urine concentration in an AVP-independent manner [158]. Despite these promising results in in vitro studies and in animal models, none of these compounds has yet been translated into therapy of NDI.

Therapeutic Strategies for Treatment of Autosomal NDI Similarly to V2R mutants, the majority of AQP2 mutants causing autosomal recessive NDI are missense mutations that lead to aberrant folding of AQP2 in the ER. Hence, finding substances that are able to reestablish natural AQP2 folding holds comparable promises for treatment of recessive NDI as it has been shown for the X-linked form. In CHO and MDCK cells, glycerol has proven the applicability of chemical chaperones to AQP2 by restoring ER export in high concentrations [99]. Yang et al. described partial restoration of cellular AQP2 processing upon treatment of conditional AQP2-T126M knock-in mice with an

1321

Hsp90 inhibitor, 17-allylamino-demethoxygeldanamycin (17-AAG), eventually resulting in improved urinary concentrating ability [159]. The precise explanation underlying the beneficial effect of this Hsp inhibitor remains to be elucidated. Furthermore, it is not unlikely that Hsp90 inhibition may have severe side effects that outweigh the advantages [160]. Therefore, lengthened studies addressing safety issues of Hsp90 or other chaperone inhibitors have to be conducted in order to elucidate the applicability of these compounds in NDI therapy. Based on the improvement of AVP-dependent cAMP signaling of collecting duct cells in a hypercalcemia-induced NDI mouse model, Sohara et al. also tested the phosphodiesterase-4 inhibitor Rolipram in the knock-in dominant NDI mice [161]. Their data indicated that Rolipram is able to increase cAMP levels leading to increased AQP2 phosphorylation and translocation to the apical membrane. Phosphodiesterase-4 is a common protein that also is involved in immunosuppressive and anti-inflammatory pathways, and therefore its inhibition may have severe side effects. Rolipram has been tested in two male patients with X-linked NDI and did not cause any relief of symptoms [162], but the potential for other PDE inhibitors in the treatment of NDI needs to be examined further.

References 1. McIlraith CH. Notes on some cases of diabetes insipidus with marked family and hereditary tendencies. Lancet. 1892;II:767–8. 2. Forssman H. On hereditary diabetes insipidus with special regard to a sex-linked form. Acta Med Scand. 1945;153:3–196. 3. Waring AJ, Kajdi L, Tappan V. A congenital defect of water metabolism. Am J Dis Child. 1945;69:323–4. 4. Williams RH, Henry C. Nephrogenic diabetes insipidus: transmitted by females and appearing during infancy in males. Ann Intern Med. 1947;27:84–95. 5. Kaplan SA. Nephrogenic diabetes insipidus. In: Holliday MA, Barratt TM, Vernier RL, editors. Pediatric nephrology. Baltimore: Williams & Wilkins; 1987. p. 623–5. 6. van Lieburg AF, Knoers NVAM, Monnens LAH. Clinical presentation and follow-up of thirty patients

1322 with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol. 1999;10:1958–64. 7. Lejarraga H, Caletti MG, Caino S, et al. Long-term growth of children with nephrogenic diabetes insipidus. Pediatr Nephrol 2008;23:2007–12. 8. Hillman DA, Neyzi O, Porter P, et al. Renal (vasopressin-resistant) diabetes insipidus: definition of the effects of homeostatic limitation in capacity to conserve water on the physical, intellectual, and emotional development of a child. Pediatrics. 1958;21:430–5. 9. Vest M, Talbot NB, Crawford JD. Hypocaloric dwarfism and hydronephrosis in diabetes insipidus. Am J Dis Child. 1963;105:175–81. 10. Forssman H. Is hereditary diabetes insipidus of nephrogenic type associated with mental deficiency? Acta Psychiatr Neurol Scand. 1955;30:577–87. 11. Macaulay D, Watson M. Hypernatremia in infants as a cause of brain damage. Arch Dis Child. 1967;42: 485–91. 12. Bichet DG. Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol. 2008;28:245–51. 13. Kanzaki S, Omura T, Miyake M, et al. Intracranial calcification in nephrogenic diabetes insipidus. JAMA. 1985;254:3349–50. 14. Schofer O, Beetz R, Kruse K, et al. Nephrogenic diabetes insipidus and intracerebral calcification. Arch Dis Child. 1990;65:885–7. 15. Hoekstra JA, van Lieburg AF, Monnens LAH, et al. Cognitive and psychosocial functioning of patients with nephrogenic diabetes insipidus. Am J Med Genet. 1996;61:81–8. 16. Uribarri J, Kaskas M. Hereditary nephrogenic diabetes insipidus and bilateral nonobstructive hydronephrosis. Nephron. 1993;65:346–9. 17. Shalev H, Romanovsky I, Knoers NV, et al. Bladder function impairment in aquaporin-2 defective nephrogenic diabetes insipidus. Nephrol Dial Transplant. 2004;19:608–13. 18. Yoo TH, Ryu DR, Song YS, et al. Congenital nephrogenic diabetes insipidus presented with bilateral hydronephrosis: genetic analysis of V2R gene mutations. Yonsei Med J. 2006;47:126–30. 19. Hong CR, Kang HG, Choi HJ, et al. X-linked recessive nephrogenic diabetes insipidus: a clinico-genetic study. J Pediatr Endocrinol Metab. 2014;27:93–9. 20. Ulinski T, Grapin C, Forin V, et al. Severe bladder dysfunction in a family with ADH receptor gene mutation responsible for X-linked nephrogenic diabetes insipidus. Nephrol Dial Transplant. 2004;19: 2928–9. 21. Monnens L, Smulders Y, van Lier H, et al. DDAVP test for assessment of renal concentrating capacity in infants and children. Nephron. 1991;29:151–4. 22. Bockenhauer D, Bichet DG. Inherited secondary nephrogenic diabetes insipidus: concentrating on humans. Am J Physiol Renal Physiol. 2013;304: F1037–42.

N.V.A.M. Knoers and E.N. Levtchenko 23. Wesche D, Deen PM, Knoers NV. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr Nephrol. 2012;27:2183–204. 24. Katsura T, Ausiello DA, Brown D. Direct demonstration of aquaporin-2 water channel recycling in stably transfected LCC-PK1 epithelial cells. Am J Physiol. 1996;39:F548–53. 25. Noda Y, Sasaki S. Regulation of aquaporin-2 trafficking and its binding protein complex. Biochim Biophys Acta. 2006;1758:1117–25. 26. Sasaki S, Noda Y. Aquaporin-2 protein dynamics within the cell. Curr Opin Nephrol Hypertens. 2007;16:348–52. 27. Bouley R, Hasler U, Lu HA, et al. Bypassing vasopressin receptor signalling pathways in nephrogenic diabetes insipidus. Semin Nephrol. 2008;28:266–78. 28. Moeller HB, Rittig S, Fenton RA. Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr Rev. 2013;34:278–301. 29. Hendriks G, Koudijs M, van Balkom BW, et al. Glycosylation is important for cell surface expression of the water channel aquaporin-2 but is not essential for tetramerization in the endoplasmic reticulum. J Biol Chem. 2004;279:2975–83. 30. Nielsen S, DiGiovanni SR, Christensen EI, et al. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci U S A. 1993;90:11663–7. 31. Fushimi K, Sasaki S, Muramo F. Phosphorylation of serine 256 is required for cAMP-dependent regulatory exocytosis of the aquaporin-2 water channel. J Biol Chem. 1997;272:14800–4. 32. Katsura T, Gustafson CE, Ausiello DA. Protein kinase A phosphorylation is involved in regulated exocytosis of aquaporin-2 in transfected LCC-PK1 cells. Am J Physiol. 1997;272:F816–22. 33. Klussmann E, Maric K, Wiesner B, et al. Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem. 1999;274:4934–8. 34. Kamsteeg EJ, Heijnen I, van Os CH, et al. The subcellular localization of an aquaporin-2 tetramer depends on the stoichiometry of phosphorylated and nonphosphorylated monomers. J Cell Biol. 2000;1:919–30. 35. Jo I, Harris HW, Amendt Raduege AM, Majewski RR, et al. Rat kidney papilla contains abundant synaptobrevin protein that participates in the fusion of antidiuretic hormone-regulated water channelcontaining endosomes in vitro. Proc Natl Acad Sci U S A. 1995;92:1876–80. 36. Liebenhoff U, Rosenthal W. Identification of Rab3-, Rab5a-, and synaptobrevin II-like proteins in a preparation of rat kidney vesicles containing the vasopressin-regulated water channel. FEBS Lett. 1995;365:209–13.

40

Nephrogenic Diabetes Insipidus in Children

37. Nielsen S, Marples D, Birn H, et al. Expression of VAMP2-like protein in kidney collecting duct intracellular vesicles. Colocalization with aquaporin-2 water channels. J Clin Invest. 1995;96:1834–44. 38. Mandon B, Chou CL, Nielsen S, Knepper MA. Syntaxin-4 is localized to the apical plasma membrane of rat renal collecting duct cells: possible role in aquaporin-2 trafficking. J Clin Invest. 1996;98:906–13. 39. Tajika Y, Masuzaki T, Suzuki T, et al. Differential regulation of AQP2 trafficking in endosomes by microtubules and actin filaments. Histochem Cell Biol. 2005;124:1–12. 40. Klussmann E, Tamma G, Lorenz D, et al. An inhibitory role of Rho in the vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem. 2001;276:20451–7. 41. Simon H, Gao Y, Franki N, Hays RH. Vasopressin depolymerizes apical F-actin in rat inner medullary collecting duct. Am J Physiol. 1993;265:C757–62. 42. Sun TX, Van Hoek A, Huang Y, et al. Aquaporin-2 localization in clathrin-coated pits: inhibition of endocytosis by dominant-negative dynamin. Am J Physiol Renal Physiol. 2002;282:F998–1011. 43. Mukhopadhyay D, Riezman H. Proteasomeindependent functions of ubiquitin in endocytosis and signaling. Science. 2007;315:201–5. 44. Kamsteeg EJ, Hendriks G, Boone M, et al. Shortchain ubiquitination of the aquaporin-2 water channel. Proc Natl Acad Sci U S A. 2006;28:18344–9. 45. Vossenkamper A, Nedvetsky PI, Wiesner B, et al. Microtubules are needed for the perinuclear positioning of aquaporin-2 after its endocytic retrieval in renal principal cells. Am J Physiol Cell Physiol. 2007;293:C1129–38. 46. Marples D, Schroer TA, Ahrens N, et al. Dynein and dynactin colocalize with AQP2 water channels in intracellular vesicles from kidney collecting duct. Am J Physiol. 1998;274:F384–94. 47. Palamidessi A, Frittoli E, Garre M, et al. Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. Cell. 2008;134:135–47. 48. Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009;10:513–25. 49. Matsumura Y, Uchida S, Rai T, et al. Transcription regulation of aquaporin-2 water channel gene by cAMP. J Am Soc Nephrol. 1997;8:861–7. 50. Carter C, Simpkiss M. The “carrier” state in nephrogenic diabetes insipidus. Lancet. 1956;II: 1069–73. 51. van den Ouweland AMW, Knoop MT, Knoers NVAM, et al. Colocalization of the gene for nephrogenic diabetes insipidus (DIR) and the vasopressin type-2 receptor (AVPR2) in the Xq28 region. Genomics. 1992;13:1350–3. 52. van den Ouweland AMW, Dreesen JCFM, Verdijk M, et al. Mutations in the vasopressin type-2 receptor gene associate with nephrogenic diabetes insipidus. Nat Genet. 1992;2:99–102.

1323 53. Pan Y, Metzenberg A, Das S, et al. Mutations of the V2 receptor are associated with X-linked nephrogenic diabetes insipidus. Nat Genet. 1992;2:103–6. 54. Rosenthal W, Seibold A, Antamarian A, et al. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature. 1992;359: 233–5. 55. Schreiner RL, Skafish PR, Anand SK, et al. Congenital nephrogenic diabetes insipidus in a baby girl. Arch Dis Child. 1978;53:906–15. 56. Langley JM, Balfe JW, Selander T, et al. Autosomal recessive inheritance of vasopressin-resistant diabetes insipidus. Am J Med Genet. 1991;38:90–4. 57. Brodehl J, Braun L. Familiarer nephrogener diabetes insipidus mit voller auspragung bei einer weiblichen saugling. Klin Wochenschr. 1964;42:563. 58. Deen PMT, Verdijk MAJ, Knoers NVAM, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science. 1994;264:92–5. 59. Mulders SM, Bichet DG, Rijss JPL, et al. An aquaporin-2 water channel mutant which causes autosomal dominant nephrogenic diabetes insipidus is retained in the Golgi complex. J Clin Invest. 1998;102:57–66. 60. Morello J-P, Bichet DG. Nephrogenic diabetes insipidus. Annu Rev Physiol. 2001;63:607–30. 61. Spanakis E, Milord E, Gragnoli C. AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance. J Cell Physiol. 2008;217:605–17. 62. Firsov D, Mandon B, Morel A, et al. Molecular analysis of vasopressin receptors in the rat nephron. Evidence for alternative splicing of the V2 receptor. Pflugers Arch. 1994;429:79–89. 63. Innamorati G, Sadeghi H, Birnbaumer M. A full active nonglycosylated V2 vasopressin receptor. Mol Pharmacol. 1996;50:467–73. 64. Innamorati G, Sadeghi H, Eberle AN, et al. Phosphorylation of the V2 vasopressin receptor. J Biol Chem. 1997;271:2486–92. 65. Innamorati G, Sadeghi HM, Tran NT, et al. A serine cluster prevents recycling of the V2 vasopressin receptor protein. Proc Natl Acad Sci U S A. 1998;95:2222–6. 66. Sch€ ulein R, Rutz C, Rosenthal W. Membrane targeting and determination of transmembrane topology of the human vasopressin V2 receptor. J Biol Chem. 1996;271:28844–52. 67. Krause G, Hermosilla R, Oksche A, et al. Molecular and conformational features of a transport-relevant domain in the C-terminal tail of the vasopressin V2 receptor. Mol Pharmacol. 2000;57:232–42. 68. Sch€ ulein R, Liebenhoff U, Muller H, et al. Properties of the human arginine vasopressin V2 receptor after site-directed mutagenesis of its putative palmitoylation site. J Biol Chem. 1996;313:611–6. 69. Sasaki S, Chiga M, Kikuchi E, Rai T, Uchida S. Hereditary nephrogenic diabetes insipidus in

1324 Japanese patients: analysis of 78 families and report of 22 new mutations in AVPR2 and AQP2. Clin Exp Nephrol. 2013;17:338–44. 70. Duzenli D, Saglar E, Deniz F, Azal O, Erdem B, Mergen H. Mutations in the AVPR2, AVP-NPII, and AQP2 genes in Turkish patients with diabetes insipidus. Endocrine. 2012;42:664–9. 71. Knoers NVAM, Deen PMT. Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr Nephrol. 2001;16:1146–52. 72. Wenkert D, Schoneberg T, Merendino Jr JJ, et al. Functional characterization of five V2 vasopressin receptor gene mutations. Mol Cell Endocrinol. 1996;124:43–50. 73. Deen PMT, Brown D. Trafficking of native and mutant mammalian MIP proteins. In: Hohmann S, Agre P, Nielsen S, editors. Aquaporins. San Diego: Academic Press; 2001. p. 235–76. 74. Robben JH, Knoers NV, Deen PM. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model. Am J Physiol Renal Physiol. 2005;289:F265–72. 75. Ellgaard L, Helenius A. ER quality control: towards an understanding at the molecular level. Curr Opin Cell Biol. 2001;13:431–7. 76. Hermosilla R, Oueslati M, Donalies U, et al. Diseasecausing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway. Traffic. 2004;5:993–1005. 77. Pan Y, Wilson P, Gitschier J. The effect of eight V2 vasopressin receptor mutations on stimulation of adenylyl cyclase and binding to vasopressin. J Biol Chem. 1994;269:31933–7. 78. Robben JH, Knoers NV, Deen PM. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol. 2006;291:F257–70. 79. Ala Y, Morin D, Sabatier N, et al. Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild phenotype. J Am Soc Nephrol. 1998;9:1861–72. 80. Bernier V, Lagace M, Lonergan M, et al. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol. 2004;18:2074–84. 81. Barak LS, Oakley RH, Laporte SA, et al. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci U S A. 2001;98:93–8. 82. Postina R, Ufer E, Pfeiffer R, et al. Misfolded vasopressin V2 receptors caused by extracellular point mutations entail congenital nephrogenic diabetes insipidus. Mol Cell Endocrinol. 2000;164:31–9. 83. Faerch M, Christensen JH, Corydon TJ, et al. Partial nephrogenic diabetes insipidus caused by a novel mutation in the AVPR2 gene. Clin Endocrinol (Oxf). 2008;68:395–403.

N.V.A.M. Knoers and E.N. Levtchenko 84. Armstrong SP, Seeber RM, Ayoub MA, et al. Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V). PLoS One. 2013;8:e65885. 85. Neocleous V, Skordis N, Shammas C, et al. Identification and characterization of a novel X-linked AVPR2 mutation causing partial nephrogenic diabetes insipidus: a case report and review of the literature. Metabolism. 2012;61:922–30. 86. Bockenhauer D, Carpentier E, Rochdi D, et al. Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus. Nephron Physiol. 2010;114:1–10. 87. Kalenga K, Persu A, Goffin E, et al. Intrafamilial phenotype variability in nephrogenic diabetes insipidus. Am J Kidney Dis. 2002;39:737–43. 88. Fushimi K, Uchida S, Harra Y, et al. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature. 1993;361:549–52. 89. Jung JS, Preston GM, Smith BL, et al. Molecular structure of the water channel through aquaporinCHIP. J Biol Chem. 1994;269:14648–54. 90. Heymann JB, Engel A. Aquaporins: phylogeny, structure, and physiology of water channels. News Physiol Sci. 1999;14:187–93. 91. Hub JS, Grubm€ uller H, de Groot BL. Dynamics and energetics of permeation through aquaporins. What do we learn from molecular dynamics simulations? Handb Exp Pharmacol. 2009;190:57–76. 92. de Groot BL, Grubm€ uller H. Water permeation across biological membranes: mechanism and dynamics of aquaporin-1 and GlpF. Science. 2001;294:2353–7. 93. Frick A, Eriksson UK, de Mattia F, et al. X-ray structure of human aquaporin 2 and its implications for nephrogenic diabetes insipidus and trafficking. Proc Natl Acad Sci U S A. 2014;111:6305–10. 94. Park YJ, Baik HW, Cheong HI, et al. Congenital nephrogenic diabetes insipidus with a novel mutation in the aquaporin 2 gene. Biomed Rep. 2014;2:596–8. 95. Rugpolmuang R, Deeb A, Hassan Y, et al. Novel AQP2 mutation causing congenital nephrogenic diabetes insipidus: challenges in management during infancy. J Pediatr Endocrinol Metab. 2014;27:193–7. 96. Leduc-Nadeau A, Lussier Y, Arthus MF, et al. New autosomal recessive mutations in aquaporin-2 causing nephrogenic diabetes insipidus through deficient targeting display normal expression in Xenopus oocytes. J Physiol. 2010;588:2205–18. 97. Deen PM, van Aubel RA, van Lieburg AF, et al. Urinary content of aquaporin 1 and 2 in nephrogenic diabetes insipidus. J Am Soc Nephrol. 1996;7:836–41. 98. Marr N, Kamsteeg EJ, van Raak M, et al. Functionality of aquaporin-2 missense mutants in recessive nephrogenic diabetes insipidus. Pflugers Arch. 2001;442:73–7. 99. Tamarappoo BK, Verkman AS. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and

40

Nephrogenic Diabetes Insipidus in Children

correction by chemical chaperones. J Clin Invest. 1998;101:2257–67. 100. De Mattia F, Savelkoul PJ, Bichet DG, et al. A novel mechanism in recessive nephrogenic diabetes insipidus: wild-type aquaporin-2 rescues the apical membrane expression of intracellularly retained AQP2-P262L. Hum Mol Genet. 2004;13:3045–56. 101. Loonen AJM, Knoers NVAM, van Os CH, et al. Aquaporin 2 mutations in nephrogenic diabetes insipidus. Semin Nephrol. 2008;28:252–65. 102. Kuwahara M, Iwai K, Ooeda T, et al. Three families with autosomal dominant nephrogenic diabetes insipidus caused by aquaporin-2 mutations in the C-terminus. Am J Hum Genet. 2001;69:738–48. 103. Kamsteeg E-J, Wormhoudt TAM, Rijss JPL, et al. An impaired routing of wild-type aquaporin-2 after tetramerization with an aquaporin-2 mutant explains dominant nephrogenic diabetes insipidus. EMBO J. 1999;18:2394–400. 104. Marr N, Bichet DG, Lonergan M, et al. Heteroligomerization of an aquaporin-2 mutant with wild-type aquaporin-2 and their misrouting to late endosomes/ lysosomes explains dominant nephrogenic diabetes insipidus. Hum Mol Genet. 2002;11:779–89. 105. de Mattia F, Savelkoul PJ, Kamsteeg EJ, et al. Lack of arginine vasopressin-induced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus. J Am Soc Nephrol. 2005;16:2872–80. 106. Savelkoul PJ, De Mattia F, Li Y, et al. p.R254Q mutation in the aquaporin-2 water channel causing dominant nephrogenic diabetes insipidus is due to a lack of arginine vasopressin-induced phosphorylation. Hum Mutat. 2009;30:E891–903. 107. Kamsteeg EJ, Savelkoul PJ, Hendriks G, et al. Missorting of the aquaporin-2 mutant E258K to multivesicular bodies/lysosomes in dominant NDI is associated with its monoubiquitination and increased phosphorylation by PKC but is due to the loss of E258. Pflugers Arch. 2008;455: 1041–54. 108. Kamsteeg EJ, Stoffels M, Tamma G, et al. Repulsion between Lys258 and upstream arginines explains the missorting of the AQP2 mutant p.Glu258Lys in nephrogenic diabetes insipidus. Hum Mutat. 2009;30:1387–96. 109. van Lieburg AF, Knoers NVAM, Mallman R, et al. Normal fibrinolytic responses to 1-desamino-8D-arginine vasopressin in patients with nephrogenic diabetes insipidus caused by mutations in the aquaporin-2 gene. Nephron. 1996;72:544–6. 110. Moses AM, Sangai G, Miller JL. Proposed cause of marker vasopressin resistance in a female with X-linked recessive V2 receptor abnormality. J Clin Endocrinol Metab. 1995;80:1184–6. 111. van Lieburg AF, Verdijk MAJ, Schoute F, et al. Clinical phenotype of nephrogenic diabetes insipidus in females heterozygous for a vasopressin type-2 receptor mutation. Hum Genet. 1995;96:70–8.

1325 112. Sato K, Fukuno H, Taniguchi T, et al. A novel mutation in the vasopressin V2 receptor gene in a woman with congenital nephrogenic diabetes insipidus. Intern Med. 1999;38:808–12. 113. Chan Seem CP, Dossetor JF, Penney MD. Nephrogenic diabetes insipidus due to a new mutation of the arginine vasopressin V2 receptor gene in a girl presenting with non-accidental injury. Ann Clin Biochem. 1999;36:779–82. 114. Faerch M, Corydon TJ, Rittig S, et al. Skewed X-chromosome inactivation causing diagnostic misinterpretation in congenital nephrogenic diabetes insipidus. Scand J Urol Nephrol. 2010;44:324–30. 115. Nomura Y, Onigata K, Nagashima T, et al. Detection of skewed X-inactivation on two female carriers of vasopressin type 2 receptor gene mutation. J Clin Endocrinol Metab. 1997;82:3434–7. 116. Migeon BR. X inactivation, female mosaicism, and sex differences in renal diseases. J Am Soc Nephrol. 2008;19:2052–9. 117. Satoh M, Ogikubo S, Yoshizawa-Ogasawara A. Correlation between clinical phenotypes and X-inactivation patterns in six female carriers with heterozygote vasopressin type 2 receptor mutations. Endocr J. 2008;55:277–84. 118. Marples D, Christensen S, Christensen EI, et al. Lithium-induced down-regulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest. 1995;95:1838–45. 119. Kwon T-H, Laursen UH, Marples D, et al. Altered expression of renal AQPs and Na+ transporters in rats with lithium-induced NDI. Am J Physiol. 2000;279: F552–64. 120. Marples D, Dorup J, Knepper MA, et al. Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Am Soc Nephrol. 1996;6:325. 121. Frokiaer J, Marples D, Knepper M, et al. Bilateral ureteral obstruction downregulates expression of the vasopressin-sensitive aquaporin-2 water channel in rat kidney medulla. J Am Soc Nephrol. 1995;6:1012. 122. Teitelbaum I, Strasheim A, McGuinness S. Decreased aquaporin aquaporin-2 content in chronic renal failure. J Am Soc Nephrol. 1996;7:1273. 123. Sands JM, Naruse M, Jacobs JD, et al. Changes in aquaporin-2 protein contribute to the urine concentrating defect in rats fed a low protein diet. J Clin Invest. 1996;97:2807–14. 124. Walker RJ, Weggery S, Bedford JJ, et al. Lithiuminduced reduction in urinary concentration ability and aquaporin-2(AQP2) excretion in healthy volunteers. Kidney Int. 2005;67:291–4. 125. Kortenoeven ML, Li Y, Shaw S, et al. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int. 2009;76:44–53. 126. Kishore BK, Ecelbarger CM. Lithium: a versatile tool for understanding renal physiology. Am J Physiol Renal Physiol. 2013;304:F1139–49.

1326 127. Christensen BM, Zuber AM, Loffing J, et al. alphaENaC-mediated lithium absorption promotes nephrogenic diabetes insipidus. J Am Soc Nephrol. 2011;22(2):253–61. 128. Kjaersgaard G, Madsen K, Marcussen N, et al. Tissue injury after lithium treatment in human and rat postnatal kidney involves glycogen synthase kinase-3β-positive epithelium. Am J Physiol Renal Physiol. 2012;302:F455–65. 129. Rao R, Zhang MZ, Zhao M, et al. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol. 2005;288:F642–9. 130. Rao R, Patel S, Hao C, et al. GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity. J Am Soc Nephrol. 2010;2:428–37. 131. Christensen BM, Marples D, Kim YH, et al. Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol. 2004;286:C952–64. 132. Berl T. Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol. 2008;19:1076–8. 133. Crawford JD, Kennedy GC. Chlorothiazide in diabetes insipidus renalis. Nature. 1959;193:891–2. 134. Monnens L, Jonkman A, Thomas C. Response to indomethacin and hydrochlorothiazide in nephrogenic diabetes insipidus. Clin Sci. 1984;66:709–15. 135. Rasher W, Rosendahl W, Henricho IA, et al. Congenital nephrogenic diabetes insipidus: vasopressin and prostaglandins in response to treatment with hydrochlorothiazide and indomethacin. Pediatr Nephrol. 1987;1:485–90. 136. Jakobsson B, Berg U. Effect of hydrochlorothiazide and indomethacin on renal function in nephrogenic diabetes insipidus. Acta Paediatr. 1994;83:522–5. 137. Alon U, Chan JCM. Hydrochlorothiazide-amiloride in the treatment of congenital nephrogenic diabetes insipidus. Am J Nephrol. 1985;5:9–13. 138. Knoers N, Monnens LAH. Amiloridehydrochlorothiazide in the treatment of congenital nephrogenic diabetes insipidus. J Pediatr. 1990;117:499–502. 139. Pattaragarn A, Alon US. Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor. Pediatr Nephrol. 2003;18:1073–6. 140. Early LE, Orloff J. The mechanism of antidiuresis associated with the administration of hydrochlorothiazide to patients with vasopressin-resistant diabetes insipidus. J Clin Invest. 1962;52:2418–27. 141. Shirley DG, Walter SJ, Laycock JF. The antidiuretic effect of chronic hydrochlorothiazide treatment in rats with diabetes insipidus. Clin Sci. 1982;63:533–8. 142. Cesar KR, Magaldi AJ. Thiazide induces water reabsorption in the inner medullary collecting duct of normal and Brattleboro rats. Am J Physiol. 1999;277:F750–6.

N.V.A.M. Knoers and E.N. Levtchenko 143. Magaldi AJ. New insights into the paradoxical effect of thiazides in diabetes insipidus therapy. Nephrol Dial Transplant. 2000;15:1903–5. 144. Kim GH, Lee JW, Oh YK, et al. Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2, Na-Cl co-transporter, and epithelial sodium channel. J Am Soc Nephrol. 2004;15:2836–43. 145. Morello J-P, Salahpour A, Laperriere A, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest. 2000;105:887–95. 146. Robben JH, Sze M, Knoers NV, et al. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. Am J Physiol Renal Physiol. 2007;292:F253–60. 147. Bernier V, Morello JP, Zarruk A, et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol. 2006;17:232–43. 148. Jean-Alphonse F, Perkovska S, Frantz MC, et al. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J Am Soc Nephrol. 2009;20:2190–203. 149. Robben JH, Kortenoeven ML, Sze M, et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci U S A. 2009;106: 12195–200. 150. Li JH, Chou CL, Li B, et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J Clin Invest. 2009;119:3115–26. 151. Olesen ET, Rutzler MR, Moeller HB, et al. Vasopressin-independent targeting of aquaporin-2 E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc Natl Acad Sci U S A. 2011;108:12949–54. 152. Bouley R, Breton S, Sun TX, et al. Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells. J Clin Invest. 2000;106:1115–26. 153. Boone M, Kortenoeven M, Robben JH, et al. Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus. Nephrol Dial Transplant. 2010;25:48–54. 154. Bouley R, Pastor Soler N, Cohen O, et al. Stimulation of AQP2 insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra). Am J Physiol Renal Physiol. 2005;288:F1103–12. 155. Bouley R, Lu HA, Nunes P, et al. Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary concentration. J Am Soc Nephrol. 2011;22: 59–72.

40

Nephrogenic Diabetes Insipidus in Children

156. Procino G, Barbieri C, Carmosino M, et al. Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells. Pflugers Arch. 2011;462:753–66. 157. Li W, Zhang Y, Bouley R, et al. Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase. Am J Physiol Renal Physiol. 2011;301:F309–18. 158. Nomura N, Nunes P, Bouley R, et al. High-throughput chemical screening identifies AG-490 as a stimulator of aquaporin 2 membrane expression and urine concentration. Am J Physiol Cell Physiol. 2014;307: C597–605.

1327 159. Yang B, Zhao D, Verkman AS. Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation. FASEB J. 2009;23:503–12. 160. Taiyab A, Sreedhar AS, Rao C. Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma. Biochem Pharmacol. 2009;78:142–52. 161. Sohara E, Rai T, Yang SS, et al. Pathogenesis and treatment of autosomal-dominant nephrogenic diabetes insipidus caused by an aquaporin 2 mutation. Proc Natl Acad Sci U S A. 2006;103:14217–22. 162. Bichet DG, Ruel N, Arthus MF, et al. Rolipram, a phosphodiesterase inhibitor, in the treatment of two male patients with congenital nephrogenic diabetes insipidus. Nephron. 1990;56:449–50.

Cystinosis and Its Renal Complications in Children

41

William A. Gahl and Galina Nesterova

Contents Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1330 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1330 History . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1330 The Basic Defect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1330 Pathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1331 Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1332 The CTNS Gene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1332 Cystinosis Variants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1333 Early Clinical Manifestations . . . . . . . . . . . . . . . . . . . . Renal Tubular Fanconi Syndrome with Rickets . . . Glomerular Damage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Growth Impairment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ocular Involvement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hypothyroidism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cognition and Psychological Aspects . . . . . . . . . . . . . . Other Clinical Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Laboratory Abnormalities . . . . . . . . . . . . . . . . . . . . . . . . . .

1333 1333 1335 1335 1336 1337 1337 1337 1338

Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Postnatal Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Prenatal Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Heterozygote Detection . . . . . . . . . . . . . . . . . . . . . . . . . . . . Differential Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1338 1338 1339 1339 1339

Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Replacement of Renal Losses . . . . . . . . . . . . . . . . . . . . . . Other Symptomatic Treatments . . . . . . . . . . . . . . . . . . . . Renal Replacement Therapy . . . . . . . . . . . . . . . . . . . . . . . Oral Cysteamine Therapy . . . . . . . . . . . . . . . . . . . . . . . . . .

1339 1340 1340 1341 1342

Cysteamine Eyedrops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1345 Other Therapeutic Considerations . . . . . . . . . . . . . . . . . . 1345 Cystinosis in Adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Growth and Appearance . . . . . . . . . . . . . . . . . . . . . . . . . . . . Myopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pancreatic Involvement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hypogonadism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Central Nervous System Involvement . . . . . . . . . . . . . Ocular Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other Complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Occupations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Treatment of Adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1346 1346 1346 1347 1347 1347 1348 1348 1348 1348 1348

Cystinosis Advocacy Groups . . . . . . . . . . . . . . . . . . . . . 1349 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1349 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1350

W.A. Gahl (*) • G. Nesterova Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA e-mail: [emailprotected]; [emailprotected] # Springer-Verlag Berlin Heidelberg (outside the USA) 2016 E.D. Avner et al. (eds.), Pediatric Nephrology, DOI 10.1007/978-3-662-43596-0_37

1329

1330

Introduction Overview Nephropathic cystinosis [1–3] deserves a special place in the annals of clinical medicine as the first treatable lysosomal storage disease. The pathophysiology itself, based upon the formation of cystine crystals within the lysosomes of cells, is remarkable. The presence of cystine crystals provides a clue to the basic defect in cystinosis, i.e., failure to transport cystine out of lysosomes [4–6]. This created a new area of biomedical investigation, explained the lysosome’s function in salvaging small molecules for reutilization by the cell, and revealed a new category of lysosomal storage disorders due to transport defects rather than enzyme deficiencies [7]. Even more striking, a rational therapy of cystine depletion (i.e., cysteamine) emerged [8–10], transforming nephropathic cystinosis from a universally fatal disease to a treatable chronic disorder with a decent quality of life and increased life span. Today, physicians can even observe the gradual dissolution of cystine crystals by cysteamine eyedrops bathing the corneas of patients’ eyes [11–13].

History Cystinosis was first described by Abderhalden in 1903 [14], when understanding of its renal disease remained rudimentary. Fanconi, de Toni, and Dubre recognized the renal tubular defect of cystinosis in the 1930s [4], and this complication retains the appellation Fanconi syndrome today. Generalized aminoaciduria was noted as a concomitant of nephropathic cystinosis in the late 1940s [15], and cystine storage within cellular lysosomes was proven in the late 1960s [16]. By 1982, the basic defect of impaired lysosomal membrane transport of cystine was reported [4–6], and therapy with the cystine-depleting aminothiol cysteamine was shown to be safe and effective by 1987 [9]. Over the past two decades, numerous nonrenal complications of cystinosis

W.A. Gahl and G. Nesterova

have been described, and oral cysteamine therapy has been shown to prevent virtually all of them [17, 18].

The Basic Defect Cystine has a molecular weight of 240 Da and consists of two molecules of cysteine (HS-CH2CH(NH3+)COO) joined by a disulfide bond. The equilibrium between cystine and cysteine depends upon their redox potentials and the pH of the milieu; if a high enough concentration of cystine is present (>2 mM), it may precipitate out of solutions because of its poor solubility [19]. Cysteine, which is very soluble, is produced by the hydrolysis of proteins; this occurs within lysosomes by the action of acidic hydrolases. Cysteine is then oxidized to cystine within lysosomes, where it accumulates if the cell is cystinotic [16, 20]. For decades, scientists investigated the cause of lysosomal cystine accumulation in cystinosis [2]. One possibility was a defective enzyme responsible for the reduction of cystine to cysteine, or for catalyzing disulfide interchange reactions between cystine and other free thiols. This hypothesis was examined, but no deficiency in a cystine-catabolizing enzyme was found [21]. Another possibility was that, in cystinosis, cystine could not exit lysosomes because a transporting system present in normal lysosomal membranes was defective in cystinosis. Indeed, normal polymorphonuclear leukocytes were able to clear themselves (i.e., their lysosomes) of cystine, but cystinotic cells could not [22]. Studies of isolated granular fractions, i.e., lysosomes, gave similar results [5]. In fact, normal, cystine-loaded lysosomes could transport cystine in either direction across their membranes, while cystinotic lysosomes could neither take up nor release cystine [4, 23]. Cystine transport in neutrophil lysosomes was subsequently shown to be ligand specific, stereospecific, and ATP-dependent [5, 6]. It displayed classical saturation kinetics (Fig. 1) and countertransport. Similar findings were observed in cultured lymphoblasts [6]. In composite, these discoveries proved that the process

41

Cystinosis and Its Renal Complications in Children

1331

Fig. 1 Lysosomal cystine transport in leukocyte granular fractions (normal lysosomes were loaded with cystine by exposure of whole leukocytes to cystine dimethylester, which is hydrolyzed to cystine within the acidic lysosome. Cystinotic lysosomes contain endogenously produced cystine. The abscissa gives the level of cystine loading per unit of hexosaminidase, i.e., per lysosome. The ordinate gives

the rate of cystine egress in picomoles per minute per unit of hexosaminidase. Normal lysosomal cystine egress exhibits saturation kinetics, while cystinotic lysosomes show virtually no cystine egress. Heterozygotes for cystinosis, with half the number of lysosomal cystine transporters, display half the normal maximal velocity of cystine egress) (Reprinted from SCIENCE [4])

of lysosomal cystine transport is carrier mediated and deficient in cystinosis. Indeed, heterozygotes for cystinosis displayed half the maximum velocity of cystine transport [24], consistent with having half the normal number of cystine carriers (Fig. 1). The later discovery of the cystinosis gene, CTNS, and studies of its gene product, cystinosin, demonstrated that this protein does indeed transport cystine, in a process driven by the hydrogen ion gradient across the lysosomal membrane [25, 26].

cystine storage (to 10–1,000 times normal levels), patients with cystinosis develop microscopic crystals of cystine, apparent within lysosomes on electron microscopy [20]. Subcellular fractionation using sucrose density gradients [16] verified the lysosomal location of cystine. Tissues containing cystine crystals include the cornea, conjunctiva, liver, spleen, kidneys, intestines, rectal mucosa, pancreas, testes, lymph nodes, bone marrow, macrophages, thyroid, muscle, and choroid plexus [2, 9]. Crystals form in macrophages but not in cultured fibroblasts or lymphoblasts. The crystals are generally hexagonal or rectangular and appear birefringent under polarizing light (Fig. 2). To preserve crystals during histological processing, tissues should be fixed in absolute alcohol rather than in aqueous solutions. Tissue damage accompanies the intracellular cystine accumulation of cystinosis, with the

Pathology Patients who have not received long-term cystinedepleting therapy exhibit specific pathological features. As a consequence of excessive cellular

1332

W.A. Gahl and G. Nesterova

transporters and pathways, including redox-based signaling or protein cysteinylation [38]. Finally, cystine crystals have been proposed to activate endogenous inflammasomes [39].

Genetics

Fig. 2 Birefringent cystine crystals in cystinosis tissue under light microscopy (note rectangular and needlelike shapes. Some crystals are undergoing dissolution due to the aqueous fixative)

greatest effects in the kidney. Renal tubules show a characteristic narrowing called a swan-neck deformity [27], followed by interstitial nephritis and endothelial glomerular proliferation, necrosis, and hyalinization. Formation of atubular glomeruli and a glomerulotubular disconnect appear to represent a maladaptation to renal injury, contributing to the progression of renal insufficiency [28, 29]. Crystals are occasionally seen within glomeruli. In the eye, the retina exhibits patchy hypopigmentation [30] crystals appear occasionally in the iris and rarely in the retina [31]. In older patients, the thyroid and testes appear fibrotic. Muscle histopathology involves a late vacuolar myopathy with variation in fiber size, atrophy of type I fibers, and ring fibers [32, 33]. In the liver of untreated adults, nodular regenerative hyperplasia can occur [34]. The pathogenesis of tissue damage in cystinosis is thought to involve cellular metabolic mitochondrial oxidative stress [35], cell dysfunction, and death, followed by replacement with fibrous tissue. Crystal enlargement could burst the lysosomes, releasing hydrolytic enzymes that might destroy the cell, but this remains a working hypothesis. There are data supporting a more ordered loss of cells through the process of apoptosis, which is putatively triggered by cystine accumulation [36]. Loss of cystinosin in proximal tubules may disrupt endolysosomal pathways, leading to the loss of urinary ligands [37], or may result in the unregulated activation of other

Cystinosis is an autosomal recessive disorder, and heterozygotes are always entirely normal. The disease occurs with an incidence of approximately one in 100,000–200,000 live births, although there are genetic isolates of cystinosis, including one with a frequency of 1 in 26,000 in Brittany [40] and another among French Canadians. Within the US population, one in 150–200 individuals carries a cystinosis (i.e., CTNS) mutation. This number allows counseling of persons, ascertained to be heterozygotes because a family member was diagnosed, with respect to their risk of having a child with cystinosis by an unrelated mate. Perhaps 600–700 cystinosis patients reside in the United States, approximately half of them having undergone a renal allograft procedure. It is estimated that 20–40 children with cystinosis are born annually in the United States. Our own patients are from all over the world, including Mexico, Brazil, Bolivia, Venezuela, India, Iran, Egypt, Australia, and a variety of European countries. The pan-ethnic distribution of the disease, along with the scarcity of reports of cystinosis in underdeveloped countries, suggests that large numbers of patients around the world are not diagnosed. In general, cystinosis breeds true within families; siblings manifest very similar clinical severities.

The CTNS Gene The cystinosis gene was mapped to chromosome 17p13 in 1995 [41] and identified in 1998 [25]. It contains 12 exons within 23 kb of genomic DNA and codes for a 367-amino acid protein, cystinosin, with seven transmembrane domains. The function of cystinosin as a cystine transporter

41

Cystinosis and Its Renal Complications in Children

has been confirmed [26]. Over 200 different CTNS mutations including deletions, insertions, nonsense, missense, and splice site mutations have been reported in Human Gene Mutation Database; they are found in different combinations in individuals with cystinosis [1, 42, 43]. The promoter [44], leader sequence, transmembrane regions, and non-transmembrane regions are affected by different mutations. The most common mutation is a 57,257 deletion removing the first 10 exons of CTNS [45, 46]. This deletion arose in Germany ~500 AD and is present in the homozygous or heterozygous state in more than half of the cystinosis patients of European descent [46]. Homozygosity for this deletion is associated with a slightly greater frequency of nonrenal complications of cystinosis in adulthood [18]. Otherwise, there is only a mild correlation of genotype and phenotype within nephropathic cystinosis patients. Two other founder mutations, W138X and G339R, have been reported among French Canadians [47] and Amish Mennonites of southwestern Ontario [48], respectively.

Cystinosis Variants Traditionally, cystinosis has been divided into three subtypes [2]. Infantile nephropathic cystinosis is the classic disease, described below and comprising 95 % of cases. Affected individuals have two severe CTNS mutations. Patients with intermediate (formerly juvenile or adolescent) cystinosis have milder disease, with diagnosis in adolescence or early adulthood; they eventually develop renal failure. Intermediate patients number fewer than 20 reported cases and carry one severe and one mild CTNS mutation [49]. Patients with ocular (formerly adult or benign) cystinosis never exhibit renal failure or retinal hypopigmentation, but have cystine crystals in their bone marrow and corneas [2]. They do have measurable residual cystine-transporting capacity in their polymorphonuclear leukocytes’ lysosomes [50]. The only clinical manifestation of ocular cystinosis is photophobia, and patients are generally diagnosed incidentally on eye

1333

examination that includes the use of a slit lamp. There exist approximately 20 ocular cystinosis patients, who have either one mild and one severe or two mild CTNS mutations [51]. Several ocular cystinosis patients from different families have at least one allele with a 928 G > A mutation in CTNS. The distinction among the three types of cystinosis is artificial, since there exists a continuum of disease severity rather than discrete categories. A Ctns/ mouse accumulates cystine in its tissues; the manifestation of renal disease depends upon the murine model’s genetic background [52, 53].

Early Clinical Manifestations As for patients with other lysosomal storage disorders, individuals with cystinosis appear entirely normal at birth. Nevertheless, the disease eventually affects nearly every tissue of the body, with variable times of onset. The signs and symptoms can be described as early and late findings, demarcated roughly by adolescence. The earliest manifestations of cystinosis involve complications of renal Fanconi syndrome and growth retardation [54].

Renal Tubular Fanconi Syndrome with Rickets Cystinosis, the most common identifiable cause of renal Fanconi syndrome in childhood, is also one of the most treatable causes, so it should be considered first when renal tubular solute wasting is recognized. In cystinosis, Fanconi syndrome is not evident at birth but generally appears at 6–12 months of age, with variable severity. Undoubtedly, some infants die of the dehydration and electrolyte imbalance associated with the Fanconi syndrome, without the benefit of a diagnosis. The Fanconi syndrome of cystinosis (Table 1) is primarily a proximal tubular defect. It includes failure to reabsorb water, bicarbonate (acidosis), electrolytes (hypokalemia and occasional hyponatremia), minerals (phosphaturia,

1334 Table 1 Characteristics of renal tubular Fanconi syndrome in cystinosis Polyuria Polydipsia Dehydration (fever) Proteinuria Glucosuria Aminoaciduria Acidosis Hypokalemia Hyponatremia (salt craving) Hypophosphatemia Hypocalcemia Hypomagnesemia Hypocarnitinemia Increase serum alkaline phosphatase Rickets Tetany Growth failure

hypocalcemia, and hypomagnesemia), amino acids, carnitine, glucose, and small molecular weight proteins (less than 50,000 Da). Capillary electrophoresis mass spectrometry (CE_MS) can detect small proteins (i.e., osteopontin, uromodulin, fragments of collagen alpha-1 chains) that reflect the tubular origin of the proteinuria and can be helpful in diagnosing FS [55]. The clinical manifestations of renal tubular Fanconi syndrome include polyuria (often 2–3 L per day in small children and sometimes up to 5–6 L per day), dehydration (sometimes with consequent fevers), and polydipsia [56]. Urine osmolality can be 200–300 mOsm/L. Large volumes of fluid intake fill the stomach and reduce appetite. Acidosis typically lowers the serum carbon dioxide level to below 20 mEq/L, and chronically untreated children can have levels below 5 mEq/L. Serum potassium concentrations below 2.0 mEq/L are not rare, and values below 3 mEq/L are common. Phosphate and calcium wasting causes rickets, with low serum phosphate and calcium and elevated heat-labile alkaline phosphatase levels (2,000–3,000 U/L in florid cases). In some cases, significant hypocalcemia triggers secondary hyperparathyroidism, exacerbating bone reabsorption. Altered metabolism of

W.A. Gahl and G. Nesterova

1,25D(OH)2 or abnormal cellular resistance to its action deserves further investigation as possible additional factors in the mechanism of rickets. Children may fail to walk because of the bone pain, and they exhibit tender, swollen wrists and ankles due to metaphyseal widening. In severe cases, frontal bossing, a rachitic rosary, and genu valgum/varum develop. Osteoporosis and epiphyseal fraying are visible on radiographs (Fig. 3). The combination of hyperphosphaturia and hypercalciuria often results in medullary nephrocalcinosis [57]. Hypocalcemia can cause painful episodes of tetany or even seizures, especially 20–30 min after a dose of an alkalinizing medication that lowers circulating concentrations of ionized calcium. Magnesium is lost commensurately with calcium, and serum magnesium levels are often low. Little is known about early structural damage in proximal tubules, although the mouse provides a model for studying the pathology. The “swan-neck” deformity follows cell dedifferentiation, defective apical endocytosis, metaplasia of Bowman’s epithelium, thickening of the basement membrane, and increased apoptosis, resulting in atubular glomeruli and renal failure [58]. The poor health of infants and small children with cystinosis makes them irritable and picky eaters. Carnitine is only ~70 % reabsorbed in cystinosis (normal, 97 %), leading to chronically low levels of free carnitine, typically 11 μM (normal, ~40 μM) [59]. Since carnitine is essential for fatty acid transport into mitochondria, carnitine deficiency may contribute to poor muscle development, although this has not been proven. The aminoaciduria of cystinosis can be quantified using the Fanconi Syndrome Index (FSI), a measurement of the daily urinary excretion of 21 specific amino acids, expressed per kg of body weight [60]. For children with cystinosis, the FSI is always above normal (94 45 μmol/kg/day) and is often ~1 mmol/kg/day. Urine organic acids have been reported elevated in children with cystinosis, but without apparent clinical consequences [2]. The Fanconi syndrome of cystinosis can mislead physicians in several ways. The combination of polyuria and glucosuria has led to the incorrect

41

Cystinosis and Its Renal Complications in Children

1335

Fig. 3 Rickets in a 16-month-old boy with nephropathic cystinosis (note widening of the metaphysis, fraying of the epiphysis, and osteoporosis)

diagnosis of diabetes mellitus, which can be readily dismissed by the finding of a normal serum glucose. Other patients have carried the diagnosis of diabetes insipidus, hyperaldosteronism, or Bartter’s syndrome for years before being correctly diagnosed as having cystinosis [2, 3]. The tubular proteinuria of cystinosis can reach nephrotic levels; some children excrete 3–4 g of protein per day. This can be taken to reflect glomerular damage, which may be present to a certain extent, but the bulk of the protein is generally of low molecular weight, reflecting tubular dysfunction. Urine protein electrophoresis can distinguish tubular from glomerular proteinuria. Finally, as cystinosis patients approach renal failure, their reduced filtration function creates the expectation that oliguria, hyperkalemia, and hyperphosphatemia will occur. In cystinosis, however, the tubular defect trumps the glomerular damage. Patients with creatinine clearances less than 30 mL/min/1.73 m2 can still have urine volumes of 3 L and, if not supplemented, profound dehydration, hypokalemia, and phosphate wasting.

function slowly but inexorably decreases. By age 10, most children with cystinosis have reached renal failure and require transplantation or dialysis. In a European study of 205 cystinosis children, the mean age for end-stage renal disease was 9.2 years [62]. However, rates of decline are somewhat variable, with milder patients maintaining function until age 12 and severely affected children losing function by age 6. The substantial reserve of human kidneys means that serum creatinine seldom rises above normal until 5 years of age, especially if growth retardation creates a reduced creatinine load on the kidneys. However, measurement of glomerular filtration rate using a 24-h urine collection and calculation of creatinine clearance generally reveals a significant deficit at the time of diagnosis even at a year of age. The uremia of cystinosis resembles that of other renal disorders, except that the growth retardation, osteodystrophy, and anemia may be somewhat exaggerated by comparison. Hypertension can accompany chronic renal failure or arise in the posttransplant period, but cystinosis itself does not predispose to this complication.

Glomerular Damage Growth Impairment Cystinosis accounts for ~5 % of chronic renal failure in children [61]. By the time a typical cystinosis infant is diagnosed at approximately 1 year of age, significant renal glomerular damage has already occurred. It has been postulated that rapid progress to renal damage could be explained by inflammation caused by cystine crystals [39]. A reasonable estimate would place the creatinine clearance at the time of diagnosis at approximately 70 % of normal, and this level of

Newborns with cystinosis are normal in height, weight, and head circumference. While head circumference is maintained, height and weight percentiles generally fall by 6–12 months of age; failure to thrive is often the first indication of the diagnosis. By 1 year of age, the average infant with cystinosis has a height at the third percentile [9]. Without treatment, growth continues at 50–60 % of the normal rate. By age 8, the average

1336 150

97

140 50 130 3 120

110 Height (cm)

Fig. 4 Natural history of growth in children with cystinosis (mean values for cystinosis children are superimposed upon a normal growth chart. On average, a child with cystinosis falls from normal height to the third percentile at 1 year of age and continues to grow slowly so that the height age is 4 years when the chronological age is 8 years) (Reprinted from the New England Journal of Medicine [9])

W.A. Gahl and G. Nesterova

Cystinosis 100 (5) 90

80

(19)

(22)

(14)

(2) (9)

(22) 70

(27) (23)

60

50

untreated child with cystinosis has the height of a 4-year-old (Fig. 4). In the past, some poorly treated, posttransplant adults achieved less than 4 f. in height. Weight usually follows height, but with greater variability. The normal head circumference, combined with reduced height and weight, gives the impression of macrocephaly, but this is relative, not absolute. In patients not receiving growth hormone therapy, bone age usually lags behind chronological age by 1–3 years. Children with retarded bone ages retain growth potential past the usual age of epiphyseal closure, but height is never gained past age 20, regardless of the bone age. The cause of impaired growth has not been definitively determined. Growth hormone is normal [63], although patients respond to supraphysiologic doses of growth hormone [64]. Hypophosphatemic rickets, acidosis, poor nutrition, renal insufficiency,

1

2

3

4 5 6 Age (yr)

7

8

9

10

and cystine storage in the bone probably all contribute to the metabolic bone disease and poor growth of cystinosis. However, with adequate nutrition, mineral replacement of renal losses, and cystinedepleting therapy, a normal growth rate can be achieved. (See below.)

Ocular Involvement A patchy retinal depigmentation has been described early in infancy in cystinosis, but the primary ophthalmic manifestation of cystinosis is photophobia. This occurs due to corneal crystals that first appear in the anterior third of the cornea. Corneal crystals are always present by 16 months of age on slit lamp examination and are diagnostic for cystinosis [13]. Prior to then, the crystals may not be apparent. The number of crystals increases with age, reaching

41

Cystinosis and Its Renal Complications in Children

a maximum discernible density by ~8 years of age. An atlas of corneal crystal density at different ages has been published [13]. Crystal density among ocular cystinosis patients appears less than that of patients with classical disease. Children with cystinosis complain of sensitivity to light at variable ages, but usually not until 5–10 years of age. They squint to the point that, without treatment, they can eventually develop blepharospasm refractory to all modes of therapy. Often, patients wear dark glasses outside and turn down the lights inside. Occasionally, a child with cystinosis may experience a corneal ulceration as a crystal breaks through the corneal epithelium. This complication occurs much more frequently in adolescence and adulthood, when haziness of the cornea also appears.

Hypothyroidism In the natural history of cystinosis, approximately half of patients are hypothyroid by age 10 [65] and 90 % by age 30 [66]. Thyroxine and free T4 are low and TSH is high, pointing to primary hypothyroidism, although partial pituitary resistance has also been reported [67]. In cystinosis, the thyroid tissue appears fibrotic with occasional crystals present.

Cognition and Psychological Aspects Children with cystinosis learn normally and have low normal full-scale IQs [68, 69]. However, recent evidence indicates isolated deficits in visual processing [70] and tactile recognition [71]. Short-term visual memory can be impaired [71], and patients may exhibit behavioral and social problems [72, 73]. The latter are related in part to their chronic disease, renal failure, and growth retardation.

Other Clinical Findings Cystinosis children are notoriously poor eaters, with understandable craving for salty foods such

1337

as pickles, ketchup, and potato chips [56]. In addition, many children exhibit a pica for hot foods such as jalapeno peppers and tabasco sauce, without an obvious explanation. Young children and infants exhibit an increased tendency toward vomiting, which is more severe in the morning prior to eating. Some of this may be related to medications, but there appears to be an intrinsic disease-specific element as well. Excessive water intake with increased thirst causes abdominal distention and a sense of fullness, which further contributes to nausea, vomiting, and poor appetite. The nausea and vomiting often decrease with age and generally cease by 7–8 years of age. Rarely, a patient may suffer from gastrointestinal immotility and have projectile vomiting upon eating or drinking slight amounts of food or water. One-third to one-half of cystinosis children 10–18 years of age have mild hepatomegaly on physical examination [65], with no identifiable cause. One 9-year-old boy had hepatic venoocclusive disease and underwent a liver transplantation [74]. Patients from lightly pigmented backgrounds sometimes appear less pigmented than other family members. This may reflect dysfunction of melanosomes, which are lysosome-related organelles, or formation of excessive cysteinyl-dopaquinone, the precursor of pheomelanin, a blond-red pigment. Alternatively, the blond pigmentation characteristic of cystinosis may reflect the high frequency of Germanic and Nordic heritage among cystinosis patients. African American and Hispanic patients have pigmentation indistinguishable from that of their siblings. Most cystinosis patients manifest decreased sweat production, causing flushing, heat avoidance, and occasional hyperthermia [75]. In addition, tear and saliva production is often reduced in cystinosis. Enuresis in children with cystinosis may reflect the large volume of urine produced daily. Patients combat infections in a normal fashion, although gastroenteritis in children with Fanconi syndrome will cause dehydration much more rapidly than in normal individuals. Idiopathic intracranial hypertension, or pseudotumor cerebri due to nonabsorptive hydrocephalus, has been reported in several patients and has been attributed, in part,

1338

to cystinosis itself [76]. Optic nerve compression due to idiopathic intracranial hypertension has caused blindness in at least two children with cystinosis.

Laboratory Abnormalities In addition to laboratory aberrations related to the Fanconi syndrome (▶ Chap. 42, “Pediatric Fanconi Syndrome”), children with cystinosis frequently exhibit mild microscopic hematuria, an elevated sedimentation rate, increased platelet counts, and anemia that is excessive for the degree of renal failure [2]. Cholesterol levels are usually elevated, with each of the lipoprotein fractions proportionally increased. The hypercholesterolemia persists after renal transplantation [17, 18].

Diagnosis Because a safe and efficacious treatment exists for cystinosis, physicians should maintain a high index of suspicion in patients demonstrating any characteristic findings. Unfortunately, the average age of diagnosis for cystinosis remains just over 1 year [2], and even today several patients escape detection for years, despite manifesting typical signs and symptoms.

Postnatal Diagnosis A family history of cystinosis will naturally point to this disease in a child with suggestive findings. However, even without a previously affected sibling, evidence of renal tubular Fanconi syndrome (polyuria, polydipsia, proteinuria, glucosuria, acidosis, dehydration, electrolyte imbalance, salt craving, and tetany) should prompt investigation for cystinosis. Other signs include poor growth, failure to walk at an appropriate age, and other evidence of rickets. The presence of typical corneal crystals on slit lamp examination by an experienced ophthalmologist will establish the

W.A. Gahl and G. Nesterova

diagnosis. Such crystals are usually not apparent within the first several months of life, but crystals are always present by 16 months of age [13]. Elevated intracellular-free (nonprotein) cystine concentrations also are diagnostic. Cystinosis patients have high concentrations of cystine in a variety of cell types, but polymorphonuclear leukocytes are the preferred cells in which to assay cystine [1–3]. While cystinotic lymphocytes have three- to fivefold elevations above normal cystine concentrations, neutrophils have 50–100 times the normal levels, i.e., 3–23 nmol half-cystine/ mg protein (normal, 12–24 h) can cause cystine to leach out of leukocytes, giving spuriously low values. Relatively little sensitivity is needed to simply make a diagnosis of cystinosis, but high sensitivity is necessary when monitoring therapy with cystine-depleting agents. (See below.) In the past, biopsies of the kidney, bone marrow, rectal mucosa, or conjunctiva were performed to make establish the diagnosis of cystinosis [2]. Such biopsies are no longer indicated.

41

Cystinosis and Its Renal Complications in Children

CTNS mutation analysis can confirm the diagnosis of nephropathic cystinosis, and a multiplex PCR methodology is available for identification of the common 57,257-bp deletion. A specific mutation panel has been optimized for the French-Canadian population [1, 7, 46]. However, molecular methods play little or no role in postnatal diagnosis of cystinosis. Development of a newborn screening test for cystinosis will potentially allow broader therapeutic success [79]. Two methods have been proposed: (a) tandem mass spectrometry for the determination of derivative seven-carbon (C7) sugars in dried blood spots (DBS), which detects homozygosity for the CTNS 57-kb deletion, and (b) molecular genetic testing for the most common CTNS mutations [80].

Prenatal Diagnosis When one child has been diagnosed with cystinosis, the disorder can be identified in subsequent pregnancies by several methods. At 8–10 weeks of gestation, chorionic villus samples can be directly assayed for cystine, as long as enough tissue (5 mg wet weight) is available [81]. At 14–16 weeks’ gestation, amniotic fluid cells can be cultured for approximately 4 weeks to obtain enough cells to measure the cystine content [82]. Measurement of cystine in a placenta will make the diagnosis at birth [83]. In addition, any of these cell sources can be used for molecular diagnosis, as long as both mutations have been previously identified in the affected sibling.

Heterozygote Detection Carrier (heterozygote) detection based upon leukocyte cystine measurement is problematic. While carrier levels can be as high as 1 nmol half-cystine/mg protein, they can also be within the normal range (80–85 % in normal subjects with normal phosphate levels) and low serum phosphate. Rickets and osteomalacia result from increased urinary wasting of phosphate and impaired 1α-hydroxylation of 25-hydroxy vitamin D3 by proximal tubule cells [29]. The maximal threshold of phosphate (TmP/GFR) is a very sensitive indicator that reflects the reabsorption of phosphate in the renal tubules. The Tm/GFR is usually very low in patients with FS (normal values 2.3–4.3 mg/dl). PTH level are normal or elevated in patients with FS. Serum 1,25dihydroxy vitamin D3 is variable [30, 31]. Rickets usually manifest in small children with bowing deformity of the lower limbs, distal femur, ulna, and the radius. Other signs include increased tendency for fractures, skull bossing, delayed fontanelle closure, craniotabes (soft skull), “rachitic rosary,” Harrison’s groove, and wrist widening.

1359

ðUp=PpÞ 100 TRP ð%Þ ¼ 1 ðUcr=Pcr Þ ðp ¼ amino acid, cr ¼ creatinine, U ¼ urine, P ¼ plasmaÞ TmP=GFR ¼ TRP Sp ðGFR ¼ glomerular filtration rate, S ¼ serumÞ

Metabolic Acidosis More than 85 % of filtered load of bicarbonate (HCO3) is reabsorbed by the proximal tubule cells (also see ▶ Chaps. 9, “Physiology of the Developing Kidney: Acid-Base Homeostasis and Its Disorders” and ▶ 39, “Renal Tubular Acidosis in Children”). This is accomplished by the coordinated function of luminal membrane Na+/H+ exchanger, luminal membrane carbonic anhydrase IVand XIV, and basolateral membrane Na+/HCO3 cotransporter [30]. Defective bicarbonate reabsorption in the proximal tubules results in hyperchloremic metabolic acidosis and is a common feature of FS. The anion gap is normal. In overt forms of FS, more than 30 % of the filtered load of HCO3 is not reabsorbed; patients have low plasma HCO3 levels (12–18 mEq L1). Fractional excretion of HCO3 (FEHCO3) under efficient alkali treatment that increases plasma HCO3 within the normal ranges is >15 % in patients with FS. Acidification in the distal tubule is usually normal, but can be sometimes impaired due to chronic hypokalemia or combined proximal-distal disease/toxicity. ð% Þ Fractional excretion of HCO 3 = ð Ucr=Pcr Þ 100 ¼ U HCO =P HCO 3 3 HCO 3 ¼ bicarbonate, cr ¼ creatinine, U ¼ urine, P ¼ plasmaÞ

Sodium and Potassium Losses Sixty to eighty percent of filtered load of Na+ is reabsorbed in the proximal tubules in the normal condition. Renal Na+ reabsorption in the proximal

1360

tubules is decreased in patients with FS. This may cause hypotension and dehydration; some patients develop hyponatremia. Hypokalemia is secondary to increased delivery of Na+ to the distal segments and activation of the renin-angiotensin system by hypovolemia. Potassium wasting may cause lifethreatening severe hypokalemia.

Hypercalciuria Hypercalciuria is commonly observed in FS. In patients with heavy low-molecular-weight proteinuria, such as in Dent disease, different mechanisms may play in opposite directions. Defective endocytosis of parathyroid hormone (PTH) increases its expression on the cell surface of proximal tubular cells, where it stimulates 25-hydroxyvitamin D3 1-hydroxylase to produce more 1,25-dihydroxyvitamin D3, raising serum levels of this vitamin. Conversely, patients lose in their urine the vitamin D3-binding protein, which binds 25-hydroxyvitamin D3 and presents it to the enzyme. The final levels of 1,25dihydroxyvitamin D3 depend on the balance of these opposite processes. Often, patients with FS have slightly elevated serum levels of 1,25dihydroxyvitamin D3, which increases intestinal Ca2+ reabsorption and causes hypercalciuria (absorptive hypercalciuria) [31]. Hypercalciuria is rarely associated with nephrolithiasis in patients with FS, possibly because of the polyuria and alkalized urine. Patients with Dent disease, however, can present with hypercalciuria and nephrolithiasis.

Hyperuricosuria (Uricosuria) Uric acid (urate) is the end product of purine metabolism in humans. Because of its small molecular size (MW = 126 D), uric acid is freely filtered from the glomerulus. Approximately 90–95 % of the filtered load of uric acid is eventually reabsorbed in the proximal tubules. A fourcomponent hypothesis has been proposed to explain the renal uric acid transport mechanism; it includes glomerular filtration, presecretory

T. Igarashi

reabsorption, secretion, and postsecretory reabsorption [32]. Hyperuricosuria is often present in FS, leading to secondary hypouricemia (750 Da in normal urine. Kidney Int. 2004;66:1994–2003. 44. Birn H, Fyfe JC, Jacobsen C, et al. Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J Clin Invest. 2000;105: 1353–61. 45. Birn H, Christensen EI. Renal albumin absorption in physiology and pathology. Kidney Int. 2006;69:440–9. 46. Dent CE, Friedman M. Hypercalciuric rickets associated with renal tubular change. Arch Dis Child. 1964;39:240–9. 47. Wrong OM, Norden AG, Freest TG, et al. Dent’s disease; a familial renal tubular syndrome with low-molecular weight proteinuria, hypercalciuria, nephroclcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. QJM. 1994;87:473–93. 48. Hodgin JB, Corey HE, Kaplan BS, et al. Dent disease presenting as partial Fanconi syndrome and hypercalciuria. Kidney Int. 2008;73:1320–3. 49. Sekine T, Komoda F, Miura K, et al. Japanese Dent disease has a wider clinical spectrum than Dent disease in Europe/USA: genetic and clinical studies of 86 unrelated patients with low-molecular-weight proteinuria. Nephrol Dial Transplant. 2014;29:376–84. 50. Suzuki Y, Okada T, Higuchi A, et al. The low molecular weight of protein components in children urine. Acta Paediatr Jpn. 1980;22:1–5. 51. Igarashi T, Hayakawa H, Shiraga H, et al. Hypercalciuria and nephrocalcinosis in patients with idiopathic low-molecular-weight proteinuria in Japan: is the disease identical to Dent’s disease in United Kingdom? Nephron. 1995;69:242–7.

1381 52. Lloyd SE, Pearce SHS, Gunter H, et al. Idiopathic low molecular weight proteinuria associated with hypercalciuria, nephrocalcinosis in Japanese children is due to mutations of the renal chloride channel (CLCN5). J Clin Invest. 1997;99:967–74. 53. Akuta N, Lloyd SE, Igarashi T, et al. Mutations of CLCN5 in Japanese children with idiopathic low molecular weight proteinuria, hypercalciuria and nephrocalcinosis. Kidney Int. 1997;52:911–6. 54. Igarashi T, Inatomi J, Ohara T, et al. Clinical and genetic studies of CLCN5 mutations in Japanese families with Dent’s disease. Kidney Int. 2000;58:520–7. 55. Jentsch TJ, Poet M, Furhmann JK, et al. Physiological functions of ClC Cl channels gleaned from human genetic disease and mouse models. Annu Rev Physiol. 2005;67:779–807. 56. Moulin P, Igarashi T, van der Smissen P, et al. Altered polarity and expression of H+-ATPase without ultrastructural changes in kidneys of Dent’s disease patients. Kidney Int. 2003;63:1285–95. 57. Frymoyer SC, Scheinman SJ, Dunham PB, et al. X-linked recessive nephrolithiasis with renal failure. N Engl J Med. 1991;325:681–6. 58. Norden AGW, Scheinman SJ, Deschodt-Lanckman MM, et al. Tubular proteinuria defined by a study of Dent’s (CLCN5 mutation) and other tubular diseases. Kidney Int. 2000;57:240–9. 59. Scheinman SJ. X-linked hypercalciuric nephrolithiasis: clinical syndromes and chloride channel mutations. Kidney Int. 1998;53:3–17. 60. Ludwig M, Utsch B, Balluch B, et al. Hypercalciuria in patients with CLCN5 mutations. Pediatr Nephrol. 2006;21:1241–50. 61. Carr G, Simmons NL, Sayer JA, et al. Disruption of clc-5 leads to redistribution of annexin A2 and promotes calcium crystal agglomeration in collecting duct epithelial cells. Cell Mol Life Sci. 2006;63: 367–77. 62. Norden AGW, Lapsley M, Lee PJ, et al. Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int. 2001;60:1885–92. 63. Hoopes Jr RR, Raja KM, Koich A, et al. Evidence for genetic heterogeneity in Dent’s disease. Kidney Int. 2004;65:1615–20. 64. Raja KA, Schurman S, D’Mello RG, et al. Responsiveness of hypercalciuria to thiazide in Dent’s disease. J Am Soc Nephrol. 2002;13:2938–44. 65. Cebotaru V, Kaul S, Devuyst O, et al. High citrate diet delays progression of renal insufficiency in the ClC-5 knockout mouse model of Dent’s disease. Kidney Int. 2005;68:642–52. 66. Guggino SE. Mechanism of disease: what can mouse models tell us about the molecular process underlying Dent disease? Nat Clin Pract Nephrol. 2007;3: 449–55. 67. Copelvitch L, Nash MA, Kaplan BS. Hypothesis: Dent disease is an under recognized cause of focal glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2:914–8.

1382 68. Lowe CU, Terrey M, MacLachlan EA. Organic aciduria, decreased renal ammonia production, hydrophthalmos and mental retardation: a clinical entity. Am J Dis Child. 1952;83:164–84. 69. Lin T, Lewis RA, Nussbaum RI. Molecular confirmation of carriers of Lowe syndrome. Ophthalmology. 1999;106:119–22. 70. Charnas LR, Bernardini I, Rader D, et al. Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991;324:1318–25. 71. Laube G, Russel-Egitt I, van’t Hoff W. Early proximal tubular dysfunction in Lowe’s syndrome. Arch Dis Child. 2004;89:479–80. 72. Attree O, Olivos IM, Okabe I, et al. The Lowe’s oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5phosphatase. Nature. 1992;358:239–42. 73. Zhang X, Jefferson AB, Auethavekiat V, et al. The protein deficient in Lowe syndrome is a phosphatidylinositol 4,5-bisphosphate 5-Phosphatase. Proc Natl Acad Sci U S A. 1995;92:4853–6. 74. Lin T, Orrison BM, Leahey AM, et al. Spectrum of mutations in the OCRL1 gene in the Lowe oculocerebrorenal syndrome. Am J Hum Genet. 1997;60:1384–8. 75. Zhang X, Hartz PA, Philip E, et al. Cell lines from kidney proximal tubules of a patient with Lowe syndrome lacks OCRL inositol polyphosphate 5-phosphatase and accumulate phosphatidylinositol 4,5-bisphosphate. J Biol Chem. 1998;273:1574–82. 76. Suchy SF, Nussbaum RL. The deficiency of PIP2 5-phosphatased in Lowe syndrome affects actin polymerization. Am J Hum Genet. 2002;71:1420–7. 77. Ungewickell A, Ward M, Ungewickell E, et al. The inositol polyphosphate 5-phosphatase Ocrl associates with endosome that are partially coated with clathrin. Proc Natl Acad Sci U S A. 2004;101:13501–6. 78. Lowe M. Structure and function of Lowe syndrome protein. Traffic. 2005;6:711–9. 79. Erdmann KS, Mao Y, McCrea HJ, et al. A role of Lowe syndrome protein OCRL in early steps of the endocytotic pathway. Dev Cell. 2007;13:377–90. 80. Faucherre A, Desbois P, Satre V, et al. Lowe syndrome protein OCRL interacts with Rac GTPase in the trans-Golgi network. Hum Mol Genet. 2003;12:2449–56. 81. Bockenhauer D, Bokenkamp A, van’t Hoff W, et al. Renal phenotype in Lowe syndrome: a selective proximal tubular dysfunction. Clin J Am Soc Nephrol. 2008;3:1430–6. 82. Velibor T, Vladimir JL, Peter K, et al. Clinical and laboratory features of Macedonian children with OCRL mutations. Pediatr Nephrol. 2011;26:557–62. 83. Hatefi Y. The mitochondrial electron transport and oxidative phosphorylation system. Annu Rev Biochem. 1985;54:1015–69. 84. Clayton DA. Structure and function of the mitochondrial genome. J Inherit Metab Dis. 1992;15:439–47.

T. Igarashi 85. DiMauro S, Bonilla E, Lombes A, et al. Mitochondrial encephalomyopathies. Neurol Clin. 1990;8:483–506. 86. Niaudet P. Mitochondrial disorders and the kidney. Arch Dis Child. 1998;78:387–90. 87. Ueda Y, Ando A, Nagata T, et al. A boy with mitochondrial disease: asymptomatic proteinuria without neuromyopathy. Pediatr Nephrol. 2004;19:107–10. 88. Morris AA, Taylor RW, Birchi-Marchin MA, et al. Neonatal Fanconi syndrome due to deficiency of complex III of the respiratory chain. Pediatr Nephrol. 1995;9:407–11. 89. Kuwertz-Broking E, Koch HG, Marquardt T, et al. Renal Fanconi syndrome: first sign of partial respiratory chain complex IV deficiency. Pediatr Nephrol. 2000;14:495–8. 90. Au KM, Lau SC, Mak YF, et al. Mitochondrial DNA deletion in a girl with Fanconi syndrome. Pediatr Nephrol. 2007;22:136–40. 91. Tzen CY, Tsai JD, Wu TY, et al. Tubulointerstitial nephritis associated with a novel mitochondrial point mutation. Kidney Int. 2001;59:846–54. 92. Szabolcs MJ, Seigle R, Shanske S, et al. Mitochondrial DNA deletion: a cause of chronic tubulointerstitial nephropathy. Kidney Int. 1994;45:1388–96. 93. Mochizuki H, Joh K, Kawame H, et al. Mitochondrial encephalomyopathies preceded by de Toni-Debré-Fanconi syndrome or focal segmental glomerulosclerosis. Clin Nephrol. 1996;46:347–52. 94. Gucer S, Talim B, Asan E, et al. Focal segmental glomerulosclerosis associated with mitochondrial cytopathy: report of two cases with special emphasis on podocytes. Pediatr Dev Pathol. 2005;8:710–7. 95. Hotta O, Inoue CN, Miyabayashi S, et al. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int. 2001;59:1236–43. 96. Barisoni L, Diomedi-Camassei F, Santorelli FM, et al. Collapsing glomerulopathy associated with inherited mitochondrial injury. Kidney Int. 2008;74:237–43. 97. Lopez LC, Schuelke M, Quinzii CM, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet. 2006;79:1125–9. 98. Niaudet P, Heidet L, Munnich A, et al. Deletion of the mitochondrial DNA in a case of de Toni-Debré-Fanconi syndrome and Pearson syndrome. Pediatr Nephrol. 1994;8:164–8. 99. Zaffanello M, Zamboni G. Therapeutic approach in a case of Pearson’s syndrome. Minerva Pediatr. 2005;57:143–6. 100. Ezgu F, Senaca S, Gunduz M, et al. Severe renal tubulopathy in a newborn due to BCS1L gene mutation: effects of different treatment modalities on the clinical course. Gene. 2013;528:364–6. 101. Matsutani H, Mizusawa Y, Shimoda M, et al. Partial deficiency of cytochrome c oxidase with isolated

42

Pediatric Fanconi Syndrome

proximal renal tubular acidosis and hypercalciuria. Clin Nephrol Urol. 1992;12:221–4. 102. Goto Y, Itami N, Kajii N, et al. Renal tubular involvement mimicking Bartter syndrome in a patient with Kearn-Sayre syndrome. J Pediatr. 1990;116:904–10. 103. Moraes CT, Shanske S, Trischler HJ, et al. Mitochondrial DNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial disease. Am J Hum Genet. 1991;48:492–501. 104. Gilber RD, Emms M. Pearson’s syndrome presenting with Fanconi syndrome. Ultrastruct Pathol. 1996;20: 473–5. 105. van’t Hoff WG, Ledermann SE, Waldron M, et al. Early-onset chronic renal failure as a presentation of infantile nephropathy cystinosis. Pediatr Nephrol. 1995;9:483–4. 106. Pennesi M, Marchetti F, Crovella S, et al. A new mutation in two siblings with cystionosis presenting with Bartter syndrome. Pediatr Nephrol. 2005;20: 217–9. 107. Yildiz B, Durmus-Aydogdu S, Kural N, et al. A patient with cystinosis presenting transient features of Bartter syndrome. Turk J Pediatr. 2006;48:260–2. 108. Theodoropolos DS, Shawker TH, Heinrichs C, et al. Medullary nephrocalcinosis in nephropathic cystinosis. Pediatr Nephrol. 1995;9:412–8. 109. Gubler MC, Lacoste M, Sich M, et al. The pathology of the kidney in cystinosis. Paris: Elsevier; 1999. 110. Town M, Jean G, Cherqui S, et al. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet. 1998;18:319–24. 111. Raggi C, Luciani A, Nevo N, et al. Differentiation and aberrations of the endolysosomal compartment characterize the early stage of nephropathic cystinosis. Hum Mol Genet. 2014;23:2266–78. 112. Gahl WA, Thoene JG, Schneidel JA. Cystinosis. N Engl J Med. 2003;347:111–21. 113. Leslie ND. Insights into pathogenesis of galactosemia. Annu Rev Nutr. 2003;23:59–80. 114. Tyfield L, Reichardt J, Fridovich-Keil J, et al. Classical galactosemia and mutation at the galactose-1-uridyl transferase (GALT) gene. Hum Mutat. 1999;13:417–30. 115. Waggoner DD, Buist NRM, Donnel GN, et al. Longterm prognosis in galactosemia: results in a survey of 350 cases. J Inherit Metab Dis. 1990;13:802–18. 116. Lai KW, Cheng LY, Choung AL, et al. Inhibitor of apoptosis proteins and ovarian dysfunction in galactosemic rats. Cell Tissue Res. 2003;311:417–25. 117. Chung MA. Galactosemia in infancy: diagnosis, management, and prognosis. Pediatr Nurs. 1997;23:563–9. 118. Berry GT, Palmieri M, Gross KC, et al. The effect of dietary fruits and vegetables on urinary galactitol excretion in galactose-1-phosphate uridyltransferase deficiency. J Inherit Metab Dis. 1993;16:91–100. 119. Berry GT, Mate PJ, Reynold RA. The rate of de novo galactose synthesis in patients with galactose-1-phosphate uridyltransferase deficiency. Mol Genet Metab. 2004;81:22–30.

1383 120. Berry GT, Nissim I, Lin Z, et al. Endogenous synthesis of galactose in normal men and patients with hereditary galactosemia. Lancet. 1995;346:1073–4. 121. Gitzelmann R, Wells HJ, Segal S. Galactose metabolism in a patient with hereditary galactokinase deficiency. Eur J Clin Invest. 1974;4:79–84. 122. Waggoner DD, Buist NRM. Long-term complications in treated galactsemia-175 US cases. Int Pediatr. 1993;8:97–199. 123. Ascota PB, Gross KC. Hidden sources of galactose in the environment. Eur J Pediatr. 1995;154:S87–92. 124. Gitzelmann R. Additional findings in galactokinase deficiency. J Pediatr. 1975;87:1007–8. 125. Slepak TI, Tang M, Slepak VZ, et al. Involvement of endoplasmic reticulum stress in a novel classic galactosemia model. Mol Genet Metab. 2007;92:78–87. 126. Ali M, Rellos P, Cox TM. Hereditary fructose intolerance. J Med Genet. 1998;35:353–65. 127. Rottmann WH, Tolan DR, Penhoet EE. Complete amino acid sequence for human aldolase B derived from cDNA and genomic clones. Proc Natl Acad Sci U S A. 1984;81:2738–42. 128. Mukai T, Yatsuki H, Joh K, et al. Human aldolase b gene: characterization of the genomic aldolase B gene and analysis of sequences required for multiple polyadenylations. J Biochem. 1987;102:1043–51. 129. Esposito G, Vitagliano L, Santamaria R, et al. Structural and functional analysis of aldolase B mutants related to hereditary fructose intolerance. FEBS Lett. 2002;531:152–6. 130. Cross NC, Cox TM. Hereditary fructose intolerance. Int J Biochem. 1990;22:685–9. 131. Morris Jr RC. An experimental renal acidification defect in patients with hereditary fructose intolerance: I. Its resemblance to renal tubular acidosis. J Clin Invest. 1967;47:1389–98. 132. Morris Jr RC. An experimental renal acidification defect in patients with hereditary fructose intolerance: II. Its distinction from classic renal acidosis and its resemblance to the renal acidification defect associated with the Fanconi syndrome of children with cystinosis. J Clin Invest. 1968;47:1648–63. 133. Richardson RMA, Little JA, Pattern RL, et al. Pathogenesis of acidosis in hereditary fructose intolerance. Metabolism. 1979;28:1133–8. 134. Levin B, Snodgrass GLAI, Oberholzer VG, et al. Fructosemia. Observations in seven cases. Am J Med. 1968;45:826–38. 135. Lu M, Holliday LS, Zhang L, et al. Interaction between aldolase and vacuolar H+-ATPase: evidence for direct coupling of glycolysis to the ATP-hydrolyzing proton pump. J Biol Chem. 2001;276:30407–13. 136. Steinmann B, Gitzelmann R. The diagnosis of hereditary fructose intolerance. Helv Paediatr Acta. 1981;36:297–316. 137. M€ uller P, Meier C, Böhme HJ, et al. Fructose breath hydrogen test- is it really a harmless diagnostic procedure? Dig Dis. 2003;21:276–8.

1384 138. Chou JY, Matern D, Mansfield BC, et al. Type I glycogen storage diseases: disorders of the glucose6-phosphatase complex. Curr Mol Med. 2002;2:121–43. 139. von Gierke E. Hepato-nephro-megalia glycogenica (Glykogenespecicher-krankheit der Lber und Nieren). Beitr Pathol Anat. 1929;82:497–513. 140. Kim SY, Vhen LY, Yiu WH, et al. Neutrophilia and elevated serum cytokines are implicated in glycogen storage disease type Ia. FEBS Lett. 2007;581:3833–8. 141. Di R, Calevo MG, Taro’s M, et al. Hepatocellular adenoma and metabolic balance in patients with type Ia glycogen storage disease. Mol Genet Metab. 2008;93:398–401. 142. Reddy SK, Kishnani PS, Sullivan JA, et al. Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. J Hepatol. 2007;47:658–63. 143. Reitsma-Bierens WCC. Renal complications in glycogen storage disease type I. Eur J Pediatr. 1993;152: S60–2. 144. Hers HG, van Hoof F, de Barsy T. Glycogen storage disease. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill; 1989. p. 425–37. 145. Matsuo N, Tsuchiya M, Cho H, et al. Proximal renal tubular acidosis in a child with type I glycogen storage disease. Acta Pediatr Scand. 1986;75:332–5. 146. Chen YT, Scheinman JI, Park HK, et al. Amelioration of proximal renal tubular dysfunction in type I glycogen storage disease with dietary therapy. N Engl J Med. 1990;323:590–3. 147. Chen YT, Coleman RA, Scheinman JI, et al. Renal disease in type I glycogen storage disease. N Engl J Med. 1988;318:7–11. 148. Verani R, Bernstein J. Renal glomerular and tubular abnormalities in glycogen storage disease type I. Arch Pathol Lab Med. 1988;112:271–4. 149. Baker L, Dahlem S, Goldfarb S, et al. Hyperfiltration and renal disease in glycogen storage disease. Kidney Int. 1989;35:1345–50. 150. Weinstein DA, Somers MJ, Wolfsdorf JI. Decreased urinary citrate excretion in type 1a glycogen storage disease. J Pediatr. 2001;138:378–82. 151. Rake JP, Visser G, Labrune P, et al. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European study on glycogen storage disease type I (ESGSD I). Eur J Pediatr. 2002;161:S20–34. 152. Yiu WH, Pan C-J, Ruef RA, et al. Angiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type I. Kidney Int. 2008;73:716–23. 153. Urushihara M, Kagami S, Ito M, et al. Transforming growth factor-beta in renal disease with glycogen storage disease I. Pediatr Nephrol. 2004;19:676–8. 154. Greene HL, Slonim AE, O’Neill Jr JA, et al. Continuous nocturnal intragastric feeding for management of type 1 glycogen storage disease. N Engl J Med. 1976;294:423–5.

T. Igarashi 155. Wolfsdorf JI, Crigler Jr JF. Cornstarch regimens for nocturnal treatment of young adults with type I glycogen storage disease. Am J Clin Nutr. 1997;65:1507–11. 156. Chen YT, Cornblath M, Sidbury JB, et al. Cornstarch therapy in type I glycogen storage disease. N Engl J Med. 1984;310:171–5. 157. Iyer SG, Chen CL, Wang CC, et al. Long-term results of living donor liver transplantation for glycogen storage disorders in children. Liver Transpl. 2007;13:848–52. 158. Fanconi G, Bickel H. Die chronishe aminoaidurie (aminosäurendiabetes oder nehrotishßglukosurisher zwergwuchs) bei der glykogenose und der cystinkrankhein. Helv Pediatr Acta. 1949;4:359–96. 159. Manz F, Bickel H, Brodehl J, et al. Fanconi-Bickel syndrome. Pediatr Nephrol. 1987;1:509–19. 160. Furlan F, Santer R, Vismara E, et al. Bilateral nuclear cataracts as the first neonatal sign of Fanconi-Bickel syndrome. J Inherit Metab Dis. 2006;29:685. 161. Santer R, Schneppenheim R, Dombrowski A, et al. Fanconi-Bickel syndrome- a congenital defect of the liver-type facilitative glucose transporter. J Inherit Metab Dis. 1998;21:191–4. 162. Yoo H-W, Shin Y-K, Seo E-J, et al. Identification of a novel mutation in the GLUT2 gene in a patient with Fanconi-Bickel syndrome presenting with neonatal diabetes mellitus and galactosaemia. Eur J Pediatr. 2002;161:351–3. 163. Santer R, Schneppenheim R, Dombrowski A, et al. Mutations in GLUT2, the gene for the livertype glucose transporter, in patients with FanconiBickel syndrome. Nat Genet. 1997;17:324–6. 164. Santer R, Groth S, Kinner M, et al. The mutation spectrum of the facilitative glucose transporter gene SLC2A2 (GLUT2) in patients with Fanconi-Bickel syndrome. Hum Genet. 2002;110:21–9. 165. Bell GI, Burnant CF, Takeda J, et al. Structure and function of mammalian facilitative sugar transporters. J Biol Chem. 1993;268:19161–4. 166. Berry GT, Baker L, Kaplan FS, et al. Diabetes-like renal glomerular disease in Fanconi-Bickel syndrome. Pediatr Nephrol. 1995;9:287–91. 167. Lee PJ, van’t Hoff WG, Leonard JV. Catch-up growth in Fanconi-Bickel syndrome with uncooked cornstarch. J Inherit Metab Dis. 1995;18:153–6. 168. Riva S, Ghisalberti C, Parini R, et al. The FanconiBickel syndrome: a case of neonatal onset. J Perinatol. 2004;24:322–3. 169. Berfer R, Smit GP, Stoker de Varies SA, et al. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia. Clin Chim Acta. 1981;114: 37–44. 170. Kvittingen EA, Jellum E, Stokke O, et al. Assay of fumarylacetoacetate fumarylhydrolase in human liver: deficient activity in a case of hereditary tyrosinemia. Clin Chim Acta. 1981;115:311–9. 171. Holme E, Lindstedt S. Diagnosis and management of tyrosinemia type I. Curr Opin Pediatr. 1995;6: 726–32.

42

Pediatric Fanconi Syndrome

172. Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr. 1976;88:434–8. 173. Castilloux J, Laberge AM, Martin SR, et al. “Silent” tyrosinemia presenting as hepatocellular carcinoma in a 10-year-old girl. J Pediatr Gastroenterol Nutr. 2007;44:375–7. 174. Mitchell G, Larochell J, Lambert M, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med. 1990;322:432–7. 175. Freeto S, Mason D, Chen J, et al. A rapid ultra performance liquid chromatography tandem mass spectrometric method for measuring amino acids associated with maple syrup urine disease, tyrosinemia and phenylketonuria. Ann Clin Biochem. 2007;44:474–81. 176. Pardis K, Weber A, Seidman EG, et al. Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet. 1990;47:338–42. 177. Nissenkorn A, Korman SH, Vardi O, et al. Carnitinedeficient myopathy as a presentation of tyrosinemia type I. J Child Neurol. 2001;16:642–4. 178. Endo F, Sun MS. Tyrosinemia type I and apoptosis of hepatocytes and renal tubular cells. J Inherit Metab Dis. 2002;25:227–34. 179. Nakamura K, Tanaka Y, Mitsubishi H, et al. Animal models of tyrosinemia. J Nutr. 2007;137:1556S–60. 180. Spencer PD, Medow MS, Moses LC, et al. Effects of succinylacetone on the uptake of sugars and amino acids by brush border vesicles. Kidney Int. 1988;34:671–7. 181. Roth KS, Carter BE, Higgins ES. Succinylacetone effects on renal tubular phosphate metabolism: a new model for experimental Fanconi syndrome. Proc Soc Exp Biol Med. 1991;196:428–31. 182. Fairney A, Francis D, Ersser RS, et al. Diagnosis and treatment of tyrosinosis. Arch Dis Child. 1968;43: 540–7. 183. Masurl-Paulet A, Poggi-Bach J, Rolland MO, et al. NTBC treatment in tyrosinemia type I: longterm outcome in French patients. J Inherit Metab Dis. 2008;31:81–7. 184. Koelink CJ, van Hasselt P, van der Ploeg A, et al. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer? Mol Genet Metab. 2006;89:310–5. 185. Shoemaker LR, Strife CF, Balisteri WF, et al. Rapid improvement of the renal tubular dysfunction associated with tyrosinemia after hepatic replacement. Pediatrics. 1992;89:251–5. 186. Das SK, Ray K. Wilson’s disease: an update. Nat Clin Pract Neurol. 2006;2:482–93. 187. Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993;5:327–37. 188. Figus A, Angius A, Loudianos G, et al. Molecular pathology and haplotype analysis of Wilson disease in Mediterranean population. Am J Hum Genet. 1995;57:1318–24.

1385 189. Vulpe C, Levinson B, Whitney S, et al. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat Genet. 1993;3:7–13. 190. Yang XL, Miura N, Kawarada Y, et al. Two forms of Wilson disease protein produced by alternative splicing are localized in distinct cellular compartments. Biochem J. 1997;326:897–902. 191. Reynolds ES, Tannen RL, Tyler HR. The renal lesion in Wilson’s disease. Am J Med. 1966;40:518–37. 192. Sozeri E, Feist D, Ruder H, et al. Proteinuria and other renal functions in Wilson’s disease. Pediatr Nephrol. 1997;11:307–11. 193. Kalra V, Mahjan S, Kesarwani PK, et al. Rare presentation of Wilson’s disease: a case report. Int Urol Nephrol. 2004;36:289–91. 194. Fulop M, Sternlieb I, Scheinberg IM. Defective urinary acidification in Wilson’s disease. Ann Intern Med. 1968;68:770–7. 195. Leu ML, Strickland GT, Gutman RA. The renal lesion on Wilson’s disease: response to penicilamine therapy. Am J Med Sci. 1970;260:381–98. 196. Elasas LG, Hayslett JP, Sprgo BH, et al. Wilson’s disease with reversible renal tubular dysfunction. Correlation with proximal tubular ultrastructure. Ann Intern Med. 1971;75:427–33. 197. Ala A, Borjigin J, Rochwarger A, et al. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology. 2005;41:668–70. 198. Page RA, Davie CA, McManus D, et al. Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease. Neurology. 2004;63:638–43. 199. Kuruvilla A, Joseh S. “Face of the giant panda” sign in Wilson’s disease; revisited. Neurol India. 2000;48:395–6. 200. Ala A, Walker A, Ashkan K, et al. Wilson’s disease. Lancet. 2007;369:397–408. 201. Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson’s disease with zinc: XV. Long-term follow-up. J Lab Clin Med. 1998;132:264–78. 202. Czlonkowska A, Gajda J, Rodo M. Effects of longterm treatment in Wilson’s disease with D-penicillamine and zinc sulphate. J Neurol. 1996;243:269–73. 203. Simell O, Perheentupa J, Rapola J, et al. Lysinuric protein intolerance. Am J Med. 1975;59:229–40. 204. Borsani G, Bassi MT, Sperandeo MP, et al. SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. Nat Genet. 1999;21:297–301. 205. Benninga MA, Lilien M, de Koning TJ, et al. Renal Fanconi syndrome with ultrastructural defects in lysinuric protein intolerance. J Inherit Metab Dis. 2007;30:402–3. 206. Golachowska MR, van Dael CML, Keuning H, et al. MYO5B mutations in patients with microvillous inclusion disease presenting with transient renal Fanconi syndrome. J Pediatr Gastroenterol Nut. 2012;54:491–8.

1386 207. Marshansky V, Ausiello DA, Brown D. Physiological importance of endosomal acidification: potential role in proximal tubulopathies. Curr Opin Nephrol Hypertens. 2002;11:527–37. 208. Winter WE, Nakamura M, House DV. Monogenic diabetes mellitus in youth. The MODY syndromes. Endocrinol Metab Clin North Am. 2000;28:765–85. 209. Hamilton AJ, Bingham C, McDonald TJ, et al. The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a β cell phenotype. J Med Genet. 2014;51:165–9. 210. Murer H, Forster I, Biber J. The sodium phosphate cotransporter family SLC34. Pflugers Arch. 2004;447:763–7. 211. Magen D, Berger L, Coady M, et al. A loss-of-function mutation in NaPi-IIa and renal Fanconi’s syndrome. N Engl J Med. 2010;362:1102–9. 212. Tieder M, Sakarcan A, Neiberger R. Elevated serum 1,25-dihydroxyvitamin D concentrations in siblings with primary Fanconi’s syndrome. N Engl J Med. 1988;319:845–9. 213. Ben-Ishay D, Dreyfuss F, Ylmann TD. Fanconi syndrome with hypouricemia in an adult. Am J Med. 1961;31:793–800. 214. Klootwijk ED, Reichold M, Helip-Wooley A, Tolaymat A, Broeker C, Robinette SL, et al. Mistargeting of peroxisomal EHHADH and inherited renal Fanconi’s syndrome. N Engl J Med. 2014;370:129–38 215. Sheldon W, Luder J, Webb B. A familial tubular absorption defect of glucose and amino acids. Arch Dis Child. 1961;36:90–5. 216. Friedman AL, Trygstad CW, Chesney RW. Autosomal dominant Fanconi syndrome with early renal failure. Am J Med Genet. 1978;2:225–32. 217. Patrick A, Vameron JS, Ogg CS. A family with a dominant form of idiopathic Fanconi syndrome leading to renal failure in adult life. Clin Nephrol. 1981;16:289–92. 218. Wen SF, Friedman AL, Oberley TD. Two case studies from a family with primary Fanconi syndrome. Am J Kidney Dis. 1989;13:240–6. 219. Tolaymat A, Sakarcan A, Neiberger R. Idiopathic Fanconi syndrome in a family. Part I. Clinical aspects. J Am Soc Nephrol. 1992;2:1310–7. 220. Wornell P, Crocker J, Wade A, et al. An Acadian variant of Fanconi syndrome. Pediatr Nephrol. 2007;22:1711–5. 221. Nieman N, Pierson M, Marchal C, et al. Nephropathie familiale glomerulotubulaire avec syndrome de Toni-Debré-Fanconi. Arch Fr Pediatr. 1968;25:43–69. 222. McVicar M, Exeni R, Susin M. Nephrotic syndrome and multiple tubular defects in children: an early sign of focal segmental glomerulosclerosis. J Pediatr. 1980;97:918–22. 223. Ren H, Wang W-M, Chen X-N, et al. Renal involvement and follow up of 130 patients with primary Sjögren syndrome. J Rheumatol. 2008;35:278–84.

T. Igarashi 224. Yang Y-S, Peng C-H, Sia S-K, et al. Acquired hypophosphatemia osteomalacia associated with Fanconi’s syndrome in Sjögren syndrome. Rheumatol Int. 2007;27:593–7. 225. Batuman V. Proximal tubular injury in myeloma. Contrib Nephrol. 2007;153:87–104. 226. Vanmassenhove J, Sallee M, Guilopain P, et al. Fanconi syndrome in lymphoma patients: report of the first case series. Nephrol Dial Transplant. 2010;25:2516–20. 227. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet. 2009;373:759–67. 228. Friedman AL, Chesney R. Fanconi’s syndrome in renal transplantation. Am J Nephrol. 1981;1: 145–7. 229. Dobrin RS, Vernier RL, Fish AJ. Acute eosinophilic interstitial nephritis and renal failure with bone marrow-lymph node granuloma and anterior uveitis. Am J Med. 1975;59:325–33. 230. Igarashi T, Kawato H, Kamoshita S, et al. Acute tubulointersitial nephritis with uveitis syndrome presenting as multiple tubular dysfunction including Fanconi’s syndrome. Pediatr Nephrol. 1992;6:547–9. 231. Wen YK. Tubulointerstitial nephritis and uveitis with Fanconi syndrome in a patient with ankylosing spondylitis. Clin Nephrol. 2009;72:315–8. 232. Tung KS, Black WC. Association of renal glomerular and tubular immune complex disease and autoimmune basement membrane antibody. Lab Invest. 1975;32:696–700. 233. Griswold WR, Krous HF, Reznik V, et al. The syndrome of autoimmune interstitial nephritis and membranous nephropathy. Pediatr Nephrol. 1997;11: 699–702. 234. Makker SP, Widstrom R, Huang J. Membranous nephropathy, interstitial nephritis, and Fanconi syndrome – glomerular antigen. Pediatr Nephrol. 1996;10:7–13. 235. Kinoshita-Katahashi N, Fukasawa H, Ishigaki S, et al. Acquired Fanconi syndrome in patients with Legionella pneumonia. BMC Nephrol. 2013;14:171. 236. Alexandridis G, Liamis G, Elisaf M. Reversible tubular dysfunction that mimicked Fanconi’s syndrome in a patient with anorexia nervosa. Int J Eat Disord. 2001;30:227–30. 237. Watanabe T. Proximal renal tubular dysfunction in primary distal renal tubular acidosis. Pediatr Nephrol. 2005;20:86–8. 238. Hall AM, Bass P, Uniwin R. Drug- induced renal Fanconi syndrome. QJM. 2014;107:261–9. 239. Cleveland WW, Adams WC, Mann JC, et al. Acquired Fanconi syndrome following degraded tetracycline. J Pediatr. 1965;66:333–42. 240. Gainza FJ, Minguela JI, Lampreabe I. Aminoglycoside-associated Fanconi’s syndrome: an underrecognized entity. Nephron. 1997;77:205–11.

42

Pediatric Fanconi Syndrome

241. Ghiculescu R, Kubler P. Aminoglycoside-associated Fanconi syndrome. Am J Kidney Dis. 2006;48: E89–93. 242. Min HK, Kim EO, Lee SJ, et al. Rifampin-associated tubulointerstitial nephritis and Fanconi syndrome presenting as hypokalemic paralysis. BMC Nephrol. 2013;14:13. 243. Tsimihodiomos V, Psychogios N, Kakaidi V, et al. Salicylate-induced proximal tubular dysfunction. Am J Kidney Dis. 2007;50:463–7. 244. Zaki EL, Springate JE. Renal injury from valproic acid: case report and literature review. Pediatr Neurol. 2002;27:318–9. 245. Bagnis CI, Deray G, Baumelou A, et al. Herbs and the kidney. Am J Kidney Dis. 2004;44:1–11. 246. Hong Y-T, Fu L-S, Chung L-H, et al. Fanconi’s syndrome, interstitial fibrosis and renal failure by aristolochic acid in Chinese herbs. Pediatr Nephrol. 2006;21:577–9. 247. Takamoto K, Kawada M, Usui T, et al. Aminoglycoside antibiotics reduce glucose reabsorption in kidney through down-regulation of SGLT1. Biochem Biophys Res Commun. 2003;308:866–71. 248. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int. 1988;33:900–11. 249. Endo A, Fujita Y, Fuchigami T, et al. Fanconi syndrome caused by valproic acid. Pediatr Nephrol. 2010;42:287–90. 250. Buttemer S, Pai M, Lau KK. Ifosfamide induced Fanconi syndrome. BMJ Case Reports. 2011;2011. 251. Zamialuski-Tucker MJ, Morris ME, Springate JE. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol. 1994;129:170–5. 252. Yaseen X, Michoudet C, Baverel G, et al. Mechanisms of the ifosfamide-induced inhibition of endocytosis in the rat proximal kidney tubule. Arch Toxicol. 2008;82:607–14. 253. Sayed-Ahmed MM, Hafez MM, Aldelemy ML, et al. Downregulation of oxidative and nitrosative signaling by L-carnitine in ifosfamide-induced Fanconi syndrome rat model. Oxid Med Cell Longev. 2012;2012:696704. 254. Pratt CB, Meyer WH, Jenkins JJ, et al. Ifosfamide, Fanconi’s syndrome, and rickets. J Clin Oncol. 1991;9:1495–9. 255. Hanquinet S, Wouters M, Devalck C, et al. Increased renal parenchymal echogenicity in ifosfamideinduced renal Fanconi syndrome. Med Pediatr Oncol. 1995;24:116–8. 256. Badary OA. Taurine attenuates Fanconi syndrome induced by ifosfamide without compromising its antitumor activity. Oncol Res. 1998;10:355–60. 257. Portill D, Nagothu KK, Megyesi J, et al. Metabolomic study of cisplatin-induced nephrotoxiciy. Kidney Int. 2006;69:2194–204. 258. François H, Coppo P, Hayman J-P, et al. Partial Fanconi syndrome induced by Imanitib therapy: a

1387 novel cause of urinary phosphate loss. Am J Kidney Dis. 2008;51:298–301. 259. Meier P, Dautheville-Gibal S, Ronco PM, et al. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant. 2002;17:148–9. 260. Ho ES, Lin DC, Mendel DB, et al. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000;11: 383–93. 261. Tanji N, Tanji K, Kambham N, et al. Adefovir nephotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol. 2001;32:734–40. 262. Daugas E, Rougier J-P, Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int. 2005;67:393–403. 263. Law ST, Li KK, Ho YY. Acquired Fanconi syndrome associated with prolonged adefovir dipivoxil therapy in a chronic hepatitis B patient. Am J Ther. 2013;20: e713–6. 264. Verheist D, Monge M, Meynard J-L, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40:1331–3. 265. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect. 2005;51:e61–5. 266. Rafat C, Fakhouri F, Ribeil JA, et al. Fanconi syndrome due to deferasirox. Am J Kidney Dis. 2009;54:931–4. 267. Rheault MN, Bechtel H, Neglia JP, et al. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer. 2011;56:674–6. 268. Murphy N, Elramah M, Vats H, et al. A case report of deferasirox-induced kidney injury and Fanconi syndrome. WMJ. 2013;112:177–80. 269. Gil HW, Yang JO, Lee EY, et al. Paraquat-induced Fanconi syndrome. Nephrology (Carlton). 2005;10:430–2. 270. Hruz P, Mayr M, Löw R, et al. Fanconi’s syndrome, acute renal failure, and tonsil ulceration after colloidal bismuth substrate intoxication. Am J Kidney Dis. 2002;39:E18. 271. Otten J, Vis HL. Acute reversible renal tubular dysfunction following intoxication with methyl-3choromone. J Pediatr. 1968;73:422–5. 272. Butler HE, Morgan JM, Smythe CM. Mercaptopurine and acquired tubular dysfunction in adult nephrosis. Arch Intern Med. 1965;116:853–6. 273. Moss AH, Gabow PA, Kaehny WD, et al. Fanconi syndrome and distal renal tubular acidosis after glue sniffing. Ann Intern Med. 1980;92:69–70. 274. Barbier O, Jacquillet G, Tau M, et al. Effect of heavy metals on, and handling by, the kidney. Nephron Physiol. 2005;99:105–10. 275. Chisolm JJ, Harrison HC, Eberlein WE, et al. Aminoaciduria, hyperphosphaturia and rickets in lead poisoning. Am J Dis Child. 1955;89:159–68.

1388 276. Logman-Adham M. Aminoaciduira and glycosuria following severe childhood lead poisoning. Pediatr Nephrol. 1998;12:218–21. 277. Goyer RA, Tsuchuja K, Leonard DL, et al. Aminoaciduria in Japanese workers in the lead and cadmium industries. Am J Clin Pathol. 1972;57:635–42. 278. Uetani M, Kobayashi E, Suwazono Y, et al. Investigation of renal damage in the cadmium-polluted Jinzu

T. Igarashi River basin, based on health examinations in 1967 and 1968. Int J Environ Health Res. 2007;17:231–42. 279. Elizbieta S-J, Roman L. Metabolic bone disease in children: etiology and treatment options. Treat Endocrinol. 2006;5:297–318. 280. Plank C, Konrad M, Dörr HG, et al. Growth failure in a girl with Fanconi syndrome and growth hormone deficiency. Nephrol Dial Transplant. 2004;19:1910–2.

Primary Hyperoaxaluria in Children

43

Pierre Cochat, Neville Jamieson, and Cecile Acquaviva-Bourdain

Contents Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1390 Primary Hyperoxaluria Type 1 (PH1) . . . . . . . . . . . Pathophysiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Oxalate Burden . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Molecular Approach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Supportive Measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Urological Aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dialysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Organ Transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Future Developments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1390 1390 1392 1393 1394 1394 1396 1396 1396 1399

Primary Hyperoxaluria Type 2 (PH2) . . . . . . . . . . . 1400 Metabolic Derangement . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1400

Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Clinical Presentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Diagnostic Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Treatment and Prognosis . . . . . . . . . . . . . . . . . . . . . . . . . . .

1400 1400 1401 1401

Primary Hyperoxaluria Type 3 (PH3) . . . . . . . . . . . Metabolic Derangement . . . . . . . . . . . . . . . . . . . . . . . . . . . . Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Clinical Presentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Diagnostic Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Treatment and Prognosis . . . . . . . . . . . . . . . . . . . . . . . . . . .

1401 1401 1401 1401 1402 1402

Diagnostic Approach to Primary Hyperoxaluria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1402 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1402 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1402

P. Cochat (*) Centre de référence des maladies rénales rares Néphrogones, Hôpital Femme Mère Enfant, Hospices Civils de Lyon & Université de Lyon, Lyon, France IBCP-UMR 5305 CNRS, Université Claude-Bernard Lyon 1, Lyon, France e-mail: [emailprotected] N. Jamieson Department of Surgery, Addenbrookes Hospital, Cambridge University Teaching Hospitals, Cambridge, UK e-mail: [emailprotected] C. Acquaviva-Bourdain Centre de référence des maladies rénales rares Néphrogones, Hôpital Femme Mère Enfant, Hospices Civils de Lyon & Université de Lyon, Lyon, France Service Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France e-mail: [emailprotected] # Springer-Verlag Berlin Heidelberg 2016 E.D. Avner et al. (eds.), Pediatric Nephrology, DOI 10.1007/978-3-662-43596-0_39

1389

1390

Introduction Hyperoxaluria may be either a secondary or a primary disease. Three distinct autosomal recessive inherited enzyme defects of glyoxylate metabolism have been related to type 1, type 2, and type 3 primary hyperoxalurias (PH), i.e., alanine: glyoxylate aminotransferase (AGT), glyoxylate reductase/hydroxypyruvate reductase (GRHPR), and 4-hydroxy-2-oxoglutarate aldolase (HOGA), respectively; in addition, a few other patients with PH have been reported without identification of PH1, PH2, nor PH3 so that other rare metabolic defects are likely to exist. Among all PH patients, type 1 accounts for 73–80 %, type 2 for 5–10 %, type 3 for 8–10 %, and others for 5–11 % [1]. The global survival rate is better for PH3 than PH2 and better for PH2 than PH1. Oxalate, a dicarboxylic acid (HOOC-COOH), is an end product of metabolism in humans. It is soluble when combined with sodium, potassium, or magnesium but highly insoluble in the form of its calcium salt and has a tendency to crystallize in the renal tubules [2]. The primary defect of inherited hyperoxaluria is overproduction of oxalate, primarily by the liver, with resultant increased excretion by the kidney. The earliest symptoms among those affected are related to hyperoxaluria, and a diagnosis of PH must be considered in any child with a first kidney stone [3]. Renal damage is ultimately due to a combination of tubular toxicity from oxalate, nephrocalcinosis with both intratubular and interstitial calcium oxalate (CaOx) deposits, obstruction from stones, and often superimposed infection that progressively lead to renal impairment and subsequent chronic kidney disease (CKD). Inflammation has been recently shown to contribute to CKD progression in animal models of calcium oxalate-induced nephrocalcinosis [4, 5]. A second phase of tissue damage develops when patients reach chronic kidney disease stage 3b (CKD-3b). At this stage, the kidneys become unable to efficiently excrete the oxalate load that they receive; as a consequence, plasma oxalate (Pox) rises and exceeds its saturation threshold, which leads to oxalate deposition in all tissues (systemic oxalosis), particularly in the

P. Cochat et al.

skeleton [6]. In the kidneys as well as in the skeleton, the activities of macrophages and giant cells are stimulated by oxalate crystals, and serum levels of the macrophage/osteoclast-derived tartrateresistant acid phosphatase 5b (TRACP-5b) enzyme have been proposed to represent a reliable marker of the total calcium oxalate burden [7]. Secondary hyperoxaluria may occur in the setting of poisoning with oxalate precursors (ethylene glycol, ascorbic acid, xylitol, etc.) or with enteric hyperoxaluria, particularly after bowel resection, which may lead to sequestration of calcium in the gut, leaving oxalate in its more soluble sodium form, which is then taken up by the colon [8]. Excess dietary intake has also been linked with secondary hyperoxaluria. Secondary hyperoxaluria must be excluded prior to investigating a patient for primary hyperoxaluria.

Primary Hyperoxaluria Type 1 (PH1) PH1 is one of the most challenging conditions for both adult and pediatric nephrologists worldwide. The diagnostic strategy has improved during recent years and can now be based on reasonable recommendations [3]. However, due to its rarity and variable phenotype, therapeutic guidelines cannot be generated entirely from evidencebased information and necessarily include expert opinions and experiences [9].

Pathophysiology PH1 (MIM 259900) is an autosomal recessive disorder (~1:100,000 live births per year in Europe), caused by the functional defect of the liver-specific peroxisomal, pyridoxal-50 -phosphate-dependent enzyme AGT (MIM 604285) leading to oxalate overproduction [10, 11]. The disease occurs because AGT activity is impaired or because AGT is mistargeted to mitochondria, which likely explains the observed heterogeneity of results obtained with enzymatic activity assays. The median age of the initial symptoms is 5–6 years;

43

Primary Hyperoaxaluria in Children

A Healthy

1391

B Stage 1

Plasma

Liver Glyoxylate

Oxalate

Glyoxylate

AGT [B6]

AGT [B6]

Glycine

Glycine

Oxalate

X

Glycolate

Urine

Plasma

Liver

Glycolate

Glycolate Oxalate

C Stage 2

Urine

D Stage 3

Plasma

Liver

Glycolate Oxalate

Plasma

Liver

Glyoxylate

Oxalate

Skeleton Oxalate

AGT [B6]

X

Skeleton Oxalate

Oxalate

Glyoxylate AGT [B6]

X

Glycine

GFR < 30-44 mL/min per 1.73 m

2

Glycolate

Glycine

ESRD/RRT

Glycolate Bone Joints

Urine

Glycolate Oxalate

Fig. 1 Primary hyperoxaluria type 1. Normally, oxalate synthesized in the liver from glyoxylate detoxification is secreted into plasma and excreted in urine (Panel A). With a moderate degree of renal insufficiency, oxalate is overproduced and excreted by the kidneys (Stage 1, Panel B), but the increased load can cause crystalluria (inset at left, showing monohydrated calcium oxalate crystal in the urine) and the production of oxalate stones in the kidney (inset at right, showing a typical infrared spectrometry analysis, Courtesy of Prof. Jean-François Sabot). In CKD-4, progressive renal damage may include diffuse nephrocalcinosis (Panel C, with the inset at left showing

diffuse nephrocalcinosis on ultrasonography (Courtesy of Prof. Jean-Pierre Pracros) and the inset at right showing oxalate crystals in the proximal renal tubule under polarized light (Courtesy of Dr. Frederique Dijoud)). In patients with CKD-5, the oxalate load cannot be cleared effectively, and oxalate crystals are deposited in all tissues (Panel D, with inset at left showing massive bone and joint involvement (Courtesy of Prof. Jean-Pierre Pracros) and the inset at right showing oxalate crystals in a bone biopsy specimen, May–Gr€ unwald–Giemsa stain (Courtesy of Dr. Georges Boivin))

end-stage renal disease (ESRD) is reached in 50 % of patients between 25 and 40 years of age [10, 12]. Based on registry data, PH1 accounts for 1–2 % of pediatric end-stage renal disease (ESRD) in Europe, USA, and Japan but is more prevalent in countries in which consanguineous marriages are common and exceeds 10 % in some North African and Middle East nations [13–17]. In addition to the progressive decline of GFR due to renal parenchymal damage, continued overproduction of oxalate by the liver combined with reduced oxalate excretion by the kidneys raises Pox above a critical saturation level. As a

result of that, oxalate deposition occurs in many organs, leading to systemic involvement, termed “oxalosis”; bones represent the major compartment where the insoluble oxalate pool is deposited (Figures 1 and 2). Calcium salts of glycolate are soluble and do not appear to cause significant disease in humans. The infantile form of PH1 often presents as a life-threatening condition with very fast progression to ESRD due to very high oxalate load combined with immature GFR; approximately half of these infants have ESRD at the time of diagnosis, and 80 % have ESRD by the age of 3 years [18, 19].

1392

P. Cochat et al.

Fig. 2 Primary hyperoxaluria type 1: simplified global course of the disease

Oxalate production

Systemic involvement Oxalate storage Nephrocalcinosis

Urolithiasis GFR CKD-1 GFR > 90

CKD-2 89 > GFR > 60

Stage 1

Recent reviews on molecular pathophysiology of the disease or therapeutic approaches allow to make management recommendations for PH1 [1, 3, 9].

Diagnosis Because of the rarity of the disease and because many physicians have limited knowledge on inherited forms of urolithiasis, there is on average a 5-year gap between the initial symptoms and the diagnosis of PH1 [10, 12]. The association between renal calculi, nephrocalcinosis, and renal impairment is strongly suggestive of PH1; in addition, family history may add important information [3]. From a clinical standpoint, PH1 is usually diagnosed in patients presenting with one of the following five clinical pictures [20, 21]: – Infant with early nephrocalcinosis and kidney failure (35 %) – Recurrent urolithiases and progressive renal failure in children or adolescents (25 %) – Occasional stone passage in adulthood (15 %) – Recurrence of the disease after renal transplantation in patients with previously unrecognized PH1 (10 %) – Asymptomatic subjects with a positive family history of PH1 (15 %)

CKD-3 59 > GFR > 30 Stage 2

CKD-4 29 > GFR > 15

CKD-5 GFR < 14

Stage 3

Based on the European pediatric registry data, the median age at first symptoms is 4 years, and the mean age at diagnosis is 7.7 years; 43 % of index PH1 patients already have ESRD at diagnosis [14]. The median age at renal replacement therapy (RRT) has decreased from 9.8 years in 1979–1989 to 1.5 years in 2000–2009, demonstrating major advances in early diagnosis and treatment [14]. Crystalluria, infrared spectroscopy, and morphologic characteristics examination allow identification and quantitative analysis of urinary crystals and stones; these analyses usually show CaOx monohydrate crystals (type Ic whewellite) in excess of 200/mm3 in cases with heavy hyperoxaluria [22]. In patients with normal or significant residual GFR, hyperoxaluria (urine oxalate, Uox >1 mmol/1.73 m2 BSA per day, control 0.5 mmol/ 1.73 m2 per day) are indicative of PH1, but some patients do not present with hyperglycoluria (Table 1) [1]. Pox concentration is not useful for diagnosis when the GFR is >40 mL/min per 1.73 m2 since it is usually normal (5 red blood cells/high-power field, red blood cell casts in the urinary sediment, or =2+ on dipstick; or impaired renal function, measured or calculated glomerular filtration rate (Schwartz formula) 0.5 g/day or red casts 8. Psychosis or seizures 9. Hemolytic anemia or leucopenia (300 mg/24” to emphasize the continuous nature of albuminuria as a risk factor for renal and cardiovascular complications [45].

Pathogenesis of Diabetic Nephropathy DN is the result of an interplay between hemodynamic and metabolic factors in the renal microcirculation [46] and the consequent activation of common intermediate pathways, associated with

49

Diabetic Nephropathy in Children

1549

HYPERGLYCEMIA

Hemodynamic factors (Hypertension, Ang II, endothelins, NO)

Increased mitochondrial superoxide production

Metabolic factors

Polyol and Hexosamine pathways

Cytokines

• • • • • •

Growth factors

DAG-PKC

ROS

AGEs

NF-KB

Thickness of glomerular basement membrane Proliferation of mesangial cells Accumulation of matrix proteins Podocytes loss Mesangium and arterial wall hyalinosis Tubulo-interstitial fibrosis & glomerulosclerosis

DIABETIC KIDNEY DISEASE

Fig. 1 Metabolic and hemodynamic factors implicated in the pathogenesis of diabetic nephropathy. NO nitric oxide, Ang II angiotensin II, ROS reactive oxidative species,

DAG-PCK diacylglycerol-protein kinase advanced glycosylated end products

increased synthesis and release of growth factors, cytokines, chemokines, and oxidant species, which are all final mediators of renal damage [6, 46] (Fig. 1). Typical morphological changes in the diabetic kidney are represented by diffuse glomerular basement membrane thickening, mesangial expansion, hyalinosis of the mesangium and arteriolar walls, broadening and effacement of podocyte foot processes, reduction in podocyte number, glomerulosclerosis, and tubulointerstitial fibrosis [47]. These morphological changes in the kidney develop years before the clinical appearance of MA and overt proteinuria, and this is an alarming aspect of DN, given that when the disease is clinically evident, some of the structural damage is already irreversible [19]. Thickening of the basement membrane is a common biopsy finding related to DN; it is associated with loss of glycosaminoglycans and therefore of negative charges, with consequent increased loss of anionic albumin [48, 49].

A subsequent increase in the size of membrane pores leads to the development of nonselective proteinuria. An imbalance between the production and the degradation of mesangial matrix proteins, together with an increase in mesangial cells number, is responsible for mesangial expansion in DN [49]. Hyperglycemia and renal hypertension together with other factors can activate pathways leading to an increased synthesis and deposition of matrix proteins, particularly by stimulating local production of cytokines and growth factors [50]. Furthermore, the same factors can inhibit proteins and enzymes implicated in the degradation of the extracellular matrix, for example, by a nonenzymatic glycation of these components [50]. As in other progressive glomerulopathies, changes in podocyte characteristics are a key feature of DN [51]. Podocytes are highly specialized epithelial cells, interconnected by foot processes, which delimit the slit diaphragm, the main

C,

AGEs

1550

size-selective barrier in the glomerulus. The diabetic milieu can induce several morphological changes in these epithelial cells, as emerged from both human and experimental studies [48]. The first detectable alteration in podocytes in the context of DN is a broadening and effacement of their foot processes [48]. These progressive podocyte changes lead to a decrease in their density and number and a detachment from the glomerular basement membrane. The last phenomena are directly correlated to levels of ACR and to the decline in GFR [48]. Podocytes can also undergo hypertrophy, apoptosis, and increased synthesis of collagen IV, whereas there is a decreased synthesis of proteins such as nephrin [48]. Another characteristic of DN is the hyalinosis of the afferent and efferent arterioles in the glomerulus, due to the accumulation of complement components, fibrinogen, immunoglobulins, albumin, and other plasma proteins [52]. Hypertrophy and sclerosis of the juxtaglomerular apparatus is another frequent finding in DN [53].

Hemodynamic Factors Hemodynamic factors implicated in the pathogenesis of DN include systemic and intraglomerular pressure and activation of vasoactive mediators [46]. Glomerular hypertension is the results of reduced resistance in both the afferent and efferent arterioles, effect which is predominant in the former. On the basis of several experimental studies, it has been suggested that a subset of patients with diabetes could be predisposed to intraglomerular hypertension, due to defects in the renal mechanisms of flow autoregulation [54]. The lack of the normal vasoconstriction in the afferent arteriole in response to increased systemic hypertension, associated with the constriction of the efferent arteriole, contributes to the increase in intraglomerular blood pressure [50]. A potential mediator of the afferent arteriole dilation is an increased oxidative burden. In fact, reactive oxygen species (ROS) can affect K+ channels in the afferent arteriole with consequent hyperpolarization and increased Ca+ influx and vasodilation. K+ channels have a dominant role in the

M. Marcovecchio and F. Chiarelli

electromechanical function of the afferent arteriole but only a minor effect on the efferent arteriole [55]. Glomerular hypertension can in turn induce the activation of several pathways and molecules, which can mediate renal injury. In particular, it has been shown that it can, for example, activate GLUT-1 in glomerular cells, thereby inducing an intracellular hyperglycemic milieu [50]. Angiotensin II is a key mediator of DN, by exerting both hemodynamic and nonhemodynamic effects [46]. The hemodynamic effects of angiotensin II include both systemic and renal vasoconstriction [56]. In the kidney, angiotensin II also increases glomerular capillary pressure and permeability. Non-hemodynamic effects of angiotensin II include activation of transforming growth factor-beta 1 (TGF-ß1) and other cytokines, activation of ROS production in mesangial cells, stimulation of extracellular matrix and inhibition of its degradation, activation of the intracellular NF-kB, and reduction in podocyte nephrin expression [56, 57]. Other factors that have been implicated in the hemodynamic changes related to DN are vasoactive hormones, which can influence the intrarenal circulation by acting on the afferent and efferent arterioles. In particular, endothelin and vasopressin are the most relevant vasoconstrictors in this context, whereas nitric oxide, bradykinin, prostaglandins, and atrial natriuretic factor are the main vasodilators [46].

Metabolic Factors Growth Factors Several growth factors have been implicated in the pathogenesis of DN, through complex intrarenal systems [58–60]. GH/IGF, TGF-ß, vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and connective tissue growth factor (CTGF) are among those more known and investigated [58–60]. The implication of the GH-IGF system in the pathogenesis of DN is well established [58, 59]. Diabetes is associated with decreased hepatic production of IGF-1 related to portal insulinopenia, with consequent lack of the

49

Diabetic Nephropathy in Children

inhibitory feedback of IGF-1 on the anterior pituitary and therefore GH hypersecretion [61, 62]. The integrity of GH receptors in peripheral tissues, other than the liver, can cause a local increased production of IGF-1, which can in turn exert paracrine effects [61, 62]. Antagonist of the GH/IGF-1 system, including somatostatin analogues, GH and IGF-1 receptors antagonists, as well as antagonists of downstream factors activated by GH/IGF-1, such as the ACE and AGE systems, have been found to have beneficial effects on the diabetic kidney in animal models [58]. TGF-ß is considered as a crucial factor in the development of renal kidney disease [58–60]. It appears to be a key point of convergence of both hemodynamic and metabolic pathways activated in DN. In the diabetic milieu, several factors can induce increased expression of this growth factor, such as hyperglycemia, hypertension, mechanical strains, and protein kinase C (PKC). TGF-ß is a pro-fibrotic cytokine, which has a key role in the expansion of extracellular matrix, by stimulating production of several components of the matrix and, in the meantime, by altering extracellular matrix composition [58–60]. VEGF is another relevant growth factor implicated in the pathogenesis of DN, even though its role in this context is not as well defined as for diabetic retinopathy [58–60]. In particular, VEGF is a key angiogenic factor, which influences the proliferation of endothelial cells and exerts a pivotal role in vascular integrity [60]. Anoxia is an important stimulus for its production as well as AGE, angiotensin II, and oxidative stress [60]. VEGF is expressed in different cells in the kidney, including podocytes and tubular cells. Increased VEGF levels have been reported in both T1D and T2D and have been related to DN [63]. In children with T1D and MA, VEGF levels are reduced when compared with diabetic children with normoalbuminuria, and they have an independent predictive value for future development of DN [64]. CTGF is one of the most recent identified growth factors with a role in DN. Increased concentrations of CTGF have been detected in the glomerulus of diabetic patients and animals

1551

[65–67]. In adult patients with T1D, increased levels of CTGF are strongly correlated with the severity of DN [68, 69] and are an independent predictor of ESRD and mortality [70]. CTGF is considered to be the downstream mediator of TGF-ß in extracellular matrix synthesis. However, there is also evidence of a TGF-ß-independent regulation of CTGF, which is related to a direct activation of its synthesis by hyperglycemia, AGEs, and static pressure [67, 71, 72].

Cytokines DN is considered an inflammatory disease, and several cytokines have been implicated in its pathogenesis: interleukin (IL)-1, IL-6, IL-18, and tumor necrosis factor-alpha (TNF-α) [73]. In the kidney, inflammatory cytokines are synthesized and released by endothelial, mesangial, glomerular, and tubular cells [73]. IL-1 has been implicated in increased vascular permeability, proliferation of extracellular matrix and abnormalities in microcirculation [73]. IL-6 has been also implicated in inducing changes in the extracellular matrix [73]. TNF-α has been shown to have a cytotoxic effect on glomerular, mesangial, and epithelial cells in the kidney [60, 73]. Chemokines and cytokines implicated in monocytes/macrophages recruitment have been related to the development and progression of DN [74]. Monocytes chemoattractant protein-1 (MCP-1) is a chemokine with the highest chemotactic activity towards monocytes. For MCP-1 a causative role in the development of DN has been suggested, through recruitment of monocyte/macrophage in the kidney [75]. Furthermore, in vitro studies have shown that MCP-1, by interacting with its receptor (CCR2) can promote fibronectin deposition in the diabetic glomerulus [76]. Blocking the MCP-1/CCR2 pathway ameliorates glomerulosclerosis, indicating that the MCP-1/CCR2 pathway could play a crucial role in the progression of DN [77]. Increased MCP-1 levels have been reported in subjects with diabetes when compared with controls, and it has been shown that plasma and urine MCP-1 levels can be used to assess renal inflammation in this disease [78].

1552

Advanced Glycation End Products and Their Receptors Another link between elevated glucose levels and DN resides in a direct effect of nonenzymatic glycosylation of cellular macromolecules, causing alterations of their structural and functional properties [79–82]. AGEs have been implicated in several biologic activities, mostly by binding to the AGE-specific receptors (RAGEs) on many cells. In particular, they can enhance oxidative stress and stimulate the release of cytokines and growth factors, which in turn accelerate chronic inflammation and endothelial dysfunction [80]. Increased serum levels of AGEs have been detected in children and adolescents with T1D, already before the development of clinically evident signs of microvascular complications [83]. Animal studies support the role of AGE in the pathogenesis of DN. In fact, blockage of AGE, with aminoguanidine, significantly reduces renal changes [84]. There is also a large body of evidence for a predictive role of the soluble form of the RAGE (sRAGE) in the development of vascular diabetic complications, including DN [85]. sRAGE can be measured in peripheral blood, and it seems to result from the expression of a RAGE splice gene variant that encodes an amino-terminally truncated form of the receptor and/or from the cleavage of the native membranous receptor [85]. Serum sRAGE levels are significantly higher in patients with diabetes than in healthy subjects and positively associated with the presence of coronary artery disease [86] and also independently related to albumin excretion [85]. A circulating C-truncated form of the RAGE (esRAGE) exists and seems to work as a scavenger for AGEs and in this way could exert a protective for diabetic complications. Reduced circulating levels of esRAGE have been found in patients with T1D and are related to the severity of vascular complications [87, 88]. Oxidative Stress Oxidative stress is one of the most important factors involved in the pathogenesis of DN [50, 82]. Several pathways have been related to an increased production of oxidative stress in the

M. Marcovecchio and F. Chiarelli

context of DN: increased mitochondrial electron transport; the AGEs-RAGE system; an increased activity of cytochrome P-450, xanthine oxidase, cyclooxygenase, and lipoxygenase; increased glucose auto-oxidation; and an impaired activity of endothelial nitric oxide synthase [89]. Many of the pathways activated by hyperglycemia can induce mitochondrial superoxide overproduction, and blockage of this effect can reduce damage related to high glucose levels [90, 91]. This increased mitochondrial production of ROS can in turn stimulate different processes, including protein kinase C activity, synthesis of growth factors and cytokines, and stimulation of NF-kB. Oxidative stress seems to play an important role also in the context of the so-called metabolic memory [92]. In fact, increased mitochondrial superoxide production consequent to hyperglycemia could induce not only immediate effects, such as activation of PKC or other pathways, but it might also damage mitochondrial DNA [92]. This, in turn, could lead to synthesis of altered subunits of the electron transport system, which could produce increased amount of superoxide even in the presence of physiological glucose levels [92].

Intracellular Factors Polyol and Hexosamine Pathways The polyol pathway has been implicated in the pathogenesis of DN, through the action of aldose reductase, the first and rate-limiting enzyme in this pathway [92]. Aldose reductase reduces the aldehyde form of glucose to sorbitol in a reaction which consumes NADPH. In physiological situations, sorbitol is then oxidized to fructose by sorbitol dehydrogenase and therefore addressed again into the glycolysis. In the presence of hyperglycemia, the production of sorbitol overcomes the potential of its oxidation by sorbitol dehydrogenase, with accumulation in several cells, including renal tubular and glomerular cells. Several mechanisms have been suggested to link the polyol pathway to the development of diabetic complications. These include a dysregulation of the cellular osmotic status, reduction of

49

Diabetic Nephropathy in Children

Na+/K+-ATPase activity, and cytosolic increase in NADH/NAD + and decrease in NADPH [92]. The depletion of NADPH appears to be the most important mediator, as it is associated with an impairment of several enzymatic reactions requiring this enzyme, such as nitric oxide synthase, cytochrome P450, and glutathione reductase, thereby altering the intracellular oxidantantioxidant status and inducing vasoconstriction and poor blood supply [92]. The hexosamine pathway converts fructose-6 phosphate in N-acetylglucosamine, which is a substrate for reactions such as proteoglycan synthesis and generation of O-linked glycoprotein [92, 93]. N-acetylglucosamine has been implicated in the activation of the transcriptional factor Sp1, which is associated with increased synthesis of factors, such as TGF-ß1 and PAI-1, which in turn are associated to the development of vascular complications [92, 93]. In addition, the hexosamine pathway is also associated with increased oxidative stress, and the effects of the activation of this pathway can be prevented by overexpression of antioxidants, such as superoxide dismutase [90].

1553

Emerging Role of MicroRNA in the Pathogenesis of Nephropathy MicroRNAs (miRNAs) are short noncoding RNAs, which regulate gene expression. They are implicated in several biological and pathological processes, including cell proliferation, differentiation, apoptosis, and carcinogenesis. Recent data suggest an important role of miRNA in the kidney, where they regulate renal development, homeostasis, and physiological functions. In addition, miRNAs have also been implicated in the pathogenesis of kidney diseases, including DN [96]. One of the main miRNAs associated with DN is mir-192, which seems to have a key role in regulating fibrosis. Other DN-associated miRNAs are mir-377, mir-200, mir-216a, mir-141, mir-29, and mir-93 [97]. The emerging information on a key role of miRNAs in the pathogenesis of DN suggests that miRNAs might have a great potential to be used, in the future, as novel diagnostic and prognostic biomarkers in the context of this vascular complication of diabetes.

Risk Factors Diacylglycerol-Protein Kinase C Pathway The diacylglycerol (DAG)-PKC system can induce several alterations, which can contribute to DN [92, 94, 95]. These mechanisms include changes in endothelial permeability, vasoconstriction, increased synthesis of extracellular matrix and stimulation of cytokines synthesis, cell growth, angiogenesis, and leukocyte adhesion [92, 94, 95]. Hyperglycemia can stimulate de novo synthesis of DAG, followed by the activation of PKC [92]. PKC modulates the activity of various enzymes, including phospholipase A2, Na+/K+ ATPase as well as the expression of genes related to components of the extracellular matrix [92, 94]. PKC-beta is the major isoform induced in the kidney by hyperglycemia, and ruboxistaurin, a PKC-beta isoform-selective inhibitor, has been shown to have a beneficial effect on microvascular complications, by normalizing endothelial dysfunction and GFR and reducing loss of visual function [84].

Glycemic Control Several observational studies have shown a strong correlation between glycemic control, as assessed by HbA1c, and DN in adults and youth with T1D and T2D [20, 98]. In addition, the probability of reverting from MA to normoalbuminuria is also influenced by glycemic control [21]. Further evidence for the key role of hyperglycemia in the pathogenesis of DN comes from two landmark interventional studies, the Diabetes Control and Complication Trial (DCCT) [99] and the United Kingdom Prospective Diabetes Study (UKPDS) [100]. The DCCT, a multicenter prospective controlled clinical trial involving 1,441 patients with T1D, undoubtedly proved the beneficial effect of maintaining low levels of HbA1c in reducing the risk of developing MA. The DCCT cohort included a group of 195 adolescents, aged 13–17 years, where intensive insulin treatment reduced the risk and progression of MA by 54 % compared

1554

to conventional treatment [101]. In addition, the DCCT follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC) [102], highlighted the important phenomenon of “metabolic memory.” In fact, even though already after 2 years since the end of the DCCT, HbA1c levels were similar between the previously intensively and conventionally treated groups, those who benefited in the past of a better metabolic control still had an advantage in terms of development of complications [102]. With regard to the adolescent cohort, the EDIC study showed that in the previously intensively treated group, the risk of MA and proteinuria decreased by 48 % and 85 %, respectively [102]. Another interesting finding of the DCCT and the UKPDS [99, 100] was the lack of a clear threshold for HbA1c below which the risk of complications was annulled; instead there was a continuous reduction in complication risk as glycemic control improved. In contrast, another study showed a threshold effect for the development of MA at an HbA1c value of about 8.1 % [103].

M. Marcovecchio and F. Chiarelli

in youth with T1D, such as an impairment in the nocturnal fall in blood pressure [112] and abnormalities in daytime diastolic blood pressure [113].

Dyslipidemia Dyslipidemia can also contribute to renal disease in the context of diabetes. Based on adult studies, subjects developing MA have higher cholesterol levels than subjects who do not progress [114], and reduction in cholesterol levels predicts regression of MA to normoalbuminuria. Triglyceride levels have also been suggested as a predictor of progression or regression of MA [115, 116]. Lipid abnormalities are also associated with rates of urinary AER and risk of MA during puberty [117, 118]. Total cholesterol and LDL cholesterol levels have been associated with albumin excretion rates and with the development of DN both in cross-sectional and longitudinal studies [118–120].

Puberty Blood Pressure Increased blood pressure in people with diabetes significantly increases the risk of progression towards ESRD [104]. Evidence also exists on a link between increased blood pressure and earlier stages of DN, such as MA [13]. A direct correlation between albumin excretion and increases in blood pressure is present, even when both these parameters are still within the normal range [105, 106]. However, the temporal relationship between MA and rises in blood pressure is not completely clear, given that different studies have often reached opposite conclusions [107–110]. On the one hand, increases in blood pressure have been found to precede MA and therefore to influence its development [108–110]. On the other hand, other studies have not supported this hypothesis and instead suggested that the two phenomena could occur together [107, 111]. The use of ambulatory blood pressure monitoring has allowed the identification of early alterations in blood pressure associated with future risk of MA

In patients with childhood-onset T1D MA often develops during puberty [121]. Puberty is characterized by many physiological changes, involving both hormonal and metabolic processes [122]. These factors together with psychological issues are frequently responsible of a poor metabolic control [122]. However, in addition to poor glycemic control, other changes occurring during puberty can contribute to the risk of developing MA [41]. Changes in sex hormones and in the GH-IGF axis have been shown to play an important role in this context [122]. These changes can interact with the diabetic milieu and the genetic background and contribute to the risk of developing DN and other vascular complications of T1D. The higher testosterone levels and free androgen index found in adolescent girls with MA when compared with matched controls without MA [123] could contribute to renal disease and also to the female predominance of this complication during puberty [20, 41, 123].

49

Diabetic Nephropathy in Children

Puberty is generally associated with a decrease in insulin sensitivity, which reaches a peak at stages 3 and 4 [124, 125]. Adolescents with T1D are more insulin resistant when compared with healthy controls [122], and this has mainly been attributed to the effect of increased GH. Circulating GH levels are increased in adolescents with T1D, whereas circulating IGF-1 levels are decreased, due to reduced portal insulin and consequent lack of effect of insulin on the expression of GH receptors in the liver [61, 62]. In contrast, as the expression of GH receptors seems to be insulin independent in other peripheral organs and tissues, such as the kidney, an increased local production of IGF-1 with an associated paracrine action could be implicated in renal disease [61, 62]. In cross-sectional studies, these high renal levels of IGF-1 have been associated with the development of DN [126]. Increased urinary GH and IGF-1 levels have been found in adolescents with T1D and correlated with albumin excretion [126]. In addition, increased urinary GH has been related to increased renal size, which in turn is a risk factor for MA [126].

Age at Diagnosis and Duration of Diabetes Duration of diabetes is another major factor associated with risk of complications [127]. In children, the relationship between diabetes duration and risk of MA has been found in some studies [30, 37, 41], but not confirmed in others [28]. The role of prepubertal duration of diabetes has been the object of a wide discussion, generated by discordant results emerged from different studies. Although in some studies [30, 39, 128, 129] the risk of developing MA was higher in children with onset of diabetes at or after puberty, suggesting that prepubertal duration was not a main determinant, other studies have underlined the contribution of prepubertal duration to the risk of developing MA [130–133]. Children with onset of diabetes before the age of 5 years may have a delayed onset of complications, but after puberty there is an acceleration in their

1555

development [41, 134]. Furthermore, some children with an early prepubertal onset of diabetes can also develop MA before puberty [41].

Genetic Factors Epidemiological and family-based studies support the role of genetic factors in its pathogenesis. The observation that only 30–50 % of subjects with T1D are at risk for DN along with that related to the increasing prevalence of DN during the first 20 years after diagnosis, followed by a plateau [135], suggests that only a subset of patients is really susceptible to this complication. The DCCT and other studies have shown a familial cluster of DN, with a 2.3 increased risk of developing nephropathy for siblings of a proband with DN when compared to siblings of a proband without DN [136]. A family history of hypertension has also been shown to be a risk factor for developing DN [137]. Parents of patients developing DN have higher blood pressure when compared to parents of subjects free of this complication [138–140], and the risk seems to be increased by three- to fourfold. In addition, a family history of dyslipidemia, insulin resistance, type 2 diabetes, or a cluster of these cardiovascular risk factors significantly increases the risk of DN [141, 142], suggesting also a role of cardiovascular genes in predisposing to this complication. DN appears to be a complex genetic traits, with the contribution of different genes and an effect of their interaction with environmental factors [143]. Several genes have been suggested as potential candidates in the pathogenesis of DN, but there is no evidence for a major effect of a single gene so far [143]. DN is the combination of albuminuria and reduced GFR, and it has been shown that both these two components are highly heritable traits and that they have a different genetic basis [143]. However, the results of genetic studies have been often conflicting, due to differences in the populations studied, to the small sample size, and also to differences in the definition of the trait analyzed [144]. Among the most common genes that have been investigated for their potential relationship with

1556

DN are those encoding for components of the renin-angiotensin system and mainly the angiotensin-converting enzyme (ACE) gene and the angiotensin receptor I gene. In particular, the insertion/deletion polymorphism in the ACE gene has been the object of intense investigations. However, as emerged from a meta-analysis, it appears to have a small effect on the risk for developing DN in European populations [145]. Polymorphisms in the ACE gene have been related also to differences in the response to treatment with ACE inhibitors (ACEI) [146], thus suggesting the importance of future pharmacogenomic approaches in this area. Other candidate genes have been those encoding lipoproteins (in particular apolipoprotein E), aldose reductase, and heparan sulfate [147]. In addition, as it is well known that inflammation, glycation, and oxidation pathways as well as growth factors play an important role in the development of vascular complications, other possible candidate genes might be those encoding for components of these systems [147]. A genome-wide association study (GWAS) in adults with T1D from the Genetics of Kidneys in Diabetes (GoKinD) cohort has identified 11 single nucleotide polymorphisms (SNPs) in 4 chromosomal regional associated with advanced stages of DN [148]. Two of these SNPs, located near the FRMD3 and CARS loci, and which were shown to be expressed in the human kidney, were replicated in the DCCT/EDIC cohort, therefore emerging as likely candidate variants influencing DN susceptibility [148]. A more recent GWAS in adults and youth with T1D has reported some evidence of a potential association between variants in the GLRA3 gene, encoding the α-3 subunit of the neuronal glycine receptor (a ligand-gated chloride channel) and albuminuria [149]. However, further studies are required to replicate these findings in other populations and to clarify the function of these genetic variants.

M. Marcovecchio and F. Chiarelli

study in young individuals with T1D, smoking was associated with 2.8-fold increased risk of MA, whereas smoking cessation caused a significant improvement in AER [152]. The link between smoking and DN can be related to an increased oxidant burden caused by cigarette smoking [153]. In addition, as smokers have also higher blood pressure when compared to nonsmokers [154], this can represent an additional connection between smoking and the risk of developing DN.

Diet A high-protein intake has been suggested as a potential risk factor for the development of DN, with a normalization of GFR associated with a reduction of protein intake [155, 156]. It seems that animal proteins exert a stronger effect than vegetable proteins [157], whereas a high intake of fish proteins has emerged as a factor able to reduce the risk of DN [158]. The exact mechanisms explaining the association between protein intake and DN are not completely clear, although glucagon, prostaglandin, and the renin-angiotensin system have been suggested as potential mediators [157, 159]. Diet can be a source of AGEs, which are key players in the pathogenesis of DN. In the context of diabetes, AGEs are mainly produced endogenously as a result of hyperglycemia [160]; however, specific foods and modes of cooking can contribute to the AGE load [161]. Other factors investigated in relation to DN are fat, minerals, vitamins, and fibers [162–164]. In particular, as DN is associated with an increased oxidant burden, the potential effect of treatment with antioxidants has been investigated, but the results have been inconclusive [165–167].

Other Factors Smoking Smoking is an independent risk factor for the development and progression of DN in adults with diabetes [150, 151]. In a large prospective

Recently, it has been shown that in adolescents with T1D, clinical markers of insulin resistance, such as body mass index, are associated with the development of MA, in addition to glycemic control [168].

49

Diabetic Nephropathy in Children

Another factor that has been related to MA is low birth weight [169]. Intrauterine growth retardation might lead to reduced nephron number and decreased renal functional reserve, with increased susceptibility to renal disease in response to other environmental factors [169]. This theory might also explain the association between short stature and risk of DN [169, 170] as well as the relationship between impaired growth during puberty and risk of MA [171]. However, no association has been found between birth weight or gestational age and MA in young people with T1D [137].

Screening and Diagnosis Urinary Albumin Excretion Measurement of albumin excretion is the basis for the diagnosis of DN [15] (Table 2). MA is the earliest detectable marker of DN and represents an important risk factor for the development of DN and cardiovascular disease [172]. MA is not only a phenomenon related to renal damage but is associated with a more generalized sieving of albumin from the blood bed, due to a general endothelial dysfunction [173]. Screening for MA can be performed in three ways: (1) 24-h collection, (2) timed collection (e.g., overnight), and (3) albumin-creatinine ratio (ACR) on a spot urinary sample [174]. 24-h or timed urine collections are often difficult to be performed, particularly in children, with lack of accuracy in this age group. Therefore, the easiest way is the assessment of the ACR in a spot urine, Table 2 Screening recommendations based on the International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines Screening recommendation for microalbuminuria Annual assessment of albumin excretion from age 10 or at onset of puberty if this is earlier, after 2 to 5 years’ diabetes duration Method: urinary albumin-creatinine ratio or first morning albumin concentration Exclude other causes of increased albumin excretion: Strenuous exercise, orthostatic proteinuria, hypertension, acute febrile illnesses, smoking, urinary infections, nephritis, menstruation

1557

preferably using the first voided urine in the morning, in order to avoid bias related to the known diurnal variation in albumin excretion. The correct interpretation of albumin excretion requires that other factors and conditions which could influence it are excluded. Exercise, urinary tract infections, acute febrile illness, immunoglobulin A or other forms of nephritis, marked hypertension, and menstrual cycle in female can all cause transient increase in albumin excretion. Given that the intraindividual daily variation in albumin excretion may fluctuate by 40–50 %, multiple measurements of albumin excretion are required [174]. The definition of MA can be (1) albumin excretion rate between 20 and 200 μg/min or 30–300 mg in 24-h urine collection; (2) ACR 2.5–25 mg/mmol in males or 3.5–25 mg/mmol in females, or 30 μg/mg for either gender; and (3) albumin concentration 30–300 mg/l in early morning urine sample [174]. Persistent MA is defined as 2 out of 3 abnormal samples collected over a period of 3–6 months [174]. Values above the upper limit for MA definition are diagnostic of macroalbuminuria or overt nephropathy. Based on the recent International Society for Pediatric and Adolescent Diabetes guidelines, screening should be performed and should start from 10 years of age, or at onset of puberty if this is earlier, with 2–5-year diabetes duration [175].

Prevention and Treatment Intensive Blood Glucose Control The DCCT and the EDIC studies have provided strong evidence for the important role of good glycemic control for the reduction of risk of micro- and macrovascular complications in subjects with T1D, including also adolescents [99, 101, 102]. In the adolescent cohort of the DCCT, the beneficial effects on complications were obtained, even though the mean HbA1c was significantly higher, by about 1 %, when compared to the adult cohort [101]. This underlines an important issue in achieving a good metabolic control during puberty. Psychological

1558

issues, together with the effect of the physiological insulin resistance [124, 125] that occurs during puberty and the numerous changes in the hormonal milieu [122], give rise to several problems in managing adolescents with T1D [122]. Similarly to the DCCT results, other studies have shown the difficulties in achieving a good glycemic control and avoiding in the meantime the risk of episodes of hypoglycemia and weight gain [176]. The issue of weight gain is of particular relevance for adolescent girls, who often omit their insulin injection in order to avoid overweight [177]. Therefore, other strategies need to be implemented to improve glycemic control, particularly during adolescence.

Blood Pressure Control In adults with T1D and MA, treatment with ACEI or angiotensin receptor blockers (ARBs) is recommended based on the evidence of a positive effect in reducing the rate of progression and also in promoting regression of MA [13]. A beneficial effect of ACEI has been shown in microalbuminuric normotensive patients, where ACE inhibition can arrest the increase in or even reduce AER [178]. Furthermore, in patients with diabetes but with albumin excretion within the normal range, ACEI have been proven to be effective in reducing the risk of developing MA [105]. This effect appears to be independent of baseline blood pressure, renal function, and type of diabetes [179]. A recent systematic review and meta-analysis has shown that in subjects with diabetes, only ACEI can prevent the doubling of serum creatinine compared to placebo [180]. In addition, in placebo-controlled studies, only ACEI (at the maximum tolerable dose) were found to significantly reduce the risk of all-cause mortality [181]. However, there is no guidance for the use of ACEI or ARBs in the pediatric population in the context of MA. In fact, these drugs have been approved and used for the treatment of hypertension, but there is no indication for MA. Few studies have been performed and confirmed the likely efficacy of ACEI in adolescents with MA, but

M. Marcovecchio and F. Chiarelli

there have been no formal randomized controlled trials (RCT) [182–185]. Overall these studies have shown that ACEI lead to a reduction in albumin excretion. However, it is difficult to draw definitive conclusions from these studies, and the issue of the potential long-term use of ACEI in individual with MA raises also the problem related to potential side effects of these drugs. A key safety issue related to the use of ACEI and ARBs is the potential risk of congenital malformation when used during pregnancy [186]. Therefore, when starting treatment with these drugs in adolescent girls, they need to be aware of this risk, and birth control measure needs to be recommended. The efficacy of ACEI in adolescents with T1D at risk for DN is currently being investigated by the multicenter Adolescent Diabetes Intervention Trial (AdDIT) [187]. The ADA recommends starting treatment with ACEI in the presence of persistent MA [188]. Similarly the recent ISPAD guidelines suggest using ACEI or ARB in the presence of persistent MA in order to prevent progression to proteinuria.

Management of Dyslipidemia Many large-scale interventional trials have demonstrated that treatment with statins, the most effective lipid-lowering drug class, significantly reduces the risk of coronary heart disease events and total mortality. People with diabetes and DN often present dyslipidemia, and statin therapy has been associated with a significant reduction in risk of macrovascular complications [189]. Statins have effects other than the reduction in cholesterol levels [190]. In fact, they have beneficial properties, such as inhibition of arterial smooth muscle cell proliferation, prevention of oxidation of LDL cholesterol, plaque stabilization, effects on macrophages, improvement of endothelial dysfunction, and anti-inflammatory and antithrombotic effects [190]. Abnormal lipid profiles are often detected in adolescents with T1D [117, 191, 192], and they have been associated with endothelial dysfunction and MA [193]. However, there

49

Diabetic Nephropathy in Children

is no consensus on the role of statin treatment in this age group mainly because no RCT has been conducted. Management of dyslipidemia in pediatric patients relies on the results of trials conducted in adults [194] and in children with familial hypercholesterolemia [195–197]. The efficacy of statins in adolescents with T1D at risk for DN is currently being investigated by the multicenter trial AdDIT [187].

Diet Intervention and Smoking Cessation A low-protein diet seems to reduce the increase in albumin excretion rate and the decline in GFR in adults with type 1 diabetes. A meta-analysis of studies investigating the effect of protein intake has shown that a diet restriction to 0.5–0.8 g/kg/ day reduces the risk of progression of DN [198]. However, there are no specific data for children and adolescents, where generally a minimum of protein intake of 1 g/kg is sufficient for normal growth, but it is not clear whether this reduces the risk of DN [199]. As smoking is common among adolescents with T1D [200] and it is related to the development of DN [150], it is important to discourage young people from smoking as early as possible.

New Potential Therapeutic Strategies New potential therapeutic possibilities for the treatment of DN are emerging, and they include drugs targeting specific pathways implicated in the pathogenesis of DN (inhibitors of advanced glycation, PKC inhibitors, glycosaminoglycans) [84, 201, 202]. However, up to now, there are few experimental data on these new potential treatments and limited information derived from studies in humans. Therefore, future studies are required for a better evaluation of these drugs as well as for the development of new therapies, which could target other specific metabolic or hemodynamic pathways implicated in the pathogenesis of DN.

1559

Renal Involvement in Youth with Type 2 Diabetes Microvascular complications, such as nephropathy, can also occur in patients with onset of T2D during adolescence [203]. Although there are fewer studies on T2D-related than T1D-related microvascular complications, it seems that there are some differences between the two forms of diabetes. In particular, vascular complications occur earlier in patients with T2D than in those with T1D, and early signs of complications can be detected already at T2D onset or soon after [11, 12]. The early appearance of complications in the context of T2D is due to the fact that T2D is characterized by a long “silent” period before diagnosis is made [203]. Overt T2D is generally preceded by a phase of insulin resistance/ hyperinsulinemia and impaired glucose tolerance, conditions known to be able to induce endothelial dysfunction and vascular damage [203]. T2D mainly occurs in obese adolescents, and the typical poor glycemic control of adolescence, due to poor adherence to therapy, can also contribute to the high risk of developing vascular complications [204]. In addition, adolescents with T2D have a greater prevalence of risk factors for diabetic complications, such as dyslipidemia, hypertension, and insulin resistance [205, 206]. Several studies have shown that the prevalence of MA is higher in T2D than in T1D youth; its onset is more rapid, and it is often detectable at the time of diagnosis [203]. In addition, whereas, at least among some populations, the incidence of nephropathy among T1D patients has declined during the past decades, this is not the case for T2D [207]. Among Pima Indian youth with T2D, MA was detected in 22 % of the population, already at the time of diagnosis, and this prevalence increased up to 60 % after 10-year diabetes duration. A study performed in American youth found MA in 40 % of the study population after a diabetes duration of 1.5 years [208]. In a more recent study, Eppens et al. reported a prevalence of microalbuminuria of 7 % at the time of diagnosis, and this prevalence rose to 28 % during a follow-up period of 3 years [209]. Recent data

1560

from the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study highlight that youth-onset T2D and its complications may be much more aggressive and treatment resistant than its adult counterpart. In the TODAY study, MA was found in 6.3 % of adolescents with T2D at baseline and rose to 16.6 % by end of study, independently of treatment [12]. A longitudinal study evaluating renal outcomes and overall survival in youth with T2D, with a prevalence of MA of 26.9 % and of macroalbuminuria of 4.7 % [210], reported that they have a fourfold increased risk of renal failure when compared with youth with T1D [210]. In addition, youth-onset T2D appears to be more aggressive than adult-onset T2D, as supported by the finding that the former group has a fivefold increased risk of ESRD than the latter one [210]. This appears to be related to the longer duration of the disease in the youth-onset T2D. These data are clearly alarming and highlight the need of prompt interventions to prevent the onset of T2D and related complications. Factors which have been associated with the development of nephropathy in youth with T2D are similar to those in youth with T1D and include high HbA1c, duration of the disease, hypertension, and dyslipidemia [11, 12]. Treatment and preventive strategies are also similar to T1D and rely on good glycemic control, treatment of hypertension, dyslipidemia, and other associated comorbidities. One important point is that screening for microalbuminuria should be started already at the time of diagnosis of T2D.

Conclusions DN represents a serious complication of childhood-onset diabetes associated with a significant morbidity due to the progressive loss in renal function and the associated risk for cardiovascular disease. Even though kidney failure and overt nephropathy are not common in children and adolescents, important structural and functional alterations at the renal level occur already during childhood and accelerate during puberty. Several risk factors have been associated with the

M. Marcovecchio and F. Chiarelli

development of DN, but a lot still needs to be clarified in order to develop better preventive and therapeutic strategies, which could reduce the burden associated with DN and therefore improve the prognosis of young people with diabetes.

References 1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69–82. 2. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet. 2009;373(9680):2027–33. 3. (IDF) IDF. http://www.idf.org/sites/default/files/EN_ 6E_Atlas_Full_0.pdf. 2014. Last accessed 21 June 2014. 4. Marcovecchio ML, Chiarelli F. Microvascular disease in children and adolescents with type 1 diabetes and obesity. Pediatr Nephrol. 2011;26(3):365–75. 5. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes. 2010; 59(12):3216–22. 6. Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013;17(1):20–33. 7. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al. Mortality from heart disease in a cohort of 23,000 patients with insulintreated diabetes. Diabetologia. 2003;46(6):760–5. 8. Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. Diabetes Care. 2006;29(11):2528–38. 9. Reinehr T. Type 2 diabetes mellitus in children and adolescents. World J Diabetes. 2013;4(6):270–81. 10. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014; 311(17):1778–86. 11. Dart AB, Martens PJ, Rigatto C, Brownell MD, Dean HJ, Sellers EA. Earlier onset of complications in youth with type 2 diabetes. Diabetes Care. 2014; 37(2):436–43. 12. TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36(6): 1735–41. 13. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–76.

49

Diabetic Nephropathy in Children

14. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32 Suppl 2:64–78. 15. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia. 1999;42(3):263–85. 16. O’Bryan GT, Hostetter TH. The renal hemodynamic basis of diabetic nephropathy. Semin Nephrol. 1997;17(2):93–100. 17. Dunger DB, Schwarze CP, Cooper JD, Widmer B, Neil HA, Shield J, et al. Can we identify adolescents at high risk for nephropathy before the development of microalbuminuria? Diabet Med. 2007;24(2):131–6. 18. Schultz CJ, Neil HA, Dalton RN, Dunger DB. Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes. Diabetes Care. 2000;23(12): 1811–5. 19. Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes. 1994;43(11): 1358–64. 20. Amin R, Widmer B, Prevost AT, Schwarze P, Cooper J, Edge J, et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ. 2008;336(7646):697–701. 21. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348(23):2285–93. 22. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia. 2006;49(1):11–9. 23. Gonzalez Suarez ML, Thomas DB, Barisoni L, Fornoni A. Diabetic nephropathy: is it time yet for routine kidney biopsy? World J Diabetes. 2013;4(6):245–55. 24. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160(8):1093–100. 25. Groop PH, Thomas MC, Moran JL, Waden J, Thorn LM, Makinen VP, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58(7):1651–8. 26. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2010;53(11):2312–9. 27. Joner G, Brinchmann-Hansen O, Torres CG, Hanssen KF. A nationwide cross-sectional study of retinopathy and microalbuminuria in young Norwegian type 1 (insulin-dependent) diabetic patients. Diabetologia. 1992;35(11):1049–54.

1561 28. Mortensen HB, Marinelli K, Norgaard K, Main K, Kastrup KW, Ibsen KK, et al. A nation-wide crosssectional study of urinary albumin excretion rate, arterial blood pressure and blood glucose control in Danish children with type 1 diabetes mellitus. Danish Study Group of Diabetes in Childhood. Diabet Med. 1990;7(10):887–97. 29. Lawson ML, Sochett EB, Chait PG, Balfe JW, Daneman D. Effect of puberty on markers of glomerular hypertrophy and hypertension in IDDM. Diabetes. 1996;45(1):51–5. 30. Kostraba JN, Dorman JS, Orchard TJ, Becker DJ, Ohki Y, Ellis D, et al. Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care. 1989;12(10):686–93. 31. Steinke JM, Mauer M. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients. Pediatr Endocrinol Rev. 2008;5 Suppl 4:958–63. 32. Amin R, Turner C, van Aken S, Bahu TK, Watts A, Lindsell DR, et al. The relationship between microalbuminuria and glomerular filtration rate in young type 1 diabetic subjects: the Oxford Regional Prospective Study. Kidney Int. 2005;68(4):1740–9. 33. Rudberg S, Persson B, Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy – an 8-year prospective study. Kidney Int. 1992;41(4):822–8. 34. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia. 2009;52(4): 691–7. 35. Norgaard K, Storm B, Graae M, Feldt-Rasmussen B. Elevated albumin excretion and retinal changes in children with type 1 diabetes are related to long-term poor blood glucose control. Diabet Med. 1989;6(4): 325–8. 36. Olsen BS, Sjolie A, Hougaard P, Johannesen J, BorchJohnsen K, Marinelli K, et al. A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish Study Group of Diabetes in Childhood. J Diabetes Complications. 2000;14(6):295–300. 37. Jones CA, Leese GP, Kerr S, Bestwick K, Isherwood DI, Vora JP, et al. Development and progression of microalbuminuria in a clinic sample of patients with insulin dependent diabetes mellitus. Arch Dis Child. 1998;78(6):518–23. 38. Rudberg S, Ullman E, Dahlquist G. Relationship between early metabolic control and the development of microalbuminuria – a longitudinal study in children with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1993;36(12):1309–14. 39. Janner M, Knill SE, Diem P, Zuppinger KA, Mullis PE. Persistent microalbuminuria in adolescents with type I (insulin-dependent) diabetes mellitus is

1562 associated to early rather than late puberty. Results of a prospective longitudinal study. Eur J Pediatr. 1994;153(6):403–8. 40. Gallego PH, Bulsara MK, Frazer F, Lafferty AR, Davis EA, Jones TW. Prevalence and risk factors for microalbuminuria in a population-based sample of children and adolescents with T1DM in Western Australia. Pediatr Diabetes. 2006;7(3):165–72. 41. Schultz CJ, Konopelska-Bahu T, Dalton RN, Carroll TA, Stratton I, Gale EA, et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care. 1999;22(3):495–502. 42. Barkai L, Vamosi I, Lukacs K. Enhanced progression of urinary albumin excretion in IDDM during puberty. Diabetes Care. 1998;21(6):1019–23. 43. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110(1):32–5. 44. Marcovecchio ML, Woodside J, Jones T, Daneman D, Neil A, Prevost T, et al. Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT): urinary screening and baseline biochemical and cardiovascular assessments. Diabetes Care. 2014;37(3):805–13. 45. American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care. 2014;37 Suppl 1:S14–80. 46. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia. 2001;44(11): 1957–72. 47. Osterby R. Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes, consequences, and prevention. Diabetologia. 1992;35(9): 803–12. 48. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007;27(2):195–207. 49. Mauer M, Najafian B. The structure of human diabetic nephropathy. In: Cortes P, Mogensen CE, editors. The diabetic kidney. Totowa: Humana Press; 2006. p. 361–74. 50. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest. 2004;34(12): 785–96. 51. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int. 1998;54(3):687–97. 52. Mauer SM, Steffes MW, Michael AF, Brown DM. Studies of diabetic nephropathy in animals and man. Diabetes. 1976;25(2 suppl):850–7. 53. Paulsen EP, Burke BA, Vernier RL, Mallare MJ, Innes Jr DJ, Sturgill BC. Juxtaglomerular body abnormalities in youth-onset diabetic subjects. Kidney Int. 1994;45(4):1132–9.

M. Marcovecchio and F. Chiarelli 54. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357(9268):1601–8. 55. Carmines PK, Bast JP, Ishii N. Altered renal microvascular function in early diabetes. In: Cortes P, Mogensen CE, editors. The diabetic kidney. Totowa: Humana Press; 2006. p. 23–36. 56. Singh R, Alavi N, Singh AK, Leehey DJ. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes. 1999; 48(10):2066–73. 57. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994;93(6):2431–7. 58. Wolf G. Growth factors and the development of diabetic nephropathy. Curr Diab Rep. 2003;3(6):485–90. 59. Cooper ME, Thomas MC. Interactions between growth factors in the kidney: implications for progressive renal injury. Kidney Int. 2003;63(4):1584–5. 60. Chiarelli F, Santilli F, Mohn A. Role of growth factors in the development of diabetic complications. Horm Res. 2000;53(2):53–67. 61. Dunger DB, Cheetham TD. Growth hormone insulinlike growth factor I axis in insulin-dependent diabetes mellitus. Horm Res. 1996;46(1):2–6. 62. Dunger DB, Acerini CL. IGF-I and diabetes in adolescence. Diabetes Metab. 1998;24(2):101–7. 63. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65(6): 2003–17. 64. Santilli F, Spagnoli A, Mohn A, Tumini S, Verrotti A, Cipollone F, et al. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. J Clin Endocrinol Metab. 2001;86(8):3871–6. 65. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 1998;53(4):853–61. 66. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol. 2000;11(1): 25–38. 67. Wahab NA, Yevdokimova N, Weston BS, Roberts T, Li XJ, Brinkman H, et al. Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J. 2001;359(Pt 1):77–87. 68. Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE, et al. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care. 2003;26(9): 2632–6.

49

Diabetic Nephropathy in Children

69. Roestenberg P, van Nieuwenhoven FA, Wieten L, Boer P, Diekman T, Tiller AM, et al. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care. 2004;27(5):1164–70. 70. Nguyen TQ, Tarnow L, Jorsal A, Oliver N, Roestenberg P, Ito Y, et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care. 2008;31(6):1177–82. 71. Hishikawa K, Oemar BS, Nakaki T. Static pressure regulates connective tissue growth factor expression in human mesangial cells. J Biol Chem. 2001; 276(20):16797–803. 72. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, et al. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding proteinrelated protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology. 2001;142(5): 1760–9. 73. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19(3):433–42. 74. Ruster C, Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci. 2008;13:944–55. 75. Sassy-Prigent C, Heudes D, Mandet C, Belair MF, Michel O, Perdereau B, et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes. 2000;49(3):466–75. 76. Giunti S, Tesch GH, Pinach S, Burt DJ, Cooper ME, Cavallo-Perin P, et al. Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia. 2008;51(1): 198–207. 77. Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, Takahashi T, et al. Inhibition of MCP-1/ CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun. 2007;360(4):772–7. 78. Chiarelli F, Cipollone F, Mohn A, Marini M, Iezzi A, Fazia M, et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care. 2002;25(10): 1829–34. 79. Chiarelli F, Mansour M, Verrotti A. Advanced glycation end-products in diabetes mellitus, with particular reference to angiopathy. Diabetes Nutr Metab. 2000;13(4):192–9. 80. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129–46. 81. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 2003; 14(8 Suppl 3):S254–8.

1563 82. Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 2007;27(2):130–43. 83. Chiarelli F, Catino M, Tumini S, Cipollone F, Mezzetti A, Vanelli M, et al. Advanced glycation end products in adolescents and young adults with diabetic angiopathy. Pediatr Nephrol. 2000;14(8–9): 841–6. 84. Williams ME. New potential agents in treating diabetic kidney disease: the fourth act. Drugs. 2006; 66(18):2287–98. 85. Humpert PM, Kopf S, Djuric Z, Wendt T, Morcos M, Nawroth PP, et al. Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diabetes Care. 2006;29(5): 1111–3. 86. Nakamura K, Yamagishi S, Adachi H, KuritaNakamura Y, Matsui T, Yoshida T, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev. 2007;23(5):368–71. 87. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y, et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care. 2005;28(11):2716–21. 88. Marcovecchio ML, Giannini C, Dalton RN, Widmer B, Chiarelli F, Dunger DB. Reduced endogenous secretory receptor for advanced glycation end products (esRAGE) in young people with type 1 diabetes developing microalbuminuria. Diabet Med. 2009;26(8):815–9. 89. DeRubertis FR, Craven PA. Oxidative and glycooxidative stress in diabetic nephropathy. In: Cortes P, Mogensen CE, editors. The diabetic kidney. Totowa: Humana Press; 2006. p. 151–72. 90. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A. 2000; 97(22):12222–6. 91. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000; 404(6779):787–90. 92. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414(6865):813–20. 93. Schleicher ED, Weigert C. Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int Suppl. 2000;77:S13–8. 94. Noh H, King GL. The role of protein kinase C activation in diabetic nephropathy. Kidney Int Suppl. 2007;(106):S49–53.

1564 95. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 2007;55(6):498–510. 96. Wei Q, Mi QS, Dong Z. The regulation and function of microRNAs in kidney diseases. IUBMB Life. 2013;65(7):602–14. 97. Kantharidis P, Wang B, Carew RM, Lan HY. Diabetes complications: the microRNA perspective. Diabetes. 2011;60(7):1832–7. 98. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol. 2006;17(4 Suppl 2):S86–9. 99. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. 100. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131): 837–53. 101. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of longterm complications in adolescents with insulindependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr. 1994;125(2):177–88. 102. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16): 2159–67. 103. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995;332(19): 1251–5. 104. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311(2):89–93. 105. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensinconverting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001; 134(5):370–9. 106. O’Hare P, Bilbous R, Mitchell T, O’Callaghan CJ, Viberti GC. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care. 2000;23(12):1823–9. 107. Poulsen PL, Hansen KW, Mogensen CE. Ambulatory blood pressure in the transition from normo- to

M. Marcovecchio and F. Chiarelli microalbuminuria. A longitudinal study in IDDM patients. Diabetes. 1994;43(10):1248–53. 108. Moore WV, Donaldson DL, Chonko AM, Ideus P, Wiegmann TB. Ambulatory blood pressure in type I diabetes mellitus. Comparison to presence of incipient nephropathy in adolescents and young adults. Diabetes. 1992;41(9):1035–41. 109. Mathiesen ER, Ronn B, Jensen T, Storm B, Deckert T. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes. 1990;39(2):245–9. 110. Microalbuminuria Collaborative Study Group, United Kingdom. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. BMJ. 1993;306(6887): 1235–9. 111. Schultz CJ, Neil HA, Dalton RN, Konopelska Bahu T, Dunger DB. Blood pressure does not rise before the onset of microalbuminuria in children followed from diagnosis of type 1 diabetes. Oxford Regional Prospective Study Group. Diabetes Care. 2001;24(3): 555–60. 112. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002;347(11):797–805. 113. Marcovecchio ML, Dalton RN, Schwarze CP, Prevost AT, Neil HA, Acerini CL, et al. Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. Diabetologia. 2009;52(6):1173–81. 114. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ. 2004;328(7448):1105. 115. Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N. Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia. 2004;47(6): 1020–8. 116. Ellis D, Lloyd C, Becker DJ, Forrest KY, Orchard TJ. The changing course of diabetic nephropathy: low-density lipoprotein cholesterol and blood pressure correlate with regression of proteinuria. Am J Kidney Dis. 1996;27(6):809–18. 117. Marcovecchio ML, Dalton RN, Prevost AT, Acerini CL, Barrett TG, Cooper JD, et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care. 2009;32(4):658–63. 118. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care. 2007;30(10):2523–8.

49

Diabetic Nephropathy in Children

119. Kordonouri O, Danne T, Hopfenmuller W, Enders I, Hovener G, Weber B. Lipid profiles and blood pressure: are they risk factors for the development of early background retinopathy and incipient nephropathy in children with insulin-dependent diabetes mellitus? Acta Paediatr. 1996;85(1):43–8. 120. Abraha A, Schultz C, Konopelska-Bahu T, James T, Watts A, Stratton IM, et al. Glycaemic control and familial factors determine hyperlipidaemia in early childhood diabetes. Oxford Regional Prospective Study of Childhood Diabetes. Diabet Med. 1999; 16(7):598–604. 121. Schultz CJ, Amin R, Dunger DB. Markers of microvascular complications in insulin dependent diabetes. Arch Dis Child. 2002;87(1):10–2. 122. Dunger DB. Diabetes in puberty. Arch Dis Child. 1992;67(5):569–70. 123. Amin R, Schultz C, Ong K, Frystyk J, Dalton RN, Perry L, et al. Low IGF-I and elevated testosterone during puberty in subjects with type 1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects: the Oxford Regional Prospective Study. Diabetes Care. 2003;26(5):1456–61. 124. Bloch CA, Clemons P, Sperling MA. Puberty decreases insulin sensitivity. J Pediatr. 1987;110(3): 481–7. 125. Caprio S, Plewe G, Diamond MP, Simonson DC, Boulware SD, Sherwin RS, et al. Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J Pediatr. 1989; 114(6):963–7. 126. Cummings EA, Sochett EB, Dekker MG, Lawson ML, Daneman D. Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes. Diabetes. 1998;47(8):1341–6. 127. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes. 1990;39(9):1116–24. 128. Dahlquist G, Rudberg S. The prevalence of microalbuminuria in diabetic children and adolescents and its relation to puberty. Acta Paediatr Scand. 1987;76(5):795–800. 129. Rogers DG, White NH, Shalwitz RA, Palmberg P, Smith ME, Santiago JV. The effect of puberty on the development of early diabetic microvascular disease in insulin-dependent diabetes. Diabetes Res Clin Pract. 1987;3(1):39–44. 130. Kordonouri O, Danne T, Enders I, Weber B. Does the long-term clinical course of type I diabetes mellitus differ in patients with prepubertal and pubertal onset? Results of the Berlin Retinopathy Study. Eur J Pediatr. 1998;157(3):202–7. 131. Holl RW, Grabert M, Heinze E, Sorgo W, Debatin KM. Age at onset and long-term metabolic control affect height in type-1 diabetes mellitus. Eur J Pediatr. 1998;157(12):972–7.

1565 132. McNally PG, Raymond NT, Swift PG, Hearnshaw JR, Burden AC. Does the prepubertal duration of diabetes influence the onset of microvascular complications? Diabet Med. 1993;10(10):906–8. 133. Donaghue KC, Fung AT, Hing S, Fairchild J, King J, Chan A, et al. The effect of prepubertal diabetes duration on diabetes. Microvascular complications in early and late adolescence. Diabetes Care. 1997;20(1):77–80. 134. Donaghue KC, Fairchild JM, Craig ME, Chan AK, Hing S, Cutler LR, et al. Do all prepubertal years of diabetes duration contribute equally to diabetes complications? Diabetes Care. 2003;26(4):1224–9. 135. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med. 1985;78(5):785–94. 136. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989;320(18):1161–5. 137. Rudberg S, Stattin EL, Dahlquist G. Familial and perinatal risk factors for microand macroalbuminuria in young IDDM patients. Diabetes. 1998;47(7):1121–6. 138. Viberti GC, Keen H, Wiseman MJ. Raised arterial pressure in parents of proteinuric insulin dependent diabetics. Br Med J (Clin Res Ed). 1987;295 (6597):515–7. 139. Krolewski AS, Canessa M, Warram JH, Laffel LM, Christlieb AR, Knowler WC, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med. 1988;318(3):140–5. 140. Marcovecchio ML, Tossavainen PH, Acerini CL, Barrett TG, Edge J, Neil A, et al. Maternal but not paternal association of ambulatory blood pressure with albumin excretion in young offspring with type 1 diabetes. Diabetes Care. 2010;33(2):366–71. 141. Roglic G, Colhoun HM, Stevens LK, Lemkes HH, Manes C, Fuller JH. Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med. 1998;15(5):418–26. 142. De Cosmo S, Bacci S, Piras GP, Cignarelli M, Placentino G, Margaglione M, et al. High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria. Diabetologia. 1997;40(10):1191–6. 143. Sale MM, Freedman BI. Genetic determinants of albuminuria and renal disease in diabetes mellitus. Nephrol Dial Transplant. 2006;21(1):13–6. 144. Conway BR, Savage DA, Maxwell AP. Identifying genes for diabetic nephropathy – current difficulties and future directions. Nephrol Dial Transplant. 2006;21(11):3012–7. 145. Tarnow L, Gluud C, Parving HH. Diabetic nephropathy and the insertion/deletion polymorphism of the

1566 angiotensin-converting enzyme gene. Nephrol Dial Transplant. 1998;13(5):1125–30. 146. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, et al. Effect of angiotensinconverting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes. 1998;47(9):1507–11. 147. Rippin JD, Patel A, Bain SC. Genetics of diabetic nephropathy. Best Pract Res Clin Endocrinol Metab. 2001;15(3):345–58. 148. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes. 2009;58(6): 1403–10. 149. Sandholm N, Forsblom C, Makinen VP, McKnight AJ, Osterholm AM, He B, et al. Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes. Diabetologia. 2014; 57(6):1143–53. 150. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994;17(2):126–31. 151. Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant. 1994;9(8):1097–102. 152. Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE, et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA. 1991;265(5):614–7. 153. Smith CJ, Steichen TJ. The atherogenic potential of carbon monoxide. Atherosclerosis. 1993;99(2): 137–49. 154. Poulsen PL, Ebbehoj E, Hansen KW, Mogensen CE. Effects of smoking on 24-h ambulatory blood pressure and autonomic function in normoalbuminuric insulin-dependent diabetes mellitus patients. Am J Hypertens. 1998;11(9):1093–9. 155. Pecis M, de Azevedo MJ, Gross JL. Chicken and fish diet reduces glomerular hyperfiltration in IDDM patients. Diabetes Care. 1994;17(7):665–72. 156. Toeller M, Buyken A, Heitkamp G, Bramswig S, Mann J, Milne R, et al. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia. 1997;40(10): 1219–26. 157. Kontessis PA, Bossinakou I, Sarika L, Iliopoulou E, Papantoniou A, Trevisan R, et al. Renal, metabolic, and hormonal responses to proteins of different origin in normotensive, nonproteinuric type I diabetic patients. Diabetes Care. 1995;18(9): 1233. 158. Mollsten AV, Dahlquist GG, Stattin EL, Rudberg S. Higher intakes of fish protein are related to a

M. Marcovecchio and F. Chiarelli lower risk of microalbuminuria in young Swedish type 1 diabetic patients. Diabetes Care. 2001;24(5): 805–10. 159. Rosenberg ME, Swanson JE, Thomas BL, Hostetter TH. Glomerular and hormonal responses to dietary protein intake in human renal disease. Am J Physiol. 1987;253(6 Pt 2):F1083–90. 160. Schmidt AM, Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab. 2000;11(9):368–75. 161. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;94(12):6474–9. 162. Kunisaki M, Fumio U, Nawata H, King GL. Vitamin E normalizes diacylglycerol-protein kinase C activation induced by hyperglycemia in rat vascular tissues. Diabetes. 1996;45 Suppl 3:S117–9. 163. Toeller M, Buyken AE, Heitkamp G, de Pergola G, Giorgino F, Fuller JH. Fiber intake, serum cholesterol levels, and cardiovascular disease in European individuals with type 1 diabetes. EURODIAB IDDM Complications Study Group. Diabetes Care. 1999;22 Suppl 2:B21–8. 164. Jensen T, Stender S, Goldstein K, Holmer G, Deckert T. Partial normalization by dietary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria. N Engl J Med. 1989;321(23):1572–7. 165. Chiarelli F, Santilli F, Sabatino G, Blasetti A, Tumini S, Cipollone F, et al. Effects of vitamin E supplementation on intracellular antioxidant enzyme production in adolescents with type 1 diabetes and early microangiopathy. Pediatr Res. 2004;56(5): 720–5. 166. Zitouni K, Harry DD, Nourooz-Zadeh J, Betteridge DJ, Earle KA. Circulating vitamin E, transforming growth factor beta1, and the association with renal disease susceptibility in two racial groups with type 2 diabetes. Kidney Int. 2005;67(5):1993–8. 167. Farvid MS, Jalali M, Siassi F, Hosseini M. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care. 2005;28(10): 2458–64. 168. Stone ML, Craig ME, Chan AK, Lee JW, Verge CF, Donaghue KC. Natural history and risk factors for microalbuminuria in adolescents with type 1 diabetes: a longitudinal study. Diabetes Care. 2006;29(9): 2072–7. 169. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia. 2005;48(8):1439–44. 170. Brenner BM, Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis. 1994;23(2):171–5.

49

Diabetic Nephropathy in Children

171. Marcovecchio ML, Heywood JJ, Dalton RN, Dunger DB. The contribution of glycemic control to impaired growth during puberty in young people with type 1 diabetes and microalbuminuria. Pediatr Diabetes. 2014;15(4):303–8. 172. Caramori ML, Fioretto P, Mauer M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol. 2006;17(2):339–52. 173. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32(4):219–26. 174. Donaghue KC, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K. ISPAD clinical practice consensus guidelines 2006–2007. Microvascular and macrovascular complications. Pediatr Diabetes. 2007;8(3):163–70. 175. Donaghue KC, Wadwa RP, Dimeglio LA, Wong TY, Chiarelli F, Marcovecchio ML, Salem M, Raza J, Hofman P, Craig ME. ISPAD Clinical Practice Consensus Guidelines 2014. Microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes 2014;15(Suppl 20):257–69. 176. Holl RW, Swift PG, Mortensen HB, Lynggaard H, Hougaard P, Aanstoot HJ, et al. Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group. Eur J Pediatr. 2003;162(1):22–9. 177. Bryden KS, Neil A, Mayou RA, Peveler RC, Fairburn CG, Dunger DB. Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes. Diabetes Care. 1999;22(12):1956–60. 178. Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. Cochrane Database Syst Rev. 2001;(1):CD002183. 179. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2005;(4):CD004136. 180. Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, et al. Comparative effectiveness of reninangiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347: f6008. 181. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;(4):CD006257. 182. Cook J, Daneman D, Spino M, Sochett E, Perlman K, Balfe JW. Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. J Pediatr. 1990;117(1 Pt 1):39–45. 183. Rudberg S, Aperia A, Freyschuss U, Persson B. Enalapril reduces microalbuminuria in young

1567 normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia. 1990;33(8):470–6. 184. Rudberg S, Osterby R, Bangstad HJ, Dahlquist G, Persson B. Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with Type I (insulin-dependent) diabetes mellitus. Diabetologia. 1999;42(5):589–95. 185. Yuksel H, Darcan S, Kabasakal C, Cura A, Mir S, Mavi E. Effect of enalapril on proteinuria, phosphaturia, and calciuria in insulin-dependent diabetes. Pediatr Nephrol. 1998;12(8):648–50. 186. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012;60(2):444–50. 187. Adolescent type 1 Diabetes cardio-renal Intervention Trial Research Group. Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT). BMC Pediatr. 2009;9:79. 188. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care. 2005;28(1):186–212. 189. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22. 190. Keane WF, Kasiske BL, O’Donnell MP, Kim Y. The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis. 1991;17(5 Suppl 1):38–42. 191. Edge JA, James T, Shine B. Longitudinal screening of serum lipids in children and adolescents with type 1 diabetes in a UK clinic population. Diabet Med. 2008;25(8):942–8. 192. Maahs DM, Wadwa RP, McFann K, Nadeau K, Williams MR, Eckel RH, et al. Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes. J Pediatr. 2007;150(2):146–50, 50 e1–2. 193. Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab. 2000;26(4): 254–64. 194. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267–78. 195. Arambepola C, Farmer AJ, Perera R, Neil HA. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis. 2007; 195(2):339–47.

1568 196. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27(8):1803–10. 197. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev (Online). 2010;(7):CD006401. 198. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med. 1996; 124(7):627–32. 199. Chiarelli F, Casani A, Verrotti A, Morgese G, Pinelli L. Diabetic nephropathy in children and adolescents: a critical review with particular reference to angiotensin-converting enzyme inhibitors. Acta Paediatr Suppl. 1998;425:42–5. 200. Masson EA, MacFarlane IA, Priestley CJ, Wallymahmed ME, Flavell HJ. Failure to prevent nicotine addiction in young people with diabetes. Arch Dis Child. 1992;67(1):100–2. 201. Fukami K, Yamagishi S, Ueda S, Okuda S. Novel therapeutic targets for diabetic nephropathy. Endocr Metab Immune Disord Drug Targets. 2007;7(2): 83–92. 202. Soro-Paavonen A, Forbes JM. Novel therapeutics for diabetic micro- and macrovascular complications. Curr Med Chem. 2006;13(15):1777–88. 203. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet. 2007;369(9575):1823–31.

M. Marcovecchio and F. Chiarelli 204. Dean HJ, Sellers EA. Comorbidities and microvascular complications of type 2 diabetes in children and adolescents. Pediatr Diabetes. 2007;8 Suppl 9:35–41. 205. Rodriguez BL, Dabelea D, Liese AD, Fujimoto W, Waitzfelder B, Liu L, et al. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study. J Pediatr. 2010;157(2):245–51. 206. Kershnar AK, Daniels SR, Imperatore G, Palla SL, Petitti DB, Pettitt DJ, et al. Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. J Pediatr. 2006;149(3):314–9. 207. Yokoyama H, Okudaira M, Otani T, Sato A, Miura J, Takaike H, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 2000;58(1):302–11. 208. Ettinger LM, Freeman K, DiMartino-Nardi JR, Flynn JT. Microalbuminuria and abnormal ambulatory blood pressure in adolescents with type 2 diabetes mellitus. J Pediatr. 2005;147(1):67–73. 209. Eppens MC, Craig ME, Cusumano J, Hing S, Chan AK, Howard NJ, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care. 2006;29(6): 1300–6. 210. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA. 2006;296(4):421–6.

Renal Manifestations of Metabolic Disorders in Children

50

Francesco Emma, William G. van’t Hoff, and Carlo Dionisi Vici

Contents

Hereditary Tyrosinemia Type 1 . . . . . . . . . . . . . . . . . . 1597

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1570

Lecithin Cholesterol Acyltransferase Deficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1597

Methylmalonic Acidemia . . . . . . . . . . . . . . . . . . . . . . . . . 1585 Renal Tubular and Glomerular Dysfunction . . . . . . . 1585 Management of End-Stage Renal Disease in Methylmalonic Acidemia . . . . . . . . . . . . . . . . . . . . . . . . 1586

Lysinuric Protein Intolerance . . . . . . . . . . . . . . . . . . . . 1598 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1598

Cobalamin Defects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1587 Glycogen Storage Diseases . . . . . . . . . . . . . . . . . . . . . . . . 1588 Clinical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1588 Glycogen Storage Disease Type I (GSD I) . . . . . . . . . 1588 Fanconi–Bickel Syndrome . . . . . . . . . . . . . . . . . . . . . . . . 1589 Mitochondrial Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . 1590 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1590 Renal Manifestations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1591 Congenital Disorders of Glycosylation . . . . . . . . . . 1592 Disorders of Uric Acid and Purine Metabolism and Transport . . . . . . . . . . . . . . . . . . . . . . . Disorders of Purine Metabolism . . . . . . . . . . . . . . . . . . . Hyperuricosuria and Hypouricemia . . . . . . . . . . . . . . . . Familial Juvenile Hyperuricemic Nephropathy . . . .

1593 1593 1594 1595

Fabry Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1595

F. Emma (*) Division of Nephrology, Bambino Gesù Children’s Hospital – IRCCS, Rome, Italy e-mail: [emailprotected] W.G. van’t Hoff Great Ormond Street Hospital, London, UK e-mail: [emailprotected] C. Dionisi Vici Division of Metabolic Diseases, Bambino Gesù Children’s Hospital – IRCCS, Rome, Italy e-mail: [emailprotected] # Springer-Verlag Berlin Heidelberg 2016 E.D. Avner et al. (eds.), Pediatric Nephrology, DOI 10.1007/978-3-662-43596-0_46

1569

1570

Introduction While the majority of children with renal dysfunction have a structural, immunological, or infective disorder, some have a metabolic defect arising from an abnormality in the biochemical pathways of cell metabolism. Moreover, improved survival of patients with metabolic disorders has uncovered in many cases symptoms secondary to chronic renal lesions that were not apparent when these diseases where first described (e.g., methylmalonic acidemia). Conversely, extrarenal manifestations have become apparent in other patients with metabolic diseases that during childhood manifest primarily with isolated renal or urological symptoms (e.g., nephropathic cystinosis). Pediatric nephrologists should always remain vigilant to the possibility of a metabolic disorder, especially when children have extrarenal symptoms. In general, the proximal renal tubule, which has a very high energy expenditure, is sensitive to metabolic disorders that interfere with ATP generation (e.g., respiratory chain defects). Tubulopathies of various forms can also be observed in diseases caused by mutations in solute carriers (e.g., Fanconi–Bickel syndrome). In other cases, the metabolic dysfunction manifests with nephrocalcinosis and/or urolithiasis, arising from defective reabsorption of a specific solute (e.g., cystine in cystinuria) or as a result of the urinary excretion of abnormally elevated plasma constituents (e.g., oxalate in primary hyperoxaluria). Tubular and tubulointerstitial lesions can also result from acute or chronic toxic insults to the tubular epithelium (e.g., myoglobinuria in fatty acid oxidation defects, methylmalonic acid in methylmalonic acidemia). In other cases, the metabolic disorder interferes with normal embryogenesis, resulting in congenital abnormalities of the kidneys and urinary tract (CAKUT) or in polycystic kidney disease (e.g., Zellweger’s syndrome). Finally, metabolic defects can cause glomerular lesions as a consequence of abnormal deposition of storage material (e.g., Fabry disease, glycogen storage diseases), defects in the synthesis of structural glomerular components (e.g.,

F. Emma et al.

congenital disorder of glycosylation type 1), or toxic damage to podocytes or endothelial cells (e.g., nephrotic syndrome in respiratory chain defects, hemolytic uremic syndrome in cobalamin C and MHTFR deficiencies). In many metabolic disorders, substrate accumulation or enzyme deficiency can be documented in the kidney but without evidence of renal dysfunction (e.g., some lysosomal storage disorders). Sometimes, the disease only manifests as changes in urine color (e.g., black in alkaptonuria, green–blue in Harnup disease) or odor (e.g., maple syrup disease, isovaleric acidemia). In other cases, renal involvement is secondary to damage of other organs; for example, renal failure can develop as a result of acute rhabdomyolysis and myoglobinuria in Tarui disease (glycogen storage disease type VII) or in peroxisomal defects. This review concentrates on those disorders in which there is a clear renal functional or structural abnormality. Disorders of the gonads and adrenal glands can produce renal symptoms and urogenital malformations but are covered elsewhere in the textbook. Likewise, renal involvement is a major feature of specific metabolic disorders (e.g., primary hyperoxaluria) that are described in detail in separate sections of the textbook and are only briefly mentioned here. Owing to the complexity of metabolic pathways, a large number of defects have been characterized to date at the molecular level. This has generated the need to develop systematic classifications of metabolic diseases, a task that was undertaken by the Society for the Study of Inborn Errors of Metabolism (SSIEM), among others. The SSIEM taxonomy categorizes diseases based on the principle that defects belonging to the same biological pathway are likely to have similar clinical features and are often treated using similar approaches. In a spirit of consistency, the authors have chosen to use the SSIEM classification in this chapter and to provide the OMIM reference ID for each disease (Table 1). Given the high number of metabolic disorders that can have renal or urological symptoms, many diseases are only presented in tabular form;

OMIM Disease Gene Main features Disorders of amino acid and peptide metabolism Cystinosis 219800 Failure to thrive, vomiting, rickets, often CTNS blond - fair hair, corneal cystine crystals, multisystem involvement Tyrosinaemia type 1 276700 Hepatomegaly, acute/ chronic liver disease, FAH hepatocellular carcinoma, rickets, neurological crises Lysinuric protein intolerance 222700 Failure to thrive, hepatosplenomegaly SLC7A7 vomiting, refusal of protein-rich foods, interstitial pneumopathy/alveolar proteinosis, immune dysfunction, encephalopathy Cystinuria 220100 SLC3A1 SLC7A9 Propionic academia 606054 Vomiting, hypotonia, failure to thrive, PCCA hyperammonemic PCCB coma, encephalopathy, cardiomyopathy

Table 1 Metabolic diseases with renal or urological involvement

+

+

Fanconi syndrome chronic renal failure

Tubulopathy chronic renal failure hypertension immune mediated glomerulonephritis tubulo-interstitial nephritis

Chronic renal failure (adult)

Calculi

+

Tubular

Fanconi syndrome chronic renal failure

Renal features

+

Glomerular

+

+

+

Tubulointerstitial

Primary renal involvement

+

Stones NC CAKUT

(continued)

HUS Infarction

50 Renal Manifestations of Metabolic Disorders in Children 1571

Rash, dysmorphism, anemia, splenomegaly, recurrent infections, systemic lupus erythematosus Ochronotic pigmentation of cartilage and collagen, arthritis Ectopia lentis, skeletal abnormalities, Marfanlike features, neuropsychiatric symptoms, thromboembolism Mental retardation ataxia, retinopathy

Main features Vomiting, hypotonia, failure to thrive, hyperammonemic coma, encephalopathy, cardiomyopathy

266130 GSS Disorders of fatty acid and ketone body metabolism Disease OMIM Main features Gene Carnitine palmitoyl transferase 255120 Fasting/illness leading deficiency 1 to encephalopathy, CPT1A seizures, hepatomegaly

236200 CBS

Homocystinuria

Oxoprolinuria

203500 HGD

OMIM Gene 251000 MUT 251100 MMAA 251110 MMAB 170100 PEPD

Alkaptonuria

Prolidase deficiency

Disease Methylmalonic academia

Table 1 (continued)

Renal tubular acidosis

Renal features

Renal colic, urolithiasis

Renal infarction hypertension

Urine turns black on standing if alkaline calculi (adults)

Lupus nephritis

Renal features Tubulopathy tubulointerstitial changes chronic renal failure

+

Tubular

Tubular +

Glomer

+

Glomerular

Tubulointerstitial

Tubulointerstitial +

Primary renal involvement

Stones NC

+

+

Stones NC

CAKUT

CAKUT

+

HUS Infarction

1572 F. Emma et al.

CPT2 201475 VLCAD 609016 HADHA 609015 HADHB

608836

Glycogen storage disease type 1a

232200 G6PC

Disorders of carbohydrate metabolism Galactosemia 230400 GALT

Fatty acid oxidation disorders

Carnitine palmitoyl transferase deficiency 2

Vomiting, diarrhea, poor growth, jaundice, liver disease, hypotonia, cataracts Hepatomegaly, hypoglycemia, poor growth, lactic acidosis

Liver disease (steatosis, hypoketotic hypoglycemia, hepatomegaly), acute neonatal illness, cardiomyopathy, myopathy, encephalopathy retinopathy, neuropathy, hypoparathyroidism

Microcephaly, cataract, cardiomyopathy, hepatomegaly, myopathy

Tubular dysfunction, nephrocalcinosis, Fanconi syndrome, hypercalciuria, hyperfiltration, rarely distal tubular acidosis, renal calculi, proteinuria, focal segmental glomerulosclerosis, chronic renal failure

Fanconi syndrome

Enlarged polycystic kidneys, Dysplastic renal parenchyma Hydronephrosis Lipid accumulation in kidney, especially in proximal convoluted tubules Renal insufficiency Renal tubulopathy, Myoglobinuria acute renal failure

+

+

+

+

+

+

+

(continued)

50 Renal Manifestations of Metabolic Disorders in Children 1573

227810 SLC2A2

229600 ALDOB

223000 LCT

606824 SGLUT1

606003 TALDO

Hereditary fructose intolerance

Congenital lactase deficiency

Glucose-galactose malabsorption

Transaldolase deficiency

OMIM Gene 232220 SLC37A4

Fanconi Bickel syndrome

Disease Glycogen storage disease type 1b

Table 1 (continued)

Skin laxity, hepatosplenomegaly, Liver failure, cirrhosis. Neonatal multi-system form (hydrops)

Acute onset after fructose ingestion: poor feeding, vomiting, poor growth, hypoglycemia, liver failure, aversion to sweets and fruit Watery diarrhea, metabolic acidosis, poor weight gain Watery diarrhea

Main features Hepatomegaly, hypoglycemia, poor growth, lactic acidosis, neutropenia, inflammatory bowel disease Hepatomegaly, rickets, poor growth, hypoglycemia

Nephrocalcinosis, hypercalciuria, hypercalcemia Calculi, nephrocalcinosis, hypercalcemia Undefined tubulopathy Genitourinary malformations Nephrocalcinosis, hypertension

Fanconi syndrome, hyperfiltration, “diabetic-like” nephropathy Fanconi syndrome, rarely acute renal failure

Renal features Focal segmental glomerulosclerosis, hyperfiltration

+

+

+

Tubular

+

Glomerular +

Tubulointerstitial

Primary renal involvement

+

+

+

Stones NC

+

CAKUT

HUS Infarction

1574 F. Emma et al.

GRHPR 613616 HOGA1 233100 SLC5A2 232600 PYGM

260000

259900 AGXT

530000 Large mtDNA deletion 540000 m.3243A>G m.3271T>C

520000 m.3243A>G m.14709T>C m.8396A>G

Kearns Sayre syndrome

MIDD

MELAS

266150 PC

Pyruvate carboxylase deficiency (some forms)

Disorders of energy metabolism GRACILE syndrome 603358 BCS1L

McArdle disease

Renal glycosuria

Primary Hyperoxaluria Types 1,2,3

Stroke-like episodes, encephalopathy, deafness, macular dystrophy, myopathy, diabetes mellitus Maternal inherited diabetes mellitus, deafness

Severe growth retardation, cholestasis, liver hemosiderosis Metabolic acidosis, neurological symptoms, hepatomegaly Ophthalmoplegia, retinal degeneration, heart block, ataxia, hyperparathyroidism

Recurrent rabdomyolisis, muscle cramps, weakness, exercise intolerance,

In severe cases PH1: Optic atrophy Retinopathy Heart block Arterial spasm Pathologic fractures Acrocyanosis Peripheral neuropathy

Focal segmental glomerulosclerosis

Focal segmental glomerulosclerosis

Bartter-like syndrome, hypomagnesemia

Tubular acidosis, renal impairment

Fanconi syndrome

Myoglobinuria, oligo/ anuric acute renal failure

Glycosuria

Calculi/ nephrocalcinosis Acute/chronic renal failure

+

+

+

+

+

+

+

+

+

(continued)

50 Renal Manifestations of Metabolic Disorders in Children 1575

220110 Multiple

611719 MRPS22

Combined oxidative phosphorylation deficiency 5

557000 Large mtDNA deletion 124000 BCS1L

607426 COQ2 614650 COQ6 614654 COQ9 614652 PDDS2 604712 RRM2B

OMIM Gene 614052 TMEM70

Complex IV deficiency

Complex III deficiency

Pearson syndrome

Mitochondrial ribonucleotide sub.2

Coenzyme Q10 deficiencyPDSS2

Coenzyme Q10 deficiencyCoQ9

Coenzyme Q10 deficiencyCoQ6

Disease Neonatal mitochondrial encephalopathy, cardiomyopathy Coenzyme Q10 deficiencyCoQ2

Table 1 (continued)

Encephalopathy, liver dysfunction, failure to thrive Encephalopathy, Leigh syndrome, epilepsy, cardiomyopathy, liver failure, myopathy, failure to thrive Cardiomyopathy, hypotonia, oedema, ascitis

Dysmyelination, seizures, failure to thrive, ophtalmoplegia, ptosis, myopathy Pancytopenia, pancreatic dysfunction

Leigh syndrome, blindness

Encephalomyopathy, cardiomyopathy

Deafness, seizures

Encephalomyopathy, liver failure, deafness

Main features Hypospadia, criptorchidism

Tubulopathy

Chronic renal failure

Tubulopathy

Proximal renal tubulopathy

Tubulopathy

Steroid resistant nephrotic syndrome

Tubulopathy

Steroid resistant nephrotic syndrome

Steroid resistant nephrotic syndrome

Renal features Genito-urinary malformations

+

+

+

+

+

+

Tubular

+

+

+

+

Glomerular

Tubulointerstitial

Primary renal involvement Stones NC CAKUT +

HUS Infarction

1576 F. Emma et al.

162000 UMOD 614723 APRT

Familial hyperuricemic nephropathy

220150 SLC22A12

258900 UMPS

Hereditary renal hypouricemia

Hereditary orotic aciduria

Adenine phosphoribosyltransferase deficiency

300322 HPRT1

Lesch Nyhan syndrome Hypoxanthine-guanine phosphoribosyl transferase (HGPRT) deficiency

Megaloblastic anemia, immunodeficiency, failure to thrive

Lesch Nyhan syndrome (complete deficiency): developmental delay, choreo-athetoid movements, self mutilation Partial deficiency: gouty arthritis Gout

IUGR, encephalopathy, seizures, deafness, ophtalmoplegia, multiorgan failure mtDNA depletion 8a 612075 Encephalopathy, seizures, impaired RRM2B vision, failure to thrive Disorders in the metabolisms of purines, pyrimidines and nucleotides SCID -adenosine deaminase 102700 Severe combined deficiency immunodeficiency ADA

612073 SUCLG1

mtDNA depletion 5

+

Proximal tubulopathy

Calculi 2,8-dihydroxyadenine (2,8-DHA) Acute/ chronic renal failure Urolithiasis (urate/ calcium oxalate), hyperuricemia, hypercalciuria, Uric acid nephropathy/ acute renal failure Obstructive uropathy orotic acid crystalluria, hematuria, urolithiasis

Gout, urolithiasis, chronic renal failure

Transient renal tubular acidosis, proteinuria, mesangial sclerosis Acute/chronic renal failure

+

Tubulopathy

+

+

+

+

+

+

+

(continued)

50 Renal Manifestations of Metabolic Disorders in Children 1577

300661 PRPS1

OMIM Gene 278300 607633 XDH 603592 XDH-AO 305920

302960 EBP

308050 NSDHL

Conradi Hunnerman syndrome

CHILD syndrome

Disorders of the metabolism of sterols Smith-Lemli-Opitz syndrome 270400 DHCR7

Phosphoribosylpyrophosphate synthetase superactivity

Glutamyl ribose-5-phosphate glycoproteinosis

Xanthinuria type 2

Disease Xanthinuria type 1

Table 1 (continued)

Hemidysplasia, ichythyosiform erythrodema, limb defects

Facial dysmorphism, hypotonia, cataract, mental retardation, abnormalities of limbs, brain, genitalia Dysmorphic features, skeletal dysplasia, cataract, ichthyosis, mental retardation

Coarse facies, optic atrophy, muscle wasting, failure to thrive, seizures, neurological deterioration Neurological deterioration, deafness, dysmorphic features, gout

Main features Myopathy, arthropathy

Female renal dysgenesis/hypoplasia Male hypospadia criptorchidism Renal dysgenesis/ hypoplasia

Cystic dysplasia, hypoplasia, agenesis, duplication, PUJ obstruction, VUR

Uric acid stones

Proteinuria, chronic renal failure

Renal cysts (rare) Acute renal failure

Renal features Calculi, acute renal failure

Tubular

+

Glomerular

Tubulointerstitial

Primary renal involvement

+

+

Stones NC +

+

+

+

CAKUT

HUS Infarction

1578 F. Emma et al.

607330 SC5DL

201750 POR

Latosterolosis

Antley-Bixler syndrome with genital anomalies

611771 APOE

Congenital disorders of glycosylation Congenital disorder of 212065 glycosylation type 1a PMM2

Lipoprotein glomerulopathy

Disorders of lipid and lipoprotein metabolism Lecithin: cholesterol 245900 acyltransferase deficiency LCAT

602398 DHCR24

Desmosterolosis

Ataxia, olivopontocerebellar hypoplasia, peripheral neuropathy, strabismus, inverted nipples, hepatomegaly, ‘Orange peel’ skin, abnormal subcutaneous fat tissue distribution, mental retardation, primary ovarian failure, prolonged prothrombin time

Elevated apolipoprotein E

Corneal lipid deposits Corneal opacities

Dysmorphic features, developmental delay, skeletal dysplasia, Arthrogryposis Osteosclerosis Dysmorphic features, cataract, hepatic cholestasis, hexadactily, mental retardation Dysmorphic features, skeletal dysplasia,

Proteinuria (congenital nephrotic syndrome), microcysts

Proteinuria, hematuria, renal failure Nephrotic syndrome (resistant to treatment), hematuria, hypertension, renal failure. Glomerular lipoprotein thrombi

Hydronephrosis, renal dysgenesis/hypoplasia Ambigous genitalia

Hypospadia

Renal dysgenesis/ hypoplasia Ambigous genitalia

+

+

+

+

+

+

+

(continued)

50 Renal Manifestations of Metabolic Disorders in Children 1579

261540 B3GALTL

603585 SLC35A1

608779 COG7

Congenital disorder of glycosylation type 1l

B3GALTL – Congenital disorder of glycosylation (Peter-plus syndrome)

Congenital disorder of glycosylation type 2f

Congenital disorder of glycosylation type 2e

301500 GLA

608776 ALG9

Disease Congenital disorder of glycosylation type 1h

Lysosomal disorders Fabry’s disease

OMIM Gene 608104 ALG8

Table 1 (continued)

X-linked disorder, acroparesthesias, angiokeratoma, hypohidrosis, strokelike episodes, corneal, lens opacities, abdominal pain, angina, cardiomyopathy, cramps

Main features Intrauterine growth retardation, neonatal, ascites protein-losing enteropathy, cerebellar hypoplasia, hepatomegaly, cataract Brain atrophy, epilepsy, mental retardation, hepatosplenomegaly Dysmorphic features, developmental delay, short limb dwarfism, cataract, coloboma, skeletal dysplasia Epilepsy, mental retardation, macrothrombocytopenia Microcephaly, epilepsy, developmental delay, hepatomealy, failure to thrive, ventricular septal defect Hyposthenuria, renal tubular acidosis, proteinuria, chronic renal failure Renal sinus parapelvic cysts, hyposthenuria,

Neurogenuc bladder, obstructive uropathy, renal tubulopathy

Proteinuria

Hydronephrosis Hydrourether, kidney/ ureteral duplication

Renal cysts

Renal features Renal cysts, tubulopathy

+

+

Tubular +

+

+

Glomerular

+

Tubulointerstitial +

Primary renal involvement Stones NC

+

+

CAKUT

HUS Infarction

1580 F. Emma et al.

256540

Galactosialidosis (early infantile form)

607014 IDUA

269920 SLC17A5

230800 GBA

254900 SCARB2/ LIMP2

Mucopolysaccharidosis type I (Hurler syndrome)

Infantile sialic acid storage disease

Gaucher’s disease

Action myoclonus renal failure syndrome

CTSA

250100 ARSA

Metachromatic leucodystrophy

Myoclonus, tremor, ataxia, horizontal saccades, dysphagia, no cognitive deterioration

Neurologic and intellectual regression, spasticity, ataxia, optic atrophy, leukodystrophy, incontinence Hydrops, edema, coarse facies, inguinal hernias, visceromegaly, spinal involvement, corneal and fundal abnormalities, cardiomyopathy, developmental delay, telangiectasias Coarse facies, corneal clouding, visceromergaly, dysostosis multiplex, developmental delay Hydrops, edema, dysmorphism, hepatosplenomegaly, hypotonia, poor growth, developmental delay Hepatosplenomegaly, hypersplenism Proteinuria, hematuria, acute glomerulonephritis, calculi Proteinuria, nephritic syndrome, focal segmental glomerulosclerosis

Proteinuria, nephrotic syndrome

Nephrotic syndrome, hypertension (due to aortic luminal narrowing)

Proteinuria, nephrotic syndrome Chronic renal failure

Renal tubular acidosis, mild aminoaciduria, mild renal impairment +

+

+

+

+

+

+

(continued)

50 Renal Manifestations of Metabolic Disorders in Children 1581

214100 PEX1 214110 PEX5 266510 PEX12

OMIM Gene Main features

Facial dysmorphism, enlarged fontanel, hypotonia, severe developmental delay, brain dyslasia, seizures, cataract, retinopathy, deafness, hepatomegaly, jaundice, hepatomegaly Disorders in the metabolism of vitamins and (non-protein) co-factors Imerslund-Grasbeck syndrome 261100 Malabsorption of vitamin B12, CUBN megaloblastic anemia, AMN peripheral neuropathy Cobalamin deficiencies cblC, 277400 Developmental delaty, cblD, cblF, cblJ (combined hydrocephalus, MMACHC methylmalonic aciduria and microcephaly, visual 277410 homocystinuria) impairment, C2orf25 nistagmous, 277380 dysmorphysms, LMBRD1 megaloblastic anemia, pancytopenia, 614857 cardiomyopathy, ABCD4 pulmonary hypertension, MTHDH deficiency 172460 Megaloblastic anemia, severe combined MTHFD1 immune deficiency

Disease Peroxisomal disorders Peroxisome biogenesis disorders – Zellweger’s spectrum disorders (including NALD, IRD)

Table 1 (continued)

+

Hemolytic uremic syndrome, glomerulopathy

Hemolytic uremic syndrome

+

Tubular

Low molecular weight proteinuria

Microcysts/large cortical cysts

Renal features

Glomerular

+

+

Tubulointerstitial

Primary renal involvement Stones NC

CAKUT

+

+

HUS Infarction

1582 F. Emma et al.

Acute intermittent porphyria

176000 HMBS

Disorders of porphyrin and heme metabolism Doss hepatic porphyria 612740 ALAD

259730 CA2

Carbonic anhydrase II deficiency (osteopetrosis with renal tubular acidosis)

Abdominal pain, constipation, vomiting, neurologic features, muscle pain Abdominal pain, constipation, acute episodes of neuropatic/ psychotic symptoms, neuropathy (usually after puberty)

Osteopetrosis, fractures, cerebral calcification, mental retardation, poor growth, hepatosplenomegaly

Rickets, developmental delay, hypercalcemia, craniosynostosis Disorders in the metabolism of trace elements and metals Wilson’s disease 277900 Liver disease, neurological symptoms, ATP7B Kayser-Fleischer rings, hemolytic anemia, cardiomyopathy Menke’s disease 309400 X-linked disorder, kinky hair, developmental ATP7A delay and regression, seizures, skin laxity and hypopigmentation, herniae, Molibdenum cofactor 252150 Severe developmental deficiency delay microcephaly, MOCS1 seizures, spasticity,

241500 ALPL

Hypophosphatasia (infantile form)

Urine may turn red/purple Acute or chronic renal failure, urinary retention, hypertension

Urine may turn red/purple Hypertension

Xanthine stones, Increased urinary xanthine, hypoxanthine, S-sulfocysteine Mixed type of RTA

Fanconi syndrome, proteinuria, rarely acute renal failure, distal RTA, hypercalciuria, calculi Bladder or ureteric diverticulae, stones, urinary infections, chronic renal failure

Hypercalciuria, nephrocalcinosis

+

+

+

+

+

+

+

+

(continued)

50 Renal Manifestations of Metabolic Disorders in Children 1583

Other disorders Blue diaper syndrome

Porphyria variegata

Disease Hereditary coproporphyria

Table 1 (continued)

211000

176200 PPOX HFE

OMIM Gene 121300 CPOX

Hypercalcemia

Main features Abdominal pain, constipation, acute episodes of neuropatic/ psychotic symptoms, neuropathy, photosensitivity, hemolytic anemia Abdominal pain, constipation, acute episodes of neuropatic/ psychotic symptoms Hypercalciuria, nephrocalcinosis Indicanuria, blue discoloration of urine

Hypertension

Renal features Hypertension

Tubular

Glomerular

Tubulointerstitial

Primary renal involvement

+

Stones NC

CAKUT

HUS Infarction

1584 F. Emma et al.

50

Renal Manifestations of Metabolic Disorders in Children

extrarenal symptoms, which are present in the vast majority of cases, are also listed but are restricted to the most common features. For each disease, the prominent type of renal or urological manifestation is indicated; the reader should keep in mind, however, that in many disorders, different types of lesions can coexist.

Methylmalonic Acidemia Isolated methylmalonic acidemia (MMA) is an autosomal recessive organic acidemia, resulting from impaired metabolism of methylmalonylcoenzyme A. The disease represents one of the most common inborn errors of organic acid metabolism and is caused by defects in the activity of the enzyme methylmalonyl-coenzyme A mutase (MUT). This enzyme is part of the mitochondrial metabolic pathway allowing carbon skeletons derived from the metabolism of branched amino acids (50 %) and odd-chain fatty acids (30 %) or from the intestinal flora (20 %) to be converted into succinyl-coenzyme A ([1, 2]). Enzyme deficiency can be complete (mut0) or partial (mut-) or may be secondary to decreased synthesis of the MUT cofactor deoxyadenosylcobalamin. These latter forms of the disease are caused by mutations in enzymes involved in the biosynthesis of adenosylcobalamin from cobalamin (MMAA, MMAB) and are more likely to respond to vitamin B12, which is associated with better prognosis [3, 4]. Patients usually present in the neonatal period or early infancy with lethargy, vomiting, poor feeding, failure to thrive, and recurrent metabolic acidosis. Cobalamin-unresponsive patients with neonatal onset of symptoms and complete deficiency of the apoenzyme have a poor prognosis with a mortality of approximately 50 % within the first decade and have a significant incidence of neurological, cardiac, and renal manifestations [2, 4, 5]. Same patients present with severe neonatal hyperammoniemia, due to secondary inhibition of intermediary metabolism pathways by propionyl-coenzyme A and other related compounds [1]. A history of hyperammonemia at diagnosis correlates with poorer cognitive outcome [6].

1585

Renal Tubular and Glomerular Dysfunction From the renal standpoint, MMA causes a tubulopathy and chronic renal failure. Most patients have evidence of tubular dysfunction during childhood, which often becomes very profound during episodes of metabolic decompensation that are usually triggered by intercurrent infection, causing massive renal salt and bicarbonate losses. In a study of seven cobalamin-unresponsive patients, five had defects in urine concentration, two had impaired urine acidification, three had urine phosphate losses, and several had hyporeninemic hypoaldosteronism [7]. Development of chronic renal impairment has also been documented during childhood in cobalaminunresponsive MMA patients. Walter et al. documented low GFR in 8 of 12 studied children, 5 of whom had a GFR 1,000 higher than the reference values after 2 months. The patient experienced subsequent neurological complications [20]. Most likely, this is due to the very limited transport capacities of the blood–brain barrier for dicarboxylic acids including methylmalonate [21]. Patients who receive combined liver–kidney transplantation may have better metabolic control after the procedure than patients receiving isolated liver transplantation [22]. Preoperative hemodialysis is advocated to decrease methylmalonate levels and the risk of metabolic decompensation during the procedure [22], although recent experiences question the validity of this approach [23]. Overall, liver transplantation in MMA remains a procedure with a significant rate of short-term mortality and morbidity. While there have been successes, worryingly liver transplantation does not seem to protect from further neurological toxicity in the medium and long term [11, 19, 20, 22, 24]. There have also been reports of isolated renal transplant in MMA [25–29]. A 24-year-old patient demonstrated improved clinical and metabolic control after an isolated renal transplant, although she developed diabetes mellitus and suffered marked cyclosporin toxicity [29]. In another report, a 12-year-old boy received isolated kidney transplantation and showed a fourfold to eightfold decrease in serum methylmalonate 6 years after transplantation, allowing to increase his protein intake without further metabolic decompensation episodes [26]; his neurological status remained compromised. A favorable outcome 12 years after transplant with an improvement in urine methylmalonate excretion has been demonstrated in a 17-year-old patient after renal transplantation who subsequently underwent a successful pregnancy [30]. A similar good outcome was also reported in a 14-year-old girl with a 4-year follow-up. Of notice, the first patient had a mutmutation, the second had cblB-type MMA, while the latter two patients had cblA-type MMA, which are often associated with milder phenotypes. Brassier et al. have reported on four patients with mut0 MMA who received a kidney graft at a

1587

mean age of 7.9 years for repeated metabolic decompensations, three of which had chronic renal failure and one had normal renal function. Renal transplantation improved renal function in all patients with chronic renal failure and metabolic parameters in all four patients, allowing increasing protein intake. Plasma methylmalonate levels decrease on average sixfold but less than what is reported in liver transplantation and remained significantly higher than normal levels. However, no acute metabolic decompensation was observed after a mean follow-up of 2.8 years. One patient died after developing hepatoblastoma and neurological complications, and a second patient experienced neurological impairment. Several other cases of renal transplantation in MMA have not been reported in the literature. Taken together, these data suggest that isolated kidney transplantation may provide partial enzyme replacement and could have a safer outcome at least in the short term compared to liver transplantation.

Cobalamin Defects Cobalamin is an essential cofactor in several metabolic pathways. Once entered into the cell, cobalamin is converted into two coenzymes, adenosylcobalamin in the mitochondria that is required for the metabolism of methylmalonate and methylcobalamin in the cytosol that is required for the metabolism of homocysteine. Genetic defects of the cobalamin pathway are autosomal recessive diseases characterized by MMA (impaired synthesis of adenosylcobalamin), homocystinuria (impaired synthesis of methylcobalamin), or both [2, 31]. Combined methylmalonic aciduria and homocystinuria (cblC type) is the most common inborn disorder of cobalamin metabolism. From the renal standpoint, hemolytic uremic syndrome (HUS) has been reported in patients with cobalamin C or with cobalamin G deficiencies, which cause defects in the biosynthesis of adenosylcobalamin and methylcobalamin [32–34] or in the activity of methionine synthase [35], respectively. Pulmonary hypertension can be

1588

observed in infants with cobalamin deficiencies [36]; therefore, defects of the cobalamin pathway should always be suspected when a child with pulmonary hypertension develops thrombotic microangiopathy [33, 35]. Patients with cobalamin C deficiency have defective function of the two enzymes dependent on these cofactors (methylmalonyl CoA mutase and N-methyl tetrahydrofolate: homocysteine methyltransferase). These children have homocystinuria, hypomethioninemia, and cystathioninuria in addition to methylmalonic aciduria. Most present in early infancy with poor feeding, failure to thrive, hypotonia, retinitis, respiratory distress, and cardiomyopathy. Investigation shows a megaloblastic anemia, pancytopenia, and liver dysfunction. Generally, the prognosis has been poor, but cases with milder phenotypes responding to hydroxycobalamin therapy have been reported [37]. Few cases are diagnosed later in older children who developed hypertension, proteinuria, and chronic renal impairment in association with FSGS or an unclassified glomerulopathy [34, 38–40]. A case of eculizumab-resistant HUS in an adult patient has also been described [41]. Patients with cobalamin G deficiency cannot convert homocysteine into methionine. In the absence of methionine synthase, they present with homocystinuria without MMA, low plasma methionine levels, and megaloblastic anemia. These patients usually develop symptoms in early infancy, which include in most cases variable degrees of neuromuscular degeneration. Labrune et al. have described one girl with pulmonary hypertension that developed HUS at the age of 19 months [31, 35]. Mechanisms underlying the development of HUS in these diseases are not well elucidated but are probably related to toxic damage of homocysteine and related compounds (including methylmalonate in cobalamin C defects) to endothelial cells [37, 39]. The genetic background also influences disease expression [24, 39]. A number of patients with defective absorption of the cobalamin–intrinsic factor (IF) complex (Imerslund–Grasbeck syndrome) have persistent proteinuria [42]. The cobalamin–IF complex

F. Emma et al.

binds to cubilin in the intestinal brush border. Cubulin expression at the cell surface requires the coexpression of amnionless and is not restricted to the intestine but is also present in the renal proximal tubule, where it interacts with megalin [43, 44]. The cubilin–megalin complex is responsible for receptor-mediated endocytosis of filtered albumin and low–molecular weight proteins; thus, patients with Imerslund–Grasbeck syndrome in which the cubilin (CUB) or the amnionless (AMN) genes are defective present with albuminuria and low–molecular weight proteinuria [43]. Other inconstant manifestations include megaloblastic anemia, poor growth, neurological deterioration in adulthood, and premature atherosclerosis [45]. Recurrent urinary tract infections and urinary tract malformations have also been reported [45].

Glycogen Storage Diseases Clinical Glycogen storage diseases (GSD) are genetic disorders of the metabolism and regulation of glycogen. Two forms of GSD have significant renal manifestations: GSD type 1 can lead to a tubulopathy and CKD, while Fanconi–Bickel syndrome presents with a characteristic renal disease.

Glycogen Storage Disease Type I (GSD I) Glycogen storage disease type I (GSD I) is transmitted in an autosomal recessive mode and is characterized by defects in the glucose-6-phosphatase complex, which is a key enzyme that converts glucose-6-phosphate into glucose and inorganic phosphate [46]. Most defects involve the catalytic unit, causing GSD Ia (80 %) or von Gierke disease, while defects in the glucose-6phosphate translocase cause GSD-Ib (20 %). Patients with GSD-I accumulate glycogen in the liver, kidney, and intestinal mucosa; they present with poor tolerance to fasting, hypoglycemia,

50

Renal Manifestations of Metabolic Disorders in Children

lactic acidosis, hypeuricemia, hyperlipidemia, growth retardation, and hepatomegaly; long-term complications include delayed puberty, hepatic adenomata, and renal disease [46]. In a majority of patients, the diagnosis is made after investigating a protruded abdomen caused by severe hepatomegaly. Life expectancy of patients has considerably improved with dietary management that allows achieving better metabolic control [47]. Chen and colleagues were among the first to draw attention to the complication of ESRD in older GSD-I patients [48]. In their 1988 review, a significant number of patients aged 13–47 years had renal dysfunction (proteinuria, hypertension, or chronic renal failure). Subsequent investigators have demonstrated renal tubular and glomerular abnormalities [49–53]. Ultrasonography shows renal enlargement secondary to glycogen deposition [54, 55]. The mechanisms of renal damage are not fully understood although there may be important comparisons with diabetic nephropathy [56]. Both diabetes mellitus and GSD-I involve increased flux through the pentose phosphate pathway, increasing triose phosphates and diacylglycerol and thereby stimulating protein kinase C and the renin–angiotensin system. Yiu demonstrated upregulation of angiotensin and increased oxidative stress in a mouse model of GSD Ia [57, 58]. These effects are directly related to kidney disease and not to systemic effects of liver dysfunction. Selective invalidation of the glucose-6-phosphatase gene in murine kidneys is sufficient to cause nephropathy [59]. These animals develop nephromegaly and renal accumulation of lipids (de novo lipogenesis), activate the renin–angiotensin system, and develop microalbuminuria [59].

1589

nephrolithiasis [47, 51, 53]. A Gitelman-like syndrome of hypomagnesemia and hypocalciuria has also been described in a patient with glycogen storage disease type II [51].

Glomerular Dysfunction Patients with GSD I develop hyperfiltration and albuminuria [48–50, 56, 60]. Nearly all patients aged more than 25 years have renal disease and microalbuminuria; more than half have proteinuria [52, 59]. In a Dutch study that reviewed data from 39 patients with GSD-I, a biphasic pattern was observed in the time course of GFR and ERPF. On average, GFR rose between 10 and 15 years of age to 180–190 ml/min/1.73 m2, and renal blood flow (RBF) increased to 850–900 ml/ min/1.73 m2. Thereafter, GFR and RBF decreased, while microalbuminuria increased [50]. Patients with better metabolic control had better renal outcome. Treatment with ACE inhibitors decreased GFR, in particular in patients with hyperfiltration [50]. Persistent hyperfiltration leads to focal and global glomerulosclerosis and to a decline in GFR [49, 50]. Other histological abnormalities include glycogen deposition in proximal tubules, glomerular enlargement, and thickening and lamellation of GBM [59, 61, 62]. Management of the metabolic abnormalities including frequent feeds and the use of uncooked cornstarch are the mainstays of treatment of GSD nephropathy [47]. Antiproteinuric and lipidlowering agents may have a role [46]. Liver transplantation has been performed to prevent malignant change in hepatic adenomata, and combined liver–kidney transplantation has also been successful [63, 64].

Fanconi–Bickel Syndrome Renal Tubular Dysfunction Proximal tubular dysfunction occurs as an early feature in GSD I but is generally subclinical, and a frank Fanconi syndrome is rare. Although tubular proteinuria and enzymuria is significantly elevated in GSD I patients, plasma electrolytes are less disturbed [46, 47, 51–53, 60, 61]. Distal tubular function is also perturbed. Hypercalciuria and hypocitraturia predispose GSD I patients to

The Fanconi–Bickel syndrome is a very rare autosomal recessive disorder of monosaccharide transport, presenting in the first year of life with hepatomegaly (due to glycogen storage), hypoglycemia, and a severe generalized proximal tubulopathy leading to rickets. The extent of the Fanconi syndrome can be equal in magnitude to that of disorders such as cystinosis or tyrosinemia

1590

but is particularly characterized by heavy glycosuria and galactosuria [65–68]. Milder phenotypes have also been described [69]. Treatment is directed toward frequent feeds (and the use of uncooked cornstarch) together with management of the tubulopathy. The condition arises due to mutations in the GLUT2 facilitative glucose transporter (encoded by the SLC2A2 gene), which is expressed in hepatocytes, in pancreatic beta cells, and in the basolateral membranes of intestinal and renal tubular epithelial cells [70, 71], Decreased monosaccharide uptake by the liver explains the postprandial hyperglycemia and hypergalactosemia, which is exacerbated by inappropriately low insulin secretion due to abnormal glucose sensing by pancreatic beta cells [72, 73]. The inability of the liver to transport glucose together with heavy losses of glucose from the renal tubule contributes to preprandial hypoglycemia [71]. Renal glomerular hyperfiltration, microalbuminuria, and diffuse mesangial expansion have been reported, and reduced GFR has been observed in some adults [74, 75]. Successful pregnancies have been reported [75, 76].

Mitochondrial Disorders Introduction Mitochondrial disorders are caused by defects in the respiratory chain enzymes, which are located in this organelle. The respiratory chain is responsible for the process of oxidative phosphorylation, in which electrons are transferred to oxygen, generating a proton gradient (complexes I-IV). The flow of protons back through the mitochondrial membrane releases energy, which allows for the formation of ATP (complex V or ATP synthase) [77]. The respiratory chain enzyme complexes are encoded partly by mitochondrial and partly by nuclear DNA. Mitochondrial DNA (mtDNA) is constituted of a single double-stranded loop that, unlike nuclear DNA, is inherited exclusively from the mother and randomly segregates during each cell division. If mutated, the proportion between mutant and wild-type mtDNA can therefore vary from tissue to tissue and can also alter over time,

F. Emma et al.

explaining the enormous heterogeneity of mitochondrial disorders [77–79]. The classification of mitochondrial disorders is based on clinical, biochemical, and molecular phenotypes. A large number of disease-causing mutations in mtDNA have been reported to date and are collected in online databases, freely accessible (http://www. mitomap.org). Some phenotypes are predominantly associated with mutations of given genes and are therefore classified as syndromes or associations [80]. The clinical features are extremely heterogeneous and often change with time, but virtually all patients have neurological symptoms at some point. The first symptoms develop before 1 month of age in approximately one-third of patients and before 2 years of age in more than 80 % of cases [79]. Frequent manifestations include myopathy, encephalopathy, seizures, developmental delay, ophthalmoplegia, retinal degeneration, cardiomyopathy, endocrinopathy, and liver disease. Exceptionally, patients remain monosymptomatic. Skeletal muscles are frequently affected, in part because somatic mutations occur more frequently in myoblasts [78]. Exercise intolerance is a common complaint, which is often dismissed as psychogenic or mislabeled as chronic fatigue syndrome or rheumatic fibromyalgia. Many patients with mtDNA mutations fall into this group; the frequent lack of a clear maternal inheritance further deflects the physician from considering a mitochondrial cytopathy [78]. Typically, patients develop progressive multisystemic involvement, with symptoms increasing in number and severity overtime as more tissues become affected. Some, such as sensorineural deafness or cardiomyopathy, may remain subclinical and require systematic testing. Specific skin and hair lesions have also been described [81]. Measurement of plasma lactate, which is often the first investigation of a child suspected of mitochondrial dysfunction, may give a normal result in many patients. Conversely the majority of patients have increased urinary excretion of lactate [78]. Careful delineation of other system involvement, tissue biopsies, and detailed biochemical and molecular studies are required to confirm a defect in mitochondrial function.

50

Renal Manifestations of Metabolic Disorders in Children

Renal Manifestations Tubular disorders represent the most frequently observed form of renal mitochondrial diseases. In a review of 42 patients with mitochondrial disorders, 21 had renal involvement [82]. Of these, only eight patients had overt diseases, suggesting that the prevalence of tubular dysfunction is underestimated. Proximal tubular cells have high metabolic rates and are very rich in mitochondria. Not surprisingly, a majority of mitochondrial tubulopathies involve the proximal tubular segments. Varying degrees of tubular dysfunction may be seen, but the commonest distinct renal phenotype is a Fanconi syndrome, usually occurring in infants with multisystem dysfunction, in which case the prognosis is poor [78, 79, 83–86]. A majority of patients also have low–molecular weight proteinuria. Generalized proximal tubular dysfunction has also been reported in children with specific mitochondrial syndromes, including Kearns–Sayre syndrome, Pearson’s syndrome, Leigh’s encephalopathy, and Coenzyme Q10 deficiency [78, 79, 87–98]. In some children, isolated renal tubular acidosis, isolated hypomagnesemia, hypercalciuria, or a Batter-like phenotype are the prominent tubular manifestations [79, 82, 90, 99–103]. The most frequent biochemical findings are defects in complex III and IV, followed by complex I deficiencies [78]. Primary glomerular diseases have been less frequently reported. These include a number of sporadic cases characterized by steroid-resistant proteinuria secondary to nonimmune forms of glomerulonephritis, mostly focal segmental glomerulosclerosis (FSFG) [78, 79, 94], and two well-defined entities, namely, mutations in the mitochondrial gene encoding for the tRNALEU and mutations in nuclear genes encoding for enzymes required for the de novo synthesis of coenzyme Q10 (CoQ10). The most frequent mtDNA defect is the 3,243 A > G point mutation in the leucine tRNA gene, which was initially described in children with MELAS syndrome (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes syndrome) [104]. Clinical manifestations of the

1591

3243 A > G mutation, however, are not restricted to full-blown MELAS syndrome but can also express as diabetes, deafness, gastrointestinal disease, neuromuscular symptoms, glomerular disease, or a combination of the above [104, 105]. Most patients with renal involvement present with asymptomatic proteinuria. Personal or familial (maternal branch) history of diabetes or deafness is frequently observed [105–114]. When sensorineural deafness is present, patients can be misleadingly diagnosed with Alport syndrome [106, 110]. In general, female patients seem to be more affected than male patients. The age of diagnosis ranges 15–50 years, although cases presenting in early childhood have been reported [105]. The prevalent renal histology finding is consistent with FSGS. Cases of chronic tubulointerstitial nephritis and cystic kidney disease have also been described [105, 108]. A peculiar vasculopathy with hyalinosis of small arteries and myocyte necrosis has been noticed in several reports [107, 112, 114]. Nephrotic syndrome develops in approximately one-third of cases. Most patients become hypertensive, and cases of preeclampsia have been described in pregnant subjects [107]. Chronic or end-stage renal failure developed within 10 years in approximately 50 % of cases after diagnosis. A majority of patients has extrarenal symptoms at diagnosis; some, in particular in younger patients, additional symptoms appear during follow-up [105–114]. Deafness has been reported in approximately two-thirds of cases and diabetes mellitus in approximately half. Other findings include neuromuscular symptoms, retinal dystrophy, and cardiomyopathy. CoQ10 biosynthesis defects deserve a special mention among mitochondrial defects since they represent the only treatable mitochondrial disorder. The link between CoQ10 and renal disease was established in 2000, when three siblings were diagnosed with a complex clinical syndrome characterized by progressive encephalopathy and steroidresistant nephrotic syndrome (SRNS) [115]. Two siblings developed ESRD and required transplantation at ages 8 and 9, respectively; the third sibling had a more severe course and died at 8 years of age after rapid neurological deterioration. The two surviving children were treated with oral CoQ10,

1592

which resulted in a substantial improvement of their neurological condition over 3 years. Two other siblings with similar clinical features were reported in 2005 [116]. Both developed SRNS at 12 months of age. The first child developed progressive encephalomyopathy and stroke-like episodes at 18 months. Oral CoQ10 therapy was initiated at 22 months of age and was able to stop encephalomyopathy progression. The younger sister was treated immediately after she developed proteinuria and had an excellent clinical response without developing neurological symptoms [117]. Mutations in the COQ2 gene were identified in these two siblings as the first report of a genetic defect associated with primary CoQ10 deficiency [118]. Other COQ2 mutations have been found in five additional patients presenting with congenital or early-onset SRNS [119–121]. Mutations in two other genes involved in CoQ10 biosynthesis have also been identified in patients with similar clinical features, namely, in the PDSS2 gene (one patient) [122] and in the COQ6 gene (11 patients from 5 different kindreds) [123]. Although disease characteristics and progression are variable, most patients developed a glomerulopathy. Symptoms always begin within the first years of life; SRNS was the presenting symptom in a majority of cases. Unless treated, renal disease rapidly progressed to ESRF. Associated clinical features included deafness and encephalomyopathy in COQ6 patients; severe forms with neonatal onset may also present with liver failure and severe lactic acidosis [119, 120]. Defects in genes required for CoQ10 biosynthesis can also present with other phenotypes. One patient with a COQ9 mutation had severe multisystem disorder with renal tubulopathy but no apparent glomerular involvement [88]. The histological picture in CoQ10-related glomerulopathies is generally consistent with FSGS; electron microscopy shows numerous dysmorphic mitochondria in the cytoplasm of podocytes [119]. One of the most important aspects of CoQ10 biosynthesis defects is the clinical response to oral treatment. Empirically, CoQ10 doses of 30–50 mg/kg per day have been given to patients, but there is no practical method to monitor the efficacy of therapy other than observing the clinical response [117, 123].

F. Emma et al.

Closely related to these disorders, mutations in the ADCK4 gene (aarF domain containing kinase 4) have been identified in 15 individuals with SRNS from 8 unrelated families [124]. ADCK4 is not directly involved with the biosynthesis of CoQ10 but interacts with enzymes of this pathway. Patients with ADCK4 mutations have reduced CoQ10 levels and mitochondrial respiratory chain activity. One patient showed partial remission following CoQ10 treatment. Compared to other cases of CoQ10 biosynthesis defects, extrarenal involvement appears less frequent, and the age of onset is higher, ranging from infancy to early adulthood [124]. Tubulointerstitial nephritis and cystic kidney diseases have been reported in sporadic cases [78, 79].

Congenital Disorders of Glycosylation Congenital disorders of glycosylation (CDG) are a group of inherited multisystem disorders in which there is defective glycosylation of proteins. The most well-known group comprises defects of N-glycosylation that are frequently disorders affecting multiple pathways [125, 126]. Conversely, defects in O-glycosylation usually result in symptoms that are more organ specific [126]. Other defects involve lipid-linked glycosylation, which resemble more N-glycosylation defects and defects involving the glycosylation of the glycophosphatidylinositol anchor, which resemble more O-glycosylation defects [126]. Since they were first described, a large number of subtypes have been identified, and new classifications have been proposed [127, 128]. The presentation of CDG can be extremely heterogeneous, ranging from fatal multisystem disorders in infancy to multiple exostoses, progeria, or developmental delay in older children [126, 127, 128]. Diagnostically, abnormal isoelectric focusing of serum transferrin is usually the first screening test (although it will not identify all forms) and when abnormal should lead to more detailed enzymatic and genetic testing. In the past, genes responsible for CDGs were identified on biochemical bases; currently, the preferred approach is to use next-generation sequencing

50

Renal Manifestations of Metabolic Disorders in Children

techniques and/or targeted sequencing after initial biochemical investigations [125]. It is estimated that >2 % of the human genome encodes for proteins involved in the biosynthesis or in the recognition of glycans; CDGs probably represent an underdiagnosed group of diseases that include milder forms that are yet to be recognized [126, 129]. The exact contribution of CDGs to genetic defects of the kidneys and urinary tract remains to be established. Children with the commonest form, phosphomannomutase 2 (PMM2)-CDG, previously termed CDG-Ia, may have dysmorphism, hypotonia, failure to thrive, diarrhea, abnormal fat pads, inverted nipples, abnormal eye movements, hepatomegaly, and cardiomyopathy [126, 127]. Investigations often show hypothyroidism and olivopontocerebellar atrophy [130]. With time, many patients that survive lose their characteristic infantile features; cases with milder phenotypes have also been described [131]. One of the commonest renal manifestations is the presence of microcysts which produce a hyperechoic picture on ultrasonography, most commonly found in children with multisystem variants [128, 132, 133]. Cysts are located predominantly in the cortex and probably arise from tubules [132]. The kidneys may be enlarged, and single cysts have also been reported [132]. Some children present a tubulopathy [132, 134]. Proteinuria has been recorded in several patients with CDG and may contribute to severe edema and ascites that these infants sometimes develop. Some have early-onset nephrotic syndrome (Jaeken and Sinha 2009; [135]); their biopsies usually show diffuse mesangial sclerosis [135, 136].

Disorders of Uric Acid and Purine Metabolism and Transport Children who develop renal calculi, acute renal failure in the neonatal period, or crystal nephropathy require investigation of their purine metabolism. Purines are involved in the synthesis of nucleotides and coenzymes, in signal transduction (e.g., cAMP), and in the generation of ATP. The

1593

metabolic end product, uric acid, and its immediate precursor, xanthine, are insoluble in urine, so that overexcretion can predispose to the development of crystal formation. Uric acid is primarily generated in the liver by xanthine oxidase, an enzyme that is inhibited by allopurinol. In lower vertebrates, uric acid is converted into allantoin by uricase; the evolutionary advantage of retaining uric acids in humans is unclear and has been hypothetically attributed to its effects on salt retention, cell oxidation, or innate immunity (upon crystallization) [137]. High uric acid levels can result from excessive purine intake, defects of purine metabolism, decreased excretion, or a combination of the above. Urates are freely filtered in the glomerulus and are reabsorbed in the renal tubule by a complex interplay between secretion and reabsorption processes [137]. Numerous proteins have been identified as urate transporters [137]. Of these, the two best-characterized proteins are URAT1 and GLUT9 that mediate the luminal and basolateral uptake of uric acid, respectively [138, 139]. This process is age and sex dependent, with children reabsorbing less of the filtered urate and consequently having lower plasma urate concentrations [140]. In adults, the fractional excretion of uric acids is approximately 10 %, usually higher in females than males; newborns excrete approximately 35 % of their filtered load, while infants younger than 1 year have a fractional excretion of uric acid ranging 13–26 % [141]. As glomerular filtration rate declines, the fractional excretion of urate increases [142].

Disorders of Purine Metabolism Urolithiasis is the commonest renal manifestation of disorders of purine production. Children may or may not have typical features of calculi (pain, hematuria, infection). In some, the diagnosis is made following family studies or during investigation of crystalluria. Very rarely, these disorders present with oliguric or anuric acute renal failure, either due to bilateral obstructive calculi [143] or due to crystal nephropathy, which can sometimes occur within the neonatal period [144, 145].

1594

Lesch–Nyhan syndrome is inherited in an X-linked recessive manner and nearly always presents in males [146]. However, heterozygous females can manifest severe symptoms [147]. The disease is due to mutations in the hypoxanthine–guanine phosphoribosyl transferase gene HPRT1. Patients are healthy at birth but demonstrate within the first months of life psychomotor delay and symptoms resembling dystonic cerebral palsy. In time, they develop action dystonia, choreoathetosis, ballismus, cognitive and attention deficits, and self-injurious behavior (biting of fingers and lips leading to mutilating loss of tissue) [148]. Most patients have an intelligence quotient (IQ) around 50; seizures are also frequent [146, 148]. The mechanisms leading to neurological symptoms are only partially understood [149]. Overproduction of uric acid is present at birth and has been estimated to be fivefold to tenfold the rate of production of healthy individuals [150]. Attenuated variants of Lesch–Nyhan syndrome have been reported [146, 151]. The so-called KelleySeegmiller syndrome corresponds to a less severe form of HPRT1 mutations; patients develop hyperuricemia and gout with mild to no neurological deficits [152]. The analysis of more than 600 cases of HPRT1 mutations shows a significant genotype–phenotype correlation [153]. The diagnosis is based on clinical and biochemical findings (hyperuricemia and hyperuricosuria) followed by molecular and genetic testing [146, 148]. Treatment includes allopurinol, which should be used carefully to avoid hyperxanthinuria, purine restriction, and high fluid intake. Alkalinization aiming at a urinary pH of 6.0–7.0 helps in preventing stone formation and dissolving existing calculi [148]. Phosphoribosyl pyrophosphate (PRPP) synthetase superactivity is also X-linked and is caused by increased activity of the enzyme that forms PRPP from ribose-5-phosphate and adenosine triphosphate (ATP) [154]. Some affected individuals have neurodevelopmental abnormalities, particularly sensorineural deafness; in these pedigrees, heterozygous female subjects can develop gout and hearing impairment [155]. The disease usually shows in young male patients with

F. Emma et al.

gouty arthritis and uric acid nephrolithiasis, sometimes leading to ESRD [148]. Patients have high plasma and urine uric acid levels. Increased generation of uric acid is present since the first year of life [148, 154]. The differentiated diagnosis is primarily with partial forms of HGPRT deficiency, which may present with very similar biological and clinical signs. Adenine phosphoribosyl transferase (APRT) deficiency is an autosomal recessive disease, secondary to mutations in the APRT gene. The enzyme catalyzes the formation of AMP from adenine and phosphoribosylpyrophosphate and acts as a salvage system for the recycling of adenine into nucleic acids. Deficiency in APRT results in the accumulation of adenine, which is oxidized by xanthine oxidase into 2,8-dihydroxyadenine, a very insoluble compound [156]. Nearly all Japanese patients carry the same mutation [157], while approximately 30 mutations have been reported in Caucasians [148]. The deficiency can also be partial [157]. Patients may develop nephrolithiasis in early childhood or remain silent for decades [148]. Infrared spectrophotometry of stones and crystals allows to distinguish 2,8-dihydroxyadenine from uric acid. Allopurinol prevents the formation of 2,8-dihydroxyadenine. In addition, dietary purine restriction and high fluid intake are recommended, but alkalinization of urines is not useful since the 2,8-dihydroxyadenine solubility is not pH dependent [148]. Undiagnosed patients may develop chronic renal failure [158]. Defects in xanthine oxidase result in xanthinuria, which is characterized by excretion of large amounts of xanthine in the urine and a tendency to form xanthine stones; uric acid levels are markedly decreased both in serum and urine. Xanthinuria also occurs in molybdenum cofactor deficiency. Hyperuricemia with subsequent hyperuricosuria is also a feature of glycogen storage disease type I (see above).

Hyperuricosuria and Hypouricemia Calculi and renal failure can occur as a result of disorders of urate transport in the renal tubule.

50

Renal Manifestations of Metabolic Disorders in Children

Hyperuricosuria and hypouricemia can occur as a result of generalized proximal tubular dysfunction (e.g., Fanconi syndrome) but can also occur in hereditary renal hypouricemia secondary to mutations in URAT1 or GLUT9 [138]. URAT1 mutations cause nephrolithiasis and exercise-induced acute renal failure in approximately 10 % of patients and are more common in the Japanese and possibly in non-Ashkenazi Jewish populations [159]. GLUT9 mutations were identified in subjects with renal hypouricemia after genome-wide association studies had shown that genetic variations in SLC2A9 have strong influence on serum uric acid concentrations [160–163].

Familial Juvenile Hyperuricemic Nephropathy Familial juvenile hyperuricemic nephropathy (FJHN) is an autosomal dominant disorder leading to hyperuricemia, gout, progressive tubulointerstitial damage, impaired urinary concentrating ability, and progressive renal failure [140, 164, 165]. The disease is secondary to mutations in the UMOD gene that encodes for uromodulin (Tamm–Horsfall protein); mutations in the same gene also cause medullary cystic kidney disease type 2 (MCKD2) [165]. Being allelic disorders, FJHN and MCKD2 are collectively referred to as uromodulin-associated kidney disease (UAKD) [166]. Uromodulin genetic variants are also associated with chronic kidney disease (CKD) and hypertension in the general population [167]. Uromodulin is a kidney-specific protein that is exclusively expressed by epithelial cells lining the thick ascending limb (TAL) of Henle’s loop [168]. It is mainly located at the apical plasma membrane and is secreted in the tubular lumen after several post-translational modifications that include N-glycosylation, proteolysis, and polymerization of secreted proteins [165, 169]. Uromodulin has been hypothesized to have a role in water and electrolyte balance in the TAL, in protecting against urinary tract infection, in preventing the formation of kidney stones, and in activating innate immunity mechanisms

1595

in the kidney. Altogether, UAKD is a rare disorder; approximately 100 mutations have been reported so far, and its prevalence is estimated to be 1/100,000 [165]. Reduced fractional excretion of uric acid is present in the majority of patients and is frequently associated with gout in adulthood [166, 170]. Mild impairment of urineconcentrating ability is an almost constant finding, sometimes resulting in polyuria and polydipsia [171]. Chronic renal failure generally occurs between the second and fourth decade of life, although a significant intra- and interfamilial variability has been observed [164, 165, 172]. There is no specific therapy, but hyperuricemia predates renal impairment, and allopurinol may reduce the progression of the nephropathy, suggesting that renal damage could be, at least in part, related to hyperuricemia [164, 165, 173]. Only limited data are available on kidney transplantation, indicating no recurrence after transplantation [174]. Tubulointerstitial nephritis associated with hyperuricemia have been reported in UMODnegative patients that harbor mutations in the transcription factor hepatocyte nuclear factor-1β (TCF2), in particular when autosomal dominant pedigrees include family members with renal malformations [175, 176]. Hypouricosuric hyperuricemia associated with progressive kidney failure, early-onset anemia, hyperkalemia, and low blood pressure have also been reported in autosomal dominant families with specific mutations in the signal sequence of the renin gene (REN). Typically, renal failure develops in mid-adulthood [177].

Fabry Disease Fabry disease is an X-linked disorder in which glycosphingolipids, predominantly globotriaosylceramide (GL-3), accumulate in plasma and tissues as a result of a deficiency of α-galactosidase A, which is encoded by the GLA gene [178, 179]. The reported incidence is approximately 1:200,000, which largely underestimates the true prevalence; newborn screenings have shown prevalence as high as 1:3,100 [178, 180]. High incidence of late-onset/mild

1596

phenotypes, however, raises important ethical issues related to when the screening should be performed. The diagnosis can be made by demonstrating deficient α-galactosidase A activity in plasma or leukocytes [181]. Sequencing of the GLA gene is particularly important in female heterozygous, which may have preserved enzyme activity [182]. Heterozygous females have long been considered asymptomatic carriers. However, many experience symptoms, and some have significant multisystemic involvement that reduces significantly their quality of life [178, 183]. Thus, Fabry disease should be regarded as a condition with a large spectrum of clinical phenotypes; female patients develop symptoms later in life and are less likely to be diagnosed during childhood [184]. Affected males usually present in childhood with recurrent painful crises of the hands and feet that are related to damage of small peripheral nerve fibers. Typically, patients complain of acute episodes of burning pain originating in the extremities and irradiating toward the limbs and of episodes of chronic burning and tingling paresthesias [185]. Other early signs include gastrointestinal symptoms (nausea, vomiting, abdominal pain) that are often underappreciated, absence or decreased sweating (anhidrosis or hypohidrosis), and a characteristic skin rash, termed angiokeratoma corporis. The rash consists in small raised skin lesions clustered around tights, buttocks, groins and, umbilicus [178]. Slit-lamp examination reveals corneal and lenticular opacities. In many patients, these signs are not recognized, and diagnosis is delayed for years. Data from 1,765 patients including 54 % males and 46 % females enrolled in the Fabry Registry show that the median ages at onset of symptoms were 9 and 13 years in males and females, respectively, but that diagnosis was on average delayed by approximately 15 years in both groups [186]. Presenting symptoms in males included neurological pain (62 %), skin signs (31 %), gastroenterological symptoms (19 %), renal signs (17 %), and ophthalmological signs (11 %) [186]. Progressive deposition of GL-3 in the heart, blood vessels, and kidneys leads to the development of valvular and conduction abnormalities,

F. Emma et al.

angina, cerebrovascular disease, and progressive renal damage, usually in adult life. Patients can develop stroke episodes; Fabry’s disease should always be excluded in young patients with unexplained stroke [187]. Overt kidney disease is rare in children, but renal histological changes can be demonstrated in children even without proteinuria [188]. The natural course of Fabry nephropathy in children has not been fully appreciated yet. Microalbuminuria and proteinuria usually develop in the second or third decade of life [186, 188, 189]. Chronic renal failure is uncommon in childhood but has been reported as early as adolescence [178, 179, 190, 191]. The urine may contain casts and desquamated cells containing lipid globules [192]. Isosthenuria indicates defective tubular function. End-stage renal failure occurs typically around the fourth decade [178, 191] and represents the primary cause of death in untreated patients with Fabry disease [193]. Data from the Fabry disease registry show a 15–20 year reduction in life expectancy in male subjects compared to the general population, which is primarily related to cardiovascular morbidity in patients that had progressed to end-stage renal failure [194]. The renal prognosis may be better in patients with residual α-galactosidase A activity [179]. Nephropathy does not recur in the allograft, and transplanted patients have better outcomes than patients maintained on dialysis [195]. Histological examination of the kidney demonstrates inclusions with a characteristic “onion skin” appearance in tubular epithelia, podocytes, and endothelium [192]. In an adult review of 24 patients (mean age 38 years), 50 % had renal sinus cysts compared to 7 % in healthy matched controls, leading the authors to suggest that multiple renal sinus cysts in a patient with kidney disease should raise suspicion of Fabry’s [196]. Recent studies indicate that approximately 1 % of adult males with undiagnosed causes of ESRF have Fabry disease; this diagnosis should be suspected in all patients with progressive chronic kidney diseases of unknown etiology [195, 197]. Urinary protein excretion is strongly associated with progression of chronic renal failure [198].

50

Renal Manifestations of Metabolic Disorders in Children

The current causal treatment is enzyme replacement therapy, which appears to be safe and efficient at improving symptoms of pain, gastrointestinal disturbances, hypo- and anhidrosis, left ventricular mass index, glomerular filtration rate, and quality of life [199, 200]. Early treatment is probably essential to impact on renal function since little benefits have been observed in patients treated when they had already developed overt proteinuria [201].

Hereditary Tyrosinemia Type 1 Hereditary tyrosinaemia type 1 (HT1) is caused by deficiencies in fumarylacetoacetate hydrolase, the final enzyme of the tyrosine degradation pathway, which is mainly expressed in the liver and in the kidneys [202]. Lack of enzyme activity causes accumulation of several toxic compounds [e.g., succinylacetone (SA) and fumarylacetoacetate (FAA)], which have important pathogenetic effects such as rendering cells more susceptible to free radicals or promoting mutagenesis. As a result, hepatic and renal cells undergo apoptotic cell death or adaptive changes in gene expression that expose patients to the risk of developing liver malignancies. In the vast majority of patients, symptoms are primarily related to liver disease; variable degrees of renal dysfunction, however, can usually be detected by routine laboratory analyses in most cases. Animal studies suggest that FAA is the main culprit for the observed glomerulosclerosis and interstitial fibrosis [203], whereas SA is primarily responsible for tubular dysfunction [204]. Typically, HT1 patients suffer from proximal tubular disease of variable degree; patients with overt Fanconi syndrome often develop severe hypophosphataemic rickets. In time, nephrocalcinosis and/or glomerulosclerosis develop in some patients, leading to chronic renal failure. Liver involvement is always present. Patients may present at different ages; in general, early onset of symptoms correlates with more severe disease [202]. Three main presentations have been characterized. In the acute-onset form, which is also the most frequent, patients present within the first 6 months of life with hepatic and

1597

systemic failure. In the subacute form (6–24 months), liver disease is less severe; most patients present with hepatosplenomegaly, coagulopathy, failure to thrive, and rickets. In the chronic form, patients develop symptoms after the age of 2 years and present with subclinical liver and/or renal tubular dysfunction. Treatment with NTBC [(2-(2nitro-4-trifluoromethylbenzoyol)1,3 cyclohexanedione), nitisinone], an inhibitor of 4-hydroxyphenylpyruvate dioxygenase, which fully suppresses SA production, has dramatically changed the outcome of this disease, which was previously a devastating disorder. With NTBC, liver failure resolves, and the risk of developing hepatocellular carcinoma is dramatically decreased. From the renal standpoint, data on NTBC efficiency are limited, with only few long-term studies available. In a large cohort study of 21 patients treated with NTBC for 10 years [205], proteinuria (present in all patients) and phosphaturia (present in half of the patients) resolved in most patients within 1 year of therapy [205]. Another multicenter study collected 45 patients with HT1 that have been treated from diagnosis with NTBC in combination with tyrosineand phenylalanine-restricted diets [206]. Forty-three percent of patients had rickets at onset, and 86 % had evidence of a tubuloptahy. After a mean follow-up of nearly 5 years, only one-third of patients had residual tubular dysfunction without evidence of glomerular disease or chronic renal failure [206]. Other anecdotal reports show rapid normalization of tubular dysfunction within the first weeks of NTBC therapy [207, 208]

Lecithin Cholesterol Acyltransferase Deficiency Lecithin cholesterol acyltransferase (LCAT) is required for the esterification of cholesterol with unsaturated fatty acid derived from lecithin. Patients with LCAT deficiency accumulate unesterified cholesterol and phosphatidylcholine in plasma and tissues [209]. Sequels of tissue accumulation occur within childhood and include grayish corneal opacities, a hemolytic anemia,

1598

and proteinuria (sometimes in the nephrotic range) leading to progressive renal failure in adulthood [209, 210]. Tendon xanthomata and atherosclerosis have been described in a few cases. Biochemically, LCAT deficiency is characterized by a low total cholesterol concentration, variable triglyceride concentration, and abnormalities of lipoprotein structure and composition. The histology of the kidney shows mesangial hypercellularity and expansion with foam lipid deposits, holes and vacuolization in the glomerular basement membrane, arteriolar narrowing due to intimal thickening, and subendothelial lipid deposits [210, 211]. More than 80 different mutations have been described; genotype–phenotype correlations have been reported [211].

Lysinuric Protein Intolerance Lysinuric protein intolerance (LPI) is an autosomal recessive defect of cationic amino acid (lysine, arginine, and ornithine) transport in the basolateral aspects of intestinal and renal tubular cells. The disease is caused by mutations in the SLC7A7 gene, which encodes the y + LAT1 protein. y + LAT1 forms heterodimers with the protein 4F2hc, which is required for the expression of the transporter at the cell surface [212]. A founder effect has been reported, explaining high incidence of the disease in Finland (1/60,000 births) and to a lesser extent in southern Italy and northern Japan. Sporadic cases have been described worldwide. Most but not all symptoms of LPI are related to derangements of the urea cycle. For long, the disease was considered to represent a benign condition if patients were treated with low-protein diet and citrulline. More careful analyses have shown, however, that LPI is a multisystemic disease that in some subjects can cause severe complications even under treatment. There is no overt genotype–phenotype correlation, and disease severity varies significantly among patients with the same mutation. Symptoms range from nearly normal features to severe protein intolerance, failure to thrive, osteoporosis, hepatosplenomegaly, respiratory failure, renal disease, and immunological disorders, chiefly

F. Emma et al.

pulmonary alveolar proteinosis, hemopagocytic lymphohystiocitosis, and immune-mediated glomerulonephritis. In the majority of cases, patients have mild proteinuria with or without microscopic hematuria; some may progress to end-stage renal failure. In a review of 39 patients aged 1–62 years, 74 % had proteinuria, 38 % hematuria, 36 % hypertension, 38 % a raised plasma creatinine, and 4 patients required dialysis [213, 214]. Renal biopsies usually show membranous glomerulonephritis or proliferative glomerulonephritis with immune complex deposits [215, 216]. In general, the most severe cases dying from alveolar proteinosis also have chronic renal failure. Cases of renal Fanconi syndrome have been reported [217]. Glomerular disease appears to be primarily related to immunological disturbances and shares similarities with lupus nephrites. High serum levels of inflammatory molecules such as sIL-2RA, sCD8, TNFα, and IL-6 are often observed in LPI patients along with elevated ferritin and LDH levels [218]. The amino acid transport defect explains part of the observed symptoms. Overproduction of nitric oxide secondary to arginine trapping in cells has been reported [219, 220]. Impaired arginine efflux in macrophages compromises their phagocytic functions [218, 221]. Patients self-select a protein-poor diet but as a consequence are nutritionally deficient in many substrates [213, 214]. The aim of treatment is to prevent hyperammonemia and to provide sufficient quantities of proteins and essential amino acids to allow normal growth. Oral supplementation with L-citrulline mitigates postprandial hyperammonemia and ameliorates protein intolerance [212, 220]. Some immune disorders associated with LPI including renal glomerular lesions may be treated with immunosuppressive medications; no systematic studies are available.

References 1. Deodato F, Boenzi S, Santorelli FM, Dionisi-Vici C. Methylmalonic and propionic aciduria. Am J Med Genet C Semin Med Genet. 2006;142C(2): 104–12.

50

Renal Manifestations of Metabolic Disorders in Children

2. Fenton WA, Gravel RA, Rosenblatt DS. Disorders of propionate and methylmalonate metabolism. In: Valle D, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson KM, et al, editors. The online metabolic and molecular bases of inherited disease. New York: McGraw-Hill. 3. Coelho D, Suormala T, Stucki M, Lerner-Ellis JP, Rosenblatt DS, Newbold RF, et al. Gene identification for the cblD defect of vitamin B12 metabolism. N Engl J Med. 2008;358(14):1454–64. 4. Horster F, Garbade SF, Zwickler T, Aydin HI, Bodamer OA, Burlina AB, et al. Prediction of outcome in isolated methylmalonic acidurias: combined use of clinical and biochemical parameters. J Inherit Metab Dis. 2009;32(5):630–9. 5. Cosson MA, Benoist JF, Touati G, Dechaux M, Royer N, Grandin L, et al. Long-term outcome in methylmalonic aciduria: a series of 30 French patients. Mol Genet Metab. 2009;97(3):172–8. 6. O’Shea CJ, Sloan JL, Wiggs EA, Pao M, Gropman A, Baker EH, et al. Neurocognitive phenotype of isolated methylmalonic acidemia. Pediatrics. 2012;129(6): e1541–51. 7. D’Angio CT, Dillon MJ, Leonard JV. Renal tubular dysfunction in methylmalonic acidaemia. Eur J Pediatr. 1991;150(4):259–63. 8. Walter JH, Michalski A, Wilson WM, Leonard JV, Barratt TM, Dillon MJ. Chronic renal failure in methylmalonic acidaemia. Eur J Pediatr. 1989;148(4):344–8. 9. Horster F, Baumgartner MR, Viardot C, Suormala T, Burgard P, Fowler B, et al. Long-term outcome in methylmalonic acidurias is influenced by the underlying defect (mut0, mut-, cblA, cblB). Pediatr Res. 2007;62(2):225–30. 10. Hauser NS, Manoli I, Graf JC, Sloan J, Venditti CP. Variable dietary management of methylmalonic acidemia: metabolic and energetic correlations. Am J Clin Nutr. 2011;93(1):47–56. 11. van’t Hoff W, McKiernan PJ, Surtees RA, Leonard JV. Liver transplantation for methylmalonic acidaemia. Eur J Pediatr. 1999;158 Suppl 2:S70–4. 12. Kruszka PS, Manoli I, Sloan JL, Kopp JB, Venditti CP. Renal growth in isolated methylmalonic acidemia. Genet Med. 2013;15(12):990–6. 13. Chandler RJ, Zerfas PM, Shanske S, Sloan J, Hoffmann V, DiMauro S, et al. Mitochondrial dysfunction in mut methylmalonic acidemia. FASEB J. 2009;23(4):1252–61. 14. Zsengeller ZK, Aljinovic N, Teot LA, Korson M, Rodig N, Sloan JL, et al. Methylmalonic acidemia: a megamitochondrial disorder affecting the kidney. Pediatr Nephrol. 2014;29:2139–46. 15. Manoli I, Sysol JR, Li L, Houillier P, Garone C, Wang C, et al. Targeting proximal tubule mitochondrial dysfunction attenuates the renal disease of methylmalonic acidemia. Proc Natl Acad Sci U S A. 2013;110(33):13552–7. 16. Morath MA, Okun JG, Muller IB, Sauer SW, Horster F, Hoffmann GF, et al. Neurodegeneration

1599

and chronic renal failure in methylmalonic aciduria–a pathophysiological approach. J Inherit Metab Dis. 2008;31(1):35–43. 17. Melo DR, Mirandola SR, Assuncao NA, Castilho RF. Methylmalonate impairs mitochondrial respiration supported by NADH-linked substrates: involvement of mitochondrial glutamate metabolism. J Neurosci Res. 2012;90(6):1190–9. 18. Schmitt CP, Mehls O, Trefz FK, Horster F, Weber TL, Kolker S. Reversible end-stage renal disease in an adolescent patient with methylmalonic aciduria. Pediatr Nephrol. 2004;19(10):1182–4. 19. van ’t Hoff WG, Dixon M, Taylor J, Mistry P, Rolles K, Rees L, et al. Combined liver-kidney transplantation in methylmalonic acidemia. J Pediatr. 1998;132(6):1043–4. 20. Vernon HJ, Sperati CJ, King JD, Poretti A, Miller NR, Sloan JL, et al. A detailed analysis of methylmalonic acid kinetics during hemodialysis and after combined liver/kidney transplantation in a patient with mut methylmalonic acidemia. J Inherit Metab Dis. 2014;37:899–907. 21. Kolker S, Sauer SW, Surtees RA, Leonard JV. The aetiology of neurological complications of organic acidaemias–a role for the blood–brain barrier. J Inherit Metab Dis. 2006;29(6):701–4; discussion 5–6. 22. Kasahara M, Horikawa R, Tagawa M, Uemoto S, Yokoyama S, Shibata Y, et al. Current role of liver transplantation for methylmalonic acidemia: a review of the literature. Pediatr Transplant. 2006;10(8): 943–7. 23. Kamei K, Ito S, Shigeta T, Sakamoto S, Fukuda A, Horikawa R, et al. Preoperative dialysis for liver transplantation in methylmalonic acidemia. Ther Apher Dial. 2011;15(5):488–92. 24. Morioka D, Kasahara M, Horikawa R, Yokoyama S, Fukuda A, Nakagawa A. Efficacy of living donor liver transplantation for patients with methylmalonic acidemia. Am J Transplant. 2007; 7(12):2782–7. 25. Brassier A, Boyer O, Valayannopoulos V, Ottolenghi C, Krug P, Cosson MA, et al. Renal transplantation in 4 patients with methylmalonic aciduria: a cell therapy for metabolic disease. Mol Genet Metab. 2013;110(1–2):106–10. 26. Clothier JC, Chakrapani A, Preece MA, McKiernan P, Gupta R, Macdonald A, et al. Renal transplantation in a boy with methylmalonic acidaemia. J Inherit Metab Dis. 2011;34(3):695–700. 27. Coman D, Huang J, McTaggart S, Sakamoto O, Ohura T, McGill J, et al. Renal transplantation in a 14-year-old girl with vitamin B12-responsive cblAtype methylmalonic acidaemia. Pediatr Nephrol. 2006;21(2):270–3. 28. Lubrano R, Elli M, Rossi M, Travasso E, Raggi C, Barsotti P, et al. Renal transplant in methylmalonic acidemia: could it be the best option? Report on a case at 10 years and review of the literature. Pediatr Nephrol. 2007;22(8):1209–14.

1600 29. Van Calcar SC, Harding CO, Lyne P, Hogan K, Banerjee R, Sollinger H, et al. Renal transplantation in a patient with methylmalonic acidaemia. J Inherit Metab Dis. 1998;21(7):729–37. 30. Lubrano R, Bellelli E, Gentile I, Paoli S, Carducci C, Carducci C, et al. Pregnancy in a methylmalonic acidemia patient with kidney transplantation: a case report. Am J Transplant. 2013;13(7):1918–22. 31. Carmel R, Green R, Rosenblatt DS, Watkins D. Update on cobalamin, folate, and homocysteine. Hematology Am Soc Hematol Educ Program. 2003:62–81. 32. Fischer S, Huemer M, Baumgartner M, Deodato F, Ballhausen D, Boneh A, et al. Clinical presentation and outcome in a series of 88 patients with the cblC defect. J Inherit Metab Dis. 2014;37:831–40. 33. Komhoff M, Roofthooft MT, Westra D, Teertstra TK, Losito A, van de Kar NC, et al. Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency. Pediatrics. 2013;132(2): e540–4. 34. Morel CF, Lerner-Ellis JP, Rosenblatt DS. Combined methylmalonic aciduria and homocystinuria (cblC): phenotype-genotype correlations and ethnic-specific observations. Mol Genet Metab. 2006;88(4):315–21. 35. Labrune P, Zittoun J, Duvaltier I, Trioche P, Marquet J, Niaudet P, et al. Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency. Eur J Pediatr. 1999;158(9):734–9. 36. Iodice FG, Di Chiara L, Boenzi S, Aiello C, Monti L, Cogo P, et al. Cobalamin C defect presenting with isolated pulmonary hypertension. Pediatrics. 2013;132(1):e248–51. 37. Menni F, Testa S, Guez S, Chiarelli G, Alberti L, Esposito S. Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria. Pediatr Nephrol. 2012;27(8): 1401–5. 38. Brunelli SM, Meyers KE, Guttenberg M, Kaplan P, Kaplan BS. Cobalamin C deficiency complicated by an atypical glomerulopathy. Pediatr Nephrol. 2002;17(10):800–3. 39. Martinelli D, Deodato F, Dionisi-Vici C. Cobalamin C defect: natural history, pathophysiology, and treatment. J Inherit Metab Dis. 2011;34(1):127–35. 40. Nogueira C, Aiello C, Cerone R, Martins E, Caruso U, Moroni I, et al. Spectrum of MMACHC mutations in Italian and Portuguese patients with combined methylmalonic aciduria and homocystinuria, cblC type. Mol Genet Metab. 2008;93(4):475–80. 41. Cornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF, et al. Adult-onset eculizumabresistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis. 2014;63(1):119–23. 42. Verroust PJ, Birn H, Nielsen R, Kozyraki R, Christensen EI. The tandem endocytic receptors

F. Emma et al. megalin and cubilin are important proteins in renal pathology. Kidney Int. 2002;62(3):745–56. 43. Storm T, Emma F, Verroust PJ, Hertz JM, Nielsen R, Christensen EI. A patient with cubilin deficiency. N Engl J Med. 2011;364(1):89–91. 44. Storm T, Zeitz C, Cases O, Amsellem S, Verroust PJ, Madsen M, et al. Detailed investigations of proximal tubular function in Imerslund-Grasbeck syndrome. BMC Med Genet. 2013;14:111. 45. Grasbeck R. Imerslund-Grasbeck syndrome (selective vitamin B(12) malabsorption with proteinuria). Orphanet J Rare Dis. 2006;1:17. 46. Froissart R, Piraud M, Boudjemline AM, VianeySaban C, Petit F, Hubert-Buron A, et al. Glucose-6phosphatase deficiency. Orphanet J Rare Dis. 2011;6:27. 47. Weinstein DA, Wolfsdorf JI. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr. 2002;161 Suppl 1:S35–9. 48. Chen YT, Coleman RA, Scheinman JI, Kolbeck PC, Sidbury JB. Renal disease in type I glycogen storage disease. N Engl J Med. 1988;318(1):7–11. 49. Baker L, Dahlem S, Goldfarb S, Kern EF, Stanley CA, Egler J, et al. Hyperfiltration and renal disease in glycogen storage disease, type I. Kidney Int. 1989;35(6):1345–50. 50. Martens DH, Rake JP, Navis G, Fidler V, van Dael CM, Smit GP. Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition. Clin J Am Soc Nephrol. 2009;4(11):1741–6. 51. Oktenli C. Renal magnesium wasting, hypomagnesemic hypocalcemia, hypocalciuria and osteopenia in a patient with glycogenosis type II. Am J Nephrol. 2000;20(5):412–7. 52. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP, et al. Guidelines for management of glycogen storage disease type I – European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002;161 Suppl 1:S112–9. 53. Restaino I, Kaplan BS, Stanley C, Baker L. Nephrolithiasis, hypocitraturia, and a distal renal tubular acidification defect in type 1 glycogen storage disease. J Pediatr. 1993;122(3):392–6. 54. Pozzato C, Botta A, Melgara C, Fiori L, Gianni ML, Riva E. Sonographic findings in type I glycogen storage disease. J Clin Ultrasound. 2001;29(8): 456–61. 55. Reitsma-Bierens WC, Smit GP, Troelstra JA. Renal function and kidney size in glycogen storage disease type I. Pediatr Nephrol. 1992;6(3):236–8. 56. Mundy HR, Lee PJ. Glycogenosis type I and diabetes mellitus: a common mechanism for renal dysfunction? Med Hypotheses. 2002;59(1):110–4. 57. Yiu WH, Mead PA, Jun HS, Mansfield BC, Chou JY. Oxidative stress mediates nephropathy in type Ia glycogen storage disease. Lab Invest. 2010;90(4): 620–9.

50

Renal Manifestations of Metabolic Disorders in Children

58. Yiu WH, Pan CJ, Ruef RA, Peng WT, Starost MF, Mansfield BC, et al. Angiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type Ia. Kidney Int. 2008;73(6):716–23. 59. Clar J, Gri B, Calderaro J, Birling MC, Herault Y, Smit GP, et al. Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy. Kidney Int. 2014;86:747–56. 60. Lee PJ, Dalton RN, Shah V, Hindmarsh PC, Leonard JV. Glomerular and tubular function in glycogen storage disease. Pediatr Nephrol. 1995;9(6):705–10. 61. Verani R, Bernstein J. Renal glomerular and tubular abnormalities in glycogen storage disease type I. Arch Pathol Lab Med. 1988;112(3):271–4. 62. Yokoyama K, Hayashi H, Hinoshita F, Yamada A, Suzuki Y, Ogura Y, et al. Renal lesion of type Ia glycogen storage disease: the glomerular size and renal localization of apolipoprotein. Nephron. 1995;70(3):348–52. 63. Martin AP, Bartels M, Schreiber S, Buehrdel P, Hauss J, Fangmann J. Successful staged kidney and liver transplantation for glycogen storage disease type Ib: a case report. Transplant Proc. 2006;38(10):3615–9. 64. Maya Aparicio AC, Bernal Bellido C, Tinoco Gonzalez J, Garcia Ruiz S, Aguilar Romero L, Marin Gomez LM, et al. Fifteen years of follow-up of a liver transplant recipient with glycogen storage disease type Ia (Von Gierke disease). Transplant Proc. 2013;45(10):3668–9. 65. Mannstadt M, Magen D, Segawa H, Stanley T, Sharma A, Sasaki S, et al. Fanconi-Bickel syndrome and autosomal recessive proximal tubulopathy with hypercalciuria (ARPTH) are allelic variants caused by GLUT2 mutations. J Clin Endocrinol Metab. 2012;97 (10):E1978–86. 66. Manz F, Bickel H, Brodehl J, Feist D, Gellissen K, Gescholl-Bauer B, et al. Fanconi-Bickel syndrome. Pediatr Nephrol. 1987;1(3):509–18. 67. Santer R, Schneppenheim R, Dombrowski A, Gotze H, Steinmann B, Schaub J. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet. 1997;17(3):324–6. 68. Santer R, Schneppenheim R, Dombrowski A, Gotze H, Steinmann B, Schaub J. Fanconi-Bickel syndrome–a congenital defect of the liver-type facilitative glucose transporter. J Inherit Metab Dis. 1998;21(3):191–4. 69. Grunert SC, Schwab KO, Pohl M, Sass JO, Santer R. Fanconi-Bickel syndrome: GLUT2 mutations associated with a mild phenotype. Mol Genet Metab. 2012;105(3):433–7. 70. Leturque A, Brot-Laroche E, Le Gall M. GLUT2 mutations, translocation, and receptor function in diet sugar managing. Am J Physiol Endocrinol Metab. 2009;296(5):E985–92. 71. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1):133–41.

1601

72. Michau A, Guillemain G, Grosfeld A, VuillaumierBarrot S, Grand T, Keck M, et al. Mutations in SLC2A2 gene reveal hGLUT2 function in pancreatic beta cell development. J Biol Chem. 2013;288(43): 31080–92. 73. Sansbury FH, Flanagan SE, Houghton JA, Shuixian Shen FL, Al-Senani AM, Habeb AM, et al. SLC2A2 mutations can cause neonatal diabetes, suggesting GLUT2 may have a role in human insulin secretion. Diabetologia. 2012;55(9):2381–5. 74. Berry GT, Baynes JW, Wells-Knecht KJ, Szwergold BS, Santer R. Elements of diabetic nephropathy in a patient with GLUT 2 deficiency. Mol Genet Metab. 2005;86(4):473–7. 75. Kedzierska K, Kwiatkowski S, Torbe A, MarchelekMysliwiec M, Marcinkiewicz O, BobrekLesiakowska K, et al. Successful pregnancy in the patient with Fanconi-Bickel syndrome undergoing daily hemodialysis. Am J Med Genet A. 2011;155A (8):2028–30. 76. Pena L, Charrow J. Fanconi-Bickel syndrome: report of life history and successful pregnancy in an affected patient. Am J Med Genet A. 2011;155A(2):415–7. 77. DiMauro S, Schon EA. Mitochondrial respiratorychain diseases. N Engl J Med. 2003;348(26): 2656–68. 78. Emma F, Bertini E, Salviati L, Montini G. Renal involvement in mitochondrial cytopathies. Pediatr Nephrol. 2012;27(4):539–50. 79. Niaudet P, Rotig A. The kidney in mitochondrial cytopathies. Kidney Int. 1997;51(4):1000–7. 80. Emma F, Montini G, Salviati L, Dionisi-Vici C. Renal mitochondrial cytopathies. Int J Nephrol. 2011;2011: 609213. 81. Bodemer C, Rotig A, Rustin P, Cormier V, Niaudet P, Saudubray JM, et al. Hair and skin disorders as signs of mitochondrial disease. Pediatrics. 1999;103(2): 428–33. 82. Martin-Hernandez E, Garcia-Silva MT, Vara J, Campos Y, Cabello A, Muley R, et al. Renal pathology in children with mitochondrial diseases. Pediatr Nephrol. 2005;20(9):1299–305. 83. Au KM, Lau SC, Mak YF, Lai WM, Chow TC, Chen ML, et al. Mitochondrial DNA deletion in a girl with Fanconi’s syndrome. Pediatr Nephrol. 2007;22(1): 136–40. 84. Kuwertz-Broking E, Koch HG, Marquardt T, Rossi R, Helmchen U, Muller-Hocker J, et al. Renal Fanconi syndrome: first sign of partial respiratory chain complex IV deficiency. Pediatr Nephrol. 2000;14(6): 495–8. 85. Mochizuki H, Joh K, Kawame H, Imadachi A, Nozaki H, Ohashi T, et al. Mitochondrial encephalomyopathies preceded by de-Toni-Debre-Fanconi syndrome or focal segmental glomerulosclerosis. Clin Nephrol. 1996;46(5):347–52. 86. Morris AA, Taylor RW, Birch-Machin MA, Jackson MJ, Coulthard MG, Bindoff LA, et al. Neonatal Fanconi syndrome due to deficiency of complex III

1602 of the respiratory chain. Pediatr Nephrol. 1995;9(4): 407–11. 87. De Meirleir L, Seneca S, Damis E, Sepulchre B, Hoorens A, Gerlo E, et al. Clinical and diagnostic characteristics of complex III deficiency due to mutations in the BCS1L gene. Am J Med Genet A. 2003;121A(2):126–31. 88. Duncan AJ, Bitner-Glindzicz M, Meunier B, Costello H, Hargreaves IP, Lopez LC, et al. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet. 2009;84(5):558–66. 89. Gilbert RD, Emms M. Pearson’s syndrome presenting with Fanconi syndrome. Ultrastruct Pathol. 1996;20(5):473–5. 90. Lee YS, Yap HK, Barshop BA, Lee YS, Rajalingam S, Loke KY. Mitochondrial tubulopathy: the many faces of mitochondrial disorders. Pediatr Nephrol. 2001;16(9):710–2. 91. Liu HM, Tsai LP, Chien YH, Wu JF, Weng WC, Peng SF, et al. A novel 3670-base pair mitochondrial DNA deletion resulting in multi-systemic manifestations in a child. Pediatr Neonatol. 2012;53(4):264–8. 92. Mori K, Narahara K, Ninomiya S, Goto Y, Nonaka I. Renal and skin involvement in a patient with complete Kearns-Sayre syndrome. Am J Med Genet. 1991;38(4):583–7. 93. Niaudet P, Heidet L, Munnich A, Schmitz J, Bouissou F, Gubler MC, et al. Deletion of the mitochondrial DNA in a case of de Toni-Debre-Fanconi syndrome and Pearson syndrome. Pediatr Nephrol. 1994;8(2):164–8. 94. O’Toole JF. Renal manifestations of genetic mitochondrial disease. Int J Nephrol Renovasc Dis. 2014;7:57–67. 95. Ogier H, Lombes A, Scholte HR, Poll-The BT, Fardeau M, Alcardi J, et al. de Toni-Fanconi-Debre syndrome with Leigh syndrome revealing severe muscle cytochrome c oxidase deficiency. J Pediatr. 1988;112(5):734–9. 96. Pitchon EM, Cachat F, Jacquemont S, Hinard C, Borruat FX, Schorderet DF, et al. Patient with Fanconi Syndrome (FS) and retinitis pigmentosa (RP) caused by a deletion and duplication of mitochondrial DNA (mtDNA). Klin Monbl Augenheilkd. 2007;224(4): 340–3. 97. Topaloglu R, Lebre AS, Demirkaya E, Kuskonmaz B, Coskun T, Orhan D, et al. Two new cases with Pearson syndrome and review of Hacettepe experience. Turk J Pediatr. 2008;50(6):572–6. 98. Tzoufi M, Makis A, Chaliasos N, Nakou I, Siomou E, Tsatsoulis A, et al. A rare case report of simultaneous presentation of myopathy, Addison’s disease, primary hypoparathyroidism, and Fanconi syndrome in a child diagnosed with Kearns-Sayre syndrome. Eur J Pediatr. 2013;172(4):557–61. 99. Emma F, Pizzini C, Tessa A, Di Giandomenico S, Onetti-Muda A, Santorelli FM, et al. “Bartter-like”

F. Emma et al. phenotype in Kearns-Sayre syndrome. Pediatr Nephrol. 2006;21(3):355–60. 100. Eviatar L, Shanske S, Gauthier B, Abrams C, Maytal J, Slavin M, et al. Kearns-Sayre syndrome presenting as renal tubular acidosis. Neurology. 1990;40(11):1761–3. 101. Goto Y, Itami N, Kajii N, Tochimaru H, Endo M, Horai S. Renal tubular involvement mimicking Bartter syndrome in a patient with Kearns-Sayre syndrome. J Pediatr. 1990;116(6):904–10. 102. Katsanos KH, Elisaf M, Bairaktari E, Tsianos EV. Severe hypomagnesemia and hypoparathyroidism in Kearns-Sayre syndrome. Am J Nephrol. 2001;21(2):150–3. 103. Matsutani H, Mizusawa Y, Shimoda M, Niimura F, Takeda A, Shimohira M, et al. Partial deficiency of cytochrome c oxidase with isolated proximal renal tubular acidosis and hypercalciuria. Child Nephrol Urol. 1992;12(4):221–4. 104. Di Donato S. Multisystem manifestations of mitochondrial disorders. J Neurol. 2009;256(5): 693–710. 105. Guery B, Choukroun G, Noel LH, Clavel P, Rotig A, Lebon S, et al. The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial tRNA(Leu) gene mutation. J Am Soc Nephrol. 2003;14(8):2099–108. 106. Cheong HI, Chae JH, Kim JS, Park HW, Ha IS, Hwang YS, et al. Hereditary glomerulopathy associated with a mitochondrial tRNA(Leu) gene mutation. Pediatr Nephrol. 1999;13(6):477–80. 107. Doleris LM, Hill GS, Chedin P, Nochy D, BellanneChantelot C, Hanslik T, et al. Focal segmental glomerulosclerosis associated with mitochondrial cytopathy. Kidney Int. 2000;58(5):1851–8. 108. Hirano M, Konishi K, Arata N, Iyori M, Saruta T, Kuramochi S, et al. Renal complications in a patient with A-to-G mutation of mitochondrial DNA at the 3243 position of leucine tRNA. Intern Med. 2002;41(2):113–8. 109. Hotta O, Inoue CN, Miyabayashi S, Furuta T, Takeuchi A, Taguma Y. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int. 2001;59(4):1236–43. 110. Jansen JJ, Maassen JA, van der Woude FJ, Lemmink HA, van den Ouweland JM, t’ Hart LM, et al. Mutation in mitochondrial tRNA(Leu(UUR)) gene associated with progressive kidney disease. J Am Soc Nephrol. 1997;8(7):1118–24. 111. Kurogouchi F, Oguchi T, Mawatari E, Yamaura S, Hora K, Takei M, et al. A case of mitochondrial cytopathy with a typical point mutation for MELAS, presenting with severe focal-segmental glomerulosclerosis as main clinical manifestation. Am J Nephrol. 1998;18(6):551–6. 112. Lowik MM, Hol FA, Steenbergen EJ, Wetzels JF, van den Heuvel LP. Mitochondrial tRNALeu(UUR) mutation in a patient with steroid-resistant nephrotic

50

Renal Manifestations of Metabolic Disorders in Children

syndrome and focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2005;20(2):336–41. 113. Nakamura S, Yoshinari M, Doi Y, Yoshizumi H, Katafuchi R, Yokomizo Y, et al. Renal complications in patients with diabetes mellitus associated with an A to G mutation of mitochondrial DNA at the 3243 position of leucine tRNA. Diabetes Res Clin Pract. 1999;44(3):183–9. 114. Seidowsky A, Hoffmann M, Glowacki F, Dhaenens CM, Devaux JP, de Sainte Foy CL, et al. Renal involvement in MELAS syndrome – a series of 5 cases and review of the literature. Clin Nephrol. 2013;80(6):456–63. 115. Rotig A, Appelkvist EL, Geromel V, Chretien D, Kadhom N, Edery P, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet. 2000;356 (9227):391–5. 116. Salviati L, Sacconi S, Murer L, Zacchello G, Franceschini L, Laverda AM, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology. 2005;65(4):606–8. 117. Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med. 2008;358(26): 2849–50. 118. Quinzii C, Naini A, Salviati L, Trevisson E, Navas P, Dimauro S, et al. A mutation in parahydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet. 2006;78(2):345–9. 119. Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol. 2007;18(10):2773–80. 120. Mollet J, Giurgea I, Schlemmer D, Dallner G, Chretien D, Delahodde A, et al. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest. 2007;117(3):765–72. 121. Scalais E, Chafai R, Van Coster R, Bindl L, Nuttin C, Panagiotaraki C, et al. Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoatepolyprenyl transferase (COQ2). Eur J Paediatr Neurol. 2013;17(6):625–30. 122. Lopez LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJ, Naini A, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet. 2006;79(6):1125–9. 123. Heeringa SF, Chernin G, Chaki M, Zhou W, Sloan AJ, Ji Z, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest. 2011;121(5):2013–24.

1603

124. Ashraf S, Gee HY, Woerner S, Xie LX, Vega-WarnerV, Lovric S, et al. ADCK4 mutations promote steroidresistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest. 2013;123(12): 5179–89. 125. Freeze HH. Understanding human glycosylation disorders: biochemistry leads the charge. J Biol Chem. 2013;288(10):6936–45. 126. Scott K, Gadomski T, Kozicz T, Morava E. Congenital disorders of glycosylation: new defects and still counting. J Inherit Metab Dis. 2014;37(4): 609–17. 127. Jaeken J, Hennet T, Matthijs G, Freeze HH. CDG nomenclature: time for a change! Biochim Biophys Acta. 2009;1792(9):825–6. 128. Jaeken J, Matthijs G, Carchon H, Van Schaftingen E. Defects of N-Glycan synthesis. In: Valle D, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson KM, et al., editors. The online metabolic and molecular bases of inherited disease. New York: McGraw-Hill. 129. Freeze HH, Chong JX, Bamshad MJ, Ng BG. Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am J Hum Genet. 2014;94(2):161–75. 130. Horslen SP, Clayton PT, Harding BN, Hall NA, Keir G, Winchester B. Olivopontocerebellar atrophy of neonatal onset and disialotransferrin developmental deficiency syndrome. Arch Dis Child. 1991;66(9):1027–32. 131. Funke S, Gardeitchik T, Kouwenberg D, Mohamed M, Wortmann SB, Korsch E, et al. Perinatal and early infantile symptoms in congenital disorders of glycosylation. Am J Med Genet A. 2013;161A(3):578–84. 132. Hertz-Pannier L, Dechaux M, Sinico M, Emond S, Cormier-Daire V, Saudubray JM, et al. Congenital disorders of glycosylation type I: a rare but new cause of hyperechoic kidneys in infants and children due to early microcystic changes. Pediatr Radiol. 2006;36(2):108–14. 133. Strom EH, Stromme P, Westvik J, Pedersen SJ. Renal cysts in the carbohydrate-deficient glycoprotein syndrome. Pediatr Nephrol. 1993;7(3): 253–5. 134. de Lonlay P, Seta N, Barrot S, Chabrol B, Drouin V, Gabriel BM, et al. A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. J Med Genet. 2001;38(1):14–9. 135. van der Knaap MS, Wevers RA, Monnens L, Jakobs C, Jaeken J, van Wijk JA. Congenital nephrotic syndrome: a novel phenotype of type I carbohydrate-deficient glycoprotein syndrome. J Inherit Metab Dis. 1996;19(6):787–91. 136. Sinha MD, Horsfield C, Komaromy D, Booth CJ, Champion MP. Congenital disorders of glycosylation: a rare cause of nephrotic syndrome. Nephrol Dial Transplant. 2009;24(8):2591–4.

1604 137. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19(6):358–71. 138. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447–52. 139. Li S, Sanna S, Maschio A, Busonero F, Usala G, Mulas A, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet. 2007;3(11):e194. 140. Cameron JS, Moro F, Simmonds HA. Gout, uric acid and purine metabolism in paediatric nephrology. Pediatr Nephrol. 1993;7(1):105–18. 141. Stapleton FB, Linshaw MA, Hassanein K, Gruskin AB. Uric acid excretion in normal children. J Pediatr. 1978;92(6):911–4. 142. Calabrese G, Simmonds HA, Cameron JS, Davies PM. Precocious familial gout with reduced fractional urate clearance and normal purine enzymes. Q J Med. 1990;75(277):441–50. 143. Sikora P, Pijanowska M, Majewski M, Bienias B, Borzecka H, Zajczkowska M. Acute renal failure due to bilateral xanthine urolithiasis in a boy with Lesch-Nyhan syndrome. Pediatr Nephrol. 2006; 21(7):1045–7. 144. Pela I, Donati MA, Procopio E, Fiorini P. LeschNyhan syndrome presenting with acute renal failure in a 3-day-old newborn. Pediatr Nephrol. 2008;23(1): 155–8. 145. Simmonds HA, Cameron JS, Barratt TM, Dillon MJ, Meadow SR, Trompeter RS. Purine enzyme defects as a cause of acute renal failure in childhood. Pediatr Nephrol. 1989;3(4):433–7. 146. Torres RJ, Puig JG. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis. 2007; 2:48. 147. Rinat C, Zoref-Shani E, Ben-Neriah Z, Bromberg Y, Becker-Cohen R, Feinstein S, et al. Molecular, biochemical, and genetic characterization of a female patient with Lesch-Nyhan disease. Mol Genet Metab. 2006;87(3):249–52. 148. Cochat P, Pichault V, Bacchetta J, Dubourg L, Sabot JF, Saban C, et al. Nephrolithiasis related to inborn metabolic diseases. Pediatr Nephrol. 2010;25(3): 415–24. 149. Visser JE, Bar PR, Jinnah HA. Lesch-Nyhan disease and the basal ganglia. Brain Res Brain Res Rev. 2000;32(2–3):449–75. 150. Kaufman JM, Greene ML, Seegmiller JE. Urine uric acid to creatinine rtio–a screening test for inherited disorders of purine metabolism. Phosphoribosyltransferase (PRT) deficiency in X-linked cerebral palsy and in a variant of gout. J Pediatr. 1968;73(4):583–92. 151. Jinnah HA, Ceballos-Picot I, Torres RJ, Visser JE, Schretlen DJ, Verdu A, et al. Attenuated variants of Lesch-Nyhan disease. Brain J Neurol. 2010; 133(Pt 3):671–89.

F. Emma et al. 152. George RL, Keenan RT. Genetics of hyperuricemia and gout: implications for the present and future. Curr Rheumatol Rep. 2013;15(2):309. 153. Fu R, Ceballos-Picot I, Torres RJ, Larovere LE, Yamada Y, Nguyen KV, et al. Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder. Brain J Neurol. 2014;137(Pt 5): 1282–303. 154. Becker MA, Smith PR, Taylor W, Mustafi R, Switzer RL. The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity. J Clin Invest. 1995;96(5):2133–41. 155. Becker MA, Puig JG, Mateos FA, Jimenez ML, Kim M, Simmonds HA. Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. Am J Med. 1988;85(3):383–90. 156. Engle SJ, Stockelman MG, Chen J, Boivin G, Yum MN, Davies PM, et al. Adenine phosphoribosyltransferase-deficient mice develop 2,8-dihydroxyadenine nephrolithiasis. Proc Natl Acad Sci U S A. 1996;93(11):5307–12. 157. Fujimori S, Akaoka I, Sakamoto K, Yamanaka H, Nishioka K, Kamatani N. Common characteristics of mutant adenine phosphoribosyltransferases from four separate Japanese families with 2,8-dihydroxyadenine urolithiasis associated with partial enzyme deficiencies. Hum Genet. 1985; 71(2):171–6. 158. Marra G, Vercelloni PG, Edefonti A, Manzoni G, Pavesi MA, Fogazzi GB, et al. Adenine phosphoribosyltransferase deficiency: an underdiagnosed cause of lithiasis and renal failure. JIMD Rep. 2012;5:45–8. 159. Ichida K, Hosoyamada M, Kamatani N, Kamitsuji S, Hisatome I, Shibasaki T, et al. Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese. Clin Genet. 2008;74(3): 243–51. 160. Doring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet. 2008;40(4):430–6. 161. Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K, et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet. 2008;83(6):744–51. 162. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008;40(4): 437–42. 163. Wallace C, Newhouse SJ, Braund P, Zhang F, Tobin M, Falchi M, et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet. 2008;82(1):139–49. 164. Moro F, Ogg CS, Simmonds HA, Cameron JS, Chantler C, McBride MB, et al. Familial juvenile

50

Renal Manifestations of Metabolic Disorders in Children

gouty nephropathy with renal urate hypoexcretion preceding renal disease. Clin Nephrol. 1991;35(6): 263–9. 165. Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst O. The rediscovery of uromodulin (TammHorsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int. 2011;80(4): 338–47. 166. Hart TC, Gorry MC, Hart PS, Woodard AS, Shihabi Z, Sandhu J, et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet. 2002;39(12):882–92. 167. Trudu M, Janas S, Lanzani C, Debaix H, Schaeffer C, Ikehata M, et al. Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med. 2013;19(12):1655–60. 168. Bachmann S, Metzger R, Bunnemann B. TammHorsfall protein-mRNA synthesis is localized to the thick ascending limb of Henle’s loop in rat kidney. Histochemistry. 1990;94(5):517–23. 169. Bachmann S, Koeppen-Hagemann I, Kriz W. Ultrastructural localization of Tamm-Horsfall glycoprotein (THP) in rat kidney as revealed by protein A-gold immunocytochemistry. Histochemistry. 1985;83(6):531–8. 170. Bleyer AJ, Hart TC. Familial juvenile hyperuricaemic nephropathy. QJM. 2003;96(11):867–8. 171. Dahan K, Devuyst O, Smaers M, Vertommen D, Loute G, Poux JM, et al. A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol. 2003; 14(11):2883–93. 172. Bollee G, Dahan K, Flamant M, Moriniere V, Pawtowski A, Heidet L, et al. Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations. Clinical journal of the American Society of Nephrology : CJASN. 2011;6(10): 2429–38. 173. Fairbanks LD, Cameron JS, Venkat-Raman G, Rigden SP, Rees L, Van THW, et al. Early treatment with allopurinol in familial juvenile hyerpuricaemic nephropathy (FJHN) ameliorates the long-term progression of renal disease. QJM. 2002;95(9):597–607. 174. Labriola L, in Dahan K, Pirson Y. Outcome of kidney transplantation in familial juvenile hyperuricaemic nephropathy. Nephrol Dial Transplant. 2007;22(10): 3070–3. 175. Bingham C, Ellard S, van’t Hoff WG, Simmonds HA, Marinaki AM, Badman MK, et al. Atypical familial juvenile hyperuricemic nephropathy associated with a hepatocyte nuclear factor-1beta gene mutation. Kidney Int. 2003;63(5):1645–51. 176. Heidet L, Decramer S, Pawtowski A, Moriniere V, Bandin F, Knebelmann B, et al. Spectrum of HNF1B mutations in a large cohort of patients who harbor

1605

renal diseases. Clin J Am Soc Nephrol. 2010;5(6): 1079–90. 177. Zivna M, Hulkova H, Matignon M, Hodanova K, Vylet’al P, Kalbacova M, et al. Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure. Am J Hum Genet. 2009;85(2):204–13. 178. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. 179. Grunfeld JP, Lidove O, Joly D, Barbey F. Renal disease in Fabry patients. J Inherit Metab Dis. 2001;24 Suppl 2:71–4; discussion 65. 180. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31–40. 181. Mayes JS, Scheerer JB, Sifers RN, Donaldson ML. Differential assay for lysosomal alphagalactosidases in human tissues and its application to Fabry’s disease. Clin Chim Acta. 1981;112(2): 247–51. 182. Linthorst GE, Vedder AC, Aerts JM, Hollak CE. Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta. 2005;353(1–2):201–3. 183. Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med. 2007;9(1):34–45. 184. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93(2):112–28. 185. Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res. 2008;64(5):550–5. 186. Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30 (2):184–92. 187. Rolfs A, Bottcher T, Zschiesche M, Morris P, Winchester B, Bauer P, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366(9499):1794–6. 188. Tondel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51(5):767–76. 189. Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R. Early renal changes in hemizygous and heterozygous patients with Fabry’s disease. Kidney Int. 1978;13(3):223–35. 190. Ramaswami U, Najafian B, Schieppati A, Mauer M, Bichet DG. Assessment of renal pathology and dysfunction in children with Fabry disease. Clin J Am Soc Nephrol. 2010;5(2):365–70.

1606 191. Schiffmann R. Natural history of Fabry disease in males: preliminary observations. J Inherit Metab Dis. 2001;24 Suppl 2:15–7; discussion 1–2. 192. Sessa A, Meroni M, Battini G, Maglio A, Brambilla PL, Bertella M, et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis. 2001;24 Suppl 2:66–70; discussion 65. 193. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24(7): 2102–11. 194. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11(11):790–6. 195. Mignani R, Feriozzi S, Schaefer RM, Breunig F, Oliveira JP, Ruggenenti P, et al. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy. Clin J Am Soc Nephrol. 2010;5(2):379–85. 196. Ries M, Bettis KE, Choyke P, Kopp JB, Austin 3rd HA, Brady RO, et al. Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. Kidney Int. 2004;66(3):978–82. 197. Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int. 2002;61(1):249–55. 198. Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol. 2010;5(12):2220–8. 199. Pisani A, Visciano B, Roux GD, Sabbatini M, Porto C, Parenti G, et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. Mol Genet Metab. 2012;107(3):267–75. 200. Wang RY, Bodamer OA, Watson MS, Wilcox WR, Diseases AWGoDCoLS. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med. 2011; 13(5):457–84. 201. Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012;27(3):1042–9. 202. de Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis. 2013;8:8. 203. Sun MS, Hattori S, Kubo S, Awata H, Matsuda I, Endo F. A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in

F. Emma et al. Fah/Hpd double mutant mice. J Am Soc Nephrol. 2000;11(2):291–300. 204. Spencer PD, Roth KS. Effects of succinylacetone on amino acid uptake in the rat kidney. Biochem Med Metab Biol. 1987;37(1):101–9. 205. Santra S, Preece MA, Hulton SA, McKiernan PJ. Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis. 2008;31(3):399–402. 206. Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis. 2008;31(1): 81–7. 207. Larochelle J, Alvarez F, Bussieres JF, Chevalier I, Dallaire L, Dubois J, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab. 2012;107(1–2):49–54. 208. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992;340(8823):813–7. 209. Gjone E. Familial lecithin: cholesterol acyltransferase deficiency–a clinical survey. Scand J Clin Lab Invest Suppl. 1974;137:73–82. 210. Imbasciati E, Paties C, Scarpioni L, Mihatsch MJ. Renal lesions in familial lecithin-cholesterol acyltransferase deficiency. Ultrastructural heterogeneity of glomerular changes. Am J Nephrol. 1986;6(1):66–70. 211. Hirashio S, Ueno T, Naito T, Masaki T. Characteristic kidney pathology, gene abnormality and treatments in LCAT deficiency. Clin Exp Nephrol. 2014;18(2): 189–93. 212. Sebastio G, Sperandeo MP, Andria G. Lysinuric protein intolerance: reviewing concepts on a multisystem disease. Am J Med Genet C Semin Med Genet. 2011;157C(1):54–62. 213. Tanner LM, Nanto-Salonen K, Niinikoski H, Jahnukainen T, Keskinen P, Saha H, et al. Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intolerance. J Pediatr. 2007;150(6):631–4, 4 e1. 214. Tanner LM, Nanto-Salonen K, Venetoklis J, Kotilainen S, Niinikoski H, Huoponen K, et al. Nutrient intake in lysinuric protein intolerance. J Inherit Metab Dis. 2007;30(5):716–21. 215. DiRocco M, Garibotto G, Rossi GA, Caruso U, Taccone A, Picco P, et al. Role of haematological, pulmonary and renal complications in the long-term prognosis of patients with lysinuric protein intolerance. Eur J Pediatr. 1993;152(5):437–40. 216. Parenti G, Sebastio G, Strisciuglio P, Incerti B, Pecoraro C, Terracciano L, et al. Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course. J Pediatr. 1995;126(2):246–51.

50

Renal Manifestations of Metabolic Disorders in Children

217. Benninga MA, Lilien M, de Koning TJ, Duran M, Versteegh FG, Goldschmeding R, et al. Renal Fanconi syndrome with ultrastructural defects in lysinuric protein intolerance. J Inherit Metab Dis. 2007;30(3): 402–3. 218. Barilli A, Rotoli BM, Visigalli R, Bussolati O, Gazzola GC, Gatti R, et al. Impaired phagocytosis in macrophages from patients affected by lysinuric protein intolerance. Mol Genet Metab. 2012;105(4): 585–9. 219. Mannucci L, Emma F, Markert M, Bachmann C, Boulat O, Carrozzo R, et al. Increased NO production

1607

in lysinuric protein intolerance. J Inherit Metab Dis. 2005;28(2):123–9. 220. Ogier de Baulny H, Schiff M, Dionisi-Vici C. Lysinuric protein intolerance (LPI): a multi organ disease by far more complex than a classic urea cycle disorder. Mol Genet Metab. 2012;106(1): 12–7. 221. Barilli A, Rotoli BM, Visigalli R, Bussolati O, Gazzola GC, Kadija Z, et al. In lysinuric protein intolerance system y + L activity is defective in monocytes and in GM-CSF-differentiated macrophages. Orphanet J Rare Dis. 2010;5:32.

Infectious Diseases and the Kidney in Children

51

Jennifer Stevens, Jethro A. Herberg, and Michael Levin

Contents Bacterial Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1610 Systemic Sepsis and Septic Shock . . . . . . . . . . . . . . . . . 1610 Specific Bacterial Infections Causing Renal Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Meningococcus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Staphylococcus Aureus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Streptococcus Pyogenes . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gastrointestinal Infections . . . . . . . . . . . . . . . . . . . . . . . . . . Mycobacterium Tuberculosis . . . . . . . . . . . . . . . . . . . . . . . Treponema Pallidum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mycoplasma Pneumoniae . . . . . . . . . . . . . . . . . . . . . . . . . . Legionnaires’ Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1613 1613 1614 1616 1620 1621 1622 1622 1622

Rickettsial Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1623 Rocky Mountain Spotted Fever . . . . . . . . . . . . . . . . . . . . 1623 Q Fever . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1624 Intravascular and Focal Bacterial Infections . . . 1625 Bacterial Endocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1625 Viral Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hepatitis B Virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hepatitis C Virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Herpes Viruses: Cytomegalovirus . . . . . . . . . . . . . . . . . . Herpes Viruses Varicella-Zoster Virus . . . . . . . . . . . . . Herpes Viruses: Epstein-Barr Virus . . . . . . . . . . . . . . . .

Herpes Viruses: Herpes Simplex Virus . . . . . . . . . . . . Human Immunodeficiency Virus . . . . . . . . . . . . . . . . . . . Human Polyomaviruses . . . . . . . . . . . . . . . . . . . . . . . . . . . . Viral Hemorrhagic Fever . . . . . . . . . . . . . . . . . . . . . . . . . . . Other Common Virus Infections . . . . . . . . . . . . . . . . . . . Coronavirus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1632 1632 1635 1637 1640 1641

Parasitic Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Malaria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Schistosomiasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Leishmaniasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Filariasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1641 1642 1644 1645 1645

Fungal Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1646 Miscellaneous Conditions . . . . . . . . . . . . . . . . . . . . . . . . . Hemorrhagic Shock and Encephalopathy . . . . . . . . . . Kawasaki Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Xanthogranulomatous Pyelonephritis (XGP) . . . . . .

1646 1646 1647 1647

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1647

1626 1627 1629 1630 1631 1632

J. Stevens (*) University Hospital Wales, Cardiff, S. Wales, UK e-mail: [emailprotected] J.A. Herberg Imperial College London, London, UK e-mail: [emailprotected] M. Levin Department of Medicine, Imperial College London, London, UK e-mail: [emailprotected] # Springer-Verlag Berlin Heidelberg 2016 E.D. Avner et al. (eds.), Pediatric Nephrology, DOI 10.1007/978-3-662-43596-0_47

1609

1610

The kidney is involved in a wide range of bacterial, viral, fungal, and parasitic diseases. In most systemic infections, renal involvement is a minor component of the illness, but in some, renal failure may be the presenting feature and the major problem in management. Although individual infectious processes may have a predilection to involve the renal vasculature, glomeruli, interstitium, or collecting systems, a purely anatomic approach to the classification of infectious diseases affecting the kidney is rarely helpful because most infections may involve several different aspects of renal function. In this chapter, a microbiological classification of the organisms affecting the kidney is adopted. Although they are important causes of renal dysfunction in infectious diseases, urinary tract infections and hemolytic uremic syndrome (HUS) are not discussed in detail because they are considered separately in ▶ Chaps. 47, “Renal Involvement in Children with HUS,” and ▶ 53, “Urinary Tract Infections in Children,” respectively. Elucidation of the cause of renal involvement in a child with evidence of infection must be based on a careful consideration of the geographic distribution of infectious diseases in different countries. A history of foreign travel; exposure to animals, insects, or unusual foods or drinks; outdoor activities such as swimming or hiking; and contact with infectious diseases must be sought in every case. The clinical examination should include a careful assessment of the skin and mucous membranes and a search for insect bites, lymphadenopathy, and involvement of other organs. A close collaboration with a pediatric infectious disease specialist and hospital microbiologist will aid the diagnosis and management of the underlying infection. A tantalizing clue to the pathogenesis of glomerular disease is the marked difference in the incidence of nephrosis and nephritis in developed and underdeveloped areas of the world. In several tropical countries, glomerulonephritis (GN) accounts for up to 4 % of pediatric hospital admissions; the incidence in temperate climates is 10- to 100-fold less. This difference might be explained by a complex interaction of several different factors, including nutrition, racial and genetically determined differences in immune responses, and exposure to infectious diseases. A

J. Stevens et al.

growing body of evidence, however, suggests that long-term exposure to infectious agents is a major factor in the increased prevalence of glomerular diseases in developing countries. Renal involvement in infectious diseases may occur by a variety of mechanisms: direct microbial invasion of the renal tissues or collecting system may take place in conditions such as staphylococcal abscess of the kidney occurring as a result of septicemic spread of the organism; ascending infection commonly occurs due to infection in the urinary tract; damage to the kidney may be caused by the systemic release of endotoxin or other toxins and activation of the inflammatory cascade during septicemia or due to a focus of infection distant from the kidney; ischemic damage may result from inadequate perfusion induced by septic shock; the kidney may be damaged by activation of the immunologic pathways or by immune complexes resulting from the infectious process. In many conditions, a combination of these mechanisms may be operative. In the assessment of renal complications occurring in infectious diseases, the possibility of druginduced nephrotoxicity caused by antimicrobial therapy should always be considered. The nephrotoxic effects of antibiotics and other antimicrobial agents are not addressed in this chapter but are covered in ▶ Chap. 67, “Handling of Drugs in Children with Abnormal Renal Function”.

Bacterial Infections Bacterial infections associated with renal disease and the likely mechanisms causing renal dysfunction are shown in Table 1.

Systemic Sepsis and Septic Shock Impaired renal function is common in systemic sepsis, and acute kidney injury (AKI) is an independent risk factor for mortality in pediatric sepsis [1]. Depending on the severity of the infection and the organism responsible, the renal involvement may vary from insignificant proteinuria to AKI requiring dialysis. The organisms causing AKI as

51

Infectious Diseases and the Kidney in Children

1611

Table 1 Likely mechanisms causing renal dysfunction in bacterial infections

Organism Neisseria meningitidis

Staphylococcus aureus

Staphylococcus epidermidis Group A Streptococcus

Haemophilus influenzae Leptospira interrogans Streptococcus pneumoniae

Site/infection Septicemia Chronic meningococcemia Renal abscess

Infection localized to the kidney

Systemic infection; toxin/ inflammation ++

Ischemia/ hypoperfusion; vasomotor nephropathy ++

Distant infection; “immunologic/ delayed”

+ ++

Distant abscess/ endocarditis Sepsis Toxic shock Shunt infection

++ ++ ++

++ ++ ++

Sepsis

++

++

Toxic shock APSGN Brazilian purpuric fever Leptospirosis, Weil’s disease Sepsis

++

++

++

++

++

++

++ ++

++ + (HUS) – neuraminidase associated

Pneumonia

Escherichia coli and Shigella Salmonella species Vibrio species Klebsiella Yersinia species Campylobacter jejuni Mycobacterium tuberculosis Treponema pallidum Mycoplasma pneumoniae Legionella Rickettsia rickettsii Coxiella burnetii

Sepsis Diarrhea Colitis Sepsis Diarrhea Cholera Sepsis Enteritis Enteritis Tuberculosis

++

++

++

++ ++ ++ ++ ++ ++

++ (HUS) ++(HUS) + + (HUS)

+ + +

+

Pneumonia

+ + +

+ (HUS)

+

Syphilis

Pneumonia Rocky Mountain spotted fever Q fever

Others

+ (HUS) Rhabdomyolysis

+ +

++ frequent complication of infection, + uncommon but recognized complication, APSGN acute poststreptococcal glomerulonephritis, HUS hemolytic uremic syndrome

1612

part of systemic sepsis vary with age and geographic location and also differ in normal and immunocompromised children. In the neonatal period, group B streptococci, coliforms, Staphylococcus aureus, and Listeria monocytogenes are the organisms usually responsible. In older children, Neisseria meningitidis, Streptococcus pneumoniae, group A Streptococcus, and Staphylococcus aureus account for most of the infections. In people who are immunocompromised, a wide range of bacteria are seen, and, similarly, in tropical countries, other pathogens, including Haemophilus influenzae, Salmonella species, and Pseudomonas pseudomallei, must be considered. Vaccines against N. meningitides, S. pneumoniae, and H. influenzae have reduced the impact of these infections, but their uptake varies in different countries. Systemic sepsis usually presents with nonspecific features: fever, tachypnea, tachycardia, and evidence of skin and organ underperfusion. The pathophysiology of renal involvement in systemic sepsis is multifactorial [2, 3]. Hypovolemia with diminished renal perfusion is the earliest event and is a consequence of the increased vascular permeability and loss of plasma from the intravascular space. Hypovolemia commonly coexists with depressed myocardial function because of the myocardial depressant effects of endotoxin or other toxins. The renal vasoconstrictor response to diminished circulating volume and reduced cardiac output further reduces glomerular filtration, and oliguria is thus a consistent and early event in severe sepsis. A number of vasodilator pathways are activated in sepsis, including nitric oxide and the kinin pathways. This may lead to inappropriate dilatation of vascular beds. Vasodilatation of capillary beds leading to warm shock is common in adults with sepsis due to Gram-negative organisms but is less commonly seen in children, in whom intense vasoconstriction is the usual response to sepsis. If renal underperfusion and vasoconstriction are persistent and severe, the reversible prerenal failure is followed by established renal failure with the characteristic features of vasomotor nephropathy or acute tubular necrosis. Other mechanisms of renal damage in systemic sepsis include direct effects of endotoxin and

J. Stevens et al.

other toxins on the kidney and release of inflammatory mediators such as tumor necrosis factor (TNF) and other cytokines, arachidonic acid metabolites, and proteolytic enzymes. Leukocyte-endothelial interactions result in physical congestion of the medullary vasculature and further decrease regional blood flow. Nitric oxide (NO) is postulated to play a key role in the pathophysiology of renal failure in sepsis. NO is produced from three cell-specific nitric oxide synthase (NOS) isoforms. Within the kidney, endothelial NOS (eNOS) is expressed in endothelial cells and plays a role in vascular relaxation, inhibition of leukocyte adhesion, and platelet aggregation. Endothelial injury in renal ischemia has been reported to impair the production of NO by eNOS. Inducible NOS (iNOS) has been implicated as an important mediator of vasodilatation and is upregulated within the medulla and the glomeruli in sepsis. The alteration of NOS expression and NO production within the systemic circulation and the kidney has supported the extensive testing of NOS inhibitors in sepsis and renal ischemia [4]. Trials of selective NO synthase inhibition did not offer any advantages over saline resuscitation [5]. Activation of coagulation is an important component of the pathophysiology of septic shock and contributes to intraglomerular thrombosis. Tubular injury then leads to cell detachment and intratubular obstruction and tubular backleak. Recovery necessitates the clearance of the necrotic cells and debris as well as the repair of the nonfatally injured cells. Activation of multiple prothrombotic and antifibrinolytic pathways occurs, together with downregulation of antithrombotic mechanisms such as the protein C pathway. Treatment with activated protein C has been shown to improve outcome of adult septic shock, but has not been confirmed to have benefit in pediatric sepsis and may carry a risk of bleeding particularly in infants [6]. The renal findings early in septic shock are oliguria, with high urine/plasma urea and creatinine ratios, low urine sodium concentration, and a high urine/plasma osmolarity ratio. Once established, renal failure supervenes, and the urine is of poor quality with low urine/plasma urea and creatinine ratios, elevated urine sodium

51

Infectious Diseases and the Kidney in Children

concentration, and low urine osmolarity. Proteinuria is usually present, and the urine sediment may contain red cells and small numbers of white cells.

Management of AKI in Systemic Sepsis The management of AKI in systemic sepsis depends on early diagnosis and administration of appropriate antibiotics to cover the expected pathogens. Reliance on creatinine and urine output to identify AKI (using, e.g., the pediatric RIFLE score [7]) may in the future be improved using alternative biomarkers, such as neutrophil gelatinaseassociated lipocalin (NGAL) [2, 8]. Management is directed at improving renal perfusion and oxygenation. Volume replacement with crystalloid or colloid should be undertaken to optimize preload. Central venous pressure or pulmonary wedge pressure monitoring is essential to guide volume replacement in children in severe shock. The use of low-dose (2–5 pg/kg/min) dopamine to reduce renal vasoconstriction together with administration of inotropic agents such as dobutamine or epinephrine to improve cardiac output may reverse prerenal failure. Early elective ventilation should be undertaken in patients with severe shock. If oliguria persists despite volume replacement and inotropic therapy, dialysis or hemofiltration should be instituted early, because septic and catabolic patients may rapidly develop hyperkalemia and severe electrolyte imbalance. In most children who develop AKI as part of systemic sepsis or septic shock, the renal failure is of short duration, and recovery can be expected within a few days of achieving cardiovascular stability and eradication of the underlying infection. Occasionally, renal cortical necrosis or infarction of the kidney may result in prolonged or permanent loss of renal function.

Specific Bacterial Infections Causing Renal Disease Meningococcus Neisseria meningitidis continues to be a major cause of systemic sepsis and meningitis in both developed and underdeveloped parts of the world.

1613

In developed countries, most cases are caused by group B and Y strains, particularly after introduction of meningococcal C vaccination, whereas epidemics of meningococcal groups A, C, and W135 continue to occur in many underdeveloped regions of the world [9]. In 2013, a meningococcal B vaccine was approved for use in Europe, Canada, and Australia, and it has been used in the United States to help control outbreaks (see www. meningitis.org/menb-vaccine). Peak incidence is in infants for group B disease and teenagers and young adults for groups C. However, the disease can occur at any age. There are two major presentations of meningococcal disease: meningococcal meningitis presents with features indistinguishable from those of other forms of meningitis, including headache, stiff neck, and photophobia. Lumbar puncture is required to identify the causative agent and distinguish this from other forms of meningitis. Despite the acute nature of the illness, the prognosis is good, and most patients with the purely meningitic form of the illness recover without sequelae. The most common sequelae is hearing loss and so all children should have a hearing test after discharge [10]. Meningococcemia with purpuric rash and shock is the second and more devastating form of the illness. Affected patients present with nonspecific symptoms of fever, vomiting, abdominal pain, and muscle ache. The diagnosis is only obvious once the characteristic petechial or purpuric rash appears. Patients with a rapidly progressive purpuric rash, hypotension, and evidence of skin and organ underperfusion have a poor prognosis, with a mortality of 10–30 %. Adverse prognostic features include hypotension, a low white cell count, absence of meningeal inflammation, thrombocytopenia, and disturbed coagulation indices or a combination of these [11]. Renal failure was seldom reported in early series of patients with meningococcemia, perhaps because most patients died rapidly of uncontrolled septic shock. With advances in intensive care, however, more children are surviving the initial period of profound hemodynamic derangement, and renal failure is more often seen as a major management problem. Children with fulminant sepsis,

1614

particularly with Gram-negative organisms including N. meningitidis, can develop renal failure in association with rhabdomyolysis [12]. The pathophysiology of meningococcal septicemia involves the activation of cytokines and inflammatory cells by endotoxin [13]. Mortality is directly related to both the plasma endotoxin concentration and the intensity of the inflammatory response, as indicated by levels of TNF and other inflammatory markers. Patients with meningococcemia have a profound capillary leak leading to severe hypovolemia. A loss of plasma proteins from the intravascular space is probably the major cause of shock, but myocardial suppression secondary to IL6 production is also important [14]. Intense vasoconstriction further impairs tissue and organ perfusion, and vasculitis with intravascular thrombosis and consumption of platelets and coagulation factors is also present. Oliguria is invariably present in children with meningococcemia during the initial phase of the disorder. This is prerenal in origin and may respond to volume replacement and inotropic support. If cardiac output cannot be improved and renal underperfusion persists, established renal failure supervenes. Occasionally, cortical necrosis or infarction of the kidneys occurs. Children with meningococcemia should be aggressively managed in a pediatric intensive care unit, with early administration of antibiotics (penicillin or a thirdgeneration cephalosporin), volume replacement, hemodynamic monitoring, and the use of inotropic agents and vasodilators. If oliguria persists despite measures to improve cardiac output, elective ventilation and dialysis should be instituted early. Because activation of coagulation pathways occurs, severe acquired protein C deficiency may result and is usually associated with substantial mortality [15]. Protein C is a natural anticoagulant which also has an important anti-inflammatory activity. Despite evidence for impaired function of the activated protein C pathway in meningococcal diseases [15] and adult trials suggesting benefit of activated protein C administration in septic shock (PROWESS trial) [16], pediatric trials of activated protein C showed no clear benefit and were associated with increased risk of intracranial bleeding in very young infants [6].

J. Stevens et al.

The role of aPC therapy in pediatric sepsis remains unclear. Most patients who survive the initial 24–48 h of the illness and regain hemodynamic stability will ultimately recover renal function even if dialysis is required for several weeks. The least common presentation of meningococcal sepsis is chronic meningococcemia. Patients with this form of the illness present insidiously with a vasculitic rash, arthritis, and evidence of multiorgan involvement. The features may overlap those of Henoch-Schonlein purpura or subacute bacterial endocarditis (SBE), and the diagnosis must be considered in patients presenting with fever, arthritis, and vasculitic rash, often accompanied by proteinuria or hematuria. Response to antibiotic treatment is good, but some patients may have persistent symptoms for many days resulting from an immune-complex vasculitis.

Staphylococcus Aureus Staphylococcal infections may affect the kidneys by direct focal invasion during staphylococcal septicemia, forming a renal abscess, by causing staphylococcal bacteremia, or by toxin-mediated mechanisms, as in the staphylococcal toxic shock syndrome. Staphylococcal Abscess. Staphylococcal renal abscess presents with fever, loin pain and tenderness, and abnormal urine sediment, as do abscesses caused by other organisms. The illness often follows either septicemia or pyelonephritis. The diagnosis is usually considered only when a patient with clinical pyelonephritis shows an inadequate response to antibiotic treatment. The diagnosis is confirmed by ultrasonography or computed tomographic scan, which shows swelling of the kidney and intrarenal collections of fluid. Antibiotic therapy alone may result in cure, and empirical therapy should cover both Gram-positive and Gram-negative organisms until microbiological diagnosis has been achieved. Treatment may require percutaneous drainage alongside antibiotic therapy, which may need to persist for 2–4 weeks. Open drainage may be necessary if this approach has failed [17].

51

Infectious Diseases and the Kidney in Children

Staphylococcal Toxic Shock Syndrome. The staphylococcal toxic shock syndrome is a systemic illness characterized by fever, shock, erythematous rash, diarrhea, confusion, and renal failure. The disorder was first described by Todd et al. in 1978 in a series of seven children [18]. During the 1980s, thousands of cases were reported in the United States. Most cases were in menstruating women in association with tampon use. Menstrual and non-menstrual cases are now equally common, including children of both sexes and all ages [19]. The illness usually begins suddenly with high fever, diarrhea, confusion, and hypotension, together with a diffuse erythroderma [20]. Mucous membrane involvement with hyperemia and ulceration of the lips and oral mucosa or vaginal mucosa, strawberry tongue, and conjunctival injection are usually seen. Desquamation of the rash occurs in the convalescent phase of the illness. Confusion is often present in the early stages of the illness and may progress to coma in severe cases. Multiple organ failure with evidence of impaired renal function, elevated levels of hepatic transaminases, thrombocytopenia, elevated CPK, and disseminated intravascular coagulation (DIC) is often seen. According to CDC criteria, the diagnosis is made on the basis of the clinical features of fever, rash, hypotension, and subsequent desquamation along with deranged function of three or more of the following organ systems: the gastrointestinal (GI), mucous membranes, renal, hepatic, hematologic, central nervous system, and muscle. Other disorders causing a similar picture, such as Rocky Mountain spotted fever, leptospirosis, measles, and streptococcal infection, must be excluded. The staphylococcal toxic shock syndrome is caused by infection or colonization with strains of S. aureus that produce one or more protein exotoxins [21]. Most cases in adults are associated with toxic shock toxin I; in children, many of the isolates associated with the syndrome produce other enterotoxins (A to F). The staphylococcal enterotoxins induce disease by acting as superantigens [22], which activate T cells bearing specific V beta regions of the T-cell receptor; this

1615

causes proliferation and cytokine release. The systemic illness and toxicity are believed to result largely from an intense inflammatory response induced by the toxin. The site of toxin production is often a trivial focus of infection or simple colonization, and bacteremia is rarely observed. Renal failure in toxic shock syndrome is usually caused by shock and renal hypoperfusion. In the early stages of the illness, oliguria and renal impairment are usually prerenal and respond to treatment of shock and measures to improve perfusion. In severe cases and in patients in whom treatment is delayed, AKI develops as a consequence of prolonged renal underperfusion, and dialysis may be required. In addition to underperfusion, direct effects of the toxin or inflammatory mediators may also contribute to the renal damage. Recovery of renal function usually occurs, but in severe cases with cortical necrosis or intense renal vasculitis, prolonged dialysis may be required. The management of staphylococcal toxic shock syndrome depends on early diagnosis and aggressive cardiovascular support with volume replacement, inotropic support, and, in severe cases, elective ventilation. If oliguria persists despite optimization of intravascular volume and administration of inotropic agents, dialysis should be commenced early [19]. Antistaphylococcal antibiotics should be started as soon as the diagnosis is suspected and the site of infection identified. Current advice in the Red Book (http://aapredbook.aappublications. org) is that initial empiric antimicrobial therapy should include an antistaphylococcal antibiotic effective against beta-lactamase-resistant organisms and a protein synthesis-inhibiting antibiotic such as clindamycin to stop further toxin production [23]. If there is a focus of infection such as a vaginal tampon, surgical wound, or infected sinuses, the site should be drained early to prevent continued toxin release into the circulation. The intravenous administration of immunoglobulins may be considered when infection is refractory to several hours of aggressive therapy, an undrainable focus is present, or persistent oliguria with pulmonary edema occurs. With aggressive intensive care, most affected patients survive, and

1616

renal recovery is usual, even in patients who have had severe shock and multiorgan failure. Relapses and recurrences of staphylococcal toxic shock syndrome occur in a proportion of affected patients because immune responses to the toxin are ineffective in some individuals. Panton-Valentine Leukocidin (PVL)Producing Staphylococcal Infection. In recent years, there have been increasing reports of severe staphylococcal disease, associated with shock and multiorgan failure, caused by strains of staphylococci producing the PVL toxin. Panton-Valentine leukocidin (PVL) is a phage-encoded toxin, which profoundly impairs the host response due to its toxic effect on leukocytes (see review [24]). PVL-producing strains are associated with tissue necrosis and increased propensity to cause abscesses in lung, bone, joint, and soft tissue infections. Perinephric abscesses have been reported [25]. There are increasing numbers of children and adults admitted with fulminant sepsis and shock due to PVL-producing strains, and renal failure is a significant component of the multiorgan failure. In addition to intensive care support, antibiotic treatment of PVL strains should include antibiotics which reduce toxin production, such as clindamycin, linezolid or rifampicin, as well as vancomycin if the strain is resistant to methicillin. Beta-lactam antibiotics should be avoided, as there is some data to suggest that PVL toxin production can be increased by these antibiotics under some conditions [23, 26]. Immunoglobulin infusion may also be of benefit. PVL sepsis is often associated with thrombosis, and prophylactic heparin should be commenced in seriously ill patients. Aggressive surgical drainage of all collections requires close consultation with orthopedic and surgical teams.

Streptococcus Pyogenes The group A streptococci (GAS) are extracellular Gram-positive organisms. They are a major worldwide cause of renal disease, usually as poststreptococcal nephritis. However, in addition to this postinfection immunologically mediated disorder, GAS can cause AKI as part of an

J. Stevens et al.

invasive infection with many features of the staphylococcal toxic shock syndrome. Acute Poststreptococcal Glomerulonephritis. Acute poststreptococcal GN (APSGN) is a delayed complication of pharyngeal infection or impetigo with certain nephritogenic strains of GAS, though many cases of postinfectious GN are unrelated to Streptococcus [27]. Worldwide, the incidence of APSGN is decreasing, although clusters of cases continue to occur [28]. APSGN after pharyngeal infection is associated with different serotypes as compared to pyoderma and skin infections [28]. Different strains can be serotyped according to the antigenic properties of the M protein found in the outer portion of the bacterial wall. The pathology and pathogenesis of the disorder is discussed in detail in ▶ Chap. 31, “Acute Postinfectious Glomerulonephritis in Children”. Detection of GAS in patients with APSGN may be possible by culture from the skin or the throat in some patients. Other evidence of infection with a GAS can be obtained through the antistreptolysinO titer (ASOT), which is increased in 60–80 % of cases. Early antibiotic treatment can reduce the proportion of cases with elevated ASOT to 30 %. Anti-deoxyribonuclease B and anti-hyaluronidase testing has been shown to be of more value than ASOT in confirming group A streptococcal infection in impetigo-associated cases. Decreased C3 and total hemolytic complement levels are found in 90 % of cases during the first 2 weeks of illness and return to normal after 4–6 weeks. Penicillin should be given to eradicate the GAS organisms. Erythromycin, clindamycin, or a firstgeneration cephalosporin can be given to patients allergic to penicillin. Early antibiotic therapy can help to prevent the immune response against the streptococcal antigens and thus the progression to glomerulonephritis and other rheumatic fever sequelae. Treatment failures have been thought to be due to the coexistence of beta-lactamaseproducing bacteria in the tonsillopharynx or due to streptococci that have invaded the epithelial cells and are protected from the antibiotics. In these instances, amoxicillin was given with clavulanate [29]. Close contacts and family members who are culture-positive for GAS should also be given penicillin, although antibiotic treatment

51

Infectious Diseases and the Kidney in Children

is not always effective in eliminating secondary cases. Recurrent episodes are rare, and immunity to the particular nephritogenic strain that caused the disease is probably lifelong. Antibiotic prophylaxis is therefore unnecessary. Most studies suggest that the prognosis for children with APSGN is good, with more than 90 % making a complete recovery. However, 10 % of cases may have a prolonged and more serious course with long-term chronic renal failure [30]. Other Streptococci. APSGN has also been described after outbreaks of group C streptococcal infection. For example, Streptococcus equi subsp. zooepidemicus has been found responsible for large epidemics in South America [31]. Group C streptococcal infection has occurred after consumption of unpasteurized milk from cattle with mastitis. Patients developed pharyngitis followed by APSGN. Endostreptosin was found in the cytoplasm of these group C strains, and during the course of the illness, patients developed antiendostreptosin antibodies. This antigen has been postulated to be the nephritogenic component of GAS. In addition, strains of group G streptococci have been implicated in occasional cases of APSGN [32]. Isolates possessed the type M12 protein antigen identical to the nephritogenic type M12 antigen of some group A streptococcal strains. Streptococcal Toxic Shock Syndrome and Invasive Group A Streptococcal Infection. Group A Streptococcus causes a severe illness with similarities to the staphylococcal toxic shock syndrome, occurring in both children and adults, associated with invasive group A streptococcal disease [33]. Patients with this syndrome present acutely with high fever, erythematous rash, mucous membrane involvement, hypotension, and multiorgan failure [34, 35]. Unlike staphylococcal toxic shock syndrome, in which the focus of infection is usually trivial and bacteremia is seldom seen, the streptococcal toxic shock syndrome is usually associated with bacteremia or a serious focus of infection such as septic arthritis, myositis, or osteomyelitis. Laboratory findings of anemia, neutrophil leukocytosis, thrombocytopenia, and DIC are often present, together with

1617

impaired renal function, hepatic derangement, and acidosis. AKI requiring dialysis occurs in a significant proportion of cases. It is not clear why there are increasing numbers of cases with invasive disease caused by GAS, nor why there has been an emergence of streptococcal toxic shock syndrome and indeed a similar syndrome caused by some Pseudomonas and Klebsiella strains. The most common antecedent of invasive GAS disease is varicella infection, with the streptococcal infection developing after the initial vesicular phase of the disease is subsiding. Strains causing toxic shock syndrome and invasive disease appear to differ from common isolates of GAS in producing large amounts of pyrogenic toxins that may have superantigenlike activity. Another important mechanism is the production by invasive GAS of an IL8 protease. IL8 serves as a molecular bridge between receptors on neutrophils and the vascular endothelium. Cleavage of this protein prevents neutrophil attachment to the endothelium and results in uncontrolled spread of the bacteria through the tissues [36]. In severe cases, necrotizing fasciitis occurs with extensive destruction of the subcutaneous tissues and is often associated with multiorgan failure. The pathophysiology of streptococcal toxic shock syndrome and that of invasive disease is similar in that superantigen toxins that induce release of cytokines and other inflammatory mediators play a role in both conditions. However, GAS toxic shock is usually more severe, carries a higher mortality, and is more often associated with focal collections or necrotizing fasciitis. Treatment of streptococcal toxic shock syndrome depends on the administration of appropriate antibiotics, aggressive circulatory support, and treatment of any multiorgan failure. Surgical intervention to drain the infective focus in the muscle, bone, joint, or body cavities is often required. Antibiotic therapy with beta-lactams should be supplemented by treatment with a protein synthesis-inhibiting antibiotic, such as clindamycin, and it is suggested that this limits new toxin production [37, 38]. Pooled intravenous immunoglobulins are now in widespread use in the treatment of toxic shock,

1618

particularly when caused by Streptococcus [39, 40], though not all studies have reported benefit [35]. Prospective observational studies have suggested that the concomitant use of immunoglobulin with clindamycin has a positive synergistic effect on mortality [41, 42]. The role of steroids remains unclear, with their hemodynamic benefit set against the detrimental effects of hyperglycemia secondary to gluconeogenesis [43, 44]. The benefit of insulin therapy to control hyperglycemia is unclear. A study in adults found that intensive insulin therapy increased the risk of serious adverse events [45]. In contrast to adult patients, in children with severe sepsis, the use of activated protein C (drotrecogin) cannot be recommended, as in a multicenter trial, fatality was increased in the treatment group [6]. Recovery of renal function occurs in patients who respond to treatment of shock and the eradication of the infection.

Streptococcus Pneumoniae Infection with S. pneumoniae is one of the most common infections in humans and causes a wide spectrum of disease, including pneumonia, otitis media, sinusitis, septicemia, and meningitis. Despite the prevalence of the organism, a significant renal involvement is relatively rare but is seen in two situations: pneumococcal septicemia in asplenic individuals or in those with other immunodeficiencies presents with fulminant septic shock in which renal failure may occur as part of a multisystem derangement. The mortality from pneumococcal sepsis in asplenic patients is high, even with early antibiotic treatment and intensive support. The second nephrologic syndrome associated with S. pneumoniae is a rare form of HUS. It accounts for 5–15 % of all HUS cases in children and typically develops 3–13 days after streptococcal infection. The incidence following streptococcal infection is 0.4–0.6 %. Since the introduction of the 7- and 13-valent vaccines, there have been reports of HUS cases caused by strain not covered in the vaccine [46]. In 1955, Gasser and colleagues described HUS as a clinical entity in children, and they included two infants with pneumonia among the five patients they described [47].

J. Stevens et al.

HUS associated with pneumococcal infection differs in pathophysiology from that caused by the commoner Vero toxin-producing E. coli. S. pneumoniae (as well as influenza and Clostridia species) produce the enzyme neuraminidase which cleaves sialic acid from the surfaces of exposed cells [48]. Neuraminidase causes desialation of red blood cells, and possibly other blood cells and endothelium, by the removal of terminal neuraminic acid, which leads to unmasking of the Thomsen-Friedenreich antigen (T antigen) which is present on the surface of red blood cells, platelets, and glomerular capillary endothelia. Normal serum contains antibodies to this antigen which cause a widespread agglutination of blood cells and platelets when the antigen is exposed, resulting in intravascular obstruction, hemolysis, thrombocytopenia, and renal failure. The direct Coombs test is positive in 90 % of cases of streptococcal HUS [49], either from bound anti-T IgM or from anti-T antibodies. The diagnosis of Thomsen-Friedenreich antibody-induced HUS should be suspected in patients with AKI, thrombocytopenia, and hemolysis after an episode of pneumonia or bacteremia caused by S. pneumoniae. Fragmented red blood cells will usually be present on blood film. Association of HUS with S. pneumoniae is defined by culture of pneumococci from a normally sterile site within a week before or after onset of signs of HUS. Clues to a pneumococcal cause, in addition to culture results, include severe clinical disease, especially pneumonia, empyema, pleural effusion, or meningitis; hemolytic anemia; positive results on a direct Coombs test; and difficulties in ABO crossmatching or a positive minor crossmatch incompatibility [46]. However, when renal disease is seen in the context of severe pneumococcal infection, it is important to maintain a broad diagnostic perspective, because of the frequency of acute tubular necrosis in septic shock and DIC. Therapy for this syndrome should be with supportive treatment and antibiotics (usually a thirdgeneration cephalosporin); dialysis may be required if renal failure occurs. Because normal serum contains antibodies against the ThomsenFriedenreich antigen, blood transfusion should be

51

Infectious Diseases and the Kidney in Children

undertaken with washed red blood cells resuspended in albumin rather than plasma [50]. Exchange transfusion and plasmapheresis have been used in some patients, with the rationale that these procedures may improve outcome by eliminating circulating neuraminidase [51]. Intravenous IgG has been used in a patient and was shown to neutralize neuraminidase present in the patient’s serum [52]. In comparison to patients with the more common diarrhea-associated HUS, S. pneumoniaeinduced HUS patients have a more severe renal disease. They are more likely to require dialysis. Their long-term outcome may be affected by the severity of the invasive streptococcal disease itself, and a significant proportion of surviving patients (30–70 %) develop end-stage renal failure [53]. A review of UK cases found an eightfold increase in early mortality as compared to diarrhea-induced HUS. Fresh frozen plasma should be avoided unless there is active bleeding as there are concerns that the preformed anti-TF antibodies are present in FFP [51].

Leptospira Leptospirosis is an acute generalized infectious disease caused by spirochetes of the genus Leptospira. It is primarily a disease of wild and domestic animals, and humans are infected only occasionally through contact with animals. Most human cases occur in summer or autumn and are associated with exposure to Leptospira-contaminated water or soil during recreational activities such as swimming or camping. In adolescents and adults, occupational exposure through farming or other contact with animals is the route of infection. The spirochete penetrates intact mucous membranes or abraded skin and disseminates to all parts of the body, including the cerebrospinal fluid (CSF). Although Leptospira do not contain classic endotoxins, the pathophysiology of the disorder has many similarities to that of endotoxemia. In severe cases, jaundice occurs because of hepatocellular dysfunction and cholestasis. Renal functional abnormalities may be profound and out of proportion to the histologic changes in the kidney [54]. Renal involvement is

1619

predominantly a result of tubular damage, and spirochetes are commonly seen in the tubular lesions. The inflammatory changes in the kidney may result from either a direct toxic effect of the organism or immune-complex nephritis. However, hypovolemia, hypotension, and reduced cardiac output caused by myocarditis may contribute to the development of renal failure. In severe cases, a hemorrhagic disorder caused by widespread vasculitis and capillary injury also occurs [54, 55]. The clinical manifestations of leptospirosis are variable. Of affected patients, 90 % have the milder anicteric form of the disorder, and only 5–10 % have severe leptospirosis with jaundice. The illness may follow a biphasic course. After an incubation period of 7–12 days, a nonspecific flulike illness lasting 4–7 days occurs, associated with septicemic spread of the spirochete. The fever then subsides, only to recur for the second, “immune,” phase of the illness. During this phase, the fever is low grade, and there may be headache and delirium caused by meningeal involvement, as well as intense muscular aching. Nausea and vomiting are common. Examination usually reveals conjunctival suffusion, erythematous rash, lymphadenopathy, and meningism. The severe form of the disease (Weil’s disease) presents with fever, impaired renal and hepatic function, hemorrhage, vascular collapse, and altered consciousness. In one series, the most common organs involved were the liver (71 %) and kidney (63 %). Cardiovascular (31 %), pulmonary (26 %), neurologic (5 %), and hematologic (21 %) involvements were less common [56]. Vasculitis, thrombocytopenia, and uremia are considered important factors in the pathogenesis of hemorrhagic disturbances and the main cause of death in severe leptospirosis [57]. Urinalysis results are abnormal during the leptospiremic phase with proteinuria, hematuria, and casts. Uremia usually appears in the second week, and AKI may develop once cardiovascular collapse and DIC are present [58]. The clinical features of leptospirosis overlap with those of several other acute infectious diseases, including Rocky Mountain spotted fever, toxic shock syndrome, and streptococcal sepsis.

1620

The diagnosis of leptospirosis should be considered in febrile patients with evidence of renal, hepatic, and mucous membrane changes and rash, particularly if a history of exposure to freshwater is found. Diagnosis can be confirmed by isolation of the spirochetes from blood or CSF in the first 10 days of the illness or from urine in the second week [58]. The organism may be seen in biopsy specimens of the kidney or skin or in the CSF by dark-field microscopy or silver staining. Serologic tests to detect leptospirosis are now sensitive and considerably aid the diagnosis. Immunoglobulin M (IgM) antibody may be detected as early as 6–10 days into the illness, and antibody titers rise progressively over the next 2–4 weeks. Some patients remain seronegative, and negative serologic test results do not completely exclude the diagnosis. In one series, levels of IgM and IgG anticardiolipin concentrations were significantly increased in leptospirosis patients with AKI [57]. Leptospirosis is treated with intravenous penicillin or other beta-lactam antibiotics. The severity of leptospirosis is reduced by antibiotic treatment, even if started late in the course of the illness [55]. Supportive treatment with volume replacement to correct hypovolemia, administration of inotropes, and correction of coagulopathy is essential in severe cases. Dialysis may be required in severe cases and may be needed for prolonged periods until recovery occurs.

Gastrointestinal Infections The diarrheal diseases caused by Escherichia coli, Salmonella, Shigella, Campylobacter, Vibrio spp., and Yersinia remain important and common bacterial infections of humans. Although improvements in hygiene and living conditions have reduced the incidence of bacterial gastroenteritis in developed countries, these infections remain common in underdeveloped areas of the world, and outbreaks and epidemics continue to occur in both developed and underdeveloped countries. Renal involvement in the enteric infections may result from any of four possible mechanisms.

J. Stevens et al.

Severe Diarrhea and Dehydration. Regardless of the causative organism, diarrhea results in hypovolemia, abnormalities of plasma electrolyte composition, and renal underperfusion. If severe dehydration occurs and is persistent, oliguria from prerenal failure is followed by vasomotor nephropathy and established renal failure. Systemic Sepsis and Endotoxemia. E. coli, Shigella, and Salmonella (particularly Salmonella typhi) may invade the bloodstream and induce septicemia or septic shock. AKI is commonly seen in infants with E. coli sepsis but is also reported with Klebsiella, Salmonella, and Shigella infections. Its pathophysiology and treatment were discussed previously. Enteric Pathogen-Associated Nephritis. Enteric infections with E. coli, Yersinia, Campylobacter, and Salmonella have been associated with several different forms of GN, including membranoproliferative GN (MPGN), interstitial nephritis, diffuse proliferative GN, and IgA nephropathy. In typhoid fever, GN ranging from mild asymptomatic proteinuria and hematuria to AKI may occur [59]. Renal biopsy findings show focal proliferation of mesangial cells, hypertrophy of endothelial cells, and congested capillary lumina. Immunofluorescent studies show IgM, IgG, and C3 deposition in the glomeruli, with Salmonella antigens detected within the granular deposits in the mesangial areas. In the IgA nephropathy after typhoid fever, Salmonella vi antigens have been demonstrated within the glomeruli. Yersinia infection has been reported as a precipitant of GN. Transient proteinuria and hematuria are found in 24 % of patients with acute Yersinia infection and elevated creatinine levels in 10 %. Renal biopsy reveals mild mesangial GN or IgA nephropathy. Yersinia antigens, immunoglobulin, and complement have been detected in the glomeruli. Yersinia pseudotuberculosis is well recognized as one of the causes of acute tubulointerstitial nephritis causing AKI, especially in children; patients have histories of drinking untreated water in endemic areas [60, 61]. The illness begins with the sudden onset of high fever, skin rash, and GI symptoms. Later in the course, periungual desquamation develops, mimicking Kawasaki disease. Elevated erythrocyte sedimentation rate,

51

Infectious Diseases and the Kidney in Children

C-reactive protein level, and thrombocytosis are noticeable, and mild degrees of proteinuria, glycosuria, and sterile pyuria are common. AKI, which typically develops 1–3 weeks after the onset of fever, follows a benign course with complete recovery. Renal biopsy mainly reveals findings of acute tubulointerstitial nephritis. Antibiotic therapy, although recommended, does not alter the clinical course, but reduces the fecal excretion of the organism [62]. Enteric Pathogen-Induced Hemolytic Uremic Syndrome. HUS is characterized by three distinct clinical signs: AKI, thrombocytopenia, and microangiopathic hemolytic anemia. It was first described in 1955 and was associated with infection by Shiga toxin-producing Shigella dysenteriae. A major breakthrough in the search for the cause of HUS occurred in the 1980s when Karmali et al. reported that 11 of 15 children with diarrhea-associated HUS had evidence of infection with a strain of E. coli that produced a toxin active on Vero cells [63]. In diarrhea-associated HUS in the United States and most of Europe, E. coli 0157:H7 is the most important of these strains. E. coli 0157:H7 occurs naturally in the GI tract of cattle and other animals, and humans become infected through contaminated food products. Most outbreaks have been associated with consumption of undercooked meat, but unpasteurized milk and cider, drinking water, and poorly chlorinated water for recreational use have also been implicated as vehicles for bacterial spread. HUS is discussed in detail in ▶ Chap. 47, “Renal Involvement in Children with HUS”.

Mycobacterium Tuberculosis The global epidemic of Mycobacterium tuberculosis is persisting. Several factors have contributed to this, including the emergence of the human immunodeficiency virus (HIV) infection epidemic, large influxes of immigrants from countries in which tuberculosis (TB) is common, the emergence of multiple-drug-resistant M. tuberculosis, and breakdown of the health services for effective control of TB in various countries. The World Health Organization

1621

(WHO) estimated that in 2012 there were 8.6 million incident cases of tuberculosis (TB) in the world, a rate of 122 per 100,000 population. Tuberculosis deaths were estimated at 1.3 million. One-third of the world’s population is currently infected with TB, and the estimated lifetime risk of developing disease is 5–10 % (http://www. who.int/mediacentre/factsheets/fs104/en/). Mycobacteria, both M. tuberculosis and atypical mycobacteria, have also emerged as important causes of opportunistic infection in immunocompromised patients undergoing dialysis and in patients undergoing renal transplantation. The possibility of mycobacterial disease must be considered in patients with fever of unknown origin or unexplained disease in the lungs or other organs. Results of the Mantoux test are often negative, and diagnosis depends on maintaining a high index of suspicion and isolating the organism from the infected site. Primary Progressive TB. Although most infected children successfully contain the infection and enter a state of latency, about 10 % develop progressive primary or postprimary infection, with mycobacteria disseminating to many organs of the body during the lymphohematogenous phase of the disease. Tubercle bacilli can be recovered from the urine in many cases of miliary TB. Hematogenously spread tuberculomata develop in the glomeruli, which results in caseating, sloughing lesions that discharge bacilli into the tubules. In most cases, the renal lesions are asymptomatic and manifest as mycobacteria in the urine or as sterile pyuria. Tuberculomata in the cortex may calcify and cavitate or may rupture into the pelvis, discharging infective organisms into the tubules, urethra, and bladder. Dysuria, loin pain, hematuria, and pyuria are the presenting features of this complication, but in many cases, the renal involvement is asymptomatic, even when radiologic and pathologic abnormalities are very extensive. Continuing tuberculous bacilluria may cause cystitis with urinary frequency and, in late cases, a contracted bladder. The intravenous urogram is abnormal in most cases. Early findings are pyelonephritis with calyceal blunting and calycealinterstitial reflux. Later, papillary cavities may be seen, indicating papillary necrosis. Ureteric

1622

strictures, focal calcification, hydronephrosis, and cavitation may also be seen. Renal function is usually well preserved, and hypertension is uncommon. In some cases, either the infection itself or reactions to the chemotherapeutic agents may result in renal failure with evidence of an interstitial nephritis [64]. Renal TB. Classic symptomatic renal TB is a late and uncommon complication in children. The average latency period between pulmonary infection with bacillemia and clinical urogenital tuberculosis is 22 years, and renal TB is more commonly seen in adults [65]. Adult studies have shown that 26–75 % of renal TB coexists with active pulmonary TB and 6–10 % of screened sputum-positive pulmonary TB patients have renal involvement. The diagnosis is established by isolation of mycobacteria from the urine or by the presence of the characteristic clinical and radiographic features in a child with current or previous TB. Renal TB is treated with drug regimens similar to those used for other forms of TB, with isoniazid, rifampicin, pyrazinamide, and ethambutol administered initially for 2 months and isoniazid and rifampicin then continued for a further 7–10 months. Late scarring and urinary obstruction may occur in cases with extensive renal involvement, and such patients should be followed by ultrasonography or intravenous urogram. Surgical intervention may be required in the form of stenting, percutaneous nephrostomy, or partial or total nephrectomy [66].

Treponema Pallidum Renal involvement in both congenital and acquired syphilis has an estimated occurrence of 0.3 % in patients with secondary syphilis and between 5 % and 16 % in those with congenital syphilis [67]. The most common manifestation of renal disease in congenital syphilis is the nephrotic syndrome, with proteinuria, hypoalbuminemia, and edema. In some patients, hematuria, uremia, and hypertension may be seen. The renal disease is usually associated with other manifestations of

J. Stevens et al.

congenital syphilis, including hepatosplenomegaly, rash, and mucous membrane findings. Nephritis in congenital syphilis is usually associated with evidence of complement activation, with depressed levels of Clq, C4, C3, and C5. Histologic findings are a diffuse proliferative GN or a membranous nephropathy. The interstitium shows a cellular infiltrate of polymorphonuclear and mononuclear cells [68]. Immunofluorescent microscopy reveals diffuse granular deposits of IgG and C3 along the glomerular basement membrane (GBM). Mesangial deposits may also contain IgM. On electron microscopy, scattered subepithelial electron-dense deposits are seen, with fusion of epithelial cell foot processes [68]. Good evidence exists that renal disease is due to an immunologically mediated reaction to treponemal antigens. Antibodies reactive against treponemal antigens can be eluted from the glomerular deposits, and treponemal antigens are present in the immune deposits. Treatment of both congenital and acquired syphilis with antibiotics results in rapid improvement in the renal manifestations [68].

Mycoplasma Pneumoniae Renal involvement is surprisingly rare in Mycoplasma pneumoniae infection considering the prevalence of this organism and its propensity to trigger immunologically mediated diseases such as erythema multiforme, arthritis, and hemolysis. Acute nephritis associated with Mycoplasma infection may occur 10–40 days after the respiratory tract infection [69]. A few cases of IgA nephropathy have been reported following Mycoplasma infection [70]. Renal histopathologic findings include type 1 MPGN, proliferative endocapillary GN, and minimal change disease [71]. Antibiotic treatment of the infection does not appear to affect the renal disease, which is self-limited in most cases [69].

Legionnaires’ Disease Since its recognition in 1976, Legionnaires’ disease, caused by Legionella pneumophila, has

51

Infectious Diseases and the Kidney in Children

emerged as an important cause of pneumonia. The disease most commonly affects the elderly but has been reported in both normal and immunocompromised children. Renal dysfunction occurs in a minority of patients [72]. Those who develop renal failure can present with transient azotemia, hematuria, proteinuria, pyuria, or cylindruria. They are usually severely ill, with bilateral pulmonary infiltrates, fever, and leukocytosis. Shock may be present, and the renal impairment has been associated with acute rhabdomyolysis with high levels of creatine phosphokinase and myoglobinuria. Renal histologic examination usually shows a tubulointerstitial nephritis or acute tubular necrosis [72, 73]. The pathogenesis of the renal impairment is uncertain, but the organism has been detected within the kidney on electron microscopy and immunofluorescent studies, which suggests a direct toxic effect. Myoglobinuria and decreased perfusion may also be contributing factors, however. Mortality has been high in reported cases of Legionnaires’ disease complicated by renal failure. Treatment is based on dialysis, intensive care, and antimicrobial therapy with erythromycin [72]. Steroid therapy may be effective for tubulointerstitial nephritis [73].

Rickettsial Diseases The rickettsial diseases are caused by a family of microorganisms that have characteristics common to both bacteria and viruses and that cause acute febrile illnesses associated with widespread vasculitis. With the exception of Q fever, all are associated with erythematous rashes. There are four groups of rickettsial diseases: 1. The typhus group includes louse-borne and murine typhus, spread by lice and fleas, respectively. 2. The spotted fever group includes Rocky Mountain spotted fever, tick typhus, and related Mediterranean spotted fever and rickettsial pox, which are spread by ticks and mites, with rodents as the natural reservoir.

1623

3. Scrub typhus, which is spread by mites. 4. Q fever, which is spread by inhalation of infected particles from infected animals. Rickettsial diseases have a worldwide distribution and vary widely in severity, from self-limited infections to fulminant and often fatal illnesses. In view of the widespread vasculitis associated with these infections, subclinical renal involvement probably occurs in many of the rickettsial diseases. However, in Rocky Mountain spotted fever, tick typhus, and Q fever, the renal involvement may be an important component of the illness.

Rocky Mountain Spotted Fever Rocky Mountain spotted fever is the most severe of the rickettsial diseases. The incidence has increased over the last decade from less than two cases per million persons in 2000 to over six million in 2010. The mortality has declined to 0.5 % in the same time period. Children under 10 years, those with a compromised immune system and those with a delayed diagnosis are at an increased risk of fatality. Prior to specific antibiotic therapy, the mortality was 25 % (http://www. cdc.gov/rmsf/stats/). The onset occurs 2–8 days after the bite of an infected tick, and the majority of cases occur during the summer months. High fever develops initially, followed by the pathognomonic rash, which occurs between the second and sixth days of the illness. The rash initially consists of small erythematous macules, but later these become maculopapular and petechial, and in untreated patients, confluent hemorrhagic areas may be seen. The rash first appears at the periphery and spreads up the trunk. Involvement of the palms and soles is a characteristic feature. Headache, restlessness, meningism, and confusion may occur together with other neurologic signs. Cardiac involvement with congestive heart failure and arrhythmia are common. Pulmonary involvement occurs in 10–40 % of cases. Infection is associated with an initial leukopenia, followed by neutrophil leukocytosis. Thrombocytopenia occurs in most cases [74].

1624

Histopathologically, the predominant lesions are in the vascular system. Rickettsiae multiply in the endothelial cells, which results in focal areas of endothelial cell proliferation, perivascular mononuclear cell infiltration, thrombosis, and leakage of red cells into the tissues. The renal lesions involve both blood vessels and interstitium, and acute tubular necrosis may occur. Acute GN with immune-complex deposition has been reported [75], but in most cases the pathology appears to be a direct consequence of the invading organism on the renal vasculature. Renal dysfunction is an important complication of Rocky Mountain spotted fever. Elevation of urea and creatinine levels occurs in a third of children, and acidosis is common. AKI was associated with increased mortality – 20 % in a recent Mexican cohort [76]. Factors at presentation that have been associated with increased risk of developing renal impairment in adults are increasing age, rising bilirubin, thrombocytopenia, and neurological involvement. In one adult case series, factors associated with increased mortality were raised creatinine, raised bilirubin and AST, hypernatremia, thrombocytopenia, increasing age, and neurological involvement [77]. Prerenal renal failure caused by hypovolemia and impaired cardiac function may respond to volume replacement and inotropic support, but AKI may subsequently occur, necessitating dialysis. Rocky Mountain spotted fever is diagnosed by the characteristic clinical picture, the exclusion of disorders with similar manifestations (e.g., measles, meningococcal disease, and leptospirosis), and detection of specific antibodies in convalescence. Culture of Rickettsia rickettsii, immunofluorescent staining, and polymerase chain reaction (PCR) testing of blood and skin biopsy specimens are available only in reference laboratories. Antibiotics should be administered in suspected cases without awaiting confirmation of the diagnosis [74]. Doxycycline is the drug of choice for children of any age. Chloramphenicol is also effective. Intensive support of shock and multiorgan failure may be required in severe cases, and peritoneal dialysis or hemodialysis may be required until renal function returns.

J. Stevens et al.

Q Fever Q fever is caused by Coxiella burnetii and has a worldwide distribution, with the animal reservoir being cattle, sheep, and goats. Human infection follows inhalation of infected particles from the environment. The clinical manifestations range from an acute self-limited febrile illness with atypical pneumonia to involvement of specific organs that causes endocarditis, hepatitis, osteomyelitis, and central nervous system disease [78]. Proliferative GN may be associated with either Q fever endocarditis, rhabdomyolysis, or a chronic infection elsewhere in the body. Tubulointerstitial nephritis (attributed to immune-complex deposition) is usually associated with chronic rather than acute disease. The incidence of renal complications in Q fever is unknown due to the small numbers of case reports, but a recent case series of 54 patients demonstrated that 33 % had renal failure [79]. Renal manifestations range from asymptomatic proteinuria and hematuria to AKI, hypertension, and nephrotic syndrome. Renal histologic findings are those of a diffuse proliferative GN, focal segmental GN, or mesangial GN. Immunofluorescent studies reveal diffuse glomerular deposits of IgM in the mesangial, together with C3 and fibrin. Coxiella burnetii antigen has not been identified within the renal lesions. IgG antibodies to cardiolipin and lupus anticoagulant have been demonstrated in acute-phase serum samples [80]. Treatment of the underlying infection may result in remission of the renal disease, but prolonged treatment may be required for endocarditis. Doxycycline is the first line recommended treatment for adults and children and has not been linked to dental staining as occurs with other tetracyclines and so can be used in children of all ages who are hospitalized with Q fever [81]. Co-trimoxazole has been used as a safe alternative (deemed safe in pregnant women) as has clarithromycin. In the acute setting, treatment should continue until 3 days after the fever has subsided (usual duration is 2–3 weeks). Chronic infection requires a longer treatment, usually 18 months (CDC recommendation).

51

Infectious Diseases and the Kidney in Children

Intravascular and Focal Bacterial Infections Nephritis has been reported in association with the presence of a wide range of microorganisms that cause chronic or persistent infection (Table 2). It is likely that any infectious agent that releases foreign antigens into the circulation, including those of very low virulence, can cause renal injury either by deposition of foreign antigens in the kidney or by the formation of immune complexes in the circulation, which are then deposited within the kidney. Nephritis is most commonly seen in association with intravascular infections such as SBE or infected ventriculoatrial shunts, but it is also seen after focal extravascular infections; ear, nose, and throat infections; and abscesses.

1625 Table 2 Focal infections causing glomerulonephritis Site of infection Infective endocarditis

Shunt infections

Bacterial Endocarditis Renal involvement is one of the diagnostic features of bacterial endocarditis. Virtually all organisms that cause endocarditis also produce renal involvement (Table 2). Although endocarditis caused by bacteria is the most common and is readily diagnosed by blood culture, unusual but important causes of culture-negative endocarditis include Q fever and Legionella infection. In the immunocompromised individual, opportunistic pathogens such as fungi and mycobacteria are important causes. The usual renal manifestations of SBE are asymptomatic proteinuria, hematuria, and pyuria. Loin pain, hypertension, nephrotic syndrome, and renal failure may occur in more severe cases. The renal lesions occurring in endocarditis are variable, and focal embolic and immunecomplex-mediated features may coexist [82, 83]. Embolic foci may be evident as areas of infarction, intracapillary thrombosis, or hemorrhage. More commonly, there is a focal necrotizing or diffuse proliferative GN. Immunofluorescent studies show glomerular deposits of IgG, IgM, IgA, and C3 along the GBM and within the mesangium. Electron microscopy reveals typical electron-dense deposits along the GBM and within the mesangium [82].

Focal abscess Osteomyelitis Pyelonephritis Pneumonia

Otitis media Gastrointestinal infection

Organism Coagulase-negative staphylococci Staphylococcus aureus Streptococcus pneumoniae Viridans streptococci Enterococci Anaerobic streptococci Diphtheroids Haemophilus influenzae Coliforms Bacteroides Coxiella burnetii Legionella Candida albicans Coagulase-negative staphylococci Staphylococcus aureus Diphtheroids Gram-negative bacilli Anaerobes Staphylococcus aureus Gram-negative bacilli Staphylococcus aureus Streptococcus pyogenes Coliforms Streptococcus pneumoniae Klebsiella Staphylococcus aureus Mycoplasma Streptococcus pneumoniae Staphylococcus aureus Yersinia Campylobacter Salmonella Shigella

Early reports suggested that the renal lesions were caused by microemboli from infected vegetations depositing in the kidney, a hypothesis supported by the occasional presence of bacteria within the renal lesions. Most subsequent evidence, however, indicates that immunologic mechanisms rather than emboli are involved in the pathogenesis in most cases: bacteria are rarely found within the kidney, and renal involvement occurs with lesions of the right side of the heart,

1626

which would not be likely to embolize to the kidney. Immune complexes containing bacterial antigens are present in the circulation, and both bacterial antigens and bacteria-specific antibodies can be demonstrated within the immune deposits in the kidney. Serum C3 level is usually low, and complement can be found within both the circulating and the deposited immune complexes. These features all support an immune-complex-mediated pathogenesis of the renal injury. Treatment of the endocarditis with antibiotics usually results in resolution of the GN and is associated with the disappearance of immune complexes from the circulation and return of C3 levels to normal. The prognosis of the renal lesions in SBE generally depends on the response of the underlying endocarditis to antibiotics or, in cases of antibiotic failure, to surgical removal of the infective vegetations [84].

Shunt Nephritis In patients previously treated by shunting for hydrocephalus, there is a well-documented association of GN with infected ventriculoatrial shunts. The incidence of shunt nephritis has decreased due to the preference of ventriculoperitoneal shunts over ventriculoatrial shunts; however, shunt nephritis has been reported with the former [85]. Coagulase-negative staphylococci are the causative organisms in 75 % of cases. It is an immune-complex disease with chronic hyperantigenemia, hyperglobulinemia, and the deposition of immunoglobulins, complement, and immune complexes on the glomerular basement membrane [86]. The clinical and pathologic findings are similar to those in SBE. Presenting features are proteinuria, hematuria, and pyuria, and they may progress to renal failure. Immune complexes containing the bacterial antigens and complement are present in the serum, and C3 is depressed. Histologic findings are those of a diffuse mesangiocapillary GN. The prognosis for the renal lesion is good if the infection is treated early. This usually involves removal of the infected shunt or replacement of a VA with a VP shunt and administration of appropriate

J. Stevens et al.

antibiotics, though possible progression to end-stage renal disease requires frequent renal monitoring of patients with ventriculoatrial shunts [87]. Certain case reports have also seen benefit with the use of steroids as adjunctive therapy [88].

Other Focal Infections GN has been reported after chronic abscesses, osteomyelitis, otitis media, pneumonia, and other focal infections (Table 2). AKI has been the presenting feature of focal infections in various sites, including the lung, pleura, abdominal cavity, sinuses, and pelvis. Many different organisms have been responsible, including S. aureus, Pseudomonas, E. coli, and Proteus species. This is probably another example of immune-complex GN. C3 level is decreased in approximately one-third of reported cases, and immunofluorescent studies reveal diffuse granular deposits of C3 in the glomeruli of all reported instances, with a variable presence of immunoglobulin. The renal lesion is that of MPGN and crescentic nephritis. The renal outcome is reported to be good with successful early treatment of the underlying infection.

Viral Infections The role of viral infections in the causation of renal disease has been less well defined than that of bacterial infections. Clearly defined associations of renal disease have been made with hepatitis B virus (HBV), hepatitis C virus (HCV), HIV, and hantaviruses, but the role of most other viruses in the pathogenesis of renal disease is not clearly defined. Most viruses causing systemic infection may trigger immunologically mediated renal injury. With increasing application of molecular techniques, it may be that a significant proportion of GNs currently considered to be idiopathic will ultimately be shown to be virus induced. In children with immunodeficiency states and those undergoing renal transplantation, viruses such as cytomegalovirus (CMV) and polyomavirus have been recognized to be associated with nephropathy.

51

Infectious Diseases and the Kidney in Children

Hepatitis B Virus About 2,000 million people alive today have been infected with hepatitis B at some point in their lives, of these 350 million become chronically infected and are carriers of the disease. There are an estimated four million acute cases per year, and per year 25 % of carriers (one million) die from cirrhosis, chronic active hepatitis, or primary hepatocellular carcinoma. The infection is most common in Africa and the Orient, where it is acquired in childhood by vertical transmission from infected mothers or by horizontal transmission from other children or adults. In developed countries, transmission in adults occurs more often by blood product exposure, sexual contact, or intravenous drug use. The epidemiology of HBV infection in children is changing following the widespread use of effective vaccination at birth, in both developed and developing countries. HBV is a complex DNA virus with an outer surface envelope (HBsAg) and an inner nucleocapsid core containing the hepatitis B core antigen (HBcAg), DNA polymerase, protein kinase activity, and viral DNA. Incomplete spherical and filamentous viral particles consisting solely of HBsAg are the major viral products in the circulation and may be present in concentrations of up to 1,014 particles per milliliter of serum. Hepatitis B e antigen (HBeAg) can be released from HBcAg by proteolytic treatment and may be found in the circulation either free or complexed to albumin or IgG antibodies. The presence of HBeAg correlates with the presence of complete viral particles and the infectivity of the individual. Infection with HBV may result in either a selflimited infectious hepatitis followed by clearance of the virus and complete recovery, or a chronic or persistent infection in which the immune response is ineffective in eliminating the virus. Chronic HBV infection with continued presence of viral antigens in the circulation caused by an ineffective host immune response provides the bestdocumented example of immunologically mediated renal injury caused by persistent infection. The risk of chronic infection varies inversely with age with 90 % of infants infected at birth

1627

developing chronic infection, compared to 25–50 % of children infected between 1 and 5 years and 1–5 % of people infected as older children and adults. Chronic infection is also common in those with immunodeficiency.

Patterns of Hepatitis B Virus Immunologically Mediated Renal Disease Several forms of renal disease secondary to hepatitis B infection have been identified including membranous glomerulonephritis, mesangioproliferative glomerulonephritis, as well as IgA nephropathy and focal segmental glomerulosclerosis (FSGS) [89]. Hepatitis B has also been linked with polyarteritis nodosa (PAN). Prodromal Illness. In the early prodromal phase of HBV hepatitis, before the onset of jaundice, some patients develop fever, maculopapular or urticarial rash, and transient arthralgias or arthritis. Occasionally, proteinuria, hematuria, or sterile pyuria is observed. The syndrome usually lasts 3–10 days and often resolves before the onset of jaundice [90]. There have been no histologic studies of the renal changes during this prodromal period. Hepatitis B Virus-Associated Polyarteritis Nodosa. HBV infection is associated with polyarteritis nodosa, a vasculitis affecting the small- and medium-sized vessels (HBV PAN). Most of these cases have been in adults, but the disorder has also been reported in children, where it is estimated that approximately one-third of PAN cases are caused by HBV [91, 92]. HBV PAN appears to be uncommon in Africa and the Orient, where infection is usually acquired in childhood, and has declined in incidence following the introduction of HBV vaccination [93]. HBV PAN presents weeks to months after a clinically mild hepatitis but may occasionally predate the hepatitis. After a prodromal illness, frank vasculitis affecting virtually any organ appears. Abdominal pain, fever, mononeuritis multiplex, and pulmonary and renal involvement may occur and can be the first clinical presentation of hepatitis B [94]. The renal involvement may appear as hypertension, hematuria, proteinuria, or renal failure. Laboratory investigations reveal a florid

1628

acute-phase response, leukocytosis, and anemia. Transaminase levels are usually elevated, and HBsAg is present in the circulation. The pathology consists of focal inflammation of small- and medium-sized arteries, with fibrinoid necrosis, leukocyte infiltration, and fibrin deposition. Renal pathology may be limited to the mediumsized arteries or may coexist with GN [95]. Circulating immune complexes containing HBsAg and anti-HBs antibodies are usually present in the circulation. C3, C4, and total hemolytic complement levels are depressed. A positive ANCA excludes HBV PAN [93]. Although most evidence suggests that the pathogenesis involves an immune-complex-mediated vasculitis, autoantibody- or cell-mediated vascular injury may coexist. If the condition is untreated, the mortality is high. Most studies suggest that steroids or immunosuppressants help to suppress the vasculitis but potentially predispose to chronic infection or progressive liver disease. Successful treatment of hepatitis B-associated PAN with nucleoside analogues such as lamivudine or newer antiviral drugs, either alone or in combination with interferon-alpha and conventional immunosuppressive therapy, has been reported [93, 96]. Hepatitis B Virus-Associated Membranous Glomerulonephritis. HBV is now the major cause of membranous GN (MGN) in children worldwide. The proportion of patients with MGN caused by HBV is directly related to the incidence of HBsAg in the population, with 80–100 % of all cases of MGN in some African and Oriental countries being associated with HBV (see ▶ Chap. 34, “Membranous Nephropathy in Children”). HBV MGN usually presents in children aged 2–12. There is a striking male predominance. The virus is usually acquired by vertical transmission from infected mothers or horizontally from infected family members. Unlike adults with HBV MGN, children do not usually have a history of hepatitis or of active liver disease, but liver function test results are generally mildly abnormal. Liver biopsy specimens may show minimal abnormalities, chronic persistent hepatitis, or (occasionally) more severe changes. The renal manifestations are usually of proteinuria, nephrotic syndrome, microscopic hematuria,

J. Stevens et al.

or (rarely) macroscopic hematuria. Hypertension occurs in less than 25 % of cases, and renal insufficiency is rare. HBsAg and HBcAg are usually present in the circulation, and HBe antigenemia is seen in a high proportion of cases. Occasionally, HBsAg may be found in the glomeruli but is absent from the circulation. C3 and C4 levels are often low, and circulating immune complexes are found in most cases. Immunohistologic study reveals deposits of IgG and C3 and (less commonly) IgM and IgA in subepithelial, subendothelial, or mesangial tissue. HBV particles may be seen on electron microscopy, and all the major hepatitis B antigens, including HBsAg, HBcAg, and HBeAg, have been localized in the glomerular capillary wall on immunofluorescence. Immunologic deposition of HBV and antibody in the glomerular capillary wall is clearly involved in the glomerular injury, but the underlying immunologic events are incompletely understood [90]. Passive trapping of circulating immune complexes may be involved, but the circulating immune complexes containing HBsAg are usually larger than would be expected to penetrate the basement membrane. HBsAg and HBcAg are anionic and are therefore unlikely to penetrate the glomerular capillary wall. In contrast, HBeAg forms smaller complexes with anti-HBe antibodies and may readily penetrate the GBM. This may explain the observation that HBeAg in the circulation frequently correlates with the severity of the disease [90]. An alternative mechanism for immune-mediated glomerular injury is the trapping of HBV antigens by antibody previously deposited in the kidney. Anti-HBe antibodies are cationic and may readily localize in the glomerulus and subsequently bind circulating antigen and complement. The third possibility is that the depositions of HBV and antibodies are consequences of glomerular injury by cellular mechanisms or autoantibodies. Little evidence supports this view at present [90]. A transgenic mouse model of HBV-associated nephropathy has been developed, in which HBsAg and HBcAg is expressed in the liver and kidney, particularly tubular epithelial cells, without viral replication. In these mice, gene expression analysis revealed

51

Infectious Diseases and the Kidney in Children

upregulation of acute-phase proteins, particularly C3, although measurable serum C3 levels were reduced. This supports the notion that local persistent expression of HBV viral proteins contributes to HBV-associated nephropathy [97]. Other Hepatitis B Virus Glomerulonephritides. HBV infection has been associated with a variety of other forms of GN in both adults and children [95]. Both MPGN and mesangial proliferative GN may be triggered by HBV. In several countries where HBV is common, the proportion of patients with these forms of nephritides who test positive for HBV greatly exceeds the incidence of positivity in the general population. As with MGN and HBV-associated PAN, circulating immune complexes and localization of HBV antigens in the glomeruli have been reported in both MPGN and mesangial proliferative GN, and it is likely that similar mechanisms are occurring [90]. Several other forms of GN have been associated with HBV, including IgA nephropathy, focal glomerulosclerosis, crescentic nephritis, and systemic lupus erythematosus, but the evidence for these associations is less consistent than for the entities discussed earlier [95].

Treatment of Hepatitis B Virus Glomerulonephritis HBV is normally cleared as a result of cellmediated responses in which cytotoxic T cells and natural killer cells eliminate infected hepatocytes. It is not surprising, therefore, that the administration of steroids and immunosuppressive agents either may have no effect on HBV disease or may increase the risk of progressive disease. Children with HBV MGN have a good prognosis, and two-thirds undergo spontaneous remission within 3 years of diagnosis. Steroid therapy does not appear to provide any additional benefit [90, 98]. Antiviral therapy with pegylated interferon-alpha and lamivudine is used to treat HBV, and in some cases, elimination of the infection with antiviral therapy in both children and adults is associated with improvement or resolution of the coexisting renal disease [99]. There are isolated case reports of pegylated interferon successfully treating IgA nephropathy associated with HBV [100]. There have been some

1629

promising results with newer antiviral agents such as adefovir and entecavir in treating HBV glomerulonephritis in combination regimens [101].

Hepatitis C Virus HCV is an enveloped, single-stranded RNA virus of approximately 9.4 kilobases in the Flaviviridae family. There are six major HCV genotypes. Hepatitis C is a common disease affecting approximately 400 million people worldwide. In the United States, 4.1 million persons are estimated to be anti-HCV positive, and 3.2 million may be chronically infected [102]. An estimated 240,000 children in the United States have antibody to HCV, and 68,000–100,000 are chronically infected. Children become infected through receipt of contaminated blood products or through vertical transmission. The risk of vertical transmission increases with higher maternal viremia and maternal coinfection with HIV. Acute HCV infection is rarely recognized in children outside of special circumstances such as a known exposure from an HCV-infected mother or after blood transfusion. Most chronically infected children are asymptomatic and have normal or only mildly abnormal alanine aminotransferase levels. Although the natural history of HCV infection during childhood seems benign in the majority of instances, the infection can take an aggressive course in a proportion of children, leading to cirrhosis and end-stage liver disease during childhood. The factors responsible for this more aggressive course are unidentified [103]. Even in adults, the natural history of HCV infection has a variable course, but a significant proportion of patients will develop some degree of liver dysfunction, and 20–30 % will eventually have end-stage liver disease as a result of cirrhosis. The risk of hepatocellular carcinoma is significant for those who have established cirrhosis. Hepatitis C is currently the most common condition leading to liver transplantation in adults in the “Western world.” GN has been described as an important complication of chronic infection with HCV

1630

in adults [104]. The clinical presentation is usually of nephrotic syndrome or proteinuria, hypertension, or hematuria, with or without azotemia. MPGN, with or without cryoglobulinemia, and MGN are most commonly described [105]. Isolated case reports of other, more unusual patterns of glomerular injury, including IgA nephropathy, focal segmental glomerulosclerosis, crescentic GN, fibrillary GN, and thrombotic microangiopathy, have also been associated with HCV infection [106]. Glomerular deposition of hepatitis antigens and antibodies has been described and is believed to play a role in pathogenesis. Cryoglobulinemia is a common accompaniment of GN that is associated with the depression of serum complement levels [106]. Renal failure may develop in 40–100 % of patients who have MPGN. The presence of viruslike particles as well as viral RNA within the kidney sections of patients with HCV-associated glomerulopathies has been reported [107]. The diagnosis should be suspected if glomerular disease is associated with chronic hepatitis, particularly with the presence of cryoglobulins, but renal biopsy is necessary to establish a definitive diagnosis. HCV infection is relatively common in children with end-stage renal disease and is an important cause of liver disease in this population. HCV-infected renal transplant recipients had higher mortality and hospitalization rates than other transplant recipients [108], and HCV infection has been reported to be associated with de novo immune-mediated GN, especially type 1 MPGN, in renal allografts, resulting in accelerated loss of graft function. The PEDS-C trials, a randomized controlled trial in children and adolescents, have shown that ribavirin and pegylated interferon is superior to pegylated interferon and placebo in treating chronic hepatitis C in this age group, and this combination constitutes the US standard of care [109]. Clinical trials are currently underway investigating the efficacy of a new generation of HCV antiviral drugs, including sofosbuvir, boceprevir, and telaprevir in combination with pegylated interferon and ribavirin. Triple therapy has been associated with a higher sustained virological response in adults [110].

J. Stevens et al.

Hepatitis C may be complicated by systemic mixed cryoglobulinemic (MC) vasculitis and in some cases by a polyarteritis nodosa (PAN)-type non-cryoglobulinemic vasculitis [111]. Treatment with interferon-α (IFN-α) and ribavirin mostly is associated with an improvement of vasculitic symptoms. In some cases, exacerbation and rarely new onset of vasculitis of the peripheral nervous system have been described after this treatment. In fulminant cases, immunosuppressive therapy with steroids, and cyclophosphamide, or rituximab may be needed to control life-threatening vasculitis prior to antiviral treatment [111].

Herpes Viruses: Cytomegalovirus CMV is one of the eight human herpes viruses. Transmission of the virus requires exposure to infected body fluids such as breast milk, saliva, urine, or blood. Individuals initially infected with CMV may be asymptomatic or display nonspecific flulike symptoms. After the initial infection CMV, like all herpes viruses, establishes latency for life but will be periodically excreted by an asymptomatic host. CMV replicates within renal cells, and on biopsy samples from immunocompromised hosts, viral inclusions can be visualized by light microscopy in cells of the convoluted tubules and collecting ducts [112]. Glomerular cells and shed renal tubular cells may have characteristic inclusions, but clinically evident renal disease is rare and is seen virtually only in immunocompromised or congenitally infected children. The clinical manifestations of CMV-induced renal disease in congenitally infected infants are variable and range from asymptomatic proteinuria to nephrotic syndrome and renal impairment. In congenital CMV infection, histologic changes of viral inclusions commonly occur in the tubules. In addition, proliferative GN has been reported, with evidence on electron microscopy of viral immune deposits in glomerular cells [113]. In CMV-infected immunocompromised patients, immune-complex GN has been documented with mesangial deposits of IgG, IgA, C3, and CMV antigens within glomeruli. Eluted glomerular

51

Infectious Diseases and the Kidney in Children

immunoglobulins have been shown to contain CMV antigens [114]. CMV is the most common viral infection after kidney transplantation. Experience with pediatric kidney transplant recipients suggests a 67 % incidence of CMV infection, with approximately 67 % being negative at the time of transplantation [115]. The direct and indirect effects of CMV infection result in a significant morbidity and mortality among kidney transplant recipients. CMV-negative patients who receive a CMV-positive allograft are at risk for primary infection and graft dysfunction. Patients who are CMV seropositive at the time of transplantation are also at risk of reactivation and superinfection. Tubulointerstitial nephritis is a well-characterized pathologic feature of renal allograft CMV disease, which can be difficult to distinguish from injury caused by rejection. Histologic evidence of endothelial cell injury and mononuclear cell infiltration in the glomeruli has been reported. CMV glomerular vasculopathy in the absence of tubulointerstitial disease, causing renal allograft dysfunction, has also been reported [116]. Beyond the acute allograft nephropathy associated with CMV viremia, CMV is known to cause chronic vascular injury. This may adversely affect the long-term outcome of the allograft and may be the explanation for the observed association with chronic allograft nephropathy. Techniques for rapidly diagnosing CMV infection include shell vial culture, pp65 antigenemia assay, PCR, and the hybrid-capture RNA-DNA hybridization assay for qualitative detection of CMV PCR. Reverse transcriptase PCR (RT PCR) can detect viral mRNA transcripts in peripheral blood but is less sensitive than pp65 or PCR [117]. Immune histocytochemistry is used for diagnosing end-organ disease. Quantitative plasma PCR testing (PCR viral load) is increasingly used for diagnosis and monitoring of CMV viremia in renal transplant recipients [117]. The American Society of Transplantation (AST) recommends monitoring for CMV by quantitative viral load monthly for the first year after transplantation, and the Kidney Disease Improving Global Outcomes (KDIGO) recommends an additional 3 monthly surveillance for the second year.

1631

Antiviral agents that have been shown to be effective against CMV include ganciclovir, valganciclovir, foscarnet, and cidofovir. Ganciclovir remains the drug of choice for treating established disease. Intravenous ganciclovir therapy is preferred in children because of the erratic absorption of oral ganciclovir. Major limitations of ganciclovir therapy are the induction of renal tubular dysfunction and bone marrow toxicity, principally neutropenia and thrombocytopenia. Dosage adjustments are necessary for recipients with renal dysfunction. Oral valganciclovir is recommended for CMV prophylaxis posttransplant [118]. Duration of chemoprophylaxis is dependent on the serostatus of the donor and recipient [115]. While it is effective in reducing the incidence of symptomatic CMV, prospective viral surveillance studies have shown subclinical infection in 12–22 % of pediatric kidney transplant recipients, hence the importance of viral surveillance [115]. Use of other antiviral agents such as foscarnet and cidofovir is limited because of nephrotoxicity and difficulty of administration. The role of high-titer CMV immunoglobulin therapy in reducing severe CMV-associated disease after stem cell transplant remains unclear [119].

Herpes Viruses Varicella-Zoster Virus The association of varicella with nephritis has been known for more than 100 years since Henoch reported on four children with nephritis that occurred after the appearance of varicella vesicles. Varicella, however, is rarely associated with renal complications. In fatal cases with disseminated varicella and in the immunocompromised individual, renal involvement is more common. Histologic findings in fatal cases include congested hemorrhagic glomeruli, endothelial cell hyperplasia, and tubular necrosis. In mild and nonfatal cases and in nonimmunocompromised individuals, varicella is occasionally associated with a variety of renal manifestations, ranging from mild nephritis to nephrotic syndrome and AKI [120]. Histologic findings include endocapillary cell proliferation, epithelial and

1632

endothelial cell hyperplasia, and inflammatory cell infiltration. Rapidly progressive nephritis has also been reported. Immunohistochemical studies reveal glomerular deposition of IgG, IgM, IgA, and C3. On electron microscopy, granular electron-dense deposits have been found in the paramesangial region, and varicella antigens may be deposited in the glomeruli. The features suggest an immune-complex nephritis. Elevated circulating levels of IgG and IgA immune complexes and depressed C3 and C4 levels support this possibility [121]. Fulminant disseminated varicella and varicella in immunocompromised patients should be treated with intravenous acyclovir.

Herpes Viruses: Epstein-Barr Virus Renal involvement is common during acute infectious mononucleosis, usually manifesting as an abnormal urine sediment, with hematuria in up to 60 % of cases. Hematuria, either microscopic or macroscopic, usually appears within the first week of the illness and lasts for a few weeks to a few months. Proteinuria is usually absent or low grade. More severe renal involvement with proteinuria, nephrotic syndrome, or acute nephritis with renal failure is much less common. AKI may be seen during the course of fulminant infectious mononucleosis with associated hepatic failure, thrombocytopenia, and encephalitis. It is usually caused by interstitial nephritis that is likely the result of immunopathologic injury precipitated by Epstein-Barr virus (EBV) infection. However, the identification of EBV DNA in the kidney raises the possibility that direct infection might play a role [122, 123]. The renal involvement must be distinguished from myoglobinuria caused by rhabdomyolysis, which may occur in infectious mononucleosis, and from bleeding into the renal tract as a result of thrombocytopenia. Renal histologic findings in EBV nephritis are an interstitial nephritis with mononuclear cell infiltration and foci of tubular necrosis. Glomeruli may show varying degrees of mesangial proliferation. On immunohistochemical study, EBV antigens are seen in glomerular and tubular deposits.

J. Stevens et al.

The prognosis for complete recovery of renal function is good. Treatment with corticosteroids may have a role in the management of EBV-induced AKI and may shorten the duration of renal failure [124]. EBV-associated posttransplantation lymphoproliferative disease is a recognized complication in renal transplant recipients. Subclinical infection occurs in 35–40 % of pediatric renal transplant recipients [115]. Latent infection of EBV in renal proximal tubular epithelial cells has been described as causing idiopathic chronic tubulointerstitial nephritis [125].

Herpes Viruses: Herpes Simplex Virus The herpes simplex virus (HSV) causes persistent infection characterized by asymptomatic latent periods interspersed with acute relapses. As with other chronic and persistent infections, immunologically mediated disorders triggered by HSV are well recognized, and it is perhaps surprising that HSV has rarely been linked to nephritis. Acute nephritis and nephrotic syndrome have been associated with herpes simplex encephalitis. Renal histology shows focal segmental GN with mesangial and segmental deposits of IgM, C3, and HSV antigens. As with other herpes viruses, HSV has been suggested as a trigger for IgA nephritis, MPGN, and membranous nephropathy, but no conclusive evidence exists of an etiologic role for HSV.

Human Immunodeficiency Virus The WHO estimate that in 2012 there were 35.3 million people living with HIV worldwide, with 3.3 million being children. Of these 260,000 were new infections (www.unaids.org – UNAIDS Global Report on the global AIDS epidemic 2013). The number of children under 15 years of age receiving antiretroviral therapy (ART) in lowand middle-income countries rose from 566,000 in 2011 to 630,000 in 2012 (www.unaids.org – Global update on HIV treatment 2013). Renal involvement occurs in 2–15 % of HIV-infected children in the United States [126–128]. Since the development of antiretroviral

51

Infectious Diseases and the Kidney in Children

therapy (ART), however, the incidence of end-stage renal disease in HIV infection in both adults and children in industrialized countries has declined, but it is predicted that the dramatic decline in AIDS-related deaths will lead to an ageing population of HIV-infected individuals who will be at risk of non-HIV-related renal problems, such that the numbers of HIV-positive ESRD patients will increase in the United States [129]. HIV infection is associated with a number of renal pathologies. HIV-associated nephropathy (HIVAN) is a syndrome of glomerular and tubular dysfunction, which can progress to end-stage renal failure. It is discussed more fully below. Glomerular syndromes other than HIVAN include a range of immune-mediated syndromes (HIV immune-complex kidney disease (HIVICK)) including MGN that resembles lupus nephritis and immune-complex GN, with IgA nephropathy and HCV-associated MPGN being the most common forms [126, 127]. There have also been several case reports of amyloid kidney. The kidneys may be affected by various other mechanisms. Opportunistic infections with organisms such as BK virus (BKV) that give rise to nephropathy and hemorrhagic cystitis have been reported in association with HIV infection [130]. Systemic infections accompanied by hypotension can cause prerenal failure leading to acute tubular necrosis. Acute tubular necrosis has also been reported in HIV patients after the use of nephrotoxic drugs such as pentamidine, foscarnet, cidofovir, amphotericin B, and aminoglycosides. Intratubular obstruction with crystal precipitation can occur with the use of sulfonamides and intravenous acyclovir. Indinavir is well recognized to cause nephropathy and renal calculi [131]. MPGN associated with mixed cryoglobulinemia and thrombotic microangiopathy/atypical HUS in association with HIV infections have been reported [132, 133].

HIV-Associated Nephropathy (HIVAN) HIVAN is characterized by both glomerular and tubular dysfunction, the pathogenesis of which is not entirely known. HIVAN is a clinicopathologic

1633

entity that includes proteinuria, azotemia, focal segmental glomerulosclerosis or mesangial hyperplasia, and tubulointerstitial disease [128]. In adults in the United States, there is a markedly increased risk of nephropathy among African American persons with HIV infection. This appears to be true in children as well, but the data are sparse. The spectrum of HIVAN seems to be coincident with the degree of AIDS symptomatology. It is thought that HIVAN can present at any point in HIV infection, but most patients with HIVAN have CD4 counts of less than 200 106 cells/mL, which suggests that it may be primarily a manifestation of late-stage disease [134]. The microscopic features of HIVAN in children comprise of classical FSGS with or without mesangial hyperplasia combined with microcystic tubular dilatation and interstitial inflammation [135]. Collapsing FSGS is the hallmark of adult disease, and this has been shown in children as well. In the affected glomeruli, visceral epithelial cells are hypertrophied and hyperplastic and contain large cytoplasmic vacuoles and numerous protein resorption droplets. There is microcystic distortion of tubule segments, which contributes to increasing kidney size. Podocyte hyperplasia can become so marked that it causes obliteration of much of the urinary space, forming “pseudocrescents” [136]. Capillary walls are wrinkled and collapsed with obliteration of the capillary lumina. The interstitium is edematous with a variable degree of T-cell infiltration. The Bowman capsule can also be dilated and filled with a precipitate of plasma protein that represents the glomerular ultrafiltrate. One of the most distinctive features of HIVAN, however, is the presence of numerous tubuloreticular inclusions within the cytoplasm of glomerular and peritubular capillary endothelial cells [136]. Immunofluorescence testing is positive for IgM and C3 in capillary walls in a coarsely granular to amorphous pattern in a segmental distribution [137]. The presence of the HIV genome in glomerular and tubular epithelium has been demonstrated using complementary DNA probes and in situ hybridization. Proviral DNA has been detected

1634

by PCR in the glomeruli, tubules, and interstitium of microdissected kidneys from patients who had pathologic evidence of HIVAN, but it has also been detected in the kidneys of HIV-positive patients with other glomerulopathies and in those with undetectable levels of viral RNA in the peripheral blood [138]. The kidney has been postulated to behave as a separate compartment to the blood with ongoing viral replication in the kidneys despite achieving serological suppression with ART [138, 139]. Transgenic murine models provide some of the strongest evidence for a direct role of HIV-1 in the induction of HIVAN. These mice do not produce infectious virus but express the HIV envelope and regulatory genes at levels sufficient to recreate the HIVAN that is seen in humans. Animal models have shown that the nef and vpr genes contribute to HIVAN through encoding for podocyte dysfunction and apoptosis of renal tubular epithelial cells, respectively [135]. HIV is thought to infect renal tubuloepithelial cells through direct cell-cell transmission which then act as a separate viral compartment and facilitates replication distant from the blood. HIVAN 1 and 2 are the host susceptibility genes identified in animal models for HIVAN. Two variants (g1and G2) in the ApoL1 gene have been identified as the susceptibility alleles that contribute to the increased risk of FSGS in African Americans (previously attributed to MYH9 on chromosome 22) [135]. HIVAN is more likely in patients with a family history of ESRD. HIVAN can manifest as mild proteinuria, nephrotic syndrome, renal tubular acidosis, hematuria, and/or AKI [128]. Nephrotic syndrome and chronic renal insufficiency are late manifestations of HIVAN. Children with HIVAN are likely to develop transient electrolytic disorders, heavy proteinuria, and AKI due to systemic infectious episodes or nephrotoxic drugs. Early stages of HIVAN can be identified by the presence of proteinuria and “urine microcysts” along with renal sonograms showing enlarged echogenic kidneys. Urinary renal tubular epithelial cells are frequently grouped together to form these microcysts, which were found in the urine of children with HIVAN who had renal tubular

J. Stevens et al.

injury [128]. Advanced stages of HIVAN typically present with nephrotic syndrome with edema, heavy proteinuria, hypoalbuminemia, and few red or white blood cells in urinary sediments. Hypertension may be present, but usually blood pressure is within or below the normal range. HIVAN in adults follows a rapidly progressive course, with end-stage renal disease developing within 1–4 months, but in children this rapid progression does not necessarily occur. Definitive diagnosis of HIVAN should be based on biopsy results, and biopsy should be performed if a significant proteinuria is present, because in approximately 50 % of HIV-infected patients with azotemia and/or proteinuria (>1 g/24 h) who undergo renal biopsy, the specimen will have histologic features consistent with other renal diseases [134].

HIV Immune-Complex Kidney Disease (HIVICK) HIVCK is thought to arise by deposition of immune complexes or by in situ formation of immune complexes in the parenchyma [126]. The immune complexes consist of HIV antigens bound to IgG and IgA. IgA nephropathy, membranous and membranoproliferative glomerulonephritis, and a lupus-like glomerulonephritis are included in HIVCK. Like HIVAN, it occurs in Afro-Caribbeans but can also be found in Caucasians [126]. Acute interstitial nephritis (AIN) results mainly from medications used to treat HIV and its complications. Nonsteroidal anti-inflammatory drugs, rifampicin, co-trimoxazole, and protease inhibitors (PI) like idinavir and ritonavir have been implicated [140]. All classes of ART can cause renal toxicity except the integrase inhibitors and the CCR5 antagonists. Tenofovir can cause proximal tubular nephropathy and can present as complete or partial Fanconi syndrome [141, 142]. Therefore, it is essential that children on ART have regular urinalysis to check for the emergence of proteinuria and hematuria. HAART should be given to children with symptomatic HIV disease. Specific treatment of HIVAN remains controversial. Several studies have looked at the role of HAART with or without

51

Infectious Diseases and the Kidney in Children

angiotensin I-converting enzyme (ACE) inhibitors, and even cyclosporin with somewhat encouraging results. However, as yet, no randomized case-controlled trials have been undertaken [126]. Most of the studies have been small and retrospective, and many have included patients both with and without renal biopsy-proven HIVAN. Cyclosporin has been used to treat HIVAN in children with remission of nephrotic syndrome [143]. Similar responses have been reported to treatment with corticosteroids in various studies; however, steroids are not currently recommended for the routine management of HIVAN. There has been short-term improvement in kidney function in children with lymphoid interstitial pneumonitis, but there is the risk of exacerbation of infection with TB when used in developing countries, and in the absence of HAART, it has not been shown to limit the progression of HIVAN in children [126–128]. The general regimen used to treat patients with HIV, including HAART, should be applied to children with HIVAN. The dosages of some medications must be adjusted to the patients’ glomerular filtration. There are reports of spontaneous regression of HIVAN with supportive management and treatment with HAART, particularly with regimens containing protease inhibitors [144]. The kidneys of transgenic mice have been found to have elevated levels of TGF-β messenger RNA and protein [145]. Furthermore, gene expression analysis on tubular epithelial cells from a patient with HIVAN found upregulation of several inflammatory mediator genes downstream of interleukin 6 and of the transcription factor NFkB [146]. Several therapeutic options have been aimed specifically at the presumed role of TGF-β in the pathogenesis of HIVAN. Treatment directed at its synthesis using gene therapy to block TGF-β gene expression is being explored. Therapy directed at decreasing the activity of TGF-β using anti-TGF-β antibodies or other inhibitory substances is also an area of investigation. To date, these novel therapeutic approaches have not yielded any promising advancement in treatment. In the HAART era, the outlook for HIV patients with ESRD has improved, but these

1635

patients fare worse than ESRD patients without HIV [147]. Most reports of HIV-infected patients on hemodialysis have shown poor prognosis, with mean patient survival times ranging from 14 to 47 months. Mortality is therefore still close to 50 % within the first year of dialysis. In general, improved survival is associated with younger age at initiation of hemodialysis and with higher CD4 counts. Complications such as infection and thrombosis tend to occur at a higher rate in HIV-infected hemodialysis patients. Cross infection with HIV in dialysis patients is very rare. Peritoneal dialysis is an alternative for HIV-infected patients. The incidence of peritonitis varies across studies, but some studies did report a higher incidence of Pseudomonas and fungal peritonitis in the HIV-positive population [148]. Infections with unusual organisms such as Pasteurella multocida, Trichosporon beigelii, and Mycobacterium avium-intracellulare complex have also been reported. Several studies, however, have suggested that there is no significant difference between the HIV-infected and non-HIV-infected populations. Of note is that virus capable of replication in vitro has been recovered from the peritoneal dialysis effluent, and it can be recoverable for up to 7 days in dialysis bags at room temperature and for up to 48 h in dry exchange tubing [148]. Kidney transplantation in HIV-infected individuals with end-stage renal disease has shown excellent 3–5-year survival rates [149, 150]. These group of patients do experience an increase risk of rejection but not of opportunistic infections. Most issues revolve around immunosuppressive therapy and interactions with ART.

Human Polyomaviruses The human polyomaviruses are members of the papovavirus family and significant pathogens in immunocompromised patients. They are non-enveloped viruses ranging in size from 45 to 55 nm, with a circular, double-stranded DNA genome that replicates in the host nucleus. The best-known species in this genus are the BKV, the JC virus (JCV), and the simian virus SV40. BKV

1636

establishes infection in the kidney and the urinary tract, and its activation causes a number of disorders, including nephropathy and hemorrhagic cystitis. BKV-associated nephropathy is a cause of renal dysfunction in renal transplantation patients [151]. JCV establishes latency mainly in the kidney, and its reactivation can result in the development of progressive multifocal leukoencephalopathy. There are a few reports of nephropathy in association with JCV infection [152, 153], but BKV poses a much bigger problem in this regard.

BK Virus BKV infection is endemic worldwide. Seroprevalence rates as high as 60–80 % have been reported among adults in the United States and Europe. The peak incidence of primary infection (as measured by acquisition of antibody) occurs in children 2–5 years of age. BKV antibody may be detected in as many as 50 % of children by 3 years of age, and in 60–100 % of children by 9 or 10 years of age; antibodies wane thereafter. BKV infection may be particularly important in the pediatric transplantation population, in whom primary infection has a high probability of occurring while the children are immunosuppressed [151]. Primary infection with BKV in healthy children is rarely associated with clinical manifestations. Mild pyrexia, malaise, vomiting, respiratory illness, pericarditis, and transient hepatic dysfunction have been reported with primary infection. Investigators hypothesize that after an initial round of viral replication at the site of entry, viremia follows with dissemination of the virus to distant sites at which latent infection is established. The most frequently recognized secondary sites of latent infection are renal and uroepithelial cells. Reactivation and urinary shedding occurs in 10–60 % of immunocompetent individuals, with higher rates among the immunocompromised [154]. Secondary infection has been reported to cause tubulointerstitial nephritis and ureteral stenosis in renal transplantation patients. It may be that renal impairment in immunocompromised patients and in nonrenal solid organ transplant recipients is found to be frequently associated with BKV infection.

J. Stevens et al.

BK Virus Nephropathy in Patients Undergoing Renal Transplantation The reported prevalence of BKV nephropathy in renal allografts is between 1 % and 8 % [155]. Asymptomatic infection is characterized by viral shedding without any apparent clinical features. Viruria, resulting from either primary or secondary infection, can persist from several weeks to years. Tubulointerstitial nephritis associated with BKV in renal transplant recipients is accompanied by histopathologic changes, with or without functional impairment. “Infection” and “disease” must be differentiated carefully. BKV infection (either primary or reactivated) can progress to BKV disease, but will not always do so [156]. Furthermore, not all cases of BKV disease lead to renal impairment. However, infection can progress to transplant dysfunction and graft loss, although the diagnosis may be complicated by the coexistence of active allograft rejection. BKV nephritis has a bimodal distribution, with 50 % of BKV-related interstitial nephritis cases occurring 4–8 weeks after transplantation and the remainder of patients developing disease months to years after transplantation. Allograft failure is due mainly to extensive viral replication in tubular epithelial cells leading to frank tubular necrosis [153]. Although damage is potentially fully reversible early in the disease, persisting viral damage leads to irreversible interstitial fibrosis. Tubular atrophy and allograft loss has been observed in 45 % of affected patients. In most cases, BKV nephropathy in adult renal transplant recipients represents a secondary infection associated with rejection and its treatment. In children, however, primary BKV infection giving rise to allograft dysfunction may occur [156]. The definitive diagnosis of BKV nephropathy requires renal biopsy. Histopathologic features include severe tubular injury with cellular enlargement, marked nuclear atypia, epithelial necrosis, denudation of tubular basement membranes, focal intratubular neutrophilic infiltration, and mononuclear interstitial infiltration, with or without concurrent tubulins [153]. This constellation of histologic features, particularly severe tubulitis, is often misinterpreted as rejection, even by the experienced pathologist. The

51

Infectious Diseases and the Kidney in Children

presence of well-demarcated basophilic or amphophilic intranuclear viral inclusions, primarily within the tubular and parietal epithelium of the Bowman capsule, can help distinguish BKV disease from rejection. Additional tests such as immunohistochemistry, PCR analysis, or electron microscopy of biopsied tissue aimed at the identification of BKV may be required. PCR assays of viral load in tubular cells have been reported to be a sensitive marker for diagnosis and monitoring. Other Implications of BK Virus in Renal Transplantation BKV infection may cause ureteral obstruction due to ureteral ulceration and stenosis at the ureteric anastomosis. BKV-associated ureteral stenosis has been reported in 3 % of renal transplant patients and usually occurs between 50 and 300 days after transplantation. Ulceration due to inflammation, proliferation of the transitional epithelial cells, and smooth muscle proliferation may lead to partial or total obstruction. High-level BKV replication is implicated in acute, lateonset, long-duration hemorrhagic cystitis after bone marrow transplantation [157]. There are two case reports in children of renal carcinomas arising in the transplanted kidney in association with BK virus nephropathy. It remains unclear whether BK virus itself has oncogenic potential in the transplant setting, but this is possible given that the big T antigen (T-Ag) expressed by polyomavirus family viruses has been shown to have the ability to disrupt chromosomal integrity [158, 159]. Treatment Whether patients with asymptomatic viremia or viruria need specific therapeutic intervention is not certain. Review of the literature suggests that careful reduction of immune suppression, combined with active surveillance for rejection, will result in clinical improvement. Reduction in immunosuppression may precipitate episodes of acute cellular rejection, which need to be judiciously treated with corticosteroids. The outcome of BKV nephropathy is unpredictable, and stabilization of renal function may occur regardless of whether maintenance immunotherapy is altered or not [160].

1637

Cyclosporin, mycophenolate, and sirolimus have all been shown to possess in vitro antiviral activity against BK virus, but these findings have not been confirmed by in vivo clinical trials. Several studies have sought to identify a particular immunosuppressant or combination of drugs that increases the risk of BK virus, but results have not favored one particular regimen over another [154]. A systematic review by Johnston et al. in adults found that there was no reduction in graft loss by combining cidofovir or leflunomide with immunosuppression reduction to treat polyomavirus-associated nephropathy [161]. Prospective trials are required to address the impact of various immunosuppressive agents on BK virus replication, and randomized controlled trials are still required to define the optimal treatment of the condition.

Viral Hemorrhagic Fever Viral hemorrhagic fever involves at least 12 distinct RNA viruses that share the propensity to cause severe disease with prominent hemorrhagic manifestations. The viral hemorrhagic fevers, widely distributed throughout both temperate and tropical regions of the world, are important causes of mortality and morbidity in many countries. Most viral hemorrhagic fevers are zoonoses (with the possible exception of dengue virus), in which the virus is endemic in animals and human infection is acquired through the bite of an insect vector. Aerosol and nosocomial transmissions from infected patients are important for Lassa, Junin, Machupo, and Congo-Crimean hemorrhagic fevers and Marburg and Ebola viruses. Viral hemorrhagic fevers have many clinical similarities but also important differences in their severity, major organs affected, prognosis, and response to treatment. In all viral hemorrhagic fevers, severe cases occur in only a minority of those affected; subclinical infection or nonspecific febrile illness occurs in the majority. Fever, myalgia, headache, conjunctival suffusion, and erythematous rash occur in all the viral hemorrhagic fevers [162]. Hemorrhagic manifestations range from petechiae and bleeding from venipuncture

1638

sites to severe hemorrhage into the GI tract, kidney, and other organs. A capillary leak syndrome, with evidence of hemoconcentration, pulmonary edema, oliguria, and ultimately shock, occurs in the most severely affected patients. Renal involvement occurs in all the viral hemorrhagic fevers, proteinuria is common, and prerenal failure is seen in all severe cases complicated by shock. However, in Congo-Crimean hemorrhagic fever and hemorrhagic fever with renal syndrome (HFRS), an interstitial nephritis, which may be hemorrhagic, is characteristic, and renal impairment is a major component of the illness.

Dengue Dengue is caused by a flavivirus that is endemic and epidemic in tropical America, Africa, and Asia, where the mosquito vector Aedes aegypti is present [163]. Classic dengue is a self-limited nonfatal disease; dengue hemorrhagic fever and dengue shock syndrome, which occur in a minority of patients, have a high mortality if not aggressively treated with fluids. After an incubation period of 5–8 days, the illness begins with fever, headache, arthralgia, weakness, vomiting, and hyperesthesia. In uncomplicated dengue, the fever usually lasts 5–7 days. Shortly after onset, a maculopapular rash appears, sparing the palms and the soles, and is occasionally followed by desquamation. Fever may reappear at the onset of the rash. In dengue hemorrhagic fever and dengue shock syndrome, the typical febrile illness is complicated by hemorrhagic manifestations, ranging from a positive tourniquet test result or petechiae to purpura, epistaxis, and GI bleeding with thrombocytopenia and evidence of a consumptive coagulopathy. Increased capillary permeability is suggested by hemoconcentration, edema, and pleural effusions [163]. In severe cases, hypotension and shock supervene, largely as a result of hypovolemia. Renal manifestations include oliguria, proteinuria, hematuria, and rising urea and creatinine. AKI occurs in patients with severe shock, primarily as a result of renal underperfusion. However, glomerular inflammatory changes may also occur. Children with dengue hemorrhagic fever show hypertrophy of

J. Stevens et al.

endothelial and mesangial cells, mononuclear cell infiltrate, thinning of basement membranes, and deposition of IgG, IgM, and C3. Electron microscopy shows viral particles within glomerular mononuclear cells [164]. The diagnosis of dengue is made by isolation of the virus from blood or by serologic testing. There is no specific antiviral treatment, and management of patients with dengue shock syndrome or dengue hemorrhagic fever depends on aggressive circulatory support and volume replacement with colloid and crystalloid [165, 166]. With correction of hypovolemia, renal impairment is usually reversible, but dialysis may be required in patients with established AKI.

Yellow Fever Yellow fever is caused by a flavivirus and is transmitted by mosquito bites, typically Aedes species. It remains an important public health problem in Africa and South America. Renal manifestations are common and include albuminuria and oliguria. Over the next few days after first manifestation of infection, shock, delirium, coma, and renal failure develop, and death occurs 7–10 days after onset of symptoms. Laboratory findings include thrombocytopenia and evidence of hemoconcentration, rising urea and creatinine levels, hypernatremia, and deranged liver function test results. Pathologic findings include necrosis of liver lobules, cloudy swelling and fatty degeneration of the proximal renal tubules, and, often, petechiae in other organs. The oliguria appears to be prerenal and is due to hypovolemia; later, acute tubular necrosis supervenes. At present, there is no effective antiviral agent for yellow fever. Congo-Crimean Hemorrhagic Fever (CCHF) Congo-Crimean hemorrhagic fever, first recognized in the Soviet Union, is now an important human disease in Eastern Europe, Asia, and Africa. It is a tick-borne zoonotic viral disease caused by CCHF virus of the genus Nairovirus (family Bunyaviridae) [167]. Severely affected patients become stuporous or comatose 5–7 days into the illness, with evidence of hepatic and renal

51

Infectious Diseases and the Kidney in Children

failure and shock. Proteinuria and hematuria are often present. The disease is fatal in 15–50 % of cases. The WHO recommends ribavirin as the treatment of choice, but a systematic metaanalysis showed no change in mortality rate in the randomized controlled trials; observational studies showed a reduction in mortality by 44 % but were heavily confounded [167, 168]. Randomized controlled trials are needed in a setting with full supportive care to further address this question. The role of immunoglobulin has also been tried, but no case-control trials have been conducted to support a beneficial effect.

Rift Valley Fever Rift Valley fever is found in many areas of sub-Saharan Africa. In humans, most infections follow mosquito bites or animal exposure. The infection may present as an uncomplicated febrile illness, with muscle aches and headaches. In 10 % of patients, encephalitis or retinal vasculitis occurs as a complication. In a small proportion of cases, a fulminant and often fatal hemorrhagic illness occurs with hematemesis, melena, epistaxis, and evidence of profound DIC. Severe hepatic derangement, renal failure, and encephalopathy are often present. Despite intensive care, mortality is high. Hemorrhagic Fever and Renal Syndrome (Hantavirus) The viruses causing HFRS all belong to the Hantavirus genus in the Bunyaviridae family. The hantaviruses are distributed worldwide and are maintained in nature through chronic infection of rodents and small mammals [169]. Transmission to humans is by aerosolized infectious excreta. Human disease usually occurs in summer among rural populations with exposure to rodent-infested barns or grain stores. Urban transmission can occur, however. At least five hantaviruses are known to cause HFRS: Hantaan, Seoul, Puumala, Porogia, and Belgrade viruses. HFRS is endemic in a belt from Norway in the west through Sweden, Finland, the Soviet Union, China, and Korea to Japan in the east. The clinical severity of HFRS varies throughout this belt. Clinical entities include Korean hemorrhagic fever, nephropathia

1639

epidemica in Scandinavia, and epidemic hemorrhagic fever in Japan and China. In general, HFRS due to Hantaan, Porogia, and Belgrade viruses is more severe and has higher mortality than that due to Puumala virus (nephropathia epidemica) or Seoul virus. Hantaan is predominant in the Far East, Porogia and Belgrade in the Balkans, and Puumala in Western Europe; Seoul has a worldwide distribution. The clinical features of the disease vary [170]. The incubation period is 4–42 days. Although HFRS occurs with the same clinical picture in children as in adults, both incidence rates and antibody prevalence rates are very low in children under 10 years of age. Mild cases are indistinguishable from other febrile illnesses. In more severe cases, fever, headache, myalgia, abdominal pain, and dizziness are associated with the development of periorbital edema, proteinuria, and hematuria. There is often conjunctival injection, pharyngeal injection, petechiae, and epistaxis or GI bleeding. The most severely affected patients develop shock and renal failure. The disease usually passes through five phases: febrile, hypotensive, oliguric, diuretic, and convalescent. Laboratory findings include anemia, lymphocytosis, thrombocytopenia, prolonged prothrombin and bleeding times, and elevated levels of fibrin degradation products. Liver enzyme levels are elevated, and urea and creatinine levels are elevated during the oliguric phase. Proteinuria and hematuria are consistent findings. The renal histopathologic findings are those of an interstitial nephritis with prominent hemorrhages in the renal medullary interstitium and renal cortex. Acute tubular necrosis may also be seen. Immunohistochemical analysis reveals deposition of IgG and C3, and the GBM, mesangial, and subendothelial deposits may be seen on electron microscopy [171]. Recovery from Hantavirus-associated disease is generally complete, although chronic renal insufficiency is a rare sequel of HFRS. In mildly affected patients, the disease is self-limiting, and spontaneous recovery occurs. However, in severe cases, with shock, bleeding, and renal failure, dialysis and intensive circulatory support may be required. Mortality rates vary depending on the strain of virus; rates are 5–15 % for hemorrhagic

1640

fever and renal syndrome in China and significantly lower for the milder Finnish form associated with the Puumala virus strain. Ribavirin is active against Hantaan viruses in vitro, and clinical trials indicate that both mortality and morbidity can be reduced by treatment with this antiviral agent if it is administered early in the course of illness. Dosages of 33 mg/kg followed by 16 mg/kg every 6 h for 4 days and then 8 mg/kg every 8 h for 3 days have been used [172].

Lassa Fever Lassa fever is a common infection in West Africa, caused by an arenavirus, and usually manifests as a nonspecific febrile illness. In 10 % of cases, a fulminant hemorrhagic disease occurs. In severe cases, proteinuria and hematuria are usually present, and renal failure may occur. Ribavirin is effective in decreasing mortality. As in other hemorrhagic fevers, intensive hemodynamic support and correction of the hemostatic derangements are important components of therapy [162]. Argentine and Bolivian Hemorrhagic Fevers Junin and Machupo viruses, the agents of Argentine and Bolivian hemorrhagic fever, respectively, cause hemorrhagic fevers with prominent neurologic features and systemic and hemorrhagic features similar to those of Lassa fever. Oliguria, shock, and renal failure occur in the most severe cases. Marburg Disease and Ebola Virus Disease Marburg and Ebola viruses have been associated with outbreaks of nosocomially transmitted hemorrhagic fever. West Africa has experienced the largest outbreak of Ebola, with several thousand cases in Liberia, Sierra Leone, and Guinea. Mortality in this outbreak has been high with 40–60 % of those affected succumbing. Both viruses cause fulminant hemorrhagic fever. Onset is with high fever, headache, sore throat, myalgia, and profound prostration. An erythematous rash on the trunk is followed by hemorrhagic conjunctivitis, bleeding, impaired renal function, shock, and

J. Stevens et al.

respiratory failure. Renal histopathologic findings in fatal cases are of tubular necrosis, with fibrin deposition in the glomeruli. There is no specific treatment for these disorders.

Other Common Virus Infections There are many ubiquitous viral pathogens that infect large proportions of the population annually and yet are rarely associated with renal disease. The literature contains scattered reports of acute nephritis after infection with many of these viruses. The improvement in molecular diagnostic techniques has led to the recognition of other viruses that play an important role in childhood illness, for example, the human metapneumovirus [213] and Boca virus [214]. The latter only appears to have the greatest clinical impact when present in combination with other viruses. There are no reports of a significant direct renal pathology with these viruses. Adenovirus. Adenovirus is a major cause of hemorrhagic cystitis and is commonly implicated as the cause of hemorrhagic cystitis in [173]. Boys are affected more often than girls, and hematuria persists for 3–5 days. Microscopic hematuria, dysuria, and frequency may occur for longer periods. Adenovirus types 11 and 21 are the usual strains isolated. It has been implicated in causing necrotizing granulomatous tubulointerstitial nephritis in transplant recipients, primarily affecting the distal nephron [174, 175]. The prevalence of viremia in adult transplant recipients is estimated at 6.5 %. Case reports in adults have reported treatment with immunosuppressant reduction, intravenous cidofovir, and immunoglobulin to try and prevent rejection [175]. Enterovirus. Picornaviruses, including enteroviruses, have been linked with acute nephritis and AKI associated with rhabdomyolysis. Coxsackie B virus can be isolated in urine. Direct infection of kidney cells is supported by in vitro work demonstrating lytic infection of human podocyte and proximal tubular epithelial cell cultures, although different strains exhibit variable degrees of

51

Infectious Diseases and the Kidney in Children

nephrotropism. Renal damage in vivo may have both a direct lytic mechanism and an immunecomplex basis [176]. In the newborn, enteroviruses cause fulminant disease with DIC, shock, and liver failure, and AKI may occur. Influenza. Influenza A viruses are important infectious agents that have caused pandemics over the last two decades. The beginning of the last decade saw outbreaks of Avian flu (H5N1and H7N7), and the latter part of the decade dealt with the pandemic of H1N1. Both cause a flulike illness with prominent respiratory and gastrointestinal symptoms. Renal failure can develop as part of the critical illness, in particular renal tubular necrosis. The WHO recommends that a standard regimen of oseltamivir used to treat seasonal flu be used to treat H5N1, but in the severely ill higher doses may be required [177, 178]. Oseltamivirresistant viruses have been reported in Southeast Asia. Peramivir and zanamivir have also been used to treat influenza A virus subtypes. Combinations of antiviral drugs with different modes of action have been explored to improve the outcome of influenza viremia, and studies are still underway in this area [177]. Measles Virus. Renal involvement from measles virus is uncommon, although measles virus can be cultured from the kidney in fatal cases. An acute GN has been reported to follow measles with evidence of immune deposits containing measles virus antigen within the glomeruli. The nephritis is generally self-limiting [179]. Mumps Virus. Mild renal involvement is common during the acute phase of mumps infection. One-third of children with mumps have abnormal urinalysis results, with microscopic hematuria or proteinuria. Mumps virus may be isolated from urine during the first 5 days of the illness, at a time when urinalysis findings are abnormal. Plasma creatinine concentrations usually remain normal, despite the abnormal urine sediment, but more severe cases in unvaccinated children have resulted in fatal interstitial nephritis with interstitial mononuclear cell infiltration, edema, and focal tubular epithelial cell damage [180]. Renal biopsy specimens in adult mumps nephritis demonstrate an MPGN with deposition of IgA,

1641

IgM, C3, and mumps virus antigen in the glomeruli, which suggests an immune-complex-mediated process [181].

Coronavirus Most coronavirus infections are mild respiratory infections with no renal involvement. Two highly pathogenic species are described, with renal cell tropism, and the renal effects of infection require further elucidation. SARS-CoV. Severe acute respiratory syndrome (SARS) was first seen in South China in 2002. It is caused by a SARS coronavirus (SARS-CoV). Predominantly, it causes a viral pneumonia, with diffuse alveolar damage; it has considerable mortality [182]. Renal effects are not generally significant in the pathophysiology of SARS. Acute renal impairment is uncommon in SARS but where present is associated with a high mortality and is a negative prognostic indicator for survival [183]. Case reports have documented rhabdomyolysis in association with SARS and AKI as a cause for AKI. SARS-CoV has been found in the kidney tissue at postmortem [184, 185]. SARS-CoV enters cells via angiotensinconverting enzyme 2 (ACE2) [186], and it is thought that the invasion of the kidney tissue reflects the virus’ tropism for ACE2, which is expressed on kidney cells. Middle East Region Coronavirus (MERSCoV). MERS-CoV causes an illness clinically similar to SARS-CoV. It was discovered following an outbreak in the Middle East in 2012, and new cases continue to arise. Mortality is high – up to 40 %. AKI has been noted in a number of case reports. In vitro studies suggest that MERS-CoV has tropism for kidney epithelial cells [187].

Parasitic Infections Chronic exposure to infectious agents is a major factor in the increased prevalence of glomerular diseases in developing countries. Malaria is the best-documented parasitic infection associated

1642

with glomerular disease, but other parasitic infections including schistosomiasis, filariasis, leishmaniasis, and possibly helminth infections may also induce nephritis or nephrosis.

Malaria Plasmodium malariae and Quartan Malaria Nephropathy Malaria is estimated to cause up to 500 million clinical cases of illness and more than one million deaths each year. The association of P. malariae (quartan) malaria and nephritis has been well known in both temperate and tropical zones since the end of the nineteenth century. Epidemiologic studies early evidence for a role of Plasmodium malariae in glomerular disease. Chronic renal disease was a major cause of morbidity and mortality in British Guiana in the 1920s. The frequent occurrence of P. malariae in the blood of these patients led to detailed epidemiologic studies that implicated malaria as a cause of the nephrosis. After the eradication of malaria from British Guiana, chronic renal disease ceased to be a major cause of death in that country [188]. The link between malaria and nephrotic syndrome was strengthened by studies in West Africa in the 1950s and 1960s that demonstrated a high prevalence of nephrotic syndrome in the Nigerian population [189]. The pattern of nephrotic syndrome differed from that in temperate climates, with an older peak age, extremely poor prognosis, and unusual histologic features. The incidence of P. malariae parasitemia in patients with the nephrotic syndrome in Nigeria was vastly in excess of that occurring in the general population, whereas the incidence of Plasmodium falciparum parasitemia was similar to that in the general population. The age distribution of nephrotic syndrome also closely paralleled that of P. malariae infection [189]. In some affected patients, circulating immune complexes and immunoglobulin, complement, and antigens were present in the glomeruli that were recognized by P. malariaespecific antisera.

J. Stevens et al.

Clinical and Histopathologic Features of Quartan Malaria Nephropathy Most patients have poorly selective proteinuria and are unresponsive to treatment with steroids or immunosuppressive agents. The characteristic lesions of quartan nephropathy are capillary wall thickening and segmental glomerular sclerosis, which lead to progressive glomerular changes and secondary tubular atrophy [189]. Cellular proliferation is conspicuously absent. Electron microscopy shows foot-process fusion, thickening of the basement membrane, and increase in subendothelial basement membrane-like material. Immunofluorescent studies show granular deposits of immunoglobulin, complement, and P. malariae antigen in approximately one-third of patients. The prognosis for the nephrotic syndrome in most African studies has been poor, regardless of whether the histologic findings were typical of quartan malaria nephropathy or whether P. malariae parasitemia was implicated. Treatment with steroids and azathioprine is generally ineffective, and a significant proportion of patients progress to renal failure. In addition to the histologic pattern, termed quartan malaria nephropathy, P. malariae infection is associated with a variety of other forms of histologic appearance, including proliferative GN and MGN. Although quartan malaria nephropathy has been clearly linked to P. malariae infection in Nigeria, studies from other regions in Africa have not revealed the typical histopathologic findings described in the Nigerian studies. Furthermore, quartan malaria nephropathy may be seen in children with no evidence of P. malariae infection or deposition of malaria antigens in the kidney. This, together with the fact that antimalarial treatment does not affect the progression of the disorder, raises the possibility that factors other than malaria might be involved in the initiation and perpetuation of the disorder. There is now a view that the patterns of childhood renal disease described in the last century may no longer be representative of the current situation. The variable patterns of renal disease throughout Africa may no longer reflect a dominant role for

51

Infectious Diseases and the Kidney in Children

“malarial glomerulopathy,” and the relative causative role of tropical infections in nephropathy remains an unanswered question [190]. Most likely, a number of different infectious processes, including malaria, hepatitis B, schistosomiasis, and perhaps other parasitic infections that cause chronic or persistent infections and often occur concurrently in malaria areas, may all result in glomerular injury and a range of overlapping histopathologic features.

Renal Disease Associated with Plasmodium falciparum Infection Plasmodium falciparum appears to be much less likely to cause a significant glomerular pathology. Epidemiologic studies have failed to show a clear association between parasitemia and the nephrotic syndrome. Whereas renal failure appears to be a common complication of severe malaria in adults, it seldom occurs in children. Renal biopsy specimens from adult patients with acute P. falciparum infections who have proteinuria or hematuria show evidence of glomerular changes, including hypercellularity, thickening of basement membranes, and hyperplasia and hypertrophy of endothelial cells [191]. Electron microscopy reveals electron-dense deposits in the subendothelial and paramesangial areas. Deposits of IgM, with or without IgG, are localized mainly in the mesangial areas. Plasmodium falciparum antigens can be demonstrated in the mesangial areas and along the capillary wall, which suggests an immune-complex GN. The changes, generally mild and transient, are probably unrelated to the AKI that may complicate severe P. falciparum infection [191]. Heavily parasitized erythrocytes play a central role in the various pathologic factors [192]. Renal failure occurring in severe P. falciparum malaria is usually associated with acidosis, volume depletion, acute intravascular hemolysis, or heavy parasitic infection that leads to acute tubular necrosis. Recent studies have confirmed an important role for volume depletion in children with severe Plasmodium falciparum malaria, who characteristically have evidence of tachycardia, tachypnea, poor perfusion, and in severe cases

1643

hypotension [193]. Volume expansion with either colloid or crystalloid results in improvement in hemodynamic indices and reduction in acidosis [194]. However, a phase 3 randomized trial of 20–40 ml/kg albumin, saline, or maintenance fluids only showed increased mortality in patients receiving bolus fluids [195]. This surprising finding has been intensively debated, and bolus fluids have been part of standard resuscitation measures for children with critical illness worldwide. A likely explanation for the adverse affects of fluid bolus is that deterioration in pulmonary or neurological condition was associated with fluid administration. As the trial was conducted in African countries where ventilator support was not available, it is not clear that the findings can be extrapolated to settings where ventilator support and modern intensive care are available. However in the light of this trial, routine volume expansion with colloid or crystalloid is currently not recommended for children with severe malaria in settings where intensive care monitoring and support is not available.

Blackwater Fever The term blackwater fever refers to the combination of severe hemolysis, hemoglobinuria, and renal failure. It was more common at the start of the twentieth century in nonimmune individuals receiving intermittent quinine therapy for P. falciparum malaria. Blackwater fever has become rare since 1950, when quinine was replaced by chloroquine. However, the disease reappeared in the 1990s, after the increase in use of quinine because of the development of chloroquine-resistant organisms. Since then, several cases have been described after therapy with halofantrine and mefloquine, molecules similar to quinine (amino alcohol family) [196]. Renal failure generally occurred in the context of severe hemolytic anemia, hemoglobinuria, and jaundice. The pathophysiology of the disorder is unclear; however, it appears that a double sensitization of the red blood cells to the P. falciparum and to the amino alcohols is necessary to provoke the hemolysis. Histopathologic findings include swelling and vacuolization of proximal tubules, necrosis

1644

and degeneration of more distal tubules, and hemoglobin deposition in the renal tubules. Recent studies indicate a better outcome with earlier initiation of intensive care and dialysis combined with necessary changes in antimalarial medications.

Schistosomiasis Schistosomiasis affects 200 million people living in endemic areas of Asia, Africa, and South America. The infection is usually acquired in childhood, but repeated infections occur throughout life. Schistosoma japonicum is found only in the Orient, whereas Schistosoma haematobium occurs throughout Africa, the Middle East, and areas of Southwest Asia. Schistosoma mansoni is widespread in Africa, South America, and Southwest Asia. Human infection begins when the cercarial forms invade through the skin, develop into schistosomula, and move to the lungs via the lymphatics or blood. They then migrate to the liver and mature in the intrahepatic portal venules, where male/female pairing takes place. The adult worm pairs then migrate to their final resting site – the venules of the mesenteric venous system of the large intestine (S. mansoni) or in the venules of the urinary tract (S. haematobium). The females release large numbers of eggs, which may